<SEC-DOCUMENT>0000886744-26-000032.txt : 20260506
<SEC-HEADER>0000886744-26-000032.hdr.sgml : 20260506
<ACCEPTANCE-DATETIME>20260506164933
ACCESSION NUMBER:		0000886744-26-000032
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		63
CONFORMED PERIOD OF REPORT:	20260331
FILED AS OF DATE:		20260506
DATE AS OF CHANGE:		20260506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GERON CORP
		CENTRAL INDEX KEY:			0000886744
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				752287752
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-20859
		FILM NUMBER:		26949376

	BUSINESS ADDRESS:	
		STREET 1:		919 EAST HILLSDALE BOULEVARD
		STREET 2:		SUITE 250
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6504737700

	MAIL ADDRESS:	
		STREET 1:		919 EAST HILLSDALE BOULEVARD
		STREET 2:		SUITE 250
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GERON CORPORATION
		DATE OF NAME CHANGE:	19960521
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>gern-20260331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019c7730-46e9-7212-bc71-75c229f2667a,g:9ff11a8a-3051-4cda-8828-c63f363e56da,d:dd6aca193f774d62ad71a733a1085238-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:gern="http://www.geron.com/20260331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>gern-20260331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0000886744</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-26">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-27">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-28">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-29">2026</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" id="f-30">DE</ix:nonNumeric><ix:nonNumeric contextRef="c-127" name="us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" id="f-571">http://fasb.org/us-gaap/2025#SecuredOvernightFinancingRateSofrMember</ix:nonNumeric><ix:nonFraction unitRef="action" contextRef="c-147" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="f-615">1</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-148" decimals="4" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="0" id="f-616">0.3333</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-148" decimals="4" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="0" id="f-658">0.3333</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="gern-20260331.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>gern:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="lawsuit"><xbrli:measure>gern:lawsuit</xbrli:measure></xbrli:unit><xbrli:unit id="action"><xbrli:measure>gern:action</xbrli:measure></xbrli:unit><xbrli:unit id="plan"><xbrli:measure>gern:plan</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:RevenuesBeforeAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:RevenuesBeforeAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:ChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:ChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:DistributorServiceFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:DistributorServiceFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:GovernmentRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:GovernmentRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:SalesReturnsAndAllowanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:SalesReturnsAndAllowanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:TotalGrossToNetAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:TotalGrossToNetAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USTreasurySecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:MunicipalSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:MunicipalSecuritiesDueInOneToTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CommercialPaperDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CorporateNoteSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CorporateNoteSecuritiesDueInOneToTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USTreasurySecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:MunicipalSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CommercialPaperDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CorporateNoteSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CorporateNoteSecuritiesDueInOneToTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gern:BiopharmaCreditPlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gern:BiopharmaCreditPlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:PrepaidPriorToThirdAnniversaryOfFundingDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gern:DebtInstrumentScenarioAxis">gern:ScenarioOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="gern:DebtInstrumentScenarioAxis">gern:ScenarioOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gern:DebtInstrumentScenarioAxis">gern:ScenarioTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="gern:DebtInstrumentScenarioAxis">gern:ScenarioTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-13</xbrli:startDate><xbrli:endDate>2025-03-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-15</xbrli:startDate><xbrli:endDate>2025-04-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-16</xbrli:startDate><xbrli:endDate>2025-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-23</xbrli:startDate><xbrli:endDate>2026-02-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-29</xbrli:startDate><xbrli:endDate>2025-08-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-12-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:ResearchAndClinicalExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:ResearchAndClinicalExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:ChemistryManufacturingAndControlExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:ChemistryManufacturingAndControlExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:CommercialExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:CommercialExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="idd6aca193f774d62ad71a733a1085238_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON D.C. 20549 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">March 31, 2026</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">000-20859</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">GERON CORPORATION</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">DELAWARE</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-7">75-2287752</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Identification No.)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-8">919 EAST HILLSDALE BOULEVARD</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-9">SUITE 250</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">FOSTER CITY</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-11">CA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">94404</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">473-7700</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">N/A</span></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Title of each class:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Trading symbol(s):</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Name of each exchange on which registered:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">GERN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%">o</span></div><div style="margin-bottom:3pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.024%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Large accelerated filer</ix:nonNumeric> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%">x</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%">o</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Non-accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%">o</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Smaller reporting company </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-21">o</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">o</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%">o</span></div><div style="margin-bottom:6pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;&#160;Yes&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">x</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date.</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Class:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding at May&#160;1, 2026:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Common Stock, $0.001 par value</span></td><td colspan="3" style="border-top:0.5pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">641,520,974</ix:nonFraction> shares</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:36pt;margin-top:12pt;text-align:center"><span><br/></span></div></div></div><div id="idd6aca193f774d62ad71a733a1085238_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GERON CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT ON FORM 10-Q</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE QUARTER ENDED MARCH 31, 2026</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:79.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#idd6aca193f774d62ad71a733a1085238_10">PART I. FINANCIAL INFORMATION</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_13">Item 1:</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd6aca193f774d62ad71a733a1085238_13">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd6aca193f774d62ad71a733a1085238_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_16">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd6aca193f774d62ad71a733a1085238_19">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_19">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd6aca193f774d62ad71a733a1085238_22">Condensed Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd6aca193f774d62ad71a733a1085238_25">Condensed Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd6aca193f774d62ad71a733a1085238_31">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_31">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd6aca193f774d62ad71a733a1085238_34">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_34">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_70">Item 2:</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd6aca193f774d62ad71a733a1085238_70">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_70">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_88">Item 3:</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd6aca193f774d62ad71a733a1085238_88">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_88">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_91">Item 4:</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd6aca193f774d62ad71a733a1085238_91">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_91">34</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#idd6aca193f774d62ad71a733a1085238_94">PART II. OTHER INFORMATION</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_97">Item 1:</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd6aca193f774d62ad71a733a1085238_97">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_97">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_100">Item 1A:</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd6aca193f774d62ad71a733a1085238_100">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_100">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_103">Item 2:</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd6aca193f774d62ad71a733a1085238_103">Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_103">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_106">Item 3:</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd6aca193f774d62ad71a733a1085238_106">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_106">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_109">Item 4:</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd6aca193f774d62ad71a733a1085238_109">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_109">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_112">Item 5:</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd6aca193f774d62ad71a733a1085238_112">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_112">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_118">Item 6:</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd6aca193f774d62ad71a733a1085238_118">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_118">86</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd6aca193f774d62ad71a733a1085238_121">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_121">87</a></span></div></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">RYTELO</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and other trademarks or service marks of Geron Corporation appearing in this Quarterly Report on Form 10-Q (this "Report") are the property of Geron Corporation. This Report contains additional trade names, trademarks and service marks of others, which are the property of their respective owners. We do not intend our use or display of other companies&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:36pt;margin-top:12pt;text-align:center"><span><br/></span></div></div></div><div id="idd6aca193f774d62ad71a733a1085238_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="idd6aca193f774d62ad71a733a1085238_13"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS (UNAUDITED)</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="idd6aca193f774d62ad71a733a1085238_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GERON CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(IN THOUSANDS, EXCEPT PER SHARE DATA) </span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED)</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">MARCH 31,<br/>2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">DECEMBER 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ASSETS</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">68,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-32">77,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-33">1,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-34">1,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">243,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">280,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">41,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">36,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other receivables</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:NontradeReceivablesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">2,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NontradeReceivablesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-40">2,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-41">133,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-42">116,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-43">6,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-44">4,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.08pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-45">498,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-46">520,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Noncurrent marketable securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">26,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">41,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-49">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-50">884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases, right-of-use assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-51">1,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-52">2,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deposits and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="gern:DepositsAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">5,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="gern:DepositsAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">5,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-55">534,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-56">570,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">12,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">11,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">9,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">30,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">1,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Liability related to sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="gern:LiabilityRelatedToSaleOfFutureRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">19,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="gern:LiabilityRelatedToSaleOfFutureRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">17,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">30,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">51,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.08pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">73,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">111,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Noncurrent operating lease liabilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">1,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">1,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Noncurrent liability related to sale of future royalties</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="gern:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">110,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="gern:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">112,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Noncurrent debt</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">119,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-74">119,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.08pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-75">305,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-76">344,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-77"></ix:nonFraction></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-78"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-79"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-80">0.001</ix:nonFraction></ix:nonFraction> par value</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-83"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-84">0.001</ix:nonFraction></ix:nonFraction> par value</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-85">641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-86">640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-87">2,088,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-88">2,080,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-89">1,859,483</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-90">1,855,841</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-91">191</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-92">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.08pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-93">229,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-94">225,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-95">534,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-96">570,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="idd6aca193f774d62ad71a733a1085238_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GERON CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(IN THOUSANDS, EXCEPT PER SHARE DATA)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED) </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">THREE MONTHS ENDED<br/>MARCH 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenues:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-97">51,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-98">39,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-99">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-100">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-101">51,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-102">39,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Costs and operating expenses:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-103">1,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-104">1,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-105">14,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-106">15,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-107">35,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-108">40,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring charges </span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:RestructuringCharges" scale="3" id="f-109">394</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="f-110">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.72pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total costs and operating expenses</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-111">51,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-112">56,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingIncomeLoss" scale="3" id="f-113">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-114">16,704</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-115">3,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-116">5,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-117">7,147</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-118">8,200</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-119">74</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-120">83</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-121">3,642</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-122">19,835</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-123"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-124">0.01</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-125"><ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-126">0.03</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares used in calculating basic and diluted net loss per share</span></td><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-127"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-128">669,375</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-129"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-130">665,905</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="idd6aca193f774d62ad71a733a1085238_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GERON CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(IN THOUSANDS)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.415%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">THREE MONTHS ENDED<br/>MARCH 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-131">3,642</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-132">19,835</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net unrealized gain (loss) on marketable securities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-133">412</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-134">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-135">48</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-136">12</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-137">4,102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-138">19,792</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="idd6aca193f774d62ad71a733a1085238_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GERON CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(IN THOUSANDS)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.796%"/><td style="width:0.1%"/></tr><tr style="height:28pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Additional <br/>Paid-In <br/>Capital </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated <br/>Deficit </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated <br/>Other <br/>Comprehensive <br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total <br/>Stockholders' <br/>Equity </span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Balance at December 31, 2025</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-139">639,856</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-140">640</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-141">2,080,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-142">1,855,841</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-143">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-144">225,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-145">3,642</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-146">3,642</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="f-147">412</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="f-148">412</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-149">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-150">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock in connection with exercise of warrants</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" format="ixt:num-dot-decimal" scale="3" id="f-151">1,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" format="ixt:num-dot-decimal" scale="3" id="f-152">1,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Issuances of common stock under equity plans</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-153">1,172</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-154">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-155">913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-156">914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 6.04pt;text-align:left;text-indent:-5.04pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation related to issuances of common stock and options for services</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="gern:APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares" scale="3" id="f-157">5</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="f-158">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="f-159">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation for equity-based awards to employees and directors</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="f-160">4,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="f-161">4,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Balance at March 31, 2026</span></td><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-162">641,033</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-163">641</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-164">2,088,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-165">1,859,483</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-166">191</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-167">229,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div id="idd6aca193f774d62ad71a733a1085238_28"></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.796%"/><td style="width:0.1%"/></tr><tr style="height:28pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Additional <br/>Paid-In <br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated <br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated <br/>Other <br/>Comprehensive <br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total <br/>Stockholders' <br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-168">606,388</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-169">606</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-170">2,051,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-171">1,772,341</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-172">261</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-173">280,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.04pt;text-align:left;text-indent:-5.04pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-174">19,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-175">19,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 6.04pt;text-align:left;text-indent:-5.04pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="f-176">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="f-177">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.04pt;text-align:left;text-indent:-5.04pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-178">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-179">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 6.04pt;text-align:left;text-indent:-5.04pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Exercise of pre-funded warrant</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="-3" name="gern:StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant" format="ixt:num-dot-decimal" scale="3" id="f-180">30,370</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="gern:StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant" scale="3" id="f-181">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="gern:StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant" scale="3" id="f-182">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.04pt;text-align:left;text-indent:-5.04pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock under equity plans</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-183">155</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-184">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-185">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 6.04pt;text-align:left;text-indent:-5.04pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation related to issuances of common stock and options for services</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="-3" name="gern:APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares" scale="3" id="f-186">5</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="f-187">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="f-188">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.04pt;text-align:left;text-indent:-5.04pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation for equity-based awards to employees and directors</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="f-189">7,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="f-190">7,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 6.04pt;text-align:left;text-indent:-5.04pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Balance at March 31, 2025</span></td><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-191">636,918</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-192">637</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-193">2,059,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-194">1,792,176</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-195">304</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-196">268,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="idd6aca193f774d62ad71a733a1085238_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GERON CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(IN THOUSANDS)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">THREE MONTHS ENDED<br/>MARCH 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cash flows from operating activities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-197">3,642</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-198">19,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-199">134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-200">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accretion and amortization on investments, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-201">1,069</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-202">2,210</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt issuance costs/debt discounts</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="f-203">286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="f-204">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense on liabilities for sales of future royalties</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="gern:NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-205">3,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="gern:NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-206">4,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-207">4,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-208">7,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-209">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-210">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Increase in allowance for doubtful accounts</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="gern:IncreaseDecreaseInAllowanceForDoubtfulAccounts" format="ixt:fixed-zero" scale="3" id="f-211">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="gern:IncreaseDecreaseInAllowanceForDoubtfulAccounts" scale="3" id="f-212">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Changes in assets and liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-213">16,651</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-214">17,508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-215">4,894</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-216">4,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-217">2,234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-218">1,688</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-219">1,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-220">563</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation and benefits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-221">21,009</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-222">13,204</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-223">20,374</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-224">6,663</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payments on royalty agreement</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-225">3,721</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PaymentsForRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-226">3,682</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="gern:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="f-227">212</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="gern:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="f-228">191</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 33.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-229">62,906</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-230">47,979</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cash flows from investing activities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of property and equipment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="gern:PaymentsUnpaidToAcquirePropertyPlantAndEquipment" scale="3" id="f-231">252</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="gern:PaymentsUnpaidToAcquirePropertyPlantAndEquipment" scale="3" id="f-232">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of marketable securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-233">34,525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-234">46,477</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from maturities and sales of marketable securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-235">86,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-236">98,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 33.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-237">51,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-238">52,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cash flows from financing activities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from issuances of common stock from equity plans</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="f-239">914</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="f-240">256</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from the exercise of warrants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="f-241">1,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="f-242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 33.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-243">2,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-244">256</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net effect of exchange rates on cash, cash equivalents and restricted cash</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-245">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-246">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-247">8,661</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-248">4,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash at the beginning of the period</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-249">79,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-250">80,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash at the end of the period</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-251">70,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-252">85,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="idd6aca193f774d62ad71a733a1085238_34"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GERON CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:700;line-height:120%"> </span></div><div id="idd6aca193f774d62ad71a733a1085238_37"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="f-253" continuedAt="f-253-1" escape="true">BASIS OF PRESENTATION, PRINCIPLES OF CONSOLIDATION, USE OF ESTIMATES AND RECENT ACCOUNTING PRONOUNCEMENTS</ix:nonNumeric></span></div><ix:continuation id="f-253-1" continuedAt="f-253-2"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The terms &#8220;Geron&#8221;, the &#8220;Company&#8221;, &#8220;we&#8221; and &#8220;us&#8221; as used in this Report refer to Geron Corporation and its wholly-owned subsidiaries, Geron UK Limited, or Geron UK, a United Kingdom company, and Geron Netherlands B.V., or Geron Netherlands, a Netherlands company. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-254" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:18pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by United States, or U.S., generally accepted accounting principles, or GAAP, for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2025, or the 2025 Form 10-K. The accompanying unaudited condensed consolidated balance sheet as of December&#160;31, 2025 has been derived from audited financial statements at that date. Operating results for the three months ended March 31, 2026 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2026 or any other period. We operate as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-255">one</ix:nonFraction> operating segment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-256" continuedAt="f-256-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-256-1">The unaudited condensed consolidated financial statements include the accounts of Geron Corporation and its wholly-owned subsidiaries, Geron UK and Geron Netherlands. For Geron UK and Geron Netherlands, we have eliminated intercompany accounts and transactions.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-257" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to accrued liabilities, revenue recognition, fair value of marketable securities, inventory valuation, operating leases (right-of-use assets), lease liabilities, income taxes, and stock-based compensation and interest expense related to sale of future royalties. We base our estimates on historical experience and on various other market specific and relevant assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="gern:SignificantAccountingPoliciesPolicyPolicyTextBlock" id="f-258" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies used in preparation of these unaudited condensed consolidated financial statements as of and for the three months ended March 31, 2026 are consistent with those discussed in Note 1 to the consolidated financial statements in the 2025 Form 10-K.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-259" continuedAt="f-259-1" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements &#8211; Issued But Not Yet Adopted</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The amendments in ASU 2024-03 address investor requests for more detailed expense information and require additional disaggregated disclosures in the notes to financial statements for certain categories of expenses that are included on the face of the income statement. This guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GERON CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="f-259-1"><ix:continuation id="f-253-2"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">years beginning after December 15, 2027, with early adoption permitted. We are evaluating the impact of this ASU on our consolidated financial statements.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other recent accounting pronouncements issued by the FASB are not believed by management to have a material impact on our financial statements.</span></div></ix:continuation></ix:continuation><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span><br/></span></div><div id="idd6aca193f774d62ad71a733a1085238_40"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-260" continuedAt="f-260-1" escape="true">REVENUE RECOGNITION</ix:nonNumeric></span></div><ix:continuation id="f-260-1"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net Product Revenue</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To date, our only source of product revenue has been from the U.S. sales of RYTELO, which we began shipping to our customers in June 2024. To date, product revenue pursuant to Named Patient Programs outside of the U.S. have been not material.</span></div><ix:nonNumeric contextRef="c-1" name="gern:ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock" id="f-261" escape="true"><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of gross product sales to net product sales by each significant category of gross-to-net adjustments was as follows for the three months ended March&#160;31, 2026 and 2025: </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.484%"><tr><td style="width:1.0%"/><td style="width:54.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.594%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross product revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-262">65,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-263">45,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross-to-net adjustments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-264">8,164</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-265">4,171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Distributor service fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-266">2,169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-267">1,526</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Government rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-268">1,658</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-269">66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns and allowances</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-270">1,591</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-271">113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total gross-to-net adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-272">13,582</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-273">5,876</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-274">51,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-275">39,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="idd6aca193f774d62ad71a733a1085238_43"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryDisclosureTextBlock" id="f-276" continuedAt="f-276-1" escape="true">INVENTORY</ix:nonNumeric></span><ix:continuation id="f-276-1" continuedAt="f-276-2"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></ix:continuation></div><ix:continuation id="f-276-2"><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All of our inventories are related to the manufacturing of RYTELO. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-277" continuedAt="f-277-1" escape="true">The following table presents our inventory as of March&#160;31, 2026 and December 31, 2025:</ix:nonNumeric></span></div><ix:continuation id="f-277-1"><div style="margin-bottom:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"/><td style="width:68.685%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-278">15,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-279">8,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-280">99,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-281">91,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-282">18,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-283">15,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total inventory</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-284">133,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-285">116,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="idd6aca193f774d62ad71a733a1085238_7146825581013"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GERON CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="f-286" continuedAt="f-286-1" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="f-286-1" continuedAt="f-286-2"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="f-287" continuedAt="f-287-1" escape="true"><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents, restricted cash and marketable securities by security type at March&#160;31, 2026 were as follows: </span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Included in cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-288">43,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="gern:CashAndCashEquivalentsUnrealizedGains" format="ixt:fixed-zero" scale="3" id="f-289">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="gern:CashAndCashEquivalentsUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="f-290">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-291">43,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-292">4,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="gern:CashAndCashEquivalentsUnrealizedGains" format="ixt:fixed-zero" scale="3" id="f-293">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="gern:CashAndCashEquivalentsUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="f-294">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-295">4,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-296">48,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="gern:CashAndCashEquivalentsUnrealizedGains" format="ixt:fixed-zero" scale="3" id="f-297">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="gern:CashAndCashEquivalentsUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="f-298">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-299">48,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market fund</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-300">1,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="gern:RestrictedCashAndCashEquivalentsGrossUnrealizedGains" format="ixt:fixed-zero" scale="3" id="f-301">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="gern:RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="f-302">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:RestrictedInvestmentsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-303">1,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="f-304">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="gern:RestrictedCashAndCashEquivalentsGrossUnrealizedGains" format="ixt:fixed-zero" scale="3" id="f-305">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="gern:RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="f-306">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:RestrictedInvestmentsAtFairValue" scale="3" id="f-307">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-308">1,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="gern:RestrictedCashAndCashEquivalentsGrossUnrealizedGains" format="ixt:fixed-zero" scale="3" id="f-309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="gern:RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="f-310">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedInvestmentsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-311">1,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities (due in less than one year)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 8.2pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-312">14,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-313">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-314">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-315">14,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Municipal securities (due in less than one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 15.4pt;text-indent:-7.21pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-316">10,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-317">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-318">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-319">10,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Municipal securities (due in one to two years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 15.4pt;text-indent:-7.21pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-320">2,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-321">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-322">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-323">2,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Government-sponsored enterprise securities (due in less than one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 15.4pt;text-indent:-7.21pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-324">2,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-325">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-326">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-327">2,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper (due in less than one year)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 8.2pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-328">66,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-329">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-330">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-331">66,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes (due in less than one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 8.2pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-332">149,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-333">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-334">130</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-335">148,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes (due in one to two years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 8.2pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-336">24,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-338">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-339">24,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-340">270,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-341">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-342">215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-343">270,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GERON CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="f-287-1"><ix:continuation id="f-286-2" continuedAt="f-286-3"><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents, restricted cash and marketable securities by security type at December&#160;31, 2025 were as follows: </span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Included in cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-344">48,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="gern:CashAndCashEquivalentsUnrealizedGains" scale="3" id="f-345">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="gern:CashAndCashEquivalentsUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="f-346">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-347">48,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-348">4,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="gern:CashAndCashEquivalentsUnrealizedGains" format="ixt:fixed-zero" scale="3" id="f-349">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="gern:CashAndCashEquivalentsUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="f-350">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-351">4,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-352">53,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="gern:CashAndCashEquivalentsUnrealizedGains" scale="3" id="f-353">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="gern:CashAndCashEquivalentsUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="f-354">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-355">53,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market fund</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-356">1,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="gern:RestrictedCashAndCashEquivalentsGrossUnrealizedGains" format="ixt:fixed-zero" scale="3" id="f-357">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="gern:RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="f-358">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:RestrictedInvestmentsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-359">1,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="f-360">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="gern:RestrictedCashAndCashEquivalentsGrossUnrealizedGains" format="ixt:fixed-zero" scale="3" id="f-361">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="gern:RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="f-362">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:RestrictedInvestmentsAtFairValue" scale="3" id="f-363">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-364">1,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="gern:RestrictedCashAndCashEquivalentsGrossUnrealizedGains" format="ixt:fixed-zero" scale="3" id="f-365">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="gern:RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="f-366">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedInvestmentsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-367">1,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities (due in less than one year)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-368">22,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-369">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-370">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-371">22,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Municipal securities (due in less than one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-372">10,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-373">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-374">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-375">10,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper (due in less than one year)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-376">79,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-377">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-378">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-379">79,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes (due in less than one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-380">167,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-381">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-382">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-383">167,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes (due in one to two years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-384">41,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-385">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-386">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-387">41,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-388">321,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-389">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-390">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-391">321,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GERON CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="f-286-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="f-392" escape="true"><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and marketable securities with unrealized losses that have been in a continuous unrealized loss position for less than 12 months and 12 months or longer at March&#160;31, 2026 and December&#160;31, 2025 were as follows: </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Less Than 12 Months </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">12 Months or Longer </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31, 2026:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Government-sponsored enterprise securities (due in less than one year)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-393">2,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-394">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-395">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-396">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-397">2,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-398">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Municipal securities (due in less than one year)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-399">4,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-400">2</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-401">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-402">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-403">4,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-404">2</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Municipal securities (due in one to two years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-405">2,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-406">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-407">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-408">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-409">2,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-410">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper (cash equivalent)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-411">4,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-412">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-413">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-414">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-415">4,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-416">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper (due in less than one year)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-417">37,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-418">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-419">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-420">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-421">37,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-422">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes (due in less than one year)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-423">93,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-424">130</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-425">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-426">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-427">93,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-428">130</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes (due in one to two years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-429">24,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-430">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-431">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-432">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-433">24,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-434">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-435">170,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-436">215</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-437">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-438">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-439">170,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-440">215</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2025:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes (due in less than one year)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-441">17,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-442">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-444">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-445">17,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-446">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes (due in one to two years)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-447">31,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-448">38</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-449">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-450">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-451">31,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-452">38</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-453">49,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-454">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-455">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-456">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-457">49,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-458">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The gross unrealized losses related to municipal securities, government-sponsored enterprise securities, commercial paper and corporate notes as of March&#160;31, 2026 and December&#160;31, 2025 were due to changes in interest rates and not credit risk. If an available-for-sale security&#8217;s fair value is less than its amortized cost basis, we evaluate whether the decline is the result of a credit loss, in which case an impairment is recorded through an allowance for credit losses. We have not recorded any allowances for credit losses on our available-for-sale securities for the three months ended March&#160;31, 2026 as we have not identified any unrealized losses for these securities attributable to credit factors. Our exposure to unrealized losses may increase in the future due to the economic pressures or uncertainties associated with local or global economic recessions as a result of ongoing geopolitical events, such as the current military conflicts between Ukraine and Russia or the United States and Iran, as well as recent and potential future disruptions in access to bank deposits or lending commitments due to bank failure. We do not intend to sell the investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost basis, which may be maturity.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="idd6aca193f774d62ad71a733a1085238_46"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GERON CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-459" continuedAt="f-459-1" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="f-459-1" continuedAt="f-459-2"><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We categorize financial instruments recorded at fair value on our condensed consolidated balance sheets based upon the level of judgment associated with inputs used to measure their fair value. The categories are as follows: </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Level 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></td></tr></table></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A financial instrument&#8217;s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Below is a description of the valuation methodologies used for financial instruments measured at fair value on our consolidated balance sheets, including the category for such financial instruments.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds and certificates of deposit are categorized as Level 1 within the fair value hierarchy as their fair values are based on quoted prices available in active markets. Commercial paper, U.S. Treasury securities, municipal securities, government-sponsored enterprise securities and corporate notes are categorized as Level 2 within the fair value hierarchy as their fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The embedded derivatives are classified within Level 3 of the fair value hierarchy. See Note 7 on Debt.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We determined the fair value of the liability related to the sale of future royalties based on our current estimates of future royalties expected to be paid to Royalty Pharma over the life of the arrangement, which are considered Level 3. See Note 7 on Debt.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level 1, Level 2, and Level 3 during the periods presented. In addition, there have been no changes to our valuation techniques as of March 31, 2026 and December 31, 2025.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GERON CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-460" escape="true"><ix:continuation id="f-459-2"><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of March&#160;31, 2026 and December&#160;31, 2025 and indicates the fair value category assigned.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.151%"><tr><td style="width:1.0%"/><td style="width:37.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.472%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.472%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.472%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.472%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.526%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices in<br/>Active Markets for<br/>Identical Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other<br/>Observable Inputs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31, 2026:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-461">45,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-462">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-463">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-464">45,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="f-465">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-466">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-467">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="f-468">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Municipal securities</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)(4)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-470">12,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-471">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-472">12,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-473">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-474">14,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-475">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-476">14,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Government-sponsored enterprises</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-477">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-478">2,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-479">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-480">2,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-481">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-482">71,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-483">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-484">71,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-485">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-486">173,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-487">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-488">173,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-489">45,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-490">275,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-491">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-492">320,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sale of future royalties</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="f-493">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="f-494">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-495">129,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-496">129,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-497">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-498">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-499">129,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-500">129,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2025:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-501">50,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-502">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-503">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-504">50,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="f-505">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-506">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-507">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="f-508">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Municipal securities</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-509">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-510">10,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-511">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-512">10,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)(4)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-513">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-514">22,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-515">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-516">22,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-517">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-518">84,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-519">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-520">84,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)(4)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-521">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-522">209,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-523">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-524">209,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-525">50,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-526">326,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-527">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-528">377,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sale of future royalties</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="f-529">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="f-530">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-531">129,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-532">129,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-533">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-534">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-535">129,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-536">129,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt">Included in cash and cash equivalents on our condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt">Included in restricted cash on our condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt">Included in current portion of marketable securities on our condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt">Included in noncurrent portion of marketable securities on our condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt">Included in current portion of liabilities related to sale of future royalties on our consolidated balance sheets.</span></div><div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Included in noncurrent portion of liabilities related to sale of future royalties on our consolidated balance sheets.</span></div></ix:continuation></ix:nonNumeric><div id="idd6aca193f774d62ad71a733a1085238_49"></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GERON CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-537" continuedAt="f-537-1" escape="true">OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS</ix:nonNumeric></span></div><ix:continuation id="f-537-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-538" escape="true"><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following as of March&#160;31, 2026 and December&#160;31, 2025: </span></div><div style="margin-bottom:12pt;text-align:center;text-indent:64.8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.818%"><tr><td style="width:1.0%"/><td style="width:65.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.498%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.498%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">MARCH 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">DECEMBER 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contract research organization and clinical trial costs</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="gern:AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-539">4,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="gern:AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-540">3,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="gern:AccruedManufacturingActivitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-541">16,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="gern:AccruedManufacturingActivitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-542">38,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Professional, legal and accounting fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-543">2,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="f-544">881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-545">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-546">3,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued revenue adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="gern:GrossToNetAdjustmentsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-547">5,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="gern:GrossToNetAdjustmentsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-548">3,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-549">1,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-550">1,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-551">30,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-552">51,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="gern:ScheduleOfAccruedCompensationAndBenefitsTableTextBlock" id="f-553" escape="true"><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation and benefits consisted of the following as of March&#160;31, 2026 and December&#160;31, 2025:</span></div><div style="margin-bottom:12pt;text-align:center;text-indent:64.8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.818%"><tr><td style="width:1.0%"/><td style="width:65.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.498%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.498%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">MARCH 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">DECEMBER 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued bonuses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedBonusesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-554">3,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedBonusesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-555">10,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued vacation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedVacationCurrent" format="ixt:num-dot-decimal" scale="3" id="f-556">2,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedVacationCurrent" format="ixt:num-dot-decimal" scale="3" id="f-557">2,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued restructuring charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestructuringReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="f-558">3,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestructuringReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="f-559">17,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherEmployeeRelatedLiabilitiesCurrent" scale="3" id="f-560">447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherEmployeeRelatedLiabilitiesCurrent" scale="3" id="f-561">549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-562">9,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-563">30,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span><br/></span></div><div id="idd6aca193f774d62ad71a733a1085238_52"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-564" continuedAt="f-564-1" escape="true">DEBT</ix:nonNumeric></span></div><ix:continuation id="f-564-1" continuedAt="f-564-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Pharmakon Loan Agreement </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2024, we entered into a loan agreement, or the Pharmakon Loan Agreement, with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership, each, a Lender, which are investment funds managed by Pharmakon Advisors, LP, and BioPharma Credit PLC, as collateral agent, that provides for a <ix:nonNumeric contextRef="c-122" name="us-gaap:LineOfCreditFacilityExpirationPeriod" format="ixt-sec:durwordsen" id="f-565">5-year</ix:nonNumeric> senior secured term loan facility of up to $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-566">250.0</ix:nonFraction>&#160;million, divided into three committed tranches: (i) a Tranche A Loan in an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-567">125.0</ix:nonFraction>&#160;million, or the Tranche A Loan, which was funded on November 1, 2024, or the Tranche A Closing Date; (ii) a Tranche B Loan in an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-568">75.0</ix:nonFraction>&#160;million, or the Tranche B Loan, which is available, subject to certain limited conditions, at our option; and (iii) a Tranche C Loan in an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-569">50.0</ix:nonFraction>&#160;million, or the Tranche C Loan, and together with the Tranche A Loan and the Tranche B Loan, collectively, the Term Loans, which is available to us upon reaching a specified trailing twelve-month RYTELO revenue milestone. The Tranche B Loan and the Tranche C Loan, once available, could have been requested on or prior to December 31, 2025. A portion of the proceeds from the Tranche A Loan were used to repay, in full, all amounts owed under the Hercules Loan Agreement, which was terminated effective November 1, 2024. The remaining proceeds will be used to fund our general corporate and working capital requirements.</span></div><div style="text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On January 5, 2026, the Pharmakon Loan Agreement was amended to extend the date for requesting the Tranche B Loan and Tranche C Loan, once available, from December 31, 2025 to July 30, 2026. The amendment also extended the date before which any Term Loan prepayment is subject to a make&#8209;whole premium, or the Makewhole Date, from November 1, 2026 to May 1, 2027. The amendment was evaluated under ASC 470-50 and determined to be a modification. The unamortized debt issuance costs will continue to be amortized over the remaining term using a revised effective interest rate. Fees incurred in connection with the amendment were not material and were expensed as incurred.</span></div></ix:continuation><div style="margin-bottom:12pt;text-indent:64.8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GERON CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="f-564-2" continuedAt="f-564-3"><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loans mature on November 1, 2029. The Term Loans bear interest at a variable rate per annum equal to <ix:nonFraction unitRef="number" contextRef="c-127" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-570">5.75</ix:nonFraction>% plus the three-month Secured Overnight Financing Rate, or SOFR, with a <span style="-sec-ix-hidden:f-571">SOFR</span> floor of <ix:nonFraction unitRef="number" contextRef="c-128" decimals="4" name="gern:DebtInstrumentFloorRate" scale="-2" id="f-572">3.00</ix:nonFraction>%. As of inception of the Tranche A Loan, the interest rate applicable to the Tranche A Loan was <ix:nonFraction unitRef="number" contextRef="c-124" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-573">10.32</ix:nonFraction>%. As of March&#160;31, 2026, the applicable interest rate was <ix:nonFraction unitRef="number" contextRef="c-129" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-574">10.80</ix:nonFraction>%. Interest is due and payable quarterly on the last day of each quarter. The Pharmakon Loan Agreement requires we pay an amount equal to <ix:nonFraction unitRef="number" contextRef="c-128" decimals="4" name="gern:PercentageOfCommitmentAmountToFundLoan" scale="-2" id="f-575">2.50</ix:nonFraction>% of the Lenders&#8217; total committed amount to fund the Term Loans, payable with respect to each Term Loan on the funding date of such Term Loan. </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may elect to prepay the Term Loans in part or in whole prior to the Maturity Date with such prepayments being subject to a prepayment premium equal to the principal amount so prepaid multiplied by <ix:nonFraction unitRef="number" contextRef="c-130" decimals="2" name="gern:PrepaymentPremiumOnPercentageOfTermLoan" scale="-2" id="f-576">3</ix:nonFraction>% if made prior to the 3rd anniversary of the funding date of the applicable Term Loan, <ix:nonFraction unitRef="number" contextRef="c-131" decimals="2" name="gern:PrepaymentPremiumOnPercentageOfTermLoan" scale="-2" id="f-577">2</ix:nonFraction>% if made on or after the 3rd anniversary of the funding date of the applicable Term Loan but prior to the 4th anniversary of the funding date of the applicable Term Loan, and <ix:nonFraction unitRef="number" contextRef="c-132" decimals="2" name="gern:PrepaymentPremiumOnPercentageOfTermLoan" scale="-2" id="f-578">1</ix:nonFraction>% if made on or after the 4th anniversary of the funding date of the applicable Term Loan but prior to the Maturity Date. In addition to the prepayment premium, prepayments of any Term Loan prior to the 2nd anniversary of the funding date of such Term Loan are subject to a make-whole amount equal to the sum of all interest that would have accrued through such 2nd anniversary. </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations under the Pharmakon Loan Agreement are secured by substantially all of our assets, including our intellectual property. Certain of our subsidiaries may, from time to time after the Tranche A Closing Date, be required to guarantee our obligations under the Pharmakon Loan Agreement and, in connection with such guarantee, pledge substantially all of their assets, including intellectual property, to secure such guarantee.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Loan Agreement contains customary affirmative and restrictive covenants and representations and warranties. We are bound by certain affirmative covenants setting forth actions that are required during the term of the Pharmakon Loan Agreement, including, without limitation, certain information delivery requirements, obligations to maintain certain insurance, and certain notice requirements. There are no financial covenants. Additionally, we are bound by certain restrictive covenants setting forth actions that are not permitted to be taken during the term of the Pharmakon Loan Agreement, including, without limitation, (i) selling or disposing of assets, (ii) amending, modifying or waiving our rights under material agreements, (iii) consummating change in control transactions unless all amounts becoming due under the Loan Agreement are paid in full immediately upon (and concurrent with) the consummation of any such change in control transaction, (iv) incurring additional indebtedness, (v) incurring non-permitted liens or encumbrance on our or our subsidiaries&#8217; assets, (vi) paying dividends or making any distribution or payment on or redeeming, retiring or purchasing any equity interests, and (vii) making payments on subordinated indebtedness, in each case, subject to specified exceptions. The Pharmakon Loan Agreement also contains the following events of default: (i) failure to pay principal, interest and other amounts when due, (ii) the breach of the covenants under the Loan Agreement, (iii) the occurrence of a material adverse change or the occurrence of a withdrawal event in respect of RYTELO, (iv) certain attachments of the credit parties assets and restraints on their business, (v) certain insolvency, liquidation, bankruptcy or similar events, (vi) certain cross-default of third-party indebtedness and royalty revenue contracts, (vii) the failure to pay certain judgments, (viii) material misrepresentations, (ix) the loan documents ceasing to create a valid security interest in a material portion of the collateral, (x) the occurrence of certain ERISA events, and (xi) the occurrence of a default under any subordination or intercreditor agreement, in each case subject to the grace periods, cure period and thresholds as specified in the Pharmakon Loan Agreement. Upon the occurrence and during the continuance of an event of default, the Lenders may, among other things, accelerate our obligations under the Pharmakon Loan Agreement (including all obligations for principal, interest and any applicable make-whole and prepayment premiums); provided that upon an event of default relating to certain insolvency, liquidation, bankruptcy or similar events, all outstanding obligations will be immediately accelerated. We concluded that the likelihood of such acceleration is remote, and therefore all debt is classified as long&#8209;term. As of March&#160;31, 2026, we were in compliance with our Pharmakon Loan Agreement covenants.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GERON CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="f-564-3" continuedAt="f-564-4"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:90%">Future Minimum Payments</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-579" escape="true"><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents future minimum payments, including interest and the end of term charge, under the Loan Agreement as of March&#160;31, 2026 (in thousands): </span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.000%"><tr><td style="width:1.0%"/><td style="width:72.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="f-580">11,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-581">11,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-582">11,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="f-583">134,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="gern:LongTermDebtMaturityAfterYearThree" format="ixt:fixed-zero" scale="3" id="f-584">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-585">170,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Less: amount representing interest</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedCapitalizedInterestCosts" format="ixt:num-dot-decimal" scale="3" id="f-586">45,780</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Less: unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-587">5,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Noncurrent portion of debt</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-588">119,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Embedded Derivatives</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The conditional exercisable call option related to the event of default is considered to be an embedded derivative which is required to be bifurcated and accounted for as a separate financial instrument. In the periods presented, the value of the embedded derivative is not material and therefore, no amount has been recognized. If an event of default becomes more probable than is currently estimated, then the embedded derivative could become material in future periods and would be recognized as a separate financial instrument at that time.  The embedded derivatives are classified within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Liabilities Related to Sale of Future Royalties</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2024, we entered into a revenue participation right purchase and sale agreement, or the Royalty Pharma Agreement, with Royalty Pharma Development Funding, LLC, or Royalty Pharma. Pursuant to the Royalty Pharma Agreement, we received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="gern:UpfrontPaymentReceived" scale="6" id="f-589">125.0</ix:nonFraction>&#160;million, or the Purchase Price, in exchange for which Royalty Pharma obtained the right, or the Revenue Participation Right, to receive certain amounts calculated as a percentage of future U.S. net sales of RYTELO for each calendar quarter, or Royalty Payments, during the term contemplated by the Royalty Pharma Agreement. Specifically, the revenue participation rate commences at <ix:nonFraction unitRef="number" contextRef="c-134" decimals="4" name="gern:PercentageOfAnnualNetSales" scale="-2" id="f-590">7.75</ix:nonFraction>% for annual U.S. net sales of up to and equal to $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-591">500.0</ix:nonFraction>&#160;million declining to <ix:nonFraction unitRef="number" contextRef="c-136" decimals="3" name="gern:PercentageOfAnnualNetSales" scale="-2" id="f-592">1.0</ix:nonFraction>% for annual U.S. net sales exceeding $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="9" id="f-593">1.0</ix:nonFraction>&#160;billion until the date when the aggregate Royalty Payments equal or exceed <ix:nonFraction unitRef="number" contextRef="c-138" decimals="2" name="gern:DebtInstrumentRoyaltyPaymentRatio" scale="0" id="f-594">1.65</ix:nonFraction> times the Purchase Price, if this occurs by June 30, 2031, or the date when the aggregate Royalty Payments equal or exceed <ix:nonFraction unitRef="number" contextRef="c-139" decimals="1" name="gern:DebtInstrumentRoyaltyPaymentRatio" scale="0" id="f-595">2.0</ix:nonFraction> times the Purchase Price.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have the option to repurchase all of the Revenue Participation Right from Royalty Pharma for a purchase price of equal to the Buy-Out-Payment, as defined below, if we entered into a definitive agreement to consummate a change of control, or Buy-Back Option. </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Buy-Out Payment&#8221; means an amount equal to (a) <ix:nonFraction unitRef="number" contextRef="c-138" decimals="2" name="gern:DebtInstrumentRoyaltyPaymentRatio" scale="0" id="f-596">1.65</ix:nonFraction> times the Purchase Price minus the aggregate Royalty Payments as of the change of control, if the change of control occurs on or prior to December 31, 2027, or (b) <ix:nonFraction unitRef="number" contextRef="c-139" decimals="1" name="gern:DebtInstrumentRoyaltyPaymentRatio" scale="0" id="f-597">2.0</ix:nonFraction> times the Purchase Price minus the aggregate Royalty Payments as of the change of control, if the change of control occurs after December 31, 2027. </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for the Royalty Pharma Agreement as a financing liability, primarily because it has significant continuing involvement in generating the future revenue on which the Royalty Payments are based. The liability related to Revenue Participation Right and the related interest expense are measured based on our current estimate of the timing and amount of expected future Royalty Payments expected to be paid over the estimated term of the Royalty Pharma Agreement using a discounted cashflow model. The liability is amortized using the effective interest rate method, resulting in recognition of interest expense over the estimated term of the agreement. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GERON CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="f-564-4"><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have determined the fair value of the liability related to the sale of future royalties is based on our current estimates of future royalties expected to be paid to Royalty Pharma over the life of the arrangement, which are considered Level 3.</span></div><ix:nonNumeric contextRef="c-1" name="gern:ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock" id="f-598" escape="true"><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity within the liability related to sale of future royalties during the three months ended March&#160;31, 2026: </span></div><div style="text-align:center;text-indent:24.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.121%"><tr><td style="width:1.0%"/><td style="width:81.003%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.059%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Liability Related to Sale of Future Royalties</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of liability related to sale of future royalties at December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-599">129,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="3" id="f-600">3,912</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Royalty payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:PaymentsForRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-601">3,721</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of liability related to sale of future royalties at March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-602">129,773</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="idd6aca193f774d62ad71a733a1085238_55"></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-603" continuedAt="f-603-1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="f-603-1" continuedAt="f-603-2"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 13 and March 14, 2025, we and certain of our current and former officers were named as defendants in <ix:nonFraction unitRef="lawsuit" contextRef="c-143" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="f-604">two</ix:nonFraction> putative securities class action lawsuits filed in the United States District Court for the Northern District of California captioned </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dabestani v. Geron Corporation, et al.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, No. 3:25-cv-02507 and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Potvin v. Geron Corporation, et al.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, No. 3:25-cv-02563, respectively. Both lawsuits allege violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder in connection with allegedly false and misleading statements concerning the commercial potential of RYTELO. The plaintiffs allege, among other things, that we overstated RYTELO's commercial potential by making materially false and misleading statements and/or concealing material adverse facts concerning RYTELO's commercial potential, including the lack of awareness among healthcare providers for RYTELO, the burden of monitoring requirements in administering the drug, and the impacts of seasonality and existing competition on RYTELO's sales, and that our stock price dropped when we disclosed in our earnings call on February 26, 2025 that we had observed flat revenue trends over the prior few months. The plaintiffs seek damages and interest, and an award of reasonable costs, including attorneys' and experts' fees. On May 29, 2025, the Court consolidated the Dabestani and Potvin cases into one consolidated action captioned </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Geron Corporation Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, or the Securities Class Action, and appointed lead plaintiffs and counsel for lead plaintiffs. On August 8, 2025, lead plaintiffs filed a consolidated amended complaint. On October 7, 2025, we filed our motion to dismiss the consolidated amended complaint.  A hearing on the motion to dismiss was held on March 19, 2026, and on March 30, 2026, the Court entered an order granting our motion to dismiss without prejudice. On April 13, 2026, lead plaintiffs filed a second amended complaint. We intend to move to dismiss the second amended complaint.   </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on April 15, 2025 and April 16, 2025, <ix:nonFraction unitRef="lawsuit" contextRef="c-144" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="f-605">three</ix:nonFraction> purported stockholders filed derivative complaints, each filed in the United States District Court for the Northern District of California, captioned </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bishop v. Scarlett, et al.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, No. 3:25-cv-03356,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Lerner v. Scarlett, et al.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, No. 3:25-cv-03401, and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Willis v. Scarlett, et al.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, No: 3:25-cv-03396, respectively. The <ix:nonFraction unitRef="lawsuit" contextRef="c-144" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="f-606">three</ix:nonFraction> lawsuits name certain of our current and former directors and officers and allege that they breached their fiduciary duties and violated federal securities laws by issuing allegedly false and misleading statements concerning the commercial potential of RYTELO. The allegations in each of the <ix:nonFraction unitRef="lawsuit" contextRef="c-144" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="f-607">three</ix:nonFraction> derivative complaints are substantially similar to the Securities Class Action. The plaintiff seeks damages and interest, and an award of reasonable costs, including attorneys' and experts' fees. The plaintiffs in </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bishop v. Scarlett, et al. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Willis v. Scarlett, et al.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> also seek punitive damages. On May 16, 2025, the Court consolidated the <ix:nonFraction unitRef="lawsuit" contextRef="c-144" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="f-608">three</ix:nonFraction> derivative complaints into <ix:nonFraction unitRef="lawsuit" contextRef="c-145" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="f-609">one</ix:nonFraction> consolidated action captioned </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Geron Corporation Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, or the Consolidated Derivative Action.  On June 17, 2025, the Court stayed the Consolidated Derivative Action pending a final ruling on the anticipated motion to dismiss in the Securities Class Action.</span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 29, 2025, a purported stockholder made a demand on our board of directors to commence a civil action against certain of our current and former directors for breaching their fiduciary duties and violating the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GERON CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="f-603-2" continuedAt="f-603-3"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">securities laws by issuing allegedly false and misleading statements concerning the commercial potential of RYTELO.  On September 19, 2025, the board of directors responded that it would defer a final decision on the demand given the other pending derivative lawsuits and the Securities Class Action.  On October 7, 2025, the purported stockholder filed a suit in the United States District Court for the Northern District of California, captioned </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jae Hyung v. Bir, et al.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, No. 3:25-cv-08575.  The derivative lawsuit names certain of our current and former directors and officers. The allegations in the derivative lawsuit are substantially similar to the Securities Class Action and the Consolidated Derivative Action.  The plaintiff seeks damages and an award of reasonable costs, including attorneys&#8217; and experts&#8217; fees. On January 23 and February 19, 2026, respectively, <ix:nonFraction unitRef="action" contextRef="c-146" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="f-610">two</ix:nonFraction> additional purported stockholders each made a similar demand on our board of directors. On March 25, 2026, the board of directors similarly responded that it would defer a final decision on the demands given the other pending derivative lawsuits and the Securities Class Action.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that additional lawsuits will be filed or allegations made by stockholders with respect to these same or other matters and also naming us and/or our officers and directors as defendants. We intend to vigorously defend against the claims brought by the plaintiffs in these matters.    </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Such lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. The outcome of the pending lawsuits and any other related lawsuits is necessarily uncertain.  We could be forced to expend significant resources and may incur substantial legal fees and costs in defending against the pending lawsuits and any other related lawsuits, and we may not prevail. Monitoring, initiating and defending against legal actions is time-consuming for our management, is likely to be expensive, and may detract from our ability to fully focus our internal resources on our business activities.  Additionally, we may not be successful in having any such lawsuits dismissed or settled within the limits of our insurance coverage. Given the early stage of these lawsuits and the inherent uncertainly of litigation, we cannot predict how long it may take to resolve the pending lawsuits or the potential outcome or possible amount of any damages. As such, we currently are unable to reasonably estimate the possible losses or a range of possible losses that may result from these matters, if any. Expenses associated with the pending lawsuits and any potential related lawsuits could be material to our consolidated financial statements if we do not prevail in the defense of such lawsuits, or even if we do prevail. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Indemnifications to Officers and Directors</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate bylaws require that we indemnify our directors, as well as those who act as directors and officers of other entities at our request, against expenses, judgments, fines, settlements and other amounts actually and reasonably incurred in connection with any proceedings arising out of their services to Geron. In addition, we have entered into separate indemnification agreements with each of our directors and officers which provide for indemnification of these directors and officers under similar circumstances and under additional circumstances. The indemnification obligations are more fully described in our bylaws and the indemnification agreements. We purchase standard insurance to cover claims or a portion of the claims made against our directors and officers. Since a maximum obligation is not explicitly stated in our bylaws or in our indemnification agreements and will depend on the facts and circumstances that arise out of any future claims, the overall maximum amount of the obligations cannot be reasonably estimated.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Severance Plan</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We maintain <ix:nonFraction unitRef="plan" contextRef="c-1" decimals="INF" name="gern:NumberOfSeverancePlan" format="ixt-sec:numwordsen" scale="0" id="f-611">two</ix:nonFraction> severance plans: one applied to (i) employees hired on or before December 31, 2021, and (ii) employees at the Senior Vice President level and above (i.e., executives), and the other applies to non&#8209;executive employees hired on or after January 1, 2022. The plans provide severance benefits upon qualifying terminations, including enhanced benefits in connection with a change of control. As of March&#160;31, 2026, all executive officers have employment agreements with severance provisions and will receive the greater of the severance benefits provided under their agreements or the applicable plan (without duplication).</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GERON CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="f-603-3"><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2025, we implemented a workforce reduction, representing approximately one-third of our workforce prior to the reduction in headcount. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See Note 11 on Restructuring for additional information.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have engaged third&#8209;party contract manufacturers to manufacture and supply additional quantities of RYTELO that meet applicable regulatory standards for current and potential future clinical trials and commercial uses. Related to those contract manufacturing agreements, we have binding commercial purchase commitments of approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:RecordedUnconditionalPurchaseObligation" scale="6" id="f-612">15.9</ix:nonFraction> million that can be cancelled, but would incur cancellation penalties, and approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:LongTermPurchaseCommitmentAmount" scale="6" id="f-613">37.7</ix:nonFraction> million in agreed upon manufacturing commitments that can be adjusted based on commercial demand of RYTELO as of March 31, 2026. Based on current plans and information available, the related commercial purchase commitments are intended to be utilized.</span></div><div style="margin-bottom:18pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we enter into agreements with CROs for clinical trials for clinical and commercial supply manufacturing and with other vendors for non-clinical research studies, investigator-led trials and other services and products for operating purposes. We have not considered these payments to be contractual obligations since the contracts are generally cancellable at any time by us upon less than <ix:nonNumeric contextRef="c-1" name="gern:PurchaseObligationWrittenNoticeTerm" format="ixt-sec:durday" id="f-614">180</ix:nonNumeric> days&#8217; prior written notice. We also have certain in-license agreements that require us to pay milestones to such third parties upon achievement of certain development, regulatory or commercial milestones. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval and commercial milestones, which may not be achieved.</span></div></ix:continuation><div id="idd6aca193f774d62ad71a733a1085238_482"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-617" continuedAt="f-617-1" escape="true">NET LOSS PER COMMON SHARE</ix:nonNumeric></span></div><ix:continuation id="f-617-1"><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of shares of common stock outstanding for the periods presented without consideration of potential common shares.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net income per share would be calculated by adjusting the weighted-average number of shares of common stock outstanding for the dilutive effect of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued, as determined using the treasury-stock method. Potential dilutive securities consist of outstanding stock options and warrants to purchase our common stock. Diluted net loss per share excludes potential dilutive securities for all periods presented as their effect would be anti-dilutive. Accordingly, basic and diluted net loss per share is the same for all periods presented in the accompanying condensed consolidated statements of operations. Since we incurred a net loss for the three months ended March 31, 2026 and 2025, the diluted net loss per share calculation excludes potential dilutive securities of <ix:nonFraction unitRef="shares" contextRef="c-149" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-618">91,845,095</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-150" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-619">80,776,089</ix:nonFraction>, respectively, related to outstanding stock options and warrants as their effect would have been anti-dilutive.</span></div></ix:continuation><div id="idd6aca193f774d62ad71a733a1085238_64"></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-620" continuedAt="f-620-1" escape="true">SEGMENT REPORTING</ix:nonNumeric></span></div><ix:continuation id="f-620-1" continuedAt="f-620-2"><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are currently developing therapies for the treatment of hematologic malignancies. To date, our main source of product revenue has been from U.S. sales of RYTELO, which began shipping to customers in June 2024. Additionally, we have generated insignificant royalty and license fee revenue under agreements that out-license technology to various companies.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-621"><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-622"><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-623"><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-624">one</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> operating and reportable segment. We define our operating segment based on internally reported financial information that is regularly reviewed by the Chief Operating Decision Maker, or CODM, to analyze financial performance, make decisions, and allocate resources. Our President and Chief Executive Officer is the CODM. </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The CODM reviews the segment's profit or loss based on net (loss) income reported on the consolidated statement of operations and comprehensive (loss) income and considers forecast-to-actuals variances on a quarterly basis for expenses that are deemed significant. Further, the CODM reviews the segment's assets based on total assets reported on the condensed consolidated balance sheet. All long-lived assets are held in the U.S.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GERON CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="f-620-2"><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our CODM views specific categories within research and development expenses and selling, general and administrative expenses as significant given the correlation between cash burn and profitability.  <ix:nonNumeric contextRef="c-1" name="us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" id="f-625" continuedAt="f-625-1" escape="true">The following table reconciles reported revenues to net (loss) income under the significant expense principle for the three months ended March 31, 2026 and 2025:</ix:nonNumeric></span></div><ix:continuation id="f-625-1"><div style="margin-bottom:12pt;text-align:center;text-indent:64.8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.727%"><tr><td style="width:1.0%"/><td style="width:61.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.579%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.030%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-626">51.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-627">39.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-628">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-629">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-630">51.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-631">39.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:OperatingCostsAndExpenses" scale="6" id="f-632">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:OperatingCostsAndExpenses" scale="6" id="f-633">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and clinical expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-634">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-635">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chemistry, manufacturing, and control expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-636">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-637">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-638">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-639">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-640">17.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-641">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-642">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-643">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other segment expenses*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-644">19.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-645">19.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total interest and other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="f-646">3.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="f-647">3.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-648">3.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-649">19.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*Other segment expenses includes stock-based compensation expense and other general and administrative expenses largely resulting from personnel costs for individuals in administrative functions and legal and professional fees.</span></div></ix:continuation></ix:continuation><div id="idd6aca193f774d62ad71a733a1085238_2199023255983"></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-650" continuedAt="f-650-1" escape="true">RESTRUCTURING</ix:nonNumeric></span></div><ix:continuation id="f-650-1"><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2025, the board of directors approved a workforce reduction representing approximately one-third of our workforce prior to the reduction in headcount. In 2025, we incurred approximately $<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="f-651">17.0</ix:nonFraction>&#160;million in restructuring and restructuring-related charges, primarily consisting of one-time employee severance payments, healthcare and related benefits, and other employee-related costs. The charges were recorded within restructuring charges in the consolidated statements of operations. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The workforce reduction was substantially completed in the first quarter of 2026. There were <ix:nonFraction unitRef="usd" contextRef="c-9" decimals="INF" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="f-652">no</ix:nonFraction> restructuring charges during the three months ended March 31, 2025.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="f-653" escape="true"><div style="margin-bottom:12pt;text-align:center;text-indent:64.8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.606%"><tr><td style="width:1.0%"/><td style="width:68.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.150%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Restructuring</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of December 31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="f-654">17,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expenses and adjustments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:RestructuringCharges" scale="3" id="f-655">394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="f-656">13,532</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of March 31, 2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="f-657">3,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="idd6aca193f774d62ad71a733a1085238_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div id="idd6aca193f774d62ad71a733a1085238_73"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:18pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This Report contains forward-looking statements that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. In some cases, forward-looking statements can be identified by the use of terminology such as &#8220;may,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;projects,&#8221; &#8220;believes,&#8221; &#8220;predicts,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; or the negative thereof or other comparable terminology. These statements are within the meaning of the &#8220;safe harbor&#8221; provisions of the Private Securities Litigation Reform Act of 1995. These statements appear throughout this Report and are statements regarding our intent, belief, or current expectations, primarily with respect to our business and related industry developments. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Report. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including the risks faced by us and described in Part II, Item 1A, titled &#8220;Risk Factors,&#8221; and in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Part I, Item 2 of this Report. </span></div><div id="idd6aca193f774d62ad71a733a1085238_76"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-bottom:18pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto included in Part I, Item 1 of this Report; and the sections titled &#8220;Business&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contained in our Form 10-K for the year ended December&#160;31, 2025 as filed with the SEC on March 2, 2026, or the 2025 Form 10-K. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Company Overview </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor, RYTELO</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (imetelstat), harnesses Nobel Prize-winning science in a treatment that scientific evidence suggests reduces proliferation of malignant cells, allowing production of new healthy cells, which we believe drives differentiated clinical benefits, potentially altering the underlying course and modifying the disease of these hematologic malignancies. </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We commercially launched RYTELO in the U.S. in June 2024 following its approval by the U.S. Food and Drug Administration, or FDA, on June 6, 2024 for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes, or lower-risk MDS, with transfusion-dependent, or TD, anemia requiring four or more red blood cell units over eight weeks who have not responded to, or have lost response to, or are ineligible for, erythropoiesis-stimulating agents, or ESAs. Lower-risk MDS is a progressive blood cancer with high unmet need, where many patients with anemia become dependent on red blood cell transfusions, which can be associated with clinical consequences and decreased quality of life. We believe that the high unmet need in lower-risk MDS and significant product differentiation, including observed benefit, of RYTELO in difficult-to-treat sub-populations such as patients with high transfusion burden and ring sideroblast negative, or RS- patients, as well as the favorable FDA label and the National Comprehensive Cancer Network, or NCCN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, Clinical Practice Guidelines in Oncology, or NCCN Guidelines&#174;, position RYTELO to potentially compete for significant market segments in lower-risk MDS, including second-line ESA ineligible patients regardless of prior treatment or RS status and first-line ESA ineligible patients.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In March 2025, we were granted marketing authorization by the European Commission, or EC, for RYTELO as a monotherapy for the treatment of adult patients with TD anemia due to very low, low or intermediate risk myelodysplastic syndromes without an isolated deletion 5q cytogenetic, or non-del 5q, abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are preparing for the planned commercialization of RYTELO in select EU markets in 2026. At this time, we are working with experienced third parties for the commercialization and marketing of RYTELO in the EU, including on critical path activities for the planned launch of RYTELO in the EU, such as reimbursement, Health Technology Assessment, or HTA, submissions, market access and distribution. To enable paid access to patients outside the U.S. through approved Named Patient Programs, or NPPs, in 2025, we partnered with Tanner Pharma, a distributor with broad global reach to support patient access.  To date, product revenue pursuant to NPPs have been minimal.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to lower-risk MDS, we are developing imetelstat for the treatment of other myeloid hematologic malignancies. Our Phase 3 IMpactMF clinical trial is evaluating imetelstat in patients with intermediate-2 or high-risk myelofibrosis, or MF, who have relapsed after or are refractory to treatment with a janus associate kinase inhibitor, or JAK inhibitor, or relapsed/refractory MF with overall survival, or OS, as the primary end</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">point. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September 2025, the trial was fully enrolled. Based on our current planning assumptions for event (death) rates in the trial, we expect the interim analysis for OS in IMpactMF may occur in the second half of 2026 and the final analysis may occur in the second half of 2028.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe that telomerase inhibition with imetelstat represents a novel mechanism of action with unique benefits in hematologic malignancies and potentially in other tumor types. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have primarily financed our operations through the sale of equity securities, draw downs on our debt facilities, cash generated from sales of RYTELO, interest income on our marketable securities, payments we received under the Royalty Pharma Agreement and our prior collaborative and licensing arrangements. As of March&#160;31, 2026, we had approximately $341.0 million in cash, cash equivalents, restricted cash and marketable securities. </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We began commercializing RYTELO in June 2024, and the commercial potential of and our ability to successfully commercialize RYTELO remains unproven. Our success in commercializing RYTELO will require, among other things, effective sales, marketing, manufacturing, distribution, information systems and pricing strategies, as well as compliance with applicable laws and regulations. Prior to our commercialization of RYTELO, substantially all of our revenues were generated from payments under prior collaboration agreements, and milestones, royalties and other revenues from our licensing arrangements. We reported a small profit for the year ended December 31, 2015, and we have not reported any profit since. We have incurred significant net losses since our inception in 1990, resulting principally from costs incurred in connection with our research and development activities and from general and administrative costs associated with our operations. As of March&#160;31, 2026, we had an accumulated deficit of approximately $1.9 billion. </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2024, we entered into a loan agreement, or the Pharmakon Loan Agreement, with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership, which are investment funds managed by Pharmakon Advisors, LP, and BioPharma Credit PLC, as collateral agent, that provides for a 5-year senior secured term loan facility of up to $250.0 million, divided into three committed tranches: (i) a $125.0 million Tranche A Loan, which was funded on November 1, 2024; (ii) a $75.0 million Tranche B Loan, which is available subject to certain limited conditions, at our option; and (iii) a $50.0 million Tranche C Loan, which is available to us upon reaching a specified trailing twelve-month RYTELO revenue milestone, and together with the Tranche A Loan and the Tranche B Loan, collectively, the Term Loans. On January 5, 2026, the Pharmakon Loan Agreement was amended to extend the date for requesting the Tranche B Loan and Tranche C Loan, once available, from December 31, 2025 to July 30, 2026. The amendment also extended the date before which any Term Loan prepayment is subject to a make&#8209;whole premium, or  the Makewhole Date, from November 1, 2026 to May 1, 2027. See <a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd6aca193f774d62ad71a733a1085238_52">Note </a>7 on Debt in Notes to Condensed Consolidated Financial Statements of this Report for additional information on the Pharmakon Loan Agreement.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2024, we entered into a revenue participation right purchase and sale agreement, or the Royalty Pharma Agreement, with Royalty Pharma Development Funding, LLC, or Royalty Pharma. Pursuant to the Royalty Pharma Agreement, we received an upfront payment of $125.0 million, or the Purchase Price, in exchange for which Royalty Pharma obtained the right to receive tiered royalty payments with respect to annual U.S. net sales, or Annual Net Sales, of RYTELO beginning on July 1, 2024, ranging from: (i) 7.75% of Annual Net Sales up to $500.0 million; (ii) 3.0% of Annual Net Sales in excess of $500.0 million but less than or equal to $1.0 billion; and (iii) 1.0% in respect of Annual Net Sales in excess of $1.0 billion, or the Royalty Payments. The Royalty Payments to Royalty Pharma are capped, such that they will cease upon reaching a multiple of 1.65 times the Purchase Price if Royalty Pharma receives Royalty Payments in that amount in respect of net sales occurring on or before June 30, 2031, or upon reaching a multiple of 2.0 times the Purchase Price thereafter. Our Royalty Payment obligations under the Royalty Pharma Agreement may be discharged in connection with a change of control of Geron in an amount equal to 1.65 times the Purchase Price minus the aggregate Royalty Payments received by Royalty Pharma as of the date of the closing of the change of control, if the closing of the change of control occurs on or prior to December 31, 2027, or in an amount equal to 2.0 times the Purchase Price minus the aggregate Royalty Payments received by Royalty Pharma as of the date of the closing of the change of control, if the closing of the change of control occurs after December 31, 2027. There are no other royalties payable on RYTELO, which was developed internally and is exclusively owned by Geron.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2025, we implemented a workforce reduction, representing approximately one-third of our workforce prior to the reduction in headcount. We recorded approximately $17.0 million in restructuring and restructuring-related charges in the fourth quarter of 2025, primarily consisting of one-time employee severance payments, healthcare and related benefits, and other employee-related costs. The workforce reduction was substantially completed in the first quarter of 2026. If we are unable to realize the expected operational efficiencies and cost savings from the restructuring, our operating results and financial condition could be adversely affected.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The significance of future losses, future revenues and any potential future profitability will depend primarily on the clinical and commercial success of RYTELO, our sole product. In this regard, our ability to generate meaningful revenue from product sales and achieve profitability is wholly dependent on our ability to successfully commercialize RYTELO in the U.S. for lower-risk MDS or to expand its indications of use. We have seen and may continue to see variability in RYTELO sales trends. </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial strategy is designed to ensure that RYTELO reaches eligible patients when they are most likely to benefit. Our commercial execution is focused on targeted engagement with high-volume accounts that treat earlier-line patients, investment in non-personal promotion and third-party education to further consistent, high-quality messaging across multiple touchpoints, and cross-functional execution of effective account management. However, our strategy to drive sales growth and our ongoing commercialization efforts has not to date achieved and may not in the future achieve meaningful sales growth, which may require us to, among others, further adjust or amend our commercialization strategy and plans and incur significant expenses, and there can be no assurance that we will be able to grow RYTELO net product revenue in future periods. In particular, our strategy may not drive new patient starts across the breadth of the eligible patient population in RYTELO's approved indication, particularly across appropriate second-line patients in RYTELO's approved indication, in a timely manner or at all, or the duration of therapy could be shorter than we expect, each of which would limit RYTELO&#8217;s growth potential and could preclude or delay our ability to generate meaningful revenue from product sales and to achieve profitability. </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in an effort to expand its indications of use, we are also developing RYTELO for the treatment of several myeloid hematologic malignancies that will continue to require additional time and significant investment in clinical trials to complete. We also expect to continue to seek regulatory approvals of RYTELO in jurisdictions outside of the U.S., such as our recent marketing authorization in the EU, and to establish arrangements with third parties to assist us in the commercialization of RYTELO in such jurisdictions. As a result, we expect research and development expenses and selling, general and administrative expenses to continue to be substantial as we continue to support the commercialization of RYTELO in the U.S. and further development of RYTELO, including the conduct and completion of our IMpactMF Phase 3 clinical trial, as well as our ongoing Phase 1 IMproveMF combination clinical trial in frontline MF, our Phase 2 investigator-led IMpress clinical trial in higher-risk MDS and acute myeloid leukemia, and our Phase 1/2 investigator-led IMAGINE clinical trial in relapsed/refractory acute myeloid leukemia, and as we pursue paths to make RYTELO available to eligible LR-MDS patients outside of the U.S., including in the EU. </span></div><div style="text-indent:64.8pt"><span><br/></span></div><div id="idd6aca193f774d62ad71a733a1085238_79"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND ESTIMATES</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</span></div><div style="margin-bottom:18pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Estimates and assumptions about future events and their effects cannot be determined with certainty. We base our estimates on historical experience and on various other assumptions believed to be applicable and reasonable under the circumstances. These estimates may change as new events occur, as additional information is obtained and as our operating environment changes. These changes historically have been minor and have been included in the condensed consolidated financial statements as soon as they became known. Based on a critical assessment of our accounting policies and the underlying judgments and uncertainties affecting the application of those policies, management believes that our condensed consolidated financial statements are fairly stated in accordance with accounting principles generally accepted in the U.S., and present a meaningful presentation of our financial condition and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A critical accounting policy is one that is both important to the portrayal of our financial condition and results of operations and requires management&#8217;s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting policies are described in Item 7, &#8220;Critical Accounting Policies and Estimates&#8221; in our 2025 Form 10-K. There have been no significant changes in our critical accounting policies and estimates during the three months ended March 31, 2026, as compared to the critical accounting policies and estimates disclosed in our 2025 Form 10-K.</span></div><div id="idd6aca193f774d62ad71a733a1085238_82"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations have fluctuated from period to period and may continue to fluctuate in the future. Results of operations for any period may be unrelated to results of operations for any other period. Thus, historical results should not be viewed as indicative of future operating results. In this regard, although we have begun to recognize revenue from RYTELO product sales in the U.S., we are early in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our commercialization efforts and our related strategy to drive sales growth in the U.S. We expect that our sales revenue may continue to vary from period to period as a result of the evolving effects of our commercialization strategy and as our commercialization efforts otherwise progress.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">RYTELO is our only product approved for marketing in the U.S. and in the EU for certain patients with lower-risk MDS. Revenue based on sales of RYTELO is dependent on our ability to successfully commercialize RYTELO in the U.S. and the EU and to obtain regulatory approvals to commercialize RYTELO in other jurisdictions and in other indications. We are subject to risks common to companies in our industry and at our stage of development, including, but not limited to, risks inherent in the development, manufacture, regulatory approval for and commercialization of RYTELO; uncertainty of non-clinical and clinical trial results or regulatory approvals or clearances; the future development of imetelstat by us and its use by patients generally, including any future efficacy or safety results from clinical or commercial use that may cause the benefit-risk profile of imetelstat to become unacceptable; the uncertain and unpredictable drug research and development process; our ability to obtain and maintain contractual arrangements, strategic partnerships, collaborations, alliances or licensing arrangements with third parties to assist us with the commercialization of RYTELO in jurisdictions outside of the U.S.; overcoming disruptions and/or delays due to macroeconomic or other global conditions, such as further changes in tariffs and other trade restrictions, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">renegotiation of existing international trade agreements or further escalation of trade tensions, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">inflation, fluctuations in interest rates, prospects of a recession, government shutdowns, bank failures and other disruptions to financial systems, civil or political unrest, military conflicts, pandemics or other health crises and supply chain and resource issues; our ability to obtain additional capital if and when needed; enforcement of our patent and proprietary rights; reliance upon our CROs, contract manufacturing organizations, or CMOs, consultants, licensees, investigators and other third parties; and potential competition. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended March 31:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.295%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Change $</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Change %</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands, except for percentage data) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Product revenue, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">51,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">39,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">12,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">51,837&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">39,603&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">12,234&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Costs and operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Cost of goods sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">14,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">15,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">35,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">40,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(4,598)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Restructuring charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(394)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(394)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Total costs and operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">51,679&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">56,307&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(4,628)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Income (loss) from operations</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(16,704)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">16,862&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(101)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">3,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">5,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1,731)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(7,147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(8,200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">1,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Other income (expense), net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(74)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(3,642)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(19,835)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">16,193&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(82)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:18pt;padding-left:10.08pt;text-indent:7.91pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Revenues:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue, Net</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2024, we announced that the FDA approved RYTELO for the treatment of adult patients with lower-risk MDS, with TD anemia requiring four or more red blood cell units over eight weeks who have not responded to, or have lost response to, or are ineligible for ESA. To date, our only source of product revenue has been from the sales of RYTELO, which we began shipping to our customers in the U.S. in June 2024. </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total product revenue, net for the three months ended March&#160;31, 2026 and 2025 were approximately $51.8 million and $39.4 million, respectively. Product revenue, net, increased by $12.4 million during the three months ended March 31, 2026, compared to the same period in 2025, primarily due to increased sales volumes and, to a lesser extent, a higher selling price, partially offset by higher gross-to-net adjustments. The increase in sales volume was primarily driven by a higher number of patients on therapy.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total gross-to-net adjustments for the three months ended March&#160;31, 2026 and 2025 were 20.8% and 13.0% of gross product revenue, respectively. The increase in gross-to-net adjustments was driven by a greater proportion of sales made under governmental managed-care pricing programs and group purchasing organizations in addition to greater volume of product returns. We expect total gross-to-net adjustments to be in the percentage range of low to mid-twenties of gross product revenue in the remaining quarters of 2026.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of gross product revenue to product revenue, net by each significant category of gross-to-net adjustments is set forth below:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center;text-indent:64.8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.212%"><tr><td style="width:1.0%"/><td style="width:59.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.715%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">65,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45,312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Gross-to-net adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chargebacks</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(8,164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,171)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Distributor service fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,526)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Government rebates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,658)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Sales returns and allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,591)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total gross-to-net adjustments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,582)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(5,876)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">51,771&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">39,436&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the divestiture of our human embryonic stem cell assets, including intellectual property and proprietary technology, to Lineage Cell Therapeutics, Inc. (formerly BioTime, Inc., which acquired Asterias Biotherapeutics, Inc.), or Lineage, in 2013, we are entitled to receive royalties on sales from certain research or commercial products utilizing our divested intellectual property. </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We recognized royalty revenues of less than $0.1 million in the three months ended March&#160;31, 2026, compared to $0.2 million for the same period in 2025. Royalty revenues in the three months ended March&#160;31, 2026 and 2025 primarily reflect estimated royalties from sales of cell-based research products from our divested stem cell assets.</span></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Future license fee and royalty revenues are dependent on additional agreements being signed, if any, our current license agreement with Lineage being maintained and the underlying patent rights for the license remaining active. </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Costs and Operating Expenses:</span></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes our costs and operating expenses:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.757%"><tr><td style="width:1.0%"/><td style="width:36.083%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.591%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.834%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Change % </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,692&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,206&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">40&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">35,425&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">40,023&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(11)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total costs and operating expenses</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">51,679&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">56,307&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:18pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold was approximately $1.7 million and $1.2 million for the three months ended March&#160;31, 2026 and 2025, respectively, which consists of raw materials, third-party manufacturing costs to manufacture the raw materials into finished product, freight, and indirect overhead costs associated with the sale of RYTELO. </span></div><div style="margin-bottom:18pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to receiving FDA approval for RYTELO in June 2024, we manufactured inventory to be sold upon commercialization and recorded the costs as research and development expense. As a result, a significant portion of the manufacturing costs related to the inventory manufactured prior to receiving FDA approval was partially expensed in a prior period and is therefore excluded from the cost of goods sold for the three months ended March&#160;31, 2026 and 2025. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We estimate our cost of sales as a percentage of product revenue, net will continue to be positively impacted for at least the next 12 months as we sell through certain inventory that was partially expensed prior to FDA approval.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2026 and 2025, our RYTELO (imetelstat) program and our research discovery program related to potential next generation telomerase inhibitors were the only research and development programs we supported. For these research and development programs, we incur direct external, personnel-related and other research and development costs. For the three months ended March&#160;31, 2026 and 2025, research and development expenses consist of expenses incurred in developing and testing imetelstat and research related to potential next generation telomerase inhibitors. These expenses include, but are not limited to, payroll and personnel expense, lab supplies, non-clinical studies, clinical trials, including support for investigator-led clinical trials, raw materials to manufacture clinical trial supply, manufacturing costs for research and clinical trial materials, sponsored research at other labs, consulting expenses, costs to maintain technology licenses and research-related overhead. </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses were as follows: </span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.060%"><tr><td style="width:1.0%"/><td style="width:56.868%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.420%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Direct external research and development expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Clinical program: imetelstat</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Personnel-related expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All other expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,956&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,078&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in research and development expenses for the three months ended March&#160;31, 2026, compared to the same period in 2025,  was primarily due a decrease in personnel-related costs due to lower labor costs driven by a decrease in headcount as a result of the workforce reduction in December 2025, partially offset by higher clinical trial costs associated with an increase of activity in our IMpactMF study. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses were $35.4 million for the three months ended March&#160;31, 2026, compared to $40.0 million for the same period in 2025. The decrease in selling, general and administrative expenses for the three months ended March&#160;31, 2026, compared to the same period in 2025, was primarily due to lower general and administrative personnel-related expenses from decreased headcount, partially offset by additional investment in marketing programs of approximately $1.8 million and approximately $1.0 million higher legal expenses.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring Charges</span></div><div style="margin-bottom:18pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2025, we implemented a workforce reduction, representing approximately one-third of our workforce prior to the reduction in headcount and recorded restructuring charges of $17.0 million. Restructuring charges consisted of termination benefits such as one-time employee severance payments, healthcare and related benefits, and other employee-related costs. </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2026, a credit of $0.4 million in restructuring charges was recognized, primarily due to lower&#8209;than&#8209;expected utilization of previously accrued amounts related to healthcare and related benefits. The credit was recorded in the condensed consolidated statement of operations as restructuring charges. </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The workforce reduction was substantially completed in the first quarter of 2026. There were no restructuring charges during the three months ended March 31, 2025.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-bottom:18pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income was $3.4 million for the three months ended March&#160;31, 2026, compared to $5.2 million for the same period in 2025. The decrease in interest income for the three months ended March&#160;31, 2026, compared to the same period in 2025, primarily reflects a decrease in interest rates between the periods and a smaller marketable securities </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">portfolio. Interest earned in future periods will depend on the size of our marketable securities portfolio and prevailing interest rates. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was $7.1 million for the three months ended March&#160;31, 2026, compared to $8.2 million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for the same period in 2025. The decrease in interest expense for the three months ended March&#160;31, 2026, compared to the same period in 2025, was primarily due to lower average interest rates related to the Royalty Pharma Agreement and the Pharmakon Loan Agreement, which were entered into in November 2024. See Note 7 on Debt in Notes to Condensed Consolidated Financial Statements of this Report for additional information.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-bottom:18pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net was an expense of $0.1 million for each of the three months ended March&#160;31, 2026 and 2025. Other income (expense), net primarily reflects realized losses on marketable securities and foreign currency transaction adjustments.</span></div><div id="idd6aca193f774d62ad71a733a1085238_85"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026, we had cash, restricted cash, cash equivalents, and marketable securities of $341.0 million, compared to $401.1 million at December&#160;31, 2025. The decrease in cash, restricted cash, cash equivalents and marketable securities during the three months ended March&#160;31, 2026 was primarily the net result of cash used in operations partially offset by the receipt of net cash proceeds from accounts receivable.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2024, we entered into the Pharmakon Loan Agreement. We drew the Tranche A Loan of $125.0 million on November 1, 2024, a portion of which was utilized to repay all outstanding indebtedness associated with the Hercules Loan Agreement. The Pharmakon Loan Agreement provides two additional committed term loan tranches, the Tranche B Loan and the Tranche C Loan, in principal amounts of $75.0 million and $50.0 million, respectively, subject to customary conditions to fund and, in the case of the Tranche C Loan, achieving certain minimum net sales milestone. The Tranche B Loan and the Tranche C Loan could have been requested on or prior to December 31, 2025. The Term Loans mature on November 1, 2029. The Term Loans bear interest at a variable rate per annum equal to 5.75% plus three-month SOFR with a SOFR floor of 3.00%. On January 5, 2026, the Pharmakon Loan Agreement was amended to extend the date for requesting the Tranche B Loan and Tranche C Loan, once available, from December 31, 2025 to July 30, 2026. The amendment also extended the Makewhole Date from November 1, 2026 to May 1, 2027. See Note 7 on Debt in Notes to Condensed Consolidated Financial Statements of this Report for additional information on the Pharmakon Loan Agreement.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2024, we entered into the Royalty Pharma Agreement with Royalty Pharma. Pursuant to the Royalty Pharma Agreement, we received $125.0 million, or the Purchase Price, in exchange for which Royalty Pharma obtained the right to receive the Royalty Payments. The Royalty Payments to Royalty Pharma are capped, such that they will cease upon reaching a multiple of 1.65 times the Purchase Price if Royalty Pharma receives Royalty Payments in that amount in respect of net sales occurring on or before June 30, 2031, or upon reaching a multiple of 2.0 times the Purchase Price thereafter. There are no other royalties payable on RYTELO, which was developed internally and is exclusively owned by Geron. See Note 7 on Debt in Notes to Condensed Consolidated Financial Statements of this Report for additional information on the Royalty Pharma Agreement.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2023, we entered into an At Market Issuance Sales Agreement, or the 2023 Sales Agreement, with B. Riley Securities, pursuant to which we could have elected to issue and sell shares of our common stock having an aggregate offering price of up to $100.0 million in such quantities and on such minimum price terms as we set from time to time through B. Riley Securities as our sales agent. We have agreed to pay B. Riley Securities an aggregate commission equal to up to 3.0% of the gross proceeds of the sales under the agreement. No sales of common stock occurred under the 2023 Sales Agreement, which was terminated in January 2026.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2026, we entered into a sales agreement, or the 2026 Sales Agreement, with TD Securities (USA) LLC, or TD Cowen, pursuant to which we may issue and sell shares of our common stock having an aggregate offering price of up to $150 million from time to time through TD Cowen as the sales agent. We will pay TD Cowen an aggregate commission rate equal to up to 2.5% of the gross proceeds of the sales price per share for common stock sold through TD Cowen under the 2026 Sales Agreement. We are not obligated to make any sales of common stock under the 2026 Sales Agreement. To date, no sales of common stock have occurred under the 2026 Sales Agreement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We have an investment policy to invest our cash in liquid, investment grade securities, such as interest-bearing money market funds, certificates of deposit, U.S. Treasury securities, municipal securities, government and agency securities, commercial paper and corporate notes. Our investment portfolio does not contain securities with exposure to sub-prime mortgages, collateralized debt obligations, asset-backed securities or auction rate securities and, to date, we have not recognized any other-than-temporary impairment charges on our marketable securities or any significant changes in aggregate fair value that would impact our cash resources or liquidity. To date, we have not experienced lack of access to our invested cash and cash equivalents; however, access to our invested cash and cash equivalents may be impacted by adverse conditions in the financial and credit markets.</span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Financing Strategy </span></div><div style="margin-bottom:18pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may, from time to time, consider additional funding through a combination of new collaborative arrangements, strategic alliances, and additional equity and debt financings or from other sources. We will continue to manage our capital structure and consider all financing opportunities, whenever they may occur, that could strengthen our long-term liquidity profile. Any such capital transactions may or may not be similar to transactions in which we have engaged in the past. There can be no assurance that any such financing opportunities will be available on acceptable terms, if at all. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Successful drug development and commercialization requires significant amounts of capital. As of March&#160;31, 2026, we had approxim</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ately $341.0 mi</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">llion in cash, cash equivalents, restricted cash and marketable securit</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ies. Based on our current operating plans and assumptions, we believe that our existing cash, cash equivalents, and marketable securities, together with anticipated net revenues from sales of RYTELO, will be sufficient to fund our projected operating requirements for the foreseeable future.  However, if we do not generate net revenues from commercial sales of RYTELO at the levels we anticipate, if we experience unforeseen events or choose to make other investments in our business, or our assumptions regarding our projected operating expenses are otherwise incorrect, we may require additional funding, which could include a combination of public or private equity offerings, debt financings (including additional tranches under the Pharmakon Loan Agreement, if available), collaborations, strategic alliances, licensing arrangements or marketing and distribution arrangements, which may not be possible. For example, changes in our operations, such as increased development, manufacturing and clinical trial expenses, or our undertaking of additional programs, business activities, or entry into strategic transactions, including potential future acquisitions of products, technologies or businesses, may cause our operating expenses to increase, perhaps significantly, which could require us to raise additional funding. If adequate funds are not available to us when we need them, our RYTELO commercialization efforts may be adversely affected and we may be unable to pursue further development of imetelstat, which would severely harm our business and we might cease operations. </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> Despite receiving FDA approval of RYTEL</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">O in the U.S. in June 2024 and marketing authorization in the EU in March 2025, the outcome of any clinical activities and/or regulatory approval process is highly uncertain, and we cannot reasonably estimate whether our future development activities may succeed, whether we will obtain regulatory approval for RYTELO in any other jurisdictions or indications we are pursuing or may in the future pursue, or whether we will be able to effectively commercialize RYTELO in the U.S. or in the EU for lower-risk MDS or other potential indications, if at all. We may never recoup our investment in any RYTELO development, which would adversely affect our financial condition and our business and business prospects, and might cause us to cease operations. In addition, our plans and timing expectations could be further delayed or interrupted by the effects of macroeconomic or other global conditions, including those resulting from further changes in tariffs and other trade restrictions, renegotiation of existing international trade agreements or further escalation of trade tensions, inflation, fluctuations in interest rates, prospects of a recession, government shutdowns, bank failures and other disruptions to financial systems, civil or political unrest, military conflicts such as the ongoing Russia and Ukraine military conflict and the ongoing military conflict involving the U.S., Israel and Iran, pandemics or other health crises and supply chain and resource issues. Further, our future capital requirements ar</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">e difficult to forecast and will depend on many factors, including:</span></div><div style="margin-bottom:6pt;padding-left:126pt;text-indent:-61.2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:57.7pt">the accuracy of the assumptions underlying our estimates for our capital needs;</span></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-61.2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:57.7pt">the overall level of sales and market acceptance of RYTELO;</span></div><div style="padding-left:126pt;text-indent:-61.2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:57.7pt">the scope, progress, timing, magnitude and costs of non-clinical and clinical development, manufacturing and commercialization of RYTELO, including commercialization in the U.S. and any commercialization in the EU for lower-risk MDS, or in any other jurisdictions or other indication we may pursue, subject to clearances and approvals by the FDA and similar international regulatory authorities;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-61.2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:57.7pt">delays or disruptions in opening sites, screening and enrolling patients or treating and following patients, in our current or any potential future clinical trials of RYTELO;</span></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-61.2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:57.7pt">the costs, timing and outcomes of regulatory reviews or other regulatory actions related to RYTELO,</span></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-61.2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:57.7pt">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims;</span></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-61.2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:57.7pt">the costs of manufacturing, developing, commercializing and marketing RYTELO, including with respect to third-party vendors and service providers and our ability to achieve any meaningful reduction in manufacturing costs; </span></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-61.2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:57.7pt">the sales price for RYTELO;</span></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-61.2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:57.7pt">the availability of coverage and adequate third-party reimbursement for RYTELO;</span></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-61.2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:57.7pt">the extent to which we acquire or in-license other drugs and technologies, or invest in businesses, products or technologies, although we currently have no commitments or agreements relating to any of these types of transactions, or to which we out-license RYTELO;</span></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-61.2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:57.7pt">the extent to which we are able</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to enter into and conduct successful commercial arrangements with third parties, including for the commercialization and marketing of RYTELO in the EU and in any other regions outside of the U.S., if approved for commercialization in such other regions; </span></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-61.2pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:57.7pt">expenses associated with the pending putative securities class action and shareholder derivative lawsuits and potential additional related lawsuits, as well as any other litigation;</span></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-61.2pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:57.7pt">the extent and scope of our selling, general and administrative expenses, including expenses associated with pending and potential future litigation; </span></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-61.2pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:57.7pt">our level of indebtedness and associated debt </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">service obligations;</span></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-61.2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:57.7pt">the costs of maintaining and operating facilities in California and New Jersey, as well as higher expenses for travel; </span></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-61.2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:57.7pt">macroeconomic or other global conditions that may reduce our ability to access equity or debt capital or other financing on preferable terms, which may adversely affect future capital requirements and forecasts; and</span></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-61.2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:57.7pt">the costs of enabling our personnel to work remotely, including providing supplies, equipment and technology necessary for them to perform their responsibilities.</span></div><div><span><br/></span></div><div style="margin-bottom:18pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the event we need to raise additional capital to fund our business, including pursuant to the 2026 Sales Agreement with TD Cowen, the Tranche B Loan and the Tranche C Loan under the Pharmakon Loan Agreement, which are subject to certain funding conditions, capital lease transactions or other financing sources, such additional capital may not be available on acceptable terms, or at all. We may be unable to raise equity capital, or may be forced to do so at a stock price or on other terms that could result in substantial dilution of ownership for our stockholders. The receptivity of the public and private debt and equity markets to proposed financings has been substantially affected by uncertainty in the general economic, market and political climate due to the effects of macroeconomic or other global conditions, such as further changes in tariffs and other trade restrictions and uncertainty around further escalation of trade tensions and renegotiation of existing international trade agreements, inflation, fluctuations in interest rates, prospects of a recession, government shutdowns, bank failures and other disruptions to financial systems, civil or political unrest, military conflicts, pandemics or other health crises and supply chain and resource issues, and may in the future be affected by other factors which are unpredictable and over which we have no control. These effects have increased market volatility and could result </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in a significant long-term disruption of global financial markets, which could reduce or eliminate our ability to raise additional funds through financings, and could negatively impact the terms upon which we may raise those funds. Similarly, these macroeconomic conditions have created extreme volatility and disruption in the equity and credit markets and is expected to have further global economic consequences. For example, the ongoing Russia-Ukraine military conflict and the ongoing military conflict involving the U.S., Israel and Iran have created extreme volatility and disruption in the equity and credit markets and have had and may continue to have further global economic consequences, including continued disruptions of the global supply chain and energy markets, which could continue to drive inflationary pressures and increase global recession risk. If the equity and credit markets deteriorate, including as a result of macroeconomic or other global conditions, such as inflation, changes in interest rates, prospects of a recession, government shutdowns, further changes in tariffs and other trade restrictions, bank failures and other disruptions to financial systems, civil or political unrest, military conflicts, pandemics or other health crises and supply chain and resource issues, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. If we are unable to effectively commercialize RYTELO, or raise additional capital, if needed, or establish alternative collaborative arrangements with third-party collaborative partners for RYTELO, when needed, the development and commercialization of RYTELO may be further delayed, altered or abandoned, which might cause us to cease operations.  </span></div><div style="margin-bottom:18pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may seek additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Due to uncertainty in the general economic, market and political climate, we may determine that it is necessary or appropriate to raise additional funds proactively to meet longer-term anticipated operating plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, including pursuant to the 2026 Sales Agreement, our stockholders may be diluted, and the terms may include liquidation or other preferences that could materially and adversely affect the rights of our existing stockholders. In addition, we have borrowed, and in the future may borrow, additional capital from institutional and commercial banking sources to fund development and our future growth, including pursuant to our Pharmakon Loan Agreement or potentially pursuant to new arrangements with different lenders. We may borrow funds on terms under agreements, such as our Pharmakon Loan Agreement, that include restrictive covenants, including covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Moreover, if we raise additional funds through alliance, collaborative or licensing arrangements with third parties, we may have to relinquish valuable rights to RYTELO or our technologies or grant licenses on terms that are not favorable to us. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Cash Flows Used in Operating Activities</span></div><div style="margin-bottom:18pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operations for the three months ended March&#160;31, 2026 and 2025 was $62.9 million and $48.0 million, respectively. The increase in net cash used in operations for the three months ended March&#160;31, 2026, compared to the same period in 2025, primarily due to payments related to workforce reduction and inventory purchases.</span></div><div style="margin-bottom:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-bottom:18pt;text-indent:64.8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by i</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">nvesting activities for the three months ended March&#160;31, 2026 and 2025 was $51.9 million and $52.4 million, respectively. The decrease in net cash provided by investing activities for the three months ended March&#160;31, 2026, compared to the same period in 2025, primarily reflects decreased proceeds the sale and maturities of marketable securities, partially offset by lower purchases of marketable securities.</span></div><div style="margin-bottom:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-bottom:18pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the three months ended March&#160;31, 2026 and 2025 was $2.4 million and $0.3 million, respectively. The increase in net cash provided by financing activities primarily reflects higher proceeds from issuances of common stock under our equity plans and proceeds from the exercise of warrants.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenditures primarily consist of our obligations under commercial purchase commitments related to our manufacturing and supply agreements for RYTELO and operating leases. </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">RYTELO requires long lead times to manufacture. Therefore, we make substantial and often long-term investments in our supply chain in order to ensure we have enough drug product to meet potential future commercialization requirements, as well as clinical trial needs. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have engaged third&#8209;party contract manufacturers to manufacture and supply additional quantities of RYTELO that meet applicable regulatory standards for current and potential future clinical trials and commercial uses. Related to those contract manufacturing agreements, we have binding commercial purchase commitments of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> approxim</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ately $15.9 million that can be cancelled, but would incur cancellation penalties, and approximately $37.7 million in agreed upon manufacturing commitments that can be adjusted based on commercial demand of RYTELO. We expect to utilize all r</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">elated commercial purchase commitments.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026, we had a long-term principal debt balance of $119.8 million related to the Pharmakon Loan Agreement.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2024, we entered into the Pharmakon Loan Agreement, and in connection with this transaction, all obligations outstanding under the Hercules Loan Agreement were repaid in full on November 1, 2024, upon which the Hercules Loan Agreement was terminated. On January 5, 2026, the Pharmakon Loan Agreement was amended to extend the date for requesting the Tranche B Loan and Tranche C Loan, once available, from December 31, 2025 to July 30, 2026. The amendment also extended the Makewhole Date from November 1, 2026 to May 1, 2027.  We expect our interest expense to increase in future periods due to the draw down of the Tranche A Loan and potential future draw downs of the other Term Loans under the Pharmakon Loan Agreement. See Note 7 on Debt in Notes to Condensed Consolidated Financial Statements of this Report for additional information on the Pharmakon Loan Agreement.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2024, we entered into the Royalty Pharma Agreement, pursuant to which we received an upfront payment of $125.0 million and Royalty Pharma obtained the right to receive Royalty Payments on future U.S. net sales of RYTELO for each calendar quarter during the term of the agreement. We are obligated to make Royalty Payments each quarter based on U.S. net sales of RYTELO at the royalty rates set forth in the agreement, which Royalty Payments are not determinable at this time, until the date when the aggregate Royalty Payments equal or exceed 1.65 times the Purchase Price, if this occurs by June 30, 2031, or the date when the aggregate Royalty Payments equal or exceed 2.0 times the Purchase Price. See Note 7 on Debt in Notes to Condensed Consolidated Financial Statements of this Report for additional information on the Royalty Pharma Agreement.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we enter into agreements with CROs for clinical trials and with other vendors for preclinical research studies, investigator-led trials and other services and products for operating purposes. We have not considered these commitments to be contractual obligations since the contracts are generally cancellable at any time by us upon less than 180 days&#8217; prior written notice. We also have certain in-license agreements that require us to pay milestones to such third parties upon achievement of certain development, regulatory or commercial milestones. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval and commercial milestones, which may not be achieved.</span></div><div id="idd6aca193f774d62ad71a733a1085238_88"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:18pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2026, there were no material changes to our quantitative and qualitative disclosures about market risk as set forth in Part II, Item 7A "Quantitative and Qualitative Disclosures About Market Risk" of our 2025 Form 10-K.</span></div><div id="idd6aca193f774d62ad71a733a1085238_91"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:18pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, prior to the filing of this Report. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of the end of the period covered by this Report, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:18pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter to which this Report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Limitations on Effectiveness of Controls and Procedures</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating disclosure controls and procedures, our management recognizes that any system of controls, however well designed and operated, can provide only reasonable assurance, and not absolute assurance, that the desired control objectives of the system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals in all future circumstances. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our Chief Executive Officer and our Chief Financial Officer have concluded, based on their evaluation as of the end of the period covered by this Report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="idd6aca193f774d62ad71a733a1085238_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="idd6aca193f774d62ad71a733a1085238_97"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="margin-bottom:18pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8 on Commitments and Contingencies in Notes to Condensed Consolidated Financial Statements of this Report for information on legal proceedings.</span></div><div id="idd6aca193f774d62ad71a733a1085238_100"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factor Summary</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of material factors that make an investment in our common stock speculative or risky. Importantly, this summary does not address all of the risks and uncertainties that we face. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider this summary to be a complete discussion of all potential risks or uncertainties that may substantially impact our business. Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks and uncertainties that we face, can be found under &#8220;Risk Factors&#8221; in Part I, Item 1A of this Report. The summary below is qualified in its entirety by that more complete discussion of such risks and uncertainties. Moreover, we operate in a competitive and rapidly changing environment. New factors emerge from time to time and it is not possible to predict the impact of all of these factors on our business, financial condition or results of operations. You should consider carefully the risks and uncertainties described under &#8220;Risk Factors&#8221; in Part I, Item 1A of this Report as part of your evaluation of an investment in our common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to the Commercialization of RYTELO&#174; (Imetelstat)</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our near-term prospects are wholly dependent on RYTELO. We have limited experience with the commercialization of RYTELO, and if we are unable to successfully commercialize RYTELO in the U.S. for lower-risk MDS, or to expand its indication of use, our ability to generate meaningful revenue or achieve profitability will be materially and adversely affected.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Although we have established commercial operations and sales, marketing and distribution infrastructure for RYTELO, we have limited experience in sustaining and scaling these operations and our commercialization efforts may be unsuccessful or less successful than anticipated. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to continue to execute on our sales, marketing and distribution plans to commercialize RYTELO, we may be unable to generate meaningful product revenue.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face competition from existing products, product candidates and technologies, and competitors may develop new products and technologies. If these products, product candidates or technologies are deemed by the healthcare community to be superior to or more cost-effective than RYTELO, it would significantly impact the development and commercial viability of RYTELO, which would severely and adversely affect our financial results, business and business prospects, and the future of RYTELO, and might cause us to cease operations.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will be subject to pricing and reimbursement regulations in the European Union, or EU, which may materially affect our ability to commercialize and receive reimbursement coverage for RYTELO in the EU.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Regulatory Approval of RYTELO</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unable to maintain regulatory approvals for RYTELO in the U.S. and the EU for lower-risk MDS, which would severely and adversely affect our business and business prospects, and might cause us to cease operations.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our regulatory approval for RYTELO in the U.S. and in the EU for certain patients with lower-risk MDS is subject to post-marketing requirements and commitments, and we may be subject to penalties or product withdrawal if we fail to comply with these regulatory requirements and commitments, or if we experience unanticipated problems with RYTELO.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Compliance with Healthcare Laws</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our relationships with healthcare providers, including physicians and third-party payors, the methods by which we promote RYTELO, and the content of our promotional materials and programs, are subject to applicable promotional, anti-kickback, fraud and abuse, and other healthcare laws and regulations, and our failure to comply </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">with these laws could expose us to criminal sanctions, civil penalties, exclusion from federal health care programs, contractual damages, reputational harm and may adversely affect our business and financial results.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to the Further Development of Imetelstat</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We cannot be certain that we will be able to continue to develop imetelstat or advance it in clinical trials, or that we will be able to receive regulatory approval for imetelstat in any other indications in the U.S., the EU or any other region, on a timely basis or at all.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">RYTELO may cause, or have attributed to it, undesirable or unintended side effects or other adverse events that could halt or limit its further commercialization, delay or prevent its regulatory approval in any other jurisdiction or indication, or cause us to delay or terminate our clinical trials.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Results and data we disclosed from prior non-clinical studies and clinical trials, as well as any data disclosed as a result of an interim analysis, may not predict success in later clinical trials or the final analysis, and we cannot assure you that any ongoing or future clinical trials of imetelstat, including IMpactMF, will lead to similar results and data that could potentially enable us to obtain any further regulatory approvals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Manufacturing RYTELO (Imetelstat)</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure by us to maintain a manufacturing supply chain to appropriately and adequately supply RYTELO for commercial and future clinical uses would adversely affect our ability to commercialize RYTELO and result in a further delay in or cessation of clinical trials, and our business and business prospects could be severely harmed, and we could cease operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Operating Results, Financial Position and Need for Additional Capital</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a history of net losses and may not achieve consistent future profitability for some time, if ever.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our failure to obtain additional capital, if and when needed, would force us to further delay, reduce or eliminate the further development of RYTELO, or to halt the commercialization of RYTELO, any of which would severely and adversely affect our financial results, business and business prospects, and might cause us to cease operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Indebtedness and Royalty Payment Obligations</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our level of indebtedness and debt service obligations could adversely affect our financial condition and may make it more difficult for us to fund our operations, including by limiting our operating and financial flexibility.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Protecting Our Intellectual Property</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain and maintain sufficient intellectual property protection and relevant regulatory exclusivities for RYTELO, both in the U.S. and in other countries, our competitors could develop and commercialize products similar or identical to RYTELO, and our ability to successfully commercialize RYTELO may be adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Managing Our Growth and Other Business Operations</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our strategic restructuring plan and the associated workforce reduction implemented in December 2025 may not result in anticipated savings and long-term value creation, could result in total costs and operating expenses that are greater than expected and could disrupt our business.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and certain of our current and former officers and directors have been named as defendants in securities class action lawsuits and derivative lawsuits. These lawsuits, and potential similar or related lawsuits, are costly to defend, could result in substantial damages, divert management&#8217;s time and attention from our business, and have a material adverse effect on our results of operations. </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">RISK FACTORS</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We operate in a dynamic and rapidly changing environment involving numerous risks and uncertainties that may have a material adverse effect on our business, financial condition or results of operations. You should carefully consider the risks and uncertainties described below, together with all of the other information included in this Report. Our business faces significant risks and uncertainties, and those described below may not be the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us or that we currently believe are immaterial may also significantly impair our business, financial condition or results of operations. If any of these risks or uncertainties occur, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">our business, financial condition or results of operations could suffer, the market price of our common stock could decline and you could lose all or part of your investment in our common stock.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">RISKS RELATED TO THE COMMERCIALIZATION OF RYTELO</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our near-term prospects are wholly dependent on RYTELO. We have limited experience with the commercialization of RYTELO, and if we are unable to successfully commercialize RYTELO in the U.S. for lower-risk MDS, or to expand its indication of use, our ability to generate meaningful revenue or achieve profitability will be materially and adversely affected.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, we received FDA approval to commercialize RYTELO in the U.S. for certain patients with lower-risk MDS, and we initiated a commercial launch of RYTELO in the U.S. in that indication. While we have generated revenue from U.S. sales of RYTELO since mid-2024, the commercialization of RYTELO marks our first effort to commercially launch a product candidate, and our ability to grow revenue on a sustained basis has not yet been proven. RYTELO is our only product approved for marketing by the FDA, and our ability to generate meaningful revenue from product sales and achieve profitability is wholly dependent on our ability to successfully commercialize RYTELO in the U.S. for lower-risk MDS or to expand its indications of use. We may not be able to successfully commercialize RYTELO for a number of reasons, including: </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to establish or demonstrate in the medical community the safety and efficacy of RYTELO and its potential advantages over, and side effects compared to, existing treatments;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">physicians may be reluctant to prescribe RYTELO until longer-term efficacy and safety data exists;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our limited historical experience in marketing, selling and distributing RYTELO;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to increase physician adoption of RYTELO through our commercialization strategy and plans, including any potential amendments or adjustments to those plans;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to achieve and maintain revenue growth in the near future under our current commercialization strategy and plans or any potential further amendments or adjustments thereto;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential future changes in the reimbursement and coverage policies of government and private payors such as Medicare, Medicaid, insurance companies, health maintenance organizations and other plan administrators;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the relative position of RYTELO as compared to alternative treatment options in healthcare guidelines and recommendations, such as those developed by the National Comprehensive Cancer Network, or NCCN, and similar guidelines and recommendations outside the U.S.;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the relative price of RYTELO as compared to alternative treatment options;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the relatively low incidence and prevalence of patients in RYTELO&#8217;s approved indication, including the reliability of our market and sales estimates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the market penetration rate of RYTELO across the breadth of eligible patient segments in its approved indication may continue to be lower than our expectations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our projections regarding the market opportunities for RYTELO may not be accurate, and the actual market for RYTELO may be smaller than we estimate;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future competitive or other market factors may adversely affect the commercial potential of RYTELO;  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to obtain and maintain regulatory approvals for RYTELO in any other jurisdictions for lower-risk MDS or for any other indications, including relapsed/refractory MF;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changed or increased regulatory restrictions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to the label for RYTELO that further restrict how we market and sell RYTELO, including adverse events observed in ongoing and future studies of imetelstat, such as our Phase 3 IMpactMF clinical trial;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the capabilities of third party manufacturers may adversely affect the success of our commercialization of RYTELO; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may need additional financial or other resources that might not be available to us to successfully commercialize RYTELO; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to maintain adequate commercial supplies of RYTELO to meet demand or at an acceptable cost or at all.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, commercialization of RYTELO may not generate sufficient revenue from product sales, and we may not become profitable in the near term, or at all. In any event, if we are unable to successfully commercialize RYTELO in the U.S. for lower-risk MDS, or to expand its indications of use, our ability to generate meaningful revenue from product sales and achieve profitability will be materially and adversely affected, which in turn would severely and adversely affect our financial results, business and business prospects, and might cause us to cease operations. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Although we have established commercial operations and sales, marketing and distribution infrastructure for RYTELO in the U.S., our commercialization strategy may ultimately be unsuccessful or less successful than anticipated</span></div><div><span><br/></span></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As a company, we have limited prior experience in selling and marketing or commercializing an approved drug product in the U.S., and we have no experience selling, marketing or commercializing an approved drug outside of the U.S. The success of our commercialization efforts is subject to, among other things, managing our internal sales, marketing, and distribution capabilities and our ability to navigate the significant expenses and risks involved with the management of such capabilities. Our initial commercialization efforts in the U.S. have not to date achieved meaningful sales growth.  Our RYTELO sales trends and resulting revenue have been and may continue to be variable. Net product revenue was approximately $51.8 million in the first quarter of 2026, $48.0 million in the fourth quarter of 2025, $47.2 million in the third quarter of 2025, and $49.0 million in the second quarter of 2025. In an effort to better execute on our plans to commercialize RYTELO and generate more meaningful product revenue, we decided to focus our  commercial execution on targeted engagement with high-volume accounts that treat earlier-line patients, and invest in non-personal promotion and third-party education to reach the full breadth of the eligible patient population, while cross-functionally collaborating for effective account management. However, our revised strategy to drive RYTELO commercial growth may still not achieve meaningful sales growth, which may require us to, among other things, further adjust or amend our commercialization strategy and plans and incur significant expenses, and there can be no assurance that we will be able to meet or grow projected RYTELO net product revenue in future periods. In particular, our strategy may not drive new patient starts in lower-risk MDS U.S. patients, particularly in second-line lower-risk MDS, in a timely manner or at all, or the duration of therapy could be shorter than we expect, each of which would limit RYTELO's growth potential and could preclude or delay our ability to generate meaningful revenue from product sales and to achieve profitability. If we are unsuccessful in accomplishing our objectives from our commercialization efforts and strategy, we may not be able to generate meaningful revenue from the commercialization of RYTELO in lower-risk MDS, or may require significant additional capital and financial resources to do make further investment in our commercial operations. Any of these outcomes would severely and adversely affect our financial results, business and business prospects, and might cause us to cease operations. </span></div><div style="text-indent:63pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2025, we announced a strategic restructuring plan designed to position us for long-term value creation and improve our financial discipline. However, there can be no assurance that our recent restructuring will result in long-term value creation or that our commercialization strategy will result in meaningful improvement in our sales performance. Additionally, we may determine that we need further changes in the future that require additional hiring or other organizational changes to adequately support our strategy, which could further increase our costs. As such, we continue to compete with many companies that currently have extensive, experienced and well-funded sales, distribution and marketing operations to recruit, hire, train and retain marketing and sales personnel. If we are unable to recruit, retain and effectively train marketing, sales and medical personnel as needed and equip them with compliant and effective materials, our efforts to successfully commercialize RYTELO could be adversely affected.</span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, although we received marketing authorization for RYTELO in the EU for the treatment of certain adult patients with TD anemia due to lower-risk MDS in March 2025, we currently have no marketing or sales organization outside of the U.S., and as a company, we have no experience selling and marketing approved drugs outside of the U.S. To successfully commercialize RYTELO in the EU or in any other regions outside the U.S. where we might seek marketing authorization in the future, we will need to develop these capabilities, which we plan to do at this time by working with experienced third-party contractors or commercialization partners. Doing so will require additional investment of capital and time. We currently intend to seek contractual arrangements, strategic partnerships, collaborations, alliances or licensing arrangements with third parties to assist us in the commercialization of RYTELO in the EU and in any other regions outside of the U.S. Any failure or delay in entering into and conducting such contractual arrangements, strategic partnerships, collaborations, alliances or licensing arrangements with third parties would adversely impact the commercialization of RYTELO in the EU or in any other regions outside the U.S. where RYTELO may be approved for marketing in the future. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not maintain acceptable prices or adequate reimbursement for RYTELO, the use of RYTELO could be severely limited.</span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to successfully commercialize RYTELO will depend significantly on maintaining acceptable prices and the availability of coverage and adequate reimbursement to patients from third-party payors. Government payors, such as the Medicare and Medicaid programs, and other third-party payors, such as private health insurers and health maintenance organizations, determine which medications they will cover and the reimbursement levels. The resulting reimbursement payment rates may not be adequate or may require significant restrictions on use or increased co-payments from commercially insured patients that patients may find unacceptably high. Patients are unlikely to use </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">RYTELO unless coverage is provided, and reimbursement is adequate to cover all or a significant portion of its cost. Therefore, coverage and adequate reimbursement are critical to market acceptance of RYTELO.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. and some jurisdictions outside the U.S., there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could impact our business. Generally, there has been increasing legislative and enforcement interest in the U.S. with respect to drug pricing, including specialty drug pricing practices, in light of the rising cost of prescription drugs and biologics. Specifically, there have been U.S. Congressional inquiries and federal and state legislative activity designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the price of drugs under Medicare, and reform government program reimbursement methodologies for drugs and biologics. For details regarding these legislative and regulatory changes and proposed changes regarding the healthcare system that may affect our ability to operate, see Item 1 &#8220;Business - Healthcare Reform&#8221; in the 2025 Form 10-K. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, government authorities and other third-party payors in the U.S. and other jurisdictions are developing increasingly sophisticated methods of controlling healthcare costs, such as by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices as a condition of coverage, are using restrictive formularies and preferred drug lists to leverage greater discounts in competitive classes, and are challenging the prices charged for medical products. The Inflation Reduction Act of 2022 includes several provisions to lower prescription drug costs for people with Medicare and reduce drug spending by the federal government, including the Medicare Drug Price Negotiation Program, which may ultimately have a negative effect on the pricing for RYTELO. However, the Medicare Drug Pricing Negotiation Program provisions of the law are currently subject to legal challenges. Further, the final CY 2026 Medicare Physician Fee Schedule rule, issued by the Centers for Medicare &amp; Medicaid Services, among other things, increases bona fide service fee documentation requirements, defines &#8220;bundled arrangement,&#8221; to require &#8220;unbundling&#8221; of both contingent and non-contingent discounts and includes sales of Part B units at the Maximum Fair Price in average sales price calculations. These changes could lower reimbursement for Medicare Part B utilization and require manufacturers to comply with new, uncertain or complex reporting obligations and drug pricing documentation practices.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payors in the U.S. As a result, the coverage determination process is often time-consuming and costly, and it will require us to provide scientific and clinical support for the use of RYTELO to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Although we have received a permanent and product-specific J-Code (J0870) for RYTELO which became effective on January 1, 2025, coverage may significantly change or may be more limited than the indications for which the drug is approved by the FDA or similar international regulatory authorities. Coverage and reimbursement may impact the demand for, or the price of RYTELO, and reimbursement policies in the U.S., the EU, and other jurisdictions may evolve which may adversely impact our ability to successfully commercialize RYTELO. Even if favorable coverage and reimbursement status is attained for RYTELO in additional indications or jurisdictions  for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. Moreover, we have in the past increased and may in the future increase the price of RYTELO, and there is no guarantee that price adjustments that we have taken or may take in the future will not negatively affect our ability to secure and maintain coverage and reimbursement for RYTELO, which could limit the price that we charge for RYTELO, limit the commercial opportunities for RYTELO and/or negatively impact our sales volumes and net revenues from sales of RYTELO. In any event, if coverage and reimbursement are not available or the reimbursement amount is inadequate, we may not be able to successfully commercialize RYTELO, which would negatively impact our business and business prospects.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If future legislation were to impose direct governmental price controls and access restrictions, it could have a significant adverse impact on our business and financial results. Managed care organizations, as well as Medicaid and other government authorities, continue to seek price discounts. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biologic product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, to encourage importation from other countries and bulk purchasing. Due to the volatility in the current economic and market dynamics, we are unable to predict the impact of any unforeseen or unknown legislative, regulatory, payor or policy actions, which may include cost containment and healthcare reform measures. Such policy actions could have a material adverse impact on future sales of RYTELO in the U.S., the EU, and in any other jurisdictions where we may seek approval in the future.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">To be commercially successful, RYTELO must be accepted by the healthcare community, which can be slow to adopt or unreceptive to new technologies and products.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy to drive sales growth and our ongoing commercialization efforts has not to date achieved and may not in the future achieve the rate of market acceptance by the healthcare community or breadth of eligible patient segments that we expect, which may require us to, among others, further adjust or amend our commercialization strategy and plans and incur significant expenses, and there can be no assurance that we will be able to grow RYTELO net product revenue in future periods. While our current priority is to drive new patient starts across the breadth of the eligible patient population in RYTELO's approved indication, we may be unable to do so in a timely manner or at all, which would limit RYTELO's growth potential and which could delay or preclude our ability to generate meaningful revenue from product sales and to achieve profitability. Furthermore, RYTELO competes with a number of conventional and widely accepted drugs and therapies manufactured and marketed by major pharmaceutical companies. The degree of market acceptance of RYTELO depends on a number of factors, including:</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical indications for which RYTELO is or may in the future be approved;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the establishment and demonstration to the medical community of the clinical efficacy and safety of RYTELO;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to demonstrate that RYTELO is superior to alternatives on the market at the time, including with respect to efficacy, safety, cost or route of administration;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of medical professionals to prescribe, and patients to use, RYTELO, or to continue to use RYTELO; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the publication of favorable safety or efficacy data concerning RYTELO by third parties or us;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on use of RYTELO alone or in combination with other products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the label and promotional claims allowed by the FDA for RYTELO, as well as any such claims allowed by similar international regulatory authorities for RYTELO, including usage for only certain indications and any limitations or warnings about the prevalence or severity of any side effects;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of market introduction of RYTELO for new indications;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of sales, marketing and distribution infrastructure for RYTELO;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of the third-party distributors and specialty pharmacies we contract with to process prescriptions and dispense RYTELO and the processes required to place orders with such distributors and specialty pharmacies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which RYTELO is approved for inclusion on formularies in hospitals and managed care organizations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing of RYTELO, both in absolute terms and relative to alternative treatments;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of coverage and adequate reimbursement by government and third-party payors; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of patients to pay out-of-pocket in the absence of coverage by third-party payors, including governmental authorities.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to demonstrate any therapeutic or economic advantage for RYTELO compared to established or standard-of-care therapies, or newly developed therapies, for myeloid hematologic malignancies. National health insurance and/or third-party payors may decide that any potential benefit that RYTELO may provide to clinical outcomes in myeloid hematologic malignancies is not adequate to justify the potential adverse effects or the costs of treatment with RYTELO. If the healthcare community does not accept RYTELO for any of the foregoing reasons, or for any other reasons, our ability to commercialize RYTELO in the U.S. or the EU for lower-risk MDS or for any other indications for which RYTELO may be approved, may be negatively impacted or precluded altogether, which would seriously and adversely affect our business and business prospects. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the market opportunities for RYTELO are smaller than we believe, our revenue may be adversely affected, and our business may suffer.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are commercializing RYTELO in lower-risk MDS, and the addressable patient population in lower-risk MDS is based on our estimates. These estimates, which have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations and market research, may prove to be </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">incorrect. Further, new information from us or others may change the estimated incidence or prevalence of patients with lower-risk MDS in the U.S. or the EU. Additionally, the potentially addressable patient population for RYTELO may not ultimately be amenable to treatment with RYTELO, we may be unable to successfully identify patients and achieve a significant market share in all eligible patient segments in RYTELO&#8217;s approved indication, or the duration of therapy for patients receiving RYTELO could be shorter than we expect, each of which would have a negative impac</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">t on sales of RYTELO in the future and may limit its growth potential. Our commercialization of RYTELO in the U.S. and our planned commercialization in the EU is limited to certain patients with lower-risk MDS, and any future potential commercialization will be limited to the therapeutic indications </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">examined in our clinical trials and approved by the FDA and similar international regulatory authorities, which would preclude us from marketing RYTELO for any other indications not expressly approved by those regulatory authorities. Future regulatory approvals for RYTELO, if any, could be conditioned upon label restrictions that materially limit the addressable patient population.   </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our market opportunity may also be limited by the pricing, reimbursement and access we are able to achieve for RYTELO, the quality and expiration of our intellectual property rights and regulatory exclusivity, duration of RYTELO treatment in lower-risk MDS and future competitor treatments that enter the market. If any of our estimates prove to be inaccurate, the market opportunities for RYTELO that we or any potential future collaborative partners develop could be significantly diminished, which would have a material adverse impact on our business and business prospects, and would adversely affect our ability to achieve profitability. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face competition from existing products, product candidates and technologies, and competitors may develop new products and technologies. If these products, product candidates or technologies are deemed by the healthcare community to be superior to or more cost-effective than RYTELO, it would significantly impact the development and commercial viability of RYTELO, which would severely and adversely affect our financial results, business and business prospects, and the future of RYTELO, and might cause us to cease operations.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical and biotechnology industries are characterized by intense and dynamic competition with rapidly advancing technologies and a strong emphasis on proprietary products. While we believe our proprietary oligonucleotide chemistry; experience with the biological mechanisms related to RYTELO, telomeres and telomerase; clinical data to date indicating potential disease-modifying activity with RYTELO treatment; and knowledge and expertise around the development of potential treatments for myeloid hematologic malignancies may provide us with certain competitive advantages, we face competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions. RYTELO competes with other products and therapies that currently exist, are being developed or will in the future be developed, some of which we may not currently be aware of.  A discussion of current and potential future competitors of RYTELO can be found in the sub&#8209;section titled &#8220;Competition&#8221; in Part I, Item 1, titled &#8220;Business&#8221; in the 2025 Form 10-K.   </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors, either alone or with their strategic partners, have substantially greater financial, technical and human resources than we do and significantly greater experience in obtaining FDA and other regulatory approvals of treatments and commercializing those treatments. Smaller companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. We anticipate increased competition in the future as new companies explore treatments for myeloid hematologic malignancies, which may significantly impact the commercial viability of RYTELO. Academic institutions, government agencies and other public and private research organizations may also conduct research, seek patent protection and establish collaborative arrangements for research, clinical development and marketing of products similar to RYTELO. These companies and institutions compete with us in recruiting and retaining qualified development and management personnel as well as in acquiring technologies complementary to the RYTELO program.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the foregoing, competitors may develop more commercially desirable or affordable products than RYTELO. Competitors have developed, or are in the process of developing, technologies that are, or in the future may be, competitive to RYTELO. Some of these products may have an entirely different approach or means of accomplishing therapeutic effects similar, or superior, to those that may be demonstrated by RYTELO. Competitors may develop products that are safer, more effective, more convenient to administer to patients, or less costly than RYTELO, and, therefore, present a serious competitive threat to RYTELO. In addition, competitors may price their products below what we may determine to be an acceptable price for RYTELO, may receive better third-party payor coverage and/or reimbursement, or may be more cost effective than RYTELO. Such competitive products or activities by competitors may render RYTELO obsolete, which may cause us to cease any further development or future commercialization of RYTELO, which would severely and adversely affect our financial results, business and business prospects, and the future of RYTELO, and might cause us to cease operations.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on a select network of third party distributors, specialty pharmacies and other vendors to distribute RYTELO in the U.S., and any failure by such distributors, specialty pharmacies and vendors could adversely affect our revenues, financial condition, or results of operations.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a select network of third party distributors, specialty pharmacies and other vendors to distribute RYTELO in the U.S., and the financial failure of any of these parties could adversely affect our revenues, financial condition or results of operations. We rely on such distributors and specialty pharmacies to effectively distribute RYTELO in a timely manner, provide certain patient support services, manage prescription intake, collect accurate patient and inventory data and collect payments from payors. While we have entered into agreements with each of these parties, they may not perform as agreed, our strategic priorities may change or they may terminate their agreements with us. Further, an inability by our distributors or specialty pharmacies to meet our patients&#8217; needs may lead to reputational harm or patient loss. In the event that such network fails to properly meet our or our patients&#8217; needs, we may need to partner with other distributors, specialty pharmacies or vendors to replace or supplement our current network and there is no guarantee that we will be able to do so on commercially reasonable terms or at all.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will be subject to pricing and reimbursement regulations in the EU, which may materially affect our ability to commercialize and receive reimbursement coverage for RYTELO in the EU.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In March 2025, we received marketing authorization for RYTELO in the EU for the treatment of adult patients with TD anemia due to lower-risk MDS without an isolated deletion 5q cytogenic abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy. The pricing of RYTELO will be subject to governmental control and other market regulations which could put pressure on the pricing and usage of RYTELO. In the EU, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate and market acceptance and sales of RYTELO will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for RYTELO and may be affected by existing and future healthcare reform measures.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The requirements governing drug pricing and reimbursement vary widely from country to country. For example, within the EU member states may restrict the range of medicinal products for which their national health insurance systems provide reimbursement and may control the prices of medicinal products for human use. Reference pricing used by various EU Member States and parallel distribution, or arbitrage between low-priced and high-priced EU Member States, can further reduce prices. An EU Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. In some countries in the EU, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of RYTELO to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for biopharmaceutical products will allow favorable reimbursement and pricing arrangements for RYTELO. Historically, products launched in the EU do not follow price structures of the U.S. and generally prices tend to be significantly lower. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of RYTELO is unavailable or limited in scope or amount, our revenues from sales and the potential profitability of RYTELO in those countries would be negatively affected.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="text-indent:64.8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-indent:64.8pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:90%">RISKS RELATED TO REGULATORY APPROVAL OF RYTELO</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to maintain regulatory approvals for RYTELO in the U.S. and the EU for lower-risk MDS, which would severely and adversely affect our business and business prospects, and might cause us to cease operations.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, we received regulatory approval from the FDA to commercialize RYTELO in the U.S. in certain patients with lower-risk MDS, and in March 2025, we received marketing authorization from the EC to commercialize RYTELO in the EU for certain adult patients with TD anemia due to lower-risk MDS. Federal, state and local governments in the U.S., and regulatory authorities in the EU, have significant regulations in place that may limit or prevent us from successfully commercializing RYTELO for lower-risk MDS. We do not currently have regulatory approval for RYTELO in any other jurisdictions or for any other indication, and governments in other jurisdictions have significant regulations that may limit or prevent us from successfully commercializing RYTELO in other jurisdictions. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory frameworks and practices of the FDA, EMA/EC and comparable authorities in other countries may change over time, and we cannot predict the nature, timing, or impact of any such developments. We cannot project with certainty if or when we might submit or gain regulatory approval for RYTELO for other indications or in other jurisdictions. The FDA, EMA/EC and other regulatory authorities exercise broad discretion throughout the product review and approval process, including in determining the specific conditions for submission, including the requirement for a pre-approval inspection of RYTELO&#8217;s listed manufacturing facility. As a result, the FDA, EMA/EC and other authorities may delay or extend application review, may decline to accept an application for substantive review, or may conclude, after review, that the information provided is inadequate to obtain or maintain approval of RYTELO. Any such decision could materially and adversely affect the timing of potential approval and our business prospects. If the FDA, for instance, determines that an NDA is not sufficiently complete for filing or issues a complete response letter, or CRL, requiring additional data or clarification, we may be required to resubmit the application and any such resubmission or CRL&#8209;driven delays could significantly postpone review and potential approval RYTELO for other indications. Even if we resubmit an NDA, it remains uncertain whether the FDA will ultimately accept the completed application or additional data, and any such outcome could delay or prevent approval of RYTELO for other indications.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Failure to maintain regulatory approval for RYTELO from the FDA in the U.S. and from the EC in the EU for lower-risk MDS, or delays in obtaining, failing to obtain, or limitations in the scope of such approvals in any other jurisdictions or for any other indications, could:</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">result in a withdrawal of RYTELO from the market or could otherwise delay, limit or preclude any revenue we may receive from the commercialization of RYTELO for lower-risk MDS;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significantly harm the commercial potential of RYTELO;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impede, halt or increase the costs of our activities and plans for clinical development;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diminish any competitive advantages that may have been available to us; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or preclude any revenue we may receive from the future commercialization of RYTELO in any other jurisdictions or for any other indications, if any.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, approved products and their manufacturers, together with other vendors involved in the commercialization process, are subject to continual review, and discovery of previously unknown problems with a product or its manufacturer, including if regulatory inspectors identify regulatory noncompliance by third-party manufacturers requiring remediation, may result in restrictions on the product or manufacturer, including import restrictions, seizure, and withdrawal of the product from the market, or may otherwise cause manufacturing delays and supply disruptions. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, if RYTELO causes serious or unexpected side effects, or if other safety risks are observed as a result of our commercialization efforts for RYTELO in the U.S. or the EU in lower-risk MDS or in current or potential future clinical trials, a number of potential significant negative consequences could result, including:</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw approval of RYTELO;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to recall RYTELO, seek to change the way it is administered, conduct additional costly, time-consuming and burdensome clinical trials or change the labeling of the product;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require revisions to the labeling of RYTELO, including limitations on approved uses or the addition of further warnings, contraindications or other safety information, or may impose restrictions on distribution in the form of additional requirements in a risk evaluation and management plan or risk management plan;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">RYTELO may be rendered less competitive and sales, if any, may decrease;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer generally among clinicians and patients;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be exposed to potential lawsuits and associated legal expenses, including costs of resolving claims;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may refuse to approve supplements to approved applications filed by us, or may suspend or revoke license approvals; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to change or stop ongoing clinical trials of RYTELO, which would negatively impact the development of RYTELO for other potential indications.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance for RYTELO, could substantially increase the costs and expenses of commercializing RYTELO, or could limit its commercial potential, which in turn could delay or prevent us from generating any meaningful revenues from the sale of the RYTELO.  If RYTELO is approved outside the U.S. and EU, we will be subject to similar requirements, considerations and risks in other regions.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our regulatory approval for RYTELO in the U.S. and in the EU for certain patients with lower-risk MDS is subject to post-marketing requirements and commitments, and we may be subject to penalties or product withdrawal if we fail to comply with these regulatory requirements and commitments, or if we experience unanticipated problems with RYTELO.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our regulatory approval for RYTELO in lower-risk MDS in the U.S. and EU are subject to non-clinical, clinical and manufacturing post-marketing requirements and/or commitments, including the requirement to assess the long-term safety of RYTELO (imetelstat) in the Phase 3 IMerge trial and a clinical trial to evaluate alternative dosing regimens in lower-risk MDS, with timelines for completion and reporting established by the FDA. In the EU, our regulatory approval for RYTELO in certain patients with TD anemia due to lower-risk MDS is subject to our commitment to submit the results from certain ongoing non-clinical and clinical studies required by the FDA, including the assessment of the long-term safety of RYTELO in the extension to the Phase 3 IMerge trial. In addition, RYTELO and the manufacturing processes and facilities, post-approval clinical data, labeling, advertising and promotional activities related to RYTELO will be subject to continual requirements of, and review by, the FDA and comparable regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, compliance with good pharmacovigilance practices, registration requirements, current Good Manufacturing Practice, or cGMP, requirements relating to quality control, quality assurance and corresponding maintenance of records and documents, and requirements regarding promotional interactions with healthcare professionals. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these post-marketing requirements and commitments on the timeline required or at all, or any other regulatory requirements, including the FDA&#8217;s regulation of promotional claims, or later discovery of previously unknown problems with RYTELO, or our manufacturers, or manufacturing processes for RYTELO, may result in actions such as:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse regulatory inspection findings;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on RYTELO manufacturing, distribution or use; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on, or prohibitions against, marketing, importing or exporting RYTELO; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional post-marketing requirements or commitments; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, untitled letters, warning letters or the withdrawal of RYTELO from the market;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">voluntary or mandatory product recalls or public notification or medical product safety alerts to healthcare professionals; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or termination of ongoing clinical trials of imetelstat in other indications; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension of review or refusal to approve pending applications or supplements to approved applications; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exclusion from participation in government-funded healthcare programs and/or eligibility for the award of government contracts for RYTELO; suspension or withdrawal of regulatory approval for RYTELO;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant civil, criminal and administrative penalties, including fines, restitutions or disgorgement of profits or revenues; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detentions; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse publicity. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The imposition of any of these penalties or other commercial limitations, including equivalent penalties or commercial limitations imposed by foreign regulatory authorities, could severely and adversely affect our financial results, business and business prospects, including the commercialization of RYTELO, and might cause us to cease operations. Similar requirements and related consequences apply outside the U.S.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any government investigation of alleged violations of law could require us to spend significant time and resources in response and could generate negative publicity. In addition, the regulations, policies or guidance of the FDA, EC or any other regulatory authority may change and new or additional statutes or government regulations may be enacted that could prevent or delay regulatory approval of our product candidates or further restrict or regulate post-approval activities. We also cannot predict the likelihood, nature, or extent of adverse government regulation that may arise from pending or future legislation or administrative action, either in the U.S. or abroad.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to fulfill the post-marketing requirements and commitments established by the FDA, or that may be or are applied to the approval and commercialization of RYTELO by any regulatory authority, or are unable to adapt to changes in existing regulatory requirements or adoption of new regulatory requirements or policies, there may be a negative impact to our business and continued regulatory approval of RYTELO. Under such circumstances, we or our respective service providers may be subject to the actions listed above, including losing marketing approval for RYTELO, which would severely and adversely affect our business and business prospects, and might cause us to cease operations. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, in connection with our marketing authorization for RYTELO in the EU for certain patients with TD anemia due to lower-risk MDS, we are subject to post-marketing requirements to submit final results from certain ongoing non-clinical and clinical studies and the completion of certain quality-related activities and study.  We are also subject to rules and regulations in the EU applicable to the manufacturing, marketing, promotion, and sale of medicinal products. If we, or a regulatory authority, discover previously unknown problems with RYTELO, such as adverse events of unanticipated severity or frequency, or problems with a facility where RYTELO is manufactured, a regulatory authority may impose restrictions relative to RYTELO or the manufacturing facility, including requiring recall or withdrawal of RYTELO from the market or suspension of manufacturing. Moreover, product labeling, advertising and promotion for RYTELO will be subject to regulatory requirements and continuing regulatory review. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with EU and EU Member State laws that apply to the conduct of clinical trials, manufacturing approval, marketing authorization of medicinal products and marketing of such products, both before and after grant of the marketing authorization, or with other applicable regulatory requirements, or failure to complete post-marketing requirements on the timeline required, may result in administrative, civil or criminal penalties. This could also result in delays or refusal to authorize the conduct of clinical trials, or to grant marketing authorization, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the marketing authorization, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties, among others. If RYTELO is approved outside the U.S. and the EU, we will be subject to similar requirements, considerations and risks in other regions.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to obtain regulatory approval to commercialize RYTELO in any other jurisdictions or for any new indications, or may experience significant delays in doing so, any of which could severely and adversely affect our business and business prospects, and might cause us to cease operations.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may never receive regulatory approval for RYTELO in any other jurisdictions or for any new indications. It can take many years to obtain approval, if approval is obtained at all. Of the large number of drugs in development, only a small percentage complete the development and regulatory approval process and are successfully commercialized. In addition, the lengthy review process and the unpredictability of ongoing or future clinical trials may result in a delay in obtaining, or our failure to obtain, regulatory approval for RYTELO in lower-risk MDS in any jurisdictions other than the U.S. and the EU, or for other indications, such as relapsed/refractory MF, in any jurisdictions. Failure to obtain approval could significantly harm our business and business prospects, render our significant clinical development expenditures unrecoverable, and might cause us to cease operations.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Securing marketing approval requires the submission of extensive non-clinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy to the satisfaction of such regulatory authorities, as well as information about the product manufacturing process and any inspections of manufacturing facilities conducted by regulatory authorities through the filing of a New Drug Application, or NDA, in the U.S. and a Marketing Authorization Application, or MAA, in the EU. Although RYTELO is approved in the U.S. and the EU in lower-risk MDS, there can be no assurance that we will receive regulatory approval for the commercialization of RYTELO for lower-risk MDS in any other jurisdiction or for any new indications, including relapsed/refractory MF or any other indications.  </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any marketing approval that we may receive for RYTELO in any other jurisdiction or for any other indication may also be limited or subject to restrictions or post-approval commitments and requirements that increase our costs or render RYTELO not commercially viable, which would harm our business and business prospects. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities may also not approve the labeling claims that are necessary or desirable for the successful commercialization of a drug, such as RYTELO. For example, although we received regulatory approval from the FDA in June 2024, and from the EC in March 2025, to commercialize RYTELO in lower-risk MDS, any future regulatory clearances that we might obtain for RYTELO may be limited to fewer or narrower indications than we might request, or may be granted subject to the performance of post-marketing studies, which may impose further requirements or restrictions on the distribution or use of RYTELO, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria, and requiring treated patients to enroll in a registry. These limitations and restrictions may limit the size of the market for RYTELO and affect reimbursement by third-party payors. Future regulatory clearances, if any, may be limited to a smaller patient population, or may require a different drug formulation or a different manufacturing process, than we might in the future decide to seek.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any delay in obtaining or failure to obtain required approvals of RYTELO in any other jurisdictions or for any other indications, or limitations on any regulatory approval that we might receive in the future, if any, could reduce the potential commercial use of RYTELO, and potential market demand for RYTELO and therefore result in decreased revenue for us from any commercialization of RYTELO in any other jurisdictions or for any other indications, any of which could severely and adversely affect our financial results and ability to raise additional capital, if needed, the price of our common stock, our business and business prospects, and might cause us to cease operations.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Although orphan drug designation has been granted to RYTELO for the treatment of MDS and MF in the U.S. and in the EU, these designations may not be maintained, which would eliminate the benefits associated with orphan drug designation, including market exclusivity, which could limit the period of exclusivity we are able to maintain for the commercialization of RYTELO, and would likely harm our business and business prospects.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA granted orphan drug designation to RYTELO in June 2015 for the treatment of MF and for the treatment of MDS in December 2015, and the EC granted orphan drug designation in December 2015 to RYTELO for the treatment of MF and in July 2020 for the treatment of MDS. Orphan drug exclusivity confers seven and ten years of exclusivity in the U.S. and EU, respectively, following approval, subject to satisfying regulatory requirements. The FDA has confirmed seven years of orphan drug exclusivity for RYTELO following its approval on June 6, 2024 for its approved indication in lower-risk MDS. On March 7, 2025, the EC granted marketing authorization for RYTELO as an orphan medicinal product indicated for the treatment of adult patients with TD anemia due to very low, low or intermediate risk MDS without an isolated deletion 5q cytogenetic (non-del 5q) abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.  </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Designation as an orphan drug does n</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ot guarantee that any regulatory authority will accelerate regulatory review of, or ultimately approve, RYTELO for any indication, or at all, in the U.S., EU or any other country, nor does it limit the ability of any regulatory authority to grant orphan drug designation to product candidates of other companies that treat the same indications as RYTELO if such products are able to demonstrate superiority to RYTELO. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may lose orphan drug exclusivity in the U.S. for certain reasons, including if the FDA determines that the request for orphan drug designation was materially defective or if we cannot ensure sufficient quantities of RYTELO to meet the needs of patients. In the EU, orphan designation may be lost before marketing authorization if it is established that the criteria for orphan designation are no longer met. Failure to maintain orphan designation status would lead to the inability to obtain or the loss of associated regulatory exclusivity. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Even if we maintain orphan drug exclusivity for RYTELO in the U.S., the exclusivity may not effectively protect RYTELO from all competition because different drugs with different active moieties can be approved for the same condition or a drug containing the same active moiety or principal molecular structure can be approved for a different indication. Even after an orphan drug product is approved, such as the approval of RYTELO in the U.S. in June 2024 for certain patients with lower-risk MDS, the FDA can subsequently grant orphan designation to a different drug with the same active moiety for the same condition, if the FDA concludes that the later drug is safer, more effective, or makes a major contribution to patient care. The occurrence of any of these events could limit the period of exclusivity we are able to maintain for RYTELO, allow competitive products to enter the market, and harm our business and business prospects. In addition, for any other indication that we are currently or may in the future seek to develop or obtain regulatory approval </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for RYTELO, orphan drug designation will neither shorten the development time nor regulatory review time for RYTELO in the US and other comparable jurisdictions, and it does not give RYTELO advantages in the regulatory review or approval process. Notably, there have been legal challenges to aspects of FDA&#8217;s regulations and policies concerning the exclusivity provisions of the Orphan Drug Act, including whether two drugs are the same drug product. Future challenges could lead to changes that affect the protections potentially afforded to our products in ways that are difficult to predict.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, in the EU, orphan market exclusivity may not effectively protect RYTELO from all competition. Following the authorization of RYTELO as an orphan medicinal product by the EC in March 2025 for certain patients with lower-risk MDS, the EC can subsequently approve similar orphan medicinal products for the same therapeutic indication or if we are unable to supply RYTELO in sufficient quantities or if a similar medicinal product with the same orphan indication is shown to be safer, more effective or otherwise clinically superior to the original orphan medicinal product. If it is established that the criteria for orphan designation are no longer met inter alia where it is shown that the product is sufficiently profitable, EU orphan market exclusivity may be reduced to six instead of 10 years, allowing similar medicinal products for the same therapeutic indication to the market sooner. In the EU, orphan drug designation for any additional indication we may pursue for RYTELO does confer certain regulatory advantages&#8212;such as protocol assistance&#8212;but it does not shorten development timelines or accelerate the EMA&#8217;s overall review process.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, the EC published a proposal to reform the current pharmaceutical framework, including revision of orphan market exclusivity. The new legislation, if adopted, is expected to start to apply from mid-2028. The proposal to reform the current pharmaceutical framework intends to revise the orphan drug designation and exclusivity regime. In the latest version of the proposal, orphan market exclusivity will be reduced from the current 10 years to 9 years. Extension by another two years will be possible for so-called &#8220;breakthrough orphan medicinal products&#8221;. Previous drafts also included the concept of &#8220;global orphan marketing authorization&#8221;, which would no longer grant additional separate orphan market exclusivity for second or further orphan therapeutic indications. Although the final text has not yet been published and RYTELO for the treatment of MDS is and remains regulated under the current regulatory framework, authorization of future indications may be affected by the new legislation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even though we reported positive top-line results from IMerge Phase 3 in January 2023 and received regulatory approval from the FDA in June 2024 to commercialize RYTELO in the U.S. for lower-risk MDS, the top-line results from IMerge Phase 3 are not necessarily predictive of RYTELO&#8217;s activity in other indications, such as in relapsed/refractory MF. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Even though we reported positive top-line results from IMerge Phase 3 in January 2023 and received regulatory approval from the FDA in June 2024 and the EC in March 2025 to commercialize RYTELO in lower-risk MDS, the top-line results from IMerge Phase 3 are not necessarily predictive of RYTELO&#8217;s activity in other indications and for other pivotal trials that may be needed to support any application to the FDA or similar international regulatory authorities for such other indications, such as in relapsed/refractory MF. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, with respect to the trial design for IMpactMF, our Phase 3 trial in relapsed/refractory MF, the FDA urged us to consider adding a third dosing arm to the trial to assess a lower dose and/or a more frequent dosing schedule that might improve the trial&#8217;s chance of success by identifying a less toxic regimen and/or more effective spleen response, one of the trial&#8217;s secondary endpoints. Based on data from IMbark, our Phase 2 clinical trial that evaluated two doses of imetelstat in relapsed/refractory MF and the results of which our IMpactMF trial is based on, we believe that testing a lower dose regimen would likely result in a lower median OS, which is the trial&#8217;s primary endpoint, in the imetelstat treatment arm. Existing data also suggest that lowering the dose would not result in a clinically meaningful reduction in toxicity, and for these reasons we determined not to add a third dosing arm to the trial design and the FDA did not object to our proposed imetelstat sodium dose and schedule of 9.4 mg/kg every three weeks. Our belief may ultimately be incorrect. Therefore, our failure to add a third dosing arm could result in a failure to maintain regulatory clearance from the FDA and similar international regulatory authorities for relapsed/refractory MF, could result in the trial&#8217;s failure, or could otherwise delay, limit or prevent marketing approval of imetelstat for relapsed/refractory MF by the FDA or similar international regulatory authorities. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities have substantial discretion in the approval process and can delay, limit or deny approval of RYTELO in other jurisdictions or indications, or require us to conduct additional non-clinical or clinical testing or abandon a program for many reasons, including:</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreement with the design or implementation of our clinical trials, including our statistical analysis of trial results;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to demonstrate that RYTELO&#8217;s efficacy results provide sufficient evidence of overall clinical benefit;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfavorable benefit-to-risk assessment, in the case of marginal efficacy and/or clinically relevant safety concerns, for any proposed indication;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using RYTELO or drugs similar to RYTELO;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreement with our interpretation of data from non-clinical studies or clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">rejection by the FDA of foreign data included in any future supplemental NDA, or sNDA, submissions for any future indications and the non-applicability of this data to the U.S. population and U.S. medical practice; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identification of critical issues as a result of a pre-approval health authority inspection that could negatively impact the integrity of data in the MAA and any future sNDA and lead to a rejection by the FDA, EMA, or similar international regulatory authorities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a determination by international regulatory authorities that regulatory approval for RYTELO should be narrowed or made more restrictive than our current approvals in the U.S. and the EU for lower-risk MDS or any future indication for which approval is sought, if any;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreement regarding the formulation, labeling and/or the specifications for RYTELO; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure of the quality or stability of RYTELO to meet acceptable regulatory standards;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the EMA or the competent authorities of the individual EU Member States or similar international regulatory authorities may lack resources or be delayed in conducting pre-approval inspections due to lack of resources or other reasons;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or any third-party service providers may be unable to demonstrate compliance with GMP, good clinical practices, or GCP, or other applicable regulatory and other requirements to the satisfaction of the FDA, the EMA, the competent authorities of the individual EU Member States or similar international regulatory authorities; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulatory policies or approval processes, or potential reduction of unmet medical need with the entry of competitive therapies to the market, could render our clinical efficacy or safety data insufficient for approval.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events may result in a failure to further develop, obtain regulatory approval for or commercialize RYTELO in any jurisdiction or in any indication other than lower-risk MDS in the U.S. and the EU, which could severely and adversely affect our business and business prospects.  </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, in recent years, there has been increased public and political scrutiny on the FDA and similar international regulatory authorities with respect to the approval process for new drugs, and as a result regulatory authorities may apply more stringent regulatory standards, especially regarding drug safety, when reviewing regulatory submissions. </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">RISKS RELATED TO COMPLIANCE WITH HEALTHCARE LAWS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with healthcare providers, including physicians and third-party payors, the methods by which we promote RYTELO, and the content of our promotional materials and programs, are subject to applicable promotional, anti-kickback, fraud and abuse, and other healthcare laws and regulations, and our failure to comply with these laws could expose us to criminal sanctions, civil penalties, exclusion from federal health care programs, contractual damages, reputational harm and may adversely affect our business and financial results. </span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates the promotional claims that may be made about drug products. In particular, FDA asserts that a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. The FDA, DOJ and other agencies actively enforce regulations related to the promotion and advertisement of pharmaceutical products. If our promotional materials or methods were found to have violated the Food, Drug, and Cosmetic Act, or False Claims Act, we could be subject to Warning or Untitled Letters, or to significant civil, criminal, or administrative penalties, which could inhibit our ability to commercialize RYTELO and generate revenue, require us to expend significant time and resources in response, and generate negative publicity. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare professionals, including but not limited to physicians, nurses, medical directors, hospitals, pharmacies, pharmacy benefit managers, group purchasing organizations, wholesalers, insurers, and all individuals employed by such entities (collectively, HCPs), and patients, caregivers, patient advocacy organizations, or medical societies, may influence the recommendation and prescription of RYTELO. There is ongoing government focus on the relationships between the pharmaceutical industry and HCPs or others who can influence the prescription or recommendation of products, and common industry activities that we may engage in such as speaker programs, advisory boards, consulting agreements with HCPs, relationships with charitable foundations providing copayment assistance, and relationships with patient organizations and patients continue to receive increased governmental attention.  </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our arrangements with HCPs and others who have the ability to influence the recommendation and prescription of RYTELO may expose us to broadly applicable federal and state fraud and abuse and other healthcare laws and regulations, including anti-kickback and false claims laws; data privacy and security laws, including the Health Insurance Portability and Accountability Act, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH; and transparency laws related to payments and/or other transfers of value made to physicians, other healthcare professionals and teaching hospitals.  Additionally, some state and local laws require certain regulatory licenses to manufacture or distribute our products commercially and/or the registration of pharmaceutical sales representatives in the jurisdiction.These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we market, sell and distribute RYTELO. For details regarding the restrictions under applicable federal and state healthcare laws and regulations that may affect our ability to operate, see Item 1 &#8220;Business-Government Regulation- Fraud and Abuse, and Transparency Laws and Regulations&#8221; of the 2025 Form 10-K. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. For example, to help patients afford our products, we have a patient assistance program and also occasionally make donations to independent charitable foundations that help financially needy patients. These types of programs designed to assist patients in affording pharmaceuticals have become the subject of scrutiny under the AKS and other federal and state laws in recent years.  If we or our vendors or donation recipients are deemed to fail to comply with laws or regulations in the operation of these programs, we could be subject to damages, fines, penalties or other criminal, civil or administrative sanctions or enforcement actions. We cannot ensure that our compliance controls, policies and procedures will be sufficient to protect against acts of our employees, business partners or vendors that may violate the laws or regulations of the jurisdictions in which we operate. A government investigation could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While we maintain a comprehensive compliance program designed with the goal of ensuring that our practices and the activities of our third party contractors and employees fall within the scope of available statutory exceptions and regulatory safe harbors whenever possible, and otherwise comply with applicable laws, it is possible that government authorities may disagree with our assessment, find fault with the conduct of our employees or contractors or conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, or could result in related shareholder lawsuits, any of which would adversely affect our business, financial condition, results of operations and prospects. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Foreign, federal and state enforcement bodies have increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. If our operations are found to be in violation of any of these or any other healthcare and privacy-related regulatory laws that may apply to us, our ability to operate our business and our results of operations could be adversely affected by: </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement and imprisonment;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs or comparable foreign programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reputational harm;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diminished profits and future earnings;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">curtailment of our operations. </span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:90%">RISKS RELATED TO THE FURTHER DEVELOPMENT OF IMETELSTAT</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We cannot be certain that we will be able to continue to develop imetelstat or advance it in clinical trials, or that we will be able to receive regulatory approval for imetelstat in any other indications in the U.S., the EU or any other region, on a timely basis or at all.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are wholly dependent on the success of RYTELO (imetelstat), which is our only approved product, and our ability to generate revenue from product sales and achieve profitability is wholly dependent on our ability to successfully commercialize RYTELO for lower-risk MDS or to expand its indications of use. In this regard, in addition to lower-risk MDS, which is the only indication for which RYTELO has received marketing approval in the U.S. and the EU, we are developing imetelstat for the treatment of several myeloid hematologic malignancies. Our ability to further develop imetelstat and to expand its indications of use to other myeloid hematologic malignancies is subject </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to significant risks and uncertainties, including, among other things, our ability to: </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">generate sufficient safety and efficacy data from the IMpactMF, IMproveMF, IMpress and IMAGINE clinical trials, as well as our studies in frontline MF and acute myeloid leukemia or high-risk MDS, to support any application for regulatory approval, without clinically meaningful safety issues, side effects or dose-limiting toxicities related to imetelstat that may negatively impact its benefit-risk profile;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ascertain that the use of imetelstat does not result in significant systemic or organ toxicities, including hepatotoxicity, or other safety issues resulting in an unacceptable benefit-risk profile;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain additional capital, if and when needed, in order to enable us to further advance imetelstat clinical trials in other myeloid hematologic malignancies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain and maintain required regulatory clearances and approvals to enable continued clinical development of imetelstat; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into and maintain commercially reasonable arrangements with third parties to provide services needed to further research, develop and commercialize RYTELO, including maintaining the agreements with our contract research organizations, or CROs, and third-party manufacturers and for territories outside of the U.S. in compliance with applicable laws;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recruit and retain sufficient qualified and experienced personnel to support the development and commercialization of RYTELO in potential other approved indications and other jurisdictions outside of the U.S. and the EU;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">achieve acceptance of RYTELO treatment by patients and the relevant medical communities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compete effectively with other approved treatments in lower-risk MDS, and relapsed/refractory MF, if imetelstat is approved in relapsed/refractory MF, and potentially other myeloid hematologic malignancies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain appropriate coverage and reimbursement levels for the cost of RYTELO from governmental authorities, private health insurers and other third-party payors; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain, maintain and enforce adequate intellectual property and regulatory exclusivity for RYTELO in the U.S., EU and globally.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> If we are not able to successfully achieve these goals and overcome other challenges that we may encounter in the research, development, manufacturing and commercialization of RYTELO in indications other than lower-risk MDS, we may be forced to abandon our development and/or commercialization of RYTELO in indications other than lower-risk MDS, which could severely harm our business and business prospects.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials of imetelstat could be interrupted, delayed, terminated or abandoned for a variety of reasons which could severely and adversely affect our financial results, business and business prospects.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The conduct and completion of our clinical trials could be interrupted, delayed or abandoned for a variety of reasons, including as a result of clinical trial failures, suspensions, terminations or delays related to:</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patient recruitment, enrollment and retention challenges and operational delays, including in connection with opening new clinical trial sites, while also competing with clinical trials for other investigational drugs in the same patient population; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">use of OS as a trial endpoint, which inherently requires prolonged periods of clinical observation and follow-up, including the need for a certain number of events, or deaths, to occur in IMpactMF prior to the interim or final analysis in that trial of OS; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">use of trial endpoints, including patient-reported outcomes, that necessitate a comprehensive analysis of the resulting data to determine trial outcomes;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and/or maintaining regulatory clearances in the U.S. or other jurisdictions to commence, conduct or modify current or potential future clinical trials of imetelstat, in a timely manner, or at all;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investigational new drug applications, or INDs, and equivalent submissions in other countries for imetelstat being placed on full or partial clinical hold, suspended or subject to other requirements by the FDA or other similar international regulatory authorities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contracting with a sufficient number of clinical trial sites to conduct current and potential future clinical trials, and ensuring that such contracts contain all necessary terms and conditions required by applicable laws, including providing for valid mechanisms to engage in cross-border data transfers, as well as identifying, recruiting and training suitable clinical investigators;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining or accessing necessary clinical data in accordance with appropriate clinical or quality practices and regulatory requirements, in a timely and accurate manner to ensure complete data sets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">responding to safety findings, recommendations or conclusions by the data safety review committees, independent data monitoring committees and/or expert committees of current and potential future clinical trials of imetelstat based on emerging data occurring during such clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing sufficient quantities that meet our specifications, cost and quality requirements, and timelines for imetelstat, or for other clinical trial materials, in a manner that meets the quality standards of the FDA and other similar international regulatory authorities, and responding to any disruptions to drug supply, clinical trial materials or quality issues that may arise;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effects of macroeconomic or other global conditions, such as inflation, fluctuations in interest rates, prospects of a recession, government shutdowns, changes in tariffs or other trade restrictions, bank failures and other disruptions to financial systems, civil or political unrest, military conflicts, pandemics or other health crises and supply chain and resource issues;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complying with current and future regulatory requirements, policies or guidelines, including domestic and international laws and regulations pertaining to fraud and abuse, transparency, and the privacy and security of health information;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reaching agreement on acceptable terms and on a timely basis, if at all, with collaborators, physician investigators, vendors and other third parties located in the U.S. or other countries, including our CROs, laboratory service providers and clinical trial sites, on all aspects of clinical development and collaborating with them successfully; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party clinical contractors, including investigators or our CROs not performing our clinical trials according to our anticipated schedule or consistent with the clinical trial protocol, GCP, or other regulatory requirements, or not performing data collection or analyses in a timely or accurate manner.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, recent actions by the current administration in the U.S. to limit federal agency budgets and personnel have resulted in reductions in the FDA's budget and employees, which may lead to slower response times, longer review periods, delayed inspections or other disruptions that we cannot currently predict. Failures or delays with respect to any of the foregoing events and such disruptions in the timely review and processing of our regulatory submissions and inspections could adversely affect our ability to conduct or complete the clinical trials being conducted by us or our investigators, or to commence, conduct and complete potential future clinical trials of imetelstat, which could increase development costs or interrupt, further delay or halt our development of imetelstat, any of which could severely and adversely affect our financial results, business and business prospects. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RYTELO may cause, or have attributed to it, undesirable or unintended side effects or other adverse events that could halt or limit its further commercialization, delay or prevent its regulatory approval in any other jurisdiction or indication, or cause us to delay or terminate our clinical trials.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While the FDA and the EC granted approval of RYTELO based on the data included in our NDA and MAA, respectively, including data from the Phase 3 IMerge trial, we cannot be certain whether the results as a larger number of patients receive RYTELO from commercial use, including results related to safety, will be consistent with the results from earlier clinical trials that served as the basis for its approval.  </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because remaining patients in ongoing clinical trials continue to receive imetelstat, additional or more severe toxicities or safety issues may be observed, and the benefit-risk profile of imetelstat will continue to be assessed, including the risk of hepatotoxicity, severe cytopenias, fatal bleeding with or without any associated thrombocytopenia, patient injury or death. New data relating to imetelstat, including from adverse event reports and our post-marketing requirements in the U.S., and from ongoing clinical trials of imetelstat, may result in changes to the product label and may adversely affect sales, or result in withdrawal of imetelstat from the market. The FDA and regulatory authorities in other jurisdictions may also consider the new data in reviewing our marketing applications for additional </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">indications and/or in other jurisdictions, or impose post-approval requirements. If any of these actions were to occur, it could result in significant expense and delay or limit our ability to generate sales revenues.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, as a result of commercialization of RYTELO, or in current or potential future clinical trials, RYTELO may cause, or have attributed to it, undesirable or unintended side effects or other adverse events affecting its safety or efficacy that could interrupt, further delay or halt its commercialization or current or potential future clinical trials. In this regard, adverse events and dose-limiting toxicities observed in previous and ongoing clinical trials include:</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hematologic toxicities, such as profound and/or prolonged thrombocytopenia or neutropenia;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">bleeding events, with or without thrombocytopenia, including Grade 3/4 bleeding events;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">febrile neutropenia;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hepatotoxicity and liver function test abnormalities, as well as hepatic failure;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">gastrointestinal events;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">infection events, with or without neutropenia, including Grade 3/4 infection events;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">muscular and joint pain;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fatigue;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">headache; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">infusion-related reactions.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If patients experience similar or more severe adverse events, or new or unusual adverse events, or if the FDA or other similar international regulatory authorities determine that efficacy and safety data from our commercialization efforts or in clinical trials do not support an adequate benefit-risk profile to justify continued treatment of patients, then the FDA or other similar international regulatory authorities may halt or restrict the commercialization of RYTELO or place one or more of our INDs on clinical hold, as occurred in March 2014. If this were to occur, there could be a significant delay in, or possible termination of, one or more of our clinical trials, and our commercialization efforts could be halted, which might cause us to cease operations. If such toxicities or other safety issues identified as a result of our commercialization of RYTELO or in any clinical trial are determined by us, the FDA or similar international regulatory authorities to result in an unacceptable benefit-risk profile, then:</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA and EC could withdraw or restrict regulatory approval for RYTELO in the U.S. and EU, respectively, for lower-risk MDS;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional information supporting the benefit-risk profile of RYTELO may be requested by the FDA or similar international regulatory authorities and if any such information is not available or, if available, not deemed acceptable, regulatory approval could be withdrawn by the FDA in the U.S. and the EC in the EU, and/or current clinical trials could be suspended, terminated, or placed on clinical hold by the FDA or similar international regulatory authorities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to retain enrolled patients in our current clinical trials may be negatively affected, resulting in incomplete data sets and the inability to adequately assess the benefit-risk profile of RYTELO in a specific patient population; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional, unexpected clinical trials or non-clinical studies may be required to be conducted; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">RYTELO may not receive or maintain regulatory clearances and approvals required to enable its continued development.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any of these events could interrupt, further delay, or halt our commercialization of RYTELO or its further development, and as a result, could preclude the commercialization of RYTELO in any additional indications, as well as increase costs for continued development in additional indications, which would have a severe adverse effect on our results of operations, financial condition and ability to raise additional capital, business and business prospects, any of which might cause us to cease operations. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results and data we disclosed from prior non-clinical studies and clinical trials, as well as any data disclosed as a result of an interim analysis, may not predict success in later clinical trials or the final analysis, and we cannot assure you that any ongoing or future clinical trials of imetelstat, including IMpactMF, will lead to similar results and data that could potentially enable us to obtain any further regulatory approvals.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The design of a clinical trial can determine whether its results will support regulatory approval of a product, and flaws in the trial design may not become apparent until the clinical trial is well advanced or during the approval process after the trial is completed. A clinical trial design that is considered appropriate for regulatory approval includes a sufficiently large sample size with appropriate statistical power, as well as proper control of bias, to allow a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">meaningful interpretation of the results. The preliminary results of imetelstat clinical trials with smaller sample sizes can be disproportionately influenced by the impact the treatment had on a few individuals, which limits the ability to generalize the results across a broader community, making the trial results of clinical trials with smaller sample sizes less reliable than trials with a larger number of patients. As a result, there may be less certainty that imetelstat will achieve a statistically significant effect in any future clinical trials. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, success in non-clinical testing and early clinical trials, including Phase 2 clinical trials, such as IMbark, does not ensure that later clinical trials will be successful, nor does it predict final clinical trial results. In addition, even though we reported positive top-line results from IMerge Phase 3 in January 2023, this does not ensure that any other clinical trials of imetelstat will be successful. Later stage clinical trials of imetelstat may fail to show an acceptable benefit-risk profile despite having progressed through non-clinical studies and initial clinical trials. Many companies in the biopharmaceutical industry have frequently suffered significant setbacks in later clinical trials, even after achieving promising results in earlier non-clinical studies or clinical trials. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In general, Phase 3 clinical trials with larger numbers of patients or longer durations of therapy may fail to replicate efficacy and safety results observed in earlier clinical trials, such as the results observed in IMbark, and if this were to occur with IMpactMF, this would adversely affect future development prospects of imetelstat, and as a result, impact the potential commercialization of imetelstat in relapsed/refractory MF.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, non-clinical and clinical data are often susceptible to varying interpretations and analyses. In some instances, there can be significant variability between different clinical trials of imetelstat due to numerous factors, including changes in trial procedures set forth in trial protocols, differences in the size and type of patient populations, and changes in and adherence to the dosing regimens. For example, although the statistical analyses comparing IMbark data to closely matched real world data, or RWD, published in the September 2021 issue of the Annals of Hematology, suggest potentially favorable OS in relapsed/refractory MF patients treated with imetelstat, compared to bipolar androgen therapy using closely matched patients&#8217; RWD, such comparative analyses between RWD and our clinical trial data have several limitations. For instance, the analyses create a balance between treatment groups with respect to commonly available covariates, but do not take into account the unmeasured and unknown covariates that may affect the outcomes of the analyses. Potential biases are introduced by factors which include, for example, the selection of the patients included in the analyses, misclassification in the matching process, the small sample size, and estimates that may not represent the outcomes for the true treated patient population. Failure to achieve results supporting a positive benefit-risk profile in current or potential future imetelstat clinical trials would interrupt, further delay, or halt, any development of imetelstat, which would have a severe adverse effect on our results of operations, financial condition and ability to raise additional capital, if needed, business and business prospects. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, preliminary data are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. Additional or updated safety and efficacy data from current or potential future clinical trials of imetelstat may result in a benefit-risk profile that does not justify the continued development and/or potential regulatory approval of imetelstat in a particular patient population, or at all. Any data reported from IMpactMF may materially differ from and be less positive than data previously reported from IMbark. Thus, reported data should be considered carefully and with caution, and not relied upon as indicative of future clinical results. Such additional data could result in a lower benefit-risk profile than initially expected, which could halt the commercialization of RYTELO, hinder the potential success of IMpactMF, IMproveMF, IMpress or IMAGINE, or cause us to abandon further development of imetelstat entirely.  </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Top-line or interim results and data may differ from future results of the same study, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Moreover, as remaining patients in IMerge Phase 3 continue to be treated and followed under the extension phase of the trial and longer-term outcomes are assessed, these additional and more mature data may alter the benefit-risk profile of imetelstat in an adverse manner, including with respect to OS. Material adverse differences in future results, compared to preliminary, interim or top-line data, could severely and adversely affect our financial results, business and business prospects, including the commercialization of RYTELO, and might cause us to cease operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct our current and potential future clinical trials of imetelstat. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to continue the development of imetelstat.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We do not have the ability to independently conduct clinical trials. Therefore, we rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, service providers, vendors, suppliers and consultants, to conduct clinical trials of imetelstat. The third parties we contract with for execution of our current and potential future clinical or investigator-sponsored trials of imetelstat play a critical role in the conduct of these trials and the subsequent collection and analysis of data. However, these third parties are not our employees, and except for contractual duties and obligations, we have limited ability to control their performance, or the amount or timing of resources that they devote to imetelstat. For example, we have retained CROs to support our clinical development activities, and any failure by our CROs to perform their contractual obligations, or disputes with our CROs about the quality of their performance or other matters, could further delay or halt our clinical development activities. These third parties may also have relationships with other commercial entities, some of which may compete with us. Under certain circumstances, these third parties may terminate their agreements with us without cause and upon immediate written notice. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Although we rely on third parties to conduct our clinical trials, we remain responsible for ensuring that each clinical trial is conducted in accordance with its investigational plan and protocol, and applicable laws. Moreover, the FDA and similar international regulatory authorities require us to comply with GCP regulations and standards for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the rights, integrity and confidentiality of patients participating in clinical trials are protected, including being adequately informed of the potential risks. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, or similar international regulatory authorities, may require us to perform additional clinical trials. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine whether any of our clinical trials comply with GCP or other applicable regulations. In addition, our clinical trials must be conducted with imetelstat produced under applicable GMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials. Our ability to comply with these regulations and standards may be contingent upon activities conducted by third parties, and if they fail to perform in accordance with contractual obligations and legal requirements, our development of imetelstat may be interrupted, further delayed or halted. Any failures by us or third parties noted above would have a severe adverse effect on our results of operations, financial condition and ability to raise additional capital, if needed, business and business prospects, including the commercialization of RYTELO, any of which might cause us to cease operations. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the execution of clinical trials and the subsequent compilation and analysis of the data produced, including the interim and final analyses for IMpactMF, requires coordination among various parties. In order for these functions to be carried out effectively and efficiently, it is imperative that these parties communicate and coordinate with one another. If the quality or accuracy of the clinical data obtained, compiled or analyzed by third parties is compromised due to their failure to adhere to our clinical trial protocols, GCP or GMP requirements, or for any other reason, we may need to enter into new arrangements with alternative third parties, which would cause delay, and could be difficult, costly or impossible.  </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Switching or adding CROs, investigators, vendors and other third parties involves additional costs and delays because of the time it takes to finalize a contract with a new CRO and for their commencement of work. Although we carefully manage our relationships with our CROs, investigators, vendors and other third parties, we and any of these third parties may nonetheless encounter challenges or delays in the future, which could have a material and adverse impact on our business and business prospects. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain principal investigators for our clinical trials serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected conduct of the trial. The FDA or comparable foreign regulatory authorities may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of any future applications for regulatory approval of imetelstat, including in any additional indications by the FDA.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not control the conduct of current or any potential future investigator-led clinical trials, and data from such trials could show marginal efficacy and/or clinically relevant safety concerns related to imetelstat resulting in an unfavorable benefit-risk assessment that could materially and adversely impact our ongoing clinical trials, or our development program as a whole.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We do not control the design or administration of investigator-led clinical trials, nor the submission, approval or maintenance of any IND or international equivalent filings required to conduct these clinical trials. In addition, we do not have control over the timing and reporting of the data from any such investigator-led clinical trials. A delay in the timely completion of or reporting of data from any current or potential future investigator-led clinical trial could have a material adverse effect on our ability to maintain regulatory approval for RYTELO in lower-risk MDS, or to further develop or advance it in clinical trials, as such delays may impede our ability to generate necessary supplemental clinical evidence, fulfill post-marketing commitments or requirements, or provide regulatory authorities with timely safety and efficacy data needed to support ongoing approval or future development. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investigator-led clinical trials may be conducted under less rigorous clinical standards than those used in company-sponsored clinical trials. Accordingly, regulatory authorities may closely scrutinize the data collected from these investigator-led clinical trials. In addition, any investigator-led clinical trials could show marginal efficacy and/or clinically relevant safety concerns that could delay, limit or preclude the further clinical development or marketing approval of RYTELO in any indication. To the extent that the results of any investigator-led clinical trials raise safety or other concerns, regulatory authorities may withdraw or restrict approval for RYTELO, question the results of such investigator-led clinical trials, or question the results of any of our clinical trials. Safety concerns arising from future investigator-led clinical trials could result in withdrawal of approval of RYTELO, partial or full clinical holds being placed on our INDs by the FDA or other similar international regulatory authorities, as occurred in March 2014, which would further delay or prevent us from commercializing RYTELO or advancing it into further clinical development. Any of the foregoing would delay or preclude any future marketing approvals for RYTELO and could cause us to discontinue our development, which would severely harm our business and prospects and could potentially cause us to cease operations. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">RISKS RELATED TO MANUFACTURING RYTELO (IMETELSTAT) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure by us to maintain a manufacturing supply chain to appropriately and adequately supply RYTELO for commercial and future clinical uses would adversely affect our ability to commercialize RYTELO and result in a further delay in or cessation of clinical trials, and our business and business prospects could be severely harmed, and we could cease operations.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture of RYTELO (imetelstat) must comply with applicable regulatory standards for commercial uses and current and potential future clinical trials. The process of manufacturing RYTELO is complex and subject to several risks, including:</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to consistently manufacture and attain sufficient production yields with acceptable quality control and quality assurance to meet market demand for our commercialization of RYTELO, as well as the needs for continuing clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain existing commercial supply agreements and to establish additional or alternative supply agreements if necessary, including our ability to successfully transfer manufacturing technology and attain regulatory approval at any such additional or alternative suppliers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reliance on third-party manufacturers and suppliers, whose efforts we do not control;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">supply chain issues, including the timely availability of product and management of shelf-life, including raw materials, active pharmaceutical ingredient, or API, and drug product and other supplies, and the cost of procuring the foregoing, any of which may be impacted by a number of factors, including the effects of macroeconomic or other global conditions, such as ongoing military conflicts, increased tariffs, renegotiation of existing international trade agreements, escalating trade tensions and other trade restrictions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">shortage of qualified personnel at any of our third party suppliers; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory acceptance and compliance with regulatory requirements, which are less well-defined for oligonucleotide products than for small molecule drugs and vary in each country.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the ongoing Russia-Ukraine military conflict and the ongoing military conflict involving the U.S., Israel and Iran have had and may continue to have further global economic consequences, including continued disruptions of the global supply chain and energy markets. For example, disruptions or perceived risks to energy supply routes, including shipping through key transit points, have resulted in increased fuel and energy prices and could continue to do so for an extended period, which could disrupt our existing supply chain and increase our cost of doing business, reduce our gross margins or otherwise negatively impact our financial results. See also the risk factor entitled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global trade issues and changes in and uncertainties with respect to trade policies and export regulations, including import and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">export license requirements, trade sanctions, tariffs and international trade disputes, could increase our costs and negatively impact net revenues from sales of RYTELO.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;  </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these and other risks, we may be unable to maintain a manufacturing infrastructure and supply chain capable of providing RYTELO for clinical and commercial use, which would delay or adversely affect our RYTELO commercialization efforts; result in lost sales; delay or result in a cessation of our current or potential future clinical trials; delay or preclude potential future regulatory approvals of RYTELO in other jurisdictions or indications; and could cause financial and reputational harm. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third parties that manufacture RYTELO fail to perform as needed, the commercial and clinical supply of RYTELO could be interrupted or limited, and we may be unable to successfully commercialize RYTELO or conduct or complete current or potential future clinical trials.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our RYTELO manufacturing supply chain relies, and will continue to rely, solely upon third-party manufacturers to perform certain manufacturing, quality control, and other technical and scientific work with respect to RYTELO, as well as to supply starting materials and manufacture the API and drug product for our commercialization of RYTELO, as well as current and potential future clinical trials. While we have established arrangements with third parties for the manufacture of RYTELO, our manufacturing supply chain is highly specialized, and as such we are reliant upon a small group of third-party manufacturers to supply starting materials and drug product, and we rely on a single source to supply the API for RYTELO. Failure by such third-party manufacturers to perform in a timely manner and in compliance with all regulatory requirements, or at all, or the termination of one of our supply agreements before we have retained and established an acceptable alternative supplier, could lead to delays or shortages in drug supply, perhaps substantially, that are necessary for our clinical activities and commercialization of RYTELO. For example, one of our third-party manufacturers received a warning letter from the FDA due to certain deficiencies in the manufacturer&#8217;s process and facilities that were not in compliance with FDA requirements and regulations governing the manufacturing, processing, packing and holding of drug product. While not related to the production of RYTELO, if the warning letter is not timely remediated by the manufacturer, it could lead to delays or shortages in drug supply, or the inability to manufacture or ship drug supply necessary for non-clinical and clinical activities, and commercialization.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we plan to retain additional third-party manufacturers to provide redundancy in our supply chain; however, we may be unable to do so on a timely basis on terms that are acceptable to us, or at all. We expect to rely on third-party manufacturers to produce and deliver sufficient quantities of RYTELO and other materials to support our commercialization of RYTELO and clinical trials on a timely basis and to comply with applicable regulatory requirements. We do not have direct control over these third-party personnel or operations. Reliance on these third-party manufacturers is subject to numerous risks, including:</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to execute timely contracts or production orders with any additional third-party manufacturers and suppliers that we may identify on acceptable terms, or at all;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays and disruptions experienced by third-party manufacturers that adversely impact the ability of such parties to fulfill their contractual obligations to us, including providing the quantities of RYTELO required to meet commercial and clinical needs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">capacity limitations and scheduling constraints experienced by third-party manufacturers due to scheduling, maintenance and other commitments, and queued manufacturing activities in contracted facilities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements by regulatory authorities to validate and qualify significant activities for any current or additional manufacturer, which could involve technology transfer, new testing, compliance inspections, and would likely require FDA or comparable foreign regulatory authority approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability of third-party manufacturers to timely formulate and manufacture RYTELO or to produce or ship RYTELO in the quantities or of the quality required to meet commercial and clinical needs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possible mislabeling by third-party manufacturers of finished drug product for both commercial and clinical use, potentially resulting in product recall and harm to our business;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decisions by third-party manufacturers to exit the contract manufacturing business during the time required to supply clinical trials or to successfully produce, store and distribute RYTELO to meet our commercial needs or before we establish an acceptable alternative supplier;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance by third-party manufacturers with GMP standards mandated by the FDA and state agencies and other government regulations, including foreign governing regulations, corresponding to similar international regulatory authorities, including any deficiencies identified during regulatory inspections, such as those identified in the warning letter issued to one of our third-party manufacturers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">breach or termination of manufacturing or supply contracts;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inadequate storage or maintenance at contracted facilities resulting in theft or spoilage; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">natural disasters that affect contracted facilities, including manufacturing, warehousing, and distribution facilities.</span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Each of these risks could lead to delays or shortages in drug supply, or the inability to manufacture or ship drug supply necessary for commercialization, and non-clinical and clinical activities, which could severely and adversely affect our financial results, business and business prospects.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, third-party manufacturers and/or any other manufacturers may need to make substantial investments to enable sufficient capacity increases and cost reductions, and to implement those regulatory and compliance standards necessary for successful commercialization of RYTELO. These third-party manufacturers may not be willing or able to achieve such capacity increases, cost reductions, or regulatory and compliance standards, and even if they do, such achievements may not be at commercially reasonable costs. Changing or adding alternative manufacturers may be prolonged, difficult and expensive, due to inherent technical complexities, regulatory risks, and because the number of potential manufacturers for oligonucleotide products is limited. It may be difficult or impossible for us to find a replacement or alternative manufacturer on acceptable terms, or at all.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:90%">RISKS RELATED TO OUR OPERATING RESULTS AND FINANCIAL POSITION</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a history of net losses and may not achieve consistent future profitability for some time, if ever.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are incurring and have incurred net losses every year since our operations began in 1990, except for one. As of March&#160;31, 2026, our accumulated deficit was approximately $1.9 billion. Losses have resulted principally from costs incurred in connection with our research and development activities and from general and administrative costs associated with our operations. Although we began commercializing RYTELO in June 2024, the commercial potential of and our ability to successfully commercialize RYTELO remains unproven, and our limited operating history as a commercial company makes our future operating results difficult to predict. We expect that our sales revenue may continue to vary from period to period as a result of the evolving effects of our commercialization strategy and as our commercialization efforts otherwise progress. If we do not generate sufficient revenue from commercial sales of RYTELO, or if we experience unforeseen events or choose to make other investments in our business, we may continue to experience negative cash flow as we fund our operations and imetelstat clinical development activities and research programs, and continue with the commercialization of RYTELO, including as a result of our obligation to pay royalty payments under the Royalty Pharma Agreement and service our debt obligations. We will need to generate significant revenues to achieve consistent future profitability, and we may never achieve consistent future profitability. Even if we do become profitable in the future, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to achieve consistent future profitability could negatively impact the market price of our common stock and our ability to sustain operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our operating results are unpredictable and may fluctuate. If our operating results are below the expectations of securities analysts or investors, the trading price of our common stock could decline. </span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results are difficult to predict and will likely fluctuate from quarter to quarter and year to year. Due to the limited historical sales data of RYTELO in lower-risk MDS since its approval by the FDA in June 2024, RYTELO sales will be difficult to predict from period to period and as a result, you should not rely on RYTELO sales results in any period as being indicative of future performance. Sales of RYTELO have in the past been below the expectations of securities analysts and investors, and sales of RYTELO have been and may in the future be below prior sequential or prior period sales, our own guidance and/or the expectations of securities analysts and investors. To the extent that we do not meet our guidance, our financial projections or estimates, or the expectations of analysts or investors, our stock price may be adversely impacted, perhaps significantly. For example, following releases of earnings for both of the quarters and years ended December 31, 2025 and 2024, our stock price declined significantly both times. As a result of this volatility, our stockholders may not be able to sell their common stock at or above the price they paid for their common stock. We believe that our quarterly and annual results of operations may be affected by a variety of factors, including:</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the overall level of demand for RYTELO in its approved indication, including across the breadth of the eligible patient segments;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which coverage and reimbursement for RYTELO is available from government and health administration authorities, private health insurers, managed care programs and other third-party payors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the amount of deductions from gross sales, including government-mandated rebates, chargebacks and discounts that can vary because of changes to the government discount percentage, including increases in the government discount percentage resulting from price increases we have taken or may take in the future, or due to different levels of utilization by entities entitled to government rebates and discounts and changes in patient demographics;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increases in the scope of eligibility for customers to purchase RYTELO at the discounted government price or to obtain government-mandated rebates on purchases of RYTELO;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our cost of sales;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and level of royalty payments under the Royalty Pharma Agreement;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, cost and level of investment in our sales and marketing efforts to support RYTELO sales;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, cost and level of investment in our research and development activities involving imetelstat and potential future product candidates; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenditures we may incur to develop and/or commercialize any additional products, product candidates, or technologies that we may develop, in-license, or acquire.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, changes in our operations, such as increased development, manufacturing and clinical trial expenses, or our undertaking of additional programs, business activities, or entry into strategic transactions, including potential future acquisitions of products, technologies or businesses may also cause significant fluctuations in our expenses. In addition, we measure compensation cost for stock-based awards made to employees at the grant date of the award, based on the fair value of the award, and recognize the cost as an expense over the employee&#8217;s requisite service period. As the variables that we use as a basis for valuing these awards change over time, including our underlying stock price, the magnitude of the expense that we must recognize may vary significantly. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For these and other reasons, it is difficult for us to accurately forecast future sales of RYTELO, operating expenses or future profits or losses. As a result, our operating results in future periods could be below our guidance or the expectations of securities analysts or investors, which could cause the trading price of our common stock to further decline, perhaps significantly.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our financial projections and estimates are subject to significant risks, assumptions, and uncertainties, and our actual results may differ materially.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our financial projections and estimates are subject to significant risks, assumptions, and uncertainties, and our actual results may differ materially. These projections and estimates include estimates of the total addressable market for RYTELO, assumptions regarding patient market share and duration of therapy for patients receiving RYTELO, as well as assumptions regarding our ability to meet demand and assumptions regarding our future costs of goods. These projections and estimates are subject to various factors beyond our control, including, for example, the level of demand for RYTELO, the extent to which coverage and reimbursement for RYTELO is available from government and health administration authorities, private health insurers, managed care programs and other third-party payors, increased costs in the supply chain, including as a result of increased tariffs, renegotiation of existing international trade agreements, escalating trade tensions and other trade restrictions, increased labor costs, changes in the regulatory environment, the impact of global health crises or macroeconomic or other global conditions, and changes in our senior management team. Our financial projections and estimates constitute forward-looking statements, are for illustrative purposes only and should not be relied upon as necessarily being indicative of future results. The assumptions and estimates underlying such financial projections and estimates are inherently uncertain and are subject to a wide variety of significant business,  economic, competitive and other risks and uncertainties. Actual results may differ materially from the results contemplated by the financial projections. Our independent auditors have not studied, reviewed, compiled or performed any procedures with respect to the projections, and accordingly, they did not express an opinion or provide any other form of assurance with respect thereto. While all financial projections, estimates and targets are necessarily speculative, we believe that the preparation of financial projections involves increasingly higher levels of uncertainty the further out the projection, estimate or target extends from the date of preparation. Accordingly, there can be no assurance that the prospective results are indicative of our future performance or that actual results will not differ materially from those presented in the financial projections or estimates.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to obtain additional capital, if and when needed, would force us to further delay, reduce or eliminate the further development of RYTELO, or to halt the commercialization of RYTELO, any of which would severely and adversely affect our financial results, business and business prospects, and might cause us to cease operations.</span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Successful drug development and commercialization requires significant amounts of capital. As of March&#160;31, 2026, we had approximately $341.0 million in cash, cash equivalents, restricted cash and marketable securities. While we believe that, based on our current operating plans and assumptions, our existing cash, cash equivalents, and marketable securities, together with anticipated net revenues from sales of RYTELO, will be sufficient to fund our projected operating requirements for the foreseeable future, if we do not generate net revenues from commercial sales of RYTELO at the levels we anticipate, if we experience unforeseen events or choose to make other investments in our business, or our assumptions </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">regarding our projected operating expenses are otherwise incorrect, we may require additional funding, which could include a combination of public or private equity offerings, debt financings (including additional tranches, if available, under the Pharmakon Loan Agreement (as defined below), collaborations, strategic alliances, licensing arrangements or marketing and distribution arrangements, which may not be possible. For example, changes in our operations, such as increased development, manufacturing and clinical trial expenses, or our undertaking of additional programs, business activities, or entry into strategic transactions, including potential future acquisitions of products, technologies or businesses, may cause our operating expenses to increase, perhaps significantly, which could require us to raise additional funding. If adequate funds are not available to us when we need them, our RYTELO commercialization efforts may be adversely affected and we may be unable to pursue further development of imetelstat, which would severely harm our business and we might cease operations.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Despite approval of RYTELO in the U.S. in June 2024 and in the EU in March 2025, the outcome of any clinical activities and/or regulatory approval process is highly uncertain, and we cannot reasonably estimate whether our future development activities may succeed, whether we will obtain regulatory approval for RYTELO in any other jurisdictions or indications we are pursuing or may in the future pursue, or whether we will be able to effectively commercialize RYTELO for lower-risk MDS in the U.S., the EU or other potential jurisdictions or indications, if at all. We may never recoup our investment in any RYTELO development, which would adversely affect our financial condition and our business and business prospects, and might cause us to cease operations. In addition, our plans and timing expectations could be further delayed or interrupted by the effects of macroeconomic or other global conditions, including those resulting from further changes in tariffs and other trade restrictions, renegotiation of existing international trade agreements or further escalation of trade tensions, inflation, fluctuations in interest rates, prospects of a recession, government shutdowns, bank failures and other disruptions to financial systems, civil or political unrest, military conflicts, pandemics or other health crises and supply chain and resource issues. Further, our future capital requirements are difficult to forecast and will depend on many factors, including:</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the accuracy of the assumptions underlying our estimates for our capital needs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the overall level of sales and market acceptance of RYTELO;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, timing, magnitude and costs of non-clinical and clinical development, manufacturing and commercialization of RYTELO, including commercialization in the U.S. and any commercialization in the EU for lower-risk MDS, or in any other jurisdictions or other indication we may pursue, subject to clearances and approvals by the FDA and similar international regulatory authorities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or disruptions in opening sites, screening and enrolling patients or treating and following patients, in our current or any potential future clinical trials of RYTELO;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcomes of regulatory reviews or other regulatory actions related to RYTELO;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of manufacturing, developing, commercializing and marketing RYTELO, including with respect to third-party vendors and service providers and our ability to achieve any meaningful reduction in manufacturing costs; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sales price for RYTELO, including the availability of coverage and adequate third-party reimbursement for RYTELO;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or in-license other drugs and technologies, or invest in businesses, products or technologies, although we currently have no commitments or agreements relating to any of these types of transactions, or to which we out-license RYTELO;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we are able to enter into and conduct successful commercialization arrangements with third parties, including for the commercialization and marketing of RYTELO in the EU and in any other regions outside of the U.S., if approved for commercialization in such other regions; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with the pending putative securities class action and shareholder derivative lawsuits and potential additional related lawsuits, as well as any other litigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent and scope of our selling, general and administrative expenses, including expenses associated with pending and potential future litigation; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our level of indebtedness and associated debt service obligations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of maintaining and operating facilities in California and New Jersey, as well as higher expenses for travel; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">macroeconomic or other global conditions that may reduce our ability to access equity or debt capital or other financing on preferable terms, which may adversely affect future capital requirements and forecasts; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of enabling our personnel to work remotely, including providing supplies, equipment and technology necessary for them to perform their responsibilities.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the event we need to raise additional capital to fund our business, including pursuant to the 2026 Sales Agreement with TD Cowen (as defined below), the Tranche B Loan and the Tranche C Loan under the Pharmakon Loan Agreement,  which are subject to certain funding conditions; capital lease transactions or other financing sources, such additional capital may not be available on acceptable terms, or at all. We may be unable to raise equity capital, or may be forced to do so at a stock price or on other terms that could result in substantial dilution of ownership for our stockholders. The receptivity of the public and private debt and equity markets to proposed financings has been substantially affected by uncertainty in the general economic, market and political climate due to the effects of macroeconomic or other global conditions, such as inflation, fluctuations in interest rates, prospects of a recession, government shutdowns, further changes in tariffs and other trade restrictions, bank failures and other disruptions to financial systems, civil or political unrest, military conflicts, pandemics or other health crises and supply chain and resource issues, and may in the future be affected by other factors which are unpredictable and over which we have no control. These effects have increased market volatility and could result in a significant long-term disruption of global financial markets, which could reduce or eliminate our ability to raise additional funds through financings, and could negatively impact the terms upon which we may raise those funds. Similarly, these macroeconomic conditions have created extreme volatility and disruption in the equity and credit markets and are expected to have further global economic consequences. For example, the ongoing Russia-Ukraine military conflict and the ongoing military conflict involving the U.S., Israel and Iran have created extreme volatility and disruption in the equity and credit markets and have had and may continue to have further global economic consequences, including continued disruptions of the global supply chain and energy markets, which could continue to drive inflationary pressures and increase global recession risk.If the equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. If we are unable to effectively commercialize RYTELO, or raise additional capital, if needed, or establish alternative collaborative arrangements with third-party collaborative partners for RYTELO when needed, the development and commercialization of RYTELO may be further delayed, altered or abandoned, which might cause us to cease operations.  </span></div><div style="text-indent:63pt"><span><br/></span></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may seek additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Due to uncertainty in the general economic, market and political climate, we may determine that it is necessary or appropriate to raise additional funds proactively to meet longer-term anticipated operating plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, including pursuant to the 2026 Sales Agreement, our stockholders may be diluted, and the terms may include liquidation or other preferences that could materially and adversely affect the rights of our existing stockholders. In addition, we have borrowed, and in the future may borrow, additional capital from institutional and commercial banking sources to fund development and our future growth, including pursuant to our Pharmakon Loan Agreement or potentially pursuant to new arrangements with different lenders. We may borrow funds on terms under agreements, such as our Pharmakon Loan Agreement, that include restrictive covenants, including covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Moreover, if we raise additional funds through alliance, collaborative or licensing arrangements with third parties, we may have to relinquish valuable rights to RYTELO or our technologies or grant licenses on terms that are not favorable to us.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:90%">RISKS RELATED TO OUR INDEBTEDNESS AND ROYALTY PAYMENT OBLIGATIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our level of indebtedness and debt service obligations could adversely affect our financial condition and may make it more difficult for us to fund our operations, including by limiting our operating and financial flexibility. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2024, we entered into the Pharmakon Loan Agreement, which we amended on January 5, 2026. We drew the Tranche A Loan of $125.0 million on November 1, 2024 and as of November 1, 2024, the total outstanding principal amount under the Pharmakon Loan Agreement was $125.0 million. The tranches for the remaining $125.0 million available to us under the Pharmakon Loan Agreement are as follows: (a) a Tranche B Loan of $75.0 million, which is available for us to request at our option until July 30, 2026, subject to certain customary and limited conditions; and (b) a Tranche C Loan of $50.0 million, which is available for us to request until July 30, 2026, subject to certain conditions, including us reaching a specified trailing twelve-month RYTELO revenue milestone on or prior to June 30, 2026. If we do not achieve such revenue milestone within the required timeline, we will not be eligible to draw down the Tranche C Loan. In addition, before we would consider drawing down any of the remaining tranches under the Pharmakon Loan Agreement, if available, we must first satisfy ourselves that we will have access to future alternate sources of capital, such as from commercial revenues or the equity capital markets or debt capital markets, in order to repay any additional principal borrowed, which we may be unable to do, in which case, our liquidity and ability to fund our operations may be substantially impaired.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All obligations under the Pharmakon Loan Agreement are secured by substantially all of our assets, including our intellectual property. Further, the terms of the Pharmakon Loan Agreement place restrictions on our operating and financial flexibility, and limit or prohibit our ability to dispose of certain assets, change our line of business, and engage in other significant transactions. Such restrictions will affect, and in many respects limit or prohibit, our ability and the ability of our subsidiaries to, among other things: </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">dispose of certain assets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">change our line of business;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engage in mergers, acquisitions or consolidations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur additional indebtedness;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">create liens on assets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pay dividends and make contributions or repurchase our capital stock; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engage in certain transactions with affiliates.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This indebtedness may create additional financing risk for us, particularly if our business or prevailing financial market conditions are not conducive to paying off or refinancing the outstanding debt obligations at maturity. If we draw down any of the remaining tranches under the Pharmakon Loan Agreement, our indebtedness will increase, which would further increase our risk of being unable to pay off or refinance our outstanding debt obligations at maturity.  </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness could also have important negative consequences, including:</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will need to repay the indebtedness by making payments of interest and principal, which will reduce the amount of cash available to finance our operations, our research and development efforts and other general corporate activities; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to comply with the obligations of our affirmative and restrictive covenants in the Pharmakon Loan Agreement could result in an event of default that, if not cured or waived, would permit the Lenders to accelerate our obligation to repay this indebtedness, and the Lenders could seek to enforce their security interest in the assets securing such indebtedness.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may borrow additional capital in the future to fund clinical development and our future growth, including pursuant to the Pharmakon Loan Agreement or potentially pursuant to new arrangements with different lenders. To the extent additional debt is added to our current debt levels, the risks described above could increase. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not have cash available in an amount sufficient to enable us to make interest or principal payments on our indebtedness when due. </span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to make scheduled interest payments on or to refinance our indebtedness depends on our future performance and ability to raise additional sources of cash, which is subject to economic, financial, competitive and other factors beyond our control. If we are unable to generate sufficient cash to service our debt, we may be required to adopt one or more alternatives, such as selling assets, restructuring our debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. If we desire to refinance our indebtedness, our ability to do so will depend on the state of the capital and lending markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Failure to satisfy our current and future debt obligations under the Pharmakon Loan Agreement or to comply with certain covenants in the Pharmakon Loan Agreement could result in an event of default, the occurrence and continuance of which provides the lenders with the right to demand immediate repayment of all outstanding obligations under the Pharmakon Loan Agreement (and in the case of certain insolvency, liquidation, bankruptcy or similar events, automatically requires immediate repayment of all outstanding obligations under the Pharmakon Loan Agreement), and to exercise remedies against us and the collateral securing the Pharmakon Loan Agreement. These events of default include, among other things:</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">insolvency, liquidation, bankruptcy or similar events; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to observe covenants under the Pharmakon Loan Agreement and ancillary collateral documents, which failure, in certain limited cases, is not cured within 10 or 20 days; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the occurrence of a withdrawal event in respect to RYTELO; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the occurrence of a material adverse change;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">material misrepresentations;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">certain cross-default of third-party indebtedness or certain default or termination events of hedging assessments; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">certain money judgments being entered against us which are not timely paid, discharged or stayed; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our assets are attached or seized.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> In the event of default, the lenders could accelerate all of the amounts due under the Pharmakon Loan Agreement. Under such circumstances, we may not have enough available cash or be able to raise additional funds through equity or debt financings to repay such indebtedness at the time of such acceleration. We may be required to delay, limit, reduce or terminate our RYTELO development or commercialization efforts or grant to others rights to develop and market RYTELO. The lenders could also exercise their rights to take possession and dispose of the collateral securing the Pharmakon Loan Agreement, which collateral includes substantially all of our property including, without limitation, our intellectual property, subject to certain exceptions. Our business, financial condition and results of operations could be materially adversely affected as a result of any of these events. </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Royalty Pharma Agreement places certain restrictions on our operational flexibility.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Royalty Pharma Agreement contains covenants that impose on us certain obligations with respect to royalty payments, diligence, reporting, indemnification and includes restrictions on intellectual property transfers and out-licenses, and certain other actions. For example, we are obligated to make royalty payments each quarter based on U.S. net sales of RYTELO at the royalty rates set forth in the Royalty Pharma Agreement, until the date when the aggregate Royalty Payments equal or exceed 1.65 times the Purchase Price, if this occurs by June 30, 2031. However, in the event we are unable to repay our obligation to Royalty Pharma before June 30, 2031, we will be required to make royalty payments equal to or exceeding 2.0 times the Purchase Price thereafter, which may negatively impact our business, financial condition and results of operations. The Royalty Pharma Agreement also limits our ability to create or incur liens or dispose of certain assets related to imetelstat. We have no rights to repurchase the revenue interests in RYTELO sold to Royalty Pharma (other than in connection with a change of control event), thereby limiting our ability to eliminate future applicability of the covenants contained in the Royalty Pharma Agreement. Compliance with these covenants may limit our flexibility in operating our business and our ability to take actions that might otherwise be advantageous to us and our stockholders.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO PROTECTING OUR INTELLECTUAL PROPERTY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain sufficient intellectual property protection and relevant regulatory exclusivities for RYTELO, both in the U.S. and in other countries, our competitors could develop and commercialize products similar or identical to RYTELO, and our ability to successfully commercialize RYTELO may be adversely affected.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Protection of our proprietary technology is critically important to our business. Our success and the success of our commercialization and planned future development of RYTELO will depend on our ability to protect our technologies and RYTELO through patents, regulatory exclusivity, and other intellectual property rights. Our success will depend in part on our ability to obtain, maintain, enforce, and extend our patents and maintain trade secrets, both in the U.S. and in other countries.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Leahy-Smith America Invents Act, or the AIA, in March 2013, the U.S. transitioned to a first-inventor-to-file system under which, assuming the other requirements for patentability are met, the first inventor to file a patent application is entitled to the patent. However, since the publication of discoveries in scientific or patent literature tends to lag behind actual discoveries by at least several months and sometimes several years, we are not able to be certain upon filing a patent application that the persons or entities that we name as inventors or applicants in our patent applications were the first to invent the inventions disclosed therein, or the first to file patent applications for these inventions. Thus, our ability to protect our patentable intellectual property depends, in part, on our ability to be the first to file patent applications with respect to our inventions, or inventions that were developed by our former collaboration partner and assigned to us, for the future development, commercialization and manufacture of RYTELO. As a result, if we are not the first inventor-to-file, we may not be able to obtain patents for discoveries that we otherwise would consider patentable and that we consider to be significant to the future success of RYTELO. Delay in the filing of a patent application for any purpose, including further development or refinement of an invention, may result in the risk of loss of patent rights.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the U.S. and in other countries. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">stop others from using or commercializing RYTELO or our technology and/or limit the duration of the patent protection for RYTELO and our technology. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While we have method-of-use patents that protect the use of RYTELO for the treatment of certain diseases, this type of patent does not prevent a generic competitor from making and marketing a product that is identical to RYTELO for an indication that is outside the scope of our approved use after our composition-of-matter patents or their patent term extensions, and any regulatory exclusivities have expired. Moreover, even if competitors do not actively promote their product for our approved indications, physicians may prescribe or use these generic products &#8220;off-label,&#8221; which would result in decreased sales for us. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our patents covering RYTELO, we also expect to rely on regulatory exclusivity, including orphan drug exclusivity of up to seven years in the U.S. and ten years in the EU following approval, to protect our rights to commercialize RYTELO for its approved uses, but such regulatory exclusivity may be limited or withdrawn. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Regulatory Approval of RYTELO -- Although orphan drug designation has been granted to RYTELO for the treatment of MDS and MF in the U.S. and in the EU, these designations may not be maintained, which would eliminate the benefits associated with orphan drug designation, including market exclusivity, which could limit the period of exclusivity we are able to maintain for the commercialization of RYTELO, and would likely harm our business and business prospects.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to orphan drug exclusivity, we expect to rely on other forms of regulatory exclusivity to protect our ability to commercialize RYTELO.  In the U.S., New Chemical Entity, or NCE, exclusivity would entitle us to four years of data exclusivity and one year of market exclusivity, for a total of five years of NCE exclusivity from the date of approval of the first-approved indication. Our request for NCE exclusivity is still pending with FDA, and might not be awarded or could be awarded and then later withdrawn. In the EU, imetelstat is designated as a New Active Substance, or NAS. For this NAS, regulatory data protection entitles us to eight years of data exclusivity and two years of market exclusivity, for a total of ten years in parallel to orphan market exclusivity. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the event that we are unsuccessful in obtaining, maintaining, enforcing and extending our patents and other intellectual property rights or having our licensors maintain the intellectual property rights we have licensed, the value of RYTELO and/or our technologies will be adversely affected, and we may not be able to further develop or commercialize RYTELO. Furthermore, such loss of intellectual property rights could impair our ability to exclude others from commercializing products similar or identical to RYTELO and therefore result in decreased sales for us. Occurrence of any of these events would materially and adversely affect our financial results, business and business prospects, and might cause us to cease operations.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent rights depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Patent and Trademark Office, or USPTO, and various governmental patent agencies in other countries require compliance with a number of procedural, documentary, fee payment, periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or patent applications. Failure to respond to official actions within prescribed time limits, and nonpayment of fees, for example, maintenance fees, renewal fees, and annuity fees, could result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the jurisdiction. In such an event, potential competitors might be able to enter the market with the same or similar products to RYTELO, and this circumstance could harm our financial condition, business and business prospects. In addition, if we are responsible for patent prosecution and maintenance of patent rights in-licensed to us or jointly owned with us, any of the foregoing could expose us to liability to the applicable patent owner or patent co-owner.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Patent terms may be inadequate to protect our competitive position on RYTELO for an adequate amount of time.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the U.S., the natural expiration of a patent is generally 20 years after its first effective nonprovisional filing date. As a result, our intellectual property may not provide us with sufficient patent rights to exclude others from commercializing products similar or identical to RYTELO.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the Hatch-Waxman Act permits one patent per approved product to receive one patent term extension of up to five years beyond its normal expiration. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. The length of the patent term extension is typically calculated as one half of period between the effective date of an IND and the submission date of an NDA less any time the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sponsor did not act with due diligence during the period, plus the time between the submission date of an NDA and the approval of that application less any time the sponsor did not act with due diligence during the period. There is also a limit on the patent term extension to a term that is no greater than fourteen years from drug approval. We have applied to the USPTO for patent term extension of some of our patents. Currently, communication of patent term extension approval and the length of the granted extension period by the USPTO may occur up to several years from filing of an application for patent term extension. If the USPTO and the FDA determine the extension period for each proposed eligible patent, we will select the one patent to be extended. We expect to apply any patent term extension that is granted in the U.S. to our method of treatment patent for MDS and MF that expires on March 15, 2033. If such patent term extension is granted, we expect the term of the patent to extend through August 2037, although such timing is subject to approval by the USPTO and could differ from our calculation. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Similar extensions are also available in certain countries and territories outside the U.S., such as in Japan, and in Europe as Supplementary Protection Certificates, or SPCs. However, we might not be granted a patent term extension at all because of failure to satisfy any of the numerous applicable requirements, including:</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to adhere to the required filing deadlines; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission of a patent term extension application after the underlying patents have expired;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to exercise due diligence during clinical development or regulatory review; or </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to otherwise meet the applicable criteria.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Moreover, the applicable authorities, including the FDA and the USPTO in the U.S., and any equivalent regulatory authorities and patent offices in other countries, may not agree with our assessment of whether such extensions are available, may refuse to grant extensions to our patents, or may grant more limited extensions than we request and could be less than five years. If we select and are granted a patent term extension on a recently filed and issued patent, we may not receive the full benefit of a possible patent term extension, if at all. If we do not have sufficient patent life and regulatory exclusivity to protect RYTELO, our financial results, business and business prospects would be materially and adversely affected, which might cause us to cease operations.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In Europe and other jurisdictions, our composition of matter patent coverage expired in September 2024, and our method of treatment patent rights for MDS and MF expire in November 2033. Our method of treatment patents may be eligible for patent term extension of up to five years under an SPC, permitted under European Council (EC) Regulation No. 469/2009, or the European SPC Regulation, upon receipt of marketing authorization, such as, for example, our method of treatment patent for MDS. In Europe, we have separate method of treatment patents covering MDS and MF, and an SPC may only be applied for once with respect to a product. Accordingly, in countries of the European Economic Area, or EEA, we must rely on regulatory exclusivity and our method of treatment patents.  </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If regulatory approval of RYTELO occurs after a patent has expired in a country that does not allow interim patent term extensions, as is the case in many jurisdictions and territories including in Europe, we will be unable to obtain any patent term extension of that expired patent, and the duration of our patent rights may be limited. Accordingly, in Europe and such other similar jurisdictions and territories, we will not be able to seek patent term extension of our composition of matter patent, as it expired in September 2024.  If we do not have sufficient patent life and regulatory exclusivity to protect RYTELO, our financial results, business and business prospects would be materially and adversely affected, which might cause us to cease operations.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, there are regulations for the listing of patents in the Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. Some of our patents have been listed in the Orange Book. Manufacturers of generic drugs may challenge the listing. If an appropriate patent covering RYTELO is not listed in the Orange Book or is subsequently removed from the Orange Book, a manufacturer of generic drugs would not be required to provide advance notice to us of any abbreviated NDA filed with the FDA to obtain permission to sell a generic version of RYTELO. Any of the foregoing could harm our competitive position, business, financial condition, results of operations and prospects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The validity, scope and enforceability of any patents listed in the Orange Book that cover RYTELO or its methods of use can be challenged by third parties and may not protect us from generic or innovator competition.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If a third party files an application under Section 505(b)(2) of the FDCA or an abbreviated new drug application, or ANDA, under Section 505(j) to obtain permission to sell a generic or follow-on version of RYTELO, and relies in whole or in part on studies conducted by or for us, the third-party will be required to certify to the FDA that either: </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1) there is no patent information listed in the Orange Book with respect to our NDA for RYTELO; (2) the patents listed in the Orange Book have expired; (3) the listed patents have not expired, but will expire on a particular date and approval is sought after patent expiration; or (4) the listed patents are invalid or will not be infringed by the manufacture, use or sale of the third-party&#8217;s generic product. A certification that the new product will not infringe the Orange Book-listed patents for RYTELO, or that such patents are invalid, is called a paragraph IV certification. If the third-party submits a paragraph IV certification to the FDA, a notice of the paragraph IV certification must also be sent to us within 20 days after the third-party&#8217;s ANDA is accepted for filing by the FDA. We may then initiate a lawsuit to defend the patents identified in the notice. The filing of a patent infringement lawsuit within 45 days of receipt of the notice automatically prevents the FDA from approving the third-party&#8217;s ANDA until the earliest of 30 months after the NDA holder&#8217;s receipt of the notice of Paragraph IV Certification, the expiration of the patent, certain settlements of the lawsuit, or the court reaches a decision in the infringement lawsuit in favor of the third-party. If the product has NCE exclusivity and the notice is given and the suit filed in the fifth year of exclusivity, the regulatory stay extends until 7.5 years after approval of the reference product.  If we do not file a patent infringement lawsuit within the required 45-day period, the third-party&#8217;s ANDA will not be subject to the 30-month stay of FDA approval.  However, if an appropriate patent covering RYTELO is not listed in the Orange Book or is subsequently removed from the Orange Book, a manufacturer of generic drugs would not be required to provide advance notice to us of any abbreviated NDA filed with the FDA to obtain permission to sell a generic version of RYTELO. Any of the foregoing could harm our competitive position, business, financial condition, results of operations and prospects.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our issued U.S. patents covering RYTELO or its methods of use may not provide adequate protection from competitive products if competitors receive approval of an ANDA application or are able to design around the patents. One or more competitors may circumvent these patents by filing a marketing application with the FDA for a competitive product containing the active moiety in RYTELO and successfully challenging the validity of the patents or successfully designing around the patents. Any successful challenge and/or designing around one or more of the patents could result in a generic version of RYTELO being commercialized before the expiration of the patents. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If the patents covering RYTELO or its methods of use are successfully challenged or designed around, or if we are unsuccessful in enforcing our patents against generics, we could face competition prior to the expiration of these patents, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. or international patent law or interpretations of such patent laws could diminish the value of our patents in general, thereby impairing our ability to protect our technologies and RYTELO.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical and biopharmaceutical companies, including ours, are highly uncertain and involve complex legal and technical questions. In particular, legal principles for biotechnology and pharmaceutical patents in the U.S. and in other countries are evolving, and the extent to which we will be able to obtain patent coverage to protect our technologies and RYTELO, or enforce or defend issued patents, is uncertain. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For instance, the U.S. has enacted and implemented wide-ranging patent reform legislation, including AIA, signed into law on September 16, 2011. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Depending on actions by Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents or patents that we might obtain in the future. Similarly, changes in patent law, regulations in other jurisdictions or the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce our existing patents or patents that we may obtain in the future. Occurrence of these events and/or significant impairment of our RYTELO patent rights could severely and adversely affect our financial results, business and business prospects, which might cause us to cease operations.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, the European Patent Package, or EU Patent Package, was approved and included regulations with the goal of providing for the possibility of a single Unitary Patent covering the Contracting Member States, and a new Unified Patent Court, or UPC, for litigation of Unitary Patents and as well as European patents not opted out from the UPC system. The EU Patent Package entered into force fully in June 2023 and currently covers 18 EU Member States. As of June 1, 2023, all European patents, including those issued prior to June 1, 2023 in principle fall under the jurisdiction of the UPC and allow for the possibility of obtaining injunctions for the UPC Member States and are at risk of central revocation at the UPC in participating UPC Member States. Under the EU Patent Package, patent holders are permitted to &#8220;opt out&#8221; their European patents (but not their Unitary Patents) from the UPC on a patent-by-patent basis during an initial seven year </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">transitional period after June 1, 2023. Owners of European patent applications who receive notice of grant after the EU Patent Package came into effect could, for the UPC Member States, either obtain a Unitary Patent or validate the European patent nationally and optionally file an opt-out demand. The EU Patent Package may increase the uncertainties and costs surrounding the enforcement or defense of our issued European patents and pending applications. The full impact on future European patent filing strategy and the enforcement or defense of our issued European patents in European jurisdictions and/or the UPC is not fully known.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Filing, prosecuting, maintaining, defending and enforcing patents for RYTELO and our technologies in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. are less extensive than those in the U.S. The requirements for patentability may differ in certain countries, particularly in developing countries; thus, even in countries where we do pursue patent protection, there can be no assurance that any patents will be issued with claims that cover RYTELO and our technologies.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents or other intellectual property rights, which could be expensive, time consuming and unsuccessful, and which could result in the invalidity or unenforceability of our patents covering RYTELO or its methods of use.  </span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe, misappropriate or otherwise violate our patents or other intellectual property rights. To counter infringement or unauthorized use, we may be required to file and prosecute legal claims against one or more third parties, which can be expensive and time-consuming, even if ultimately successful. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The initiation of a claim against a third party by us may also cause the third party to bring counter claims against us, such as claims asserting that our patents are invalid or unenforceable. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of written description or non-statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte reexaminations, inter partes review, or IPR, or post-grant review, or oppositions or similar proceedings outside the U.S., in parallel with litigation or even outside the context of litigation. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or  may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. The standards that courts use to interpret patents are not always applied predictably or uniformly and can change, particularly as new technologies develop. As a result, we cannot predict with certainty how much protection, if any, will be given to our patents if we attempt to enforce them and they are challenged in court and if any such lawsuits will ultimately be resolved successfully. Further, even if we prevail, the infringer may file an appeal and the court judgment may be overturned and/or that an adverse decision may be issued by an appeals court relating to the validity or enforceability of our patents. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly in a manner insufficient to achieve our business objectives. Even if we establish infringement, we may not seek, or the court may decide not to grant, an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection for RYTELO, which could have a material adverse effect on our business, financial condition, results of operations and prospects. Additionally, any adverse outcome could allow third parties to commercialize RYTELO and compete directly with us, without payment to us.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, if we are engaged in intellectual property litigation, there would be public announcements of filings, briefings, hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these events to be negative, it could have an adverse effect on the price of our common stock.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in jurisdictions outside the U.S. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology and pharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. For example, many countries outside the U.S. have compulsory licensing laws under which a patent owner must grant licenses to third parties. Proceedings to enforce our patent rights in jurisdictions outside the U.S. could result in substantial costs and divert our efforts and attention from other aspects of our business, and could put our patents at risk of being invalidated or interpreted narrowly. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to protect our intellectual property rights in the U.S or worldwide and challenges to our owned or licensed patent rights would result in costly and time-consuming legal proceedings that could prevent or limit development or commercialization of RYTELO.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our patents or those patent rights we have licensed, including patent rights that we may seek with respect to inventions made by past or future collaborators, may be challenged through administrative or judicial proceedings, which could result in the loss of important patent rights. For example, where more than one party seeks U.S. patent protection for the same technology in patent applications that are subject to the law before the implementation of the AIA, the USPTO may declare an interference proceeding in order to ascertain the party to which the patent should be issued. Patent interferences are typically complex, highly contested legal proceedings, subject to appeal. They are usually expensive and prolonged and can cause significant delays in the issuance of patents. Our pending patent applications or our issued patents, or those we have licensed and may license from others, may be drawn into interference proceedings or be challenged through post-grant review procedures or litigation, any of which could delay or prevent the issuance of patents, or result in the loss of issued patent rights. We may not be able to obtain from our past or future collaborators the information needed to support our patent rights which could result in the loss of important patent rights. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the AIA, interference proceedings between patent applications filed on or after March 16, 2013, have been replaced with other types of proceedings, including derivation proceedings. The AIA also includes post-grant review procedures subjecting U.S. patents to post-grant review procedures similar to European oppositions, such as IPR, covered business method post-grant reviews and other post-grant reviews. This applies to all our U.S. patents and those we have licensed and may license from others, even those issued before March 16, 2013. A third party could attempt to use the USPTO procedures to invalidate patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. U.S. patents owned or licensed by us may therefore be subject to post-grant review procedures, as well as other forms of review and re-examination. In addition, the IPR process under the AIA permits any person, whether they are accused of infringing the patent at issue or not, such as entities associated with hedge funds, to challenge the validity of certain patents. Significant impairment of our RYTELO patent rights could severely and adversely affect our financial results, business and business prospects, which might cause us to cease operations. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain jurisdictions, such as Europe, China, Japan, New Zealand and Australia, permit third parties to file third party observations, oppositions or invalidation trials against granted patents and/or patent applications. Because we seek to enable potential global commercialization of RYTELO, securing both proprietary protection and freedom to operate outside of the U.S. is important to our business.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Third party proceedings such as oppositions and invalidation trials require significant time and costs, and if we are unsuccessful or are unable to commit these types of resources to protect our RYTELO patent rights, we could lose our patent rights and we could be prevented or limited in the development and commercialization of RYTELO.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As more groups become engaged in scientific research and product development in the areas of telomerase biology and hematologic malignancies, the risk of our patents, or patents that we have in-licensed, being challenged through patent interferences, derivation proceedings, IPRs, post-grant proceedings, oppositions, invalidation trials, re-examinations, litigation or other means will likely increase. Challenges to our patents through these procedures would be extremely expensive and time-consuming, even if the outcome was favorable to us. An adverse outcome in a patent dispute could severely harm our ability to further develop or commercialize RYTELO, or could otherwise have a material adverse effect on our business, and might cause us to cease operations, by:</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">causing us to lose patent rights in the relevant jurisdiction(s);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subjecting us to litigation, or other types of proceedings aimed at preventing us from commercializing RYTELO in the relevant jurisdiction(s);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requiring us to obtain licenses to certain patents and patent applications;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">forcing us to cease using the disputed technology; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requiring us to develop or obtain alternative technologies. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to infringement claims that are costly to defend, and such claims may limit our ability to use disputed technologies and prevent us from pursuing research, development, manufacturing or commercialization of RYTELO.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of RYTELO will depend upon our ability to research, develop, manufacture, market and sell RYTELO without infringing or otherwise violating the intellectual property and other proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries, and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">many pharmaceutical companies, including potential competitors, have substantial patent portfolios. Since we cannot be aware of all intellectual property rights potentially relating to RYTELO and its uses, we do not know with certainty that RYTELO, or the commercialization thereof, does not and will not infringe or otherwise violate any third party&#8217;s intellectual property. For example, we are aware that certain third parties have or may be prosecuting patents and patent estates that may relate to RYTELO, and while these patents have expired, or we believe that a reasonable court should find they are invalid and/or would not be infringed by the manufacture, use or sale of RYTELO, it is possible that the owner(s) of these patents will assert claims against us in the future.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the event our technologies infringe the rights of others or require the use of discoveries and technologies controlled by third parties, we may be prevented from pursuing research, development, manufacturing or commercialization of RYTELO, or may be required to obtain unblocking licenses from such third parties, develop alternative non-infringing technologies, which we may not be able to do at an acceptable cost or on acceptable terms, or at all, or cease the commercialization and continued development of RYTELO. If we are unable to resolve an infringement claim successfully, we could be subject to an injunction that would prevent us from commercializing RYTELO and could also require us to pay substantial damages.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while our past collaboration agreements have terminated, we are still subject to indemnification obligations to certain collaborators, including with respect to claims of third-party patent infringement. In addition to infringement claims, in the future we may also be subject to other claims relating to intellectual property, such as claims that we have misappropriated the trade secrets of third parties. Our success therefore depends significantly on our ability to operate without infringing patents and the proprietary rights of others. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may become aware of discoveries and technologies controlled by third parties that are advantageous or necessary to further develop or manufacture RYTELO. Under such circumstances, we may initiate negotiations for licenses to other technologies as the need or opportunity arises. We may not be able to obtain a license to a technology required to pursue the research, development, manufacturing or commercialization of RYTELO on commercially favorable terms, or at all, or such licenses may be terminated on certain grounds, including as a result of our failure to comply with any material obligations under such licenses. If we do not obtain a necessary license or if such a license is terminated, we may need to redesign such technologies or obtain rights to alternative technologies, which may not be possible, and even if possible, could cause further delays in the development efforts for RYTELO and could increase the development and/or production costs of RYTELO. In cases where we are unable to license necessary technologies, we could be subject to litigation and prevented from pursuing research, development, manufacturing or commercialization of RYTELO, which would materially and adversely impact our business. Failure by us to obtain rights to alternative technologies or a license to any technology that may be required to pursue research, development, manufacturing or commercialization of RYTELO would further delay current and potential future clinical trials of RYTELO and any applications for regulatory approval, impair our ability to sell RYTELO, and therefore result in decreased sales of RYTELO for us. Occurrence of any of these events could materially and adversely affect our business and might cause us to cease operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a registered trademark, RYTELO, for our product and failure to maintain such trademark could adversely affect our business.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have a registered trademark, RYTELO, which is the commercial trade name for imetelstat, in a number of countries and regions, including in the U.S. and Europe. Our product trademark, RYTELO, is approved for use as name of the imetelstat medicinal product by the FDA and the EC. Opposition or cancellation proceedings, however, may be filed against our trademarks, and our trademarks may not survive such proceedings. If our U.S. trademark application which forms the basis for our international registration, or IR, for our commercial trade name is withdrawn or abandoned within the first five years of our IR, we will lose our IR registrations which could adversely affect our business. We may be unable to maintain or enforce our current and future trademarks, and if we fail to satisfy the applicable regulatory requirements, we may not have enforceable trademark rights or registrations in such jurisdictions.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may become involved in disputes with past or future collaborator(s) over intellectual property inventorship, ownership or use, and publications by us, or by investigators, scientific consultants, research collaborators or others. Such disputes could impair our ability to obtain patent protection or protect our proprietary information, which, in either case, could have a significant impact on our business.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inventions discovered under research, material transfer or other collaboration agreements may become jointly owned by us and the other party to such agreements in some cases and may be the exclusive property of either party in other cases. Under some circumstances, it may be difficult to determine who invents and owns a particular invention, or whether it is jointly owned, and disputes can arise regarding inventorship, ownership and use of those inventions. These </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">disputes could be costly and time-consuming, and an unfavorable outcome could have a significant adverse effect on our business if we are not able to protect or license rights to these inventions. In addition, clinical trial investigators, scientific consultants and research collaborators generally have contractual rights to publish data and other proprietary information, subject to review by the trial sponsor. Publications by us, or by investigators, scientific consultants, previous employees, research collaborators or others, either with permission or in contravention of the terms of their agreements with us or with our past or future collaborators, may impair our ability to obtain patent protection or protect proprietary information, which could have a material adverse effect on our business and might cause us to cease operations. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Much of the information and know-how that is critical to our business is not patentable, and we may not be able to prevent others from obtaining this information and establishing competitive enterprises.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patent and trademark protection, we rely on trade secrets to protect our proprietary technology, especially in circumstances in which we believe patent protection is not appropriate or available. We attempt to protect our proprietary technology in part by entering into confidentiality agreements with our employees, consultants, collaborators and contractors. However, certain consultants and third parties with whom we have business relationships, and to whom in some cases we have disclosed trade secrets and other proprietary knowledge, may also provide services to other parties in the medical device/pharmaceutical industry, including companies, universities and research organizations that are developing competing products. In addition, some of our former employees who were exposed to certain of our trade secrets and other proprietary knowledge in the course of their employment may seek employment with, and become employed by, our competitors. We cannot provide assurance that these agreements will not be breached, that we would have adequate remedies for any breach, or that our trade secrets will not otherwise become known or be independently discovered by competitors, any of which would harm our business significantly. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Trade secret protection does not prevent independent discovery of the technology or proprietary information or use of the same. Competitors may independently duplicate or exceed our technology in whole or in part. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us in countries where we do not have patent protection.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:90%">RISKS RELATED TO MANAGING OUR GROWTH AND OTHER BUSINESS OPERATIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our strategic restructuring plan and the associated workforce reduction implemented in December 2025 may not result in anticipated savings and long-term value creation, could result in total costs and operating expenses that are greater than expected and could disrupt our business.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our strategic restructuring plan announced in December 2025, we implemented a workforce reduction, representing approximately one-third of our workforce prior to the reduction in headcount. We may not realize, in full or in part, the anticipated benefits on our 2026 operating expenses from our restructuring efforts due to unforeseen difficulties, delays or unexpected costs. We incurred approximately $17.0 million in restructuring and restructuring-related charges for the year ended December 31, 2025, primarily consisting of one-time employee severance payments, healthcare and related benefits, and other employee-related costs. The workforce reduction was substantially completed in the first quarter of 2026. If we are unable to realize the expected operational efficiencies and cost savings from the restructuring, our operating results and financial condition could be adversely affected. We also cannot guarantee that we will not have to undertake additional workforce reductions or restructuring activities in the future. Furthermore, our workforce reduction may be disruptive to our operations, or could yield unanticipated consequences, such as attrition beyond planned staff reductions, or disruptions in our day-to-day operations. Our workforce reductions could also harm our ability to attract and retain qualified management, scientific, clinical, and manufacturing personnel who are critical to our business. Any failure to attract or retain qualified personnel could prevent us from successfully developing and commercializing our product candidates in the future, if approved.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to successfully retain or recruit key personnel to support the commercialization and further development of RYTELO or to otherwise successfully manage our growth.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to successfully commercialize RYTELO in the U.S. and in the EU for lower-risk MDS, and to continue to develop RYTELO in other myeloid hematologic malignancies depends to a significant extent on the skills, experience and efforts of our executive officers and key members of our staff. In addition, we need to recruit, maintain, motivate and integrate additional personnel with expertise and experience in sales, marketing, market access, commercial </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">operations, pricing, clinical science, biostatistics, clinical operations, pharmacovigilance, quality, manufacturing, regulatory affairs, medical affairs, legal affairs, and compliance to enable us to further commercialize and further develop RYTELO.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We face intense competition for qualified individuals from numerous pharmaceutical, biopharmaceutical and biotechnology companies, as well as academic and other research institutions, and competition in our geographic regions is particularly intense. The substantial risks and uncertainties related to our commercialization and further development of RYTELO, and the risks and uncertainties regarding our future business viability could have an adverse impact on our ability to retain and recruit qualified personnel. We may also face higher than expected personnel costs in order to attract new personnel due to shortages in qualified applicants, or to maintain our current management and personnel due to the increased number of opportunities in the biotechnology sector. If we are unable to successfully retain, motivate and incentivize our existing personnel, or to attract, assimilate and retain other highly qualified personnel in the future on acceptable terms, our ability to commercialize and further develop RYTELO will be impaired, and our business and the price of our common stock would be adversely impacted.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our personnel are currently performing their duties in multiple jurisdictions, and if we are unable or fail to comply with employment, tax, benefits and other laws in such jurisdictions, we may face penalties, fines or litigation.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to develop, manufacture and commercialize RYTELO depends, in part, on our ability to effectively manage any future growth. Our management may have to divert financial and other resources, as well as devote a substantial amount of time, to managing growth activities, such as enhancing operational, financial and management processes and systems. If we do not effectively manage the expansion of our operations, we could experience weaknesses in our infrastructure and ability to comply with applicable legal and regulatory requirements and regulations, operational mistakes or shortcomings, loss of business opportunities, loss of employees and reduced productivity among remaining employees.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management transition creates uncertainties and could harm our business.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Over the past few years, we have experienced significant changes in executive leadership, and more could occur.  For example, on August 6, 2025, we announced the appointment of Harout Semerjian as our President and Chief Executive Officer and a member of our board of directors, effective August 7, 2025.  In addition, in October 2025, we appointed a new EVP, Chief Commercial Officer and in November 2024, we appointed a new EVP of Research and Development. Additionally, in connection with our strategic restructuring plan announced in December 2025, we implemented a workforce reduction, representing approximately one-third of our workforce prior to the reduction in headcount.  Changes to company strategy, which can often times occur with the appointment of new executives and departure of prior executives, can create uncertainty, may negatively impact our ability to execute quickly and effectively, and may ultimately be unsuccessful. In addition, executive leadership transition periods are often difficult as the new executives gain detailed knowledge of our operations, and friction can result from changes in strategy and management style. Management transition inherently causes some loss of institutional knowledge, which may have a disruptive impact on our ability to implement our strategy and could have a material adverse effect on our financial condition and our business and business prospects can negatively affect strategy and execution. Until we integrate new personnel, and unless they are able to succeed in their positions, we may be unable to successfully manage and grow our business, and our results of operations and financial condition could suffer as a result. </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Although we intend  to establish potential future collaborative arrangements for RYTELO, we may be unable to establish such collaborative arrangements on acceptable terms, or at all, and may have to delay, alter or abandon commercialization or further development of RYTELO.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We intend to develop RYTELO broadly for hematologic malignancies, and to continue to commercialize, market and sell RYTELO in the U.S. for certain patients with lower-risk MDS ourselves. At this time, we do not plan to commercialize RYTELO independently in the EU (or in any other regions outside of the U.S. where RYTELO may be approved for marketing in the future). Accordingly, we plan to work with experienced third parties for the commercialization and marketing of RYTELO in the EU, including on critical path activities for the planned launch of RYTELO in the EU, such as reimbursement, Health Technology Assessment, or HTA, submissions, market access and distribution, and we may otherwise seek collaborative partners, at an appropriate time, to assist us in the potential development and commercialization of RYTELO outside the U.S., and to provide funding for such activities. We face significant competition in seeking appropriate collaborative partners, and these potential collaborative arrangements are complex and time consuming to negotiate, document and implement. In addition, the terms of our Pharmakon Loan Agreement may limit our ability to enter into certain collaborative arrangements and any future debt agreements may continue or further limit our ability to enter into such agreements. We may not be able to establish collaborative </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">arrangements on acceptable terms, or at all. In this regard, collaborative arrangements with third parties may require us to relinquish material rights, including revenue from commercialization, or assume material ongoing development obligations that we would have to fund or otherwise support.</span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to negotiate collaborative arrangements, we may have to:</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay, curtail or abandon the additional development of RYTELO;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay, curtail or abandon the commercialization of RYTELO in jurisdictions where it is approved;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce the scope of potential future sales or marketing activities; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increase our expenditures and undertake development or commercialization activities at our own expense, which will require additional capital than our current resources.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have established subsidiaries in the United Kingdom and the Netherlands, which exposes us to additional costs and risks.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The wholly-owned subsidiaries we have established in the U.K. and the Netherlands subject us to certain additional costs and risks associated with doing business outside the U.S., including:</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the increased complexity and costs inherent in managing international operations in geographically disparate locations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges and costs of complying with diverse regulatory, financial and legal requirements, which are subject to change at any time;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potentially adverse tax consequences, including changes in applicable tax laws and regulations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potentially costly trade laws, tariffs, export quotas, custom duties or other trade restrictions, and any changes to them, including in connection with new Trump administration changes;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges inherent in efficiently managing employees in diverse geographies, including the need to adapt systems, policies, benefits and compliance programs to differing labor and other regulations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">natural disasters, political and economic instability, including terrorism and civil and political unrest, military conflicts, outbreak of health epidemics, and the resulting global economic and social impacts; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the U.S.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may experience additional risks related to operating outside of the U.S. that could materially adversely affect our business.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have employees located outside of the U.S., conduct clinical trials outside of the U.S., and are pursuing paths to make  RYTELO available to LR-MDS patients outside of the U.S., including in the EU, which may subject us to additional risks, including risks related to operating outside of the U.S., such as:  </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks of potential noncompliance by us or by any third parties we engage with legal requirements applicable to privacy, data protection, information security and other matters;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks of potential noncompliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased taxes outside of the U.S., including withholding and payroll taxes;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties staffing and managing operations outside of the U.S.;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complexities associated with managing multiple payor reimbursement regimes and government payors in foreign countries;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the U.S.;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential liability under the Foreign Corrupt Practices Act of 1977 or comparable regulations outside of the U.S.; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For example, the current administration in the U.S. has called for substantial changes to foreign trade policy and has recently imposed significant increases in tariffs on international trade and the renegotiation of international trade agreements. We cannot predict what effects these and potential additional tariffs or renegotiation of existing </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">international trade agreements, scope and nature of tariffs in the future, including as a result of litigation or other challenges, will have on our business, including in the context of escalating global trade and political tensions. However, such tariffs and other trade restrictions could increase our cost of doing business, reduce our gross margins or otherwise negatively impact our financial results. Likewise, the ongoing Russia-Ukraine military conflict and the ongoing military conflict involving the U.S., Israel and Iran have had and may continue to have further global economic consequences, including continued disruptions of the global supply chain and energy markets, which could disrupt our existing supply chain and increase our cost of doing business, reduce our gross margins or otherwise negatively impact our financial results. See the risk factors titled, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global trade issues and changes in and uncertainties with respect to trade policies and export regulations, including import and export license requirements, trade sanctions, tariffs and international trade disputes, could increase our costs and negatively impact net revenues from sales of RYTELO</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Failure by us to maintain a manufacturing supply chain to appropriately and adequately supply RYTELO for commercial and future clinical uses would adversely affect our ability to commercialize RYTELO and result in a further delay in or cessation of clinical trials, and our business and business prospects could be severely harmed, and we could cease operations.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainty in the regulatory framework and future legislation could lead to disruption in the execution of international multi-center clinical trials, the monitoring of adverse events through pharmacovigilance programs, the evaluation of the benefit-risk profiles of new medicinal products, and determination of marketing authorization across different jurisdictions. Changes to existing regulations may add considerably to the time from clinical development to marketing authorization and commercialization of products in foreign jurisdictions and increase our costs. We cannot predict the impact of such changes and future regulation on our business or the results of our operations. These and other risks associated with international operations may materially adversely affect our ability to attain or maintain profitable operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global trade issues and changes in and uncertainties with respect to trade policies and export regulations, including import and export license requirements, trade sanctions, tariffs and international trade disputes, could increase our costs and negatively impact net revenues from sales of RYTELO. </span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There is inherent risk, based on the complex relationships among the U.S. and the countries in which we now conduct or may in the future conduct our business, that political, diplomatic, and national security factors can lead to global trade restrictions and changes in trade policies and export regulations that may adversely affect our business and operations. Compliance with applicable regulatory requirements regarding the export of products may create delays in the introduction of RYTELO in international markets, including in the EU, or, in some cases, prevent the export of RYTELO to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the provision of certain products and services to countries, governments and persons targeted by U.S. sanctions. The U.S. and other countries have imposed and may continue to impose new trade restrictions and export regulations, have levied tariffs and taxes on certain goods, and could continue to significantly increase tariffs on a broad array of goods, including pharmaceutical and biological products. Notwithstanding the U.S. Supreme Court&#8217;s recent decision invalidating tariffs imposed under the International Emergency Economic Powers Act, the magnitude and impact of tariffs are uncertain and are subject to a variety of factors, including the effective date and duration of additional tariffs, changes in the amount, scope and nature of tariffs in the future, including as a result of litigation or other challenges, any retaliatory tariffs that other countries may impose in response to tariffs levied by the United States and any mitigating actions that may become available.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing trade tensions between the U.S. and other jurisdictions have resulted in multiple rounds of tariffs and potential tariffs affecting pharmaceuticals and pharmaceutical ingredients, including finished drug products, manufacturing equipment, and related supplies. In April 2025, the U.S. government imposed a 10% baseline global tariff and in August 2025, the U.S. imposed higher &#8220;reciprocal&#8221; tariffs on numerous other territories, including EU Member States and South Korea. While the U.S. Supreme Court recently issued a ruling invalidating tariffs imposed by the Trump administration under the International Emergency Economic Powers Act, other tariffs imposed by the U.S. government remain in place, including the 10% global tariff imposed by the Trump administration under Section 122 of the Trade Act of 1974 following the U.S. Supreme Court decision. Moreover, the Bureau of Industry and Security, U.S. Department of Commerce, has initiated an investigation to determine whether pharmaceutical ingredients, including finished drug product, manufactured outside the U.S. pose a national security risk and should be subject to additional tariffs.  Unlike consumer goods, pharmaceuticals face unique regulatory constraints that make rapid supply chain adjustments particularly difficult and costly</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Although a significant portion of our supply chain for imetelstat is currently based in the U.S., the active pharmaceutical ingredient, or API, for imetelstat is manufactured in South Korea and our 47mg vial of RYTELO drug product is currently manufactured in Italy. In addition, in the future we may choose to utilize other contract manufacturers for different presentations of imetelstat and source materials for our supply chain from other international jurisdictions. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, such global or industry-specific tariffs, or the renegotiation of current international trade agreements, or other trade restrictions could result in additional costs on our business, including generally increasing our manufacturing costs, and may decrease our gross margins and increase our supply chain complexity. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, other governments have imposed and may continue to impose retaliatory tariffs, trade restrictions or trade barriers impacting RYTELO, which could impose additional costs and complexity on our business, including with respect to our planned commercialization of RYTELO in select EU markets in 2026 or restrict our ability to sell RYTELO in the EU or in other international markets where we may obtain approval of RYTELO.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, the continued threats of new or increased tariffs, sanctions, trade restrictions and trade barriers as well as ongoing changes in U.S. and foreign government trade policies, including potential modifications to existing international trade agreements, have had and may continue to have a generally disruptive impact on the global economy and, therefore, could negatively impact revenues from sales of RYTELO. Given the significant volatility and uncertainty regarding the scope and duration of such tariffs and other aspects of U.S. and foreign government trade policies, the ultimate impact on our operations and financial results is uncertain and could be significant in the future. </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to obtain or maintain sufficient insurance on commercially reasonable terms or with adequate coverage against potential liabilities in order to protect ourselves against claims such as product liability or personal injury claims arising from our commercialization of RYTELO, claims related to clinical trial conduct, or claims related to data protection.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our business exposes us to potential product liability and other risks that are inherent in the testing, manufacturing and marketing of human therapeutic products. We may become subject to product liability or personal injury claims related to the commercialization of RYTELO, or claims related to clinical trial conduct, including if the use of RYTELO is alleged to have injured patients, such as injuries alleged to arise from any hepatotoxicity or hemorrhagic event associated with the use of RYTELO. We currently have product liability and clinical trial liability insurance that we believe is adequate, but we may experience losses in excess of our coverage or that are not covered by our insurance, and we may not be able to maintain this type of insurance for the commercialization of RYTELO, or any of our current or potential future clinical trials of RYTELO. In addition, this type of insurance may become too expensive for us to afford because of the highly risky and uncertain nature of commercialization of RYTELO, clinical trials generally and the high cost of insurance for our business activities. We may be unable to obtain or maintain clinical trial insurance in all of the jurisdictions where we conduct current or potential future clinical trials. In addition, business liability, product liability and cybersecurity insurance are becoming increasingly expensive, particularly for biotechnology and pharmaceutical companies, and the pool of insurers offering insurance coverage to biotechnology and pharmaceutical companies generally is becoming smaller, making it more difficult to obtain insurance for our business activities at a reasonable price, or at all. Being unable to obtain or maintain product liability, clinical trial liability, cybersecurity or other insurance for our business activities in the future on acceptable terms or with adequate coverage against potential liabilities would have a material adverse effect on our business, and could cause us to limit or cease our commercialization and further development of RYTELO. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We and certain of our current and former officers and directors have been named as defendants in securities class action lawsuits and derivative lawsuits. These lawsuits, and potential similar or related lawsuits, could result in substantial damages, divert management&#8217;s time and attention from our business, and have a material adverse effect on our results of operations. These lawsuits, and any other lawsuits to which we are subject, will be costly to defend or pursue and are uncertain in their outcome.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Securities class action lawsuits and/or derivative lawsuits have often been brought against companies, including biotechnology and biopharmaceutical companies, that experience volatility in the market price of their securities. This risk is especially relevant for us because we often experience significant stock price volatility in connection with our activities.  On March 13 and March 14, 2025, we and certain of our current and former officers were named as defendants in two putative securities class action lawsuits filed in the United States District Court for the Northern District of California captioned </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dabestani v. Geron Corporation, et al.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, No. 3:25-cv-02507 and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Potvin v. Geron Corporation, et al.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, No. 3:25-cv-02563, respectively. Both lawsuits allege violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder in connection with allegedly false and misleading statements concerning the commercial potential of RYTELO. The plaintiffs allege, among other things, that we overstated RYTELO's commercial potential by making materially false and misleading statements and/or concealing material adverse facts concerning RYTELO's commercial potential, including the lack of awareness among healthcare providers for RYTELO, the burden of monitoring requirements in administering the drug, and the impacts of seasonality and existing competition on RYTELO's sales, and that our stock price dropped when we disclosed in our earnings call on February 26, 2025 that we had observed flat revenue trends over the prior few months. The plaintiffs seek damages and interest, and an award of reasonable costs, including attorneys' and experts' fees. On May 29, 2025, the Court consolidated the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dabestani</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Potvin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">cases into one consolidated action captioned </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Geron Corporation Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, or the Securities Class Action, and appointed lead plaintiffs and counsel for lead plaintiffs. On August 8, 2025, lead plaintiffs filed a consolidated amended complaint. On October 7, 2025, we filed our motion to dismiss the consolidated amended complaint.  A hearing on the motion to dismiss was held on March 19, 2026, and on March 30, 2026, the Court entered an order granting our motion to dismiss without prejudice. On April 13, 2026, lead plaintiffs filed a second amended complaint. We intend to move to dismiss the second amended complaint.  </span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on April 15, 2025 and April 16, 2025, three purported stockholders filed derivative complaints, each filed in the United States District Court for the Northern District of California, captioned </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bishop v. Scarlett, et al.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">No. 3:25-cv-03356,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Lerner v. Scarlett, et al.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, No. 3:25-cv-03401, and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Willis v. Scarlett, et al.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, No: 3:25-cv-03396, respectively. The three lawsuits name certain of our current and former directors and officers and allege that they breached their fiduciary duties and violated federal securities laws by issuing allegedly false and misleading statements concerning the commercial potential of RYTELO. The allegations in each of the three derivative complaints are substantially similar to the Securities Class Action. The plaintiff seeks damages and interest, and an award of reasonable costs, including attorneys' and experts' fees. The plaintiffs in </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bishop v. Scarlett, et al. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Willis v. Scarlett, et al.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> also seek punitive damages. On May 16, 2025, the Court consolidated the three derivative complaints into one consolidated action captioned </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Geron Corporation Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, or the Consolidated Derivative Action.  On June 17, 2025, the Court stayed the Consolidated Derivative Action pending a final ruling on the anticipated motion to dismiss in the Securities Class Action.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 29, 2025, a purported stockholder made a demand on our board of directors to commence a civil action against certain of our current and former directors for breaching their fiduciary duties and violating the securities laws by issuing allegedly false and misleading statements concerning the commercial potential of RYTELO.  On September 19, 2025, the board of directors responded that it would defer a final decision on the demand given the other pending derivative lawsuits and the Securities Class Action.  On October 7, 2025, the purported stockholder filed a suit in the United States District Court for the Northern District of California, captioned </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jae Hyung v. Bir, et al.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, No. 3:25-cv-08575.  The derivative lawsuit names certain of our current and former directors and officers. The allegations in the derivative lawsuit are substantially similar to the Securities Class Action and the Consolidated Derivative Action.  The plaintiff seeks damages and an award of reasonable costs, including attorneys&#8217; and experts&#8217; fees. On January 23 and February 19, 2026, respectively, two additional purported stockholders each made a similar demand on our board of directors. On March 25, 2026, our board of directors similarly responded that it would defer a final decision on the demands given the other pending derivative lawsuits and the Securities Class Action.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have also been subject to securities class action lawsuits in the past. In 2020, three securities class action lawsuits were filed against us and certain of our officers. One of the lawsuits was voluntarily dismissed, and we settled the other two lawsuits and a final judgment was entered in October 2023.  In 2020 and 2021, seven shareholder derivative actions were filed in a number of courts, naming as defendants certain of our then current officers and certain of our then current and former members of our board.  All seven of the shareholder derivative actions were dismissed with prejudice.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that additional lawsuits might be filed, or allegations might be received from stockholders, with respect to these same matters as alleged in the pending lawsuits or other matters and also naming us and/or our officers and directors as defendants. Such lawsuits and any other related lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. The outcome of the pending lawsuits and any other related lawsuits is necessarily uncertain. We could be forced to expend significant resources and may incur substantial legal fees and costs in the defense of the pending lawsuits and any related or additional lawsuits, and we may not prevail. Monitoring, initiating and defending against legal actions is also time-consuming for our management, is likely to be expensive and may detract from our ability to fully focus our internal resources on our business activities.  Given the early stage of these lawsuits and the inherent uncertainly of litigation, we cannot predict how long it may take to resolve the pending lawsuits or the amount of costs we may incur, or the potential outcome or the possible amount of any damages we may be required to pay. A decision adverse to our interests in the pending lawsuits or in similar or related litigation, could result in the payment of substantial damages or settlements, or possibly fines, and, although we maintain liability insurance, we may not be successful in having any such lawsuits dismissed or settled within the limits of our insurance coverage.  If any judgment or settlement against us and costs or expenses associated with the pending litigation exceed our insurance coverage or insurance coverage is denied, we may be forced to bear some or all of these costs and expenses directly, which could be substantial and could have a material adverse effect on our business, our stock price, cash flow, results of operations and financial condition.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to third-party litigation, and such litigation would be costly to defend or pursue and uncertain in its outcome.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our business may bring us into conflict with our licensees, licensors, or others with whom we have contractual or other business relationships, or with our competitors or others whose interests differ from ours. Our commercialization of RYTELO may result in product or personal injury disputes, or other disputes with health care providers, patients or other third parties as a result of our commercialization efforts. We may experience employment-related disputes. We may become involved in performance or other disputes with the CROs we have retained to support our clinical development activities, or with other third parties such as service providers, vendors, manufacturers, suppliers or consultants. If we are unable to resolve those conflicts on terms that are satisfactory to all parties, we may become involved in litigation brought by or against us. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lawsuits are subject to inherent uncertainties, and defense and disposition costs depend upon many unknown factors. Despite the availability of insurance, we may incur substantial legal fees and costs in connection with litigation. Lawsuits could result in judgments against us that require us to pay damages, enjoin us from certain activities, or otherwise negatively affect our legal or contractual rights, which could have a significant adverse effect on our business. In addition, the inherent uncertainty of such litigation could lead to increased volatility in our stock price and a decrease in the value of our stockholders&#8217; investment in our securities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to export control and import laws and regulations, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties to sell our products outside the U.S., to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.  </span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:90%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:90%">RISKS RELATED TO INFORMATION TECHNOLOGY SYSTEMS, DATA SECURITY AND DATA PRIVACY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our information technology systems or data, or those of third parties with whom we work, are or were compromised, we could experience adverse consequences resulting from such compromise, including regulatory investigations or actions; litigation; fines and penalties; a disruption of our business operations, including our clinical trials; reputational harm; loss of revenue and profits; and other adverse consequences.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we and third parties with whom we work collect, receive, store, use, transfer, make accessible, protect, secure, dispose of, transmit, disclose, or otherwise process proprietary, confidential, and sensitive data, including personal data such as health-related data and participant study related data, intellectual property, and trade secrets (collectively, sensitive information). In addition, we rely on third-party service providers to establish and maintain appropriate information technology and data security protections, including disaster recovery and business continuity procedures, over the information technology systems they provide us to operate our critical business systems, including cloud-based infrastructure and systems, employee email, and data storage and management systems. However, except for the initial cyber security assessments that we conduct for critical service providers and contractual duties and obligations, we have limited ability to control or monitor third parties&#8217; safeguards and actions related to such matters. Furthermore, while we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. Most of our employees work remotely, resulting in increased risks of loss or theft of company devices as well as increased risks to our information technology systems and data, as employees utilize network connections, computers, and devices outside our premises and networks, including working at home and while in transit and in public locations.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Future or past business transactions, such as acquisitions or integrations, could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our information technology systems, including in our remote work environment, and those of the third parties with whom we work, have been in the past and may continue to be vulnerable to evolving threats. These threats are prevalent, continue to increase, and come from a variety of sources such as traditional &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threats actors, or internal bad actors, personnel, sophisticated nation states and nation-state-supported actors. These threats include, but are not limited to, social-engineering attacks, targeted phishing campaigns, malicious code or malware, unauthorized intrusions, denial-of-service attacks, personnel misconduct or errors, ransomware attacks, supply-chain attacks, software bugs, computer viruses, server malfunctions, software, hardware or data center failures, loss of data or other information technology assets, natural disasters, terrorism, war, telecommunication and electrical failures and attacks enhanced or facilitated by artificial intelligence, or AI, and other similar threats. In particular, ransomware attacks are becoming increasingly prevalent and severe and can lead to significant interruptions in operations, loss of sensitive data and income, reputational harm, and diversion of funds. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we were to experience such an attack, extortion payments might alleviate the negative impact of a ransomware attack, but we might be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. Similarly, supply-chain attacks and attacks on clinical trial sites as well as regulatory and health authorities have increased in frequency and severity, and we cannot guarantee that third parties and infrastructure in our supply chain or our third-party partners&#8217; supply chains, or of clinical trial sites and regulatory and health authorities, have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of or disruption to our information technology systems or the third-party information technology systems that support us and the services provided to us, or remediate and recover compromised systems in a timely manner.  </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Such incidents or threats may result in unauthorized, unlawful or accidental loss, corruption, access, modification, destruction, alteration, acquisition or disclosure of sensitive information. The costs to us to attempt to protect against such security incidents could be significant, including potentially requiring us to modify our business, and while we have implemented security measures, policies and procedures designed to protect our information technology systems from cybersecurity threats and to identify and remediate vulnerabilities, such measures may not be fully implemented, complied with or successful in protecting our systems and information. We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. We may be unable in the future to detect cybersecurity threats or vulnerabilities in our information technology systems because such threats and techniques change frequently, are sophisticated in nature, and may not be detected until after a security incident has occurred. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. Unremediated high risk or critical vulnerabilities pose material risks to our business, particularly due to the reliance on software vendors to adequately patch and implement fixes to address critical or high-risk vulnerabilities in a timely manner. Further, we may be materially impacted by software updates applied by our software vendors if such updates cause significant downtime to our systems. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we or third parties with whom we work experience or are perceived to have experienced a breach, we may experience material adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections), interruptions in our operations, including disruption of our commercialization and development efforts, interruptions or restrictions on processing sensitive data (which could result in delays in obtaining, or our inability to obtain, regulatory approvals and significantly increase our costs to recover or reproduce the data), reputational harm, litigation (including class action claims), indemnification obligations, negative publicity, financial loss, and other harms. In addition, such a breach may require public notification of the breach, or we may choose to voluntarily notify relevant stakeholders, or take other actions, such as providing credit monitoring and identity theft protection services, and we have done so in the past. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position. Additionally, sensitive </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">information of the Company could be leaked, disclosed, or revealed as a result of or in connection with our employees&#8217;, personnel&#8217;s, or vendors&#8217; use of generative AI technologies. </span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Many of our contracts with relevant stakeholders include obligations relating to the safeguard of sensitive information, and a breach could lead to claims against us by such stakeholders. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities, damages, or claims relating to our data privacy and security obligations. In addition, failure to maintain effective internal accounting controls related to data security breaches and cybersecurity in general could impact our ability to produce timely and accurate financial statements and could subject us to regulatory scrutiny. While we do maintain cyber liability insurance, our insurance coverages may not be sufficient in type or amount to cover us against any such losses, claims, or liabilities related to security breaches, cyber-attacks, cyber intrusion, or other related breaches or disruptions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and third parties with whom we work are subject to stringent and changing U.S. and foreign laws, regulations, rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our (or the third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue and profits; and other adverse business impacts.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we process personal data and other sensitive data, including proprietary and confidential business data, trade secrets, intellectual property, clinical trial participant data, and other sensitive third-party data. We are therefore subject to or affected by numerous data privacy and security obligations, such as federal, state, local and foreign laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts, and other obligations governing the processing of personal data. These obligations may change, are subject to differing interpretations and may be inconsistent or conflict among jurisdictions. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. This evolution may create uncertainty in our business; affect us or our collaborators&#8217;, service providers&#8217; and contractors&#8217; ability to operate in certain jurisdictions or to collect, store, transfer, use and share personal data; necessitate the acceptance of more onerous obligations in our contracts; result in liability; or impose additional costs on us. These obligations may necessitate changes to our information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. In addition, these obligations may require us to change our business model. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example, the European Union&#8217;s General Data Protection Regulation, or the EU GDPR, and the United Kingdom&#8217;s GDPR, or the UK GDPR (collectively, the &#8220;GDPR&#8221;), impose strict requirements on the processing of personal data. For example, under GDPR, government regulators may impose temporary or definitive bans on data processing, fines of up to 20 million Euros under the EU GDPR, 17.5 million pounds sterling under the UK GDPR or, in each case, 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be unable to transfer personal data from the EEA, the UK and other jurisdictions to the U.S. or other countries due to data localization requirements or limitations on cross-border data flows. The EEA and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the EEA and the UK have significantly restricted the transfer of personal data to the U.S. and other countries whose privacy laws it believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the U.S. in compliance with law, such as the EEA and UK&#8217;s standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto, these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the U.S. If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the U.S., or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the U.S., are subject to increased scrutiny from regulators, individual litigants, and activist groups, and some EEA regulators have prevented companies from transferring personal data out of the EEA for allegedly violating the EU GDPR&#8217;s cross-border data transfer limitations. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Likewise, we expect that there will continue to be new proposed laws, regulations and industry standards relating to data privacy and security in the U.S. For example, HIPAA, as amended by HITECH, imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health data. Additionally, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020, or CPRA, collectively CCPA, imposes obligations on businesses to which it applies. These obligations include, but are not limited to, providing specific disclosures in privacy notices and affording California residents certain rights related to their personal data. The CCPA allows for statutory fines for noncompliance. While the CCPA contains limited exceptions for clinical trial data, the CCPA&#8217;s implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. In addition, the CPRA establishes a California Privacy Protection Agency to implement and enforce the CPRA, which could increase the risk of an enforcement action, and applies to personal data of business representatives and employees. Other states have also enacted data privacy and security laws. For example, Virginia passed the Consumer Data Protection Act, and Colorado passed the Colorado Privacy Act, both of which differ from the CPRA and became effective in 2023. If we become subject to new data privacy and security laws, at the state level or otherwise, the risk of enforcement action against us could increase because we may become subject to additional obligations, and the number of individuals or entities that can initiate actions against us may increase.</span></div><div style="text-indent:63pt"><span><br/></span></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, the Network and Information Security Directive (&#8220;NIS2&#8221;) regulates resilience and incident response capabilities of entities operating in a number of sectors, including the health sector. Non-compliance with NIS2 may lead up to administrative fines of a maximum of 10 million Euros or up to 2% of the total worldwide revenue of the preceding fiscal year.</span></div><div style="text-indent:63pt"><span><br/></span></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our employees and personnel use generative AI technologies to perform their work, and the disclosure and use of personal data in generative AI technologies is subject to various privacy laws and other privacy obligations. Governments have passed and are likely to pass additional laws regulating generative AI. Our use of this technology could result in additional compliance costs, regulatory investigations and actions, and lawsuits. If we are unable to use generative AI, it could make our business less efficient and result in competitive disadvantages.</span></div><div style="text-indent:63pt"><span><br/></span></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to data privacy and security laws, we are contractually subject to industry standards adopted by industry groups and we are, and may become in the future, subject to such obligations. Moreover, clinical trial participants or research subjects about whom we or our vendors obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. We are also bound by other contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. We may publish privacy policies, marketing materials, white papers, and other statements, such as statements relating to compliance with certain certifications or self-regulatory principles concerning data privacy and security. Regulators in the U.S. are increasingly scrutinizing these statements, and if these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, misleading or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that, in the future, we may fail or be perceived to have failed to comply with applicable data privacy and security obligations. Moreover, despite our best compliance efforts, we may not be successful in achieving compliance if our personnel or third parties with whom we work fail to comply with such obligations, which could negatively impact our business operations and compliance posture. If we or the third parties with whom we work fail, or are perceived to have failed, to address or comply with data privacy and security obligations, we could face significant consequences. These consequences may include, but are not limited to, government enforcement actions; litigation; additional reporting requirements and/or oversight; bans on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including: interruptions or stoppages in our business operations including, as relevant, clinical trials; inability to process personal data or to operate in certain jurisdictions; limited ability to continue to develop or commercialize RYTELO; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or revision or restructuring of our operations. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:90%">RISKS RELATED TO OUR COMMON STOCK AND FINANCIAL REPORTING</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Historically, our stock price has been extremely volatile and your investment may suffer a decline in value.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Historically, our stock price has been extremely volatile. Between January&#160;1, 2016 and March&#160;31, 2026, our stock has traded as high as $6.38 per share and as low as $0.89 per share. Between April&#160;1, 2025 and March&#160;31, 2026, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the price has ranged between a high of $1.95 per share and a low of $1.04 per share. The significant market price fluctuations of our common stock have been due to and may in the future be influenced by a variety of factors, including:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of and market opportunity for future sales of RYTELO;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements regarding regulatory approval or non-approval of RYTELO in any other jurisdictions or indications, or specific label indications for RYTELO, or restrictions, warnings or limitations in its use;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements regarding the research and development of imetelstat, or adverse efficacy or safety results of, further delays in the commencement, enrollment or conduct of, discontinuation of, or further modifications or refinements to any current or potential future clinical trials, or our inability to successfully continue the development of imetelstat;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain additional capital, if and when needed, to further advance our development program;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in laws or regulations applicable to RYTELO, including laws or regulations concerning the commercialization of RYTELO or clinical trial requirements for approval or other regulatory developments related to RYTELO;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse developments concerning our manufacturers, including our inability to obtain adequate product supply for RYTELO or inability to do so at acceptable prices;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and growth of the market opportunity for RYTELO in its currently approved and any potential future approved indications;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes or other developments relating to RYTELO proprietary rights, including patents, litigation matters and our ability to obtain, enforce and defend patent protection and maintain regulatory exclusivity for RYTELO and our technologies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and timing of any future collaboration agreements for the further development and commercialization of RYTELO that we may establish;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of significant acquisitions, strategic partnerships, collaborations, joint ventures or capital commitments by us or our competitors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased or continuing operating losses;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general domestic and international market conditions or market conditions relating to the biopharmaceutical and pharmaceutical industries, especially given the volatility caused by macroeconomic or other global conditions, </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceptions of the biotechnology and pharmaceutical industry by the public, legislature, regulators and the investment community;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to meet the estimates and projections of the investment community or general public;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publication of commentary, articles or research reports about us or our industry, or positive or negative recommendations or withdrawal of research coverage by securities analysts, bloggers, news media or other third parties; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or expected sales of common stock by stockholders; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of or developments concerning pending and potential future litigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions instituted by activist shareholders or others;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other events or factors that are beyond our control; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the occurrence of any other risks and uncertainties discussed under the heading &#8220;Risk Factors.&#8221;</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as further discussed in the Risk Factor above titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We and certain of our current and former officers and directors have been named as defendants in securities class action lawsuits and derivative lawsuits. These lawsuits, and potential similar or related lawsuits, could result in substantial damages, divert management&#8217;s time and attention from our business, and have a material adverse effect on our results of operations. These lawsuits, and any other lawsuits to which we are subject, may be costly to defend or pursue and are uncertain in their outcome</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; we and certain of our current and former officers and directors have been named as defendants in securities class action and derivative lawsuits. Such lawsuits have often been instituted against companies, including us, whose securities have experienced periods of volatility in market price. The pending lawsuits and any lawsuits brought against us in the future could result in substantial costs and divert our management&#8217;s attention and resources, which could have a material adverse effect on our financial condition and business operations and lead to increased volatility in our stock price and a decrease in the value of our stockholders&#8217; investment in our securities.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to maintain compliance with the continued listing requirements of the Nasdaq Global Select Market may result in our common stock being delisted from the Nasdaq Global Select Market, which could negatively impact the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">price of our common stock, liquidity, our ability to access the capital markets and our stockholders&#8217; ability to sell their shares.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is currently listed on the Nasdaq Global Select Market, or Nasdaq, under the symbol &#8220;GERN.&#8221; The listing standards of Nasdaq provide that a company, in order to qualify for continued listing, must maintain a minimum stock price of $1.00 and satisfy standards relative to minimum stockholders&#8217; equity, minimum market value of publicly held shares and various additional requirements. Historically, our stock price has been extremely volatile and recently, our stock has traded as low as $1.04 per share through May&#160;1, 2026. While our common stock is currently listed on Nasdaq, we can give no assurance that we will be able to maintain compliance with the continued listing requirements for Nasdaq. If we fail to maintain compliance with any such continued listing requirement, there can also be no assurance that we will be able to regain compliance with any such continued listing requirement in the future or that our common stock will not be delisted in the future. If Nasdaq delists our securities from trading on its exchange for failure to meet the listing standards, we and our stockholders could face significant negative consequences including: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limited availability of market quotations for our securities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a determination that the common stock is a &#8220;penny stock&#8221;, which would require brokers trading in the common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for shares of common stock;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> a limited amount of analyst coverage, if any; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> a decreased ability to issue additional securities or obtain additional financing in the future.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Delisting from Nasdaq could also result in other negative consequences, including the potential loss of confidence by suppliers, customers and employees, the loss of institutional investor interest and fewer business development opportunities.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our charter, bylaws and Delaware law may inhibit potential acquisition bids for us, which may adversely affect the market price of our common stock and/or prevent holders of our common stock from benefiting from what they believe may be the positive aspects of acquisitions and takeovers. </span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Provisions of our charter documents and bylaws may make it substantially more difficult for a third party to acquire control of us and may prevent changes in our management, including provisions that prevent stockholders from taking actions by written consent, divide the board of directors into separate classes with terms of office that are structured to prevent all of the directors from being elected in any one year and set forth procedures for nominating directors and submitting proposals for consideration at stockholders&#8217; meetings.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, our certificate of incorporation provides our board of directors with the authority to issue up to 3,000,000 shares of undesignated preferred stock and to determine or alter the rights, preferences, privileges and restrictions granted to or imported upon these shares without further vote or action by our stockholders. The issuance of shares of preferred stock may delay or prevent a change in control transaction without further action by our stockholders. As a result, the market price of our common stock may be adversely affected. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If in the future, we issue preferred stock that has preference over our common stock with respect to the payment of dividends or upon our liquidation, dissolution or winding up, or if we issue preferred stock with voting rights that dilute the voting power of our common stock, the rights of holders of our common stock or the market price of our common stock could be adversely affected.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Provisions of Delaware law may also inhibit potential acquisition bids for us or prevent us from engaging in business combinations. In addition, we have individual severance agreements with our executive officers and a company-wide severance plan, either of which could require a potential acquirer to pay a higher price. Either collectively or individually, these provisions may prevent holders of our common stock from benefiting from what they may believe are the positive aspects of acquisitions and takeovers, including the potential realization of a higher rate of return on their investment from these types of transactions. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The exclusive forum provisions in our amended and restated bylaws could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or any of our directors, officers, or employees, or the underwriters of any offering giving rise to such claim, which may discourage lawsuits with respect to such claims.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated bylaws provide that, unless we consent to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for:</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any derivative claim or cause of action or proceeding brought on our behalf;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any claim or cause of action for breach of a fiduciary duty owed by any of our current or former directors, officers or other employees, or our stockholders, to us or to our stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any claim or cause of action against us or any of our current or former directors, officers or other employees, or our stockholders, arising pursuant to any provision of the General Corporation Law of the State of Delaware, our certificate of incorporation, or our bylaws;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any claim or cause of action seeking to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any claim or cause of action as to which the General Corporation Law of the State of Delaware confers jurisdiction on the Court of Chancery of the State of Delaware; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any claim or cause of action against us or any of our current or former directors, officers or other employees, or our stockholders, governed by the internal affairs doctrine or otherwise related to our internal affairs.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all claims brought to enforce any duty or liability created by the Securities Act of 1933, as amended, or the Securities Act, or the rules and regulations thereunder. Our amended and restated bylaws provide that the federal district courts of the United States of America will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or the Federal Forum Provision, including for all causes of action asserted against any defendant named in such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. The application of the Federal Forum Provision means that suits brought by our stockholders to enforce any duty or liability created by the Securities Act must be brought in federal court and cannot be brought in state court, and our stockholders cannot waive compliance with the federal securities laws and the rules and regulations thereunder.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While the Delaware courts have determined that such choice of forum provisions are facially valid and several state trial courts have enforced such provisions and required that suits asserting Securities Act claims be filed in federal court, there is no guarantee that courts of appeal will affirm the enforceability of such provisions, and a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such an instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated bylaws. This may require significant additional costs associated with resolving such action in other jurisdictions, which costs could be borne by stockholders, and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any person or entity purchasing or otherwise acquiring or holding any interest in any of our securities shall be deemed to have notice of and consented to the exclusive forum provisions in our amended and restated bylaws, including the Federal Forum Provision. These provisions could limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, or our stockholders or the underwriters of any offering giving rise to such claims, which may discourage lawsuits with respect to such claims. Furthermore, if a court were to find the exclusive forum provisions contained in our bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could have a material and adverse impact on our business and our financial condition.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We do not intend to pay cash dividends on our common stock in the foreseeable future.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We do not anticipate paying cash dividends on our common stock in the foreseeable future. Any payment of cash dividends will depend upon our financial condition, results of operations, capital requirements and other factors, and will be at the discretion of our board of directors. In addition, the terms of our Pharmakon Loan Agreement restrict our ability to pay dividends and any future debt agreements may continue to or further restrict our ability to pay dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders for the foreseeable future.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our employees, independent contractors, principal investigators, clinical trial sites, CROs, consultants or vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, principal investigators, clinical trial sites, CROs, consultants or vendors may engage in fraudulent or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate the FDA&#8217;s or similar international regulatory authorities&#8217; regulations, including those laws requiring the reporting of true, complete and accurate information; manufacturing standards; healthcare fraud and abuse laws and regulations; or laws that require the true, complete and accurate reporting of financial information or data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials or creating fraudulent data in our non-clinical studies or clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by our employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could adversely affect our business, financial condition, results of operations or prospects through: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the imposition of civil, criminal and administrative penalties, damages and monetary fines;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contractual damages;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reputational harm;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diminished potential profits and future earnings; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">curtailment of our operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could have a material adverse effect on our business and stock price.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, requires that we establish and maintain an adequate internal control structure and procedures for financial reporting. Our Annual Reports on Form 10-K must contain an annual assessment by management of the effectiveness of our internal control over financial reporting and must include disclosure of any material weaknesses in internal control over financial reporting that we have identified. In addition, our independent registered public accounting firm must provide an opinion annually on the effectiveness of our internal control over financial reporting. As described further below, we identified a material weakness in our internal control over financial reporting that existed as of September 30, 2025, which we remediated as of December 31, 2025. However, in the future, any testing by us conducted in connection with Section 404, or any testing by our independent registered public accounting firm, may reveal additional deficiencies in our internal control over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The requirements of Section 404 are ongoing and also apply to future years. We expect that our internal control over financial reporting will continue to evolve as our business develops, including in connection with our commercialization of RYTELO. Although we are committed to continue to improve our internal control processes and we will continue to review our internal control over financial reporting, any control system, regardless of how well designed, operated and evaluated, can provide only reasonable, not absolute, assurance that its objectives will be met. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Therefore, we cannot assure you that additional material weaknesses or significant deficiencies will not exist or otherwise be discovered in the future, particularly in light of our increased reliance on personnel working remotely. If material weaknesses or other significant deficiencies continue to occur, such weaknesses or deficiencies could result in misstatements of our results of operations, restatements of our financial statements, a decline in our stock price, or other material adverse effects on our business, reputation, results of operations, financial condition or liquidity.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have previously identified a material weakness in our internal control over financial reporting and may identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, which </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">may result in material misstatements of our consolidated financial statements or cause us to fail to meet our periodic reporting obligations.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis. We previously identified a material weakness in internal control related to the design and operation of certain Information Technology General Controls, or ITGCs, related to user access and program change management for our Enterprise Resource Planning and payment processing systems. Consequently, IT application controls and IT dependent manual business process controls that rely upon information from these systems, were also deemed ineffective. Although the material weakness identified did not result in any material misstatements in our consolidated financial statements for the periods presented in this Report and there were otherwise no changes to our previously issued financial statements, our management concluded that these control deficiencies existed as of September 30, 2025 and constitute a material weakness. Accordingly, our internal control over financial reporting and our disclosure controls and procedures were not effective as of September 30, 2025. While we subsequently remediated this material weakness as of December 31, 2025, we cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Our failure to implement and maintain effective internal control over financial reporting could result in errors in our consolidated financial statements that could result in a restatement of our previously issued financial statements and could cause us to fail to meet our periodic reporting obligations, any of which could diminish investor confidence in us and cause a decline in the price of our common stock</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">New income, sales, use, excise or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could affect the tax treatment of our domestic and foreign sales and earnings. Any new taxes could adversely affect our domestic and international business operations and our business and financial condition. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, the Inflation Reduction Act of 2022 included provisions that impacted the U.S. federal income taxation of corporations, including imposing a minimum tax on the book income of certain large corporations and an excise tax on certain corporate stock repurchases that is imposed on the corporation repurchasing such stock. In addition, the U.S. government recently enacted legislation commonly referred to as the One Big Beautiful Bill Act, that (along with other recent U.S. federal tax reform) has resulted in significant changes to the taxation of business entities including, among other changes, changes to the taxation of income derived from international operations, changes in the deduction and amortization of research and development expenditures, and limitations on the deductibility of business interest. Future guidance from the Internal Revenue Service and other tax authorities with respect to any legislation may affect us, and certain aspects of such legislation could be repealed or modified or sunset in future years. Changes in tax reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future United States tax expense. </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Our net operating loss carryforwards attributable to tax years beginning before January 1, 2018 could expire unused and be unavailable to offset future income tax liabilities. In addition, federal net operating losses incurred in taxable years beginning after December 31, 2017, can be carried forward indefinitely, but the deductibility of such federal net operating losses in a taxable year is limited to 80% of taxable income in such year. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point cumulative change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes (such as research and development tax credits) to offset its post-change taxable income or taxes may be limited. Changes in our stock ownership have occurred in the past, and future ownership changes, some of which may be outside our control, could occur in the future, as a result of shifts in our stock ownership. If a limitation were to apply, utilization of a portion of our domestic net operating loss and tax credit carryforwards could be limited in future periods, and a portion of the carryforwards may expire before being available to reduce future income tax liabilities, which could adversely impact our financial position. At the state level, there may be periods during which the use of net operating loss carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For example, in June 2024, California enacted legislation that, with certain exceptions, suspends the use of California net operating losses to offset California income and limits the use of California business tax credits to offset California taxes, for taxable years beginning after 2023 and before 2027.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="idd6aca193f774d62ad71a733a1085238_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS, AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-bottom:18pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="idd6aca193f774d62ad71a733a1085238_106"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-bottom:18pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="idd6aca193f774d62ad71a733a1085238_109"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:18pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="idd6aca193f774d62ad71a733a1085238_112"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-bottom:18pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2026, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) <ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-659"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-660">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-661"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-662">terminated</ix:nonNumeric></ix:nonNumeric> any &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as those terms are defined in Item 408 of Regulation S-K.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="idd6aca193f774d62ad71a733a1085238_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;EXHIBITS</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:52.687%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="12" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Incorporation by Reference</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Filing</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Filing Date</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">File No.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.1+</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="amendednon-employeedirecto.htm">Amended Non-Employee Director Compensation Policy, effective March 12, 2026</a></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.2</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886744/000088674426000008/firstamendmenttoloanagreem.htm">First Amendment to Loan Agreement, dated January 5, 2026, among the Registrant, BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership.</a></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.25</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10-K</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">March 2, 2026</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">000-20859</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.3+*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="consultingagreementbyandbe.htm">Consulting Agreement by and between the Company and Andrew Grethlein, effective October 16, 2025.</a></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.4+*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="employmentagreementbyandbe.htm">E</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="employmentagreementbyandbe.htm">mployment Agreement by and between the Company and Timothy Williams, effective April 13, 2026.</a></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">31.1+</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="gern-20260331xexx311.htm">Certification of Chief Executive Officer pursuant to Form of Rule 13a&#8209;14(a), as adopted pursuant to Section 302(a) of the Sarbanes&#8209;Oxley Act of 2002</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="gern-20260331xexx311.htm">.</a></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">31.2+</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="gern-20260331xexx312.htm">Certification of Chief Financial Officer pursuant to Form of Rule 13a&#8209;14(a), as adopted pursuant to Section 302(a) of the Sarbanes&#8209;Oxley Act of 2002</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="gern-20260331xexx312.htm">.</a></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">32.1+</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="gern-20260331xexx321.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes&#8209;Oxley Act of 2002</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="gern-20260331xexx321.htm">.**</a></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">32.2+</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="gern-20260331xexx322.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes&#8209;Oxley Act of 2002</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="gern-20260331xexx322.htm">.**</a></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">101</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following materials from the Registrant&#8217;s March&#160;31, 2026  Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2026 formatted in Inline Extensible Business Reporting Language (iXBRL) include: (i) Condensed Consolidated Balance Sheets as of March&#160;31, 2026 and December&#160;31, 2025, (ii) Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March&#160;31, 2026 and 2025, (iii) Condensed Consolidated Statements of Stockholders&#8217; Equity for the three months ended  March&#160;31, 2026 and 2025, (iv) Condensed Consolidated Statements of Cash Flows for the three months ended  March&#160;31, 2026 and 2025 and (v) Notes to Condensed Consolidated Financial Statements.</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">104</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_____________________</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">+</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.37pt">Filed herewith.</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22pt">Management contract or compensation plan or arrangement.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">**</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17pt">The certifications attached as Exhibits 32.1 and 32.2 that accompany this Report are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Report), irrespective of any general incorporation language contained in such filing.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="idd6aca193f774d62ad71a733a1085238_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:57.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">GERON CORPORATION</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date: May&#160;6, 2026</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">/s/ MICHELLE ROBERTSON</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MICHELLE ROBERTSON</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Vice President, Chief Financial Officer and Treasurer (Duly Authorized Officer and Principal Financial and Accounting Officer)</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>amendednon-employeedirecto.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head><title>Amended Non-Employee Director Compensation Policy, effective March 12, 2026</title></head><body><div style="background-color:#E4E4E4;font-family:Arial, sans-serif;word-wrap:break-word"><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt"><div style="position:absolute;top:728.64pt"><div style="width:514pt"></div></div><div style="position:absolute"><div style="width:514pt"><div style="line-height:7.44pt;position:absolute;top:27pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:505.51pt;position:absolute;text-decoration:none;white-space:pre">Exhibit 10.1</font></div></div></div><div><div id="id2e16416130149e994e0a09b6455db62_1" style="position:absolute;top:58.32pt"></div><div style="line-height:6.77pt;position:absolute;top:58.32pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:248.43pt;position:absolute;white-space:pre">GERON</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:285.07pt;letter-spacing:-0.04em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:287.17pt;letter-spacing:-0.01em;position:absolute;white-space:pre">CORPORATION</font></div><div style="line-height:6.77pt;position:absolute;top:70.37pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:173.44pt;position:absolute;white-space:pre">NON-EMPLOYEE DIRECTOR COMPENSATION POLICY </font></div><div style="line-height:6.77pt;position:absolute;top:94.77pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:128.24pt;position:absolute;white-space:pre">ORIGINALLY</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:193.76pt;letter-spacing:-0.03em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:195.96pt;position:absolute;white-space:pre">ADOPTED</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:244.81pt;letter-spacing:-0.03em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:247.01pt;position:absolute;white-space:pre">BY</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:260.89pt;letter-spacing:-0.03em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:263.09000000000003pt;position:absolute;white-space:pre">THE</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:284.18pt;letter-spacing:-0.03em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:286.38pt;position:absolute;white-space:pre">BOARD</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:322.47pt;letter-spacing:-0.03em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:324.67pt;position:absolute;white-space:pre">OF</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:338.54pt;letter-spacing:-0.03em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:340.74pt;position:absolute;white-space:pre">DIRECTORS&#58;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:403.49pt;letter-spacing:-0.03em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:405.69pt;position:absolute;white-space:pre">MARCH</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:444.55pt;letter-spacing:-0.03em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:446.75pt;position:absolute;white-space:pre">10,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:459.25pt;letter-spacing:-0.03em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:461.45pt;position:absolute;white-space:pre">2014</font></div><div style="line-height:6.77pt;position:absolute;top:119.17pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:121.55pt;position:absolute;white-space:pre">AMENDED</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:173.18pt;letter-spacing:-0.03em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:175.38pt;position:absolute;white-space:pre">BY</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:189.26pt;letter-spacing:-0.03em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:191.45999999999998pt;position:absolute;white-space:pre">THE</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:212.55pt;letter-spacing:-0.03em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:214.75pt;position:absolute;white-space:pre">BOARD</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:250.83999999999997pt;letter-spacing:-0.03em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:253.04000000000002pt;position:absolute;white-space:pre">OF</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:266.91pt;letter-spacing:-0.03em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:269.11pt;position:absolute;white-space:pre">DIRECTORS&#58;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:331.86pt;letter-spacing:-0.03em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:334.06pt;position:absolute;white-space:pre">FEBRUARY</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:389.58pt;letter-spacing:-0.025em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:391.83pt;position:absolute;white-space:pre">12,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:404.33pt;letter-spacing:-0.03em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:406.53000000000003pt;position:absolute;white-space:pre">2015,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:429.03000000000003pt;letter-spacing:-0.03em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:431.23pt;position:absolute;white-space:pre">MAY</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:455.1pt;letter-spacing:-0.03em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:457.3pt;position:absolute;white-space:pre">6,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:464.8pt;letter-spacing:-0.03em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:467pt;letter-spacing:-0.01em;position:absolute;white-space:pre">2015,</font></div><div style="line-height:6.77pt;position:absolute;top:130.62pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:136.64pt;position:absolute;white-space:pre">FEBRUARY</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:192.16pt;letter-spacing:-0.025em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:194.41pt;position:absolute;white-space:pre">11,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:206.90999999999997pt;letter-spacing:-0.02em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:209.20999999999998pt;position:absolute;white-space:pre">2016,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:231.70999999999998pt;letter-spacing:-0.02em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:234.01pt;position:absolute;white-space:pre">JANUARY</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:282.33pt;letter-spacing:-0.025em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:284.58pt;position:absolute;white-space:pre">31,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:297.08pt;letter-spacing:-0.02em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:299.38pt;position:absolute;white-space:pre">2018,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:321.88pt;letter-spacing:-0.02em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:324.17999999999995pt;position:absolute;white-space:pre">MAY</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:348.04999999999995pt;letter-spacing:-0.02em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:350.35pt;position:absolute;white-space:pre">15,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:362.85pt;letter-spacing:-0.025em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:365.1pt;position:absolute;white-space:pre">2018,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:387.6pt;letter-spacing:-0.02em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:389.9pt;position:absolute;white-space:pre">OCTOBER</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:439.86pt;letter-spacing:-0.02em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:442.15999999999997pt;position:absolute;white-space:pre">1,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:449.65999999999997pt;letter-spacing:-0.025em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:451.90999999999997pt;letter-spacing:-0.01em;position:absolute;white-space:pre">2018,</font></div><div style="line-height:6.77pt;position:absolute;top:142.62pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:50.5pt;position:absolute;white-space:pre">JANUARY</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:98.82pt;letter-spacing:-0.005em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:101.27000000000001pt;position:absolute;white-space:pre">30,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:113.77000000000001pt;letter-spacing:-0.005em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:116.22pt;position:absolute;white-space:pre">2019,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:138.72pt;letter-spacing:-0.005em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:141.17000000000002pt;position:absolute;white-space:pre">FEBRUARY</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:196.69pt;letter-spacing:-0.005em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:199.14pt;position:absolute;white-space:pre">12,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:211.64pt;letter-spacing:-0.005em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:214.09pt;position:absolute;white-space:pre">2020,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:236.59pt;letter-spacing:-0.005em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:239.04pt;position:absolute;white-space:pre">FEBRUARY</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:294.56pt;letter-spacing:-0.005em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:297.01pt;position:absolute;white-space:pre">16,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:309.51pt;letter-spacing:-0.005em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:311.96pt;position:absolute;white-space:pre">2022,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:334.46pt;letter-spacing:-0.005em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:336.91pt;position:absolute;white-space:pre">MARCH</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:375.77pt;letter-spacing:-0.005em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:378.22pt;position:absolute;white-space:pre">7,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:385.72pt;letter-spacing:-0.005em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:388.17pt;position:absolute;white-space:pre">2022, FEBRUARY 14, 2024, MARCH 6, </font></div><div style="line-height:6.77pt;position:absolute;top:154.62pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:164.07pt;position:absolute;white-space:pre">2025, MAY 4, 2025, FEBRUARY 17, 2026 AND MARCH 12, 2026</font></div><div style="line-height:6.93pt;position:absolute;top:179.77pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:75.84pt;position:absolute;text-decoration:none;white-space:pre">Each</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:95.80000000000001pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:98.10000000000001pt;position:absolute;text-decoration:none;white-space:pre">member</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:130.83pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.13pt;position:absolute;text-decoration:none;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:141.46pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:143.76pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.96pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:158.26pt;position:absolute;text-decoration:none;white-space:pre">board</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:181.02pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:183.32pt;position:absolute;text-decoration:none;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:191.65pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:193.95pt;position:absolute;text-decoration:none;white-space:pre">directors</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:228.9pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:231.20000000000002pt;position:absolute;text-decoration:none;white-space:pre">(the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:246.73pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:249.03pt;position:absolute;text-decoration:none;white-space:pre">&#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:italic;font-weight:bold;left:253.46pt;position:absolute;text-decoration:none;white-space:pre">Board</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:279.01pt;position:absolute;text-decoration:none;white-space:pre">&#8221;)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:286.77pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:289.07pt;position:absolute;text-decoration:none;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:297.4pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:299.70000000000005pt;position:absolute;text-decoration:none;white-space:pre">Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:324.68pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:326.98pt;position:absolute;text-decoration:none;white-space:pre">Corporation</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:375.27pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:377.57000000000005pt;position:absolute;text-decoration:none;white-space:pre">(the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:393.1pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:395.4pt;position:absolute;text-decoration:none;white-space:pre">&#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:italic;font-weight:bold;left:399.83000000000004pt;position:absolute;text-decoration:none;white-space:pre">Company</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:439.25pt;position:absolute;text-decoration:none;white-space:pre">&#8221;)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:447.01pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:449.36pt;position:absolute;text-decoration:none;white-space:pre">who is a Non-Employee </font></div><div style="line-height:6.93pt;position:absolute;top:191.77pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">Director</font><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:87.52000000000001pt;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.02000000000001pt;position:absolute;text-decoration:none;white-space:pre">(as defined in the Geron Corporation 2018 Equity Incentive Plan (the &#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:italic;font-weight:bold;left:373.89pt;position:absolute;text-decoration:none;white-space:pre">2018 Plan</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:415.82pt;position:absolute;text-decoration:none;white-space:pre">&#8221;)) shall</font><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:448.27pt;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:450.77pt;position:absolute;text-decoration:none;white-space:pre">be eligible to receive </font></div><div style="line-height:6.93pt;position:absolute;top:203.77pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">cash and equity compensation as set forth in this Geron Corporation</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:326.19pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:328.39pt;position:absolute;text-decoration:none;white-space:pre">Non-Employee</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:389.44pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:391.64pt;position:absolute;text-decoration:none;white-space:pre">Director</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:424.92pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:427.12pt;position:absolute;text-decoration:none;white-space:pre">Compensation</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:484.84000000000003pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:487.04pt;position:absolute;text-decoration:none;white-space:pre">Policy</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:512.5699999999999pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:514.77pt;position:absolute;text-decoration:none;white-space:pre">(this</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:532.53pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font></div><div style="line-height:6.93pt;position:absolute;top:215.77pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">&#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:italic;font-weight:bold;left:58.67pt;position:absolute;text-decoration:none;white-space:pre">Policy</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:84.17pt;position:absolute;text-decoration:none;white-space:pre">&#8221;).</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.43pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.68pt;position:absolute;text-decoration:none;white-space:pre">The</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.21000000000001pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.46000000000001pt;position:absolute;text-decoration:none;white-space:pre">cash</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.21pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:134.46pt;position:absolute;text-decoration:none;white-space:pre">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:148.89000000000001pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.14000000000001pt;position:absolute;text-decoration:none;white-space:pre">equity</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.11pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:178.36pt;position:absolute;text-decoration:none;white-space:pre">compensation</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:233.85000000000002pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:236.10000000000002pt;position:absolute;text-decoration:none;white-space:pre">described</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:274.38pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:276.63pt;position:absolute;text-decoration:none;white-space:pre">in this Policy shall</font><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:350.72pt;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:353.22pt;position:absolute;text-decoration:none;white-space:pre">be paid or granted, as applicable, automatically </font></div><div style="line-height:6.93pt;position:absolute;top:227.77pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">and without further action of the Board to each Non-Employee</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:305.35pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:307.55pt;position:absolute;text-decoration:none;white-space:pre">Director</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:340.83pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:343.03000000000003pt;position:absolute;text-decoration:none;white-space:pre">who</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:360.25pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:362.45pt;position:absolute;text-decoration:none;white-space:pre">is</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:369.11pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:371.31pt;position:absolute;text-decoration:none;white-space:pre">eligible</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:401.25pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:403.45pt;position:absolute;text-decoration:none;white-space:pre">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:411.22pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:413.42pt;position:absolute;text-decoration:none;white-space:pre">receive</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:442.24pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:444.44pt;position:absolute;text-decoration:none;white-space:pre">such</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:462.76pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:464.96000000000004pt;position:absolute;text-decoration:none;white-space:pre">cash</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:482.71000000000004pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:484.91pt;position:absolute;text-decoration:none;white-space:pre">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:493.24pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:495.44pt;position:absolute;text-decoration:none;white-space:pre">equity</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:520.41pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font></div><div style="line-height:6.93pt;position:absolute;top:239.77pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">compensation,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.23pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.43pt;position:absolute;text-decoration:none;white-space:pre">unless</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:139.41pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:141.61pt;position:absolute;text-decoration:none;white-space:pre">such</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:159.93pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.13pt;position:absolute;text-decoration:none;white-space:pre">Non-Employee</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:223.18pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:225.38pt;position:absolute;text-decoration:none;white-space:pre">Director declines the receipt of such cash or equity compensation by written </font></div><div style="line-height:6.93pt;position:absolute;top:251.77pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">notice to the Company.</font></div><div style="line-height:6.93pt;position:absolute;top:276.92pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:75.79pt;position:absolute;text-decoration:none;white-space:pre">This</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:93.55000000000001pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:96pt;position:absolute;text-decoration:none;white-space:pre">Policy,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:124.03pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:126.48pt;position:absolute;text-decoration:none;white-space:pre">as</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:134.8pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:137.25pt;position:absolute;text-decoration:none;white-space:pre">amended,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:175.81pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:178.26pt;position:absolute;text-decoration:none;white-space:pre">is</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:184.92000000000002pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:187.37pt;position:absolute;text-decoration:none;white-space:pre">effective</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:222.29000000000002pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:224.74pt;position:absolute;text-decoration:none;white-space:pre">as</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:233.06pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:235.51pt;position:absolute;text-decoration:none;white-space:pre">of January</font><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:277.42pt;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:279.92pt;position:absolute;text-decoration:none;white-space:pre">1, 2026, and shall</font><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:350.71000000000004pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:353.16pt;position:absolute;text-decoration:none;white-space:pre">remain</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:380.89000000000004pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:383.34000000000003pt;position:absolute;text-decoration:none;white-space:pre">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:391.11pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:393.56pt;position:absolute;text-decoration:none;white-space:pre">effect</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:416.28000000000003pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:418.73pt;position:absolute;text-decoration:none;white-space:pre">until</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:437.04pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:439.49pt;position:absolute;text-decoration:none;white-space:pre">it</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:445.03000000000003pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:447.48pt;position:absolute;text-decoration:none;white-space:pre">is</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:454.14000000000004pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:456.59000000000003pt;position:absolute;text-decoration:none;white-space:pre">revised</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.44pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:487.89000000000004pt;position:absolute;text-decoration:none;white-space:pre">or rescinded by </font></div><div style="line-height:6.93pt;position:absolute;top:288.92pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.19pt;position:absolute;text-decoration:none;white-space:pre">further action of the Board. Capitalized terms not explicitly defined in this Policy but defined in the 2018 Plan shall</font><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:515.87pt;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:518.37pt;position:absolute;text-decoration:none;white-space:pre">have the </font></div><div style="line-height:6.93pt;position:absolute;top:300.92pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.19pt;position:absolute;text-decoration:none;white-space:pre">same definitions as in the 2018 Plan, except when specific reference is made to the Directors&#8217; Market Value</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.85pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:488.1pt;position:absolute;text-decoration:none;white-space:pre">Stock</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:510.86pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:513.11pt;position:absolute;text-decoration:none;white-space:pre">Purchase</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:549.1800000000001pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font></div><div style="line-height:6.93pt;position:absolute;top:312.92pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.19pt;position:absolute;text-decoration:none;white-space:pre">Plan</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:71.95pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:74.2pt;position:absolute;text-decoration:none;white-space:pre">(the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:89.72999999999999pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.97999999999999pt;position:absolute;text-decoration:none;white-space:pre">&#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:italic;font-weight:bold;left:96.41pt;position:absolute;text-decoration:none;white-space:pre">Market</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:italic;font-weight:bold;left:126.39pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:italic;font-weight:bold;left:128.64pt;position:absolute;text-decoration:none;white-space:pre">Value</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:italic;font-weight:bold;left:153.06pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:italic;font-weight:bold;left:155.31pt;position:absolute;text-decoration:none;white-space:pre">Stock</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:italic;font-weight:bold;left:178.07pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:italic;font-weight:bold;left:180.32pt;position:absolute;text-decoration:none;white-space:pre">Plan</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.75pt;position:absolute;text-decoration:none;white-space:pre">&#8221;),</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:210.01pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:212.26pt;position:absolute;text-decoration:none;white-space:pre">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:220.03pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:222.28pt;position:absolute;text-decoration:none;white-space:pre">which</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:246.7pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:248.95pt;position:absolute;text-decoration:none;white-space:pre">case</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:266.13pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:268.38pt;position:absolute;text-decoration:none;white-space:pre">such</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:286.7pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:288.95pt;position:absolute;text-decoration:none;white-space:pre">terms</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:311.14pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:313.39pt;position:absolute;text-decoration:none;white-space:pre">shall</font><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:332.25pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:334.5pt;position:absolute;text-decoration:none;white-space:pre">have</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:353.36pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:355.61pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:367.81pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:370.06pt;position:absolute;text-decoration:none;white-space:pre">definitions</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:412.79pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:415.04pt;position:absolute;text-decoration:none;white-space:pre">set</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:426.13pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:428.38pt;position:absolute;text-decoration:none;white-space:pre">forth in the Market Value Stock </font></div><div style="line-height:6.93pt;position:absolute;top:324.92pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.19pt;position:absolute;text-decoration:none;white-space:pre">Plan.</font></div><div style="line-height:6.77pt;position:absolute;top:350.12pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:54.239999999999995pt;position:absolute;text-decoration:none;white-space:pre">1.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:64.19pt;position:absolute;text-decoration:none;white-space:pre">CASH</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:91.96pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:94.16pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">COMPENSATION.</font></div><div style="line-height:6.93pt;position:absolute;top:375.27pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:75.84pt;position:absolute;text-decoration:none;white-space:pre">(a)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:120.24pt;position:absolute;text-decoration:none;white-space:pre">Annual</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:151.91pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:154.16pt;position:absolute;text-decoration:none;white-space:pre">Retainers.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:197.72pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.97pt;position:absolute;text-decoration:none;white-space:pre">Each</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:219.93pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:222.13pt;position:absolute;text-decoration:none;white-space:pre">Non-Employee</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:283.18pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:285.38pt;position:absolute;text-decoration:none;white-space:pre">Director</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:318.65999999999997pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:320.90999999999997pt;position:absolute;text-decoration:none;white-space:pre">shall</font><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:339.77pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:342.02pt;position:absolute;text-decoration:none;white-space:pre">be</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:351.45pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:353.7pt;position:absolute;text-decoration:none;white-space:pre">eligible</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:383.64pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:385.89pt;position:absolute;text-decoration:none;white-space:pre">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:393.66pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:395.91pt;position:absolute;text-decoration:none;white-space:pre">receive</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:424.73pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:426.98pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:439.18pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:441.43pt;position:absolute;text-decoration:none;white-space:pre">following</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:480.29pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:482.49pt;position:absolute;text-decoration:none;white-space:pre">annual</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:509.12pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:511.32pt;position:absolute;text-decoration:none;white-space:pre">retainers</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:545.6999999999999pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font></div><div style="line-height:6.93pt;position:absolute;top:387.27pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">for service as (i) an individual, member and&#47;or chairperson of the Board and (ii) an individual, member or chairperson of a </font></div><div style="line-height:6.93pt;position:absolute;top:399.27pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">committee of the Board (&#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:italic;font-weight:bold;left:159.09pt;position:absolute;text-decoration:none;white-space:pre">Committee</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:203.46pt;position:absolute;text-decoration:none;white-space:pre">&#8221;) set forth below, as applicable.</font></div><div style="position:absolute;top:424.42pt;width:612pt"><div style="font-size:0pt;left:59.09pt;position:absolute;width:495.75pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tr style="height:0"><td style="padding:0;width:230.25pt"></td><td style="padding:0;width:192.75pt"></td><td style="padding:0;width:72.75pt"></td></tr><tr style="height:24pt"><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:0.75pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top"><div style="position:absolute;width:230.25pt"><div><div style="line-height:6.77pt;position:absolute;top:14.63pt;width:230.25pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:70.6pt;position:absolute;text-decoration:none;white-space:pre">Board</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:97.25pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:99.6pt;position:absolute;text-decoration:none;white-space:pre">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:109.03pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:111.38pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">Committee</font></div></div></div></td><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:0.75pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top"><div style="left:230.25pt;position:absolute;width:192.75pt"><div><div style="line-height:6.77pt;position:absolute;top:14.63pt;width:192.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:58.4pt;position:absolute;text-decoration:none;white-space:pre">Type</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:80.05pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:82.4pt;position:absolute;text-decoration:none;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:90.72999999999999pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:93.08pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">Retainer*</font></div></div></div></td><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:1pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:absolute;width:72.75pt"><div><div style="line-height:6.77pt;position:absolute;top:2.63pt;width:72.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:8.7pt;position:absolute;text-decoration:none;white-space:pre">Amount</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:43.7pt;letter-spacing:-0.065em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:45.55pt;position:absolute;text-decoration:none;white-space:pre">(Per </font></div><div style="line-height:6.77pt;position:absolute;top:14.13pt;width:72.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:24.3pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">Year)</font></div></div></div></td></tr><tr style="height:12.75pt"><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:0.75pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top" rowspan="3"><div style="position:absolute;top:24pt;width:230.25pt"><div><div style="line-height:6.77pt;position:absolute;top:2.63pt;width:230.25pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:4.45pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">Board</font></div></div></div></td><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:0.75pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top"><div style="left:230.25pt;position:absolute;top:24pt;width:192.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:192.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.53pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">Chair</font></div></div></div></td><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:1pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:absolute;top:24pt;width:72.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:72.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:20.47pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">$40,000</font></div></div></div></td></tr><tr style="height:12.75pt"><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:0.75pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top"><div style="left:230.25pt;position:absolute;top:36.75pt;width:192.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:192.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:43.31pt;position:absolute;text-decoration:none;white-space:pre">Lead</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:63.27pt;letter-spacing:-0.035em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:65.42pt;position:absolute;text-decoration:none;white-space:pre">Independent</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.81pt;letter-spacing:-0.035em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:116.96000000000001pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">Director</font></div></div></div></td><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:1pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:absolute;top:36.75pt;width:72.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:72.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:20.47pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">$30,000</font></div></div></div></td></tr><tr style="height:12.75pt"><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:0.75pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top"><div style="left:230.25pt;position:absolute;top:49.5pt;width:192.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:192.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:79.75pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">Member</font></div></div></div></td><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:1pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:absolute;top:49.5pt;width:72.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:72.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:20.47pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">$50,000</font></div></div></div></td></tr><tr style="height:12.75pt"><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:0.75pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="position:absolute;top:62.25pt;width:230.25pt"><div><div style="line-height:6.77pt;position:absolute;top:2.63pt;width:230.25pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:4.45pt;position:absolute;text-decoration:none;white-space:pre">Audit</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:28.89pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:31.14pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">Committee</font></div></div></div></td><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:0.75pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top"><div style="left:230.25pt;position:absolute;top:62.25pt;width:192.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:192.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.53pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">Chair</font></div></div></div></td><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:1pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:absolute;top:62.25pt;width:72.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:72.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:20.47pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">$25,000</font></div></div></div></td></tr><tr style="height:12.75pt"><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:0.75pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top"><div style="left:230.25pt;position:absolute;top:75pt;width:192.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:192.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.37pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">Member</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:87.62pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.07pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">(Non-Chair)</font></div></div></div></td><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:1pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:absolute;top:75pt;width:72.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:72.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:20.47pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">$12,500</font></div></div></div></td></tr><tr style="height:12.75pt"><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:0.75pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="position:absolute;top:87.75pt;width:230.25pt"><div><div style="line-height:6.77pt;position:absolute;top:2.63pt;width:230.25pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:4.45pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">Compensation</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:64.9pt;letter-spacing:0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:67.65pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">Committee</font></div></div></div></td><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:0.75pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top"><div style="left:230.25pt;position:absolute;top:87.75pt;width:192.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:192.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.53pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">Chair</font></div></div></div></td><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:1pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:absolute;top:87.75pt;width:72.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:72.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:20.47pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">$15,000</font></div></div></div></td></tr><tr style="height:12.75pt"><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:0.75pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top"><div style="left:230.25pt;position:absolute;top:100.5pt;width:192.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:192.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.37pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">Member</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:87.62pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.07pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">(Non-Chair)</font></div></div></div></td><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:1pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:absolute;top:100.5pt;width:72.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:72.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:22.92pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">$7,500</font></div></div></div></td></tr><tr style="height:12.75pt"><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:0.75pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="position:absolute;top:113.25pt;width:230.25pt"><div><div style="line-height:6.77pt;position:absolute;top:2.63pt;width:230.25pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:4.45pt;position:absolute;text-decoration:none;white-space:pre">Nominating</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:54.99pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:56.99pt;position:absolute;text-decoration:none;white-space:pre">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:73.11pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:75.11pt;position:absolute;text-decoration:none;white-space:pre">Corporate</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:119.51pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:121.56pt;position:absolute;text-decoration:none;white-space:pre">Governance</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:173.17pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:175.17pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">Committee</font></div></div></div></td><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:0.75pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top"><div style="left:230.25pt;position:absolute;top:113.25pt;width:192.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:192.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.53pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">Chair</font></div></div></div></td><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:1pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:absolute;top:113.25pt;width:72.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:72.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:20.47pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">$10,000</font></div></div></div></td></tr><tr style="height:12.75pt"><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:0.75pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top"><div style="left:230.25pt;position:absolute;top:126pt;width:192.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:192.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.37pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">Member</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:87.62pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.07pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">(Non-Chair)</font></div></div></div></td><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:1pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:absolute;top:126pt;width:72.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:72.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:22.92pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">$5,000</font></div></div></div></td></tr><tr style="height:12.75pt"><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:0.75pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top" rowspan="2"><div style="position:absolute;top:138.75pt;width:230.25pt"><div><div style="line-height:6.77pt;position:absolute;top:2.63pt;width:230.25pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:4.45pt;position:absolute;text-decoration:none;white-space:pre">Strategic</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:42.730000000000004pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:44.830000000000005pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">Committee</font></div></div></div></td><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:0.75pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top"><div style="left:230.25pt;position:absolute;top:138.75pt;width:192.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:192.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.53pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">Chair</font></div></div></div></td><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:1pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:absolute;top:138.75pt;width:72.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:72.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:20.47pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">$15,000</font></div></div></div></td></tr><tr style="height:13.5pt"><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:0.75pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top"><div style="left:230.25pt;position:absolute;top:151.5pt;width:192.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:192.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.37pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">Member</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:87.62pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.07pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">(Non-Chair)</font></div></div></div></td><td style="border-bottom:0.75pt solid #010101;border-left:0.75pt solid #010101;border-right:1pt solid #010101;border-top:0.75pt solid #010101;font-size:0;text-align:left;vertical-align:top"><div style="left:423pt;position:absolute;top:151.5pt;width:72.75pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:72.75pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:22.92pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">$7,500</font></div></div></div></td></tr></table></div></div></div><div style="line-height:6.93pt;position:absolute;top:607.82pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:58.79pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre">*</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;white-space:pre"><font style="left:63.29pt;position:absolute"><font style="display:inline-block;height:6.93pt;width:29.1pt"></font></font><font style="left:92.39pt;position:absolute">The Lead Independent Director and the chairperson of the Board are eligible to receive a retainer for </font></font></div><div style="line-height:6.93pt;position:absolute;top:619.82pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:92.39pt;position:absolute;text-decoration:none;white-space:pre">service as the Lead Independent Director or chairperson, as applicable, and an additional retainer for </font></div><div style="line-height:6.93pt;position:absolute;top:631.82pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:92.39pt;position:absolute;text-decoration:none;white-space:pre">service</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.67pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:122.97pt;position:absolute;text-decoration:none;white-space:pre">as</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.29pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.54pt;position:absolute;text-decoration:none;white-space:pre">a</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:137.97pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.27pt;position:absolute;text-decoration:none;white-space:pre">member</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:173pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:175.3pt;position:absolute;text-decoration:none;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:183.63pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:185.93pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:198.13pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:200.43pt;position:absolute;text-decoration:none;white-space:pre">Board.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:227.35000000000002pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:229.64999999999998pt;position:absolute;text-decoration:none;white-space:pre">The</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:245.18pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:247.48000000000002pt;position:absolute;text-decoration:none;white-space:pre">chairperson</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:294.09pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:296.39pt;position:absolute;text-decoration:none;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:304.72pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:307.02pt;position:absolute;text-decoration:none;white-space:pre">each</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:325.31pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:327.61pt;position:absolute;text-decoration:none;white-space:pre">Committee</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:371.97999999999996pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:374.28pt;position:absolute;text-decoration:none;white-space:pre">is</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:380.94pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:383.19pt;position:absolute;text-decoration:none;white-space:pre">eligible</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:413.13pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:415.43pt;position:absolute;text-decoration:none;white-space:pre">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:423.2pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:425.5pt;position:absolute;text-decoration:none;white-space:pre">receive</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:454.32pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:456.62pt;position:absolute;text-decoration:none;white-space:pre">a</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:461.05pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:463.34999999999997pt;position:absolute;text-decoration:none;white-space:pre">retainer</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:493.84pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:496.14pt;position:absolute;text-decoration:none;white-space:pre">for </font></div><div style="line-height:6.93pt;position:absolute;top:643.82pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:92.39pt;position:absolute;text-decoration:none;white-space:pre">service as the chairperson, but not an additional retainer for service as a member of the Committee.</font></div><div style="line-height:6.93pt;position:absolute;top:668.97pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:75.84pt;position:absolute;text-decoration:none;white-space:pre">The</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.37pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:93.62pt;position:absolute;text-decoration:none;white-space:pre">annual</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.25pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:122.5pt;position:absolute;text-decoration:none;white-space:pre">retainers</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:156.88pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:159.18pt;position:absolute;text-decoration:none;white-space:pre">shall</font><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:178.04000000000002pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:180.29000000000002pt;position:absolute;text-decoration:none;white-space:pre">be</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:189.72pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:191.97pt;position:absolute;text-decoration:none;white-space:pre">paid</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:209.17000000000002pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:211.42000000000002pt;position:absolute;text-decoration:none;white-space:pre">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:219.19pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:221.44pt;position:absolute;text-decoration:none;white-space:pre">arrears</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:248.61pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:250.86pt;position:absolute;text-decoration:none;white-space:pre">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:258.63pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:260.88pt;position:absolute;text-decoration:none;white-space:pre">four</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:277.53999999999996pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:279.78999999999996pt;position:absolute;text-decoration:none;white-space:pre">equal</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:301.42pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:303.67pt;position:absolute;text-decoration:none;white-space:pre">quarterly</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:339.73pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:341.98pt;position:absolute;text-decoration:none;white-space:pre">installments,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:392.74pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:394.99pt;position:absolute;text-decoration:none;white-space:pre">earned</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:421.61pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:423.86pt;position:absolute;text-decoration:none;white-space:pre">upon</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:443.86pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:446.11pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:458.31000000000006pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:460.56000000000006pt;position:absolute;text-decoration:none;white-space:pre">completion</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:505.5pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:507.75pt;position:absolute;text-decoration:none;white-space:pre">of service </font></div><div style="line-height:6.93pt;position:absolute;top:680.97pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">in each calendar quarter. Notwithstanding the foregoing, each person who is elected or appointed to be a</font></div><div style="line-height:6.93pt;position:absolute;top:693.02pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">Non-Employee Director or who is appointed to serve on one of the Committees set forth above or as the Lead Independent </font></div><div style="line-height:6.93pt;position:absolute;top:705.02pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">Director or chairperson of the Board or one of the Committees set forth above, in each case other than on the first day of a </font></div><div style="line-height:6.93pt;position:absolute;top:717.02pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">calendar</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:88.06pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.36pt;position:absolute;text-decoration:none;white-space:pre">quarter,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:121.15pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:123.44999999999999pt;position:absolute;text-decoration:none;white-space:pre">shall</font><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:142.31pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:144.61pt;position:absolute;text-decoration:none;white-space:pre">be</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:154.04pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:156.34pt;position:absolute;text-decoration:none;white-space:pre">eligible</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.28pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:188.58pt;position:absolute;text-decoration:none;white-space:pre">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:196.35000000000002pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:198.65pt;position:absolute;text-decoration:none;white-space:pre">receive</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:227.47pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:229.77pt;position:absolute;text-decoration:none;white-space:pre">a</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:234.20000000000002pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:236.5pt;position:absolute;text-decoration:none;white-space:pre">pro</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:249.83pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.13pt;position:absolute;text-decoration:none;white-space:pre">rata</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:267.09pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:269.39pt;position:absolute;text-decoration:none;white-space:pre">amount</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:299.36pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:301.65999999999997pt;position:absolute;text-decoration:none;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:309.99pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:312.29pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:324.49pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:326.79pt;position:absolute;text-decoration:none;white-space:pre">annual</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:353.42pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:355.72pt;position:absolute;text-decoration:none;white-space:pre">retainers</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:390.1pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:392.40000000000003pt;position:absolute;text-decoration:none;white-space:pre">described</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:430.68pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:432.98pt;position:absolute;text-decoration:none;white-space:pre">above</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:456.84000000000003pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:459.14pt;position:absolute;text-decoration:none;white-space:pre">with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:476.90000000000003pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:479.2pt;position:absolute;text-decoration:none;white-space:pre">respect</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:507.48pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:509.78000000000003pt;position:absolute;text-decoration:none;white-space:pre">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:517.55pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:519.85pt;position:absolute;text-decoration:none;white-space:pre">the </font></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt"><div style="position:absolute;top:728.64pt"><div style="width:514pt"></div></div><div style="position:absolute"><div style="width:514pt"></div></div><div><div style="line-height:6.93pt;position:absolute;top:58.32pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">calendar</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:88.06pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.36pt;position:absolute;text-decoration:none;white-space:pre">quarter</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:118.65pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.94999999999999pt;position:absolute;text-decoration:none;white-space:pre">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:128.72pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.02pt;position:absolute;text-decoration:none;white-space:pre">which</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.44pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:157.69pt;position:absolute;text-decoration:none;white-space:pre">such</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:176.01pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:178.26pt;position:absolute;text-decoration:none;white-space:pre">person</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:204.91pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:207.16pt;position:absolute;text-decoration:none;white-space:pre">becomes</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:242.11pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:244.36pt;position:absolute;text-decoration:none;white-space:pre">a</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:248.79000000000002pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:251.04000000000002pt;position:absolute;text-decoration:none;white-space:pre">Non-Employee</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:312.09000000000003pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:314.34000000000003pt;position:absolute;text-decoration:none;white-space:pre">Director,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:350.12pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:352.37pt;position:absolute;text-decoration:none;white-space:pre">a</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:356.8pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:359.05pt;position:absolute;text-decoration:none;white-space:pre">member</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:391.78000000000003pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:394.03000000000003pt;position:absolute;text-decoration:none;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:402.36pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:404.61pt;position:absolute;text-decoration:none;white-space:pre">one</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:419.04pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:421.29pt;position:absolute;text-decoration:none;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:429.62pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:431.87pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:444.07pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:446.32pt;position:absolute;text-decoration:none;white-space:pre">Committees,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:497.08pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:499.33pt;position:absolute;text-decoration:none;white-space:pre">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:507.66pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:509.91pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:522.11pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:524.36pt;position:absolute;text-decoration:none;white-space:pre">Lead </font></div><div style="line-height:6.93pt;position:absolute;top:70.32pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">Independent</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.63pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:106.03pt;position:absolute;text-decoration:none;white-space:pre">Director</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:139.31pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:141.71pt;position:absolute;text-decoration:none;white-space:pre">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:150.04pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:152.44pt;position:absolute;text-decoration:none;white-space:pre">chairperson</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:199.05pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:201.45000000000002pt;position:absolute;text-decoration:none;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:209.78pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:212.18pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:224.38pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:226.78pt;position:absolute;text-decoration:none;white-space:pre">Board</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:251.20000000000002pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:253.60000000000002pt;position:absolute;text-decoration:none;white-space:pre">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:261.93pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:264.33pt;position:absolute;text-decoration:none;white-space:pre">one</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:278.76pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:281.15999999999997pt;position:absolute;text-decoration:none;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:289.49pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:291.89pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:304.09pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:306.49pt;position:absolute;text-decoration:none;white-space:pre">Committees,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:357.25pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:359.65000000000003pt;position:absolute;text-decoration:none;white-space:pre">as</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:367.97pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:370.37pt;position:absolute;text-decoration:none;white-space:pre">applicable,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:413.90000000000003pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:416.3pt;position:absolute;text-decoration:none;white-space:pre">which</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:440.72pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:443.07pt;position:absolute;text-decoration:none;white-space:pre">pro</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:456.40000000000003pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:458.75pt;position:absolute;text-decoration:none;white-space:pre">rata</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:473.71000000000004pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:476.06pt;position:absolute;text-decoration:none;white-space:pre">amount</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:506.03000000000003pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:508.38pt;position:absolute;text-decoration:none;white-space:pre">reflects</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:537.76pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:540.11pt;position:absolute;text-decoration:none;white-space:pre">a </font></div><div style="line-height:6.93pt;position:absolute;top:82.32pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">reduction for each day during the calendar quarter prior to the date of such election or appointment.</font></div><div style="line-height:6.93pt;position:absolute;top:107.47pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:75.84pt;position:absolute;text-decoration:none;white-space:pre">The annual retainers shall</font><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:178.74pt;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:181.24pt;position:absolute;text-decoration:none;white-space:pre">be paid on a pro-rata basis in arrears after the end of each quarter in the form of cash, or </font></div><div style="line-height:6.93pt;position:absolute;top:119.47pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">alternatively, subject to each Non-Employee Director&#8217;s written election pursuant to the requirements set forth in the </font></div><div style="line-height:6.93pt;position:absolute;top:131.47pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">following paragraph,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:138.05pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:140.3pt;position:absolute;text-decoration:none;white-space:pre">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:148.07pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:150.32pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.52pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.77pt;position:absolute;text-decoration:none;white-space:pre">form</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:184.20000000000002pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.45000000000002pt;position:absolute;text-decoration:none;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:194.78pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:197.03pt;position:absolute;text-decoration:none;white-space:pre">fully</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:215.9pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:218.15pt;position:absolute;text-decoration:none;white-space:pre">vested</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:243.67000000000002pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:245.92000000000002pt;position:absolute;text-decoration:none;white-space:pre">shares</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:270.89pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:273.14pt;position:absolute;text-decoration:none;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:281.46999999999997pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:283.71999999999997pt;position:absolute;text-decoration:none;white-space:pre">Common</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:320.92pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:323.17pt;position:absolute;text-decoration:none;white-space:pre">Stock</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:345.93pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:348.18pt;position:absolute;text-decoration:none;white-space:pre">on</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:358.18pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:360.43pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:372.63pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:374.88pt;position:absolute;text-decoration:none;white-space:pre">same</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:395.40000000000003pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:397.65000000000003pt;position:absolute;text-decoration:none;white-space:pre">date</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:414.28000000000003pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> as </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:426.6pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:438.8pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:441.05pt;position:absolute;text-decoration:none;white-space:pre">cash</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:458.8pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:461.05pt;position:absolute;text-decoration:none;white-space:pre">retainer</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:491.54pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:493.79pt;position:absolute;text-decoration:none;white-space:pre">would</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:518.78pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font></div><div style="line-height:6.93pt;position:absolute;top:143.47pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">otherwise</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:93.08000000000001pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:95.33000000000001pt;position:absolute;text-decoration:none;white-space:pre">have</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.19pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:116.44pt;position:absolute;text-decoration:none;white-space:pre">been paid (the </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:italic;font-weight:bold;left:175.53pt;position:absolute;text-decoration:none;white-space:pre">Payment Date</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:233.51000000000002pt;position:absolute;text-decoration:none;white-space:pre">&#8221;).</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:243.77pt;letter-spacing:0.2em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:248.27pt;position:absolute;text-decoration:none;white-space:pre">Such shares of Common Stock shall be issued under the Market Value Stock </font></div><div style="line-height:6.93pt;position:absolute;top:155.47pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">Plan based on the Market Value (as defined in the Market Value Stock Plan) as of the Payment Date for retainers paid for </font></div><div style="line-height:6.93pt;position:absolute;top:167.47pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">service in and after 2019.</font></div><div style="line-height:6.93pt;position:absolute;top:191.62pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:75.84pt;position:absolute;text-decoration:none;white-space:pre">Subject to the following</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:172.13pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:174.57999999999998pt;position:absolute;text-decoration:none;white-space:pre">sentence,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:211.46pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:213.91pt;position:absolute;text-decoration:none;white-space:pre">all</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:223.88pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:226.33pt;position:absolute;text-decoration:none;white-space:pre">written</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:254.62pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:257.07pt;position:absolute;text-decoration:none;white-space:pre">elections</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:292.56pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:295.01pt;position:absolute;text-decoration:none;white-space:pre">must</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:314.44pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:316.89pt;position:absolute;text-decoration:none;white-space:pre">be</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:326.32pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:328.77pt;position:absolute;text-decoration:none;white-space:pre">submitted</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:368.16999999999996pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:370.62pt;position:absolute;text-decoration:none;white-space:pre">(A)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:384.5pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:386.95000000000005pt;position:absolute;text-decoration:none;white-space:pre">with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:404.71000000000004pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:407.15999999999997pt;position:absolute;text-decoration:none;white-space:pre">respect</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:435.44000000000005pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:437.89pt;position:absolute;text-decoration:none;white-space:pre">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:445.65999999999997pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:448.11pt;position:absolute;text-decoration:none;white-space:pre">continuing</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:490.85pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:493.29999999999995pt;position:absolute;text-decoration:none;white-space:pre">Non-Employee </font></div><div style="line-height:6.93pt;position:absolute;top:203.62pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">Directors, prior to January 1 of each calendar year in which the Non-Employee Director is electing to receive fully vested </font></div><div style="line-height:6.93pt;position:absolute;top:215.62pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">shares of Common Stock in lieu of all or a portion of the cash retainer that would otherwise be paid, or (B) with respect to any </font></div><div style="line-height:6.93pt;position:absolute;top:227.62pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">person who first becomes a Non-Employee Director in any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:290.11pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:292.36pt;position:absolute;text-decoration:none;white-space:pre">calendar</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:326.18pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:328.43pt;position:absolute;text-decoration:none;white-space:pre">year,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:348.12pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:350.37pt;position:absolute;text-decoration:none;white-space:pre">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:358.14pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:360.39pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:372.59000000000003pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:374.84000000000003pt;position:absolute;text-decoration:none;white-space:pre">first</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:390.93pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:393.18pt;position:absolute;text-decoration:none;white-space:pre">month</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:418.72pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:420.97pt;position:absolute;text-decoration:none;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:429.3pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:431.55pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:443.75pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:446pt;position:absolute;text-decoration:none;white-space:pre">next</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:463.2pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:465.45pt;position:absolute;text-decoration:none;white-space:pre">quarter</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:493.74pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:495.99pt;position:absolute;text-decoration:none;white-space:pre">following</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:534.85pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:537.1pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:549.3pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font></div><div style="line-height:6.93pt;position:absolute;top:239.62pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">quarter</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:82.53pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:84.78pt;position:absolute;text-decoration:none;white-space:pre">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:92.55000000000001pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.80000000000001pt;position:absolute;text-decoration:none;white-space:pre">which</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:119.22pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:121.47pt;position:absolute;text-decoration:none;white-space:pre">he</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:130.9pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.15pt;position:absolute;text-decoration:none;white-space:pre">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:141.48pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:143.73pt;position:absolute;text-decoration:none;white-space:pre">she</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:157.05pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:159.3pt;position:absolute;text-decoration:none;white-space:pre">first</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:175.39000000000001pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:177.64000000000001pt;position:absolute;text-decoration:none;white-space:pre">became</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:208.13pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:210.38pt;position:absolute;text-decoration:none;white-space:pre">a</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:214.81pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:217.06pt;position:absolute;text-decoration:none;white-space:pre">Non-Employee Director (such elections, the &#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:italic;font-weight:bold;left:400.16pt;position:absolute;text-decoration:none;white-space:pre">Annual Elections</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:472.05pt;position:absolute;text-decoration:none;white-space:pre">&#8221;), and all Annual </font></div><div style="line-height:6.93pt;position:absolute;top:251.62pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">Elections must also be submitted during an &#8220;open window period&#8221;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:319.81pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:322.16pt;position:absolute;text-decoration:none;white-space:pre">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:329.93pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:332.28000000000003pt;position:absolute;text-decoration:none;white-space:pre">accordance</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:377.19pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:379.54pt;position:absolute;text-decoration:none;white-space:pre">with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:397.3pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:399.6pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:411.8pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:414.1pt;position:absolute;text-decoration:none;white-space:pre">Company&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:460.18pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:462.48pt;position:absolute;text-decoration:none;white-space:pre">then-effective</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:517.93pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:520.23pt;position:absolute;text-decoration:none;white-space:pre">Insider</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:547.98pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font></div><div style="line-height:6.93pt;position:absolute;top:263.62pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">Trading</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:85.87pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:88.17pt;position:absolute;text-decoration:none;white-space:pre">Compliance</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:136.43pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:138.73pt;position:absolute;text-decoration:none;white-space:pre">Program</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:173.15pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:175.45pt;position:absolute;text-decoration:none;white-space:pre">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:183.78pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.08pt;position:absolute;text-decoration:none;white-space:pre">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:200.51000000000002pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:202.81pt;position:absolute;text-decoration:none;white-space:pre">other</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:223.34pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:225.64000000000001pt;position:absolute;text-decoration:none;white-space:pre">policy</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:250.61pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:252.91pt;position:absolute;text-decoration:none;white-space:pre">on</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:262.90999999999997pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:265.21pt;position:absolute;text-decoration:none;white-space:pre">trading in Company securities and when the Non-Employee Director </font></div><div style="line-height:6.93pt;position:absolute;top:275.62pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">submitting the Annual Election is not otherwise aware of any material,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:336.94pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:339.34000000000003pt;position:absolute;text-decoration:none;white-space:pre">nonpublic</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:379.31pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:381.71000000000004pt;position:absolute;text-decoration:none;white-space:pre">information</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:428.88pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:431.28000000000003pt;position:absolute;text-decoration:none;white-space:pre">with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:449.04pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:451.44pt;position:absolute;text-decoration:none;white-space:pre">respect</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:479.72pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:482.12pt;position:absolute;text-decoration:none;white-space:pre">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:489.89pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:492.29pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:504.49pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:506.89pt;position:absolute;text-decoration:none;white-space:pre">Company</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:545.75pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:548.15pt;position:absolute;text-decoration:none;white-space:pre">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:556.48pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font></div><div style="line-height:6.93pt;position:absolute;top:287.62pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:68.67pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:71.07pt;position:absolute;text-decoration:none;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:79.4pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:81.8pt;position:absolute;text-decoration:none;white-space:pre">its</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.23pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:93.63pt;position:absolute;text-decoration:none;white-space:pre">securities</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.34pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.74pt;position:absolute;text-decoration:none;white-space:pre">(collectively,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.14000000000001pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:188.54000000000002pt;position:absolute;text-decoration:none;white-space:pre">each,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:209.33pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:211.73000000000002pt;position:absolute;text-decoration:none;white-space:pre">an</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:221.16pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:223.56pt;position:absolute;text-decoration:none;white-space:pre">&#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:italic;font-weight:bold;left:227.99pt;position:absolute;text-decoration:none;white-space:pre">Open</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:italic;font-weight:bold;left:250.20000000000002pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:italic;font-weight:bold;left:252.65pt;position:absolute;text-decoration:none;white-space:pre">Window</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:286.53pt;position:absolute;text-decoration:none;white-space:pre">&#8221;). If</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:305.95pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:308.3pt;position:absolute;text-decoration:none;white-space:pre">a</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:312.73pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:315.08pt;position:absolute;text-decoration:none;white-space:pre">Non-Employee</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:376.13pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:378.48pt;position:absolute;text-decoration:none;white-space:pre">Director</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:411.76pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:414.11pt;position:absolute;text-decoration:none;white-space:pre">is</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:420.77pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:423.12pt;position:absolute;text-decoration:none;white-space:pre">unable</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:449.75pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:452.1pt;position:absolute;text-decoration:none;white-space:pre">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:459.87pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:462.22pt;position:absolute;text-decoration:none;white-space:pre">submit</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:489.42pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:491.77pt;position:absolute;text-decoration:none;white-space:pre">an</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:501.2pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:503.55pt;position:absolute;text-decoration:none;white-space:pre">Annual</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:532.97pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font></div><div style="line-height:6.93pt;position:absolute;top:299.62pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">Election</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:87.51pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:89.86pt;position:absolute;text-decoration:none;white-space:pre">within</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:115.39pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:117.74000000000001pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.94pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.29pt;position:absolute;text-decoration:none;white-space:pre">applicable</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:173.32pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:175.67000000000002pt;position:absolute;text-decoration:none;white-space:pre">timeframe</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:216.70000000000002pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:219.05pt;position:absolute;text-decoration:none;white-space:pre">set</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:230.14000000000001pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:232.49pt;position:absolute;text-decoration:none;white-space:pre">forth</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:251.92000000000002pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:254.27pt;position:absolute;text-decoration:none;white-space:pre">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:262.04pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:264.39pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:276.59pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:278.94pt;position:absolute;text-decoration:none;white-space:pre">preceding sentence</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:355.21000000000004pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:357.51pt;position:absolute;text-decoration:none;white-space:pre">due</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:371.94pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:374.24pt;position:absolute;text-decoration:none;white-space:pre">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:382.01pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:384.31pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:396.51pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:398.81pt;position:absolute;text-decoration:none;white-space:pre">fact</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:413.77pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:416.07pt;position:absolute;text-decoration:none;white-space:pre">that</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:431.04pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:433.34000000000003pt;position:absolute;text-decoration:none;white-space:pre">there</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:453.3pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:455.6pt;position:absolute;text-decoration:none;white-space:pre">were</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:475.01pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:477.31pt;position:absolute;text-decoration:none;white-space:pre">no</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:487.31pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:489.61pt;position:absolute;text-decoration:none;white-space:pre">Open</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:511.26pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:513.56pt;position:absolute;text-decoration:none;white-space:pre">Windows</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:551.87pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font></div><div style="line-height:6.93pt;position:absolute;top:311.62pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">within</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:79.77000000000001pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:82.07pt;position:absolute;text-decoration:none;white-space:pre">such</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.39pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:102.69pt;position:absolute;text-decoration:none;white-space:pre">applicable</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:143.72pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:146.02pt;position:absolute;text-decoration:none;white-space:pre">timeframe</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:187.05pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:189.35000000000002pt;position:absolute;text-decoration:none;white-space:pre">during</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:215.45000000000002pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:217.75pt;position:absolute;text-decoration:none;white-space:pre">which</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:242.17000000000002pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:244.47pt;position:absolute;text-decoration:none;white-space:pre">an</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:253.9pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:256.2pt;position:absolute;text-decoration:none;white-space:pre">Annual</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:285.62pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:287.92pt;position:absolute;text-decoration:none;white-space:pre">Election could be submitted, then the Annual Election for that </font></div><div style="line-height:6.93pt;position:absolute;top:323.62pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">calendar year shall</font><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:129.11pt;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.61pt;position:absolute;text-decoration:none;white-space:pre">be due no later than the tenth business day following the commencement of the next Open Window </font></div><div style="line-height:6.93pt;position:absolute;top:335.62pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">(provided that an Annual Election is actually submitted during such next Open Window). If, as a result of the preceding </font></div><div style="line-height:6.93pt;position:absolute;top:347.62pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">sentence, an Annual Election for any calendar year is submitted after the date that is thirty days prior to the end of the next </font></div><div style="line-height:6.93pt;position:absolute;top:359.62pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">quarter, then such Annual Election shall</font><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:214.60000000000002pt;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:217.10000000000002pt;position:absolute;text-decoration:none;white-space:pre">be applicable only to the quarters ending after the end of such next quarter. Subject to </font></div><div style="line-height:6.93pt;position:absolute;top:371.62pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">the preceding sentence, an Annual Election to be paid in Common Stock shall</font><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:365.82pt;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:368.32pt;position:absolute;text-decoration:none;white-space:pre">be applied to each quarter&#8217;s payment during the </font></div><div style="line-height:6.93pt;position:absolute;top:383.62pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">calendar year of such Annual Election.</font></div><div style="line-height:6.93pt;position:absolute;top:409.02pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:75.84pt;position:absolute;text-decoration:none;white-space:pre">(b)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:120.24pt;position:absolute;text-decoration:none;white-space:pre">Expenses. </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:164.66pt;position:absolute;text-decoration:none;white-space:pre">Each Non-Employee Director shall</font><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:305.31pt;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:307.81pt;position:absolute;text-decoration:none;white-space:pre">be eligible for reimbursement from the Company for all </font></div><div style="line-height:6.93pt;position:absolute;top:421.02pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">reasonable</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.95pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:99.2pt;position:absolute;text-decoration:none;white-space:pre">out-of-pocket</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:153.59pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.84pt;position:absolute;text-decoration:none;white-space:pre">expenses</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:191.91pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:194.16pt;position:absolute;text-decoration:none;white-space:pre">incurred</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:227.45000000000002pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:229.70000000000002pt;position:absolute;text-decoration:none;white-space:pre">by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:239.70000000000002pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:241.95000000000002pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:254.15pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:256.4pt;position:absolute;text-decoration:none;white-space:pre">Non-Employee</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:317.45pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:319.7pt;position:absolute;text-decoration:none;white-space:pre">Director</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:352.98pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:355.23pt;position:absolute;text-decoration:none;white-space:pre">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:363pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:365.25pt;position:absolute;text-decoration:none;white-space:pre">connection</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:409.08pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:411.33pt;position:absolute;text-decoration:none;white-space:pre">with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:429.09000000000003pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:431.34000000000003pt;position:absolute;text-decoration:none;white-space:pre">his</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:443pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:445.25pt;position:absolute;text-decoration:none;white-space:pre">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:453.58pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:455.83pt;position:absolute;text-decoration:none;white-space:pre">her</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:468.59000000000003pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:470.84000000000003pt;position:absolute;text-decoration:none;white-space:pre">attendance</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:513.53pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:515.78pt;position:absolute;text-decoration:none;white-space:pre">at</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:522.98pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:525.23pt;position:absolute;text-decoration:none;white-space:pre">Board </font></div><div style="line-height:6.93pt;position:absolute;top:433.02pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">and Committee meetings.</font></div><div style="line-height:6.93pt;position:absolute;top:458.22pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:75.84pt;position:absolute;text-decoration:none;white-space:pre">To the extent that any taxable reimbursements are provided to a Non-Employee Director, they shall</font><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:473.39pt;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:475.89pt;position:absolute;text-decoration:none;white-space:pre">be provided in </font></div><div style="line-height:6.93pt;position:absolute;top:470.22pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">accordance with Section 409A of the Internal Revenue Code of 1986, as amended, and the Treasury Regulations and other </font></div><div style="line-height:6.93pt;position:absolute;top:482.22pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">guidance</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.30000000000001pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:92.55000000000001pt;position:absolute;text-decoration:none;white-space:pre">thereunder</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:135.27pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:137.52pt;position:absolute;text-decoration:none;white-space:pre">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:151.95pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:154.2pt;position:absolute;text-decoration:none;white-space:pre">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:168.63pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:170.88pt;position:absolute;text-decoration:none;white-space:pre">state</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:189.17000000000002pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:191.42000000000002pt;position:absolute;text-decoration:none;white-space:pre">law</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:205.84pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:208.09pt;position:absolute;text-decoration:none;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:216.42000000000002pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:218.67000000000002pt;position:absolute;text-decoration:none;white-space:pre">similar</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:246.4pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:248.65pt;position:absolute;text-decoration:none;white-space:pre">effect,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:273.87pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:276.12pt;position:absolute;text-decoration:none;white-space:pre">including,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:316.36pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:318.61pt;position:absolute;text-decoration:none;white-space:pre">but</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:331.38pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:333.63pt;position:absolute;text-decoration:none;white-space:pre">not</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:346.40000000000003pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:348.65000000000003pt;position:absolute;text-decoration:none;white-space:pre">limited</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:376.93pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:379.18pt;position:absolute;text-decoration:none;white-space:pre">to,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:389.45pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:391.7pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:403.90000000000003pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:406.15000000000003pt;position:absolute;text-decoration:none;white-space:pre">following</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:445.01pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:447.26pt;position:absolute;text-decoration:none;white-space:pre">provisions&#58;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:491.68pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:493.93pt;position:absolute;text-decoration:none;white-space:pre">(i)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:503.36pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:505.61pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:517.81pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:520.06pt;position:absolute;text-decoration:none;white-space:pre">amount </font></div><div style="line-height:6.93pt;position:absolute;top:494.22pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">of any such expenses eligible for reimbursement during the Non-Employee Director&#8217;s taxable year may not affect the </font></div><div style="line-height:6.93pt;position:absolute;top:506.22pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">expenses</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.31pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:92.56pt;position:absolute;text-decoration:none;white-space:pre">eligible</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:122.5pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:124.75pt;position:absolute;text-decoration:none;white-space:pre">for</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:136.41pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:138.66pt;position:absolute;text-decoration:none;white-space:pre">reimbursement</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:198.58pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:200.83pt;position:absolute;text-decoration:none;white-space:pre">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:208.60000000000002pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:210.85000000000002pt;position:absolute;text-decoration:none;white-space:pre">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:225.28pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:227.53pt;position:absolute;text-decoration:none;white-space:pre">other</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:248.06pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:250.31pt;position:absolute;text-decoration:none;white-space:pre">taxable</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:279.14pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:281.39pt;position:absolute;text-decoration:none;white-space:pre">year&#59;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:301.35pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:303.6pt;position:absolute;text-decoration:none;white-space:pre">(ii)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:315.8pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:318.05pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:330.25pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:332.5pt;position:absolute;text-decoration:none;white-space:pre">reimbursement</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:392.42pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:394.67pt;position:absolute;text-decoration:none;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:403pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:405.25pt;position:absolute;text-decoration:none;white-space:pre">an</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:414.68pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:416.93pt;position:absolute;text-decoration:none;white-space:pre">eligible</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:446.87pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:449.12pt;position:absolute;text-decoration:none;white-space:pre">expense</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:481.3pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:483.55pt;position:absolute;text-decoration:none;white-space:pre">must</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:502.98pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:505.23pt;position:absolute;text-decoration:none;white-space:pre">be</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:514.66pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:516.91pt;position:absolute;text-decoration:none;white-space:pre">made</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:538.54pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:540.79pt;position:absolute;text-decoration:none;white-space:pre">no </font></div><div style="line-height:6.93pt;position:absolute;top:518.22pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">later than the last day of the Non-Employee Director&#8217;s taxable year that immediately follows the taxable year in which the </font></div><div style="line-height:6.93pt;position:absolute;top:530.22pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">expense was incurred&#59; and (iii) the right to any reimbursement may not be subject to liquidation or exchange for another </font></div><div style="line-height:6.93pt;position:absolute;top:542.22pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">benefit.</font></div><div style="line-height:6.93pt;position:absolute;top:567.47pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:54.239999999999995pt;position:absolute;text-decoration:none;white-space:pre">2.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:84.24pt;position:absolute;text-decoration:none;white-space:pre">EQUITY</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:123.66pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:125.91pt;position:absolute;text-decoration:none;white-space:pre">COMPENSATION.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:211.13pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:213.38pt;position:absolute;text-decoration:none;white-space:pre">The</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:228.90999999999997pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:231.15999999999997pt;position:absolute;text-decoration:none;white-space:pre">options</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:260.59pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:262.89pt;position:absolute;text-decoration:none;white-space:pre">described</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:301.17pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:303.42pt;position:absolute;text-decoration:none;white-space:pre">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:311.19pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:313.44pt;position:absolute;text-decoration:none;white-space:pre">this</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:327.87pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> Policy will </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:373.18pt;position:absolute;text-decoration:none;white-space:pre">be</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:382.61pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:385.06pt;position:absolute;text-decoration:none;white-space:pre">granted</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:415.02pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:417.47pt;position:absolute;text-decoration:none;white-space:pre">under</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:440.23pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:442.68pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:454.88pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:457.33pt;position:absolute;text-decoration:none;white-space:pre">2018</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:477.33pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:479.78000000000003pt;position:absolute;text-decoration:none;white-space:pre">Plan</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:497.54pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:499.99pt;position:absolute;text-decoration:none;white-space:pre">and shall</font><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:535.78pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre"> </font></div><div style="line-height:6.93pt;position:absolute;top:579.47pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">be</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:63.67pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:66.12pt;position:absolute;text-decoration:none;white-space:pre">subject</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:94.41pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:96.86pt;position:absolute;text-decoration:none;white-space:pre">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:104.63pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.08000000000001pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:119.28pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:121.72999999999999pt;position:absolute;text-decoration:none;white-space:pre">terms</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:143.92000000000002pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:146.37pt;position:absolute;text-decoration:none;white-space:pre">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:160.8pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:163.25pt;position:absolute;text-decoration:none;white-space:pre">conditions</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:204.88pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:207.33pt;position:absolute;text-decoration:none;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:215.66pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:218.11pt;position:absolute;text-decoration:none;white-space:pre">(i)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:227.54000000000002pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:229.99pt;position:absolute;text-decoration:none;white-space:pre">this</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:244.42000000000002pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:246.87pt;position:absolute;text-decoration:none;white-space:pre">Policy,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:274.9pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:277.35pt;position:absolute;text-decoration:none;white-space:pre">(ii)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:289.55pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:292pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:304.2pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:306.65pt;position:absolute;text-decoration:none;white-space:pre">2018</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:326.65000000000003pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:329.1pt;position:absolute;text-decoration:none;white-space:pre">Plan</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:346.86pt;letter-spacing:-0.005em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:349.31pt;position:absolute;text-decoration:none;white-space:pre">and (ii)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:378.44pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:380.64pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:392.84000000000003pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:395.04pt;position:absolute;text-decoration:none;white-space:pre">forms</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:418.36pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:420.56pt;position:absolute;text-decoration:none;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:428.89pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:431.09000000000003pt;position:absolute;text-decoration:none;white-space:pre">Option</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:458.85pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:461.1pt;position:absolute;text-decoration:none;white-space:pre">Agreements</font><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:509.37pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font></div><div style="line-height:6.93pt;position:absolute;top:591.47pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">approved</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:91.43pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:93.68pt;position:absolute;text-decoration:none;white-space:pre">by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:103.68pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:105.93pt;position:absolute;text-decoration:none;white-space:pre">the Board for the grant of options</font><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:239.70000000000002pt;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:242.20000000000002pt;position:absolute;text-decoration:none;white-space:pre">to Non-Employee Directors under the 2018 Plan.</font></div><div style="line-height:6.93pt;position:absolute;top:616.62pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:75.84pt;position:absolute;text-decoration:none;white-space:pre">(a)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:120.24pt;position:absolute;text-decoration:none;white-space:pre">Initial Grants. </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:183.81pt;position:absolute;text-decoration:none;white-space:pre">Each person who first becomes a Non-Employee Director, whether through election by the </font></div><div style="line-height:6.93pt;position:absolute;top:628.62pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:57.24pt;position:absolute;text-decoration:none;white-space:pre">stockholders</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:107.75pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:109.95pt;position:absolute;text-decoration:none;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:118.28pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.48pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.68pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:134.88pt;position:absolute;text-decoration:none;white-space:pre">Company</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:173.74pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:175.94pt;position:absolute;text-decoration:none;white-space:pre">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:184.27pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.47pt;position:absolute;text-decoration:none;white-space:pre">appointment</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:236.41pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:238.61pt;position:absolute;text-decoration:none;white-space:pre">by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:248.61pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:250.81pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:263.01pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:265.21pt;position:absolute;text-decoration:none;white-space:pre">Board</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:289.63pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:291.83pt;position:absolute;text-decoration:none;white-space:pre">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:299.6pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:301.8pt;position:absolute;text-decoration:none;white-space:pre">fill</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:313.44pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:315.64pt;position:absolute;text-decoration:none;white-space:pre">a</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:320.07pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:322.27pt;position:absolute;text-decoration:none;white-space:pre">vacancy,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:357.49pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:359.69pt;position:absolute;text-decoration:none;white-space:pre">automatically shall be granted a Nonstatutory </font></div><div style="line-height:6.93pt;position:absolute;top:640.62pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:57.24pt;position:absolute;text-decoration:none;white-space:pre">Stock Option to purchase 270,000 shares of Common Stock (a &#8220;First Director Option&#8221;) on the date of his or her initial </font></div><div style="line-height:6.93pt;position:absolute;top:652.62pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:57.24pt;position:absolute;text-decoration:none;white-space:pre">election or appointment to be a Non-Employee Director.&#160; For the avoidance of doubt, an executive chairman of the Board </font></div><div style="line-height:6.93pt;position:absolute;top:664.62pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:57.24pt;position:absolute;text-decoration:none;white-space:pre">shall</font><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:76.1pt;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:78.6pt;position:absolute;text-decoration:none;white-space:pre">not be eligible to receive a First Director Option pursuant to this Section 2(a).</font></div><div style="line-height:6.93pt;position:absolute;top:691.02pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:75.59pt;position:absolute;text-decoration:none;white-space:pre">(b)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:120.24pt;position:absolute;text-decoration:none;white-space:pre">Annual Grants. </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:189.39pt;position:absolute;text-decoration:none;white-space:pre">Subject to Section 2(c) below, on the date of each annual meeting of the Company&#8217;s </font></div><div style="line-height:6.93pt;position:absolute;top:703.02pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:53.99pt;position:absolute;text-decoration:none;white-space:pre">stockholder each person who is then a Non-Employee Director and shall be continuing as a Non-Employee Director </font></div><div style="line-height:6.93pt;position:absolute;top:715.02pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:53.99pt;position:absolute;text-decoration:none;white-space:pre">following the date of such annual meeting (other than any Non-Employee Director receiving a First Director Option on the </font></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt"><div style="position:absolute;top:728.64pt"><div style="width:514pt"></div></div><div style="position:absolute"><div style="width:514pt"></div></div><div><div style="line-height:6.93pt;position:absolute;top:58.32pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:53.99pt;position:absolute;text-decoration:none;white-space:pre">date of such annual meeting) automatically shall be granted (i) a Nonstatutory Stock Option to purchase 220,000 shares of </font></div><div style="line-height:6.93pt;position:absolute;top:70.32pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:53.99pt;position:absolute;text-decoration:none;white-space:pre">Common Stock (a &#8220;Subsequent Director Option&#8221;).&#160; For the avoidance of doubt, an executive chairman of the Board shall</font><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:537.36pt;position:absolute;text-decoration:none;white-space:pre"> </font></div><div style="line-height:6.93pt;position:absolute;top:82.32pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:53.99pt;position:absolute;text-decoration:none;white-space:pre">not be eligible to receive a Subsequent Director Option pursuant to this Section 2(b).</font></div><div style="line-height:6.93pt;position:absolute;top:106.32pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:70.74pt;position:absolute;text-decoration:none;white-space:pre">(c)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:84.24pt;position:absolute;text-decoration:none;white-space:pre">Annual Grants for New Non-Employee Directors. </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:298.24pt;position:absolute;text-decoration:none;white-space:pre">If a person is elected or appointed to be a Non-Employee </font></div><div style="line-height:6.93pt;position:absolute;top:118.32pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:52.74pt;position:absolute;text-decoration:none;white-space:pre">Director for the first time other than at an annual general meeting of the Company&#8217;s stockholders, such Non-Employee </font></div><div style="line-height:6.93pt;position:absolute;top:130.32pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:52.74pt;position:absolute;text-decoration:none;white-space:pre">Director automatically shall be granted a Subsequent Director Option with respect to the next annual general meeting in </font></div><div style="line-height:6.94pt;position:absolute;top:142.32pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:52.74pt;position:absolute;text-decoration:none;white-space:pre">accordance with Section 2(b) above, </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:italic;font-weight:normal;left:200.89000000000001pt;position:absolute;text-decoration:none;white-space:pre">provided</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:236.41pt;position:absolute;text-decoration:none;white-space:pre"> that the date of such initial election or appointment is not less than four </font></div><div style="line-height:6.93pt;position:absolute;top:154.32pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:52.74pt;position:absolute;text-decoration:none;white-space:pre">calendar months prior to the date of the next annual general meeting. If the date of such initial election or appointment is </font></div><div style="line-height:6.93pt;position:absolute;top:166.32pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:52.74pt;position:absolute;text-decoration:none;white-space:pre">less than four calendar months prior to the date of the next annual general meeting, such Non-Employee Director shall not </font></div><div style="line-height:6.93pt;position:absolute;top:178.32pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:52.74pt;position:absolute;text-decoration:none;white-space:pre">be granted a Subsequent Director Option under Section 2(b) above with respect to such next annual general meeting.</font></div><div style="line-height:6.77pt;position:absolute;top:202.32pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:66.24pt;position:absolute;text-decoration:none;white-space:pre">(d)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:84.24pt;position:absolute;text-decoration:none;white-space:pre">Terms</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:111.97999999999999pt;letter-spacing:-0.035em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:114.13pt;position:absolute;text-decoration:none;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:122.46pt;letter-spacing:-0.035em;position:absolute;text-decoration:none;white-space:pre"> Options. </font></div><div style="line-height:7.44pt;position:absolute;top:228.72pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:88.74pt;position:absolute;text-decoration:none;white-space:pre">(i)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.24pt;position:absolute;text-decoration:underline;white-space:pre">Exercise</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:154.62pt;letter-spacing:-0.015em;position:absolute;text-decoration:underline;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:156.97pt;position:absolute;text-decoration:underline;white-space:pre">Price</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:177.49pt;position:absolute;text-decoration:none;white-space:pre">.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:179.99pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:182.34pt;position:absolute;text-decoration:none;white-space:pre">The</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:197.87pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:200.22pt;position:absolute;text-decoration:none;white-space:pre">exercise</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:232.93pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:235.28pt;position:absolute;text-decoration:none;white-space:pre">price</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:255.24pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:257.59pt;position:absolute;text-decoration:none;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:265.92pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:268.27pt;position:absolute;text-decoration:none;white-space:pre">each</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:286.56pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:288.90999999999997pt;position:absolute;text-decoration:none;white-space:pre">First</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:307.23pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:309.58pt;position:absolute;text-decoration:none;white-space:pre">Director</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:342.86pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:345.21pt;position:absolute;text-decoration:none;white-space:pre">Option</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:372.96999999999997pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:375.32pt;position:absolute;text-decoration:none;white-space:pre">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:389.75pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:392.1pt;position:absolute;text-decoration:none;white-space:pre">Subsequent</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:438.18pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:440.53000000000003pt;position:absolute;text-decoration:none;white-space:pre">Director</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:473.81pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:476.16pt;position:absolute;text-decoration:none;white-space:pre">Option </font></div><div style="line-height:7.44pt;position:absolute;top:240.6pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:52.74pt;position:absolute;text-decoration:none;white-space:pre">shall</font><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:71.6pt;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:74.1pt;position:absolute;text-decoration:none;white-space:pre">be equal to 100% of the Fair Market Value of the Common Stock subject to such option (as determined in </font></div><div style="line-height:7.44pt;position:absolute;top:252.48pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:52.74pt;position:absolute;text-decoration:none;white-space:pre">accordance with the 2018 Plan) on the date such option is granted.</font></div><div style="line-height:6.93pt;position:absolute;top:277.61pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:84.24pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre">(ii)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;white-space:pre"><font style="left:96.03999999999999pt;position:absolute"><font style="display:inline-block;height:6.93pt;width:30.15pt"></font></font></font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:126.19pt;position:absolute;text-decoration:underline;white-space:pre">Vesting</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:157.26999999999998pt;position:absolute;text-decoration:none;white-space:pre">.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:159.76999999999998pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:162.01999999999998pt;position:absolute;text-decoration:none;white-space:pre">Each</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:181.98pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:184.23pt;position:absolute;text-decoration:none;white-space:pre">First</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:202.55pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:204.8pt;position:absolute;text-decoration:none;white-space:pre">Director</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:238.07999999999998pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:240.32999999999998pt;position:absolute;text-decoration:none;white-space:pre">Option</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:268.09pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:270.34pt;position:absolute;text-decoration:none;white-space:pre">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:284.77pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:287.02pt;position:absolute;text-decoration:none;white-space:pre">Subsequent</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:333.1pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:335.35pt;position:absolute;text-decoration:none;white-space:pre">Director</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:368.63pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:370.88pt;position:absolute;text-decoration:none;white-space:pre">Option shall vest</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:438.59000000000003pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:440.84000000000003pt;position:absolute;text-decoration:none;white-space:pre">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:455.27pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:457.47pt;position:absolute;text-decoration:none;white-space:pre">become</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:488.53000000000003pt;letter-spacing:-0.025em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:490.78000000000003pt;position:absolute;text-decoration:none;white-space:pre">exercisable as </font></div><div style="line-height:6.93pt;position:absolute;top:289.61pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">follows&#58;</font></div><div style="line-height:6.93pt;position:absolute;top:314.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:119.64000000000001pt;position:absolute;text-decoration:none;white-space:pre">(A)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:156.24pt;position:absolute;text-decoration:none;white-space:pre">Each First Director Option shall vest and become exercisable in installments cumulatively as to 33 </font></div><div style="line-height:6.93pt;position:absolute;top:326.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">1&#47;3% of the shares of Common Stock subject to such option</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:294.05pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:296.35pt;position:absolute;text-decoration:none;white-space:pre">on</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:306.35pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:308.65pt;position:absolute;text-decoration:none;white-space:pre">each</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:326.94pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:329.24pt;position:absolute;text-decoration:none;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:337.57pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:339.87pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:352.07pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:354.37pt;position:absolute;text-decoration:none;white-space:pre">first,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:372.96000000000004pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:375.26pt;position:absolute;text-decoration:none;white-space:pre">second</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:403.01pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:405.31pt;position:absolute;text-decoration:none;white-space:pre">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:419.74pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:422.04pt;position:absolute;text-decoration:none;white-space:pre">third</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:440.91pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:443.21000000000004pt;position:absolute;text-decoration:none;white-space:pre">anniversaries</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:495.91pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:498.21000000000004pt;position:absolute;text-decoration:none;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:506.54pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:508.84000000000003pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:521.04pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:523.34pt;position:absolute;text-decoration:none;white-space:pre">date</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:539.97pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:542.27pt;position:absolute;text-decoration:none;white-space:pre">of </font></div><div style="line-height:6.93pt;position:absolute;top:338.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">grant of such option, subject to the Non-Employee Director&#8217;s Continuous Service through such dates.</font></div><div style="line-height:6.93pt;position:absolute;top:363.91pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:119.64000000000001pt;position:absolute;text-decoration:none;white-space:pre">(B)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:156.24pt;position:absolute;text-decoration:none;white-space:pre">Each Subsequent Director Option shall vest and become exercisable as to 100% of the shares of </font></div><div style="line-height:6.93pt;position:absolute;top:375.91pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">Common Stock subject to such option on the earlier of the (i) date of the next annual meeting of the Company&#8217;s stockholders </font></div><div style="line-height:6.93pt;position:absolute;top:387.91pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">(the &#8220;Next Annual Meeting&#8221;) or (ii) first anniversary of the grant</font><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:313.38pt;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:315.88pt;position:absolute;text-decoration:none;white-space:pre">date</font><font style="color:#ff0000;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:332.51pt;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:335.01pt;position:absolute;text-decoration:none;white-space:pre">of such option, subject to the Non-Employee</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:514.01pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:516.21pt;position:absolute;text-decoration:none;white-space:pre">Director&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:556.71pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font></div><div style="line-height:6.93pt;position:absolute;top:399.91pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">Continuous</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.33000000000001pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:102.53pt;position:absolute;text-decoration:none;white-space:pre">Service</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:132.48pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:134.68pt;position:absolute;text-decoration:none;white-space:pre">through</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:165.78pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:167.98pt;position:absolute;text-decoration:none;white-space:pre">such</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.3pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:188.5pt;position:absolute;text-decoration:none;white-space:pre">dates. For the sake of clarity, if a</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:319.72pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:321.92pt;position:absolute;text-decoration:none;white-space:pre">Non-Employee</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:382.97pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:385.17pt;position:absolute;text-decoration:none;white-space:pre">Director</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:418.45pt;letter-spacing:-0.03em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:420.65000000000003pt;position:absolute;text-decoration:none;white-space:pre">either </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:445.88pt;position:absolute;text-decoration:none;white-space:pre">(x) does not stand for </font></div><div style="line-height:6.93pt;position:absolute;top:411.91pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">reelection at the Next Annual Meeting and is a member of the class of directors whose term expires at the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:476.19pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:478.49pt;position:absolute;text-decoration:none;white-space:pre">Next</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:497.91pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:500.21000000000004pt;position:absolute;text-decoration:none;white-space:pre">Annual</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:529.63pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font></div><div style="line-height:6.93pt;position:absolute;top:423.91pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">Meeting</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:87.53pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:89.83000000000001pt;position:absolute;text-decoration:none;white-space:pre">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:98.16pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:100.46000000000001pt;position:absolute;text-decoration:none;white-space:pre">(y)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:112.12pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:114.42pt;position:absolute;text-decoration:none;white-space:pre">otherwise</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:153.26pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:155.56pt;position:absolute;text-decoration:none;white-space:pre">resigns</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:183.87pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:186.17000000000002pt;position:absolute;text-decoration:none;white-space:pre">from</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:205.60000000000002pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:207.9pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:220.10000000000002pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:222.4pt;position:absolute;text-decoration:none;white-space:pre">Board</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:246.82000000000002pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:249.12pt;position:absolute;text-decoration:none;white-space:pre">effective</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:284.04pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:286.34pt;position:absolute;text-decoration:none;white-space:pre">at</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:293.54pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:295.84pt;position:absolute;text-decoration:none;white-space:pre">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:304.17pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:306.46999999999997pt;position:absolute;text-decoration:none;white-space:pre">on</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:316.47pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:318.77pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:330.97pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:333.27pt;position:absolute;text-decoration:none;white-space:pre">date</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:349.90000000000003pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:352.2pt;position:absolute;text-decoration:none;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:360.53000000000003pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:362.83pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:375.03000000000003pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:377.33pt;position:absolute;text-decoration:none;white-space:pre">Next</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:396.75pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:399.05pt;position:absolute;text-decoration:none;white-space:pre">Annual</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:428.47pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:430.77pt;position:absolute;text-decoration:none;white-space:pre">Meeting</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:464.06pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:466.36pt;position:absolute;text-decoration:none;white-space:pre">and, in either case, the </font></div><div style="line-height:6.93pt;position:absolute;top:435.91pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">Non-Employee Director&#8217;s Continuous Service terminates at or on the date of the Next Annual Meeting, then such Non-</font></div><div style="line-height:6.93pt;position:absolute;top:447.91pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">Employee Director&#8217;s Continuous Service shall be deemed to have continued through the date of the Next Annual Meeting for </font></div><div style="line-height:6.93pt;position:absolute;top:459.91pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">purposes of this Policy.</font></div><div style="font-size:12pt;line-height:6.93pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:484.01pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:119.64000000000001pt;position:absolute;text-decoration:none;white-space:pre;width:13.88pt">(C)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:156.24pt;position:absolute;text-decoration:none;white-space:pre;width:66.61pt">Notwithstanding</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:222.85000000000002pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre;width:3.64pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:226.49pt;position:absolute;text-decoration:none;white-space:pre;width:33.85pt">Sections</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:260.34000000000003pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre;width:3.64pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:263.98pt;position:absolute;text-decoration:none;white-space:pre;width:19.99pt">2(d)(</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:283.97pt;position:absolute;text-decoration:underline;white-space:pre;width:6.1pt">i)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:290.07000000000005pt;position:absolute;text-decoration:none;white-space:pre;width:13.88pt">(A)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:303.95000000000005pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre;width:3.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:307.64pt;position:absolute;text-decoration:none;white-space:pre;width:14.43pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:322.07000000000005pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre;width:3.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:325.76pt;position:absolute;text-decoration:none;white-space:pre;width:39.41pt">2(d)(i)(B)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:365.17pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre;width:3.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:368.86pt;position:absolute;text-decoration:none;white-space:pre;width:26.36pt">above,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:395.22pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre;width:3.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:398.90999999999997pt;position:absolute;text-decoration:none;white-space:pre;width:12.2pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:411.11pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre;width:3.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:414.8pt;position:absolute;text-decoration:none;white-space:pre;width:28.86pt">vesting</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:443.66pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre;width:3.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:447.35pt;position:absolute;text-decoration:none;white-space:pre;width:8.33pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:455.68pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre;width:3.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:459.37pt;position:absolute;text-decoration:none;white-space:pre;width:4.43pt">a</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:463.8pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre;width:3.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:467.49pt;position:absolute;text-decoration:none;white-space:pre;width:18.32pt">First</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.81pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre;width:3.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:489.5pt;position:absolute;text-decoration:none;white-space:pre;width:33.28pt">Director</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:522.78pt;letter-spacing:-0.01em;position:absolute;text-decoration:none;white-space:pre;width:3.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:526.47pt;position:absolute;text-decoration:none;white-space:pre;width:27.76pt">Option</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:554.23pt;position:absolute;text-decoration:none;white-space:pre;width:2.5pt"> </font></div><div style="line-height:6.93pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:496.01pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre;width:14.43pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:68.67pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre;width:3.05pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:71.72pt;position:absolute;text-decoration:none;white-space:pre;width:46.08pt">Subsequent</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:117.80000000000001pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre;width:3.05pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:120.85pt;position:absolute;text-decoration:none;white-space:pre;width:33.28pt">Director</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:154.13pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre;width:3.05pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:157.18pt;position:absolute;text-decoration:none;white-space:pre;width:27.76pt">Option</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:184.94pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre;width:3.05pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:187.99pt;position:absolute;text-decoration:none;white-space:pre;width:18.86pt">shall</font><font style="color:#0000ff;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:206.85000000000002pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre;width:3.05pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:209.9pt;position:absolute;text-decoration:none;white-space:pre;width:344.32pt">be subject to (i) full acceleration in the event of a Change in Control and (ii) partial</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:554.22pt;position:absolute;text-decoration:none;white-space:pre;width:2.5pt"> </font></div><div style="line-height:6.93pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:508.01pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre;width:123.45pt">acceleration in the event of the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:177.69pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre;width:2.42pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:180.11pt;position:absolute;text-decoration:none;white-space:pre;width:61.05pt">Non-Employee</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:241.16pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre;width:2.47pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:243.63pt;position:absolute;text-decoration:none;white-space:pre;width:40.5pt">Director&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:284.13pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre;width:2.42pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:286.55pt;position:absolute;text-decoration:none;white-space:pre;width:46.04pt">termination</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:332.59000000000003pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre;width:2.47pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:335.06pt;position:absolute;text-decoration:none;white-space:pre;width:8.33pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:343.39pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre;width:2.42pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:345.81pt;position:absolute;text-decoration:none;white-space:pre;width:46.09pt">Continuous</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:391.90000000000003pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre;width:2.47pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:394.37pt;position:absolute;text-decoration:none;white-space:pre;width:29.95pt">Service</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:424.32pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre;width:2.42pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:426.74pt;position:absolute;text-decoration:none;white-space:pre;width:10pt">by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:436.74pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre;width:2.47pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:439.21000000000004pt;position:absolute;text-decoration:none;white-space:pre;width:26.08pt">reason</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:465.29pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre;width:2.42pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:467.71000000000004pt;position:absolute;text-decoration:none;white-space:pre;width:8.33pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:476.04pt;letter-spacing:-0.015em;position:absolute;text-decoration:none;white-space:pre;width:2.47pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:478.51pt;position:absolute;text-decoration:none;white-space:pre;width:12.2pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:490.71000000000004pt;letter-spacing:-0.02em;position:absolute;text-decoration:none;white-space:pre;width:2.42pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:493.13pt;position:absolute;text-decoration:none;white-space:pre;width:61.05pt">Non-Employee</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:554.18pt;position:absolute;text-decoration:none;white-space:pre;width:2.5pt"> </font></div><div style="line-height:6.93pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:520.01pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre;width:439.23pt">Director&#8217;s Disability or death pursuant to, and in accordance with, the 2018 Plan and each Option Agreement.</font></div><div style="line-height:7.44pt;position:absolute;top:544.11pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:54.239999999999995pt;position:absolute;text-decoration:none;white-space:pre">3.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:bold;left:84.24pt;position:absolute;text-decoration:none;white-space:pre"> NON-EMPLOYEE DIRECTOR COMPENSATION LIMIT.&#160; </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:351.55pt;position:absolute;text-decoration:none;white-space:pre">Notwithstanding the foregoing, the aggregate </font></div><div style="line-height:7.44pt;position:absolute;top:557.31pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">value of all compensation granted or paid, as applicable, to any individual for service as a Non-Employee Director shall in </font></div><div style="line-height:7.44pt;position:absolute;top:570.51pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54.24pt;position:absolute;text-decoration:none;white-space:pre">no event exceed the limits set forth in Section IV(c) of the 2018 Plan.</font></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>consultingagreementbyandbe.htm
<DESCRIPTION>EX-10.3
<TEXT>
<html><head><title>Consulting Agreement by and between the Company and Andrew Grethlein, effective October 16, 2025.</title></head><body><div style="background-color:#E4E4E4;font-family:Arial, sans-serif;word-wrap:break-word"><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt"><div style="position:absolute;top:728.64pt"><div style="width:522pt"></div></div><div style="position:absolute"><div style="width:522pt"><div style="line-height:7.44pt;position:absolute;top:28pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:519.19pt;position:absolute;white-space:pre">Exhibit 10.3</font></div></div></div><div><div id="id9a0094da72a45e5ab881a00f9c0d9e7_1" style="position:absolute;top:66.96pt"></div><div style="line-height:7.44pt;position:absolute;top:66.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:262.55pt;position:absolute;text-decoration:none;white-space:pre">Consulting</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:313.86pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:316.37pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre">Agreement</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:93.31pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:151.49pt">This Consulting Agreement (the &#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:241.49pt;position:absolute;text-decoration:none;white-space:pre;width:51.89pt">Agreement</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:293.38pt;position:absolute;text-decoration:none;white-space:pre;width:186.94pt">&#8221;), effective as of October 16, 2025 (the &#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:480.32pt;position:absolute;text-decoration:none;white-space:pre;width:66.7pt">Effective Date</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:547.02pt;position:absolute;text-decoration:none;white-space:pre;width:11.29pt">&#8221;),</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.31pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:106.51pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:342.73pt">sets forth the terms and conditions established between Geron Corporation (&#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:396.73pt;position:absolute;text-decoration:none;white-space:pre;width:29.92pt">Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:426.65pt;position:absolute;text-decoration:none;white-space:pre;width:131.68pt">&#8221;), with a place of business at</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.3299999999999pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:119.71pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:5.5pt">3</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:59.5pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:62.09pt;position:absolute;text-decoration:none;white-space:pre;width:30.54pt">Sylvan</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:92.63pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:95.22pt;position:absolute;text-decoration:none;white-space:pre;width:23.51pt">Way,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:118.73pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:121.32pt;position:absolute;text-decoration:none;white-space:pre;width:22.59pt">Suite</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:143.91pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:146.5pt;position:absolute;text-decoration:none;white-space:pre;width:19.25pt">202,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:165.75pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:168.34pt;position:absolute;text-decoration:none;white-space:pre;width:51.61pt">Parsippany,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:219.95pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:222.54pt;position:absolute;text-decoration:none;white-space:pre;width:20.76pt">New</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:243.3pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.54pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:245.84pt;position:absolute;text-decoration:none;white-space:pre;width:27.48pt">Jersey</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:273.32pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:275.90999999999997pt;position:absolute;text-decoration:none;white-space:pre;width:30.55pt">07054&#59;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:306.46000000000004pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.64pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:309.1pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:324.98pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.64pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:327.62pt;position:absolute;text-decoration:none;white-space:pre;width:35.42pt">Andrew</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:363.04pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.54pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:365.58pt;position:absolute;text-decoration:none;white-space:pre;width:7.03pt">J.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:372.61pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.64pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:375.25pt;position:absolute;text-decoration:none;white-space:pre;width:44.26pt">Grethlein,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:419.51pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:422.1pt;position:absolute;text-decoration:none;white-space:pre;width:35.42pt">residing</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:457.52pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:460.11pt;position:absolute;text-decoration:none;white-space:pre;width:7.93pt">at</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:468.04pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.74pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:470.78pt;position:absolute;text-decoration:none;white-space:pre;width:16.5pt">628</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:487.28pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:489.87pt;position:absolute;text-decoration:none;white-space:pre;width:43.99pt">Johnstone</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:533.86pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.49pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:536.35pt;position:absolute;text-decoration:none;white-space:pre;width:21.97pt">Lane</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.3199999999999pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:132.91pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:26.58pt">B865,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:80.58pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.58pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:83.16pt;position:absolute;text-decoration:none;white-space:pre;width:38.16pt">Barnard,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:121.32pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.58pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:123.9pt;position:absolute;text-decoration:none;white-space:pre;width:39.08pt">Vermont</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:162.98000000000002pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.48pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:165.45999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:27.5pt">05031</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:192.96pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:195.64pt;position:absolute;text-decoration:none;white-space:pre;width:8.54pt">(&#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:204.18pt;position:absolute;text-decoration:none;white-space:pre;width:51.92pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:256.1pt;position:absolute;text-decoration:none;white-space:pre;width:8.54pt">&#8221;)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:264.64pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.63pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:267.27pt;position:absolute;text-decoration:none;white-space:pre;width:19.54pt">with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:286.81pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.43pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:289.24pt;position:absolute;text-decoration:none;white-space:pre;width:31.13pt">respect</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:320.37pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.63pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:323pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:331.55pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.43pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:333.98pt;position:absolute;text-decoration:none;white-space:pre;width:45.81pt">consulting</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:379.79pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.43pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:382.22pt;position:absolute;text-decoration:none;white-space:pre;width:35.41pt">services</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:417.63pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.48pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:420.11pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:428.66pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.58pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:431.24pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">be</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:441.62pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.58pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:444.2pt;position:absolute;text-decoration:none;white-space:pre;width:39.09pt">provided</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:483.29pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.58pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:485.87pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:496.87pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.58pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:499.45pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:547.0899999999999pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.63pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:549.72pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.27pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:146.11pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.33pt">Geron. This Agreement supersedes all other understandings, oral or written, between Geron and Consultant with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.3299999999999pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:159.31pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:138.62pt">regard to Consultant&#8217;s services.</font></div><div style="line-height:7.62pt;position:absolute;top:185.71pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:54pt;position:absolute;text-decoration:underline;white-space:pre">1.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:62.25pt;letter-spacing:0.25em;position:absolute;text-decoration:underline;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:67.75pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:underline;white-space:pre">Services</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:105.49000000000001pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre">.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:211.46pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">a)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:27.48pt">Scope</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:153.48pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt">.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:156.23pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.51pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:161.74pt;position:absolute;text-decoration:none;white-space:pre;width:396.56pt">Consultant will provide advice and consultation with respect to company operations and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.3pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:224.66pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:37.55pt">strategy,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:91.55pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.6pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:94.15pt;position:absolute;text-decoration:none;white-space:pre;width:41.53pt">including</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:135.68pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.65pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:138.32999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:66.86pt">manufacturing,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:205.19pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.7pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:207.89pt;position:absolute;text-decoration:none;white-space:pre;width:27.19pt">CMC,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:235.08pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.7pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:237.78pt;position:absolute;text-decoration:none;white-space:pre;width:29.33pt">supply</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:267.11pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.6pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:269.71000000000004pt;position:absolute;text-decoration:none;white-space:pre;width:26.56pt">chain,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:296.27pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.45pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:298.72pt;position:absolute;text-decoration:none;white-space:pre;width:33.28pt">quality,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:332pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.65pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:334.65pt;position:absolute;text-decoration:none;white-space:pre;width:39.67pt">technical</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:374.32pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:377.07pt;position:absolute;text-decoration:none;white-space:pre;width:45.8pt">operations</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:422.87pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.8pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:425.67pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:441.55pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.6pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:444.15pt;position:absolute;text-decoration:none;white-space:pre;width:22.59pt">other</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:466.74pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.65pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:469.39pt;position:absolute;text-decoration:none;white-space:pre;width:35.41pt">services</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:504.8pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.65pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:507.45pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">as</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:516.61pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.65pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:519.26pt;position:absolute;text-decoration:none;white-space:pre;width:39.08pt">mutually</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.3399999999999pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:237.86pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:29.3pt">agreed</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:83.3pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:86.14pt;position:absolute;text-decoration:none;white-space:pre;width:21.37pt">from</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:107.50999999999999pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.74pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:110.25pt;position:absolute;text-decoration:none;white-space:pre;width:19.53pt">time</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:129.78pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.74pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:132.51999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:141.07pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:143.91pt;position:absolute;text-decoration:none;white-space:pre;width:39.5pt">time (the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:183.41pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:186.25pt;position:absolute;text-decoration:none;white-space:pre;width:4.88pt">&#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:191.13pt;position:absolute;text-decoration:none;white-space:pre;width:38.46pt">Services</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:229.59pt;position:absolute;text-decoration:none;white-space:pre;width:11.29pt">&#8221;),</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:240.88pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:243.67pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">as</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:252.83pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:255.67pt;position:absolute;text-decoration:none;white-space:pre;width:42.13pt">requested</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:297.8pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:300.59000000000003pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:311.59pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:314.43pt;position:absolute;text-decoration:none;white-space:pre;width:30.23pt">Geron.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:344.66pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:347.45pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:395.09pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:397.93pt;position:absolute;text-decoration:none;white-space:pre;width:20.76pt">shall</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:418.69pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:421.53pt;position:absolute;text-decoration:none;white-space:pre;width:22.6pt">work</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:444.13pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:446.97pt;position:absolute;text-decoration:none;white-space:pre;width:25.04pt">under</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:472.01pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:474.8pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:488.23pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:491.07pt;position:absolute;text-decoration:none;white-space:pre;width:39.07pt">direction</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:530.14pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:532.8299999999999pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:541.99pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:544.8299999999999pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.26pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:251.06pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:476pt">Chief Executive Officer of Geron and shall have no management, supervisory or decision-making authority.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:277.61pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:9.77pt">b)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:84.91pt">Standard of Care.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:210.91pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:4.9pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:215.81pt;position:absolute;text-decoration:none;white-space:pre;width:342.47pt">Consultant agrees to utilize Consultant&#8217;s reasonable best efforts and expertise</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.28pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:290.81pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:105.87pt">to perform the Services.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:159.87pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:4.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:164.69pt;position:absolute;text-decoration:none;white-space:pre;width:393.48pt">Consultant may not subcontract or otherwise delegate Consultant&#8217;s obligations under this</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.1700000000001pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:304.01pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:236.29pt">Agreement without Geron&#8217;s prior written consent.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:290.28999999999996pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:7.91pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:298.2pt;position:absolute;text-decoration:none;white-space:pre;width:260.05pt">Consultant will comply with all laws, regulations, and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.25pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:317.21pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.24pt">ordinances applicable to Consultant&#8217;s performance of the Services and Consultant&#8217;s other obligations under this</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.24pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:330.41pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:48.84pt">Agreement</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:102.84pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.89pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:105.72999999999999pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:121.61pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:124.45pt;position:absolute;text-decoration:none;white-space:pre;width:14.66pt">has</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:139.11pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:141.95pt;position:absolute;text-decoration:none;white-space:pre;width:53.61pt">obtained (or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:195.56pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:198.4pt;position:absolute;text-decoration:none;white-space:pre;width:28.08pt">before</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:226.48pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:229.32pt;position:absolute;text-decoration:none;white-space:pre;width:49.46pt">performing</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:278.78pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:281.47pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:294.9pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:297.74pt;position:absolute;text-decoration:none;white-space:pre;width:37.24pt">Services</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:334.98pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:337.82pt;position:absolute;text-decoration:none;white-space:pre;width:17.09pt">will</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:354.91pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.89pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:357.8pt;position:absolute;text-decoration:none;white-space:pre;width:31.14pt">obtain)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:388.94pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:391.78pt;position:absolute;text-decoration:none;white-space:pre;width:110.26pt">all governmental permits</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:502.04pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:504.88pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:520.76pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.74pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:523.5pt;position:absolute;text-decoration:none;white-space:pre;width:34.8pt">licenses</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.3pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:343.61pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:483.82pt">required for Consultant to perform the Services and Consultant&#8217;s other obligations under this Agreement.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:537.8199999999999pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:6.35pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:544.1700000000001pt;position:absolute;text-decoration:none;white-space:pre;width:14.04pt">All</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.21pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:356.81pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.19pt">Services Consultant provides to Geron after the Effective Date will be deemed to be provided pursuant to this</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.19pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:370.01pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:50.69pt">Agreement.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:395.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:8.54pt">c)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:74.44pt">Time and Place</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:200.44pt;position:absolute;text-decoration:none;white-space:pre;width:357.89pt">. Consultant will provide Services as needed upon reasonable request by Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.3299999999999pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:408.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:95.2pt">or its representatives.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:149.2pt;letter-spacing:0.15em;position:absolute;text-decoration:none;white-space:pre;width:5.14pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:154.34pt;position:absolute;text-decoration:none;white-space:pre;width:17.09pt">The</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:171.43pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.9pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:174.32999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:37.24pt">Services</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:211.57pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.94pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:214.51pt;position:absolute;text-decoration:none;white-space:pre;width:18.93pt">may</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:233.44pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.8pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:236.24pt;position:absolute;text-decoration:none;white-space:pre;width:32.36pt">include</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:268.6pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.8pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:271.4pt;position:absolute;text-decoration:none;white-space:pre;width:60.77pt">consultations,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:332.17pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.94pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:335.11pt;position:absolute;text-decoration:none;white-space:pre;width:22pt">upon</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:357.11pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.8pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:359.91pt;position:absolute;text-decoration:none;white-space:pre;width:47.01pt">reasonable</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:406.92pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.8pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:409.72pt;position:absolute;text-decoration:none;white-space:pre;width:29.61pt">notice,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:439.33pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.9pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:442.23pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:450.78pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.9pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:453.68pt;position:absolute;text-decoration:none;white-space:pre;width:42.44pt">meetings,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:496.12pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.8pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:498.92pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:509.92pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.9pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:512.8199999999999pt;position:absolute;text-decoration:none;white-space:pre;width:45.49pt">telephone,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.31pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.16pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:422.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.23pt">e-mail, or letter, and whatever literature research, analysis, or computation Geron or its representatives may deem</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.23pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:435.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:52.81pt">appropriate.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:106.81pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:4.95pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:111.75999999999999pt;position:absolute;text-decoration:none;white-space:pre;width:29.93pt">Unless</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:141.69pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.77pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:144.45999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:42.74pt">otherwise</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:187.2pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.77pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:189.97pt;position:absolute;text-decoration:none;white-space:pre;width:47pt">terminated</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:236.97pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:239.84pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">as</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:249pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:251.87pt;position:absolute;text-decoration:none;white-space:pre;width:39.09pt">provided</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:290.96000000000004pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.62pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:293.58000000000004pt;position:absolute;text-decoration:none;white-space:pre;width:26.87pt">below</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:320.45pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.67pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:323.12pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:332.28pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.77pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:335.05pt;position:absolute;text-decoration:none;white-space:pre;width:39.69pt">extended</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:374.74pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:377.61pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:388.61pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.72pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:391.33pt;position:absolute;text-decoration:none;white-space:pre;width:30.53pt">mutual</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:421.86pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.77pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:424.63pt;position:absolute;text-decoration:none;white-space:pre;width:45.78pt">agreement</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:470.41pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.92pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:473.33pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:481.88pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:484.75pt;position:absolute;text-decoration:none;white-space:pre;width:34.5pt">writing,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:519.25pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.72pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:521.97pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:535.4pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.77pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:538.1700000000001pt;position:absolute;text-decoration:none;white-space:pre;width:20.14pt">term</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.31pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:448.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.31pt">of this Agreement shall commence on the Effective Date and expire one (1) year from the Effective Date (the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.31pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:461.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:4.88pt">&#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:58.88pt;position:absolute;text-decoration:none;white-space:pre;width:26.25pt">Term</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:85.13pt;position:absolute;text-decoration:none;white-space:pre;width:377.04pt">&#8221;). The parties may extend the Term of this Agreement through a written amendment.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:488.21pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:9.77pt">d)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:115.94pt">Independent Contractor</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:241.94pt;position:absolute;text-decoration:none;white-space:pre;width:316.38pt">. Consultant&#8217;s relationship with Geron will be that of an independent</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.3199999999999pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:501.41pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.27pt">contractor, and nothing in this Agreement shall be construed to create a partnership, joint venture, or employer-</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:514.61pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:42.74pt">employee</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:96.74000000000001pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.54pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:99.28pt;position:absolute;text-decoration:none;white-space:pre;width:54.65pt">relationship.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:153.93pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.54pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:156.47pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:204.11pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:206.7pt;position:absolute;text-decoration:none;white-space:pre;width:7.33pt">is</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:214.03pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:216.62pt;position:absolute;text-decoration:none;white-space:pre;width:14.05pt">not</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:230.67pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:233.26pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:246.69pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.54pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:249.23pt;position:absolute;text-decoration:none;white-space:pre;width:23.81pt">agent</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:273.03999999999996pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.49pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:275.53pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:284.69pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.44pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:287.13pt;position:absolute;text-decoration:none;white-space:pre;width:61.65pt">representative</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:348.78pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.54pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:351.32pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:360.48pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:363.07pt;position:absolute;text-decoration:none;white-space:pre;width:27.48pt">Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:390.55pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.39pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:392.94pt;position:absolute;text-decoration:none;white-space:pre;width:32.35pt">(except</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:425.29pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:427.88pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">as</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:437.04pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:439.63pt;position:absolute;text-decoration:none;white-space:pre;width:50.66pt">specifically</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:490.29pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.39pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:492.68pt;position:absolute;text-decoration:none;white-space:pre;width:12.21pt">set</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:504.89pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:507.48pt;position:absolute;text-decoration:none;white-space:pre;width:21.37pt">forth</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:528.85pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.54pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:531.39pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:539.94pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.54pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:542.48pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">this</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.36pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:527.81pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:55.55pt">Agreement)&#59;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:109.55pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.86pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:112.41pt;position:absolute;text-decoration:none;white-space:pre;width:7.33pt">is</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:119.74pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.81pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:122.55pt;position:absolute;text-decoration:none;white-space:pre;width:14.05pt">not</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:136.6pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.86pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:139.45999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:46.4pt">authorized</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:185.86pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.81pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:188.67pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:197.22pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.81pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:200.03pt;position:absolute;text-decoration:none;white-space:pre;width:23.81pt">make</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:223.84pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.81pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:226.65pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:242.53pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.81pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:245.34pt;position:absolute;text-decoration:none;white-space:pre;width:65.02pt">representation,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:310.36pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.81pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:313.17pt;position:absolute;text-decoration:none;white-space:pre;width:35.4pt">contract</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:348.57pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.86pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:351.43pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:360.59pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.81pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:363.4pt;position:absolute;text-decoration:none;white-space:pre;width:55.56pt">commitment</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:418.96pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.71pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:421.67pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">on</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:432.67pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.81pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:435.48pt;position:absolute;text-decoration:none;white-space:pre;width:27.47pt">behalf</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:462.95pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.81pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:465.76pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:474.92pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.81pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:477.73pt;position:absolute;text-decoration:none;white-space:pre;width:30.53pt">Geron&#59;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:508.26pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.86pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:511.12pt;position:absolute;text-decoration:none;white-space:pre;width:17.09pt">will</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:528.21pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.86pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:531.0699999999999pt;position:absolute;text-decoration:none;white-space:pre;width:14.05pt">not</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:545.12pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.86pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:547.98pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">be</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.36pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:541.01pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:32.96pt">entitled</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:86.96000000000001pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:89.83pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:98.38pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:101.25pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:117.13pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:120pt;position:absolute;text-decoration:none;white-space:pre;width:25.5pt">of the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:145.5pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:148.37pt;position:absolute;text-decoration:none;white-space:pre;width:34.8pt">benefits</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:183.17pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:186.04pt;position:absolute;text-decoration:none;white-space:pre;width:46.87pt">that Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:232.91pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:235.78pt;position:absolute;text-decoration:none;white-space:pre;width:28.09pt">makes</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:263.87pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:266.74pt;position:absolute;text-decoration:none;white-space:pre;width:39.67pt">available</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:306.40999999999997pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:309.28pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:317.83pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:320.7pt;position:absolute;text-decoration:none;white-space:pre;width:63.06pt">its employees,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:383.76pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:386.63pt;position:absolute;text-decoration:none;white-space:pre;width:20.16pt">such</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:406.79pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:409.61pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">as</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:418.77pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:421.64pt;position:absolute;text-decoration:none;white-space:pre;width:25.66pt">group</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:447.3pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:450.12pt;position:absolute;text-decoration:none;white-space:pre;width:108.24pt">insurance, profit-sharing</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.36pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:554.21pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:151.03pt">or retirement benefits (and waives</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:205.03pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.92pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:207.95pt;position:absolute;text-decoration:none;white-space:pre;width:350.38pt">the right to receive any such benefits)&#59; and will be solely responsible for all tax</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.3299999999999pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:567.41pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:30.53pt">returns</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:84.53pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.5pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:87.03pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:102.91pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.6pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:105.50999999999999pt;position:absolute;text-decoration:none;white-space:pre;width:42.14pt">payments</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:147.65pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.5pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:150.15pt;position:absolute;text-decoration:none;white-space:pre;width:36.63pt">required</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:186.78pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.6pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:189.38pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:197.93pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.6pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:200.53pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">be</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:210.91pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.5pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:213.41pt;position:absolute;text-decoration:none;white-space:pre;width:20.14pt">filed</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:233.55pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.6pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:236.15pt;position:absolute;text-decoration:none;white-space:pre;width:19.54pt">with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:255.69pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.6pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:258.28999999999996pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:267.45pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.5pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:269.95pt;position:absolute;text-decoration:none;white-space:pre;width:23.81pt">made</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:293.76pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.5pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:296.26pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:304.81pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.6pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:307.40999999999997pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:323.29pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.5pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:325.79pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">tax</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:339.22pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.6pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:341.82pt;position:absolute;text-decoration:none;white-space:pre;width:39.69pt">authority</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:381.51pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.6pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:384.11pt;position:absolute;text-decoration:none;white-space:pre;width:19.54pt">with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:403.65pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.6pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:406.25pt;position:absolute;text-decoration:none;white-space:pre;width:31.13pt">respect</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:437.38pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.5pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:439.88pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:448.43pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.6pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:451.03pt;position:absolute;text-decoration:none;white-space:pre;width:55.55pt">performance</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:506.58pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.6pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:509.18pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:518.3399999999999pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.65pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:520.99pt;position:absolute;text-decoration:none;white-space:pre;width:37.24pt">Services</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.23pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:580.61pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.36pt">and receipt of fees under this Agreement. Consultant agrees to accept exclusive liability for complying with all</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.36pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:593.81pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:471.29pt">applicable state and federal laws, including without limitation laws governing self-employed individuals.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:525.29pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:530.88pt;position:absolute;text-decoration:none;white-space:pre;width:27.48pt">Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.36pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:607.01pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.38pt">will not withhold or make payments for taxes, social security, unemployment insurance or disability insurance</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.38pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:620.21pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:358.49pt">contributions, or obtain workers&#8217; compensation insurance on Consultant&#8217;s behalf.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:646.66pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:48.86pt">Inspection</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:138.86pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt">.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:141.61pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.15pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:146.76pt;position:absolute;text-decoration:none;white-space:pre;width:27.48pt">Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:174.24pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.77pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:177.01pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:186.17000000000002pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.92pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:189.09pt;position:absolute;text-decoration:none;white-space:pre;width:35.42pt">Geron&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:224.51pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.77pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:227.28pt;position:absolute;text-decoration:none;white-space:pre;width:46.4pt">authorized</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:273.68pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:276.55pt;position:absolute;text-decoration:none;white-space:pre;width:61.65pt">representative</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:338.2pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.92pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:341.12pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:357pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:359.87pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:375.75pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:378.62pt;position:absolute;text-decoration:none;white-space:pre;width:60.45pt">governmental</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:439.07pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.92pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:441.99pt;position:absolute;text-decoration:none;white-space:pre;width:31.14pt">agency</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:473.13pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:476pt;position:absolute;text-decoration:none;white-space:pre;width:26.87pt">which</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:502.87pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.77pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:505.64pt;position:absolute;text-decoration:none;white-space:pre;width:70.32pt">regulates Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:575.96pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:659.86pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:521.92pt">may, at all reasonable times during the term of this Agreement and for three (3) years thereafter, upon reasonable</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:575.92pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.06pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:673.06pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:29.61pt">notice,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:83.61pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.48pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:86.09pt;position:absolute;text-decoration:none;white-space:pre;width:31.14pt">inspect</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:117.22999999999999pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.48pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:119.71pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:135.59pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.53pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:138.12pt;position:absolute;text-decoration:none;white-space:pre;width:21.98pt">audit</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:160.1pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.48pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:162.57999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:176.01pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.48pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:178.49pt;position:absolute;text-decoration:none;white-space:pre;width:29.03pt">books,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:207.52pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.48pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:210pt;position:absolute;text-decoration:none;white-space:pre;width:32.36pt">records</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:242.36pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.53pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:244.89pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:260.77pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.48pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:263.25pt;position:absolute;text-decoration:none;white-space:pre;width:18.31pt">data</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:281.56pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.48pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:284.03999999999996pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:293.2pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.48pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:295.68pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:343.32pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.53pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:345.85pt;position:absolute;text-decoration:none;white-space:pre;width:33.57pt">relating</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:379.42pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.48pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:381.9pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:390.45pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.48pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:392.93pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:406.36pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.48pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:408.84pt;position:absolute;text-decoration:none;white-space:pre;width:37.24pt">Services</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:446.08pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.53pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:448.61pt;position:absolute;text-decoration:none;white-space:pre;width:12.82pt">for</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:461.43pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.48pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:463.91pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:477.34pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.48pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:479.82pt;position:absolute;text-decoration:none;white-space:pre;width:96.11pt">purpose of evaluating</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:575.93pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:686.26pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:521.97pt">Consultant's compliance with this Agreement and any law, regulation or policy applicable to Geron. Consultant shall</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:575.97pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:699.46pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:521.88pt">retain all applicable books, records, and data for three (3) years subsequent to the expiration or termination of this</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:575.88pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:712.66pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:465.39pt">Agreement or such longer period as required by applicable local or international regulatory requirements,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:519.39pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.31pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:521.7pt;position:absolute;text-decoration:none;white-space:pre;width:28.69pt">except</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:550.39pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.35pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:552.74pt;position:absolute;text-decoration:none;white-space:pre;width:23.21pt">those</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:575.95pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.06pt"> </font></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt"><div style="position:absolute;top:728.64pt"><div style="width:522pt"></div></div><div style="position:absolute"><div style="width:522pt"></div></div><div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:66.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">documents</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:101.64pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:3.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:105.37pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:114.53pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.67pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:118.2pt;position:absolute;text-decoration:none;white-space:pre;width:18.31pt">data</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:136.51pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:3.53pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:140.04000000000002pt;position:absolute;text-decoration:none;white-space:pre;width:36.63pt">returned</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:176.67000000000002pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:3.58pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:180.25pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:188.8pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:3.63pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:192.43pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:205.86pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:3.63pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:209.49pt;position:absolute;text-decoration:none;white-space:pre;width:27.48pt">Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:236.97pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:3.63pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:240.6pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:249.76pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.67pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:253.43pt;position:absolute;text-decoration:none;white-space:pre;width:35.42pt">Geron&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:288.85pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.67pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:292.52pt;position:absolute;text-decoration:none;white-space:pre;width:46.4pt">authorized</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:338.92pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:3.63pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:342.55pt;position:absolute;text-decoration:none;white-space:pre;width:61.65pt">representative</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:404.2pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:3.63pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:407.83pt;position:absolute;text-decoration:none;white-space:pre;width:7.93pt">at</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:415.76pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.67pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:419.43pt;position:absolute;text-decoration:none;white-space:pre;width:39.64pt">Geron&#8217;s </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:459.07pt;position:absolute;text-decoration:none;white-space:pre;width:31.75pt">request</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:490.82pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:4.08pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:494.9pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:510.78pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.98pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:514.76pt;position:absolute;text-decoration:none;white-space:pre;width:12.82pt">for</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:527.5799999999999pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:4.03pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:531.61pt;position:absolute;text-decoration:none;white-space:pre;width:26.87pt">which</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.48pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.98pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:562.46pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:575.89pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.56pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:80.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:27.48pt">Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:81.48pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.21pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:84.69pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:93.85pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.26pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:97.11pt;position:absolute;text-decoration:none;white-space:pre;width:35.42pt">Geron&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:132.53pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.26pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:135.79000000000002pt;position:absolute;text-decoration:none;white-space:pre;width:46.4pt">authorized</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:182.19pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:3.11pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:185.3pt;position:absolute;text-decoration:none;white-space:pre;width:61.65pt">representative</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:246.95pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.26pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:250.21pt;position:absolute;text-decoration:none;white-space:pre;width:17.09pt">will</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:267.3pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.26pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:270.56pt;position:absolute;text-decoration:none;white-space:pre;width:32.37pt">assume</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:302.93pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:3.11pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:306.03999999999996pt;position:absolute;text-decoration:none;white-space:pre;width:59.85pt">responsibility</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:365.89pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:3.11pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:369pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">as</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:378.16pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.26pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:381.42pt;position:absolute;text-decoration:none;white-space:pre;width:25.64pt">stated</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:407.06pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.26pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:410.32pt;position:absolute;text-decoration:none;white-space:pre;width:29.01pt">above.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:439.33pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.26pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:442.59pt;position:absolute;text-decoration:none;white-space:pre;width:133.27pt">If Consultant is notified of an</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:575.86pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:93.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:521.96pt">inspection by a governmental agency, Consultant shall take all reasonable steps necessary to provide prompt notice of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:575.96pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:106.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:437.84pt">inspection to Geron and cure any deficiencies identified by said inspection at Consultant&#8217;s expense.</font></div><div style="line-height:7.44pt;position:absolute;top:132.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:54pt;position:absolute;text-decoration:underline;white-space:pre">2.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:62.25pt;letter-spacing:0.25em;position:absolute;text-decoration:underline;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:67.75pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:underline;white-space:pre">Compensation.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:159.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">a)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:20.75pt">Fees</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:146.75pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt">.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:149.5pt;letter-spacing:0.154em;position:absolute;text-decoration:none;white-space:pre;width:4.75pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:154.25pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">In</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:163.41pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.57pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:165.98pt;position:absolute;text-decoration:none;white-space:pre;width:59.23pt">consideration</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:225.20999999999998pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.47pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:227.68pt;position:absolute;text-decoration:none;white-space:pre;width:12.82pt">for</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:240.5pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.51pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:243.01pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:256.44pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.47pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:258.90999999999997pt;position:absolute;text-decoration:none;white-space:pre;width:39.99pt">Services,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:298.9pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.47pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:301.37pt;position:absolute;text-decoration:none;white-space:pre;width:27.48pt">Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:328.85pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.47pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:331.32pt;position:absolute;text-decoration:none;white-space:pre;width:17.09pt">will</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:348.40999999999997pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.42pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:350.83000000000004pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">pay</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:366.71000000000004pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.62pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:369.33000000000004pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:416.97pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.67pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:419.64pt;position:absolute;text-decoration:none;white-space:pre;width:4.88pt">a</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:424.52pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.47pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:426.99pt;position:absolute;text-decoration:none;white-space:pre;width:36.65pt">monthly</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:463.64pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.57pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:466.21pt;position:absolute;text-decoration:none;white-space:pre;width:33.56pt">retainer</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:499.77pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.62pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:502.39pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:511.55pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.72pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:514.27pt;position:absolute;text-decoration:none;white-space:pre;width:44pt">$5,000.00</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.27pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.31pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:172.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:38.9pt">USD per</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:92.9pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.63pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:95.53pt;position:absolute;text-decoration:none;white-space:pre;width:28.1pt">month</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:123.63pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:126.31pt;position:absolute;text-decoration:none;white-space:pre;width:12.82pt">for</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:139.13pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:141.81pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">up</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:152.81pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.63pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:155.44pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:163.99pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.53pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:166.51999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:29.92pt">twenty</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:196.44pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.53pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:198.97pt;position:absolute;text-decoration:none;white-space:pre;width:18.32pt">(20)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:217.29pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.58pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:219.87pt;position:absolute;text-decoration:none;white-space:pre;width:24.44pt">hours</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:244.31pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:246.99pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:256.15pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:258.83000000000004pt;position:absolute;text-decoration:none;white-space:pre;width:37.24pt">Services</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:296.07pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:298.75pt;position:absolute;text-decoration:none;white-space:pre;width:14.04pt">per</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:312.79pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.58pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:315.37pt;position:absolute;text-decoration:none;white-space:pre;width:28.1pt">month</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:343.47pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.63pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:346.1pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:354.65pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.63pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:357.28pt;position:absolute;text-decoration:none;white-space:pre;width:20.14pt">each</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:377.42pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:380.1pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:389.26pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:391.94pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:405.37pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:408.05pt;position:absolute;text-decoration:none;white-space:pre;width:17.7pt">first</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:425.75pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.58pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:428.33pt;position:absolute;text-decoration:none;white-space:pre;width:21.97pt">three</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:450.3pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.53pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:452.83pt;position:absolute;text-decoration:none;white-space:pre;width:44.41pt">months of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:497.24pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.58pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:499.82pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:513.25pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:515.9300000000001pt;position:absolute;text-decoration:none;white-space:pre;width:23.8pt">Term</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:539.73pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:542.46pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.3399999999999pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.41pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:185.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">up</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:65pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.98pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:68.98pt;position:absolute;text-decoration:none;white-space:pre;width:26.2pt">to ten</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:95.18pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.67pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:98.85pt;position:absolute;text-decoration:none;white-space:pre;width:18.32pt">(10)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:117.17pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:120.95pt;position:absolute;text-decoration:none;white-space:pre;width:24.44pt">hours</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:145.39pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.67pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:149.06pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:158.22pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.67pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:161.89pt;position:absolute;text-decoration:none;white-space:pre;width:37.24pt">Services</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:199.13pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:3.83pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:202.96pt;position:absolute;text-decoration:none;white-space:pre;width:14.04pt">per</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:217pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.67pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:220.67pt;position:absolute;text-decoration:none;white-space:pre;width:28.1pt">month</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:248.77pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.67pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:252.44pt;position:absolute;text-decoration:none;white-space:pre;width:44.85pt">thereafter.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:297.28999999999996pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:3.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:301.02pt;position:absolute;text-decoration:none;white-space:pre;width:17.09pt">The</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:318.11pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.67pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:321.78pt;position:absolute;text-decoration:none;white-space:pre;width:42.73pt">aggregate</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:364.51pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.67pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:368.18pt;position:absolute;text-decoration:none;white-space:pre;width:19.53pt">total</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:387.71pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:391.49pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:400.65pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:404.43pt;position:absolute;text-decoration:none;white-space:pre;width:10.98pt">all</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:415.41pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.67pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:419.08pt;position:absolute;text-decoration:none;white-space:pre;width:17.7pt">fees</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:436.78pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.67pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:440.45pt;position:absolute;text-decoration:none;white-space:pre;width:12.82pt">for</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:453.27pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:3.63pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:456.9pt;position:absolute;text-decoration:none;white-space:pre;width:37.24pt">Services</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:494.14pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.67pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:497.81pt;position:absolute;text-decoration:none;white-space:pre;width:45.79pt">performed</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:543.6pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:547.38pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.38pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.26pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:198.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:448.25pt">Consultant will not exceed $60,000.00 USD for the Term, without prior written approval from Geron.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:225.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:9.77pt">b)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:43.37pt">Expenses</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:169.37pt;position:absolute;text-decoration:none;white-space:pre;width:388.98pt">. Geron will reimburse Consultant for out-of-pocket expenses incurred by Consultant in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.35pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:238.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:49.46pt">performing</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:103.46000000000001pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.83pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:106.28999999999999pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:119.72pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:122.5pt;position:absolute;text-decoration:none;white-space:pre;width:39.99pt">Services,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:162.49pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:165.26999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:39.09pt">provided</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:204.36pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:207.04pt;position:absolute;text-decoration:none;white-space:pre;width:16.48pt">that</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:223.52pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.83pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:226.35pt;position:absolute;text-decoration:none;white-space:pre;width:20.16pt">such</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:246.51pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:249.19pt;position:absolute;text-decoration:none;white-space:pre;width:39.7pt">expenses</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:288.89pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:291.66999999999996pt;position:absolute;text-decoration:none;white-space:pre;width:13.42pt">are</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:305.09000000000003pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:307.87pt;position:absolute;text-decoration:none;white-space:pre;width:42.74pt">necessary</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:350.61pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:353.39pt;position:absolute;text-decoration:none;white-space:pre;width:12.82pt">for</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:366.21pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:368.89pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:382.32pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:385pt;position:absolute;text-decoration:none;white-space:pre;width:55.55pt">performance</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:440.55pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:443.33pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:452.49pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:455.27pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:468.7pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:471.48pt;position:absolute;text-decoration:none;white-space:pre;width:37.24pt">Services</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:508.72pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:511.5pt;position:absolute;text-decoration:none;white-space:pre;width:46.71pt">hereunder,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.21pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:251.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:13.42pt">are</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:67.42pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.81pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:70.23pt;position:absolute;text-decoration:none;white-space:pre;width:47.01pt">reasonable</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:117.24000000000001pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.81pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:120.05pt;position:absolute;text-decoration:none;white-space:pre;width:16.48pt">(for</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:136.53pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.81pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:139.34pt;position:absolute;text-decoration:none;white-space:pre;width:39.99pt">example,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:179.32999999999998pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.81pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:182.14pt;position:absolute;text-decoration:none;white-space:pre;width:14.05pt">not</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:196.19pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.86pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:199.05pt;position:absolute;text-decoration:none;white-space:pre;width:28.71pt">luxury</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:227.76pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.81pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:230.57pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:239.73pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.81pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:242.54pt;position:absolute;text-decoration:none;white-space:pre;width:17.7pt">first</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:260.24pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.86pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:263.1pt;position:absolute;text-decoration:none;white-space:pre;width:25.03pt">class)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:288.13pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.86pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:290.99pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:306.87pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.81pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:309.68pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:318.23pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.81pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:321.04pt;position:absolute;text-decoration:none;white-space:pre;width:49.44pt">accordance</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:370.48pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.81pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:373.29pt;position:absolute;text-decoration:none;white-space:pre;width:19.54pt">with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:392.83pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.81pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:395.64pt;position:absolute;text-decoration:none;white-space:pre;width:34.19pt">policies</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:429.83pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.81pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:432.64pt;position:absolute;text-decoration:none;white-space:pre;width:39.09pt">provided</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:471.73pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.81pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:474.54pt;position:absolute;text-decoration:none;white-space:pre;width:41.38pt">by Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:515.9200000000001pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.81pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:518.73pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:534.61pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.81pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:537.4200000000001pt;position:absolute;text-decoration:none;white-space:pre;width:20.76pt">have</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.1800000000001pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:264.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:20.76pt">been</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:74.76pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.55pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:77.31pt;position:absolute;text-decoration:none;white-space:pre;width:40.92pt">approved</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:118.23pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.5pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:120.73pt;position:absolute;text-decoration:none;white-space:pre;width:50.66pt">specifically</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:171.39pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.5pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:173.89pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:182.44pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.55pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:184.99pt;position:absolute;text-decoration:none;white-space:pre;width:31.75pt">writing</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:216.74pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.45pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:219.19pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:227.74pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.55pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:230.29pt;position:absolute;text-decoration:none;white-space:pre;width:36.02pt">advance</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:266.31pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.55pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:268.86pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:279.86pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.45pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:282.31pt;position:absolute;text-decoration:none;white-space:pre;width:27.48pt">Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:309.78999999999996pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.55pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:312.34pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">up</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:323.34pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.45pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:325.79pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:334.34pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.45pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:336.79pt;position:absolute;text-decoration:none;white-space:pre;width:4.88pt">a</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:341.67pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.55pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:344.22pt;position:absolute;text-decoration:none;white-space:pre;width:34.18pt">specific</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:378.4pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.55pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:380.95pt;position:absolute;text-decoration:none;white-space:pre;width:25.64pt">dollar</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:406.59pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.5pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:409.09pt;position:absolute;text-decoration:none;white-space:pre;width:35.73pt">amount.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:444.82pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.55pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:447.37pt;position:absolute;text-decoration:none;white-space:pre;width:37.25pt">Invoices</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:484.62pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.5pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:487.12pt;position:absolute;text-decoration:none;white-space:pre;width:12.82pt">for</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:499.94pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.6pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:502.54pt;position:absolute;text-decoration:none;white-space:pre;width:39.7pt">expenses</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:542.24pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.6pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:544.8399999999999pt;position:absolute;text-decoration:none;white-space:pre;width:13.42pt">are</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.26pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:278.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:143.49pt">required prior to reimbursement.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:304.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:8.54pt">c)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:34.51pt">Equity.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:160.51pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:4.93pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:165.44pt;position:absolute;text-decoration:none;white-space:pre;width:60.34pt">In connection</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:225.78pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.9pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:228.68pt;position:absolute;text-decoration:none;white-space:pre;width:329.64pt">with Consultant&#8217;s termination as an employee of Geron, Consultant agrees</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.3199999999999pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:317.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:30.83pt">that all</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:84.83pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.13pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:87.96000000000001pt;position:absolute;text-decoration:none;white-space:pre;width:23.21pt">stock</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:111.17pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.08pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:114.25pt;position:absolute;text-decoration:none;white-space:pre;width:32.38pt">options</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:146.63pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.08pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:149.70999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:32.97pt">granted</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:182.68pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.08pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:185.76pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:194.31pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.08pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:197.39pt;position:absolute;text-decoration:none;white-space:pre;width:17.1pt">him</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:214.49pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.18pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:217.67pt;position:absolute;text-decoration:none;white-space:pre;width:28.71pt">during</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:246.38pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.08pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:249.46pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:262.89pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.23pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:266.12pt;position:absolute;text-decoration:none;white-space:pre;width:28.09pt">period</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:294.21000000000004pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.18pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:297.39pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:306.55pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.28pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:309.83000000000004pt;position:absolute;text-decoration:none;white-space:pre;width:12.83pt">his</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:322.66pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.13pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:325.79pt;position:absolute;text-decoration:none;white-space:pre;width:54.96pt">employment</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:380.75pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.13pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:383.88pt;position:absolute;text-decoration:none;white-space:pre;width:7.93pt">at</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:391.81pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.23pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:395.04pt;position:absolute;text-decoration:none;white-space:pre;width:27.48pt">Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:422.52pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.08pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:425.6pt;position:absolute;text-decoration:none;white-space:pre;width:17.09pt">will</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:442.69pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.23pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:445.92pt;position:absolute;text-decoration:none;white-space:pre;width:18.33pt">stop</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:464.25pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.08pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:467.33pt;position:absolute;text-decoration:none;white-space:pre;width:31.76pt">vesting</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:499.09pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.23pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:502.32pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">as</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:511.48pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.23pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:514.71pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:523.87pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.13pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:527pt;position:absolute;text-decoration:none;white-space:pre;width:12.83pt">his</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:539.8299999999999pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.08pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:542.9100000000001pt;position:absolute;text-decoration:none;white-space:pre;width:15.26pt">last</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.1700000000001pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.61pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:330.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">day</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:69.88pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.72pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:72.6pt;position:absolute;text-decoration:none;white-space:pre;width:67.03pt">of employment</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:139.63pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.67pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:142.3pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:158.18pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.57pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:160.75pt;position:absolute;text-decoration:none;white-space:pre;width:16.48pt">that</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:177.23000000000002pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.52pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:179.75pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:195.63pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.57pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:198.2pt;position:absolute;text-decoration:none;white-space:pre;width:39.09pt">unvested</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:237.29pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.57pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:239.86pt;position:absolute;text-decoration:none;white-space:pre;width:23.21pt">stock</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:263.07pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.57pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:265.64pt;position:absolute;text-decoration:none;white-space:pre;width:32.38pt">options</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:298.02pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.67pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:300.69pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:316.57pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.57pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:319.14pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:335.02pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.57pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:337.59pt;position:absolute;text-decoration:none;white-space:pre;width:39.09pt">unvested</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:376.68pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.47pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:379.15pt;position:absolute;text-decoration:none;white-space:pre;width:40.89pt">restricted</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:420.04pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.57pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:422.61pt;position:absolute;text-decoration:none;white-space:pre;width:23.2pt">share</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:445.81pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.47pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:448.28pt;position:absolute;text-decoration:none;white-space:pre;width:21.38pt">units</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:469.66pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.67pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:472.33pt;position:absolute;text-decoration:none;white-space:pre;width:17.09pt">will</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:489.42pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.62pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:492.04pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">be</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:502.42pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.57pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:504.99pt;position:absolute;text-decoration:none;white-space:pre;width:41.5pt">cancelled</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:546.49pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.57pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:549.06pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">as</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.22pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.46pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:344.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:63.16pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.65pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:66.81pt;position:absolute;text-decoration:none;white-space:pre;width:491.47pt">that date&#59; provided, however, that the stock option granted to Consultant on February 16, 2022, for 750,000</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.28pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:357.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:308.43pt">shares of common stock at an exercise price of $1.06 per share (the &#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:362.43pt;position:absolute;text-decoration:none;white-space:pre;width:58.11pt">2022 Option</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:420.54pt;position:absolute;text-decoration:none;white-space:pre;width:137.78pt">&#8221;) shall continue to vest during</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.3199999999999pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:370.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:54.33pt">the Term of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:108.33pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.83pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:112.16pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">this</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:128.04000000000002pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.93pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:131.97pt;position:absolute;text-decoration:none;white-space:pre;width:51.59pt">Agreement,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:183.56pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.93pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:187.49pt;position:absolute;text-decoration:none;white-space:pre;width:31.14pt">subject</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:218.63pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.83pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:222.46pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:231.01pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.93pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:234.94pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:250.82pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:254.6pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:263.15pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:266.93pt;position:absolute;text-decoration:none;white-space:pre;width:49.44pt">accordance</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:316.37pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.83pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:320.2pt;position:absolute;text-decoration:none;white-space:pre;width:19.54pt">with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:339.74pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:343.52pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:356.95pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.93pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:360.88pt;position:absolute;text-decoration:none;white-space:pre;width:24.42pt">terms</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:385.3pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.83pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:389.13pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:398.29pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.83pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:402.12pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:415.55pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.83pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:419.38pt;position:absolute;text-decoration:none;white-space:pre;width:22pt">2018</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:441.38pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:445.16pt;position:absolute;text-decoration:none;white-space:pre;width:29.31pt">Equity</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:474.47pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:478.15pt;position:absolute;text-decoration:none;white-space:pre;width:40.9pt">Incentive</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:519.05pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.93pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:522.98pt;position:absolute;text-decoration:none;white-space:pre;width:22.29pt">Plan,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:545.27pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.83pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:549.1pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">as</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.26pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.61pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:383.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:42.44pt">amended,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:96.44pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.31pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:99.75pt;position:absolute;text-decoration:none;white-space:pre;width:32.66pt">and the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:132.41pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.16pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:135.57pt;position:absolute;text-decoration:none;white-space:pre;width:28.1pt">option</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:163.67000000000002pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.11pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:166.78pt;position:absolute;text-decoration:none;white-space:pre;width:45.78pt">agreement</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:212.56pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.06pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:215.62pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">underlying</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:263.26pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.11pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:266.37pt;position:absolute;text-decoration:none;white-space:pre;width:20.16pt">such</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:286.53pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.11pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:289.64pt;position:absolute;text-decoration:none;white-space:pre;width:22pt">2022</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:311.64pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:3.01pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:314.65pt;position:absolute;text-decoration:none;white-space:pre;width:33.29pt">Option.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:347.94pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:3.01pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:350.95pt;position:absolute;text-decoration:none;white-space:pre;width:21.98pt">With</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:372.93pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.11pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:376.04pt;position:absolute;text-decoration:none;white-space:pre;width:31.13pt">respect</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:407.17pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.06pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:410.23pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:418.78pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.21pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:421.99pt;position:absolute;text-decoration:none;white-space:pre;width:55.58pt">Consultant&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:477.57pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.16pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:480.73pt;position:absolute;text-decoration:none;white-space:pre;width:51.31pt">outstanding</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:532.04pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:3.01pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:535.05pt;position:absolute;text-decoration:none;white-space:pre;width:23.21pt">stock</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.26pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.56pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:396.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:32.38pt">options</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:86.38pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.46pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:89.84pt;position:absolute;text-decoration:none;white-space:pre;width:16.48pt">that</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:106.32pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.56pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:109.88pt;position:absolute;text-decoration:none;white-space:pre;width:448.31pt">are vested as of his last day of employment and with respect to the 2022 Option, to the extent that</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.19pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:410.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.27pt">additional shares become vested thereunder pursuant to the immediately preceding sentence, Consultant agrees</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.27pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:423.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.3pt">that the period for which Consultant may exercise each such vested stock options shall either be (i) the period</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.3pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:436.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.35pt">provided in the Separation Agreement and Release entered into by and between Consultant and the Company,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.35pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:449.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:191.55pt">dated on or about the date hereof, provided</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:245.55pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.98pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:248.53pt;position:absolute;text-decoration:none;white-space:pre;width:39.71pt">that such</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:288.24pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.98pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:291.22pt;position:absolute;text-decoration:none;white-space:pre;width:67.8pt">agreement is in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:359.02pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.93pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:361.95pt;position:absolute;text-decoration:none;white-space:pre;width:28.06pt">effect&#59;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:390.01pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.03pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:393.04pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:402.2pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.98pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:405.18pt;position:absolute;text-decoration:none;white-space:pre;width:13.42pt">(ii)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:418.6pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.98pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:421.58pt;position:absolute;text-decoration:none;white-space:pre;width:72.68pt">the earlier of (x)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:494.26pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.98pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:497.24pt;position:absolute;text-decoration:none;white-space:pre;width:61.07pt">the expiration</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.31pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:462.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:30.76pt">date of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:84.76pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.2pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:87.96000000000001pt;position:absolute;text-decoration:none;white-space:pre;width:66.74pt">the option, and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:154.7pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.25pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:157.95pt;position:absolute;text-decoration:none;white-space:pre;width:12.82pt">(y)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:170.76999999999998pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.15pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:173.92000000000002pt;position:absolute;text-decoration:none;white-space:pre;width:42.34pt">(aa) three</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:216.26pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.15pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:219.41pt;position:absolute;text-decoration:none;white-space:pre;width:32.38pt">months</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:251.79pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.25pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:255.04pt;position:absolute;text-decoration:none;white-space:pre;width:79pt">after Consultant&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:334.04pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.25pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:337.29pt;position:absolute;text-decoration:none;white-space:pre;width:34.43pt">last day</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:371.72pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.25pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:374.97pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">as</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:384.13pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.25pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:387.38pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">an</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:397.76pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.25pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:401.01pt;position:absolute;text-decoration:none;white-space:pre;width:42.74pt">employee</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:443.75pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.25pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:447pt;position:absolute;text-decoration:none;white-space:pre;width:62.76pt">of Geron with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:509.76pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.1pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:512.86pt;position:absolute;text-decoration:none;white-space:pre;width:45.4pt">respect all</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.26pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:476.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:28.09pt">vested</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:82.09pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.93pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:86.02000000000001pt;position:absolute;text-decoration:none;white-space:pre;width:32.38pt">options</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:118.4pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.93pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:122.33pt;position:absolute;text-decoration:none;white-space:pre;width:435.99pt">other than the 2022 Option, and (bb) three months after the termination of this Agreement with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.3199999999999pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:489.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:86.11pt">respect to the 2022 </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:140.11pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:30pt">Option</font><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:7.15pt;font-style:normal;font-weight:normal;left:170.11pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;top:-2.667pt;vertical-align:super;white-space:pre;width:5.23pt"><a style="color:inherit;text-decoration:inherit;z-index:1" href="#id9a0094da72a45e5ab881a00f9c0d9e7_1">1.</a></font></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt"><div style="position:absolute;top:728.64pt"><div style="width:522pt"></div></div><div style="position:absolute"><div style="width:522pt"></div></div><div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:77.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:9.77pt">d)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:78.13pt">Documentation. </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:204.13pt;position:absolute;text-decoration:none;white-space:pre;width:354.08pt">Consultant will submit to Geron invoices for Consultant&#8217;s fees and expenses in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.21pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:91.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:57.85pt">the form of </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:111.85pt;position:absolute;text-decoration:none;white-space:pre;width:52.01pt">Exhibit A </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:163.86pt;position:absolute;text-decoration:none;white-space:pre;width:394.29pt">within fifteen (15) days after the end of the month in which the invoiced expense is</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.15pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:104.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.27pt">incurred. Geron issues purchase orders, accepts invoices and makes payments through Geron&#8217;s Coupa vendor</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.27pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:117.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:28.39pt">portal.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:82.39pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.03pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:87.42pt;position:absolute;text-decoration:none;white-space:pre;width:53.68pt">To facilitate</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:141.1pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.7pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:143.8pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:157.23000000000002pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.85pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:160.07999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:49.49pt">submission</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:209.57pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.7pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:212.27pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:221.43pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.6pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:224.03pt;position:absolute;text-decoration:none;white-space:pre;width:36.64pt">invoices</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:260.66999999999996pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.7pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:263.37pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:279.25pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.7pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:281.95pt;position:absolute;text-decoration:none;white-space:pre;width:29.9pt">receipt</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:311.85pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:314.6pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:323.76pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:326.51pt;position:absolute;text-decoration:none;white-space:pre;width:44.89pt">payments,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:371.4pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:374.15pt;position:absolute;text-decoration:none;white-space:pre;width:10.98pt">all</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:385.13pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.85pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:387.98pt;position:absolute;text-decoration:none;white-space:pre;width:34.82pt">vendors</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:422.8pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.85pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:425.65pt;position:absolute;text-decoration:none;white-space:pre;width:13.42pt">are</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:439.07pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.7pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:441.77pt;position:absolute;text-decoration:none;white-space:pre;width:50.68pt">encouraged</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:492.45pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.8pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:495.25pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:503.8pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.8pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:506.6pt;position:absolute;text-decoration:none;white-space:pre;width:38.47pt">establish</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:545.0699999999999pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:547.8199999999999pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">an</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.2pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.56pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:130.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:34.19pt">account</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:88.19pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.83pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:91.02000000000001pt;position:absolute;text-decoration:none;white-space:pre;width:467.18pt">on Geron&#8217;s Coupa vendor portal. Once established as a vendor in Geron&#8217;s systems, a link will be sent via</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.2pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:143.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:70.61pt">email to enable</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:124.61pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:4.14pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:128.75pt;position:absolute;text-decoration:none;white-space:pre;width:34.82pt">vendors</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:163.57pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:4.14pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:167.70999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:176.26pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:4.14pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:180.4pt;position:absolute;text-decoration:none;white-space:pre;width:38.47pt">establish</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:218.87pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:4.04pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:222.91pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">an</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:233.29pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:4.14pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:237.43pt;position:absolute;text-decoration:none;white-space:pre;width:34.19pt">account</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:271.62pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:4.19pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:275.81pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">on</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:286.81pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:4.14pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:290.95pt;position:absolute;text-decoration:none;white-space:pre;width:36.65pt">Coupa&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:327.6pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:4.14pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:331.74pt;position:absolute;text-decoration:none;white-space:pre;width:30.54pt">vendor</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:362.28pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:4.19pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:366.47pt;position:absolute;text-decoration:none;white-space:pre;width:28.39pt">portal.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:394.86pt;letter-spacing:0.177em;position:absolute;text-decoration:none;white-space:pre;width:6.42pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:401.28pt;position:absolute;text-decoration:none;white-space:pre;width:43.98pt">Questions</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:445.26pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:4.14pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:449.4pt;position:absolute;text-decoration:none;white-space:pre;width:24.43pt">about</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:473.83pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:4.09pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:477.92pt;position:absolute;text-decoration:none;white-space:pre;width:28.08pt">access</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:506pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:4.04pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:510.04pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:518.5899999999999pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:4.14pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:522.73pt;position:absolute;text-decoration:none;white-space:pre;width:35.42pt">Geron&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.15pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.41pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:157.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:28.71pt">Coupa</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:82.71000000000001pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.51pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:85.22pt;position:absolute;text-decoration:none;white-space:pre;width:59.03pt">vendor portal</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:144.25pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.21pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:146.45999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:15.26pt">can</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:161.72pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.26pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:163.98000000000002pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">be</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:174.36pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.26pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:176.62pt;position:absolute;text-decoration:none;white-space:pre;width:17.71pt">sent</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:194.33pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.21pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:196.54pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:205.09pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.26pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:207.35pt;position:absolute;text-decoration:none;white-space:pre;width:109.67pt">CoupaHelp&#64;geron.com.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:317.02pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.26pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:319.28pt;position:absolute;text-decoration:none;white-space:pre;width:12.22pt">As</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:331.5pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.16pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:333.66pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">an</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:344.04pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.26pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:346.3pt;position:absolute;text-decoration:none;white-space:pre;width:46.38pt">alternative</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:392.68pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.26pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:394.94pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:403.49pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.26pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:405.75pt;position:absolute;text-decoration:none;white-space:pre;width:52.52pt">establishing</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:458.27pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.26pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:460.53pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">an</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:470.91pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.16pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:473.07pt;position:absolute;text-decoration:none;white-space:pre;width:34.19pt">account</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:507.26pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.3pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:509.56pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">on</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:520.56pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.26pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:522.8199999999999pt;position:absolute;text-decoration:none;white-space:pre;width:35.42pt">Geron&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.24pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.2pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:170.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:28.71pt">Coupa</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:82.71000000000001pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:3.55pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:86.25999999999999pt;position:absolute;text-decoration:none;white-space:pre;width:63.07pt">vendor portal,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:149.32999999999998pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:3.55pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:152.88pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:200.52pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:204.11pt;position:absolute;text-decoration:none;white-space:pre;width:18.93pt">may</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:223.04pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:3.55pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:226.59pt;position:absolute;text-decoration:none;white-space:pre;width:29.93pt">submit</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:256.52pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:260.11pt;position:absolute;text-decoration:none;white-space:pre;width:36.64pt">invoices</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:296.75pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:300.34000000000003pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">as</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:309.5pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:313.09pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">an</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:323.47pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:3.55pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:327.02pt;position:absolute;text-decoration:none;white-space:pre;width:48.22pt">attachment</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:375.24pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:378.83pt;position:absolute;text-decoration:none;white-space:pre;width:11.6pt">to&#58;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:390.43pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:394.02pt;position:absolute;text-decoration:none;white-space:pre;width:143.57pt">invoices&#64;geron.coupahost.com.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:537.5899999999999pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:3.55pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:541.14pt;position:absolute;text-decoration:none;white-space:pre;width:17.09pt">The</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.23pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.16pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:183.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:42.75pt">foregoing</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:96.75pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.2pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:98.95pt;position:absolute;text-decoration:none;white-space:pre;width:7.33pt">is</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:106.28pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.1pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:108.38pt;position:absolute;text-decoration:none;white-space:pre;width:4.88pt">a</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:113.25999999999999pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.24pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:115.5pt;position:absolute;text-decoration:none;white-space:pre;width:37.25pt">no-reply</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:152.75pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.2pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:154.95pt;position:absolute;text-decoration:none;white-space:pre;width:24.41pt">email</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:179.36pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.24pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:181.6pt;position:absolute;text-decoration:none;white-space:pre;width:32.98pt">address</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:214.58pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.24pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:216.82pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:232.7pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.2pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:234.9pt;position:absolute;text-decoration:none;white-space:pre;width:39.08pt">purchase</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:273.98pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.24pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:276.22pt;position:absolute;text-decoration:none;white-space:pre;width:23.2pt">order</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:299.41999999999996pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.24pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:301.65999999999997pt;position:absolute;text-decoration:none;white-space:pre;width:51.9pt">information</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:353.56pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.2pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:355.76pt;position:absolute;text-decoration:none;white-space:pre;width:29.33pt">should</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:385.09pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.2pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:387.29pt;position:absolute;text-decoration:none;white-space:pre;width:14.05pt">not</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:401.34pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.24pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:403.58pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">be</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:413.96pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.2pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:416.16pt;position:absolute;text-decoration:none;white-space:pre;width:37.86pt">included</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:454.02pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.2pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:456.22pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:464.77pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.2pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:466.97pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:480.4pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.2pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:482.6pt;position:absolute;text-decoration:none;white-space:pre;width:22pt">body</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:504.6pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.2pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:506.8pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:515.96pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.24pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:518.2pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:531.63pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.2pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:533.8299999999999pt;position:absolute;text-decoration:none;white-space:pre;width:24.41pt">email</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.24pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.2pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:196.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:63.16pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.71pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:66.87pt;position:absolute;text-decoration:none;white-space:pre;width:34.21pt">through</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:101.08pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:3.57pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:104.65pt;position:absolute;text-decoration:none;white-space:pre;width:453.61pt">links. Payment-related questions may be sent to&#58; accountspayable&#64;geron.com. Consultant will also</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.26pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:209.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:405.5pt">submit to Geron a completed IRS Form W-9, Request for Taxpayer Identification Number.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:459.5pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.15pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:464.65pt;position:absolute;text-decoration:none;white-space:pre;width:93.65pt">Geron cannot make</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:558.3pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:223.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:105.81pt">payment of consulting</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:159.81pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.65pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:163.45999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:17.7pt">fees</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:181.16pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.65pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:184.81pt;position:absolute;text-decoration:none;white-space:pre;width:21.98pt">until</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:206.79pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.7pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:210.49pt;position:absolute;text-decoration:none;white-space:pre;width:6.71pt">it</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:217.2pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.65pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:220.85pt;position:absolute;text-decoration:none;white-space:pre;width:15.89pt">has</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:236.74pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.55pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:240.29pt;position:absolute;text-decoration:none;white-space:pre;width:39.06pt">received</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:279.35pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.65pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:283pt;position:absolute;text-decoration:none;white-space:pre;width:14.65pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:297.65pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.65pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:301.3pt;position:absolute;text-decoration:none;white-space:pre;width:48.23pt">completed</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:349.53pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.65pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:353.18pt;position:absolute;text-decoration:none;white-space:pre;width:22.91pt">W-9.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:376.09pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:381.82pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:429.46pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.7pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:433.16pt;position:absolute;text-decoration:none;white-space:pre;width:17.09pt">will</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:450.25pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.7pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:453.95pt;position:absolute;text-decoration:none;white-space:pre;width:17.71pt">also</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:471.66pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.55pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:475.21pt;position:absolute;text-decoration:none;white-space:pre;width:29.93pt">submit</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:505.14pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.7pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:508.84pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:524.72pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.65pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:528.37pt;position:absolute;text-decoration:none;white-space:pre;width:29.91pt">further</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.28pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.66pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:236.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:208.37pt">documentation reasonably requested by Geron.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:262.37pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:267.37pt;position:absolute;text-decoration:none;white-space:pre;width:290.78pt">Geron will pay the fees and expenses within thirty (30) days after</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.15pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:249.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:410.06pt">receipt of the invoice and any such further documentation which may be requested by Geron.</font></div><div style="line-height:6.58pt;position:absolute;top:262.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:9.5pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:underline;white-space:pre">________________________</font></div><div style="line-height:6.93pt;position:absolute;top:274.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:6.5pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;top:-2.425pt;vertical-align:super;white-space:pre">1</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:57.25pt;letter-spacing:-0.01em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:59.65pt;position:absolute;white-space:pre">For</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:73.53999999999999pt;letter-spacing:-0.01em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:75.94pt;position:absolute;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:88.14pt;letter-spacing:-0.01em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:90.53999999999999pt;position:absolute;white-space:pre">avoidance</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:131.03pt;letter-spacing:-0.02em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:133.32999999999998pt;position:absolute;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:141.66pt;letter-spacing:-0.01em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:144.06pt;position:absolute;white-space:pre">doubt, so</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:180.72pt;letter-spacing:-0.005em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:183.17pt;position:absolute;white-space:pre">long</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:200.94pt;letter-spacing:-0.015em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:203.29pt;position:absolute;white-space:pre">as</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:211.61pt;letter-spacing:-0.015em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:213.96pt;position:absolute;white-space:pre">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:257.25pt;letter-spacing:-0.015em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:259.6pt;position:absolute;white-space:pre">signs</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:280.15pt;letter-spacing:-0.015em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:282.5pt;position:absolute;white-space:pre">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:296.93pt;letter-spacing:-0.015em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:299.28pt;position:absolute;white-space:pre">does</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:317.6pt;letter-spacing:-0.015em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:319.95pt;position:absolute;white-space:pre">not</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:332.72pt;letter-spacing:-0.015em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:335.07pt;position:absolute;white-space:pre">revoke</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:362.26pt;letter-spacing:-0.02em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:364.56pt;position:absolute;white-space:pre">the Separation</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:421.98pt;letter-spacing:-0.005em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:424.43pt;position:absolute;white-space:pre">Agreement</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:468.81pt;letter-spacing:-0.015em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:471.16pt;position:absolute;white-space:pre">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:485.59pt;letter-spacing:-0.005em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:488.04pt;position:absolute;white-space:pre">Release,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:521.5799999999999pt;letter-spacing:-0.005em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:524.03pt;position:absolute;white-space:pre">he</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:533.46pt;letter-spacing:-0.02em;position:absolute;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:535.76pt;position:absolute;white-space:pre">will have </font></div><div style="line-height:6.93pt;position:absolute;top:286.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;white-space:pre">the period set forth in Section 4.1(ii)(d) of his prior employment agreement to exercise all of his vested stock options.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:315.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:8.54pt">e)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:99.43pt">Fair Market Value. </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:225.43pt;position:absolute;text-decoration:none;white-space:pre;width:332.83pt">Geron and Consultant acknowledge and agree that the compensation set</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.26pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:328.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:54.53pt">forth herein</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:108.53pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:5.35pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:113.88pt;position:absolute;text-decoration:none;white-space:pre;width:20.76pt">fully</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:134.64pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:5.35pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:139.99pt;position:absolute;text-decoration:none;white-space:pre;width:39.69pt">complies</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:179.68pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:5.4pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:185.08pt;position:absolute;text-decoration:none;white-space:pre;width:19.54pt">with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:204.62pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:5.2pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:209.82pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:223.25pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:5.35pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:228.6pt;position:absolute;text-decoration:none;white-space:pre;width:45.82pt">provisions</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:274.41999999999996pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:5.4pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:279.82pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:288.98pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:5.4pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:294.38pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">42</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:305.38pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:5.35pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:310.73pt;position:absolute;text-decoration:none;white-space:pre;width:29.63pt">U.S.C.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:340.36pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:5.35pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:345.71pt;position:absolute;text-decoration:none;white-space:pre;width:41.54pt">1320a-7b</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:387.25pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:5.35pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:392.6pt;position:absolute;text-decoration:none;white-space:pre;width:17.09pt">(the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:409.69pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:5.35pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:415.04pt;position:absolute;text-decoration:none;white-space:pre;width:4.88pt">&#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:419.92pt;position:absolute;text-decoration:none;white-space:pre;width:69.61pt">Anti-Kickback</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:489.53pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:5.35pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:494.88pt;position:absolute;text-decoration:none;white-space:pre;width:33.58pt">Statute</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:528.46pt;position:absolute;text-decoration:none;white-space:pre;width:8.54pt">&#8221;)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:537pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:5.4pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:542.4pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.28pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.31pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:341.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:44.57pt">represents</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:98.57pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:4.12pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:102.69pt;position:absolute;text-decoration:none;white-space:pre;width:33.14pt">the fair</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:135.82999999999998pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:4.07pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:139.9pt;position:absolute;text-decoration:none;white-space:pre;width:30.52pt">market</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:170.42000000000002pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:4.12pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:174.54000000000002pt;position:absolute;text-decoration:none;white-space:pre;width:23.81pt">value</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:198.35pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:4.07pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:202.42pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:211.58pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:3.97pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:215.55pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:228.98pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:4.07pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:233.05pt;position:absolute;text-decoration:none;white-space:pre;width:35.41pt">services</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:268.46000000000004pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:3.97pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:272.43pt;position:absolute;text-decoration:none;white-space:pre;width:39.09pt">provided</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:311.52pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:4.02pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:315.54pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:324.09pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:4.02pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:328.11pt;position:absolute;text-decoration:none;white-space:pre;width:27.48pt">Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:355.59pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:4.02pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:359.61pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:370.61pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:4.02pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:374.63pt;position:absolute;text-decoration:none;white-space:pre;width:50.39pt">Consultant,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:425.02pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:4.02pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:429.04pt;position:absolute;text-decoration:none;white-space:pre;width:45.79pt">negotiated</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:474.83pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.91pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:478.74pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:487.29pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:4.02pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:491.31pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">an</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:501.69pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:4.07pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:505.76pt;position:absolute;text-decoration:none;white-space:pre;width:52.51pt">arms-length</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.27pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.31pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:354.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:50.98pt">transaction,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:104.97999999999999pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.89pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:107.87pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:123.75pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:126.53pt;position:absolute;text-decoration:none;white-space:pre;width:32.04pt">has not</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:158.57pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.29pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:161.86pt;position:absolute;text-decoration:none;white-space:pre;width:20.76pt">been</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:182.62pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.24pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:185.86pt;position:absolute;text-decoration:none;white-space:pre;width:49.45pt">determined</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:235.31pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.14pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:238.45pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:247pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.24pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:250.24pt;position:absolute;text-decoration:none;white-space:pre;width:4.88pt">a</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:255.12pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.14pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:258.26pt;position:absolute;text-decoration:none;white-space:pre;width:32.97pt">manner</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:291.23pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.14pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:294.37pt;position:absolute;text-decoration:none;white-space:pre;width:16.48pt">that</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:310.85pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.29pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:314.14pt;position:absolute;text-decoration:none;white-space:pre;width:22.59pt">takes</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:336.73pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.14pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:339.87pt;position:absolute;text-decoration:none;white-space:pre;width:17.1pt">into</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:356.97pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.24pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:360.21pt;position:absolute;text-decoration:none;white-space:pre;width:34.19pt">account</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:394.4pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.29pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:397.69pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:411.12pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.24pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:414.36pt;position:absolute;text-decoration:none;white-space:pre;width:32.98pt">volume</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:447.34pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.24pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:450.58pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:459.74pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.29pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:463.03pt;position:absolute;text-decoration:none;white-space:pre;width:23.81pt">value</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:486.84pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.24pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:490.08pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:499.24pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.29pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:502.53pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:518.4100000000001pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.24pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:521.65pt;position:absolute;text-decoration:none;white-space:pre;width:36.61pt">referrals</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.26pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.66pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:368.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:63.16pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.07pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:66.23pt;position:absolute;text-decoration:none;white-space:pre;width:37.27pt">business</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:103.5pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.07pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:106.57pt;position:absolute;text-decoration:none;white-space:pre;width:231.65pt">otherwise generated between Geron and Consultant.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:338.22pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.15pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:343.37pt;position:absolute;text-decoration:none;white-space:pre;width:214.87pt">Nothing contained in this Agreement constitutes</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.24pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:381.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.27pt">or shall be construed in any manner as an obligation or inducement for Consultant to recommend the prescribing,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.27pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:394.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:387.49pt">purchase, use, or preferential formulary status or dispensing of any of Geron&#8217;s products.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:421.06pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:7.32pt">f)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:123.9pt">Transparency Disclosure.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:249.9pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:8.33pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:258.23pt;position:absolute;text-decoration:none;white-space:pre;width:299.96pt">Consultant acknowledges that, under the provisions of Section</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.19pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:434.26pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.2pt">1128G of the Social Security Act, 42 U.S.C. 1320a-7h, as well as other applicable laws and regulations, Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.2pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:447.46pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.12pt">may be required to disclose certain payments and other transfers of value provided by Geron to health care</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.12pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:460.66pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:76.87pt">professionals and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:130.87pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:133.65pt;position:absolute;text-decoration:none;white-space:pre;width:51.61pt">institutions,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:185.26pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:187.94pt;position:absolute;text-decoration:none;white-space:pre;width:41.53pt">including</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:229.47pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:232.2pt;position:absolute;text-decoration:none;white-space:pre;width:42.14pt">payments</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:274.34000000000003pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:277.02pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:292.9pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:295.68pt;position:absolute;text-decoration:none;white-space:pre;width:70.22pt">reimbursements</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:365.9pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:368.68pt;position:absolute;text-decoration:none;white-space:pre;width:23.81pt">made</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:392.49pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:395.27pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:404.43pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:407.21pt;position:absolute;text-decoration:none;white-space:pre;width:39.09pt">provided</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:446.3pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:449.08pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:460.08pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:462.81pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:471.97pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:474.75pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">on</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:485.75pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:488.48pt;position:absolute;text-decoration:none;white-space:pre;width:27.47pt">behalf</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:515.95pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:518.73pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:527.89pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:530.6700000000001pt;position:absolute;text-decoration:none;white-space:pre;width:27.48pt">Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.15pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.41pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:473.86pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:62.55pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.42pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:65.97pt;position:absolute;text-decoration:none;white-space:pre;width:71.44pt">connection with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:137.41pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:3.32pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:140.73000000000002pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:154.16pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.47pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:157.63pt;position:absolute;text-decoration:none;white-space:pre;width:39.99pt">Services.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:197.62pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.65pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:203.27pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:250.91pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.47pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:254.38pt;position:absolute;text-decoration:none;white-space:pre;width:62.29pt">acknowledges</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:316.67pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.37pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:320.04pt;position:absolute;text-decoration:none;white-space:pre;width:19.23pt">that,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:339.27pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:3.32pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:342.59pt;position:absolute;text-decoration:none;white-space:pre;width:70.85pt">notwithstanding</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:413.44pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.42pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:416.86pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:432.74pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.42pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:436.16pt;position:absolute;text-decoration:none;white-space:pre;width:41.54pt">provision</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:477.7pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:3.32pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:481.02pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:489.57pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:3.32pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:492.89pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:506.32pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:3.32pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:509.64pt;position:absolute;text-decoration:none;white-space:pre;width:36.63pt">contrary</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:546.27pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:3.32pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:549.5899999999999pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.14pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.41pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:487.06pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">this</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:69.88pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.7pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:72.58pt;position:absolute;text-decoration:none;white-space:pre;width:106.38pt">Agreement, information</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:178.95999999999998pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.3pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:181.26pt;position:absolute;text-decoration:none;white-space:pre;width:24.43pt">about</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:205.69pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.45pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:208.14pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:221.57pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.45pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:224.02pt;position:absolute;text-decoration:none;white-space:pre;width:42.14pt">payments</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:266.15999999999997pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.34pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:268.5pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:284.38pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.45pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:286.83000000000004pt;position:absolute;text-decoration:none;white-space:pre;width:70.22pt">reimbursements</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:357.05pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.34pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:359.39pt;position:absolute;text-decoration:none;white-space:pre;width:39.09pt">provided</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:398.48pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.3pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:400.78pt;position:absolute;text-decoration:none;white-space:pre;width:43.96pt">hereunder</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:444.74pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.34pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:447.08pt;position:absolute;text-decoration:none;white-space:pre;width:18.93pt">may</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:466.01pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.45pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:468.46pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">be</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:478.84pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.45pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:481.29pt;position:absolute;text-decoration:none;white-space:pre;width:40.92pt">disclosed</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:522.21pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.4pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:524.61pt;position:absolute;text-decoration:none;white-space:pre;width:33.59pt">without</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.2pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.31pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:500.26pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:26.86pt">notice</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:80.86pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.97pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:84.83pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:95.83pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:3.92pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:99.75pt;position:absolute;text-decoration:none;white-space:pre;width:458.42pt">Geron and may be made publicly available by the recipient federal or state agency, consistent with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.1700000000001pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:513.46pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.2pt">applicable law. Consultant will provide Geron or Geron&#8217;s designee with any information necessary for Geron to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.2pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:526.66pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:74.2pt">comply with the </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:128.2pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:44.6pt">foregoing.</font></div><div style="line-height:7.44pt;position:absolute;top:553.06pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:54pt;position:absolute;text-decoration:underline;white-space:pre">3.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:62.25pt;letter-spacing:0.227em;position:absolute;text-decoration:underline;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:67.49pt;position:absolute;text-decoration:underline;white-space:pre">Developments</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:133.44pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:underline;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:136.05pt;position:absolute;text-decoration:underline;white-space:pre">Arising</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:170.86pt;letter-spacing:-0.022em;position:absolute;text-decoration:underline;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:173.37pt;position:absolute;text-decoration:underline;white-space:pre">from</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:196.57pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:underline;white-space:pre"> Services.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:579.51pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">a)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:4.88pt">&#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:130.88pt;position:absolute;text-decoration:none;white-space:pre;width:65.95pt">Developments</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:196.82999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:361.22pt">&#8221; include, without limitation, ideas, concepts, discoveries, inventions,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.05pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:592.71pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:117.24pt">developments, know-how,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:171.24pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:3.29pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:174.53pt;position:absolute;text-decoration:none;white-space:pre;width:26.86pt">patent</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:201.39pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:3.24pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:204.63pt;position:absolute;text-decoration:none;white-space:pre;width:27.79pt">rights,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:232.42pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.19pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:235.61pt;position:absolute;text-decoration:none;white-space:pre;width:21.97pt">trade</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:257.58000000000004pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:3.29pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:260.87pt;position:absolute;text-decoration:none;white-space:pre;width:32.66pt">secrets,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:293.53pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.19pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:296.72pt;position:absolute;text-decoration:none;white-space:pre;width:49.77pt">techniques,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:346.49pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:3.29pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:349.78pt;position:absolute;text-decoration:none;white-space:pre;width:38.78pt">writings,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:388.56pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.34pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:391.9pt;position:absolute;text-decoration:none;white-space:pre;width:21.06pt">data,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:412.96pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.19pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:416.15pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:432.03pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.19pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:435.22pt;position:absolute;text-decoration:none;white-space:pre;width:22.59pt">other</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:457.81pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:3.24pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:461.05pt;position:absolute;text-decoration:none;white-space:pre;width:25.04pt">rights</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:486.09pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.19pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:489.28pt;position:absolute;text-decoration:none;white-space:pre;width:39.07pt">(whether</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:528.35pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:3.24pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:531.5899999999999pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:540.75pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.19pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:543.94pt;position:absolute;text-decoration:none;white-space:pre;width:14.05pt">not</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:557.99pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.36pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:605.91pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:47pt">protectible</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:101pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.67pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:103.67pt;position:absolute;text-decoration:none;white-space:pre;width:454.33pt">under applicable patent, trademark, copyright, trade secret, or other intellectual property laws) that are</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:619.11pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:98.42pt">conceived, developed,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:152.42000000000002pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.97pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:155.39pt;position:absolute;text-decoration:none;white-space:pre;width:26.56pt">made,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:181.95pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.07pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:185.02pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:194.18pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.07pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:197.25pt;position:absolute;text-decoration:none;white-space:pre;width:34.8pt">reduced</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:232.05pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.07pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:235.12pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:243.67pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.07pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:246.74pt;position:absolute;text-decoration:none;white-space:pre;width:34.78pt">practice</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:281.52pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.07pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:284.59000000000003pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:295.59000000000003pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.07pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:298.65999999999997pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:346.3pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.97pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:349.27pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:357.82pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.07pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:360.89pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:374.32pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.07pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:377.39pt;position:absolute;text-decoration:none;white-space:pre;width:28.7pt">course</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:406.09pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.07pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:409.16pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:418.32pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.97pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:421.29pt;position:absolute;text-decoration:none;white-space:pre;width:49.46pt">performing</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:470.75pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.92pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:473.67pt;position:absolute;text-decoration:none;white-space:pre;width:37.24pt">Services</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:510.91pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.07pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:513.98pt;position:absolute;text-decoration:none;white-space:pre;width:25.04pt">under</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:539.02pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.07pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:542.0899999999999pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">this</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:557.97pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.66pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:632.31pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:51.59pt">Agreement.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:658.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:9.77pt">b)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:134.09pt">Disclosure of Developments.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:260.09000000000003pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:265.77pt;position:absolute;text-decoration:none;white-space:pre;width:206.55pt">Consultant will deliver all projects or tasks (&#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:472.32pt;position:absolute;text-decoration:none;white-space:pre;width:58pt">Deliverables</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:530.3199999999999pt;position:absolute;text-decoration:none;white-space:pre;width:28.11pt">&#8221;) and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.4300000000001pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:671.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:247.64pt">promptly and fully disclose all Developments, to Geron.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:697.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:8.54pt">c)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:203.57pt">Background and Third-Party Technology.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:329.57pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:6.43pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:336pt;position:absolute;text-decoration:none;white-space:pre;width:222.19pt">Inventions, know-how patent rights trade secrets</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.19pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:710.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:43.39pt">and other</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:97.39pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:4.28pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:101.67pt;position:absolute;text-decoration:none;white-space:pre;width:48.82pt">intellectual</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:150.49pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:4.33pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:154.82pt;position:absolute;text-decoration:none;white-space:pre;width:37.25pt">property</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:192.07pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:4.23pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:196.3pt;position:absolute;text-decoration:none;white-space:pre;width:25.04pt">rights</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:221.34pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:4.33pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:225.67pt;position:absolute;text-decoration:none;white-space:pre;width:57.68pt">(collectively,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:283.35pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:4.28pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:287.63pt;position:absolute;text-decoration:none;white-space:pre;width:4.88pt">&#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:292.51pt;position:absolute;text-decoration:none;white-space:pre;width:53.11pt">Intellectual</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:345.62pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:4.33pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:349.95pt;position:absolute;text-decoration:none;white-space:pre;width:42.12pt">Property</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:392.07pt;position:absolute;text-decoration:none;white-space:pre;width:8.54pt">&#8221;)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:400.61pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:4.33pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:404.94pt;position:absolute;text-decoration:none;white-space:pre;width:47.94pt">developed,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:452.88pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:4.23pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:457.11pt;position:absolute;text-decoration:none;white-space:pre;width:40.6pt">acquired,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:497.71pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:4.28pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:501.99pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:511.15pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:4.33pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:515.48pt;position:absolute;text-decoration:none;white-space:pre;width:42.74pt">otherwise</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.22pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.16pt"> </font></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt"><div style="position:absolute;top:728.64pt"><div style="width:522pt"></div></div><div style="position:absolute"><div style="width:522pt"></div></div><div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:66.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:276.66pt">obtained by Consultant prior to this Agreement (collectively, &#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:330.66pt;position:absolute;text-decoration:none;white-space:pre;width:115.26pt">Background Technology</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:445.92pt;position:absolute;text-decoration:none;white-space:pre;width:112.22pt">&#8221;) or licensed or obtained</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.14pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:80.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:211.47pt">by Consultant from third parties (collectively, &#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:265.47pt;position:absolute;text-decoration:none;white-space:pre;width:114.89pt">Third-Party Technology</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:380.36pt;position:absolute;text-decoration:none;white-space:pre;width:177.8pt">&#8221;) may not be used by Consultant in the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.1600000000001pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:93.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.14pt">performance of Services unless (i) specifically identified by Consultant and approved in writing by Geron, or (ii)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.14pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:106.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:443.62pt">Consultant has an unqualified right to use such Intellectual Property for the performance of Services.</font></div><div style="line-height:7.44pt;position:absolute;top:133.01pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:54pt;position:absolute;text-decoration:underline;white-space:pre">4.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:62.25pt;letter-spacing:0.231em;position:absolute;text-decoration:underline;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:67.54pt;position:absolute;text-decoration:underline;white-space:pre">Ownership</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:119.45pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:underline;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:122.00999999999999pt;position:absolute;text-decoration:underline;white-space:pre">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:139.73000000000002pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:underline;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:142.34pt;position:absolute;text-decoration:underline;white-space:pre">Assignment</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:197.31pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:underline;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:199.87pt;position:absolute;text-decoration:underline;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:209.03pt;letter-spacing:-0.004em;position:absolute;text-decoration:underline;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:211.74pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:underline;white-space:pre">Developments.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:158.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">a)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:49.15pt">Generally.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:175.15pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:8.26pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:183.41pt;position:absolute;text-decoration:none;white-space:pre;width:374.9pt">Consultant hereby acknowledges and agrees that Geron shall be the sole and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.31pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:171.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.33pt">exclusive owner of all Developments made in the course of performing Services. Consultant hereby irrevocably</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.3299999999999pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:185.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:75.7pt">assigns to Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:129.7pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.86pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:133.56pt;position:absolute;text-decoration:none;white-space:pre;width:10.98pt">all</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:144.54000000000002pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.91pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:148.45pt;position:absolute;text-decoration:none;white-space:pre;width:23.51pt">right,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:171.95999999999998pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.86pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:175.82pt;position:absolute;text-decoration:none;white-space:pre;width:19.83pt">title,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:195.65pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.76pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:199.41pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:215.29pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.76pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:219.05pt;position:absolute;text-decoration:none;white-space:pre;width:32.35pt">interest</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:251.4pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.76pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:255.16pt;position:absolute;text-decoration:none;white-space:pre;width:47.02pt">worldwide</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:302.18pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.86pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:306.03999999999996pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:314.59pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.86pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:318.45pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:334.33pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.76pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:338.09pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:346.64pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.71pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:350.35pt;position:absolute;text-decoration:none;white-space:pre;width:10.98pt">all</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:361.33pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.91pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:365.24pt;position:absolute;text-decoration:none;white-space:pre;width:63.51pt">Developments</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:428.75pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.86pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:432.61pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:448.49pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.86pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:452.35pt;position:absolute;text-decoration:none;white-space:pre;width:10.98pt">all</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:463.33pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.76pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:467.09pt;position:absolute;text-decoration:none;white-space:pre;width:49.43pt">Intellectual</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:516.52pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.91pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:520.4300000000001pt;position:absolute;text-decoration:none;white-space:pre;width:37.86pt">Property</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.29pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.66pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:198.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:28.71pt">Rights</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:82.71000000000001pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:4.75pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:87.46000000000001pt;position:absolute;text-decoration:none;white-space:pre;width:68.11pt">related thereto.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:155.57pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:6.93pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:162.5pt;position:absolute;text-decoration:none;white-space:pre;width:395.73pt">Consultant understands and agrees that Consultant has no right to use Developments</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.23pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:211.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:211.09pt">except as necessary to perform the Services.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:265.09000000000003pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:7.51pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:272.6pt;position:absolute;text-decoration:none;white-space:pre;width:285.69pt">Consultant hereby covenants that upon request of Geron, its</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.29pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:224.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.3pt">successors, or its legal representatives, whether during or after the term of this Agreement, Consultant will sign</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.3pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:237.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:481.49pt">and have delivered all documents needed to complete conveyance or protect Geron&#8217;s rights in Developments.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:264.46pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:54.97pt">Assignment</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:144.97pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.15pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:148.12pt;position:absolute;text-decoration:none;white-space:pre;width:17.72pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:165.84pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.95pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:168.79000000000002pt;position:absolute;text-decoration:none;white-space:pre;width:34.81pt">Waiver</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:203.6pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:206.6pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:215.76pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.15pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:218.91pt;position:absolute;text-decoration:none;white-space:pre;width:28.08pt">Other</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:246.99pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:3.1pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:250.09pt;position:absolute;text-decoration:none;white-space:pre;width:33.29pt">Rights.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:283.38pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.43pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:288.81pt;position:absolute;text-decoration:none;white-space:pre;width:7.32pt">If</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:296.13pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.15pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:299.28pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:315.15999999999997pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:3.1pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:318.26pt;position:absolute;text-decoration:none;white-space:pre;width:49.43pt">Intellectual</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:367.69pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:3.05pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:370.74pt;position:absolute;text-decoration:none;white-space:pre;width:37.86pt">Property</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:408.6pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:3.1pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:411.7pt;position:absolute;text-decoration:none;white-space:pre;width:31.46pt">Rights,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:443.16pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:446.16pt;position:absolute;text-decoration:none;white-space:pre;width:41.53pt">including</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:487.69pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.95pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:490.64pt;position:absolute;text-decoration:none;white-space:pre;width:25.64pt">moral</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:516.28pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:3.05pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:519.3299999999999pt;position:absolute;text-decoration:none;white-space:pre;width:56.65pt">rights, in the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:575.98pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:277.66pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:508.46pt">Developments cannot (as a matter of law) be assigned by Consultant to Geron as provided in Section 4(a), then&#58;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:562.46pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:3.03pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:565.49pt;position:absolute;text-decoration:none;white-space:pre;width:10.37pt">(i)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:575.86pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.2pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:290.86pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:101.64pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.32pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:103.96000000000001pt;position:absolute;text-decoration:none;white-space:pre;width:69.01pt">unconditionally</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:172.97pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.27pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:175.24pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:191.12pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.32pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:193.44pt;position:absolute;text-decoration:none;white-space:pre;width:50.06pt">irrevocably</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:243.5pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.27pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:245.77pt;position:absolute;text-decoration:none;white-space:pre;width:30.53pt">waives</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:276.3pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.32pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:278.62pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:292.05pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.27pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:294.32pt;position:absolute;text-decoration:none;white-space:pre;width:54.94pt">enforcement</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:349.26pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.37pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:351.63pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:360.79pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.32pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:363.11pt;position:absolute;text-decoration:none;white-space:pre;width:20.16pt">such</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:383.27pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.27pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:385.54pt;position:absolute;text-decoration:none;white-space:pre;width:25.04pt">rights</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:410.58pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.32pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:412.9pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:428.78pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.27pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:431.05pt;position:absolute;text-decoration:none;white-space:pre;width:10.98pt">all</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:442.03pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.37pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:444.4pt;position:absolute;text-decoration:none;white-space:pre;width:28.69pt">claims</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:473.09pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.27pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:475.36pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:491.24pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.32pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:493.56pt;position:absolute;text-decoration:none;white-space:pre;width:40.82pt">causes of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:534.38pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:537.2pt;position:absolute;text-decoration:none;white-space:pre;width:26.86pt">action</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:564.06pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.77pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:566.83pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:575.99pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.61pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:304.06pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:69.88pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.01pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:72.89pt;position:absolute;text-decoration:none;white-space:pre;width:19.55pt">kind</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:92.44pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.96pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:95.4pt;position:absolute;text-decoration:none;white-space:pre;width:31.14pt">against</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:126.54pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.01pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:129.55pt;position:absolute;text-decoration:none;white-space:pre;width:27.48pt">Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:157.03pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.96pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:159.99pt;position:absolute;text-decoration:none;white-space:pre;width:19.54pt">with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:179.53pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.96pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:182.49pt;position:absolute;text-decoration:none;white-space:pre;width:31.13pt">respect</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:213.62pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.01pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:216.63pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:225.18pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.96pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:228.14pt;position:absolute;text-decoration:none;white-space:pre;width:20.16pt">such</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:248.3pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.96pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:251.26pt;position:absolute;text-decoration:none;white-space:pre;width:28.09pt">rights&#59;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:279.35pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.01pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:282.36pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:298.24pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.01pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:301.25pt;position:absolute;text-decoration:none;white-space:pre;width:13.42pt">(ii)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:314.67pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.01pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:317.68pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:326.23pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.96pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:329.19pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:342.62pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.01pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:345.63pt;position:absolute;text-decoration:none;white-space:pre;width:26.86pt">extent</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:372.49pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.01pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:375.5pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:423.14pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.01pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:426.15pt;position:absolute;text-decoration:none;white-space:pre;width:29.31pt">cannot</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:455.46pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.91pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:458.37pt;position:absolute;text-decoration:none;white-space:pre;width:12.82pt">(as</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:471.19pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.01pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:474.2pt;position:absolute;text-decoration:none;white-space:pre;width:4.88pt">a</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:479.08pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.86pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:481.94pt;position:absolute;text-decoration:none;white-space:pre;width:40.38pt">matter of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:522.3199999999999pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.14pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:527.46pt;position:absolute;text-decoration:none;white-space:pre;width:19.53pt">law)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:546.99pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.14pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:552.13pt;position:absolute;text-decoration:none;white-space:pre;width:23.81pt">make</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:575.94pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:4.74pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:317.26pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:20.16pt">such</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:74.16pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.74pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:79.9pt;position:absolute;text-decoration:none;white-space:pre;width:32.66pt">waiver,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:112.56pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.74pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:118.3pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:165.94pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.74pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:171.68pt;position:absolute;text-decoration:none;white-space:pre;width:69.01pt">unconditionally</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:240.69pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.74pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:246.43pt;position:absolute;text-decoration:none;white-space:pre;width:26.87pt">grants</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:273.3pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.74pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:279.03999999999996pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:287.59000000000003pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.74pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:293.33000000000004pt;position:absolute;text-decoration:none;white-space:pre;width:27.48pt">Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:320.81pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.74pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:326.55pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">an</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:336.93pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.74pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:342.67pt;position:absolute;text-decoration:none;white-space:pre;width:44.27pt">exclusive,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:386.94pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.74pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:392.68pt;position:absolute;text-decoration:none;white-space:pre;width:43.65pt">perpetual,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:436.33pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.74pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:442.07pt;position:absolute;text-decoration:none;white-space:pre;width:55.94pt">irrevocable, </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:498.01pt;position:absolute;text-decoration:none;white-space:pre;width:77.94pt">worldwide, fully-</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:330.46pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:521.96pt">paid license, with the right to sublicense through multiple levels of sublicensees, under any and all such rights (a) to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:575.96pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:343.66pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:521.99pt">reproduce, create derivative works of, distribute, publicly perform, publicly display, digitally transmit, and otherwise</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:575.99pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:356.86pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:521.83pt">use the Developments in any medium or format, whether now known or hereafter discovered, (b) to use, make, have</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:575.83pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:370.06pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:373.61pt">made, sell, offer to sell, import, and otherwise exploit any product or service based</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:427.61pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:430.39pt;position:absolute;text-decoration:none;white-space:pre;width:13.75pt">on,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:444.14pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:446.92pt;position:absolute;text-decoration:none;white-space:pre;width:52.23pt">embodying,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:499.15pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:501.93pt;position:absolute;text-decoration:none;white-space:pre;width:61.98pt">incorporating,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:563.9100000000001pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.83pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:566.74pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:575.9pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.2pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:383.26pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:32.97pt">derived</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:86.97pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.06pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:89.03pt;position:absolute;text-decoration:none;white-space:pre;width:21.37pt">from</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:110.4pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.11pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:112.50999999999999pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:125.94pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.16pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:128.1pt;position:absolute;text-decoration:none;white-space:pre;width:66.26pt">Developments,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:194.36pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.06pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:196.42pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:212.3pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.06pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:214.36pt;position:absolute;text-decoration:none;white-space:pre;width:12.2pt">(c)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:226.56pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.11pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:228.67pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:237.22pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.06pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:239.28pt;position:absolute;text-decoration:none;white-space:pre;width:36.01pt">exercise</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:275.28999999999996pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.16pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:277.45pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:293.33000000000004pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.06pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:295.39pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:311.27pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.06pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:313.33pt;position:absolute;text-decoration:none;white-space:pre;width:10.98pt">all</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:324.31pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.2pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:326.51pt;position:absolute;text-decoration:none;white-space:pre;width:22.59pt">other</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:349.1pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.2pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:351.3pt;position:absolute;text-decoration:none;white-space:pre;width:196.94pt">present or future rights in the Developments.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:409.66pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:9.77pt">b)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:21.97pt">Title</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:147.97pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:7.38pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:155.35pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:164.51pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:7.38pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:171.89pt;position:absolute;text-decoration:none;white-space:pre;width:65.95pt">Developments</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:237.84pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt">.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:240.59pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:9.76pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:250.35pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:297.99pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:7.43pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:305.41999999999996pt;position:absolute;text-decoration:none;white-space:pre;width:47.32pt">represents,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:352.74pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:7.43pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:360.16999999999996pt;position:absolute;text-decoration:none;white-space:pre;width:40.6pt">warrants,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:400.77pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:7.43pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:408.2pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:424.08pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:7.28pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:431.36pt;position:absolute;text-decoration:none;white-space:pre;width:43.97pt">covenants</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:475.33pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:7.43pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:482.76pt;position:absolute;text-decoration:none;white-space:pre;width:16.48pt">that</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:499.24pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:7.43pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:506.67pt;position:absolute;text-decoration:none;white-space:pre;width:30.52pt">neither</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:537.19pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:7.43pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:544.62pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.05pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.36pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:422.86pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.09pt">Developments nor any element thereof will be subject to any restriction, mortgage, lien, claim, pledge, security</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.0899999999999pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:436.06pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:287.01pt">interest, or encumbrance when delivered by Consultant to Geron.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:461.86pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:8.54pt">c)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:13.44pt">No</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:139.44pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:3.11pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:142.55pt;position:absolute;text-decoration:none;white-space:pre;width:17.1pt">Use</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:159.65pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.15pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:162.8pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:171.96pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:3.06pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:175.02pt;position:absolute;text-decoration:none;white-space:pre;width:57.39pt">Third-Party</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:232.41pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:3.11pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:235.51999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:42.11pt">Facilities</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:277.63pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.15pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:280.78pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:291.15999999999997pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:3.11pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:294.27pt;position:absolute;text-decoration:none;white-space:pre;width:50.38pt">Resources.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:344.65pt;letter-spacing:0.145em;position:absolute;text-decoration:none;white-space:pre;width:5.29pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:349.94pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:397.58pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:3.06pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:400.64pt;position:absolute;text-decoration:none;white-space:pre;width:20.76pt">shall</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:421.4pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:3.06pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:424.46pt;position:absolute;text-decoration:none;white-space:pre;width:14.05pt">not</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:438.51pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:3.06pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:441.57pt;position:absolute;text-decoration:none;white-space:pre;width:23.81pt">make</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:465.38pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.15pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:468.53pt;position:absolute;text-decoration:none;white-space:pre;width:14.66pt">use</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:483.19pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.15pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:486.34pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:495.5pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:3.01pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:498.51pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:514.39pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:3.11pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:517.5pt;position:absolute;text-decoration:none;white-space:pre;width:40.58pt">facilities,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.0799999999999pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.06pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:475.06pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:423.49pt">funds, personnel, or other resources of any third party in the performance of Services hereunder.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:501.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:9.77pt">d)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:58.63pt">Cooperation</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:184.63pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:3.65pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:188.28pt;position:absolute;text-decoration:none;white-space:pre;width:17.72pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:206pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:3.65pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:209.65pt;position:absolute;text-decoration:none;white-space:pre;width:51.61pt">Assistance.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:261.26pt;letter-spacing:0.17200000000000001em;position:absolute;text-decoration:none;white-space:pre;width:6.03pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:267.28999999999996pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:314.93pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:3.75pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:318.68pt;position:absolute;text-decoration:none;white-space:pre;width:19.84pt">will,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:338.52pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:3.65pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:342.16999999999996pt;position:absolute;text-decoration:none;white-space:pre;width:7.93pt">at</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:350.1pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.7pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:353.8pt;position:absolute;text-decoration:none;white-space:pre;width:35.42pt">Geron&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:389.22pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.7pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:392.92pt;position:absolute;text-decoration:none;white-space:pre;width:34.8pt">request&#58;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:427.72pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.7pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:431.42pt;position:absolute;text-decoration:none;white-space:pre;width:10.37pt">(i)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:441.79pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:445.38pt;position:absolute;text-decoration:none;white-space:pre;width:42.73pt">cooperate</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:488.11pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.7pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:491.81pt;position:absolute;text-decoration:none;white-space:pre;width:19.54pt">with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:511.35pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:3.65pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:515pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:530.88pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:3.55pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:534.4300000000001pt;position:absolute;text-decoration:none;white-space:pre;width:23.82pt">assist</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.25pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.31pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:514.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.3pt">Geron, both during and after the term of this Agreement, in perfecting, maintaining, protecting, and enforcing</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.3pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:527.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:64.27pt">Geron&#8217;s rights</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:118.27pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.77pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:122.04pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:130.59pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.72pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:134.31pt;position:absolute;text-decoration:none;white-space:pre;width:103.49pt">the Developments&#59; and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:237.8pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.77pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:241.57pt;position:absolute;text-decoration:none;white-space:pre;width:50.8pt">(ii) execute</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:292.37pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.77pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:296.14pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:312.02pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.72pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:315.74pt;position:absolute;text-decoration:none;white-space:pre;width:74.17pt">deliver to Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:389.91pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.77pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:393.68pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:409.56pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.77pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:413.33pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">documents</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:460.97pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.67pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:464.64pt;position:absolute;text-decoration:none;white-space:pre;width:34.19pt">deemed</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:498.83pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.77pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:502.6pt;position:absolute;text-decoration:none;white-space:pre;width:42.74pt">necessary</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:545.3399999999999pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.72pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:549.06pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.22pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.71pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:541.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:64.23pt">appropriate by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:118.23pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.13pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:121.36pt;position:absolute;text-decoration:none;white-space:pre;width:27.48pt">Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:148.84pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.98pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:151.82pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:160.37pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.98pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:163.35pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">its</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:173.73000000000002pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.13pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:176.86pt;position:absolute;text-decoration:none;white-space:pre;width:43.35pt">discretion</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:220.21pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.98pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:223.19pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:231.74pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.13pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:234.87pt;position:absolute;text-decoration:none;white-space:pre;width:33.26pt">perfect,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:268.13pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.98pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:271.11pt;position:absolute;text-decoration:none;white-space:pre;width:41.21pt">maintain,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:312.32pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.98pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:315.3pt;position:absolute;text-decoration:none;white-space:pre;width:33.27pt">protect,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:348.57pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.98pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:351.55pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:360.71pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.13pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:363.84pt;position:absolute;text-decoration:none;white-space:pre;width:32.96pt">enforce</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:396.8pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.13pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:399.93pt;position:absolute;text-decoration:none;white-space:pre;width:35.42pt">Geron&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:435.35pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.13pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:438.48pt;position:absolute;text-decoration:none;white-space:pre;width:25.04pt">rights</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:463.52pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.03pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:466.55pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:475.1pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.13pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:478.23pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:491.66pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.13pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:494.79pt;position:absolute;text-decoration:none;white-space:pre;width:63.51pt">Developments</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.3pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.71pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:554.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:63.16pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.86pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:66.02pt;position:absolute;text-decoration:none;white-space:pre;width:224.55pt">otherwise carry out the purpose of this Agreement.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:290.57pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:4.89pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:295.46000000000004pt;position:absolute;text-decoration:none;white-space:pre;width:262.71pt">Geron will reimburse Consultant for any reasonable out-of-</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:567.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:458.94pt">pocket expenses actually incurred by Consultant in fulfilling Consultant&#8217;s obligations under this section.</font></div><div style="line-height:7.62pt;position:absolute;top:594.01pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:54pt;position:absolute;text-decoration:underline;white-space:pre">5.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:62.25pt;letter-spacing:0.25em;position:absolute;text-decoration:underline;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:67.75pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:underline;white-space:pre">Confidentiality</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:137.23000000000002pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre">.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:619.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">a)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:55.55pt">Proprietary</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:181.55pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:6.64pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:188.19pt;position:absolute;text-decoration:none;white-space:pre;width:60.16pt">Information.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:248.35pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:6.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:255.04pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:302.68pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:6.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:309.37pt;position:absolute;text-decoration:none;white-space:pre;width:17.09pt">will</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:326.46000000000004pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:6.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:333.15pt;position:absolute;text-decoration:none;white-space:pre;width:19.52pt">treat</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:352.66999999999996pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:6.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:359.36pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">as</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:368.52pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:6.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:375.21000000000004pt;position:absolute;text-decoration:none;white-space:pre;width:52.5pt">confidential</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:427.71pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:6.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:434.4pt;position:absolute;text-decoration:none;white-space:pre;width:10.98pt">all</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:445.38pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:6.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:452.07pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">non-public</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:499.71pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:6.64pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:506.35pt;position:absolute;text-decoration:none;white-space:pre;width:51.9pt">information</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.25pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.36pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:632.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:40.92pt">disclosed</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:94.92pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.45pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:97.37pt;position:absolute;text-decoration:none;white-space:pre;width:460.79pt">to Consultant by Geron or its representatives or generated in the course of providing Services under this</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.1600000000001pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:646.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:60.13pt">Agreement (&#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:114.13pt;position:absolute;text-decoration:none;white-space:pre;width:115.71pt">Proprietary Information</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:229.84pt;position:absolute;text-decoration:none;white-space:pre;width:11.29pt">&#8221;).</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:672.61pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:9.77pt">b)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:69.32pt">Nondisclosure.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:195.32pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:6.43pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:201.75pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:249.39pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:6.33pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:255.72pt;position:absolute;text-decoration:none;white-space:pre;width:17.09pt">will</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:272.81pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:6.33pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:279.14pt;position:absolute;text-decoration:none;white-space:pre;width:14.05pt">not</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:293.19pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:6.43pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:299.62pt;position:absolute;text-decoration:none;white-space:pre;width:14.66pt">use</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:314.28pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:6.43pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:320.71000000000004pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:329.87pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:6.38pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:336.25pt;position:absolute;text-decoration:none;white-space:pre;width:35.42pt">disclose</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:371.66999999999996pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:6.33pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:378pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:386.55pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:6.28pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:392.83pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:408.71pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:6.43pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:415.14pt;position:absolute;text-decoration:none;white-space:pre;width:22.59pt">party</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:437.73pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:6.28pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:444.01pt;position:absolute;text-decoration:none;white-space:pre;width:22.59pt">other</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:466.6pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:6.33pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:472.93pt;position:absolute;text-decoration:none;white-space:pre;width:18.93pt">than</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:491.86pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:6.43pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:498.29pt;position:absolute;text-decoration:none;white-space:pre;width:27.48pt">Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:525.77pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:6.43pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:532.2pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:541.36pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:6.43pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:547.79pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">its</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.1700000000001pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.56pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:685.81pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.21pt">representatives any Proprietary Information without the prior written consent of Geron, except as may be</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.21pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:699.01pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:116.26pt">necessary in the course of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:170.26pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.33pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:173.59pt;position:absolute;text-decoration:none;white-space:pre;width:49.46pt">performing</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:223.05pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.33pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:226.38pt;position:absolute;text-decoration:none;white-space:pre;width:39.99pt">Services.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:266.37pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.41pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:271.78pt;position:absolute;text-decoration:none;white-space:pre;width:43.05pt">However,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:314.83pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.18pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:318.01pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:365.65pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.28pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:368.93pt;position:absolute;text-decoration:none;white-space:pre;width:17.09pt">will</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:386.02pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.23pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:389.25pt;position:absolute;text-decoration:none;white-space:pre;width:14.05pt">not</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:403.3pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.23pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:406.53pt;position:absolute;text-decoration:none;white-space:pre;width:20.76pt">have</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:427.29pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.23pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:430.52pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:446.4pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.23pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:449.63pt;position:absolute;text-decoration:none;white-space:pre;width:57.16pt">obligation of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:506.79pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.23pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:510.02pt;position:absolute;text-decoration:none;white-space:pre;width:48.23pt">confidence</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.25pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.56pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:712.21pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:69.88pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.56pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:72.44pt;position:absolute;text-decoration:none;white-space:pre;width:34.82pt">non-use</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:107.25999999999999pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.56pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:109.82pt;position:absolute;text-decoration:none;white-space:pre;width:19.54pt">with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:129.36pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.51pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:131.87pt;position:absolute;text-decoration:none;white-space:pre;width:355.39pt">respect to Proprietary Information which Consultant can document to have been&#58;</font></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt"><div style="position:absolute;top:728.64pt"><div style="width:522pt"></div></div><div style="position:absolute"><div style="width:522pt"></div></div><div><div style="line-height:7.62pt;position:absolute;top:80.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:126pt;position:absolute;text-decoration:none;white-space:pre">(i)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:150pt;position:absolute;text-decoration:none;white-space:pre">rightfully</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:191.52pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:193.57999999999998pt;position:absolute;text-decoration:none;white-space:pre">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:202.13pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:204.29pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:217.72pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:219.88pt;position:absolute;text-decoration:none;white-space:pre">public</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:247.36pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:249.42000000000002pt;position:absolute;text-decoration:none;white-space:pre">domain</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:282.4pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:284.46000000000004pt;position:absolute;text-decoration:none;white-space:pre">as</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:293.62pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:295.82pt;position:absolute;text-decoration:none;white-space:pre">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:304.98pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:307.03999999999996pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:320.47pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:322.63pt;position:absolute;text-decoration:none;white-space:pre">Effective</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:362.9pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:364.96000000000004pt;position:absolute;text-decoration:none;white-space:pre">Date</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:385.71000000000004pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:387.77pt;position:absolute;text-decoration:none;white-space:pre">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:396.93pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:399.13pt;position:absolute;text-decoration:none;white-space:pre">which</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:426pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:428.16pt;position:absolute;text-decoration:none;white-space:pre">comes</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:456.25pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:458.31pt;position:absolute;text-decoration:none;white-space:pre">into</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:475.41pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:477.57pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:491pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:493.16pt;position:absolute;text-decoration:none;white-space:pre">public</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:520.64pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:522.7pt;position:absolute;text-decoration:none;white-space:pre">domain </font></div><div style="line-height:7.62pt;position:absolute;top:93.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:150pt;position:absolute;text-decoration:none;white-space:pre">through no wrongful act or omission of Consultant&#59; or</font></div><div style="line-height:7.62pt;position:absolute;top:119.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:125.95000000000002pt;position:absolute;text-decoration:none;white-space:pre">(ii)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:148.55pt;position:absolute;text-decoration:none;white-space:pre">developed independently by Consultant without any use of any Proprietary Information or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:545.21pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre"> </font></div><div style="line-height:7.62pt;position:absolute;top:132.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:148.55pt;position:absolute;text-decoration:none;white-space:pre">Geron facilities, and without the participation of any Geron personnel&#59; or</font></div><div style="line-height:7.62pt;position:absolute;top:158.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:126pt;position:absolute;text-decoration:none;white-space:pre">(iii)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:153pt;position:absolute;text-decoration:none;white-space:pre">rightfully disclosed to Consultant without restriction</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:383.53pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:386.24pt;position:absolute;text-decoration:none;white-space:pre">by a third party under no obligation of </font></div><div style="line-height:7.62pt;position:absolute;top:171.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:153pt;position:absolute;text-decoration:none;white-space:pre">confidentiality to Geron.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:198.46pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:138.65pt">Legally Required Disclosure. </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:228.65pt;position:absolute;text-decoration:none;white-space:pre;width:347.25pt">Confidentiality obligations under this Agreement shall not apply to Proprietary</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:575.9pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.26pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:211.66pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:52.51pt">Information</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:106.50999999999999pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:109.2pt;position:absolute;text-decoration:none;white-space:pre;width:16.48pt">that</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:125.68pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:128.51999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:7.33pt">is</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:135.85pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:138.57999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:36.63pt">required</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:175.20999999999998pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:178pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:189pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:191.69pt;position:absolute;text-decoration:none;white-space:pre;width:15.87pt">law</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:207.56pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.64pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:210.2pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:218.75pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:221.44pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">be</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:231.82pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:234.51pt;position:absolute;text-decoration:none;white-space:pre;width:43.97pt">disclosed&#59;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:278.48pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:281.21000000000004pt;position:absolute;text-decoration:none;white-space:pre;width:41.84pt">provided,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:323.05pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:325.89pt;position:absolute;text-decoration:none;white-space:pre;width:40.61pt">however,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:366.5pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:369.19pt;position:absolute;text-decoration:none;white-space:pre;width:16.48pt">that</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:385.67pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:388.51pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:436.15pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:438.99pt;position:absolute;text-decoration:none;white-space:pre;width:37.87pt">provides</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:476.86pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:479.59pt;position:absolute;text-decoration:none;white-space:pre;width:96.31pt">prompt written notice</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:575.9pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:224.86pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:32.8pt">of such</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:86.8pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.39pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:90.19pt;position:absolute;text-decoration:none;white-space:pre;width:130.43pt">required disclosure to Geron,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:220.62pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.39pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:224.01pt;position:absolute;text-decoration:none;white-space:pre;width:351.9pt">makes a reasonable effort to obtain a protective or other order maintaining the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:575.91pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:238.06pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:522pt">confidentiality of the Proprietary Information, and takes reasonable steps to enable Geron to seek a protective order or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:576pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:251.26pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:444.8pt">otherwise prevent disclosure of such information. Notwithstanding the confidentiality obligations</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:498.8pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:4.5pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:503.3pt;position:absolute;text-decoration:none;white-space:pre;width:12.21pt">set</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:515.51pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:4.4pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:519.9100000000001pt;position:absolute;text-decoration:none;white-space:pre;width:21.37pt">forth</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:541.28pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:4.5pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:545.78pt;position:absolute;text-decoration:none;white-space:pre;width:30.22pt">herein,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:576pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.56pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:264.46pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:49.25pt">pursuant to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:103.25pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:106.03999999999999pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">18</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:117.03999999999999pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:119.83pt;position:absolute;text-decoration:none;white-space:pre;width:21.38pt">USC</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:141.20999999999998pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:143.9pt;position:absolute;text-decoration:none;white-space:pre;width:32.97pt">Section</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:176.87pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:179.66pt;position:absolute;text-decoration:none;white-space:pre;width:37.57pt">1833(b),</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:217.23pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:220.02pt;position:absolute;text-decoration:none;white-space:pre;width:101.32pt">Consultant shall not be</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:321.34pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:324.13pt;position:absolute;text-decoration:none;white-space:pre;width:18.93pt">held</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:343.06pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:345.85pt;position:absolute;text-decoration:none;white-space:pre;width:45.17pt">criminally</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:391.02pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:393.81pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:402.97pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:405.76pt;position:absolute;text-decoration:none;white-space:pre;width:55.32pt">civilly liable</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:461.08pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:463.87pt;position:absolute;text-decoration:none;white-space:pre;width:43.75pt">under any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:507.62pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:510.41pt;position:absolute;text-decoration:none;white-space:pre;width:42.5pt">federal or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:552.9100000000001pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:555.7pt;position:absolute;text-decoration:none;white-space:pre;width:20.14pt">state</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:575.84pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.71pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:277.66pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:21.97pt">trade</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:75.97pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:4.91pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:80.88pt;position:absolute;text-decoration:none;white-space:pre;width:46.45pt">secret law</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:127.33pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:4.91pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:132.24pt;position:absolute;text-decoration:none;white-space:pre;width:94.84pt">for the disclosure of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:227.08pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:4.91pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:231.99pt;position:absolute;text-decoration:none;white-space:pre;width:4.88pt">a</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:236.87pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:4.91pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:241.78pt;position:absolute;text-decoration:none;white-space:pre;width:86.26pt">trade secret that is</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:328.04pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:4.91pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:332.95pt;position:absolute;text-decoration:none;white-space:pre;width:26.86pt">made&#58;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:359.81pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:6.94pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:366.75pt;position:absolute;text-decoration:none;white-space:pre;width:12.82pt">(1)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:379.57pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:4.91pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:384.48pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:393.03pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:4.91pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:397.94pt;position:absolute;text-decoration:none;white-space:pre;width:178.03pt">confidence to a federal, state, or local</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:575.97pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:290.86pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:521.98pt">government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:575.98pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:304.06pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:229.96pt">investigating a suspected violation of law&#59; or (2)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:283.96000000000004pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:5.16pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:289.12pt;position:absolute;text-decoration:none;white-space:pre;width:286.77pt">in a complaint or other document filed in a lawsuit or other</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:575.89pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:317.26pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:197.55pt">proceeding, if such filing is made under seal.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:341.46pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:8.54pt">c)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:120.52pt">Third-Party Information.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:246.51999999999998pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:4.96pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:251.48000000000002pt;position:absolute;text-decoration:none;white-space:pre;width:306.92pt">Consultant understands that Geron has received and in the future will</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.4pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:354.66pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:300.42pt">receive from third parties confidential or proprietary information (&#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:354.42pt;position:absolute;text-decoration:none;white-space:pre;width:118.09pt">Third-Party Information</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:472.51pt;position:absolute;text-decoration:none;white-space:pre;width:85.82pt">&#8221;) subject to a duty</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.3299999999999pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:367.86pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.43pt">on Geron&#8217;s part to maintain the confidentiality of such information and to use it only for certain limited purposes.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.4300000000001pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:381.06pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">In</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:63.16pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:65.84pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:79.27pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:82pt;position:absolute;text-decoration:none;white-space:pre;width:18.92pt">case</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:100.92pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:103.65pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:112.81pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:115.53999999999999pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:131.42000000000002pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:134.1pt;position:absolute;text-decoration:none;white-space:pre;width:51.28pt">Third-Party</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:185.38pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:188.06pt;position:absolute;text-decoration:none;white-space:pre;width:55.26pt">Information,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:243.32pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:246pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:293.64pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.63pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:296.27pt;position:absolute;text-decoration:none;white-space:pre;width:28.08pt">agrees</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:324.35pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:327.08pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:335.63pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.58pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:338.21pt;position:absolute;text-decoration:none;white-space:pre;width:23.81pt">abide</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:362.02pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:364.75pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:375.75pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:378.43pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:394.31pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:396.99pt;position:absolute;text-decoration:none;white-space:pre;width:43.96pt">additional</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:440.95pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:443.68pt;position:absolute;text-decoration:none;white-space:pre;width:57.39pt">requirements</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:501.07pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:503.8pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">as</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:512.96pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:515.69pt;position:absolute;text-decoration:none;white-space:pre;width:42.74pt">necessary</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.4300000000001pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:394.26pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:247.52pt">for Geron to comply with such third-party agreement.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:301.52pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:6.34pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:307.86pt;position:absolute;text-decoration:none;white-space:pre;width:250.51pt">During and after Consultant&#8217;s relationship with Geron,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.37pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:407.46pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.35pt">Consultant will keep in confidence and trust all Third-Party Information&#59; Consultant will not use Third-Party</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.35pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:420.66pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:120.83pt">Information, except as may</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:174.82999999999998pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:177.67000000000002pt;position:absolute;text-decoration:none;white-space:pre;width:291.36pt">be necessary and authorized in the course of performing Services&#59;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:469.03pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.89pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:471.92pt;position:absolute;text-decoration:none;white-space:pre;width:86.47pt">and Consultant will</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.39pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:433.86pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:14.05pt">not</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:68.05pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:70.92pt;position:absolute;text-decoration:none;white-space:pre;width:38.17pt">disclose,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:109.09pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:111.91pt;position:absolute;text-decoration:none;white-space:pre;width:29.9pt">lecture</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:141.81pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:144.63pt;position:absolute;text-decoration:none;white-space:pre;width:24.75pt">upon,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:169.38pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.67pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:172.05pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:181.20999999999998pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:184.03pt;position:absolute;text-decoration:none;white-space:pre;width:32.38pt">publish</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:216.41pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:219.23pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:227.78pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.67pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:230.45pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:246.33pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:249.15pt;position:absolute;text-decoration:none;white-space:pre;width:20.76pt">third</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:269.90999999999997pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:272.73pt;position:absolute;text-decoration:none;white-space:pre;width:22.59pt">party</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:295.32pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:298.14pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:314.02pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:316.84pt;position:absolute;text-decoration:none;white-space:pre;width:51.28pt">Third-Party</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:368.12pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:370.94pt;position:absolute;text-decoration:none;white-space:pre;width:52.51pt">Information</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:423.45pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:426.27pt;position:absolute;text-decoration:none;white-space:pre;width:33.59pt">without</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:459.86pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.72pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:462.58pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:476.01pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:478.83pt;position:absolute;text-decoration:none;white-space:pre;width:31.13pt">written</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:509.96pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.72pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:512.6800000000001pt;position:absolute;text-decoration:none;white-space:pre;width:33.59pt">consent</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:546.27pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:549.14pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.3pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:447.06pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:153.26pt">a duly authorized officer of Geron.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:473.46pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:9.77pt">d)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:311.3pt">No Improper Use of Information of Prior Employers and Others.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:437.3pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.4pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:442.7pt;position:absolute;text-decoration:none;white-space:pre;width:115.51pt">Consultant represents that</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.21pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:486.66pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:55.58pt">Consultant&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:109.58pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:112.4pt;position:absolute;text-decoration:none;white-space:pre;width:42.74pt">execution</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:155.14pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:157.95999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:167.12pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.72pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:169.84pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">this</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:185.72pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:188.54pt;position:absolute;text-decoration:none;white-space:pre;width:51.59pt">Agreement,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:240.13pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:242.95pt;position:absolute;text-decoration:none;white-space:pre;width:53.12pt">engagement</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:296.07pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:298.94pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">as</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:308.1pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:310.92pt;position:absolute;text-decoration:none;white-space:pre;width:4.88pt">a</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:315.8pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:318.62pt;position:absolute;text-decoration:none;white-space:pre;width:45.19pt">consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:363.81pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:366.68pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:377.68pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:380.5pt;position:absolute;text-decoration:none;white-space:pre;width:30.23pt">Geron,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:410.73pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:413.55pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:429.43pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:432.25pt;position:absolute;text-decoration:none;white-space:pre;width:55.55pt">performance</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:487.8pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:490.62pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:499.78pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:502.6pt;position:absolute;text-decoration:none;white-space:pre;width:55.58pt">Consultant&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.1800000000001pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:499.86pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.13pt">proposed tasks for Geron in the development of its business does not and will not breach any agreement with any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.13pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:513.06pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.2pt">former employer or other entity, including any noncompete agreement or any agreement to keep in confidence or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.2pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:526.26pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.22pt">refrain from using information acquired by Consultant prior to Consultant&#8217;s consulting relationship with Geron.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.22pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:539.46pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.2pt">Consultant further represents that Consultant has not entered into, and will not enter into, any agreement which</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.2pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:552.66pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:407.7pt">conflicts with or would, if performed by him, cause Consultant to breach this Agreement.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:461.7pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.85pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:467.55pt;position:absolute;text-decoration:none;white-space:pre;width:90.59pt">During Consultant&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.14pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:565.86pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.15pt">relationship with Geron, Consultant will not improperly make use of, or disclose, any information or trade secrets</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.15pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:579.06pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.17pt">of any former employer or other third party, nor will Consultant bring onto the premises of Geron or use any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.1700000000001pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:592.26pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:485.37pt">unpublished documents or any property belonging to any former employer or other third party, in violation of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:539.37pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.91pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:542.28pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.1600000000001pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:605.46pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:28.08pt">lawful</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:82.08pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.48pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:84.56pt;position:absolute;text-decoration:none;white-space:pre;width:50.06pt">agreements</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:134.62pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.48pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:137.1pt;position:absolute;text-decoration:none;white-space:pre;width:19.54pt">with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:156.64pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.43pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:159.07pt;position:absolute;text-decoration:none;white-space:pre;width:16.48pt">that</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:175.55pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.37pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:177.92000000000002pt;position:absolute;text-decoration:none;white-space:pre;width:29.91pt">former</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:207.83pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.53pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:210.36pt;position:absolute;text-decoration:none;white-space:pre;width:41.52pt">employer</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:251.88pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.53pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:254.41pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:263.57pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.37pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:265.94pt;position:absolute;text-decoration:none;white-space:pre;width:20.76pt">third</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:286.7pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.43pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:289.13pt;position:absolute;text-decoration:none;white-space:pre;width:25.34pt">party.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:314.47pt;letter-spacing:0.168em;position:absolute;text-decoration:none;white-space:pre;width:4.76pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:319.23pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:366.87pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.48pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:369.35pt;position:absolute;text-decoration:none;white-space:pre;width:17.09pt">will</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:386.44pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.48pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:388.92pt;position:absolute;text-decoration:none;white-space:pre;width:14.66pt">use</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:403.58pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.48pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:406.06pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:414.61pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.33pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:416.94pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:430.37pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.48pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:432.85pt;position:absolute;text-decoration:none;white-space:pre;width:55.55pt">performance</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:488.4pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.48pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:490.88pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:500.04pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.48pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:502.52pt;position:absolute;text-decoration:none;white-space:pre;width:55.58pt">Consultant&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.1pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:618.66pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.18pt">tasks only information that is generally known and used by persons with training and experience comparable to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.1800000000001pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:631.86pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.17pt">Consultant&#8217;s own, is common knowledge in the industry or otherwise legally in the public domain or is otherwise</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.1700000000001pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:645.06pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:145.67pt">provided or developed by Geron.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:671.61pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:8.54pt">e)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:187.1pt">Ownership of Proprietary Information.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:313.1pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.43pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:318.53pt;position:absolute;text-decoration:none;white-space:pre;width:239.61pt">All Proprietary Information shall be the sole property</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.14pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:684.81pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:39.82pt">of Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:93.82pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.89pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:96.71000000000001pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:112.59pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:115.38pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">its</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:125.76pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.94pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:128.7pt;position:absolute;text-decoration:none;white-space:pre;width:34.52pt">assigns,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:163.22pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.89pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:166.11pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:181.99pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:184.78pt;position:absolute;text-decoration:none;white-space:pre;width:27.48pt">Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:212.26pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.89pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:215.15pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:231.03pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:233.82pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">its</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:244.2pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.94pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:247.14pt;position:absolute;text-decoration:none;white-space:pre;width:31.77pt">assigns</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:278.90999999999997pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.89pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:281.8pt;position:absolute;text-decoration:none;white-space:pre;width:20.76pt">shall</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:302.56pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:305.35pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">be</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:315.73pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.89pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:318.62pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:332.05pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:334.84pt;position:absolute;text-decoration:none;white-space:pre;width:17.71pt">sole</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:352.55pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.89pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:355.44pt;position:absolute;text-decoration:none;white-space:pre;width:27.48pt">owner</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:382.92pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.94pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:385.86pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:395.02pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.89pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:397.91pt;position:absolute;text-decoration:none;white-space:pre;width:10.98pt">all</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:408.89pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:411.68pt;position:absolute;text-decoration:none;white-space:pre;width:21.97pt">trade</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:433.65pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.89pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:436.54pt;position:absolute;text-decoration:none;white-space:pre;width:32.66pt">secrets,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:469.2pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.94pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:472.14pt;position:absolute;text-decoration:none;white-space:pre;width:33.89pt">patents,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:506.03pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.89pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:508.92pt;position:absolute;text-decoration:none;white-space:pre;width:49.17pt">copyrights,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.0899999999999pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.51pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:698.01pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:42.38pt">and other</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:96.38pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.36pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:99.74000000000001pt;position:absolute;text-decoration:none;white-space:pre;width:25.04pt">rights</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:124.78pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:3.32pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:128.1pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:136.65pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:3.32pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:139.97pt;position:absolute;text-decoration:none;white-space:pre;width:48.24pt">connection</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:188.21pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:3.42pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:191.63pt;position:absolute;text-decoration:none;white-space:pre;width:44.26pt">therewith.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:235.89pt;letter-spacing:0.154em;position:absolute;text-decoration:none;white-space:pre;width:5.6pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:241.49pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:289.13pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.47pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:292.6pt;position:absolute;text-decoration:none;white-space:pre;width:29.92pt">hereby</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:322.52pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:3.32pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:325.84pt;position:absolute;text-decoration:none;white-space:pre;width:31.77pt">assigns</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:357.61pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:3.32pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:360.93pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:369.48pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:3.32pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:372.8pt;position:absolute;text-decoration:none;white-space:pre;width:27.48pt">Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:400.28pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:3.42pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:403.7pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:419.58pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.72pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:423.3pt;position:absolute;text-decoration:none;white-space:pre;width:25.04pt">rights</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:448.34pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:3.22pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:451.56pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:499.2pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.36pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:502.56pt;position:absolute;text-decoration:none;white-space:pre;width:18.93pt">may</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:521.49pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:3.32pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:524.81pt;position:absolute;text-decoration:none;white-space:pre;width:20.76pt">have</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:545.5699999999999pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.47pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:549.04pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.2pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.31pt"> </font></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt"><div style="position:absolute;top:728.64pt"><div style="width:522pt"></div></div><div style="position:absolute"><div style="width:522pt"></div></div><div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:66.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.14pt">acquire in such Proprietary Information and recognizes that all Proprietary Information shall be the sole and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.14pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:80.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:192.69pt">exclusive property of Geron and its assigns.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:105.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:7.32pt">f)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:130.28pt">Return of Geron Property.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:256.28pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:6.24pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:262.52pt;position:absolute;text-decoration:none;white-space:pre;width:295.69pt">All documents, records, apparatus, equipment and other physical</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.21pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:119.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.23pt">property, whether or not pertaining to Proprietary Information furnished to Consultant by Geron or produced by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.23pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:132.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.2pt">Consultant or others in connection with the Services shall be and remain the sole property of Geron (hereinafter,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.2pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:145.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:4.88pt">&#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:58.88pt;position:absolute;text-decoration:none;white-space:pre;width:91.22pt">Company Property</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:150.1pt;position:absolute;text-decoration:none;white-space:pre;width:11.29pt">&#8221;).</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:161.39pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.27pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:166.66pt;position:absolute;text-decoration:none;white-space:pre;width:284.75pt">Consultant shall return to Geron all such materials and property</font><font style="color:#00c000;font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:451.41pt;position:absolute;text-decoration:none;white-space:pre;width:6.03pt">, </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:457.44pt;position:absolute;text-decoration:none;white-space:pre;width:100.83pt">as and when requested</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.27pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:158.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:65pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.61pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:67.61pt;position:absolute;text-decoration:none;white-space:pre;width:30.23pt">Geron.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:97.84pt;letter-spacing:0.363em;position:absolute;text-decoration:none;white-space:pre;width:6.94pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:104.78pt;position:absolute;text-decoration:none;white-space:pre;width:22.59pt">Even</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:127.37pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.46pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:129.82999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:6.71pt">if</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:136.54000000000002pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.51pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:139.05pt;position:absolute;text-decoration:none;white-space:pre;width:27.48pt">Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:166.53pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.46pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:168.99pt;position:absolute;text-decoration:none;white-space:pre;width:20.16pt">does</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:189.15pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.61pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:191.76pt;position:absolute;text-decoration:none;white-space:pre;width:14.05pt">not</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:205.81pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.66pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:208.47pt;position:absolute;text-decoration:none;white-space:pre;width:9.78pt">so</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:218.25pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.51pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:220.76pt;position:absolute;text-decoration:none;white-space:pre;width:34.5pt">request,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:255.26pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.61pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:257.87pt;position:absolute;text-decoration:none;white-space:pre;width:22pt">upon</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:279.87pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.61pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:282.48pt;position:absolute;text-decoration:none;white-space:pre;width:50.67pt">termination</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:333.15pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.61pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:335.76pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:344.92pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.66pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:347.58pt;position:absolute;text-decoration:none;white-space:pre;width:55.58pt">Consultant&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:403.16pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.51pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:405.67pt;position:absolute;text-decoration:none;white-space:pre;width:45.81pt">consulting</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:451.48pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.61pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:454.09pt;position:absolute;text-decoration:none;white-space:pre;width:51.9pt">relationship</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:505.99pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.61pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:508.6pt;position:absolute;text-decoration:none;white-space:pre;width:19.54pt">with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:528.14pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.61pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:530.75pt;position:absolute;text-decoration:none;white-space:pre;width:27.48pt">Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.23pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:171.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.19pt">for any reason, Consultant shall return all such Company Property, together with all copies thereof, and any other</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.19pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:185.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:36pt">material</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:90pt;letter-spacing:-0.07200000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.1pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:92.1pt;position:absolute;text-decoration:none;white-space:pre;width:46.41pt">containing</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:138.51pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.2pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:140.70999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:149.87pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.2pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:152.07pt;position:absolute;text-decoration:none;white-space:pre;width:44.59pt">disclosing</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:196.66pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.25pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:198.91pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:214.79pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.2pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:216.99pt;position:absolute;text-decoration:none;white-space:pre;width:66.26pt">Developments,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:283.25pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.2pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:285.45pt;position:absolute;text-decoration:none;white-space:pre;width:51.28pt">Third-Party</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:336.73pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.2pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:338.93pt;position:absolute;text-decoration:none;white-space:pre;width:52.51pt">Information</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:391.44pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.25pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:393.69pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:402.85pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.2pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:405.05pt;position:absolute;text-decoration:none;white-space:pre;width:49.45pt">Proprietary</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:454.5pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.2pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:456.7pt;position:absolute;text-decoration:none;white-space:pre;width:52.51pt">Information</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:509.21pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.2pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:511.41pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:527.29pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.25pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:529.54pt;position:absolute;text-decoration:none;white-space:pre;width:28.68pt">certify</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.22pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:198.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:62.55pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.74pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:65.28999999999999pt;position:absolute;text-decoration:none;white-space:pre;width:31.75pt">writing</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:97.03999999999999pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.64pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:99.68pt;position:absolute;text-decoration:none;white-space:pre;width:16.48pt">that</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:116.16pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:118.95pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:166.59pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:169.38pt;position:absolute;text-decoration:none;white-space:pre;width:14.66pt">has</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:184.04pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:186.83pt;position:absolute;text-decoration:none;white-space:pre;width:20.76pt">fully</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:207.59pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.74pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:210.33pt;position:absolute;text-decoration:none;white-space:pre;width:40.91pt">complied</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:251.24pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.74pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:253.98pt;position:absolute;text-decoration:none;white-space:pre;width:19.54pt">with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:273.52pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.74pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:276.26pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:289.69pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:292.48pt;position:absolute;text-decoration:none;white-space:pre;width:42.75pt">foregoing</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:335.23pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.74pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:337.97pt;position:absolute;text-decoration:none;white-space:pre;width:47.33pt">obligation.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:385.3pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:4.92pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:390.22pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:437.86pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:440.65pt;position:absolute;text-decoration:none;white-space:pre;width:28.08pt">agrees</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:468.73pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:471.52pt;position:absolute;text-decoration:none;white-space:pre;width:16.48pt">that</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:488pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:490.79pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:538.4300000000001pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:541.12pt;position:absolute;text-decoration:none;white-space:pre;width:17.09pt">will</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.21pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:211.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.17pt">not copy, delete, or alter any information contained upon any Company Property before Consultant returns it to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.1700000000001pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:224.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:30.23pt">Geron.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:84.23pt;letter-spacing:0.154em;position:absolute;text-decoration:none;white-space:pre;width:4.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:88.82pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">In</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:97.97999999999999pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.35pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:100.33pt;position:absolute;text-decoration:none;white-space:pre;width:38.78pt">addition,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:139.11pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.35pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:141.45999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:6.71pt">if</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:148.17000000000002pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.41pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:150.57999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:198.22pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.41pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:200.63pt;position:absolute;text-decoration:none;white-space:pre;width:14.66pt">has</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:215.29pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.41pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:217.7pt;position:absolute;text-decoration:none;white-space:pre;width:20.16pt">used</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:237.86pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.35pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:240.21pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:256.09000000000003pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.35pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:258.44pt;position:absolute;text-decoration:none;white-space:pre;width:37.25pt">personal</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:295.69pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.31pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:298pt;position:absolute;text-decoration:none;white-space:pre;width:44.27pt">computer,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:342.27pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.35pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:344.62pt;position:absolute;text-decoration:none;white-space:pre;width:29.61pt">server,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:374.23pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.35pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:376.58pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:385.74pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.41pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:388.15pt;position:absolute;text-decoration:none;white-space:pre;width:28.07pt">e-mail</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:416.22pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.31pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:418.53pt;position:absolute;text-decoration:none;white-space:pre;width:30.54pt">system</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:449.07pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.31pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:451.38pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:459.93pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.35pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:462.28pt;position:absolute;text-decoration:none;white-space:pre;width:34.48pt">receive,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:496.76pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.35pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:499.11pt;position:absolute;text-decoration:none;white-space:pre;width:24.12pt">store,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:523.23pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.35pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:525.5799999999999pt;position:absolute;text-decoration:none;white-space:pre;width:32.66pt">review,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.24pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:237.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.22pt">prepare or transmit any company information, including but not limited to, Proprietary Information, Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.22pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:251.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.22pt">agrees to provide Geron with a computer-useable copy of all such Proprietary Information and then permanently</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.22pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:264.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.25pt">delete and expunge such Proprietary Information from those systems&#59; and Consultant agrees to provide Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.25pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:277.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.21pt">access to his system as reasonably requested to verify that the necessary copying and&#47;or deletion is completed.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.21pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:290.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.19pt">Consultant further agrees that any property situated on Geron&#8217;s premises and owned by Geron is subject to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.19pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:303.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:97.47pt">inspection by Geron&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:151.47pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:154.31pt;position:absolute;text-decoration:none;white-space:pre;width:42.75pt">personnel</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:197.06pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.89pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:199.95pt;position:absolute;text-decoration:none;white-space:pre;width:7.93pt">at</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:207.88pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.89pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:210.77pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:226.65pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:229.49pt;position:absolute;text-decoration:none;white-space:pre;width:42pt">time with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:271.49pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:274.28pt;position:absolute;text-decoration:none;white-space:pre;width:45.68pt">or without</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:319.96pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.89pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:322.85pt;position:absolute;text-decoration:none;white-space:pre;width:193.73pt">further notice. Consultant will not take with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:516.5799999999999pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:519.4200000000001pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:535.3pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:538.14pt;position:absolute;text-decoration:none;white-space:pre;width:20.16pt">such</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.3pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:317.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:315.09pt">material or property or any reproduction thereof upon such termination.</font></div><div style="line-height:7.44pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:341.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:54pt;position:absolute;text-decoration:underline;white-space:pre;width:22.6pt">Data</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:76.6pt;letter-spacing:-0.004em;position:absolute;text-decoration:underline;white-space:pre;width:2.71pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:79.31pt;position:absolute;text-decoration:underline;white-space:pre;width:36.02pt">Privacy</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:115.33pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:underline;white-space:pre;width:2.66pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:117.99000000000001pt;position:absolute;text-decoration:underline;white-space:pre;width:17.72pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:135.70999999999998pt;letter-spacing:-0.004em;position:absolute;text-decoration:underline;white-space:pre;width:2.71pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:138.42000000000002pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:underline;white-space:pre;width:41.01pt">Security.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:358.61pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">a)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:40.91pt">Personal</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:166.91pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.96pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:169.87pt;position:absolute;text-decoration:none;white-space:pre;width:25.35pt">Data.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:195.22pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.24pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:200.45999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">In</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:209.62pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.91pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:212.53pt;position:absolute;text-decoration:none;white-space:pre;width:48.24pt">connection</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:260.77pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.91pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:263.68pt;position:absolute;text-decoration:none;white-space:pre;width:19.54pt">with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:283.22pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.91pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:286.13pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">this</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:302.01pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.96pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:304.97pt;position:absolute;text-decoration:none;white-space:pre;width:51.59pt">Agreement,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:356.56pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.91pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:359.47pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:407.11pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.96pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:410.07pt;position:absolute;text-decoration:none;white-space:pre;width:17.09pt">will</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:427.16pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.96pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:430.12pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">be</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:440.5pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.81pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:443.31pt;position:absolute;text-decoration:none;white-space:pre;width:36.63pt">required</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:479.94pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.91pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:482.85pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:491.4pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.91pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:494.31pt;position:absolute;text-decoration:none;white-space:pre;width:33.59pt">provide</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:527.9pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.91pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:530.81pt;position:absolute;text-decoration:none;white-space:pre;width:27.48pt">Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.29pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.41pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:371.81pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:53.48pt">with certain</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:107.47999999999999pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:3.55pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:111.03pt;position:absolute;text-decoration:none;white-space:pre;width:37.25pt">personal</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:148.28pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.6pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:151.88pt;position:absolute;text-decoration:none;white-space:pre;width:54.65pt">information,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:206.53pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:3.55pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:210.08pt;position:absolute;text-decoration:none;white-space:pre;width:41.53pt">including</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:251.61pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:3.55pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:255.16pt;position:absolute;text-decoration:none;white-space:pre;width:14.05pt">but</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:269.21000000000004pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.6pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:272.81pt;position:absolute;text-decoration:none;white-space:pre;width:14.05pt">not</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:286.86pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.49pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:290.35pt;position:absolute;text-decoration:none;white-space:pre;width:31.13pt">limited</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:321.48pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:3.45pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:324.93pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:333.48pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:3.55pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:337.03pt;position:absolute;text-decoration:none;white-space:pre;width:55.58pt">Consultant&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:392.61pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.6pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:396.21pt;position:absolute;text-decoration:none;white-space:pre;width:26.56pt">name,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:422.77pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:3.45pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:426.22pt;position:absolute;text-decoration:none;white-space:pre;width:31.74pt">contact</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:457.96pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:3.65pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:461.61pt;position:absolute;text-decoration:none;white-space:pre;width:54.65pt">information,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:516.26pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:3.55pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:519.81pt;position:absolute;text-decoration:none;white-space:pre;width:38.45pt">financial</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.26pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.36pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:385.01pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:244.03pt">account information and professional qualifications (&#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:298.03pt;position:absolute;text-decoration:none;white-space:pre;width:113.32pt">Consultant Information</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:411.35pt;position:absolute;text-decoration:none;white-space:pre;width:146.93pt">&#8221;). Consultant agrees that Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.28pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:398.21pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:55.6pt">may collect,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:109.6pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:4.29pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:113.89pt;position:absolute;text-decoration:none;white-space:pre;width:14.66pt">use</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:128.55pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:4.19pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:132.74pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:148.62pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:4.19pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:152.81pt;position:absolute;text-decoration:none;white-space:pre;width:23.2pt">share</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:176.01pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:4.19pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:180.2pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:227.84pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:4.24pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:232.08pt;position:absolute;text-decoration:none;white-space:pre;width:52.51pt">Information</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:284.59000000000003pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:4.14pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:288.73pt;position:absolute;text-decoration:none;white-space:pre;width:12.82pt">for</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:301.55pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:4.19pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:305.74pt;position:absolute;text-decoration:none;white-space:pre;width:39.1pt">purposes</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:344.84pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:4.19pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:349.03pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:358.19pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:4.19pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:362.38pt;position:absolute;text-decoration:none;white-space:pre;width:43.36pt">managing</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:405.74pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:4.14pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:409.88pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:423.31pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:4.19pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:427.5pt;position:absolute;text-decoration:none;white-space:pre;width:51.9pt">relationship</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:479.4pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:4.29pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:483.69pt;position:absolute;text-decoration:none;white-space:pre;width:19.54pt">with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:503.23pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:4.29pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:507.52pt;position:absolute;text-decoration:none;white-space:pre;width:50.69pt">Consultant&#59;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.21pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.31pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:411.41pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:81.18pt">managing Geron's</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:135.18pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:139.01999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:37.27pt">business</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:176.29000000000002pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:180.13pt;position:absolute;text-decoration:none;white-space:pre;width:48.85pt">operations&#59;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:228.98pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:232.82pt;position:absolute;text-decoration:none;white-space:pre;width:47.03pt">complying</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:279.85pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:3.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:283.53999999999996pt;position:absolute;text-decoration:none;white-space:pre;width:19.54pt">with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:303.08000000000004pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:306.87pt;position:absolute;text-decoration:none;white-space:pre;width:27.48pt">Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:334.35pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:3.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:338.04pt;position:absolute;text-decoration:none;white-space:pre;width:34.19pt">policies</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:372.23pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:3.74pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:375.97pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:391.85pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:3.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:395.54pt;position:absolute;text-decoration:none;white-space:pre;width:21.36pt">legal</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:416.9pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.84pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:420.74pt;position:absolute;text-decoration:none;white-space:pre;width:51.91pt">obligations&#59;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:472.65pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.64pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:476.29pt;position:absolute;text-decoration:none;white-space:pre;width:44.57pt">protecting</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:520.86pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:3.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:524.55pt;position:absolute;text-decoration:none;white-space:pre;width:33.74pt">Geron's</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.29pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.41pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:424.61pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:25.04pt">rights</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:79.03999999999999pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:4.81pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:83.85pt;position:absolute;text-decoration:none;white-space:pre;width:18.63pt">and,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:102.47999999999999pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:4.91pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:107.39pt;position:absolute;text-decoration:none;white-space:pre;width:450.78pt">in general, enabling the operations of Geron. Consultant understands and agrees that Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.1700000000001pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:437.81pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.15pt">Information may be Processed in countries where data protection rules may be different from those of the country</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.15pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:451.01pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.21pt">where Consultant Information originates. Consultant Information will be kept for the period necessary to fulfill</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.21pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:464.21pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:115.49pt">the above-listed purposes,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:169.49pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.95pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:172.44pt;position:absolute;text-decoration:none;white-space:pre;width:27.49pt">unless</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:199.93pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:202.93pt;position:absolute;text-decoration:none;white-space:pre;width:4.88pt">a</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:207.81pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.95pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:210.76pt;position:absolute;text-decoration:none;white-space:pre;width:28.09pt">longer</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:238.85pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:241.85pt;position:absolute;text-decoration:none;white-space:pre;width:39.07pt">retention</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:280.91999999999996pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.95pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:283.87pt;position:absolute;text-decoration:none;white-space:pre;width:28.09pt">period</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:311.96pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.95pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:314.91pt;position:absolute;text-decoration:none;white-space:pre;width:7.33pt">is</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:322.24pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:325.24pt;position:absolute;text-decoration:none;white-space:pre;width:36.63pt">required</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:361.87pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.95pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:364.82pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:373.98pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.85pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:376.83pt;position:absolute;text-decoration:none;white-space:pre;width:42.12pt">permitted</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:418.95pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.95pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:421.9pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:432.9pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.95pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:435.85pt;position:absolute;text-decoration:none;white-space:pre;width:18.62pt">law.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:454.47pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.9pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:457.37pt;position:absolute;text-decoration:none;white-space:pre;width:10.07pt">If,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:467.44pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.95pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:470.39pt;position:absolute;text-decoration:none;white-space:pre;width:12.82pt">for</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:483.21pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:486.21pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:499.64pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.95pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:502.59pt;position:absolute;text-decoration:none;white-space:pre;width:55.55pt">performance</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.14pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.46pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:477.41pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:63.16pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:66.95pt;position:absolute;text-decoration:none;white-space:pre;width:37.24pt">Services</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:104.19pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.79pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:107.97999999999999pt;position:absolute;text-decoration:none;white-space:pre;width:44.95pt">under this</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:152.93pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.74pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:156.67000000000002pt;position:absolute;text-decoration:none;white-space:pre;width:51.59pt">Agreement,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:208.26pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:3.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:211.95pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:259.59000000000003pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:263.18pt;position:absolute;text-decoration:none;white-space:pre;width:42.75pt">Processes</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:305.93pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.74pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:309.66999999999996pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:323.1pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:3.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:326.79pt;position:absolute;text-decoration:none;white-space:pre;width:37.86pt">Personal</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:364.65pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:3.64pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:368.29pt;position:absolute;text-decoration:none;white-space:pre;width:52.51pt">Information</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:420.8pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:3.54pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:424.34pt;position:absolute;text-decoration:none;white-space:pre;width:12.82pt">(as</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:437.16pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:440.75pt;position:absolute;text-decoration:none;white-space:pre;width:32.97pt">defined</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:473.72pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:3.69pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:477.41pt;position:absolute;text-decoration:none;white-space:pre;width:30.53pt">below)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:507.94pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:511.53pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:520.69pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.74pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:524.4300000000001pt;position:absolute;text-decoration:none;white-space:pre;width:33.74pt">Geron's</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.1700000000001pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.46pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:490.61pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:47.02pt">employees</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:101.02000000000001pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:104.7pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:113.86pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:117.53999999999999pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:126.7pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.42pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:130.12pt;position:absolute;text-decoration:none;white-space:pre;width:69.93pt">non-employees,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:200.05pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.88pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:203.93pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:251.57pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.93pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:255.5pt;position:absolute;text-decoration:none;white-space:pre;width:28.08pt">agrees</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:283.58000000000004pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.88pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:287.46000000000004pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:296.01pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:299.74pt;position:absolute;text-decoration:none;white-space:pre;width:19.55pt">hold</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:319.29pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.88pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:323.17pt;position:absolute;text-decoration:none;white-space:pre;width:10.98pt">all</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:334.15pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.93pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:338.08pt;position:absolute;text-decoration:none;white-space:pre;width:20.16pt">such</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:358.24pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.88pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:362.12pt;position:absolute;text-decoration:none;white-space:pre;width:37.86pt">Personal</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:399.98pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:403.66pt;position:absolute;text-decoration:none;white-space:pre;width:52.51pt">Information</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:456.17pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:459.9pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:468.45pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.88pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:472.33pt;position:absolute;text-decoration:none;white-space:pre;width:48.23pt">confidence</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:520.56pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.88pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:524.44pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:540.3199999999999pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.88pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:544.2pt;position:absolute;text-decoration:none;white-space:pre;width:14.05pt">not</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.25pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.56pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:503.81pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:35.42pt">disclose</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:89.42pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.96pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:92.38pt;position:absolute;text-decoration:none;white-space:pre;width:6.1pt">it</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:98.47999999999999pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.96pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:101.44pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:109.99000000000001pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.06pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:113.05pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:128.93pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.06pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:131.99pt;position:absolute;text-decoration:none;white-space:pre;width:41.63pt">person or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:173.62pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.06pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:176.68pt;position:absolute;text-decoration:none;white-space:pre;width:25.03pt">entity</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:201.71pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.91pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:204.62pt;position:absolute;text-decoration:none;white-space:pre;width:22.59pt">other</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:227.21pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.96pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:230.17pt;position:absolute;text-decoration:none;white-space:pre;width:18.93pt">than</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:249.1pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.96pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:252.06pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">as</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:261.22pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.96pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:264.18pt;position:absolute;text-decoration:none;white-space:pre;width:59.22pt">contemplated</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:323.4pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.06pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:326.46pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:337.46pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.91pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:340.37pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">this</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:356.25pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.06pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:359.31pt;position:absolute;text-decoration:none;white-space:pre;width:48.84pt">Agreement</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:408.15pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.96pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:411.11pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:420.27pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.06pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:423.33pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">as</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:432.49pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.96pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:435.45pt;position:absolute;text-decoration:none;white-space:pre;width:36.63pt">required</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:472.08pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.96pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:475.04pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:486.04pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.91pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:488.95pt;position:absolute;text-decoration:none;white-space:pre;width:18.62pt">law.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:507.57pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.91pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:510.48pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.12pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.61pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:517.01pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:28.08pt">agrees</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:82.08pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:4.03pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:86.11pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:94.66pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.98pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:98.64pt;position:absolute;text-decoration:none;white-space:pre;width:40.31pt">promptly</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:138.95pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.98pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:142.93pt;position:absolute;text-decoration:none;white-space:pre;width:415.3pt">notify Geron at privacy&#64;geron.com of any loss of, inadvertent disclosure of, unauthorized</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.23pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:530.21pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.19pt">access to or acquisition of or misuse of such Personal Information or any media containing such Personal</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.19pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:543.41pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:222.95pt">Information. For purposes of this Agreement&#58; (i) &#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:276.95pt;position:absolute;text-decoration:none;white-space:pre;width:101.34pt">Personal Information</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:378.29pt;position:absolute;text-decoration:none;white-space:pre;width:179.89pt">&#8221; means any information that alone or in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.1800000000001pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:556.61pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:165.18pt">combination with other information,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:219.18pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:4.14pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:223.32pt;position:absolute;text-decoration:none;white-space:pre;width:15.26pt">can</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:238.58pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:4.14pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:242.72pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">be</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:253.1pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:4.29pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:257.39pt;position:absolute;text-decoration:none;white-space:pre;width:20.16pt">used</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:277.55pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:4.14pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:281.69pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:290.24pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:4.04pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:294.28pt;position:absolute;text-decoration:none;white-space:pre;width:36.94pt">identify,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:331.22pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:4.24pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:335.46pt;position:absolute;text-decoration:none;white-space:pre;width:39.38pt">describe,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:374.84pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:4.14pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:378.98pt;position:absolute;text-decoration:none;white-space:pre;width:26.24pt">locate</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:405.22pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:4.14pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:409.36pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:418.52pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:4.19pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:422.71pt;position:absolute;text-decoration:none;white-space:pre;width:31.74pt">contact</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:454.45pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:4.19pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:458.64pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">an</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:469.02pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:4.14pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:473.16pt;position:absolute;text-decoration:none;white-space:pre;width:47.33pt">individual,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:520.49pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:4.24pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:524.73pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:540.61pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:4.24pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:544.85pt;position:absolute;text-decoration:none;white-space:pre;width:13.42pt">(ii)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.27pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:569.81pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:4.88pt">&#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:58.88pt;position:absolute;text-decoration:none;white-space:pre;width:35.41pt">Process</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:94.28999999999999pt;position:absolute;text-decoration:none;white-space:pre;width:4.88pt">&#8221;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:99.17pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:4.98pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:104.15pt;position:absolute;text-decoration:none;white-space:pre;width:28.09pt">means</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:132.24pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:5.13pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:137.37pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:153.25pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:5.08pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:158.32999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:135.02pt">access, receipt, viewing, use,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:293.35pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:5.18pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:298.53pt;position:absolute;text-decoration:none;white-space:pre;width:259.77pt">transfer, retrieval, transaction with, analysis of or other</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.3pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:583.01pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:391.17pt">handling of Personal Information by any means, or the ability to do any of the foregoing.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:609.46pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:9.77pt">b)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:90.07pt">Security Measures.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:216.07pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.05pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:221.12pt;position:absolute;text-decoration:none;white-space:pre;width:337.08pt">To protect the confidentiality and security of Geron Proprietary Information</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.2pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:622.66pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:297.11pt">provided to Consultant under this Agreement, Consultant agrees to&#58;</font></div><div style="line-height:7.62pt;position:absolute;top:649.06pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:111.2pt;position:absolute;text-decoration:none;white-space:pre">i.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:126pt;position:absolute;text-decoration:none;white-space:pre">Access,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:159.89pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:164.63pt;position:absolute;text-decoration:none;white-space:pre">store</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:186pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:188.66pt;position:absolute;text-decoration:none;white-space:pre">and process</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:240.26999999999998pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:242.98000000000002pt;position:absolute;text-decoration:none;white-space:pre">Geron Proprietary Information on a</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:399.3pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:401.96pt;position:absolute;text-decoration:none;white-space:pre">device</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:430.65pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:433.31pt;position:absolute;text-decoration:none;white-space:pre">that is</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:459.87pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:462.53pt;position:absolute;text-decoration:none;white-space:pre">private to Consultant </font></div><div style="line-height:7.62pt;position:absolute;top:662.26pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:126pt;position:absolute;text-decoration:none;white-space:pre">(i.e., not a shared or public device)&#59;</font></div><div style="line-height:7.62pt;position:absolute;top:675.46pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:108.1pt;position:absolute;text-decoration:none;white-space:pre">ii.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:126pt;position:absolute;text-decoration:none;white-space:pre">Follow strong password protection practices and do not share passwords that would enable a user </font></div><div style="line-height:7.62pt;position:absolute;top:688.66pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:126pt;position:absolute;text-decoration:none;white-space:pre">to access Geron Proprietary Information or Geron-related email&#59;</font></div><div style="line-height:7.62pt;position:absolute;top:701.91pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:105.1pt;position:absolute;text-decoration:none;white-space:pre">iii.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:125.8pt;position:absolute;text-decoration:none;white-space:pre">Employ</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:160.61pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:163.17pt;position:absolute;text-decoration:none;white-space:pre">an</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:173.55pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:176.01pt;position:absolute;text-decoration:none;white-space:pre">industry-standard</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:252.95999999999998pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:255.51999999999998pt;position:absolute;text-decoration:none;white-space:pre">firewall</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:289.69pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:292.15pt;position:absolute;text-decoration:none;white-space:pre">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:308.03pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:310.59pt;position:absolute;text-decoration:none;white-space:pre">antivirus</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:349.06pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:351.57pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre">software&#59;</font></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt"><div style="position:absolute;top:728.64pt"><div style="width:522pt"></div></div><div style="position:absolute"><div style="width:522pt"></div></div><div><div style="line-height:7.62pt;position:absolute;top:66.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:105.7pt;position:absolute;text-decoration:none;white-space:pre">iv.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:126pt;position:absolute;text-decoration:none;white-space:pre">Do not store Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:210.59pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:213.3pt;position:absolute;text-decoration:none;white-space:pre">Proprietary</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:262.75pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:265.46000000000004pt;position:absolute;text-decoration:none;white-space:pre">Information on</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:331.72pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:334.43pt;position:absolute;text-decoration:none;white-space:pre">filesharing</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:381.44pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:384.15pt;position:absolute;text-decoration:none;white-space:pre">platforms,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:429.03pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:431.74pt;position:absolute;text-decoration:none;white-space:pre">such Box, Dropbox,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:520.3299999999999pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:523.04pt;position:absolute;text-decoration:none;white-space:pre">Google </font></div><div style="line-height:7.62pt;position:absolute;top:80.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:126pt;position:absolute;text-decoration:none;white-space:pre">Docs, etc., unless specifically authorized by Geron&#59;</font></div><div style="line-height:7.62pt;position:absolute;top:93.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:108.7pt;position:absolute;text-decoration:none;white-space:pre">v.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:126pt;position:absolute;text-decoration:none;white-space:pre">Notify Geron immediately if a device (e.g., computer, USB drive or phone) or application system </font></div><div style="line-height:7.62pt;position:absolute;top:106.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:126pt;position:absolute;text-decoration:none;white-space:pre">(e.g.,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:148.29pt;letter-spacing:-0.07200000000000001em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:150.25pt;position:absolute;text-decoration:none;white-space:pre">email)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:178.32pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:180.38pt;position:absolute;text-decoration:none;white-space:pre">storing</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:210.92000000000002pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:212.98000000000002pt;position:absolute;text-decoration:none;white-space:pre">Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:240.45999999999998pt;letter-spacing:-0.068em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:242.47pt;position:absolute;text-decoration:none;white-space:pre">Proprietary</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:291.91999999999996pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:294.03pt;position:absolute;text-decoration:none;white-space:pre">Information</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:346.53999999999996pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:348.6pt;position:absolute;text-decoration:none;white-space:pre">is</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:355.93pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:357.99pt;position:absolute;text-decoration:none;white-space:pre">suspected</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:400.74pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:402.8pt;position:absolute;text-decoration:none;white-space:pre">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:411.35pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:413.41pt;position:absolute;text-decoration:none;white-space:pre">be</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:423.79pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:425.85pt;position:absolute;text-decoration:none;white-space:pre">lost,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:444.48pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:446.54pt;position:absolute;text-decoration:none;white-space:pre">hacked,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:480.43pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:482.49pt;position:absolute;text-decoration:none;white-space:pre">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:491.65pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:493.76pt;position:absolute;text-decoration:none;white-space:pre">compromised.</font></div><div style="line-height:7.44pt;position:absolute;top:132.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:54pt;position:absolute;text-decoration:underline;white-space:pre">6.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:62.25pt;letter-spacing:0.213em;position:absolute;text-decoration:underline;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:67.34pt;position:absolute;text-decoration:underline;white-space:pre">Consultant&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:127.2pt;letter-spacing:-0.022em;position:absolute;text-decoration:underline;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:129.70999999999998pt;position:absolute;text-decoration:underline;white-space:pre">Other</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:157.79000000000002pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:underline;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:160.35pt;position:absolute;text-decoration:underline;white-space:pre">Activities</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:204.3pt;letter-spacing:-0.022em;position:absolute;text-decoration:underline;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:206.81pt;position:absolute;text-decoration:underline;white-space:pre">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:224.53pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:underline;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:227.09pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:underline;white-space:pre">Obligations.</font></div><div style="line-height:7.62pt;position:absolute;top:158.81pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre">a)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:104.7pt;position:absolute;text-decoration:none;white-space:pre">No</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:118.14pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:120.7pt;position:absolute;text-decoration:none;white-space:pre">Conflicts</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:162.83pt;position:absolute;text-decoration:none;white-space:pre">.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:165.58pt;letter-spacing:0.213em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:170.67000000000002pt;position:absolute;text-decoration:none;white-space:pre">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:218.31pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:220.92000000000002pt;position:absolute;text-decoration:none;white-space:pre">represents</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:265.49pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:267.95pt;position:absolute;text-decoration:none;white-space:pre">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:283.83pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:286.39pt;position:absolute;text-decoration:none;white-space:pre">warrants</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:324.24pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:326.75pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre">that&#58;</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:185.21pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:10.37pt">(i)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:150pt;position:absolute;text-decoration:none;white-space:pre;width:55.58pt">Consultant&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:205.57999999999998pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.66pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:208.24pt;position:absolute;text-decoration:none;white-space:pre;width:42.13pt">rendering</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:250.37pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.61pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:252.98000000000002pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:262.14pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.66pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:264.8pt;position:absolute;text-decoration:none;white-space:pre;width:37.24pt">Services</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:302.03999999999996pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.51pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:304.55pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:320.43pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.51pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:322.94pt;position:absolute;text-decoration:none;white-space:pre;width:55.55pt">performance</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:378.49pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.66pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:381.15pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:390.31pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.56pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:392.87pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">this</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:408.75pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.66pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:411.41pt;position:absolute;text-decoration:none;white-space:pre;width:48.84pt">Agreement</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:460.25pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.66pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:462.91pt;position:absolute;text-decoration:none;white-space:pre;width:20.16pt">does</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:483.07pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.56pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:485.63pt;position:absolute;text-decoration:none;white-space:pre;width:14.05pt">not</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:499.68pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.76pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:502.44pt;position:absolute;text-decoration:none;white-space:pre;width:33.57pt">conflict</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:536.01pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.66pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:538.6700000000001pt;position:absolute;text-decoration:none;white-space:pre;width:19.54pt">with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.21pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:198.41pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:150pt;position:absolute;text-decoration:none;white-space:pre;width:371.93pt">and will not violate any obligations Consultant has to any other person or entity&#59; and</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:224.26pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:13.42pt">(ii)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:150pt;position:absolute;text-decoration:none;white-space:pre;width:407.92pt">If Consultant is employed by any third party, Consultant has disclosed the nature and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:557.9200000000001pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:237.46pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:150pt;position:absolute;text-decoration:none;white-space:pre;width:407.85pt">existence of this Agreement to Consultant&#8217;s employer to the fullest extent required by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:557.85pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:250.66pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:150pt;position:absolute;text-decoration:none;white-space:pre;width:396.29pt">employer&#8217;s policies and is in compliance with such policies as they affect this Agreement.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:277.11pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:9.77pt">b)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:108pt;position:absolute;text-decoration:none;white-space:pre;width:57.39pt">Competitive</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:165.39pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:6.2pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:171.59pt;position:absolute;text-decoration:none;white-space:pre;width:43.95pt">Activities</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:215.54000000000002pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt">.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:218.29000000000002pt;letter-spacing:0.177em;position:absolute;text-decoration:none;white-space:pre;width:8.48pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:226.76999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:31.15pt">During</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:257.91999999999996pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:6.05pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:263.97pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:277.4pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:6.2pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:283.6pt;position:absolute;text-decoration:none;white-space:pre;width:23.8pt">Term</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:307.4pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:6.25pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:313.65pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:322.81pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:6.1pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:328.90999999999997pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">this</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:344.78999999999996pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:6.25pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:351.03999999999996pt;position:absolute;text-decoration:none;white-space:pre;width:48.84pt">Agreement</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:399.88pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:6.25pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:406.13pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:422.01pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:6.2pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:428.21pt;position:absolute;text-decoration:none;white-space:pre;width:12.82pt">for</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:441.03pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:6.25pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:447.28pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">one</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:463.16pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:6.1pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:469.26pt;position:absolute;text-decoration:none;white-space:pre;width:12.82pt">(1)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:482.08pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:6.1pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:488.18pt;position:absolute;text-decoration:none;white-space:pre;width:18.92pt">year</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:507.1pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:6.25pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:513.35pt;position:absolute;text-decoration:none;white-space:pre;width:44.85pt">thereafter,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.2pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.41pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:290.31pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:108pt;position:absolute;text-decoration:none;white-space:pre;width:450.18pt">Consultant will not, without Geron&#8217;s prior written consent solicit or hire any employees of Geron to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.1800000000001pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:303.51pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:108pt;position:absolute;text-decoration:none;white-space:pre;width:214.34pt">work for an employer that competes with Geron.</font></div><div style="line-height:7.44pt;position:absolute;top:329.31pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:54pt;position:absolute;text-decoration:underline;white-space:pre">7.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:62.25pt;letter-spacing:-0.004em;position:absolute;text-decoration:underline;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:64.96pt;position:absolute;text-decoration:underline;white-space:pre">Legal</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:91.22pt;letter-spacing:0.004em;position:absolute;text-decoration:underline;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:94.01pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:underline;white-space:pre">Compliance.</font></div><div style="line-height:7.62pt;position:absolute;top:355.71pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre">Debarment</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:143.12pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:145.82999999999998pt;position:absolute;text-decoration:none;white-space:pre">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:163.55pt;letter-spacing:0.17200000000000001em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:168.19pt;position:absolute;text-decoration:none;white-space:pre">Exclusion</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:214pt;position:absolute;text-decoration:none;white-space:pre">.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:216.75pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:221.49pt;position:absolute;text-decoration:none;white-space:pre">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:269.13pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:273.87pt;position:absolute;text-decoration:none;white-space:pre">represents</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:318.44pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:323.18pt;position:absolute;text-decoration:none;white-space:pre">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:339.06pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:343.8pt;position:absolute;text-decoration:none;white-space:pre">warrants</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:381.65pt;letter-spacing:0.177em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:386.34pt;position:absolute;text-decoration:none;white-space:pre">that</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:402.82pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:407.56pt;position:absolute;text-decoration:none;white-space:pre">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:455.2pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:459.94pt;position:absolute;text-decoration:none;white-space:pre">has</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:474.6pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:479.34pt;position:absolute;text-decoration:none;white-space:pre">not</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:493.39pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:498.13pt;position:absolute;text-decoration:none;white-space:pre">been debarred</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:560.1pt;letter-spacing:0.09em;position:absolute;text-decoration:none;white-space:pre"> </font></div><div style="line-height:7.62pt;position:absolute;top:368.91pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre">under</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:79.03999999999999pt;letter-spacing:0.08600000000000001em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:82.73pt;position:absolute;text-decoration:none;white-space:pre">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:96.16pt;letter-spacing:0.09em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:99.9pt;position:absolute;text-decoration:none;white-space:pre">Federal</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:132.86pt;letter-spacing:0.08600000000000001em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:136.55pt;position:absolute;text-decoration:none;white-space:pre">Food,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:161.91pt;letter-spacing:0.09em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:165.65pt;position:absolute;text-decoration:none;white-space:pre">Drug,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:191pt;letter-spacing:0.09em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:194.74pt;position:absolute;text-decoration:none;white-space:pre">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:210.62pt;letter-spacing:0.09em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:214.36pt;position:absolute;text-decoration:none;white-space:pre">Cosmetic</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:255.88pt;letter-spacing:0.09em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:259.62pt;position:absolute;text-decoration:none;white-space:pre">Act</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:275.49pt;letter-spacing:0.095em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:279.28pt;position:absolute;text-decoration:none;white-space:pre">(21</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:293.94pt;letter-spacing:0.09em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:297.68pt;position:absolute;text-decoration:none;white-space:pre">U.S.C.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:327.31pt;letter-spacing:0.09em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:331.05pt;position:absolute;text-decoration:none;white-space:pre">335a)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:356.09pt;letter-spacing:0.095em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:359.88pt;position:absolute;text-decoration:none;white-space:pre">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:369.04pt;letter-spacing:0.081em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:372.68pt;position:absolute;text-decoration:none;white-space:pre">excluded</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:412.37pt;letter-spacing:0.09em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:416.11pt;position:absolute;text-decoration:none;white-space:pre">from</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:437.48pt;letter-spacing:0.095em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:441.27pt;position:absolute;text-decoration:none;white-space:pre">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:457.15pt;letter-spacing:0.09em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:460.89pt;position:absolute;text-decoration:none;white-space:pre">government </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:516.1600000000001pt;position:absolute;text-decoration:none;white-space:pre">health care or </font></div><div style="line-height:7.62pt;position:absolute;top:382.11pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre">procurement program including, but not limited to, Medicare or Medicaid, and is not, to the best of Consultant&#8217;s </font></div><div style="line-height:7.62pt;position:absolute;top:395.31pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre">knowledge, the subject of any pending proceeding that may result in Consultant&#8217;s debarment or exclusion. Should </font></div><div style="line-height:7.62pt;position:absolute;top:408.51pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre">Consultant be notified of any such proceeding, Consultant will notify Geron immediately.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:434.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">a)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:91.37pt">OFAC Compliance</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:217.37pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt">.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:220.12pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.96pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:224.07999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:334.19pt">Consultant represents and warrants that (a) Consultant is (i) not currently</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.27pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:448.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.26pt">identified on the Specially Designated Nationals and Blocked Persons List maintained by the Office of Foreign</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.26pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:461.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:213.84pt">Assets Control, Department of the Treasury (&#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:267.84000000000003pt;position:absolute;text-decoration:none;white-space:pre;width:31.14pt">OFAC</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:298.98pt;position:absolute;text-decoration:none;white-space:pre;width:259.26pt">&#8221;) and&#47;or on any other similar list maintained by OFAC</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.24pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:474.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:37.87pt">pursuant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:91.87pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.41pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:94.28pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:102.83pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.35pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:105.18pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:121.06pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.35pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:123.41pt;position:absolute;text-decoration:none;white-space:pre;width:50.07pt">authorizing</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:173.48000000000002pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.26pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:175.74pt;position:absolute;text-decoration:none;white-space:pre;width:31.44pt">statute,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:207.18pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.35pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:209.53pt;position:absolute;text-decoration:none;white-space:pre;width:42.12pt">executive</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:251.65pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.35pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:254pt;position:absolute;text-decoration:none;white-space:pre;width:23.2pt">order</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:277.2pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.41pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:279.61pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:288.77pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.41pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:291.18pt;position:absolute;text-decoration:none;white-space:pre;width:44.57pt">regulation</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:335.75pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.35pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:338.1pt;position:absolute;text-decoration:none;white-space:pre;width:57.68pt">(collectively,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:395.78pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.26pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:398.04pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:411.47pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.26pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:413.73pt;position:absolute;text-decoration:none;white-space:pre;width:33.26pt">&#8220;List&#8221;),</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:446.99pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.35pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:449.34pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:465.22pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.35pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:467.57pt;position:absolute;text-decoration:none;white-space:pre;width:13.42pt">(ii)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:480.99pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.41pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:483.4pt;position:absolute;text-decoration:none;white-space:pre;width:14.05pt">not</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:497.45pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.41pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:499.86pt;position:absolute;text-decoration:none;white-space:pre;width:4.88pt">a</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:504.74pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.35pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:507.09pt;position:absolute;text-decoration:none;white-space:pre;width:29.32pt">person</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:536.4100000000001pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.26pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:538.6700000000001pt;position:absolute;text-decoration:none;white-space:pre;width:19.54pt">with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.21pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:487.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:27.49pt">whom</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:81.49pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.12pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:83.61pt;position:absolute;text-decoration:none;white-space:pre;width:4.88pt">a</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:88.49000000000001pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.12pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:90.61pt;position:absolute;text-decoration:none;white-space:pre;width:29.29pt">citizen</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:119.9pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.12pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:122.02pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:131.18pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.17pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:133.35pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:146.78pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.12pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:148.9pt;position:absolute;text-decoration:none;white-space:pre;width:29.92pt">United</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:178.82pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.12pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:180.94pt;position:absolute;text-decoration:none;white-space:pre;width:26.25pt">States</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:207.19pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.12pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:209.31pt;position:absolute;text-decoration:none;white-space:pre;width:7.33pt">is</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:216.64pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.17pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:218.81pt;position:absolute;text-decoration:none;white-space:pre;width:45.19pt">prohibited</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:264pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.12pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:266.12pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:274.66999999999996pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.12pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:276.78999999999996pt;position:absolute;text-decoration:none;white-space:pre;width:31.14pt">engage</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:307.93pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.12pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:310.05pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:318.6pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.17pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:320.77pt;position:absolute;text-decoration:none;white-space:pre;width:52.51pt">transactions</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:373.28pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.12pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:375.4pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:386.4pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.12pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:388.52pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:404.4pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.12pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:406.52pt;position:absolute;text-decoration:none;white-space:pre;width:21.97pt">trade</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:428.49pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.17pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:430.66pt;position:absolute;text-decoration:none;white-space:pre;width:41.22pt">embargo,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:471.88pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.12pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:474pt;position:absolute;text-decoration:none;white-space:pre;width:42.74pt">economic</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:516.74pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.12pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:518.86pt;position:absolute;text-decoration:none;white-space:pre;width:39.39pt">sanction,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.25pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:500.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.26pt">or other prohibition of United States law, regulation, or Executive Order of the President of the United States, (b)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.26pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:514.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.35pt">none of the funds or other assets of Consultant constitute property of, or are beneficially owned, directly or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.35pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:527.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.22pt">indirectly, by any Embargoed Person (as hereinafter defined), (c) no Embargoed Person has any interest of any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.22pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:540.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.25pt">nature whatsoever in Consultant (whether directly or indirectly), (d) none of the funds of Consultant have been</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.25pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:553.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.33pt">derived from any unlawful activity with the result that the investment in Consultant is prohibited by law, and (e)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.3299999999999pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:566.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.26pt">Consultant has implemented procedures, and will consistently apply those procedures, to ensure the foregoing</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.26pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:580.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:66.55pt">representations</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:120.55pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.83pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:123.38pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:139.26pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.83pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:142.09pt;position:absolute;text-decoration:none;white-space:pre;width:45.78pt">warranties</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:187.87pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.83pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:190.7pt;position:absolute;text-decoration:none;white-space:pre;width:30.52pt">remain</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:221.22pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:223.9pt;position:absolute;text-decoration:none;white-space:pre;width:17.09pt">true</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:240.99pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.83pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:243.82pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:259.7pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.83pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:262.53pt;position:absolute;text-decoration:none;white-space:pre;width:30.51pt">correct</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:293.03999999999996pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:295.77pt;position:absolute;text-decoration:none;white-space:pre;width:7.93pt">at</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:303.7pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.88pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:306.58000000000004pt;position:absolute;text-decoration:none;white-space:pre;width:10.98pt">all</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:317.56pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.88pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:320.44pt;position:absolute;text-decoration:none;white-space:pre;width:85.04pt">times. &#8220;Embargoed</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:405.48pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.83pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:408.31pt;position:absolute;text-decoration:none;white-space:pre;width:34.81pt">Person&#8221;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:443.12pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.83pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:445.95pt;position:absolute;text-decoration:none;white-space:pre;width:28.09pt">means</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:474.04pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.83pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:476.87pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:492.75pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.83pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:495.58pt;position:absolute;text-decoration:none;white-space:pre;width:32.07pt">person,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:527.65pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.88pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:530.53pt;position:absolute;text-decoration:none;white-space:pre;width:27.78pt">entity,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.31pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:593.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:63.16pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.36pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:65.52pt;position:absolute;text-decoration:none;white-space:pre;width:52.52pt">government</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:118.04pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.36pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:120.4pt;position:absolute;text-decoration:none;white-space:pre;width:31.14pt">subject</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:151.54000000000002pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.36pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:153.9pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:162.45pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.32pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:164.76999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:21.97pt">trade</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:186.74pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.32pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:189.06pt;position:absolute;text-decoration:none;white-space:pre;width:48.84pt">restrictions</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:237.9pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.36pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:240.26pt;position:absolute;text-decoration:none;white-space:pre;width:25.04pt">under</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:265.3pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.36pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:267.65999999999997pt;position:absolute;text-decoration:none;white-space:pre;width:19.55pt">U.S.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:287.21000000000004pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.22pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:289.43pt;position:absolute;text-decoration:none;white-space:pre;width:18.62pt">law,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:308.05pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.32pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:310.37pt;position:absolute;text-decoration:none;white-space:pre;width:41.53pt">including</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:351.9pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.32pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:354.22pt;position:absolute;text-decoration:none;white-space:pre;width:14.05pt">but</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:368.27pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.36pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:370.63pt;position:absolute;text-decoration:none;white-space:pre;width:14.05pt">not</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:384.68pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.27pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:386.95pt;position:absolute;text-decoration:none;white-space:pre;width:31.13pt">limited</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:418.08pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.22pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:420.3pt;position:absolute;text-decoration:none;white-space:pre;width:11.3pt">to,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:431.6pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.32pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:433.92pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:447.35pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.32pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:449.67pt;position:absolute;text-decoration:none;white-space:pre;width:56.16pt">International</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:505.83pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.36pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:508.19pt;position:absolute;text-decoration:none;white-space:pre;width:50.06pt">Emergency</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.25pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:606.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.19pt">Economic Powers Act, 50 U.S.C. &#167;1701 et seq., The Trading with the Enemy Act, 50 U.S.C. App. 1 et seq., and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.19pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:619.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:269.59pt">any Executive Orders or regulations promulgated thereunder.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:645.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:9.77pt">b)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:63.8pt">Anti-Bribery.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:189.8pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.23pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:193.03pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:240.67000000000002pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.23pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:243.9pt;position:absolute;text-decoration:none;white-space:pre;width:20.76pt">shall</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:264.65999999999997pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.23pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:267.89pt;position:absolute;text-decoration:none;white-space:pre;width:32.98pt">comply</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:300.87pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:3.18pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:304.05pt;position:absolute;text-decoration:none;white-space:pre;width:10.98pt">all</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:315.03pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.23pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:318.26pt;position:absolute;text-decoration:none;white-space:pre;width:45.17pt">applicable</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:363.43pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:3.08pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:366.51pt;position:absolute;text-decoration:none;white-space:pre;width:51.89pt">anti-bribery</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:418.4pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:3.18pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:421.58pt;position:absolute;text-decoration:none;white-space:pre;width:22.9pt">laws,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:444.48pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.23pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:447.71pt;position:absolute;text-decoration:none;white-space:pre;width:41.53pt">including</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:489.24pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:3.18pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:492.42pt;position:absolute;text-decoration:none;white-space:pre;width:14.05pt">but</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:506.47pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.23pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:509.7pt;position:absolute;text-decoration:none;white-space:pre;width:14.05pt">not</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:523.75pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:3.23pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:526.98pt;position:absolute;text-decoration:none;white-space:pre;width:31.13pt">limited</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.11pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.31pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:658.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:62.55pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:3.99pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:66.53999999999999pt;position:absolute;text-decoration:none;white-space:pre;width:491.55pt">U.S. Foreign Corrupt Practices Act. Consultant further warrants that it shall not make any payment, either</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.0899999999999pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:671.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:111.97pt">directly or indirectly, of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:165.97pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:4.98pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:170.95pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:186.83pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:4.98pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:191.81pt;position:absolute;text-decoration:none;white-space:pre;width:44.16pt">money or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:235.97pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:4.98pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:240.95pt;position:absolute;text-decoration:none;white-space:pre;width:110.45pt">other consideration (a &#8220;</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:351.4pt;position:absolute;text-decoration:none;white-space:pre;width:41.52pt">Payment</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:392.92pt;position:absolute;text-decoration:none;white-space:pre;width:11.29pt">&#8221;),</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:404.21pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:4.93pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:409.14pt;position:absolute;text-decoration:none;white-space:pre;width:66.14pt">to government</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:475.28pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:5.03pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:480.31pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:489.47pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:4.98pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:494.45pt;position:absolute;text-decoration:none;white-space:pre;width:63.67pt">political party</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.12pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.66pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:685.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:97.53pt">officials, officials of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:151.53pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:6.71pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:158.24pt;position:absolute;text-decoration:none;white-space:pre;width:55.55pt">international</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:213.79pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:6.76pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:220.55pt;position:absolute;text-decoration:none;white-space:pre;width:61.98pt">organizations,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:282.53pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:6.71pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:289.24pt;position:absolute;text-decoration:none;white-space:pre;width:46.4pt">candidates</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:335.64pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:6.61pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:342.25pt;position:absolute;text-decoration:none;white-space:pre;width:12.82pt">for</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:355.07pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:6.71pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:361.78pt;position:absolute;text-decoration:none;white-space:pre;width:27.48pt">public</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:389.26pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:6.71pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:395.97pt;position:absolute;text-decoration:none;white-space:pre;width:28.38pt">office,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:424.35pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:6.71pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:431.06pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:440.22pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:6.76pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:446.98pt;position:absolute;text-decoration:none;white-space:pre;width:65.93pt">representatives</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:512.9100000000001pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:6.71pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:519.62pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:528.78pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:6.71pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:535.49pt;position:absolute;text-decoration:none;white-space:pre;width:22.59pt">other</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.0799999999999pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:2.71pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:698.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:46.43pt">businesses</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:100.43pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.98pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:104.41pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:113.57pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.98pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:117.55pt;position:absolute;text-decoration:none;white-space:pre;width:33.6pt">persons</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:151.15pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.98pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:155.13pt;position:absolute;text-decoration:none;white-space:pre;width:402.89pt">acting on behalf of any of the foregoing (hereinafter collectively referred as &#8220;Officials&#8221;)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.02pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:711.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.04pt">where such Payment would constitute violation of any law, including without limitation the U.S. Foreign Corrupt</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.04pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt"><div style="position:absolute;top:728.64pt"><div style="width:522pt"></div></div><div style="position:absolute"><div style="width:522pt"></div></div><div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:66.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.13pt">Practices Act. In no event shall Consultant make any Payment either directly or indirectly to Officials if such</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.13pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:80.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:184.22pt">Payment is for the purpose of influencing</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:238.22pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:240.9pt;position:absolute;text-decoration:none;white-space:pre;width:40.92pt">decisions</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:281.82pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.83pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:284.65pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:293.81pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:296.53999999999996pt;position:absolute;text-decoration:none;white-space:pre;width:31.14pt">actions</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:327.68pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.83pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:330.51pt;position:absolute;text-decoration:none;white-space:pre;width:19.54pt">with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:350.05pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:352.73pt;position:absolute;text-decoration:none;white-space:pre;width:31.13pt">respect</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:383.86pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:386.59pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:395.14pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:397.82pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:411.25pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:413.93pt;position:absolute;text-decoration:none;white-space:pre;width:31.14pt">subject</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:445.07pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:447.8pt;position:absolute;text-decoration:none;white-space:pre;width:28.07pt">matter</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:475.87pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:478.6pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:487.76pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:490.49pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">this</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:506.37pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.83pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:509.2pt;position:absolute;text-decoration:none;white-space:pre;width:48.84pt">Agreement</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.04pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.56pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:93.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:63.16pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.99pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:66.15pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:82.03pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.94pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:84.97pt;position:absolute;text-decoration:none;white-space:pre;width:22.59pt">other</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:107.56pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.99pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:110.55pt;position:absolute;text-decoration:none;white-space:pre;width:27.47pt">aspect</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:138.01999999999998pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.99pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:141.01pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:150.17000000000002pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.09pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:153.26pt;position:absolute;text-decoration:none;white-space:pre;width:404.86pt">Geron&#8217;s business. Consultant shall report any violation of this warranty promptly to Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.12pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:106.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.13pt">and agrees to respond to any inquiries about any potential violations and make appropriate records available to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.13pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:119.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.11pt">Geron. At any time upon the request of Geron, Consultant agrees to promptly certify in writing its ongoing</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.11pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:132.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:246.06pt">compliance with the warranties contained in this clause.</font></div><div style="line-height:7.44pt;position:absolute;top:159.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:54pt;position:absolute;text-decoration:underline;white-space:pre">8.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:62.25pt;letter-spacing:0.25em;position:absolute;text-decoration:underline;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:67.75pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:underline;white-space:pre">Miscellaneous.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:185.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">a)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:59.23pt">Termination</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:185.23pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt">.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:187.98pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:6.42pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:194.4pt;position:absolute;text-decoration:none;white-space:pre;width:364.23pt">Either Geron or Consultant may terminate this Agreement at any time, with or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.63pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:198.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.66pt">without cause, upon thirty (30) days prior written notice. In the event of termination Consultant will be</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.6600000000001pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:212.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:115.1pt">compensated for Services</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:169.1pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:172.82999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:34.79pt">actually</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:207.62pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:211.35pt;position:absolute;text-decoration:none;white-space:pre;width:38.46pt">rendered</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:249.81pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:253.54pt;position:absolute;text-decoration:none;white-space:pre;width:31.92pt">but not</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:285.46000000000004pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:289.24pt;position:absolute;text-decoration:none;white-space:pre;width:36.18pt">yet paid</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:325.42pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:329.1pt;position:absolute;text-decoration:none;white-space:pre;width:87.51pt">for by Geron, upon</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:416.61pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:420.29pt;position:absolute;text-decoration:none;white-space:pre;width:49.49pt">submission</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:469.78pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.68pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:473.46pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:489.34pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:493.07pt;position:absolute;text-decoration:none;white-space:pre;width:38.47pt">approval</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:531.54pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre;width:3.78pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:535.3199999999999pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:544.48pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:548.21pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">an</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.5899999999999pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.66pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:225.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:35.11pt">invoice.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:89.11pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.36pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:94.47pt;position:absolute;text-decoration:none;white-space:pre;width:37.25pt">Sections</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:131.72pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.28pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:135pt;position:absolute;text-decoration:none;white-space:pre;width:423.69pt">3, 4, 5, 6(a), 7, 8 and 9(a), 9(c) and 9(d) of this Agreement will survive any termination of the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.69pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:238.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:51.59pt">Agreement.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:265.01pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:9.77pt">b)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:48.24pt">Injunctive</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:174.24pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:4.31pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:178.55pt;position:absolute;text-decoration:none;white-space:pre;width:27.46pt">Relief</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:206.01pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt">.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:208.76pt;letter-spacing:0.168em;position:absolute;text-decoration:none;white-space:pre;width:6.59pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:215.35pt;position:absolute;text-decoration:none;white-space:pre;width:47.64pt">Consultant</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:262.99pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:4.31pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:267.3pt;position:absolute;text-decoration:none;white-space:pre;width:28.08pt">agrees</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:295.38pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:4.31pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:299.69pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:315.57pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:4.31pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:319.88pt;position:absolute;text-decoration:none;white-space:pre;width:62.29pt">acknowledges</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:382.17pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:4.31pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:386.48pt;position:absolute;text-decoration:none;white-space:pre;width:16.48pt">that</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:402.96pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:4.36pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:407.32pt;position:absolute;text-decoration:none;white-space:pre;width:4.88pt">a</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:412.2pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:4.31pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:416.51pt;position:absolute;text-decoration:none;white-space:pre;width:29.3pt">breach</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:445.81pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:4.31pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:450.12pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:459.28pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:4.31pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:463.59pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:479.47pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:4.31pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:483.78pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:492.94pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:4.2pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:497.14pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:510.57pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:4.31pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:514.88pt;position:absolute;text-decoration:none;white-space:pre;width:43.97pt">covenants</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.85pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.31pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:278.21pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:74.2pt">contained herein</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:128.2pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.8pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:132pt;position:absolute;text-decoration:none;white-space:pre;width:17.09pt">will</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:149.09pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.75pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:152.84pt;position:absolute;text-decoration:none;white-space:pre;width:24.42pt">result</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:177.26pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:3.75pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:181.01pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">in</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:189.56pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.8pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:193.36pt;position:absolute;text-decoration:none;white-space:pre;width:47.6pt">irreparable</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:240.96pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.85pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:244.81pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:260.69pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.8pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:264.49pt;position:absolute;text-decoration:none;white-space:pre;width:47.03pt">continuing</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:311.52pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.8pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:315.32pt;position:absolute;text-decoration:none;white-space:pre;width:34.19pt">damage</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:349.51pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.7pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:353.21pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:361.76pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.8pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:365.56pt;position:absolute;text-decoration:none;white-space:pre;width:27.48pt">Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:393.04pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.7pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:396.74pt;position:absolute;text-decoration:none;white-space:pre;width:12.82pt">for</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:409.56pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.85pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:413.41pt;position:absolute;text-decoration:none;white-space:pre;width:26.87pt">which</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:440.28pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.7pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:443.98pt;position:absolute;text-decoration:none;white-space:pre;width:21.97pt">there</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:465.95pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.85pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:469.8pt;position:absolute;text-decoration:none;white-space:pre;width:17.09pt">will</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:486.89pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.85pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:490.74pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">be</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:501.12pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:3.85pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:504.97pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">no</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:515.97pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:3.8pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:519.77pt;position:absolute;text-decoration:none;white-space:pre;width:39.07pt">adequate</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.8399999999999pt;letter-spacing:-0.013000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:2.61pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:291.41pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:32.97pt">remedy</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:86.97pt;letter-spacing:-0.018000000000000002em;position:absolute;text-decoration:none;white-space:pre;width:2.93pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:89.9pt;position:absolute;text-decoration:none;white-space:pre;width:7.93pt">at</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:97.83pt;letter-spacing:-0.022em;position:absolute;text-decoration:none;white-space:pre;width:2.88pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:100.71000000000001pt;position:absolute;text-decoration:none;white-space:pre;width:458.06pt">law and that, in the event of such breach, Geron, in addition to any other remedies it may have, will be</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.77pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:304.61pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.74pt">entitled to a restraining order, injunction, or other similar remedy in order to specifically enforce the provisions of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.74pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:317.81pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:18.63pt">this </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:72.63pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre;width:50.69pt">Agreement.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:344.26pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:300.48pt">No Assignment&#59; Governing Law&#59; Binding Effect&#59; Amendments</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:390.48pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt">.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:393.23pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.76pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:398.99pt;position:absolute;text-decoration:none;white-space:pre;width:176.93pt">Consultant will not assign Consultant&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:575.9200000000001pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.41pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:357.46pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:25.04pt">rights</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:79.03999999999999pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.99pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:82.03pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:91.19pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:3.04pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:94.22999999999999pt;position:absolute;text-decoration:none;white-space:pre;width:36.62pt">delegate</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:130.85pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.99pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:133.84pt;position:absolute;text-decoration:none;white-space:pre;width:55.58pt">Consultant&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:189.42pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.89pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:192.31pt;position:absolute;text-decoration:none;white-space:pre;width:66.56pt">responsibilities</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:258.87pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.89pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:261.76pt;position:absolute;text-decoration:none;white-space:pre;width:25.04pt">under</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:286.8pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.89pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:289.69pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">this</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:305.57pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.99pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:308.56pt;position:absolute;text-decoration:none;white-space:pre;width:48.84pt">Agreement</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:357.4pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.89pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:360.29pt;position:absolute;text-decoration:none;white-space:pre;width:33.59pt">without</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:393.88pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.89pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:396.77pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:410.2pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.89pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:413.09pt;position:absolute;text-decoration:none;white-space:pre;width:21.37pt">prior</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:434.46pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.89pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:437.35pt;position:absolute;text-decoration:none;white-space:pre;width:31.13pt">written</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:468.48pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.99pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:471.47pt;position:absolute;text-decoration:none;white-space:pre;width:79.64pt">consent of Geron.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:551.11pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.32pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:556.4300000000001pt;position:absolute;text-decoration:none;white-space:pre;width:19.54pt">This</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:575.97pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:370.66pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:218.77pt">Agreement will be governed by California law.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:272.77pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:6.55pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:279.32pt;position:absolute;text-decoration:none;white-space:pre;width:296.56pt">This Agreement may be amended only in writing by the parties</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:575.88pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:383.86pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:30.22pt">hereto.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:401.11pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:8.54pt">c)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:137.08pt">Insider Trading Compliance.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:263.08000000000004pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:5.03pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:268.11pt;position:absolute;text-decoration:none;white-space:pre;width:289.93pt">Federal law prohibits you from trading Geron&#8217;s stock if you have</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.04pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:414.31pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:36pt">material</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:90pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.38pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:92.38pt;position:absolute;text-decoration:none;white-space:pre;width:43.98pt">nonpublic</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:136.36pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.34pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:138.7pt;position:absolute;text-decoration:none;white-space:pre;width:51.9pt">information</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:190.6pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.34pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:192.94pt;position:absolute;text-decoration:none;white-space:pre;width:24.43pt">about</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:217.37pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.38pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:219.75pt;position:absolute;text-decoration:none;white-space:pre;width:30.23pt">Geron.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:249.98pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:4.92pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:254.9pt;position:absolute;text-decoration:none;white-space:pre;width:35.42pt">Geron&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:290.32pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.38pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:292.7pt;position:absolute;text-decoration:none;white-space:pre;width:31.13pt">current</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:323.83pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.38pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:326.21pt;position:absolute;text-decoration:none;white-space:pre;width:30.53pt">Insider</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:356.74pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.38pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:359.12pt;position:absolute;text-decoration:none;white-space:pre;width:34.8pt">Trading</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:393.92pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.34pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:396.26pt;position:absolute;text-decoration:none;white-space:pre;width:28.09pt">Policy</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:424.35pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.34pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:426.69pt;position:absolute;text-decoration:none;white-space:pre;width:15.26pt">can</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:441.95pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.34pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:444.29pt;position:absolute;text-decoration:none;white-space:pre;width:10.38pt">be</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:454.67pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.34pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:457.01pt;position:absolute;text-decoration:none;white-space:pre;width:25.66pt">found</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:482.67pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.34pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:485.01pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">on</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:496.01pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.34pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:498.35pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:511.78pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.34pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:514.12pt;position:absolute;text-decoration:none;white-space:pre;width:43.96pt">Corporate</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.0799999999999pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:427.51pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:53.12pt">Governance</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:107.12pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.38pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:109.5pt;position:absolute;text-decoration:none;white-space:pre;width:20.76pt">page</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:130.26pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.38pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:132.64pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:141.8pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.38pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:144.18pt;position:absolute;text-decoration:none;white-space:pre;width:35.42pt">Geron&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:179.6pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.49pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:182.09pt;position:absolute;text-decoration:none;white-space:pre;width:33.58pt">website</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:215.67pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.49pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:218.16pt;position:absolute;text-decoration:none;white-space:pre;width:83.36pt">(www.geron.com).</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:301.52pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:4.92pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:306.44pt;position:absolute;text-decoration:none;white-space:pre;width:18.94pt">You</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:325.38pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.34pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:327.72pt;position:absolute;text-decoration:none;white-space:pre;width:23.8pt">agree</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:351.52pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.38pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:353.9pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:362.45pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.34pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:364.79pt;position:absolute;text-decoration:none;white-space:pre;width:32.98pt">comply</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:397.77pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.34pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:400.11pt;position:absolute;text-decoration:none;white-space:pre;width:19.54pt">with</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:419.65pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.44pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:422.09pt;position:absolute;text-decoration:none;white-space:pre;width:35.42pt">Geron&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:457.51pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.34pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:459.85pt;position:absolute;text-decoration:none;white-space:pre;width:30.53pt">Insider</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:490.38pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.54pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:492.92pt;position:absolute;text-decoration:none;white-space:pre;width:34.8pt">Trading</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:527.72pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.34pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:530.06pt;position:absolute;text-decoration:none;white-space:pre;width:28.09pt">Policy</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.15pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:440.71pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:152.66pt">during the term of this Agreement.</font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:467.11pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:9.77pt">d)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:68.39pt">Whistleblower</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:194.39pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.94pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:198.32999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:31.44pt">Policy.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:229.76999999999998pt;letter-spacing:0.15em;position:absolute;text-decoration:none;white-space:pre;width:6.14pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:235.91pt;position:absolute;text-decoration:none;white-space:pre;width:27.48pt">Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:263.39pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:3.85pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:267.24pt;position:absolute;text-decoration:none;white-space:pre;width:23.8pt">treats</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:291.03999999999996pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.94pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:294.98pt;position:absolute;text-decoration:none;white-space:pre;width:48.24pt">complaints</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:343.22pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.94pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:347.15999999999997pt;position:absolute;text-decoration:none;white-space:pre;width:24.43pt">about</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:371.59000000000003pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.94pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:375.53pt;position:absolute;text-decoration:none;white-space:pre;width:50.99pt">accounting,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:426.52pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:3.85pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:430.37pt;position:absolute;text-decoration:none;white-space:pre;width:33.57pt">internal</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:463.94pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:3.9pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:467.84pt;position:absolute;text-decoration:none;white-space:pre;width:48.24pt">accounting</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:516.0799999999999pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:3.9pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:519.98pt;position:absolute;text-decoration:none;white-space:pre;width:38.17pt">controls,</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.15pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:2.2pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:480.31pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:461.11pt">auditing matters, questionable financial practices, or violations of the Code of Conduct seriously.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:515.11pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:7.57pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:522.6800000000001pt;position:absolute;text-decoration:none;white-space:pre;width:35.42pt">Geron&#8217;s</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.1pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:493.51pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:210.76pt">Whistleblower Policy is available upon request.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:264.76pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:4.88pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:269.64pt;position:absolute;text-decoration:none;white-space:pre;width:288.5pt">Anonymous complaints to an independent third-party (NASDAQ</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.14pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:506.71pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:463.98pt">OMX) can be submitted by e-mail at Geron&#64;openboard.info or by telephone at (855) 662-0145.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:517.98pt;letter-spacing:0.181em;position:absolute;text-decoration:none;white-space:pre;width:7.73pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:525.71pt;position:absolute;text-decoration:none;white-space:pre;width:32.36pt">Further</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.0699999999999pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:519.91pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:283.35pt">information can be found at http&#58;&#47;&#47;www.openboard.info&#47;GERN&#47;.</font></div></div></div><div style="--justify:justify;--position:absolute;background-color:#FFFFFF;border:1px solid #CCCC;content-visibility:auto;float:none;font-size:0;height:792pt;margin:10px auto 10px auto;overflow:hidden;padding:0;position:relative;width:612pt"><div style="position:absolute;top:728.64pt"><div style="width:522pt"></div></div><div style="position:absolute"><div style="width:522pt"></div></div><div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:90.56pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:90pt;position:absolute;text-decoration:none;white-space:pre;width:8.54pt">e)</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:126pt;position:absolute;text-decoration:none;white-space:pre;width:48.22pt">Electronic</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:174.22pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:3.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:178.04pt;position:absolute;text-decoration:none;white-space:pre;width:48.55pt">Signature.</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:bold;left:226.59pt;letter-spacing:0.1em;position:absolute;text-decoration:none;white-space:pre;width:5.61pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:232.2pt;position:absolute;text-decoration:none;white-space:pre;width:17.09pt">The</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:249.29000000000002pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:3.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:253.11pt;position:absolute;text-decoration:none;white-space:pre;width:29.3pt">parties</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:282.40999999999997pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:3.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:286.23pt;position:absolute;text-decoration:none;white-space:pre;width:23.8pt">agree</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:310.03pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:3.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:313.85pt;position:absolute;text-decoration:none;white-space:pre;width:16.48pt">that</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:330.33000000000004pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:3.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:334.2pt;position:absolute;text-decoration:none;white-space:pre;width:42.74pt">execution</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:376.94pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:3.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:380.76pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:389.92pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:3.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:393.74pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">this</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:409.62pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:3.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:413.44pt;position:absolute;text-decoration:none;white-space:pre;width:48.84pt">Agreement</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:462.28pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:3.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:466.15pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:477.15pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:3.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:480.97pt;position:absolute;text-decoration:none;white-space:pre;width:36.04pt">industry</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:517.01pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:3.82pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:520.8299999999999pt;position:absolute;text-decoration:none;white-space:pre;width:37.25pt">standard</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.0799999999999pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.06pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:103.76pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:86.4pt">electronic signature</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:140.4pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.33pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:142.73000000000002pt;position:absolute;text-decoration:none;white-space:pre;width:37.85pt">software</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:180.57999999999998pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.43pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:183.01pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:198.89pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.28pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:201.17pt;position:absolute;text-decoration:none;white-space:pre;width:12.21pt">&#47;or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:213.38pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.33pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:215.71pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:226.71pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.43pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:229.14pt;position:absolute;text-decoration:none;white-space:pre;width:50.69pt">exchanging</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:279.83000000000004pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre;width:2.43pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:282.26pt;position:absolute;text-decoration:none;white-space:pre;width:20.16pt">PDF</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:302.41999999999996pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:2.28pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:304.7pt;position:absolute;text-decoration:none;white-space:pre;width:44.58pt">signatures</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:349.28pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.48pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:351.76pt;position:absolute;text-decoration:none;white-space:pre;width:20.76pt">shall</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:372.52pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.48pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:375pt;position:absolute;text-decoration:none;white-space:pre;width:20.76pt">have</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:395.76pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.33pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:398.09pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:411.52pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.33pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:413.85pt;position:absolute;text-decoration:none;white-space:pre;width:22.59pt">same</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:436.44pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.33pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:438.77pt;position:absolute;text-decoration:none;white-space:pre;width:21.36pt">legal</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:460.13pt;letter-spacing:-0.036000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.38pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:462.51pt;position:absolute;text-decoration:none;white-space:pre;width:22.58pt">force</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:485.09pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.33pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:487.42pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">and</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:503.3pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.33pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:505.63pt;position:absolute;text-decoration:none;white-space:pre;width:25.01pt">effect</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:530.64pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre;width:2.48pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:533.12pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">as</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:542.28pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.33pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:544.61pt;position:absolute;text-decoration:none;white-space:pre;width:13.43pt">the</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.04pt;letter-spacing:-0.04em;position:absolute;text-decoration:none;white-space:pre;width:2.31pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:116.96pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:504.09pt">exchange of original signatures, and that in any proceeding arising under or relating to this Agreement, each party</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.0899999999999pt;position:absolute;text-decoration:none;white-space:pre;width:2.75pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:130.16pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:64.01pt">hereby waives</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:118.01pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:120.88pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:136.76pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.01pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:139.76999999999998pt;position:absolute;text-decoration:none;white-space:pre;width:20.76pt">right</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:160.53pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.01pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:163.54000000000002pt;position:absolute;text-decoration:none;white-space:pre;width:8.55pt">to</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:172.09pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.97pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:175.06pt;position:absolute;text-decoration:none;white-space:pre;width:20.75pt">raise</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:195.81pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:198.68pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">any</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:214.56pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.01pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:217.57pt;position:absolute;text-decoration:none;white-space:pre;width:33.58pt">defense</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:251.15pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.01pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:254.16pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">or</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:263.32pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.01pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:266.33000000000004pt;position:absolute;text-decoration:none;white-space:pre;width:29.91pt">waiver</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:296.24pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.01pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:299.25pt;position:absolute;text-decoration:none;white-space:pre;width:25.04pt">based</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:324.29pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.97pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:327.26pt;position:absolute;text-decoration:none;white-space:pre;width:22pt">upon</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:349.26pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.97pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:352.23pt;position:absolute;text-decoration:none;white-space:pre;width:42.74pt">execution</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:394.97pt;letter-spacing:-0.054em;position:absolute;text-decoration:none;white-space:pre;width:2.97pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:397.94pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:407.1pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.01pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:410.11pt;position:absolute;text-decoration:none;white-space:pre;width:15.88pt">this</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:425.99pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.01pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:429pt;position:absolute;text-decoration:none;white-space:pre;width:48.84pt">Agreement</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:477.84pt;letter-spacing:-0.05em;position:absolute;text-decoration:none;white-space:pre;width:3.01pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:480.85pt;position:absolute;text-decoration:none;white-space:pre;width:11pt">by</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:491.85pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:494.72pt;position:absolute;text-decoration:none;white-space:pre;width:28.09pt">means</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:522.81pt;letter-spacing:-0.045em;position:absolute;text-decoration:none;white-space:pre;width:3.07pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:525.88pt;position:absolute;text-decoration:none;white-space:pre;width:9.16pt">of</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:535.04pt;letter-spacing:-0.063em;position:absolute;text-decoration:none;white-space:pre;width:2.87pt"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:537.9100000000001pt;position:absolute;text-decoration:none;white-space:pre;width:20.16pt">such</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:558.0699999999999pt;letter-spacing:-0.059000000000000004em;position:absolute;text-decoration:none;white-space:pre;width:2.11pt"> </font></div><div style="line-height:7.62pt;position:absolute;text-align:justify;text-align-last:var(--justify);top:143.36pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre;width:344.62pt">electronic signatures or maintenance of the executed agreement electronically.</font></div><div style="line-height:7.62pt;position:absolute;top:169.86pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre">AGREED</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:98.57pt;letter-spacing:-0.031em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:100.97999999999999pt;position:absolute;text-decoration:none;white-space:pre">AND</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:124.8pt;letter-spacing:-0.027em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:127.26pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre">ACCEPTED&#58;</font></div><div style="line-height:7.62pt;position:absolute;top:196.26pt;width:612pt"><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:54pt;position:absolute;text-decoration:none;white-space:pre">Geron</font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:81.48pt;letter-spacing:-0.004em;position:absolute;text-decoration:none;white-space:pre"> </font><font style="font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:84.19pt;letter-spacing:-0.009000000000000001em;position:absolute;text-decoration:none;white-space:pre">Corporation</font></div><div style="position:absolute;top:207.26pt;width:612pt"><div style="font-size:0pt;left:54pt;position:absolute;width:501pt"><div><table style="border-collapse:collapse;display:inline-table;width:100%"><tr style="height:0"><td style="padding:0;width:243pt"></td><td style="padding:0;width:6pt"></td><td style="padding:0;width:252pt"></td></tr><tr style="height:11.25pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:14.25pt"><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="position:absolute;top:11.25pt;width:243pt"><div><div style="line-height:7.62pt;position:absolute;top:2.63pt;width:243pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:2.63pt;position:absolute;text-decoration:none;white-space:pre">&#47;s&#47; HAROUT SEMERJIAN</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-bottom:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:249pt;position:absolute;top:11.25pt;width:252pt"><div><div style="line-height:7.62pt;position:absolute;top:2.63pt;width:252pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:2.63pt;position:absolute;text-decoration:none;white-space:pre">&#47;s&#47; ANDREW J. GRETHLEIN</font></div></div></div></td></tr><tr style="height:14.25pt"><td style="border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="position:absolute;top:25.5pt;width:243pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:243pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:absolute;text-decoration:none;white-space:pre">HAROUT SEMERJIAN</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="border-top:1pt solid #000;font-size:0;text-align:left;vertical-align:top"><div style="left:249pt;position:absolute;top:25.5pt;width:252pt"><div><div style="line-height:6.93pt;position:absolute;top:2.63pt;width:252pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:10pt;font-style:normal;font-weight:normal;left:2.63pt;position:absolute;text-decoration:none;white-space:pre">ANDREW J. GRETHLEIN</font></div></div></div></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:absolute;top:39.75pt;width:243pt"><div><div style="line-height:7.63pt;position:absolute;top:2.63pt;width:243pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:italic;font-weight:normal;left:2.63pt;position:absolute;text-decoration:none;white-space:pre">President and Chief Executive Officer</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"></td></tr><tr style="height:14.25pt"><td style="font-size:0;text-align:left;vertical-align:top"><div style="position:absolute;top:68.25pt;width:243pt"><div><div style="line-height:7.62pt;position:absolute;top:2.63pt;width:243pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:2.63pt;position:absolute;text-decoration:none;white-space:pre">Date&#58; 13-Oct-2025</font></div></div></div></td><td style="font-size:0;text-align:left;vertical-align:top"></td><td style="font-size:0;text-align:left;vertical-align:top"><div style="left:249pt;position:absolute;top:68.25pt;width:252pt"><div><div style="line-height:7.62pt;position:absolute;top:2.63pt;width:252pt"><font style="color:#000000;font-family:&#39;Times New Roman&#39;, serif;font-size:11pt;font-style:normal;font-weight:normal;left:2.63pt;position:absolute;text-decoration:none;white-space:pre">Date&#58; 13-Oct-2025</font></div></div></div></td></tr></table></div></div></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>4
<FILENAME>employmentagreementbyandbe.htm
<DESCRIPTION>EX-10.4
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i1d3ffaa217284c45ae569d6924ceac62_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:80%">Exhibit 10.4</font></div></div><div style="padding-left:109.42pt;padding-right:109.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:1.20pt">EMPLOYMENT</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.05em;line-height:1.20pt"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.008em;line-height:1.20pt">AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:1.20pt"> </font></div><div><font><br></font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">This</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Employment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">is</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">made</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">effective</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">as</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">April</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">13,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">2026</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), by and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">between</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Timothy Williams (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Geron</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Corporation, a</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">desires</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">employ</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">provide</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">personal</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">services</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company and to provide Executive with certain compensation and benefits in return for Executive&#8217;s services&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:36pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">wishes</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">employed</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">provide</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">personal</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">services</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the Company in return for certain compensation and benefits&#59; and</font></div><div style="margin-top:12.05pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Now, Therefore</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, in consideration of the mutual promises and covenants contained herein, it is hereby agreed by and between the parties hereto as follows&#58;</font></div><div style="margin-top:11.8pt;padding-left:18.12pt;padding-right:18.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:14.50pt">ARTICLE</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.029em;line-height:14.50pt"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.041em;line-height:14.50pt">I</font></div><div style="padding-left:18.05pt;padding-right:18.05pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:13.30pt">DEFINITIONS</font></div><div style="margin-top:12pt;padding-left:53.95pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">For</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">purposes</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Agreement,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">following</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">terms</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">are</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">defined</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">as</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%">follows&#58;</font></div><div style="margin-top:12pt;padding-left:89.95pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">means</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Directors of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%">Company.</font></div><div style="margin-top:12pt;padding-left:89.95pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Cause</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">means</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%">following&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:36pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any willful act or omission by Executive constituting dishonesty, fraud or other malfeasance against the Company&#59;</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s conviction of a felony under the laws of the United States or any state thereof or any other jurisdiction in which the Company conducts business&#59;</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">debarment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">U.S.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Food</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Drug</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Administration</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(FDA)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">from</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">working in or providing services to any pharmaceutical or biotechnology company under the Generic Drug Enforcement Act of 1992, or other ineligibility under any law or regulation to perform Executive&#8217;s duties to the Company&#59; or</font></div><div style="margin-top:12pt;padding-left:107.85pt;padding-right:36pt;text-indent:-17.9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">breach</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">material</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">policies</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%">Company.</font></div><div style="margin-top:12pt;padding-left:89.95pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Change</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Control</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">shall</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">have</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">meaning</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">set</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">forth</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Equity</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Incentive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%">Plan.</font></div><div style="margin-top:12pt;padding-left:89.95pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">1.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Code</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">means</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Internal</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Revenue</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Code</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">1986,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">as</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%">amended.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">1.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">means</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Geron</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Corporation,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">wholly-owned</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">subsidiaries,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">its</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">successors in interest.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">1.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Comparable Employment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means employment on terms that provide (a) the same or greater rate of base pay or salary as</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in effect</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">immediately prior to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s termination, (b) the same, equivalent</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">higher</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">job</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">title</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and level of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">responsibility</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">as</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">had</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">prior</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to Executive&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">termination, (c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">equivalent</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">higher</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">bonus</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">opportunity</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">as</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">bonus</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">opportunity</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">for</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">year</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">preceding</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">year</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%">in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">which</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">termination</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">occurs,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">a</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">principal</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">work</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">location</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">that</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">is</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">both</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">no</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:4.761%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:-0.022em;line-height:12.25pt">1</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">more</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">than</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">forty-five</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(45) miles from Executive&#8217;s principal work location immediately prior to Executive&#8217;s termination and (ii) no more than thirty (30) miles farther from Executive&#8217;s principal weekday residence than was Executive&#8217;s principal work location immediately prior to the termination.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">1.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Covered</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Termination</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">means</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">an Involuntary</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Termination</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Without Cause</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">that occurs</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">at any time, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">that such termination constitutes a &#8220;separation from service&#8221; within the meaning of Section 409A of the Code and the regulations promulgated thereunder, including Treasury Regulation Section 1.409A-1(h) (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Separation from Service</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">1.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Involuntary Termination Without Cause</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Executive&#8217;s dismissal or discharge other than (i) for Cause, or (ii) after an involuntary or voluntary filing of a petition under chapter 7 or 11 of 11</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">USC Section 101</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">et. seq., an assignment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">for the benefit</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of creditors, a liquidation of the company&#8217;s assets in formal proceeding or otherwise or any other event of insolvency by the Company, in any case, without an offer of Comparable Employment by the Company or a successor, acquirer, or affiliate of the Company.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">For</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">purposes</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">this</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Agreement,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">termination</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">employment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">due</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s death or disability will not constitute a termination for Cause.</font></div><div style="margin-top:12pt;padding-left:89.95pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">1.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Inducement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">means</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">2018</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Inducement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Award</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%">Plan.</font></div><div style="margin-top:12pt;padding-left:89.95pt;padding-right:36pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">1.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Equity</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Incentive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">means</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">2018</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Equity</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Incentive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Award</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%">Plan.</font></div><div style="margin-top:12.05pt;padding-left:18.22pt;padding-right:18.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:14.50pt">ARTICLE</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.029em;line-height:14.50pt"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.02em;line-height:14.50pt">II</font></div><div style="padding-left:18.32pt;padding-right:18.32pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:13.30pt">EMPLOYMENT</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.022em;line-height:13.30pt"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:13.30pt">BY</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.027em;line-height:13.30pt"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:13.30pt">THE</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.031em;line-height:13.30pt"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:13.30pt">COMPANY</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Position</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Duties.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Subject</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">terms</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">set</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">forth</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">herein,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">agrees</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">employ Executive in the position of Executive Vice President, Chief Legal Officer.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">During the Executive&#8217;s employment in this position, Executive will report to the Chief</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive Officer.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive shall</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">serve</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in an employee capacity and shall perform such duties as are assigned to Executive by the Chief Executive Officer and, except as otherwise instructed by the Chief Executive Officer, such other duties as are customarily associated with the position of Executive Vice President, Chief Legal Officer.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">During Executive&#8217;s employment with the Company, Executive will devote Executive&#8217;s best efforts and substantially</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">all</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">business</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">time</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">attention</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(except</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">for</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">vacation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">periods</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">as</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">set</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">forth</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">herein and reasonable periods of illness or other incapacities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">permitted by the Company&#8217;s general employment policies or as otherwise set forth in this Agreement) to the business of the Company.</font></div><div style="margin-top:11.85pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Employment at Will.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Both the Company and Executive acknowledge and agree that Executive&#8217;s employment with the Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">is &#8220;at-will&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and not for any specified period of time,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and may be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">terminated</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">at</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">time</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">with</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">without</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Cause,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">with</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">without</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">prior notice&#59; provided, however, that if Executive&#8217;s employment with the Company is terminated under circumstances that constitute a Covered Termination, Executive will be eligible to receive certain severance payments and benefits as set forth in Article IV below. Executive is also eligible for severance benefits under the Amended and Restated Severance Plan.</font></div><div style="margin-top:12.05pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Employment Policies.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The employment relationship between the parties shall also be governed</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">general</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">employment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">policies</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">practices</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">including</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">but</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">not limited</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to those</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.095em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">policies</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">relating</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.1em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.109em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">protection</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.109em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.113em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">confidential</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.10400000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">information</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.109em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">assignment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.08600000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.095em;line-height:120%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:4.761%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:-0.022em;line-height:12.25pt">2</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12.05pt;padding-left:17.95pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">inventions.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.363em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.109em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the event</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">a</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">conflict</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">between</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">terms</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">this</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">general</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">employment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">policies or practices, this Agreement shall control.</font></div><div style="margin-top:12.15pt;padding-left:18pt;padding-right:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Indemnification.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Company shall provide for indemnification of the Executive as set forth in the Indemnification Agreement attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12.05pt;padding-left:18.25pt;padding-right:18.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:14.50pt">ARTICLE</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.029em;line-height:14.50pt"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.02em;line-height:14.50pt">III</font></div><div style="padding-left:18.37pt;padding-right:18.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:13.30pt">COMPENSATION</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive shall receive for services to be rendered hereunder such annual base salary as is approved by the Board or the Compensation Committee of the Board, payable on the regular payroll dates of the Company, subject to increase in the sole discretion of the Board or Compensation Committee of the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">As of the Effective Date of this Agreement, Executive&#8217;s Base Salary is $520,000.</font></div><div style="margin-top:11.8pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Bonus</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">As</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Effective</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of this</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Agreement, Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">shall</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">eligible</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">earn,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">for each</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">fiscal</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">year</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">ending</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">December</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">31 during</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">employment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">with</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company, an annual discretionary cash bonus (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Annual Bonus</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) targeted at fifty percent (50%) of Executive&#8217;s Base</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Salary.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">discretionary Annual Bonus</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">will be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">paid</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">during the standard timing for</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">year-end performance bonuses, with the eligibility cutoff date for participation being October 1st in the performance year for which any bonus may be paid. The Annual Bonus is tied to the achievement of certain performance goals established for the Company and each individual and prorated for the individual&#8217;s initial performance period (assuming commencement of employment in the middle of a calendar year)&#59; provided, however, that in order to be eligible for an Annual Bonus for the initial performance period the Effective Date must be on or before September 30th. The total bonus pool generated</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">for</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">distribution,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">if</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">is</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">determined</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">at</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">discretion</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">then</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">distributed</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">based on individual performance.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If the Company determines, in its reasonable discretion, that Executive has engaged</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">misconduct</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">intended</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">affect</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">payment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Annual</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Bonus</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">has</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">otherwise engaged in any act or omission that would constitute Cause for termination of employment, as defined by Section 1.2 of the Agreement, Executive will automatically and immediately forfeit Executive&#8217;s entire Annual</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Bonus.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.168em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Annual</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Bonus</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">has</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">already</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">been</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">paid</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">such</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Annual</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Bonus</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">will</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">deemed unearned, and the Company shall have the right to recover the entire amount of the Annual Bonus paid to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">for</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">calendar</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">year(s)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">which</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">such</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">misconduct</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">other</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">act</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">omission</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">constituting</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Cause occurred.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Without</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">limiting</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">foregoing,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">such</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">misconduct</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">other</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">act</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">omission</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">constituting</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Cause will subject Executive to disciplinary action up to and including termination of employment.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In addition, any Annual Bonus paid to Executive for the calendar year(s) in which such misconduct or other Cause occurred</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">is</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">subject</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">recoupment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">accordance</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">with</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Dodd&#8211;Frank</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Wall</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Street</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Reform</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Consumer Protection</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Act</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">implementing</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">regulations,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">other</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">clawback</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">policy</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">adopted</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and any compensation recovery policy otherwise required by applicable laws, regulations, or statutes. Recovery</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">an</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Annual</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Bonus</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">accordance</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">with</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">this</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Section</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">shall</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">not</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">constitute</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">an</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">event giving rise to a right by Executive to voluntarily terminate Executive&#8217;s employment for Cause based on such recovery by the Company, nor shall it constitute &#8220;constructive termination&#8221;, or any similar term or circumstance under the Agreement or any other plan or agreement with the Company.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">New Hire Stock Option</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.166em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In accordance with the terms approved by Board or the Company&#8217;s Compensation Committee of the Board, the Executive shall receive a time-based option (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">New Hire Option</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to purchase two million and five hundred thousand (2,500,000) shares of Company common</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.08600000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">stock</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">having</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.095em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">an</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.08600000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">exercise</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">price</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">equal</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.1em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.08600000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.109em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">fair</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">market</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.081em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">value</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.09em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.08600000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.095em;line-height:120%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:4.761%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:-0.022em;line-height:12.25pt">3</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">common</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.08600000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">stock,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.1em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">as reported by the Nasdaq Global Select Market, on the first date of Executive&#8217;s employment, and vesting with respect to 12.5% of the shares on the six-month anniversary of the Executive&#8217;s first date of employment and with respect to the remaining shares on each monthly anniversary of the Executive&#8217;s first date of employment in equal installments over 42 months thereafter.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The New Hire Option serves as</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">an</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">inducement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">material</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">entering</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">into</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">employment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">with</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">will</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">granted under the Company&#8217;s Equity Incentive Plan as non-statutory stock options.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The vesting of the New Hire Option shall be subject to Executive&#8217;s continued service to the Company through the applicable vesting dates,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">provided,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">that</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">upon</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">occurrence</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">a</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Change</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Control,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">subject</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">continued</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">service to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">through the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">date of such Change</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Control,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">New</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Hire</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Option</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">shall</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">vest</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and become exercisable</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">with</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">respect</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">one</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">hundred</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">percent</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(100%)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">unvested</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">shares</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">subject</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">thereto.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">New Hire</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Option</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">otherwise</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">shall</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">subject</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">governed</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">all</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">respects</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">terms</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">2018 Inducement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Award</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">stock</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">option</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">for</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">option</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">grant</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">entered</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">into</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">between the Company and Executive.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Standard Company Benefits&#59; Vacation.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive shall be entitled to all rights and benefits for which Executive is eligible under the terms and conditions of the Company&#8217;s benefit and compensation plans, practices, policies, and programs, as in effect from time to time, that are provided by the Company to its executive employees generally.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Except as specifically provided herein, nothing in this Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">is construed or interpreted to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">provide greater rights, participation, coverage, or benefits under such benefit plans or programs provided to executive employees pursuant to the terms and conditions of such benefit plans and programs. Executive will be eligible for vacation accruals in accordance with the Company&#8217;s current time off policy, starting with twenty (20) days per year.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">3.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Sign-On Bonus</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">. Executive shall be paid a cash sign-on bonus in the amount of $90,000. The Sign-On Bonus will be paid on the first scheduled payroll following the Effective Date, provided however,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">if</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">has</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">voluntarily</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">left</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">is</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">no</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">longer</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">employed</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">on</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the first anniversary of the Effective Date, the Sign-On Bonus will be deemed unearned, and the Company shall</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">have</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">right</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">recover</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">entire</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">portion,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">which</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">shall</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">reimbursed</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company within thirty (30) days after such voluntary departure by Executive. The Sign-On Bonus will be subject to applicable taxes.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If the Company determines, in its reasonable discretion, that Executive has engaged in any misconduct</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">has</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">otherwise</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">engaged</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">act</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">omission</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">that</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">would</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">constitute</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Cause</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">for</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">termination of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">employment,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">as</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">defined</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Section</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">this</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Agreement,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Sign-On</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Bonus</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">will</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">deemed</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">unearned, and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">shall</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">have</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">right</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">recover</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">entire</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">amount</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Sign-On</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Bonus.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Without</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">limiting the foregoing, any such misconduct or other act or omission constituting Cause will subject Executive to disciplinary action up to and including termination of employment. The Sign-On Bonus is subject to recoupment in accordance with The Dodd&#8211;Frank Wall Street Reform and Consumer Protection Act and any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">implementing</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">regulations,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">other</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">clawback</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">policy</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">adopted</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">compensation recovery policy otherwise required by applicable laws, regulations or statutes.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Recovery by the Company of the Sign-On Bonus in accordance with this Section shall not constitute an event giving rise to a right by Executive to voluntarily terminate his employment for Cause based</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">on</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">such</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">recovery</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">nor</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">shall</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">it</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">constitute</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;constructive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">termination,&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">similar</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">term or circumstance under the Agreement or any other plan or agreement with the Company. If the Executive&#8217;s employment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">terminates for</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any reason</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">other</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">than</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">a</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Covered</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Termination, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:4.761%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:-0.022em;line-height:12.25pt">4</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">amounts paid under</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">this</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Section</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">will</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">repayable</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">within</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">60</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">days</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">following</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">last</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">day</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">employment.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.029em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.02em;line-height:120%">IV</font></div><div style="padding-left:18.27pt;padding-right:18.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:13.30pt">SEVERANCE</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.045em;line-height:13.30pt"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:13.30pt">BENEFITS</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.027em;line-height:13.30pt"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:13.30pt">AND</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.031em;line-height:13.30pt"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:13.30pt">RELEASE</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Severance</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Benefits.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:0.109em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">employment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.063em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">terminates</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">due</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">a</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Covered</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Termination after the date of execution of this Agreement, Executive shall receive&#58;</font></div><div style="margin-top:12.05pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Payment of Accrued Obligations Upon Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Upon a termination of Executive&#8217;s employment for any reason at any time following the Effective Date, the Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">shall</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">pay</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">a</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">single</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">lump-sum</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">cash</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">payment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">as</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">soon</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">as</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">administratively</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">practicable following</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">termination,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">aggregate</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">amount</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(A)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">earned</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">but</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">unpaid</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Base</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Salary, and (B) accrued but unpaid vacation pay.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In addition, Executive shall be promptly paid for incurred but unreimbursed business expenses upon Executive&#8217;s submission of such expenses in accordance with the Company&#8217;s expense reimbursement policies.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The amounts set forth in this Section 4.1(i) are collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Accrued Obligations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;.</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:36pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Severance Upon a Covered Termination</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If Executive&#8217;s employment terminates due to a Covered Termination at any time after the Effective Date, then, in addition to the Accrued </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%">Obligations&#58;</font></div><div style="margin-top:12.1pt;padding-left:18pt;padding-right:36pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive shall be paid target Annual Bonus for the fiscal year in which the termination</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">occurs, prorated</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">for</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the length</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">service provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">during the calendar</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">year</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">through</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the termination date, payable in a single lump-sum payment within thirty (30) days following the date of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%">termination&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">shall</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">paid</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">an</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">aggregate</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">amount</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">equal</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">twelve</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(12)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">months of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Base</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Salary</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">effect</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">on the date of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">termination, payable</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">a</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">single</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">lump-sum amount on the sixtieth (60</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">) day following the date of termination&#59;</font></div><div style="margin-top:12.05pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">covered</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">dependents</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">will</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">eligible</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">continue their health care benefit coverage as permitted by COBRA (Internal Revenue Code Section 4980B) at the Company&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">expense</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">for</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">lesser</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">twelve</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(12)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">months</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">following</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Covered</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Termination,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">until the Executive and&#47;or Executive&#8217;s covered dependents are no longer eligible for COBRA (for clarification and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">as</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">an example, in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">event</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">is</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">covered</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">another</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">health plan, etc.).</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Thereafter, Executive and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">covered</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">dependents</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">shall be entitled</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">maintain</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">coverage</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">for Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s eligible</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">dependents</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">at</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">own</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">expense</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">for</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">balance</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">that</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">is</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">entitled</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to coverage under COBRA&#59; and</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:36pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the New Hire Option, along with any subsequent options or other exercisable equity interest in the Company held by Executive as of the date of termination shall remain outstanding and exercisable through the earlier of (i) the second (2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">) anniversary of the date of termination or (ii) the original expiration date of the option or other equity interest. Notwithstanding the foregoing, if Executive&#8217;s employment terminates due to a Covered Termination at any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">time</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">after</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Effective</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Date,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">will</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">receive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">greater</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">severance</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">benefits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">above,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%">or </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(ii) the severance benefits provided for</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in the Amended and Restated Severance Plan attached hereto</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">as </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.004em;line-height:120%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">C</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">which</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">may</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">amended</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">from</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">time-to-time</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">at</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">sole</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%">discretion, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">that is in effect at the time of termination. For the avoidance of doubt, all </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:4.761%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:-0.022em;line-height:12.25pt">5</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">amounts payable under this Agreement shall be subject to applicable federal, state, local or foreign tax withholding requirements.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:36pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Parachute Payments.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If any payment or benefit Executive would receive in connection with a Change in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Control from the Company or otherwise (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Payment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) would (i) constitute a &#8220;parachute payment&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">within</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">meaning</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Section</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">280G</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Code,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">but</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">for</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">this</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">sentence,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">subject</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Excise Tax</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), then such Payment shall be reduced to the Reduced Amount. The &#8220;Reduced Amount&#8221; shall be either (x) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (y) the largest portion, up to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and including the total, of the Payment, whichever amount, after taking</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">into</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">account</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">all applicable federal, state</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">local employment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">taxes, income</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">taxes, and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Excise</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Tax</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(all computed</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">at the highest applicable</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">marginal</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">rate),</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">results</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">receipt,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">on</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">an</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">after-tax</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">basis,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">greater</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">amount</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If a reduction in payments or benefits constituting &#8220;parachute payments&#8221; is necessary so that the Payment equals</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Reduced</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Amount,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">reduction</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">shall</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">occur</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">following</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">order</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">unless</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">elects</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">writing a</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">different</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">order</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(provided,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">however,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">that</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">such</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">election</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">shall</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">subject</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">approval)&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">reduction of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">cash</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">payments&#59;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">cancellation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">accelerated</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">vesting</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">stock</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">awards&#59;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">reduction</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">employee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">benefits.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.136em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">event</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">that</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">acceleration</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">vesting</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">stock</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">award</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">compensation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">is</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">reduced,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">such</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">acceleration</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of vesting shall be cancelled in the reverse order of the date of grant of Executive&#8217;s stock awards unless Executive elects in writing a different order for cancellation.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">for</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">general</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">audit</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">purposes</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">shall</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">engage</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">a</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">nationally</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">recognized</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">public</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">accounting</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">firm</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Accounting Firm</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to perform the foregoing calculations. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Accounting Firm</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">engaged</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">make</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">determinations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">hereunder</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">shall</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">provide</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">its</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">calculations,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">together</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">with</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">detailed supporting</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">documentation,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">within</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">fifteen</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(15)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">calendar</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">days</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">after</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">date on which Executive&#8217;s right to a Payment is triggered (if requested at that time by the Company or Executive) or such other time as requested by the Company or Executive. If the Accounting Firm determines</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">that</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">no</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Excise</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Tax</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">is</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">payable</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">with</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">respect</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">a</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Payment,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">either</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">before</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">after</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">application of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Reduced</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Amount,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">it</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">shall</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">furnish</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">with</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">an</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">opinion</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">reasonably</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">acceptable to Executive that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding, and conclusive upon the Company and Executive.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:36pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Release.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, Executive&#8217;s right to receive the amounts provided for in Sections 4.1(ii) and 4.2, and the Change of Control acceleration in any stock option agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">shall</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">subject</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">conditioned</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">upon</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">execution</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">non-revocation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">a</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">release of claims in substantially the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Release</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) (as such form may be modified to take into account changes in the law) within fifty (50) days following the termination date. Such</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Release</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">shall</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">specifically</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">relate</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">all</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">rights</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">claims</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">existence</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">at</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">time</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">such execution and shall confirm Executive&#8217;s obligations under the Proprietary Information and Inventions Agreement (as defined below).</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">It is understood that Executive has a certain period to consider whether to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">execute</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">such</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Release,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">as</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">set</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">forth</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Release,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">may</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">revoke</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">such</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Release</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">within</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%">seven</font></div><div style="margin-top:0.2pt;padding-left:18pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(7) business days after execution. In the event Executive does not execute such Release within the applicable period, or if Executive revokes such Release within the subsequent seven (7) business day period, none of the aforesaid benefits set forth in Sections 4.1(ii), 4.2, and the Change of Control </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:4.761%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:-0.022em;line-height:12.25pt">6</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:0.2pt;padding-left:18pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">acceleration in any stock option agreement shall be payable to Executive under this Agreement and this Agreement shall be null and void.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Section 409A.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed by the Company at the time of the Separation from Service to be a &#8220;specified employee&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">for</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">purposes</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Section</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">409A(a)(2)(B)(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Code,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">extent</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">delayed</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">commencement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of any portion of the benefits to which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, such portion of Executive&#8217;s benefits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">shall</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">not</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">prior</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">earlier</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">expiration</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">six-month</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">period measured</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">from</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Separation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">from</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Service</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">death.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.15em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Upon the first business day following the expiration of the applicable Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this Section 4.4 shall be paid in a lump sum to Executive (or Executive&#8217;s estate</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">beneficiaries),</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">remaining</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">payments</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">due</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">under</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">shall</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">paid</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">as</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">otherwise provided herein.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">For purposes of Section 409A of the Code,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s right</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">receive the payments of compensation pursuant to the Agreement shall be treated as a right to receive a series of separate payments</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">accordingly,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">each</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">payment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.063em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">shall</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">at</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.063em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">all</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">times</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">considered</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">a</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">separate</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">distinct</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">payment.</font></div><div style="margin-top:11.85pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">4.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Mitigation.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive shall not be required to mitigate damages or the amount of any </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%">payment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%">under this</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%">by</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%">seeking other</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%">employment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%">otherwise, nor</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%">shall the amount </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">payment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">for</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">under</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">this</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">reduced</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">compensation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">earned</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive as</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">a</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">result</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">employment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">another</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">employer</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">retirement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">benefits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">received</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">after the date of the Covered Termination, or otherwise.</font></div><div style="margin-top:12pt;padding-left:18.17pt;padding-right:18.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.029em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.041em;line-height:120%">V</font></div><div style="padding-left:18.3pt;padding-right:18.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:13.30pt">PROPRIETARY</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.045em;line-height:13.30pt"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:13.30pt">INFORMATION</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.05em;line-height:13.30pt"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:13.30pt">OBLIGATIONS</font></div><div style="margin-top:12.05pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Agreement.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive agrees to abide by the Proprietary Information and Inventions Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Proprietary Information and Inventions Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Remedies.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s duties under the Proprietary Information and Inventions Agreement shall survive termination of Executive&#8217;s employment with the Company and the termination of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">this</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Agreement.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.17200000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">acknowledges</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">that</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">a</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">remedy</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">at</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">law</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">for</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">breach</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or threatened</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">breach</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by Executive of the provisions of the Proprietary Information and Inventions Agreement would be inadequate,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">therefore</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">agrees</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">that</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">shall</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">entitled</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">injunctive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">relief</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">case of any such breach or threatened breach.</font></div><div style="margin-top:12pt;padding-left:18.12pt;padding-right:18.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.029em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.02em;line-height:120%">VI</font></div><div style="padding-left:18.3pt;padding-right:18.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">OUTSIDE</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">ACTIVITIES</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">No Other Employment.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Except with the prior written consent of the Board, Executive shall</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">not</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">during</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">term</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">employment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">with</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">undertake</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">engage</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">other employment, occupation, or business enterprise.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, during the term of Executive&#8217;s employment with the Company, Executive may (a) undertake or engage in any other employment,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">occupation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">business</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">enterprise</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">which</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">is</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">a</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">passive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">investor,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and&#47;or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">engage in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">civic</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">not-for-profit</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">activities,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">each</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">case,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">so</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">long</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">as</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">such</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">activities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">do</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">not</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">materially</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">interfere</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">with the performance of Executive&#8217;s duties hereunder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:4.761%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:-0.022em;line-height:12.25pt">7</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12.05pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">No Conflicting Business Interests.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">During the term of Executive&#8217;s employment by the Company, except on behalf of the Company, Executive shall not directly or indirectly, whether as an officer,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">director,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">stockholder,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">partner,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">proprietor,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">associate,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">representative,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">consultant,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">capacity whatsoever</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">engage</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">become</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">financially</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">interested</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">employed</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">have</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">business</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">connection with any other person, corporation, firm, partnership, or other entity whatsoever which were known by Executive to compete directly with the Company, throughout the world, in any line of business engaged in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">planned</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">engaged</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company&#59;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">that</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">anything</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">above</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">contrary notwithstanding, Executive may own, as a passive investor, securities of any competitor corporation, so long</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">as</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">direct</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">holdings</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">one</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">such</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">corporation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">shall</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">not</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">aggregate</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">constitute</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">more than 1% of the voting stock of such corporation.</font></div><div style="margin-top:12.05pt;padding-left:18.22pt;padding-right:18.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:14.50pt">ARTICLE</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.029em;line-height:14.50pt"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.02em;line-height:14.50pt">VII</font></div><div style="padding-left:18.15pt;padding-right:18.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:13.30pt">NONINTERFERENCE</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">While employed by the Company, and for one (1) year immediately following the date on which Executive terminates employment or otherwise ceases providing services to the Company, Executive agrees not to interfere with the business of the Company by soliciting or attempting to solicit any employee of the Company to terminate such employee&#8217;s employment in order to become an employee, consultant, or independent contractor to or for any pharmaceutical or biotechnology competitor of the Company.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s duties under this Article VII shall survive termination of Executive&#8217;s employment with the Company and the termination of this Agreement.</font></div><div style="margin-top:11.9pt;padding-left:18.1pt;padding-right:18.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:14.50pt">ARTICLE</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.029em;line-height:14.50pt"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.016em;line-height:14.50pt">VIII</font></div><div style="padding-left:18.3pt;padding-right:18.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:13.30pt">DEBARMENT</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive certifies that Executive has never been&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a) debarred by any relevant authorities, pursuant</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">applicable</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">law,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">including,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">but</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">not</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">limited</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Section</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">306(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">US</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Federal</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Food, Drug, and Cosmetic Act&#59; (b) convicted of any of the felonies identified among the Exclusion Authorities listed on the U.S. Department of Health and Human Services (HHS) Office of Inspector General website&#59; or (c) listed as being suspended, debarred, or excluded, or otherwise ineligible to participate in Federal procurement or non-procurement programs, including, but not limited to, being listed on the List of Excluded</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Individuals&#47;Entities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(LEIE)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">database</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">on</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">HHS</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Office</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Inspector</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">General</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">website.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive becomes suspended, debarred, or excluded pursuant to any of the foregoing, Executive must notify the Company immediately in writing.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.029em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.02em;line-height:120%">IX</font></div><div style="padding-left:18.05pt;padding-right:18.05pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">GENERAL</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">PROVISIONS</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">9.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Notices.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Any notices provided hereunder must be in writing and shall be deemed effective</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">upon</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the earlier</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">personal delivery</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(including</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">personal</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">delivery</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">telex)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the third</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">day</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">after mailing by first class mail, to the Company at its primary office location and to Executive at Executive&#8217;s address as listed on the Company payroll.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">9.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Section 409A.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">To the extend applicable, this Agreement shall be interpreted in accordance with Section 409A of the Code and Department of Treasury regulations and other interpretative</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">guidance</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">issued</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">thereunder,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">including</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">without</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">limitation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">such</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">regulations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">other</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">such guidance</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">that</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">may</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">issued</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">after</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Effective</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Section</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">409A</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">provision</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of this Agreement to the contrary, in the event that following the Effective Date, the Company determines in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">good</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">faith</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">that</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">compensation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">benefits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">payable</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">under</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">this</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:4.761%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:-0.022em;line-height:12.25pt">8</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">may</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">not</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">either</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">exempt from or compliant with Section 409A, the Company may adopt such amendments to this Agreement or adopt other policies or procedures (including amendments, policies and procedures with retroactive effect),</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.145em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.136em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">take</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.136em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.159em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">other</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.154em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">commercially</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.136em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">reasonable</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.136em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">actions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.136em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">necessary</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.14em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.154em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">appropriate</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.136em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.127em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">preserve</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.136em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the intended</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">tax</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">treatment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">compensation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">benefits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">payable</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">hereunder,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">including</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">without</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">limitation actions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">intended</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">exempt</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">compensation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">benefits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">payable</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">under</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">this</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">from</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Section 409A,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and&#47;or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">comply</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">with</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">requirements</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Section</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">409A,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">provided,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">that</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">this</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Section</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">8.2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">does not, and shall not be construed so as to, create any obligation on the part of the Company to adopt any such amendments,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">policies</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">procedures</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">take</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">other</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">such</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">actions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">create</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">liability</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">on</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">part of the Company for any failure to do so.</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">9.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Severability.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Whenever</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">possible,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">each</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">provision</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">this</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">will</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">interpreted</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal, or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality, or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed, and enforced in such jurisdiction as if such invalid, illegal, or unenforceable provisions had never been contained herein.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">9.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Waiver.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:0.131em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">either</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">party</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">should</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">waive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">breach</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">provisions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">this</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Agreement,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">they shall</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">not</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">thereby</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">deemed</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">have</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">waived</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">preceding</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">succeeding</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">breach</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">same</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">other provision of this Agreement.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">9.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Complete Agreement.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement and Exhibits A, B, C and D hereto constitute the entire agreement between Executive and the Company and are the complete, final, and exclusive embodiment of their agreement with regard to this subject matter (except for the Equity Incentive Plan and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Inducement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">award</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">agreements</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">thereunder,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Amended</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Restated</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Severance</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Plan, and any successors thereto).</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">As of the Effective Date, this Agreement supersedes any prior agreement between Executive and the Company or any predecessor employer in its entirety. Executive and the Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">acknowledge</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">agree</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">that</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">this</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">is</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">entered</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">into</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">without</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">reliance</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">on</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">promise</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or representation other than those expressly contained herein or therein and cannot be modified or amended except in a writing signed by a duly authorized officer of the Company.</font></div><div style="margin-top:12.1pt;padding-left:18pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">9.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Counterparts and Electronic Signatures.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement may be executed in separate counterparts,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">one</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">which</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">need</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">not</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">contain</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">signatures</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">more</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">than</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">one</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">party,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">but</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">all</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">which</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">taken together</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">will</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">constitute</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">one</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">same</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Agreement.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.11800000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">parties</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">agree</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">that</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">execution</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">this</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Agreement by industry standard electronic signature software and&#47;or by exchanging PDF signatures shall have the same</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">legal</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">force</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">effect</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">as</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">exchange</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">original</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">signatures,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">that</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">proceeding</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">arising</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">under or relating to this Agreement, each party hereby waives any right to raise any defense or waiver based upon</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">execution</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">this</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">means</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">such</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">electronic</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">signatures</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">maintenance</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">executed agreement electronically.</font></div><div style="margin-top:13.25pt;padding-left:18pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">9.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Headings.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">headings</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">sections</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">hereof</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">are</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">inserted</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">for</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">convenience</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">only</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">shall not be deemed to constitute a part hereof nor to affect the meaning thereof.</font></div><div style="margin-top:12.05pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">9.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Successors and Assigns.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company, and their respective successors, assigns, heirs, executors, and administrators, except</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">that</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">may not</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">assign any of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s duties </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:4.761%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:-0.022em;line-height:12.25pt">9</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12.05pt;padding-left:17.95pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">hereunder and Executive may not assign any of Executive&#8217;s rights hereunder, without the written consent of the Company, which shall not be withheld unreasonably.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">9.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Arbitration.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">event</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">contractual,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">statutory or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">tort</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">dispute</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or claim</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">relating</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">arising</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">out</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">employment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">relationship</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">with</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(including</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">but</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">not</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">limited</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any claims of wrongful termination or age, sex, race, or other discrimination, but not including workers&#8217; compensation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">claims), Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company agree</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">that all such disputes</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">will be</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">finally resolved</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by binding arbitration conducted by a single neutral arbitrator associated with the American Arbitration Association</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Foster City, California.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company hereby waive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">their</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">respective</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">rights</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to have any such disputes or claims tried to a judge or jury. However, the Company agrees that this arbitration</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">provision</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">will</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">not</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">apply</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">claim,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">either</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">for</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">injunctive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">relief. The</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">administrative</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">costs</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">arbitration</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">proceeding</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">between</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">fees and costs of the arbitrator shall be borne by the Company.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">9.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Attorneys&#8217;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Fees</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">either</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">party</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">hereto</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">brings</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">action</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">enforce</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">rights</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">hereunder,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">each party in any such action shall be responsible for its own attorneys&#8217; fees and costs incurred in connection with such action.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">9.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive acknowledges that Executive (a) has had the opportunity to discuss this matter with and obtain advice from independent counsel of Executive&#8217;s own choice and has</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">been</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">advised</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">do so</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">by the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company, (b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">has</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">carefully</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">read</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">fully</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">understands</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">all the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">provisions of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">this</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Agreement,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">is</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">knowingly</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">voluntarily</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">entering</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">into</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">this</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Agreement.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.113em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">represents that Executive (i) is familiar with the restrictive covenants set forth in the Proprietary Information and Inventions Agreement and (ii) is fully aware of Executive&#8217;s obligations thereunder.</font></div><div style="margin-top:12.05pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">9.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Choice of Law.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">All questions concerning the construction, validity and interpretation of this Agreement will be governed by the law of the State of California.</font></div><div style="margin-top:12pt;padding-left:17.95pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">9.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Personal Information</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive understands that the Company may hold certain personal</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">information</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">about</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">him</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">her,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.05em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">including,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">but</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">not</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">limited</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">your</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">name,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">home</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">address,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.045em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">telephone number, date of birth, social security number, salary, nationality, and job title (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Personal Data</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Certain Personal Data may also constitute &#8220;Sensitive Personal Data&#8221; within the meaning of applicable local law.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Such data include, but are not limited to, Personal Data and any changes thereto, and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">other appropriate personal and financial data</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">about</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">you.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">lawful basis</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">for</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">processing Personal Data and Sensitive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Personal Data include fulfilling its role as an</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">employer, compliance with law, and legitimate business interest.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive hereby provides express consent to the Company to process such Personal Data and Sensitive Personal Data and to transfer any such Personal Data and Sensitive Personal</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Data</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">third</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">parties</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">outside</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">country</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">which</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">you</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">are</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">employed</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">retained,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">for</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.059000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">purposes of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">administrating</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">managing</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">your</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">employment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">relationship</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">with</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">may,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">at</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">any time, review his or her Personal Data, request any necessary corrections to it, or withdraw his or her consent in writing by contacting the Company&#59; however, withdrawal of your consent may affect your employment with the Company.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:36pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">9.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Eligibility to Work</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In accordance with federal law, all new employees are required to present evidence of their eligibility to be employed</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the United States and this Agreement is</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">subject to proof</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Executive&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">ability</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">lawfully</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">work</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">United</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">States.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Accordingly,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.036000000000000004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">requests</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">that Executive provide the Company with appropriate documentation for this purpose within 72</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">hours of the first day of employment.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Acceptable documents include, but are not </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:4.761%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:-0.022em;line-height:12.25pt">10</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;padding-left:18pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">limited to, a birth certificate, a passport, a visa, permanent residence card, or driver&#8217;s license and social security card.</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">9.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Pre-Employment Screenings as a Condition of Employment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">. As a condition of employment, Executive will be required to submit to a background check which must yield results considered</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.081em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">acceptable</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.08600000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.081em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.08600000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Standard</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.081em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">screenings include</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.08600000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">verification</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.081em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.08600000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">prior</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.08600000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">employment and education, a drug test, and a criminal history check.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Additional screenings, such as a credit</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">check or Department of Motor Vehicles record check, may be applicable based on job function.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Further, the Company will require the receipt of professional references that are predominately positive in content and character.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.181em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If the results of any of these screenings are determined by the Company to be noncompliant</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">with</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">its policies,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">procedures,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">general business</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">requirements,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">reserves</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the right to unilaterally revoke this Agreement, with no obligation or liability to you.</font></div><div style="margin-top:12.05pt;padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;REMAINDER</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.044em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">OF</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.044em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">THIS</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.005em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">PAGE</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">LEFT BLANK&#59;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.054em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">SIGNATURE</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">PAGE</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">TO</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.022em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.011em;line-height:120%">FOLLOW</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:-0.009000000000000001em;line-height:120%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:4.761%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:-0.022em;line-height:12.25pt">11</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12.7pt;padding-left:45pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">In</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;letter-spacing:0.018000000000000002em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Witness Whereof</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the parties have</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">executed</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">this Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">on</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">the respective dates</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.004em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">set</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%">forth below&#58;</font></div><div style="margin-top:12pt;padding-right:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.428%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">GERON CORPORATION</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; HAROUT SEMERJIAN</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">HAROUT SEMERJIAN</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; 25-Mar-2026</font></td></tr></table></div><div style="margin-top:9pt;padding-right:36pt"><font><br></font></div><div style="margin-top:7.8pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Accepted</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.04em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">agreed</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.027em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%">this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.022em;line-height:120%">26.00 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">day</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.031em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.009000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">March,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.013000000000000001em;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;letter-spacing:-0.018000000000000002em;line-height:120%">2026,</font></div><div style="padding-right:36pt"><font><br></font></div><div style="padding-right:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:47.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.470%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; TIMOTHY WILLIAMS</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">TIMOTHY WILLIAMS</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:4.761%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;letter-spacing:-0.022em;line-height:12.25pt">12</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>gern-20260331xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="if232d0894f9c406786bfba87aa8a672f_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">FORM OF RULE 13A-14(A)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302(A) OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Harout Semerjian, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:64.8pt;text-indent:-64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:57.3pt">I have reviewed this quarterly report on Form 10-Q of Geron Corporation&#59;</font></div><div style="margin-bottom:6pt;padding-left:64.8pt;text-indent:-64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:57.3pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:64.8pt;text-indent:-64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:57.3pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:64.8pt;text-indent:-64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:57.3pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:130.5pt;text-indent:-64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.71pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:130.5pt;text-indent:-64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:130.5pt;text-indent:-64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.71pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:130.5pt;text-indent:-64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:64.8pt;text-indent:-64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:57.3pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:130.5pt;text-indent:-64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.71pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:130.5pt;text-indent:-64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;6, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; HAROUT SEMERJIAN</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">HAROUT SEMERJIAN</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>gern-20260331xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="iea117dfba47f4ce19d0a5bba356dcb31_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">FORM OF RULE 13A-14(A)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302(A) OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Michelle Robertson, certify that&#58;</font></div><div style="margin-bottom:5pt;padding-left:64.8pt;text-indent:-64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:57.3pt">I have reviewed this quarterly report on Form 10-Q of Geron Corporation&#59;</font></div><div style="margin-bottom:5pt;padding-left:64.8pt;text-indent:-64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:57.3pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;padding-left:64.8pt;text-indent:-64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:57.3pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:5pt;padding-left:64.8pt;text-indent:-64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:57.3pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;padding-left:130.5pt;text-indent:-64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.71pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;padding-left:130.5pt;text-indent:-64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;padding-left:130.5pt;text-indent:-64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.71pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;padding-left:130.5pt;text-indent:-64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;padding-left:64.8pt;text-indent:-64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:57.3pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;padding-left:130.5pt;text-indent:-64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.71pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;padding-left:130.5pt;text-indent:-64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"></td><td style="width:61.857%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.943%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;6, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; MICHELLE ROBERTSON</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MICHELLE ROBERTSON</font></td><td colspan="3" style="border-top:0.5pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Vice President, Chief Financial Officer and Treasurer (Duly Authorized Officer and Principal Financial and Accounting Officer)</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>gern-20260331xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ie1a740d0265b478aa03d693c0abb3017_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Geron Corporation (the &#8220;Company&#8221;) hereby certifies, to such officer&#8217;s knowledge, that&#58;</font></div><div style="margin-bottom:6pt;padding-left:130.5pt;text-indent:-64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:55.37pt">the accompanying quarterly report on Form 10-Q of the Company for the quarter ended March&#160;31, 2026 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:6pt;padding-left:130.5pt;text-indent:-64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:52.6pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; May&#160;6, 2026</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; HAROUT SEMERJIAN</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">HAROUT SEMERJIAN</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">President and Chief Executive Officer</font></td></tr></table></div><div style="margin-bottom:12pt;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>gern-20260331xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i66a725365e344db397831c9471c158e2_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Geron Corporation (the &#8220;Company&#8221;) hereby certifies, to such officer&#8217;s knowledge, that&#58;</font></div><div style="margin-bottom:6pt;padding-left:130.5pt;text-indent:-64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:55.37pt">the accompanying quarterly report on Form 10-Q of the Company for the quarter ended March&#160;31, 2026 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:6pt;padding-left:130.5pt;text-indent:-64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:52.6pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; May&#160;6, 2026</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; MICHELLE ROBERTSON</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MICHELLE ROBERTSON</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Vice President, Chief Financial Officer and Treasurer (Duly Authorized Officer and Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>gern-20260331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019c7730-46e9-7212-bc71-75c229f2667a,g:9ff11a8a-3051-4cda-8828-c63f363e56da-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:gern="http://www.geron.com/20260331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.geron.com/20260331">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gern-20260331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gern-20260331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gern-20260331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gern-20260331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.geron.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTS" roleURI="http://www.geron.com/role/BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTS">
        <link:definition>9952157 - Disclosure - BASIS OF PRESENTATION, PRINCIPLES OF CONSOLIDATION USE OF ESTIMATES AND RECENT ACCOUNTING PRONOUNCEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITION" roleURI="http://www.geron.com/role/REVENUERECOGNITION">
        <link:definition>9952158 - Disclosure - REVENUE RECOGNITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORY" roleURI="http://www.geron.com/role/INVENTORY">
        <link:definition>9952159 - Disclosure - INVENTORY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTS" roleURI="http://www.geron.com/role/FINANCIALINSTRUMENTS">
        <link:definition>9952160 - Disclosure - FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.geron.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>9952161 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILS" roleURI="http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILS">
        <link:definition>9952162 - Disclosure - OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBT" roleURI="http://www.geron.com/role/DEBT">
        <link:definition>9952163 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.geron.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>9952164 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERCOMMONSHARE" roleURI="http://www.geron.com/role/NETLOSSPERCOMMONSHARE">
        <link:definition>9952165 - Disclosure - NET LOSS PER COMMON SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTREPORTING" roleURI="http://www.geron.com/role/SEGMENTREPORTING">
        <link:definition>9952166 - Disclosure - SEGMENT REPORTING</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURING" roleURI="http://www.geron.com/role/RESTRUCTURING">
        <link:definition>9952167 - Disclosure - RESTRUCTURING</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTSPolicies" roleURI="http://www.geron.com/role/BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTSPolicies">
        <link:definition>9955511 - Disclosure - BASIS OF PRESENTATION, PRINCIPLES OF CONSOLIDATION USE OF ESTIMATES AND RECENT ACCOUNTING PRONOUNCEMENTS (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONTables" roleURI="http://www.geron.com/role/REVENUERECOGNITIONTables">
        <link:definition>9955512 - Disclosure - REVENUE RECOGNITION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORYTables" roleURI="http://www.geron.com/role/INVENTORYTables">
        <link:definition>9955513 - Disclosure - INVENTORY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSTables" roleURI="http://www.geron.com/role/FINANCIALINSTRUMENTSTables">
        <link:definition>9955514 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.geron.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>9955515 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSTables" roleURI="http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSTables">
        <link:definition>9955516 - Disclosure - OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTTables" roleURI="http://www.geron.com/role/DEBTTables">
        <link:definition>9955517 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTREPORTINGTables" roleURI="http://www.geron.com/role/SEGMENTREPORTINGTables">
        <link:definition>9955518 - Disclosure - SEGMENT REPORTING (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGTables" roleURI="http://www.geron.com/role/RESTRUCTURINGTables">
        <link:definition>9955519 - Disclosure - RESTRUCTURING (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTSDetails" roleURI="http://www.geron.com/role/BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTSDetails">
        <link:definition>9955520 - Disclosure - BASIS OF PRESENTATION, PRINCIPLES OF CONSOLIDATION USE OF ESTIMATES AND RECENT ACCOUNTING PRONOUNCEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONDetails" roleURI="http://www.geron.com/role/REVENUERECOGNITIONDetails">
        <link:definition>9955521 - Disclosure - REVENUE RECOGNITION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORYDetails" roleURI="http://www.geron.com/role/INVENTORYDetails">
        <link:definition>9955522 - Disclosure - INVENTORY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails" roleURI="http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails">
        <link:definition>9955523 - Disclosure - FINANCIAL INSTRUMENTS - Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails" roleURI="http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails">
        <link:definition>9955524 - Disclosure - FINANCIAL INSTRUMENTS - Cash Equivalents and Marketable Securities with Unrealized Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSDetails" roleURI="http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails">
        <link:definition>9955525 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedLiabilitiesDetails" roleURI="http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedLiabilitiesDetails">
        <link:definition>9955526 - Disclosure - OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS - Schedule of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedCompensationandBenefitsDetails" roleURI="http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedCompensationandBenefitsDetails">
        <link:definition>9955527 - Disclosure - OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS - Schedule of Accrued Compensation and Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTAdditionalInformationDetails" roleURI="http://www.geron.com/role/DEBTAdditionalInformationDetails">
        <link:definition>9955528 - Disclosure - DEBT - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails" roleURI="http://www.geron.com/role/DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails">
        <link:definition>9955529 - Disclosure - DEBT - Schedule of Future Minimum Payments Under Loan Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTScheduleofSaleofFutureRoyaltiesDetails" roleURI="http://www.geron.com/role/DEBTScheduleofSaleofFutureRoyaltiesDetails">
        <link:definition>9955530 - Disclosure - DEBT - Schedule of Sale of Future Royalties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.geron.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>9955531 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERCOMMONSHAREDetails" roleURI="http://www.geron.com/role/NETLOSSPERCOMMONSHAREDetails">
        <link:definition>9955532 - Disclosure - NET LOSS PER COMMON SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTREPORTINGDetails" roleURI="http://www.geron.com/role/SEGMENTREPORTINGDetails">
        <link:definition>9955533 - Disclosure - SEGMENT REPORTING (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGAdditionalInformationDetails" roleURI="http://www.geron.com/role/RESTRUCTURINGAdditionalInformationDetails">
        <link:definition>9955534 - Disclosure - RESTRUCTURING - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGSummaryofChargesandSpendingRelatedtoRestructuringDetails" roleURI="http://www.geron.com/role/RESTRUCTURINGSummaryofChargesandSpendingRelatedtoRestructuringDetails">
        <link:definition>9955535 - Disclosure - RESTRUCTURING - Summary of Charges and Spending Related to Restructuring (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="gern_DepositsAndOtherAssetsNoncurrent" abstract="false" name="DepositsAndOtherAssetsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gern_LiabilityRelatedToSaleOfFutureRoyaltiesCurrent" abstract="false" name="LiabilityRelatedToSaleOfFutureRoyaltiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gern_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" abstract="false" name="LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gern_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant" abstract="false" name="StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gern_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant" abstract="false" name="StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" abstract="false" name="IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gern_APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares" abstract="false" name="APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gern_NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties" abstract="false" name="NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gern_IncreaseDecreaseInAllowanceForDoubtfulAccounts" abstract="false" name="IncreaseDecreaseInAllowanceForDoubtfulAccounts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gern_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gern_PaymentsUnpaidToAcquirePropertyPlantAndEquipment" abstract="false" name="PaymentsUnpaidToAcquirePropertyPlantAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gern_SignificantAccountingPoliciesPolicyPolicyTextBlock" abstract="false" name="SignificantAccountingPoliciesPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock" abstract="false" name="ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="gern_ScheduleOfAccruedCompensationAndBenefitsTableTextBlock" abstract="false" name="ScheduleOfAccruedCompensationAndBenefitsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock" abstract="false" name="ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="gern_RevenuesBeforeAdjustmentsMember" abstract="true" name="RevenuesBeforeAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_TotalGrossToNetAdjustmentsMember" abstract="true" name="TotalGrossToNetAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_ChargebacksMember" abstract="true" name="ChargebacksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_DistributorServiceFeesMember" abstract="true" name="DistributorServiceFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_GovernmentRebatesMember" abstract="true" name="GovernmentRebatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_SalesReturnsAndAllowanceMember" abstract="true" name="SalesReturnsAndAllowanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_USTreasurySecuritiesDueInLessThanOneYearMember" abstract="true" name="USTreasurySecuritiesDueInLessThanOneYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_MunicipalSecuritiesDueInLessThanOneYearMember" abstract="true" name="MunicipalSecuritiesDueInLessThanOneYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_MunicipalSecuritiesDueInOneToTwoYearsMember" abstract="true" name="MunicipalSecuritiesDueInOneToTwoYearsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember" abstract="true" name="USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_CommercialPaperDueInLessThanOneYearMember" abstract="true" name="CommercialPaperDueInLessThanOneYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" abstract="true" name="CorporateNoteSecuritiesDueInLessThanOneYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" abstract="true" name="CorporateNoteSecuritiesDueInOneToTwoYearsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_CashAndCashEquivalentsUnrealizedGains" abstract="false" name="CashAndCashEquivalentsUnrealizedGains" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gern_CashAndCashEquivalentsUnrealizedLosses" abstract="false" name="CashAndCashEquivalentsUnrealizedLosses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedGains" abstract="false" name="RestrictedCashAndCashEquivalentsGrossUnrealizedGains" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" abstract="false" name="RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" abstract="false" name="CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" abstract="false" name="AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gern_AccruedManufacturingActivitiesCurrent" abstract="false" name="AccruedManufacturingActivitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gern_GrossToNetAdjustmentsCurrent" abstract="false" name="GrossToNetAdjustmentsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gern_BiopharmaCreditPlcMember" abstract="true" name="BiopharmaCreditPlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_PharmakonLoanAgreementMember" abstract="true" name="PharmakonLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember" abstract="true" name="RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_TrancheAMember" abstract="true" name="TrancheAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_TrancheBMember" abstract="true" name="TrancheBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_TrancheCMember" abstract="true" name="TrancheCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_TermLoansMember" abstract="true" name="TermLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember" abstract="true" name="PrepaidPriorToThirdAnniversaryOfFundingDateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember" abstract="true" name="PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember" abstract="true" name="PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_DebtInstrumentScenarioAxis" abstract="true" name="DebtInstrumentScenarioAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="gern_DebtInstrumentScenarioDomain" abstract="true" name="DebtInstrumentScenarioDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_ScenarioOneMember" abstract="true" name="ScenarioOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_ScenarioTwoMember" abstract="true" name="ScenarioTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_DebtInstrumentFloorRate" abstract="false" name="DebtInstrumentFloorRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gern_PercentageOfCommitmentAmountToFundLoan" abstract="false" name="PercentageOfCommitmentAmountToFundLoan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gern_PrepaymentPremiumOnPercentageOfTermLoan" abstract="false" name="PrepaymentPremiumOnPercentageOfTermLoan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gern_UpfrontPaymentReceived" abstract="false" name="UpfrontPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gern_PercentageOfAnnualNetSales" abstract="false" name="PercentageOfAnnualNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gern_DebtInstrumentRoyaltyPaymentRatio" abstract="false" name="DebtInstrumentRoyaltyPaymentRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="gern_LongTermDebtMaturityAfterYearThree" abstract="false" name="LongTermDebtMaturityAfterYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gern_RoyaltiesRollForward" abstract="true" name="RoyaltiesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gern_NumberOfSeverancePlan" abstract="false" name="NumberOfSeverancePlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gern_PurchaseObligationWrittenNoticeTerm" abstract="false" name="PurchaseObligationWrittenNoticeTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gern_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_ResearchAndClinicalExpensesMember" abstract="true" name="ResearchAndClinicalExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_ChemistryManufacturingAndControlExpensesMember" abstract="true" name="ChemistryManufacturingAndControlExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gern_CommercialExpensesMember" abstract="true" name="CommercialExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>gern-20260331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019c7730-46e9-7212-bc71-75c229f2667a,g:9ff11a8a-3051-4cda-8828-c63f363e56da-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item"/>
  <link:roleRef roleURI="http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="gern-20260331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019c7730-47b6-7c02-a865-e60b75802733" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019c7730-47b6-77ee-94bb-4e12190c0268" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019c7730-47b6-7c02-a865-e60b75802733" xlink:to="loc_us-gaap_AccountsPayableCurrent_019c7730-47b6-77ee-94bb-4e12190c0268" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019c7730-47b6-7750-9319-4611e0e6d719" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019c7730-47b6-7c02-a865-e60b75802733" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019c7730-47b6-7750-9319-4611e0e6d719" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_019c7730-47b6-737a-b254-12e73d7713e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019c7730-47b6-7c02-a865-e60b75802733" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_019c7730-47b6-737a-b254-12e73d7713e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_LiabilityRelatedToSaleOfFutureRoyaltiesCurrent_019c7730-47b6-7346-b830-4a2f4bfd627a" xlink:href="gern-20260331.xsd#gern_LiabilityRelatedToSaleOfFutureRoyaltiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019c7730-47b6-7c02-a865-e60b75802733" xlink:to="loc_gern_LiabilityRelatedToSaleOfFutureRoyaltiesCurrent_019c7730-47b6-7346-b830-4a2f4bfd627a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019c7730-47b6-71c3-94b6-7849c2e8a9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019c7730-47b6-7c02-a865-e60b75802733" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_019c7730-47b6-71c3-94b6-7849c2e8a9f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019c7730-47b6-7e4c-a7c7-ea9227f68131" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019c7730-47b6-77fa-8d0d-a45f29e690a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019c7730-47b6-7e4c-a7c7-ea9227f68131" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019c7730-47b6-77fa-8d0d-a45f29e690a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_019c7730-47b6-76c3-a9ab-a35d0698622a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019c7730-47b6-7e4c-a7c7-ea9227f68131" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_019c7730-47b6-76c3-a9ab-a35d0698622a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_019c7730-47b6-7cd0-8ee7-0e79c21c0b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019c7730-47b6-7e4c-a7c7-ea9227f68131" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_019c7730-47b6-7cd0-8ee7-0e79c21c0b2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_019c7730-47b6-7730-b083-ff1e98333cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019c7730-47b6-7e4c-a7c7-ea9227f68131" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_019c7730-47b6-7730-b083-ff1e98333cd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NontradeReceivablesCurrent_019c7730-47b6-77b9-b77b-f75073ae7db2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NontradeReceivablesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019c7730-47b6-7e4c-a7c7-ea9227f68131" xlink:to="loc_us-gaap_NontradeReceivablesCurrent_019c7730-47b6-77b9-b77b-f75073ae7db2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_019c7730-47b6-7077-80e8-2ea9c37776f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019c7730-47b6-7e4c-a7c7-ea9227f68131" xlink:to="loc_us-gaap_InventoryNet_019c7730-47b6-7077-80e8-2ea9c37776f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019c7730-47b6-7b61-88c7-adcc04ab5ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019c7730-47b6-7e4c-a7c7-ea9227f68131" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019c7730-47b6-7b61-88c7-adcc04ab5ba6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019dbfe2-08a0-74a3-b247-330464ef4728" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019dbfe2-08a0-7dcc-bd3d-7f041698eb96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019dbfe2-08a0-74a3-b247-330464ef4728" xlink:to="loc_us-gaap_LiabilitiesCurrent_019dbfe2-08a0-7dcc-bd3d-7f041698eb96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019dbfe2-08a0-7bd9-a4bf-226009bba732" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019dbfe2-08a0-74a3-b247-330464ef4728" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019dbfe2-08a0-7bd9-a4bf-226009bba732" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_019dbfe2-08a0-74c4-a592-8d983539aa89" xlink:href="gern-20260331.xsd#gern_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019dbfe2-08a0-74a3-b247-330464ef4728" xlink:to="loc_gern_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_019dbfe2-08a0-74c4-a592-8d983539aa89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_019dbfe2-08a0-7bcc-ba4e-2304ee4ca73b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019dbfe2-08a0-74a3-b247-330464ef4728" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_019dbfe2-08a0-7bcc-ba4e-2304ee4ca73b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019c7730-47b6-738d-a5f4-4a58301978c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019c7730-47b6-776f-8a16-0adf5ced25b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019c7730-47b6-738d-a5f4-4a58301978c6" xlink:to="loc_us-gaap_AssetsCurrent_019c7730-47b6-776f-8a16-0adf5ced25b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_019c7730-47b6-7b13-94f7-552d97d3d033" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019c7730-47b6-738d-a5f4-4a58301978c6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_019c7730-47b6-7b13-94f7-552d97d3d033" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019c7730-47b6-73de-991b-7c9f10c3737c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019c7730-47b6-738d-a5f4-4a58301978c6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019c7730-47b6-73de-991b-7c9f10c3737c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_019c7730-47b6-71b1-92ea-bc722604146c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019c7730-47b6-738d-a5f4-4a58301978c6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_019c7730-47b6-71b1-92ea-bc722604146c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_DepositsAndOtherAssetsNoncurrent_019c7730-47b6-7385-8773-ccc850960a34" xlink:href="gern-20260331.xsd#gern_DepositsAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019c7730-47b6-738d-a5f4-4a58301978c6" xlink:to="loc_gern_DepositsAndOtherAssetsNoncurrent_019c7730-47b6-7385-8773-ccc850960a34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019c7730-47b6-7bd2-a28c-683a978afe2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_019c7730-47b6-792c-b169-df8c86f6ee6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019c7730-47b6-7bd2-a28c-683a978afe2d" xlink:to="loc_us-gaap_PreferredStockValue_019c7730-47b6-792c-b169-df8c86f6ee6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_019c7730-47b6-7329-92c0-8d88aa5a8a31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019c7730-47b6-7bd2-a28c-683a978afe2d" xlink:to="loc_us-gaap_CommonStockValue_019c7730-47b6-7329-92c0-8d88aa5a8a31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_019c7730-47b6-7cdf-9444-77923f126c04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019c7730-47b6-7bd2-a28c-683a978afe2d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_019c7730-47b6-7cdf-9444-77923f126c04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019c7730-47b6-7c76-812f-5493b63f2895" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019c7730-47b6-7bd2-a28c-683a978afe2d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019c7730-47b6-7c76-812f-5493b63f2895" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019dbfe3-df03-7f55-adac-8c2af23b22d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019c7730-47b6-7bd2-a28c-683a978afe2d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019dbfe3-df03-7f55-adac-8c2af23b22d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019c7730-47b6-744e-8fc5-384503c0b738" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019c7730-47b6-794b-bf83-2868946ba16a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019c7730-47b6-744e-8fc5-384503c0b738" xlink:to="loc_us-gaap_Liabilities_019c7730-47b6-794b-bf83-2868946ba16a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019c7730-47b6-79b7-bb12-9eaba50ca67e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019c7730-47b6-744e-8fc5-384503c0b738" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019c7730-47b6-79b7-bb12-9eaba50ca67e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019c7730-47b6-7f7e-a656-834f25d256d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019c7730-47b6-744e-8fc5-384503c0b738" xlink:to="loc_us-gaap_StockholdersEquity_019c7730-47b6-7f7e-a656-834f25d256d5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="gern-20260331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019c7730-47b6-7718-95ef-02c22df1662a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019c7730-47b6-7824-85cf-487f3233cdce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019c7730-47b6-7718-95ef-02c22df1662a" xlink:to="loc_us-gaap_OperatingIncomeLoss_019c7730-47b6-7824-85cf-487f3233cdce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_019c7730-47b6-7a2e-a3ac-3134aa1172ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019c7730-47b6-7718-95ef-02c22df1662a" xlink:to="loc_us-gaap_InvestmentIncomeInterest_019c7730-47b6-7a2e-a3ac-3134aa1172ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_019c7730-47b6-7a9c-a6d5-1e6f8ca27dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019c7730-47b6-7718-95ef-02c22df1662a" xlink:to="loc_us-gaap_InterestExpenseNonoperating_019c7730-47b6-7a9c-a6d5-1e6f8ca27dd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_019c7730-47b6-7b19-bd90-e241afe396da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019c7730-47b6-7718-95ef-02c22df1662a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_019c7730-47b6-7b19-bd90-e241afe396da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019c7730-47b6-768e-ad53-c3d2b64cd289" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c7730-47b6-767e-944a-bc9490aab496" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_019c7730-47b6-768e-ad53-c3d2b64cd289" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c7730-47b6-767e-944a-bc9490aab496" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019c7730-47b6-7542-a1f9-6a27685ec131" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_019c7730-47b6-768e-ad53-c3d2b64cd289" xlink:to="loc_us-gaap_OperatingExpenses_019c7730-47b6-7542-a1f9-6a27685ec131" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019c7730-47b6-7aa9-8e9d-42a38afd4716" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_019c7730-47b6-7b4a-ba27-9e73d5e22917" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_019c7730-47b6-7aa9-8e9d-42a38afd4716" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_019c7730-47b6-7b4a-ba27-9e73d5e22917" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019c7730-47b6-70de-a12c-33e3ad8b94d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_019c7730-47b6-7aa9-8e9d-42a38afd4716" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019c7730-47b6-70de-a12c-33e3ad8b94d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_019c7730-47b6-7f0d-8a0b-4a19afc9e916" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_019c7730-47b6-7aa9-8e9d-42a38afd4716" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_019c7730-47b6-7f0d-8a0b-4a19afc9e916" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_019dc3e7-4a01-7ac6-aeaf-eaedce846386" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_019c7730-47b6-7aa9-8e9d-42a38afd4716" xlink:to="loc_us-gaap_RestructuringCharges_019dc3e7-4a01-7ac6-aeaf-eaedce846386" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="gern-20260331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_019c7730-47b6-760e-83da-4f5a362a2f20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019c7730-47b6-7a70-b6ce-ebbccc1d6334" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_019c7730-47b6-760e-83da-4f5a362a2f20" xlink:to="loc_us-gaap_NetIncomeLoss_019c7730-47b6-7a70-b6ce-ebbccc1d6334" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_019c7730-47b6-79a3-91a6-5668a1e23516" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_019c7730-47b6-760e-83da-4f5a362a2f20" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_019c7730-47b6-79a3-91a6-5668a1e23516" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019c7730-47b6-7618-82a8-0d05e6e8efb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_019c7730-47b6-760e-83da-4f5a362a2f20" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019c7730-47b6-7618-82a8-0d05e6e8efb9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="gern-20260331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019c7730-47b6-766f-907d-4a8745cd4281" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_PaymentsUnpaidToAcquirePropertyPlantAndEquipment_019c7730-47b6-7990-a37f-095a87493d0c" xlink:href="gern-20260331.xsd#gern_PaymentsUnpaidToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019c7730-47b6-766f-907d-4a8745cd4281" xlink:to="loc_gern_PaymentsUnpaidToAcquirePropertyPlantAndEquipment_019c7730-47b6-7990-a37f-095a87493d0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_019c7730-47b6-75d8-9fd4-61ec1653b32a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019c7730-47b6-766f-907d-4a8745cd4281" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_019c7730-47b6-75d8-9fd4-61ec1653b32a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_019c7730-47b6-7572-b5be-79bb9a094342" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019c7730-47b6-766f-907d-4a8745cd4281" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_019c7730-47b6-7572-b5be-79bb9a094342" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c7730-47b6-7637-86e0-4ae2738b0afb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019c7730-47b6-7793-be70-6f4a01d69c79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c7730-47b6-7637-86e0-4ae2738b0afb" xlink:to="loc_us-gaap_NetIncomeLoss_019c7730-47b6-7793-be70-6f4a01d69c79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_019c7730-47b6-7462-8275-fce2bac8caff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c7730-47b6-7637-86e0-4ae2738b0afb" xlink:to="loc_us-gaap_DepreciationAndAmortization_019c7730-47b6-7462-8275-fce2bac8caff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019c7730-47b6-76c8-a272-a5e651c066e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c7730-47b6-7637-86e0-4ae2738b0afb" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019c7730-47b6-76c8-a272-a5e651c066e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_019c7730-47b6-7e2d-91a3-acb2ef992bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c7730-47b6-7637-86e0-4ae2738b0afb" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_019c7730-47b6-7e2d-91a3-acb2ef992bf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties_019c7730-47b6-7696-9034-dd84a8834acc" xlink:href="gern-20260331.xsd#gern_NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c7730-47b6-7637-86e0-4ae2738b0afb" xlink:to="loc_gern_NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties_019c7730-47b6-7696-9034-dd84a8834acc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019c7730-47b6-7c26-9b26-ddc07b221f63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c7730-47b6-7637-86e0-4ae2738b0afb" xlink:to="loc_us-gaap_ShareBasedCompensation_019c7730-47b6-7c26-9b26-ddc07b221f63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_019c7730-47b6-7878-a69e-b25a7443e439" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c7730-47b6-7637-86e0-4ae2738b0afb" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_019c7730-47b6-7878-a69e-b25a7443e439" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_IncreaseDecreaseInAllowanceForDoubtfulAccounts_019c7730-47b6-7be0-9ca4-78d7cf400f9d" xlink:href="gern-20260331.xsd#gern_IncreaseDecreaseInAllowanceForDoubtfulAccounts"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c7730-47b6-7637-86e0-4ae2738b0afb" xlink:to="loc_gern_IncreaseDecreaseInAllowanceForDoubtfulAccounts_019c7730-47b6-7be0-9ca4-78d7cf400f9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_019c7730-47b6-78ca-84be-4fbcee62dd4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c7730-47b6-7637-86e0-4ae2738b0afb" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_019c7730-47b6-78ca-84be-4fbcee62dd4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_019c7730-47b6-716f-9a85-ce86a1f18752" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c7730-47b6-7637-86e0-4ae2738b0afb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_019c7730-47b6-716f-9a85-ce86a1f18752" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019c7730-47b6-748d-bbe3-9d99a716a50f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c7730-47b6-7637-86e0-4ae2738b0afb" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019c7730-47b6-748d-bbe3-9d99a716a50f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019c7730-47b6-7ede-b28c-dcfb32b8a00d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c7730-47b6-7637-86e0-4ae2738b0afb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019c7730-47b6-7ede-b28c-dcfb32b8a00d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_019c7730-47b6-72f7-99c4-df7e366b0cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c7730-47b6-7637-86e0-4ae2738b0afb" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_019c7730-47b6-72f7-99c4-df7e366b0cf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_019dc299-1cb5-7689-b695-327027478c42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c7730-47b6-7637-86e0-4ae2738b0afb" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_019dc299-1cb5-7689-b695-327027478c42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_019dc299-1cb5-7389-8561-f862c9d6e9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c7730-47b6-7637-86e0-4ae2738b0afb" xlink:to="loc_us-gaap_PaymentsForRoyalties_019dc299-1cb5-7389-8561-f862c9d6e9d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_IncreaseDecreaseInOperatingLeaseLiabilities_019df8b4-0835-7c48-bd67-e361428db076" xlink:href="gern-20260331.xsd#gern_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c7730-47b6-7637-86e0-4ae2738b0afb" xlink:to="loc_gern_IncreaseDecreaseInOperatingLeaseLiabilities_019df8b4-0835-7c48-bd67-e361428db076" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019c7730-47b6-74f5-b5d0-5c8d292f58d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_019c7730-47b6-791b-9e4d-e6253144d614" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019c7730-47b6-74f5-b5d0-5c8d292f58d0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_019c7730-47b6-791b-9e4d-e6253144d614" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_019c7730-47b6-7599-a7b3-236e3aa9cb28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019c7730-47b6-74f5-b5d0-5c8d292f58d0" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_019c7730-47b6-7599-a7b3-236e3aa9cb28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019c7730-47b6-76e4-8b3f-50689bfa799b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c7730-47b6-7cde-a6c0-398c19957169" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019c7730-47b6-76e4-8b3f-50689bfa799b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c7730-47b6-7cde-a6c0-398c19957169" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019c7730-47b6-7774-b81b-21e8624dfd35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019c7730-47b6-76e4-8b3f-50689bfa799b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019c7730-47b6-7774-b81b-21e8624dfd35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019c7730-47b6-7696-8da6-b51bf7dcb255" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019c7730-47b6-76e4-8b3f-50689bfa799b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019c7730-47b6-7696-8da6-b51bf7dcb255" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019c7730-47b6-7365-af97-11bd7bf34979" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019c7730-47b6-76e4-8b3f-50689bfa799b" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019c7730-47b6-7365-af97-11bd7bf34979" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.geron.com/role/INVENTORYDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#INVENTORYDetails"/>
  <link:calculationLink xlink:role="http://www.geron.com/role/INVENTORYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_019c7730-4892-7b9c-98c4-2e244cbe3ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_019c7730-4892-71e3-9f68-11903fc3a299" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_019c7730-4892-7b9c-98c4-2e244cbe3ec7" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_019c7730-4892-71e3-9f68-11903fc3a299" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_019c7730-4892-77f3-a725-84484b534996" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_019c7730-4892-7b9c-98c4-2e244cbe3ec7" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_019c7730-4892-77f3-a725-84484b534996" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_019c7730-4892-7a49-abb8-bacad727b1c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_019c7730-4892-7b9c-98c4-2e244cbe3ec7" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_019c7730-4892-7a49-abb8-bacad727b1c5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_019dc2a8-10b3-70b7-a1f3-00910f92b032" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedGains_019dc2a8-10b3-7c5e-8062-11be8e298ed0" xlink:href="gern-20260331.xsd#gern_RestrictedCashAndCashEquivalentsGrossUnrealizedGains"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_019dc2a8-10b3-70b7-a1f3-00910f92b032" xlink:to="loc_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedGains_019dc2a8-10b3-7c5e-8062-11be8e298ed0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses_019dc2a8-10b3-7256-b1f3-da5312d551f5" xlink:href="gern-20260331.xsd#gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_019dc2a8-10b3-70b7-a1f3-00910f92b032" xlink:to="loc_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses_019dc2a8-10b3-7256-b1f3-da5312d551f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsAtFairValue_019dc2a8-10b3-7523-b379-5c8b9c7d929c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedInvestmentsAtFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_019dc2a8-10b3-70b7-a1f3-00910f92b032" xlink:to="loc_us-gaap_RestrictedInvestmentsAtFairValue_019dc2a8-10b3-7523-b379-5c8b9c7d929c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_019dc2a8-10b3-7290-bac2-5baf25ebe53f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CashAndCashEquivalentsUnrealizedLosses_019dc2a8-10b3-7736-8972-a115c413c26a" xlink:href="gern-20260331.xsd#gern_CashAndCashEquivalentsUnrealizedLosses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_019dc2a8-10b3-7290-bac2-5baf25ebe53f" xlink:to="loc_gern_CashAndCashEquivalentsUnrealizedLosses_019dc2a8-10b3-7736-8972-a115c413c26a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019dc2a8-10b3-7baa-b205-72e4e490c176" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_019dc2a8-10b3-7290-bac2-5baf25ebe53f" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019dc2a8-10b3-7baa-b205-72e4e490c176" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CashAndCashEquivalentsUnrealizedGains_019dc2a8-10b3-750b-bd0d-5be710c338fd" xlink:href="gern-20260331.xsd#gern_CashAndCashEquivalentsUnrealizedGains"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_019dc2a8-10b3-7290-bac2-5baf25ebe53f" xlink:to="loc_gern_CashAndCashEquivalentsUnrealizedGains_019dc2a8-10b3-750b-bd0d-5be710c338fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_019dc2a8-10b3-7c10-a2d1-328806371658" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019dc2a8-10b3-780f-86bc-d3304c3795e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_019dc2a8-10b3-7c10-a2d1-328806371658" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019dc2a8-10b3-780f-86bc-d3304c3795e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019dc2a8-10b3-745d-b83d-c095f3c91931" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_019dc2a8-10b3-7c10-a2d1-328806371658" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019dc2a8-10b3-745d-b83d-c095f3c91931" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019dc2a8-10b3-7296-8350-0bf068bfef14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_019dc2a8-10b3-7c10-a2d1-328806371658" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019dc2a8-10b3-7296-8350-0bf068bfef14" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails"/>
  <link:calculationLink xlink:role="http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019dc2a8-10b3-7b29-a90c-d48b4250da4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019dc2a8-10b3-70a2-9294-9aef9301bfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019dc2a8-10b3-7b29-a90c-d48b4250da4f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019dc2a8-10b3-70a2-9294-9aef9301bfa5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019dc2a8-10b3-7c34-858d-3fb16c204a66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019dc2a8-10b3-7b29-a90c-d48b4250da4f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019dc2a8-10b3-7c34-858d-3fb16c204a66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019dc2a8-10b3-7767-9e05-8d72dd9fda50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019dc2a8-10b3-73a5-915f-f8c9df909dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019dc2a8-10b3-7767-9e05-8d72dd9fda50" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019dc2a8-10b3-73a5-915f-f8c9df909dbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019dc2a8-10b3-7e8b-9767-545f298b61f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019dc2a8-10b3-7767-9e05-8d72dd9fda50" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019dc2a8-10b3-7e8b-9767-545f298b61f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#FAIRVALUEMEASUREMENTSDetails"/>
  <link:calculationLink xlink:role="http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_019c7730-4892-7a8b-95ca-629dc3105e18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_019c7730-4892-7734-903c-c137e544bdf3" xlink:href="gern-20260331.xsd#gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_019c7730-4892-7a8b-95ca-629dc3105e18" xlink:to="loc_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_019c7730-4892-7734-903c-c137e544bdf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019c7730-4892-7e48-9e5e-36b458b8f0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_019c7730-4892-7a8b-95ca-629dc3105e18" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019c7730-4892-7e48-9e5e-36b458b8f0b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_019dc2da-f54c-70a7-a38f-214f68a4a3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_019dc2da-f54c-7255-84af-80c363b1ba1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_019dc2da-f54c-70a7-a38f-214f68a4a3f7" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_019dc2da-f54c-7255-84af-80c363b1ba1e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019c7730-4892-7824-8322-38498421eece" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent_019c7730-4892-7f25-9b96-435ed53a3100" xlink:href="gern-20260331.xsd#gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019c7730-4892-7824-8322-38498421eece" xlink:to="loc_gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent_019c7730-4892-7f25-9b96-435ed53a3100" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_AccruedManufacturingActivitiesCurrent_019c7730-4892-75aa-b71e-c118197b9ad2" xlink:href="gern-20260331.xsd#gern_AccruedManufacturingActivitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019c7730-4892-7824-8322-38498421eece" xlink:to="loc_gern_AccruedManufacturingActivitiesCurrent_019c7730-4892-75aa-b71e-c118197b9ad2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_019c7730-4892-7b38-82fa-6cbc60f1f89f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019c7730-4892-7824-8322-38498421eece" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_019c7730-4892-7b38-82fa-6cbc60f1f89f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_019c7730-4892-722f-8b28-9e906226f14e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019c7730-4892-7824-8322-38498421eece" xlink:to="loc_us-gaap_InterestPayableCurrent_019c7730-4892-722f-8b28-9e906226f14e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_GrossToNetAdjustmentsCurrent_019c7730-4892-7cf2-88e2-66f6e2e6a9d5" xlink:href="gern-20260331.xsd#gern_GrossToNetAdjustmentsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019c7730-4892-7824-8322-38498421eece" xlink:to="loc_gern_GrossToNetAdjustmentsCurrent_019c7730-4892-7cf2-88e2-66f6e2e6a9d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019c7730-4892-7032-b218-91ccdb3cf2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019c7730-4892-7824-8322-38498421eece" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019c7730-4892-7032-b218-91ccdb3cf2f2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedCompensationandBenefitsDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedCompensationandBenefitsDetails"/>
  <link:calculationLink xlink:role="http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedCompensationandBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019dc2eb-79a4-7ae9-8d1b-c53e946b306c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_019dc2eb-79a4-7c05-9535-409f39a327b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019dc2eb-79a4-7ae9-8d1b-c53e946b306c" xlink:to="loc_us-gaap_AccruedBonusesCurrent_019dc2eb-79a4-7c05-9535-409f39a327b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedVacationCurrent_019dc2eb-79a4-7a4e-a6da-f696e54eb331" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedVacationCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019dc2eb-79a4-7ae9-8d1b-c53e946b306c" xlink:to="loc_us-gaap_AccruedVacationCurrent_019dc2eb-79a4-7a4e-a6da-f696e54eb331" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveCurrent_019dc2eb-79a4-75e3-9731-525f195f448a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019dc2eb-79a4-7ae9-8d1b-c53e946b306c" xlink:to="loc_us-gaap_RestructuringReserveCurrent_019dc2eb-79a4-75e3-9731-525f195f448a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_019dc2eb-79a4-76e3-95b0-ab3497e661ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019dc2eb-79a4-7ae9-8d1b-c53e946b306c" xlink:to="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_019dc2eb-79a4-76e3-95b0-ab3497e661ef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.geron.com/role/DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails"/>
  <link:calculationLink xlink:role="http://www.geron.com/role/DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_019c7730-4892-7a63-94c9-ea31fdbd2045" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_019c7730-4892-73c5-84a1-13e94fbcc3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_019c7730-4892-7a63-94c9-ea31fdbd2045" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_019c7730-4892-73c5-84a1-13e94fbcc3a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedCapitalizedInterestCosts_019c7730-4892-77e2-9265-cc4abc1158d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedCapitalizedInterestCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_019c7730-4892-7a63-94c9-ea31fdbd2045" xlink:to="loc_us-gaap_AccumulatedCapitalizedInterestCosts_019c7730-4892-77e2-9265-cc4abc1158d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_019c7730-4892-7557-b604-6c170987c16f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_019c7730-4892-7a63-94c9-ea31fdbd2045" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_019c7730-4892-7557-b604-6c170987c16f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_019c7730-4892-7de5-ae17-69b00e4ec3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_019c7730-4892-7e5a-b66f-48e78b0146c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_019c7730-4892-7de5-ae17-69b00e4ec3f1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_019c7730-4892-7e5a-b66f-48e78b0146c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_019c7730-4892-773a-8fcc-27fbbb8bb91d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_019c7730-4892-7de5-ae17-69b00e4ec3f1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_019c7730-4892-773a-8fcc-27fbbb8bb91d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_019c7730-4892-7dfc-9c3d-b569a4b6c1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_019c7730-4892-7de5-ae17-69b00e4ec3f1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_019c7730-4892-7dfc-9c3d-b569a4b6c1f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_019c7730-4892-7557-a4d3-879b86b2b614" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_019c7730-4892-7de5-ae17-69b00e4ec3f1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_019c7730-4892-7557-a4d3-879b86b2b614" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_LongTermDebtMaturityAfterYearThree_019c7730-4892-7054-a022-b68eed71c428" xlink:href="gern-20260331.xsd#gern_LongTermDebtMaturityAfterYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_019c7730-4892-7de5-ae17-69b00e4ec3f1" xlink:to="loc_gern_LongTermDebtMaturityAfterYearThree_019c7730-4892-7054-a022-b68eed71c428" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>gern-20260331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019c7730-46e9-7212-bc71-75c229f2667a,g:9ff11a8a-3051-4cda-8828-c63f363e56da-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="gern-20260331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019c7730-47b6-7be0-94fa-10cb86d6df58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019c7730-47b6-78eb-907d-f40c0cfcb66e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019c7730-47b6-7be0-94fa-10cb86d6df58" xlink:to="loc_us-gaap_StatementTable_019c7730-47b6-78eb-907d-f40c0cfcb66e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019c7730-47b6-7b1f-b629-1321b325e9b9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019c7730-47b6-78eb-907d-f40c0cfcb66e" xlink:to="loc_srt_ProductOrServiceAxis_019c7730-47b6-7b1f-b629-1321b325e9b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c7730-47b6-7b1f-b629-1321b325e9b9_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019c7730-47b6-7b1f-b629-1321b325e9b9" xlink:to="loc_srt_ProductsAndServicesDomain_019c7730-47b6-7b1f-b629-1321b325e9b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c7730-47b6-7ee5-a30b-0fa9c0c04c90" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019c7730-47b6-7b1f-b629-1321b325e9b9" xlink:to="loc_srt_ProductsAndServicesDomain_019c7730-47b6-7ee5-a30b-0fa9c0c04c90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_019c7730-47b6-76a9-9f24-513bc1e9a7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019c7730-47b6-7ee5-a30b-0fa9c0c04c90" xlink:to="loc_us-gaap_ProductMember_019c7730-47b6-76a9-9f24-513bc1e9a7fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_019c7730-47b6-7af1-b64d-4524584c1c39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019c7730-47b6-7ee5-a30b-0fa9c0c04c90" xlink:to="loc_us-gaap_RoyaltyMember_019c7730-47b6-7af1-b64d-4524584c1c39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_019c7730-47b6-768e-92ba-b4563a85b3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019c7730-47b6-7be0-94fa-10cb86d6df58" xlink:to="loc_us-gaap_RevenuesAbstract_019c7730-47b6-768e-92ba-b4563a85b3c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c7730-47b6-708d-9e40-d256ee0dcb88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_019c7730-47b6-768e-92ba-b4563a85b3c6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c7730-47b6-708d-9e40-d256ee0dcb88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_019c7730-47b6-7d68-8102-2eda0301f8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019c7730-47b6-7be0-94fa-10cb86d6df58" xlink:to="loc_us-gaap_OperatingExpensesAbstract_019c7730-47b6-7d68-8102-2eda0301f8ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_019c7730-47b6-7022-8fed-912b7aafa882" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019c7730-47b6-7d68-8102-2eda0301f8ae" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_019c7730-47b6-7022-8fed-912b7aafa882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019c7730-47b6-758d-a18a-d1611da7e997" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019c7730-47b6-7d68-8102-2eda0301f8ae" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019c7730-47b6-758d-a18a-d1611da7e997" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_019c7730-47b6-73e0-ab67-1133fc31c277" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019c7730-47b6-7d68-8102-2eda0301f8ae" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_019c7730-47b6-73e0-ab67-1133fc31c277" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_019dbffb-33c0-782d-9e28-567d3eab5590" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019c7730-47b6-7d68-8102-2eda0301f8ae" xlink:to="loc_us-gaap_RestructuringCharges_019dbffb-33c0-782d-9e28-567d3eab5590" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019c7730-47b6-7239-bdf3-018172606dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019c7730-47b6-7d68-8102-2eda0301f8ae" xlink:to="loc_us-gaap_OperatingExpenses_019c7730-47b6-7239-bdf3-018172606dcb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019c7730-47b6-78ba-b96a-d421d0b55ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019c7730-47b6-7be0-94fa-10cb86d6df58" xlink:to="loc_us-gaap_OperatingIncomeLoss_019c7730-47b6-78ba-b96a-d421d0b55ac5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_019c7730-47b6-7fe0-8ddf-ac84aba4d39e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019c7730-47b6-7be0-94fa-10cb86d6df58" xlink:to="loc_us-gaap_InvestmentIncomeInterest_019c7730-47b6-7fe0-8ddf-ac84aba4d39e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_019c7730-47b6-7eff-96f0-3e467eb190d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019c7730-47b6-7be0-94fa-10cb86d6df58" xlink:to="loc_us-gaap_InterestExpenseNonoperating_019c7730-47b6-7eff-96f0-3e467eb190d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_019c7730-47b6-7730-bdff-7e04b5869c81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019c7730-47b6-7be0-94fa-10cb86d6df58" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_019c7730-47b6-7730-bdff-7e04b5869c81" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019c7730-47b6-7bc9-b911-cc6e0ecbb27b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019c7730-47b6-7be0-94fa-10cb86d6df58" xlink:to="loc_us-gaap_NetIncomeLoss_019c7730-47b6-7bc9-b911-cc6e0ecbb27b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019c7730-47b6-7df5-a53b-dfef7ebd58ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019c7730-47b6-7be0-94fa-10cb86d6df58" xlink:to="loc_us-gaap_EarningsPerShareBasic_019c7730-47b6-7df5-a53b-dfef7ebd58ea" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019c7730-47b6-7668-b575-ca07b20d9ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019c7730-47b6-7be0-94fa-10cb86d6df58" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019c7730-47b6-7668-b575-ca07b20d9ed1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019c7730-47b6-752a-91bb-32bf8353a7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019c7730-47b6-7be0-94fa-10cb86d6df58" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019c7730-47b6-752a-91bb-32bf8353a7ce" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019c7730-47b6-7650-8523-dea51cbc539f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019c7730-47b6-7be0-94fa-10cb86d6df58" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019c7730-47b6-7650-8523-dea51cbc539f" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="gern-20260331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019c7730-47b6-70ae-ab10-07119e1ed646" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019c7730-47b6-728a-9de0-26d60ce4d29b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019c7730-47b6-70ae-ab10-07119e1ed646" xlink:to="loc_us-gaap_StatementTable_019c7730-47b6-728a-9de0-26d60ce4d29b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019c7730-47b6-7557-98aa-6d3d93eb5dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019c7730-47b6-728a-9de0-26d60ce4d29b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019c7730-47b6-7557-98aa-6d3d93eb5dc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019c7730-47b6-7557-98aa-6d3d93eb5dc4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019c7730-47b6-7557-98aa-6d3d93eb5dc4" xlink:to="loc_us-gaap_EquityComponentDomain_019c7730-47b6-7557-98aa-6d3d93eb5dc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019c7730-47b6-7b91-accf-5eed2b21550d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019c7730-47b6-7557-98aa-6d3d93eb5dc4" xlink:to="loc_us-gaap_EquityComponentDomain_019c7730-47b6-7b91-accf-5eed2b21550d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019c7730-47b6-77ab-bda8-2adb04e8a93d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019c7730-47b6-7b91-accf-5eed2b21550d" xlink:to="loc_us-gaap_CommonStockMember_019c7730-47b6-77ab-bda8-2adb04e8a93d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_019c7730-47b6-77cf-ae1c-624ddb276295" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019c7730-47b6-7b91-accf-5eed2b21550d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_019c7730-47b6-77cf-ae1c-624ddb276295" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_019c7730-47b6-7f31-84b5-580efd89414f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019c7730-47b6-7b91-accf-5eed2b21550d" xlink:to="loc_us-gaap_RetainedEarningsMember_019c7730-47b6-7f31-84b5-580efd89414f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019c7730-47b6-7844-b9fb-59c685dae605" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019c7730-47b6-7b91-accf-5eed2b21550d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019c7730-47b6-7844-b9fb-59c685dae605" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019c7730-47b6-70ae-ab10-07119e1ed646" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019c7730-47b6-771c-9c24-1a21e53f227a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019c7730-47b6-771c-9c24-1a21e53f227a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019c7730-47b6-74dc-919a-5ffd74b8366b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_us-gaap_StockholdersEquity_019c7730-47b6-74dc-919a-5ffd74b8366b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019c7730-47b6-712f-b69b-1877efafac39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_us-gaap_NetIncomeLoss_019c7730-47b6-712f-b69b-1877efafac39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_019c7730-47b6-7160-9b6b-57e1b9f231a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_019c7730-47b6-7160-9b6b-57e1b9f231a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019c7730-47b6-73aa-b71f-c26c1a48e0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019c7730-47b6-73aa-b71f-c26c1a48e0fa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant_019dd608-eb9e-7e3e-82d3-03a3bc127101" xlink:href="gern-20260331.xsd#gern_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_gern_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant_019dd608-eb9e-7e3e-82d3-03a3bc127101" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant_019dd608-eb9e-7e08-a3a6-61aa1eb34a10" xlink:href="gern-20260331.xsd#gern_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_gern_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant_019dd608-eb9e-7e08-a3a6-61aa1eb34a10" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue_019c7730-47b6-7835-8b8d-a07a5a452679" xlink:href="gern-20260331.xsd#gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue_019c7730-47b6-7835-8b8d-a07a5a452679" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_019dc238-fc4e-753c-90df-f9693539671f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_019dc238-fc4e-753c-90df-f9693539671f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_019c7730-47b6-7b41-b853-519f95e2b6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_019c7730-47b6-7b41-b853-519f95e2b6b6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares_019dc256-615f-76db-a552-b2ad24e57a7a" xlink:href="gern-20260331.xsd#gern_APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_gern_APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares_019dc256-615f-76db-a552-b2ad24e57a7a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_019df88d-ce1e-7632-92f5-1ced2fa7bbb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_019df88d-ce1e-7632-92f5-1ced2fa7bbb5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_019df88e-008a-73c5-bade-73a208144c94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_019df88e-008a-73c5-bade-73a208144c94" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019c7730-47b6-7858-9c19-b1dacd4dddd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019c7730-47b6-7269-9db8-6d2263d2c8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.geron.com/role/REVENUERECOGNITIONDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#REVENUERECOGNITIONDetails"/>
  <link:definitionLink xlink:role="http://www.geron.com/role/REVENUERECOGNITIONDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_019c7730-4892-7c72-9393-95a735cac451" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_019c7730-4892-7364-9a9b-d4cfa1b988cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c7730-4892-7c72-9393-95a735cac451" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_019c7730-4892-7364-9a9b-d4cfa1b988cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019c7730-4892-7428-8801-300020f3e936" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019c7730-4892-7364-9a9b-d4cfa1b988cb" xlink:to="loc_srt_ProductOrServiceAxis_019c7730-4892-7428-8801-300020f3e936" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c7730-4892-7428-8801-300020f3e936_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019c7730-4892-7428-8801-300020f3e936" xlink:to="loc_srt_ProductsAndServicesDomain_019c7730-4892-7428-8801-300020f3e936_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c7730-4892-781c-9910-405a5a2bdece" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019c7730-4892-7428-8801-300020f3e936" xlink:to="loc_srt_ProductsAndServicesDomain_019c7730-4892-781c-9910-405a5a2bdece" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_019c7730-4892-7b5e-83ec-8f931fba3b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019c7730-4892-781c-9910-405a5a2bdece" xlink:to="loc_us-gaap_ProductMember_019c7730-4892-7b5e-83ec-8f931fba3b2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_RevenuesBeforeAdjustmentsMember_019c7730-4892-712a-91e6-1b750a031ebf" xlink:href="gern-20260331.xsd#gern_RevenuesBeforeAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_019c7730-4892-7b5e-83ec-8f931fba3b2e" xlink:to="loc_gern_RevenuesBeforeAdjustmentsMember_019c7730-4892-712a-91e6-1b750a031ebf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_TotalGrossToNetAdjustmentsMember_019c7730-4892-755a-a93a-d26afebe95f1" xlink:href="gern-20260331.xsd#gern_TotalGrossToNetAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_019c7730-4892-7b5e-83ec-8f931fba3b2e" xlink:to="loc_gern_TotalGrossToNetAdjustmentsMember_019c7730-4892-755a-a93a-d26afebe95f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_ChargebacksMember_019c7730-4892-7a20-94bb-c0fa96e8059f" xlink:href="gern-20260331.xsd#gern_ChargebacksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gern_TotalGrossToNetAdjustmentsMember_019c7730-4892-755a-a93a-d26afebe95f1" xlink:to="loc_gern_ChargebacksMember_019c7730-4892-7a20-94bb-c0fa96e8059f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_DistributorServiceFeesMember_019dc2a1-7101-75d9-8795-167c1d2c227f" xlink:href="gern-20260331.xsd#gern_DistributorServiceFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gern_TotalGrossToNetAdjustmentsMember_019c7730-4892-755a-a93a-d26afebe95f1" xlink:to="loc_gern_DistributorServiceFeesMember_019dc2a1-7101-75d9-8795-167c1d2c227f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_GovernmentRebatesMember_019c7730-4892-7ba0-8e57-9075329cb2c9" xlink:href="gern-20260331.xsd#gern_GovernmentRebatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gern_TotalGrossToNetAdjustmentsMember_019c7730-4892-755a-a93a-d26afebe95f1" xlink:to="loc_gern_GovernmentRebatesMember_019c7730-4892-7ba0-8e57-9075329cb2c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_SalesReturnsAndAllowanceMember_019c7730-4892-72d5-9c96-e01c61bafb7d" xlink:href="gern-20260331.xsd#gern_SalesReturnsAndAllowanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gern_TotalGrossToNetAdjustmentsMember_019c7730-4892-755a-a93a-d26afebe95f1" xlink:to="loc_gern_SalesReturnsAndAllowanceMember_019c7730-4892-72d5-9c96-e01c61bafb7d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c7730-4892-766b-a00d-f33186e6c395" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c7730-4892-7c72-9393-95a735cac451" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c7730-4892-766b-a00d-f33186e6c395" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_019dc2a8-10b3-7f9d-b261-10bd44147d08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsTable_019dc2a8-10b3-7b57-8d23-809a88972d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfInvestmentHoldingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_019dc2a8-10b3-7f9d-b261-10bd44147d08" xlink:to="loc_us-gaap_SummaryOfInvestmentHoldingsTable_019dc2a8-10b3-7b57-8d23-809a88972d9d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019dc2a8-10b3-7f71-9512-4c01394e66f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable_019dc2a8-10b3-7b57-8d23-809a88972d9d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019dc2a8-10b3-7f71-9512-4c01394e66f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-7f71-9512-4c01394e66f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019dc2a8-10b3-7f71-9512-4c01394e66f9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-7f71-9512-4c01394e66f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-71ec-b209-6355fc959c28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019dc2a8-10b3-7f71-9512-4c01394e66f9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-71ec-b209-6355fc959c28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_019dc2a8-10b3-740b-9a4d-5b57674ad090" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-71ec-b209-6355fc959c28" xlink:to="loc_us-gaap_MoneyMarketFundsMember_019dc2a8-10b3-740b-9a4d-5b57674ad090" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_019dc2a8-10b3-7460-9568-0e082d88005a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-71ec-b209-6355fc959c28" xlink:to="loc_us-gaap_CommercialPaperMember_019dc2a8-10b3-7460-9568-0e082d88005a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_019dc2a8-10b3-7bfa-bf5d-0aff040c3e84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-71ec-b209-6355fc959c28" xlink:to="loc_us-gaap_CertificatesOfDepositMember_019dc2a8-10b3-7bfa-bf5d-0aff040c3e84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_USTreasurySecuritiesDueInLessThanOneYearMember_019dc2a8-10b3-7150-9847-682a34abe218" xlink:href="gern-20260331.xsd#gern_USTreasurySecuritiesDueInLessThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-71ec-b209-6355fc959c28" xlink:to="loc_gern_USTreasurySecuritiesDueInLessThanOneYearMember_019dc2a8-10b3-7150-9847-682a34abe218" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_MunicipalSecuritiesDueInLessThanOneYearMember_019dc2a8-10b3-70b1-80c4-8c36ed935ae2" xlink:href="gern-20260331.xsd#gern_MunicipalSecuritiesDueInLessThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-71ec-b209-6355fc959c28" xlink:to="loc_gern_MunicipalSecuritiesDueInLessThanOneYearMember_019dc2a8-10b3-70b1-80c4-8c36ed935ae2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_MunicipalSecuritiesDueInOneToTwoYearsMember_019df09a-db2b-7cf6-8ae3-649ee36d8a3b" xlink:href="gern-20260331.xsd#gern_MunicipalSecuritiesDueInOneToTwoYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-71ec-b209-6355fc959c28" xlink:to="loc_gern_MunicipalSecuritiesDueInOneToTwoYearsMember_019df09a-db2b-7cf6-8ae3-649ee36d8a3b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember_019dc2a8-10b3-78dd-a4c7-896ee483496a" xlink:href="gern-20260331.xsd#gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-71ec-b209-6355fc959c28" xlink:to="loc_gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember_019dc2a8-10b3-78dd-a4c7-896ee483496a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CommercialPaperDueInLessThanOneYearMember_019dc2a8-10b3-7339-9b35-3fb9d8c5e6fb" xlink:href="gern-20260331.xsd#gern_CommercialPaperDueInLessThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-71ec-b209-6355fc959c28" xlink:to="loc_gern_CommercialPaperDueInLessThanOneYearMember_019dc2a8-10b3-7339-9b35-3fb9d8c5e6fb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CorporateNoteSecuritiesDueInLessThanOneYearMember_019dc2a8-10b3-7fa2-a7ff-f216b3f0c3dc" xlink:href="gern-20260331.xsd#gern_CorporateNoteSecuritiesDueInLessThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-71ec-b209-6355fc959c28" xlink:to="loc_gern_CorporateNoteSecuritiesDueInLessThanOneYearMember_019dc2a8-10b3-7fa2-a7ff-f216b3f0c3dc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember_019dc2a8-10b3-7ffb-8089-c0c87b50fc2d" xlink:href="gern-20260331.xsd#gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-71ec-b209-6355fc959c28" xlink:to="loc_gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember_019dc2a8-10b3-7ffb-8089-c0c87b50fc2d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_019dc2a8-10b3-7e41-b531-6caa9aa752a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_019dc2a8-10b3-7f9d-b261-10bd44147d08" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_019dc2a8-10b3-7e41-b531-6caa9aa752a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_019dc2a8-10b3-7a0c-a835-cbd0d801f262" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_019dc2a8-10b3-7e41-b531-6caa9aa752a2" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_019dc2a8-10b3-7a0c-a835-cbd0d801f262" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CashAndCashEquivalentsUnrealizedGains_019dc2a8-10b3-7002-82e0-7d7d4991efb0" xlink:href="gern-20260331.xsd#gern_CashAndCashEquivalentsUnrealizedGains"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_019dc2a8-10b3-7e41-b531-6caa9aa752a2" xlink:to="loc_gern_CashAndCashEquivalentsUnrealizedGains_019dc2a8-10b3-7002-82e0-7d7d4991efb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CashAndCashEquivalentsUnrealizedLosses_019dc2a8-10b3-7758-bfed-39194d70d16d" xlink:href="gern-20260331.xsd#gern_CashAndCashEquivalentsUnrealizedLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_019dc2a8-10b3-7e41-b531-6caa9aa752a2" xlink:to="loc_gern_CashAndCashEquivalentsUnrealizedLosses_019dc2a8-10b3-7758-bfed-39194d70d16d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019dc2a8-10b3-745c-a1a9-465d24643cca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_019dc2a8-10b3-7e41-b531-6caa9aa752a2" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019dc2a8-10b3-745c-a1a9-465d24643cca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_019dc2a8-10b3-7a42-9fd8-4460921d0a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndInvestmentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_019dc2a8-10b3-7f9d-b261-10bd44147d08" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_019dc2a8-10b3-7a42-9fd8-4460921d0a2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_019dc2a8-10b3-72e2-8e58-e33c85a4ecf2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_019dc2a8-10b3-7a42-9fd8-4460921d0a2f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_019dc2a8-10b3-72e2-8e58-e33c85a4ecf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedGains_019dc2a8-10b3-7b7e-baae-c01b6304be64" xlink:href="gern-20260331.xsd#gern_RestrictedCashAndCashEquivalentsGrossUnrealizedGains"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_019dc2a8-10b3-7a42-9fd8-4460921d0a2f" xlink:to="loc_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedGains_019dc2a8-10b3-7b7e-baae-c01b6304be64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses_019dc2a8-10b3-72d9-9673-f0a886ecd514" xlink:href="gern-20260331.xsd#gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_019dc2a8-10b3-7a42-9fd8-4460921d0a2f" xlink:to="loc_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses_019dc2a8-10b3-72d9-9673-f0a886ecd514" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsAtFairValue_019dc2a8-10b3-7245-91b4-548aec89269a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedInvestmentsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_019dc2a8-10b3-7a42-9fd8-4460921d0a2f" xlink:to="loc_us-gaap_RestrictedInvestmentsAtFairValue_019dc2a8-10b3-7245-91b4-548aec89269a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_019dc2a8-10b3-7abc-a123-569214012997" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_019dc2a8-10b3-7f9d-b261-10bd44147d08" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_019dc2a8-10b3-7abc-a123-569214012997" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_019dc2a8-10b3-7160-8575-fd21763f6c41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_019dc2a8-10b3-7abc-a123-569214012997" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_019dc2a8-10b3-7160-8575-fd21763f6c41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019dc2a8-10b3-736f-8298-4a5a8b05e24a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_019dc2a8-10b3-7abc-a123-569214012997" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019dc2a8-10b3-736f-8298-4a5a8b05e24a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019dc2a8-10b3-7498-a5d3-728100cb1f39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_019dc2a8-10b3-7abc-a123-569214012997" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019dc2a8-10b3-7498-a5d3-728100cb1f39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019dc2a8-10b3-7ee4-8008-eb1a6ea73e95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_019dc2a8-10b3-7abc-a123-569214012997" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019dc2a8-10b3-7ee4-8008-eb1a6ea73e95" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails"/>
  <link:definitionLink xlink:role="http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019dc2a8-10b3-7bd5-96df-2d060631677f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019dc2a8-10b3-7743-b3ad-d1a2ab7825d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019dc2a8-10b3-7bd5-96df-2d060631677f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019dc2a8-10b3-7743-b3ad-d1a2ab7825d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019dc2a8-10b3-7556-afd1-40efa550402d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019dc2a8-10b3-7743-b3ad-d1a2ab7825d4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019dc2a8-10b3-7556-afd1-40efa550402d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-7556-afd1-40efa550402d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019dc2a8-10b3-7556-afd1-40efa550402d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-7556-afd1-40efa550402d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-7822-b8b7-6654eed56531" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019dc2a8-10b3-7556-afd1-40efa550402d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-7822-b8b7-6654eed56531" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember_019dc2cd-a688-79a8-9c1d-38520f6571d6" xlink:href="gern-20260331.xsd#gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-7822-b8b7-6654eed56531" xlink:to="loc_gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember_019dc2cd-a688-79a8-9c1d-38520f6571d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_MunicipalSecuritiesDueInLessThanOneYearMember_019dc2cf-0393-738e-96d0-731e5f56f96c" xlink:href="gern-20260331.xsd#gern_MunicipalSecuritiesDueInLessThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-7822-b8b7-6654eed56531" xlink:to="loc_gern_MunicipalSecuritiesDueInLessThanOneYearMember_019dc2cf-0393-738e-96d0-731e5f56f96c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_MunicipalSecuritiesDueInOneToTwoYearsMember_019dc2b8-7e93-72f3-862f-33a9eb1c5dfd" xlink:href="gern-20260331.xsd#gern_MunicipalSecuritiesDueInOneToTwoYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-7822-b8b7-6654eed56531" xlink:to="loc_gern_MunicipalSecuritiesDueInOneToTwoYearsMember_019dc2b8-7e93-72f3-862f-33a9eb1c5dfd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_019dc2d0-fd45-71c9-bf44-603e37a6b07e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-7822-b8b7-6654eed56531" xlink:to="loc_us-gaap_CommercialPaperMember_019dc2d0-fd45-71c9-bf44-603e37a6b07e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CommercialPaperDueInLessThanOneYearMember_019dc2a8-10b3-737b-8955-b6283577d3cb" xlink:href="gern-20260331.xsd#gern_CommercialPaperDueInLessThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-7822-b8b7-6654eed56531" xlink:to="loc_gern_CommercialPaperDueInLessThanOneYearMember_019dc2a8-10b3-737b-8955-b6283577d3cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CorporateNoteSecuritiesDueInLessThanOneYearMember_019dc2a8-10b3-7d05-b067-babae2a26448" xlink:href="gern-20260331.xsd#gern_CorporateNoteSecuritiesDueInLessThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-7822-b8b7-6654eed56531" xlink:to="loc_gern_CorporateNoteSecuritiesDueInLessThanOneYearMember_019dc2a8-10b3-7d05-b067-babae2a26448" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember_019dc2a8-10b3-7032-a109-948835483eaf" xlink:href="gern-20260331.xsd#gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-7822-b8b7-6654eed56531" xlink:to="loc_gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember_019dc2a8-10b3-7032-a109-948835483eaf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_019dc2a8-10b3-748e-87fe-c62b522b214e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019dc2a8-10b3-7bd5-96df-2d060631677f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_019dc2a8-10b3-748e-87fe-c62b522b214e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019dc2a8-10b3-7946-abdb-8d1dbd6d33d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_019dc2a8-10b3-748e-87fe-c62b522b214e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019dc2a8-10b3-7946-abdb-8d1dbd6d33d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019dc2a8-10b3-7e0b-867d-ab79ce6f620a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_019dc2a8-10b3-748e-87fe-c62b522b214e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019dc2a8-10b3-7e0b-867d-ab79ce6f620a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019dc2a8-10b3-71cb-9495-0ad1176ddecc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_019dc2a8-10b3-748e-87fe-c62b522b214e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019dc2a8-10b3-71cb-9495-0ad1176ddecc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019dc2a8-10b3-7f16-a58e-d7424a9b960b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019dc2a8-10b3-7bd5-96df-2d060631677f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019dc2a8-10b3-7f16-a58e-d7424a9b960b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019dc2a8-10b3-7a6f-a242-d0b4b0adb1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019dc2a8-10b3-7f16-a58e-d7424a9b960b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019dc2a8-10b3-7a6f-a242-d0b4b0adb1b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019dc2a8-10b3-7781-bde5-e23c7e1ec0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019dc2a8-10b3-7f16-a58e-d7424a9b960b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019dc2a8-10b3-7781-bde5-e23c7e1ec0b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019dc2a8-10b3-735b-974a-4d0444e0edbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019dc2a8-10b3-7f16-a58e-d7424a9b960b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019dc2a8-10b3-735b-974a-4d0444e0edbd" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#FAIRVALUEMEASUREMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c7730-4892-7f41-a7fe-6fe20f7bc636" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c7730-4892-7fa4-8ded-c0c7958c26ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c7730-4892-7f41-a7fe-6fe20f7bc636" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c7730-4892-7fa4-8ded-c0c7958c26ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c7730-4892-7fe8-a261-3af30a8ae13c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c7730-4892-7fa4-8ded-c0c7958c26ac" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c7730-4892-7fe8-a261-3af30a8ae13c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c7730-4892-7fe8-a261-3af30a8ae13c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c7730-4892-7fe8-a261-3af30a8ae13c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c7730-4892-7fe8-a261-3af30a8ae13c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c7730-4892-7dd8-8288-19be500b6a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c7730-4892-7fe8-a261-3af30a8ae13c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c7730-4892-7dd8-8288-19be500b6a0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_019c7730-4892-7464-b59d-c3fe01ba560b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c7730-4892-7dd8-8288-19be500b6a0b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_019c7730-4892-7464-b59d-c3fe01ba560b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_019c7730-4892-7105-a20c-5f0bada97a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c7730-4892-7dd8-8288-19be500b6a0b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_019c7730-4892-7105-a20c-5f0bada97a9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019c7730-4892-7f37-b74d-5a9153a07a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c7730-4892-7dd8-8288-19be500b6a0b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019c7730-4892-7f37-b74d-5a9153a07a4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_019c7730-4892-78f0-90c5-cde0df64b4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c7730-4892-7fa4-8ded-c0c7958c26ac" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_019c7730-4892-78f0-90c5-cde0df64b4a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019c7730-4892-78f0-90c5-cde0df64b4a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_019c7730-4892-78f0-90c5-cde0df64b4a2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019c7730-4892-78f0-90c5-cde0df64b4a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019c7730-4892-78a2-bea4-a073ae92faeb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_019c7730-4892-78f0-90c5-cde0df64b4a2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019c7730-4892-78a2-bea4-a073ae92faeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_019c7730-4892-7182-9b51-606006e4352e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019c7730-4892-78a2-bea4-a073ae92faeb" xlink:to="loc_us-gaap_MoneyMarketFundsMember_019c7730-4892-7182-9b51-606006e4352e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_019c7730-4892-7b28-92d7-4c787650cc49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019c7730-4892-78a2-bea4-a073ae92faeb" xlink:to="loc_us-gaap_CertificatesOfDepositMember_019c7730-4892-7b28-92d7-4c787650cc49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_019c7730-4892-75ec-9254-fbde420623ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019c7730-4892-78a2-bea4-a073ae92faeb" xlink:to="loc_us-gaap_MunicipalBondsMember_019c7730-4892-75ec-9254-fbde420623ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019c7730-4892-771a-92be-fd1591320b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c7730-4892-7fa4-8ded-c0c7958c26ac" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019c7730-4892-771a-92be-fd1591320b1c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c7730-4892-771a-92be-fd1591320b1c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019c7730-4892-771a-92be-fd1591320b1c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c7730-4892-771a-92be-fd1591320b1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c7730-4892-792c-91cc-9155ebfdf1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019c7730-4892-771a-92be-fd1591320b1c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c7730-4892-792c-91cc-9155ebfdf1b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_019c7730-4892-7662-9d0d-daee55c5ba75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c7730-4892-792c-91cc-9155ebfdf1b2" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_019c7730-4892-7662-9d0d-daee55c5ba75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_019c7730-4892-7215-8a9b-e5901c0a6b71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c7730-4892-792c-91cc-9155ebfdf1b2" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_019c7730-4892-7215-8a9b-e5901c0a6b71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_019c7730-4892-7805-bce0-0e73200997ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c7730-4892-792c-91cc-9155ebfdf1b2" xlink:to="loc_us-gaap_CommercialPaperMember_019c7730-4892-7805-bce0-0e73200997ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNoteSecuritiesMember_019c7730-4892-7024-a07e-5e2ab268f6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateNoteSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c7730-4892-792c-91cc-9155ebfdf1b2" xlink:to="loc_us-gaap_CorporateNoteSecuritiesMember_019c7730-4892-7024-a07e-5e2ab268f6b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_019dc2da-0087-7f83-99df-7479f04df53c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c7730-4892-7f41-a7fe-6fe20f7bc636" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_019dc2da-0087-7f83-99df-7479f04df53c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_019c7730-4892-701d-bdef-123b45e4e6a1" xlink:href="gern-20260331.xsd#gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019dc2da-0087-7f83-99df-7479f04df53c" xlink:to="loc_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_019c7730-4892-701d-bdef-123b45e4e6a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019c7730-4892-75b7-b99b-287358fda284" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019dc2da-0087-7f83-99df-7479f04df53c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019c7730-4892-75b7-b99b-287358fda284" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_019c7730-4892-778b-9afb-8b3f75fbd8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019dc2da-0087-7f83-99df-7479f04df53c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_019c7730-4892-778b-9afb-8b3f75fbd8b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019dc2da-497c-7495-9e97-d83b180f8000" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c7730-4892-7f41-a7fe-6fe20f7bc636" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019dc2da-497c-7495-9e97-d83b180f8000" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_019dc2d8-5ae1-7531-802d-ffd65bcd54da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019dc2da-497c-7495-9e97-d83b180f8000" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_019dc2d8-5ae1-7531-802d-ffd65bcd54da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_019dc2d8-5ae1-70b3-8557-406f3b9ceee9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019dc2da-497c-7495-9e97-d83b180f8000" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_019dc2d8-5ae1-70b3-8557-406f3b9ceee9" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.geron.com/role/DEBTAdditionalInformationDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#DEBTAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.geron.com/role/DEBTAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7d0f-bb1d-fb75af39aa87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019c7730-4892-7291-9c20-882f15620e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7d0f-bb1d-fb75af39aa87" xlink:to="loc_us-gaap_DebtInstrumentTable_019c7730-4892-7291-9c20-882f15620e5e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019c7730-4892-71cc-bb64-f741753c0019" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019c7730-4892-7291-9c20-882f15620e5e" xlink:to="loc_srt_CounterpartyNameAxis_019c7730-4892-71cc-bb64-f741753c0019" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c7730-4892-71cc-bb64-f741753c0019_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_019c7730-4892-71cc-bb64-f741753c0019" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c7730-4892-71cc-bb64-f741753c0019_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c7730-4892-7a63-aaa6-74da4c9425d2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_019c7730-4892-71cc-bb64-f741753c0019" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c7730-4892-7a63-aaa6-74da4c9425d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_BiopharmaCreditPlcMember_019c7730-4892-7589-aff3-ce2248a2b0d1" xlink:href="gern-20260331.xsd#gern_BiopharmaCreditPlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c7730-4892-7a63-aaa6-74da4c9425d2" xlink:to="loc_gern_BiopharmaCreditPlcMember_019c7730-4892-7589-aff3-ce2248a2b0d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_019c7730-4892-7523-b5b2-8658eac16863" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019c7730-4892-7291-9c20-882f15620e5e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_019c7730-4892-7523-b5b2-8658eac16863" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019c7730-4892-7523-b5b2-8658eac16863_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019c7730-4892-7523-b5b2-8658eac16863" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019c7730-4892-7523-b5b2-8658eac16863_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019c7730-4892-7a6b-b94e-61f1a8968148" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019c7730-4892-7523-b5b2-8658eac16863" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019c7730-4892-7a6b-b94e-61f1a8968148" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_PharmakonLoanAgreementMember_019c7730-4892-71a5-9d28-96fbb2ff2f03" xlink:href="gern-20260331.xsd#gern_PharmakonLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019c7730-4892-7a6b-b94e-61f1a8968148" xlink:to="loc_gern_PharmakonLoanAgreementMember_019c7730-4892-71a5-9d28-96fbb2ff2f03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember_019c7730-4892-79f7-bb02-f9849eaf775b" xlink:href="gern-20260331.xsd#gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019c7730-4892-7a6b-b94e-61f1a8968148" xlink:to="loc_gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember_019c7730-4892-79f7-bb02-f9849eaf775b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_019c7730-4892-7b7c-be24-18b78f3e59de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019c7730-4892-7291-9c20-882f15620e5e" xlink:to="loc_us-gaap_CreditFacilityAxis_019c7730-4892-7b7c-be24-18b78f3e59de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_019c7730-4892-7b7c-be24-18b78f3e59de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_019c7730-4892-7b7c-be24-18b78f3e59de" xlink:to="loc_us-gaap_CreditFacilityDomain_019c7730-4892-7b7c-be24-18b78f3e59de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_019c7730-4892-7e9c-8ad6-a6ec3b9ca72c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_019c7730-4892-7b7c-be24-18b78f3e59de" xlink:to="loc_us-gaap_CreditFacilityDomain_019c7730-4892-7e9c-8ad6-a6ec3b9ca72c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_TrancheAMember_019c7730-4892-7583-98e9-137e1c308302" xlink:href="gern-20260331.xsd#gern_TrancheAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_019c7730-4892-7e9c-8ad6-a6ec3b9ca72c" xlink:to="loc_gern_TrancheAMember_019c7730-4892-7583-98e9-137e1c308302" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_TrancheBMember_019c7730-4892-7517-8e85-ab4da3d9e7ec" xlink:href="gern-20260331.xsd#gern_TrancheBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_019c7730-4892-7e9c-8ad6-a6ec3b9ca72c" xlink:to="loc_gern_TrancheBMember_019c7730-4892-7517-8e85-ab4da3d9e7ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_TrancheCMember_019c7730-4892-7137-b911-c955f7c892f1" xlink:href="gern-20260331.xsd#gern_TrancheCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_019c7730-4892-7e9c-8ad6-a6ec3b9ca72c" xlink:to="loc_gern_TrancheCMember_019c7730-4892-7137-b911-c955f7c892f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_TermLoansMember_019c7730-4892-7d67-aa07-32ade672d5c5" xlink:href="gern-20260331.xsd#gern_TermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_019c7730-4892-7e9c-8ad6-a6ec3b9ca72c" xlink:to="loc_gern_TermLoansMember_019c7730-4892-7d67-aa07-32ade672d5c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019c7730-4892-7168-a472-b8b06ece3fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019c7730-4892-7291-9c20-882f15620e5e" xlink:to="loc_us-gaap_DebtInstrumentAxis_019c7730-4892-7168-a472-b8b06ece3fd3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019c7730-4892-7168-a472-b8b06ece3fd3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_019c7730-4892-7168-a472-b8b06ece3fd3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019c7730-4892-7168-a472-b8b06ece3fd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019c7730-4892-77e0-97a2-8d380bbb2d48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_019c7730-4892-7168-a472-b8b06ece3fd3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019c7730-4892-77e0-97a2-8d380bbb2d48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember_019c7730-4892-752e-83b1-3144fa3bb27e" xlink:href="gern-20260331.xsd#gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019c7730-4892-77e0-97a2-8d380bbb2d48" xlink:to="loc_gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember_019c7730-4892-752e-83b1-3144fa3bb27e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember_019c7730-4892-793f-81f5-30fdc5fa8560" xlink:href="gern-20260331.xsd#gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019c7730-4892-77e0-97a2-8d380bbb2d48" xlink:to="loc_gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember_019c7730-4892-793f-81f5-30fdc5fa8560" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember_019c7730-4892-7b1a-80ce-4767ac291436" xlink:href="gern-20260331.xsd#gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019c7730-4892-77e0-97a2-8d380bbb2d48" xlink:to="loc_gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember_019c7730-4892-7b1a-80ce-4767ac291436" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019c7730-4892-770d-a74f-c03cf12fa8b6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019c7730-4892-7291-9c20-882f15620e5e" xlink:to="loc_srt_RangeAxis_019c7730-4892-770d-a74f-c03cf12fa8b6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019c7730-4892-770d-a74f-c03cf12fa8b6_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019c7730-4892-770d-a74f-c03cf12fa8b6" xlink:to="loc_srt_RangeMember_019c7730-4892-770d-a74f-c03cf12fa8b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019c7730-4892-7595-8716-63047cefbd12" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019c7730-4892-770d-a74f-c03cf12fa8b6" xlink:to="loc_srt_RangeMember_019c7730-4892-7595-8716-63047cefbd12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019c7730-4892-7f45-a8a0-25717d66cc4a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019c7730-4892-7595-8716-63047cefbd12" xlink:to="loc_srt_MinimumMember_019c7730-4892-7f45-a8a0-25717d66cc4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019c7730-4892-70aa-b1c1-526ba43e0426" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019c7730-4892-7595-8716-63047cefbd12" xlink:to="loc_srt_MaximumMember_019c7730-4892-70aa-b1c1-526ba43e0426" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_DebtInstrumentScenarioAxis_019c7730-4892-7687-83fa-d5d51b5f1069" xlink:href="gern-20260331.xsd#gern_DebtInstrumentScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019c7730-4892-7291-9c20-882f15620e5e" xlink:to="loc_gern_DebtInstrumentScenarioAxis_019c7730-4892-7687-83fa-d5d51b5f1069" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_DebtInstrumentScenarioDomain_019c7730-4892-7687-83fa-d5d51b5f1069_default" xlink:href="gern-20260331.xsd#gern_DebtInstrumentScenarioDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gern_DebtInstrumentScenarioAxis_019c7730-4892-7687-83fa-d5d51b5f1069" xlink:to="loc_gern_DebtInstrumentScenarioDomain_019c7730-4892-7687-83fa-d5d51b5f1069_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_DebtInstrumentScenarioDomain_019c7730-4892-7df1-a4a4-7c0e981d84e9" xlink:href="gern-20260331.xsd#gern_DebtInstrumentScenarioDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gern_DebtInstrumentScenarioAxis_019c7730-4892-7687-83fa-d5d51b5f1069" xlink:to="loc_gern_DebtInstrumentScenarioDomain_019c7730-4892-7df1-a4a4-7c0e981d84e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_ScenarioOneMember_019c7730-4892-7420-b097-d2835eb21ac2" xlink:href="gern-20260331.xsd#gern_ScenarioOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gern_DebtInstrumentScenarioDomain_019c7730-4892-7df1-a4a4-7c0e981d84e9" xlink:to="loc_gern_ScenarioOneMember_019c7730-4892-7420-b097-d2835eb21ac2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_ScenarioTwoMember_019c7730-4892-70b8-bb17-5e754f3bccb8" xlink:href="gern-20260331.xsd#gern_ScenarioTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gern_DebtInstrumentScenarioDomain_019c7730-4892-7df1-a4a4-7c0e981d84e9" xlink:to="loc_gern_ScenarioTwoMember_019c7730-4892-70b8-bb17-5e754f3bccb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_019c7730-4892-7af4-8b79-52f23f1d2047" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7d0f-bb1d-fb75af39aa87" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_019c7730-4892-7af4-8b79-52f23f1d2047" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019c7730-4892-7496-9410-0110f3e59ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7d0f-bb1d-fb75af39aa87" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019c7730-4892-7496-9410-0110f3e59ca5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019c7730-4892-7fb9-8381-2172a0156cef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7d0f-bb1d-fb75af39aa87" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019c7730-4892-7fb9-8381-2172a0156cef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_019c7730-4892-7090-b38f-e733546d2f37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019c7730-4892-7fb9-8381-2172a0156cef" xlink:to="loc_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_019c7730-4892-7090-b38f-e733546d2f37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_DebtInstrumentFloorRate_019c7730-4892-7f9a-bc43-fdbaf72bb606" xlink:href="gern-20260331.xsd#gern_DebtInstrumentFloorRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7d0f-bb1d-fb75af39aa87" xlink:to="loc_gern_DebtInstrumentFloorRate_019c7730-4892-7f9a-bc43-fdbaf72bb606" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_019c7730-4892-7606-aa41-03ebc3a9ca55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7d0f-bb1d-fb75af39aa87" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_019c7730-4892-7606-aa41-03ebc3a9ca55" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_PercentageOfCommitmentAmountToFundLoan_019c7730-4892-7d91-a21c-2386abffd228" xlink:href="gern-20260331.xsd#gern_PercentageOfCommitmentAmountToFundLoan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7d0f-bb1d-fb75af39aa87" xlink:to="loc_gern_PercentageOfCommitmentAmountToFundLoan_019c7730-4892-7d91-a21c-2386abffd228" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_PrepaymentPremiumOnPercentageOfTermLoan_019c7730-4892-7d49-a32c-08906d1eac3d" xlink:href="gern-20260331.xsd#gern_PrepaymentPremiumOnPercentageOfTermLoan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7d0f-bb1d-fb75af39aa87" xlink:to="loc_gern_PrepaymentPremiumOnPercentageOfTermLoan_019c7730-4892-7d49-a32c-08906d1eac3d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_UpfrontPaymentReceived_019c7730-4892-7367-b113-2c5c6469fd3f" xlink:href="gern-20260331.xsd#gern_UpfrontPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7d0f-bb1d-fb75af39aa87" xlink:to="loc_gern_UpfrontPaymentReceived_019c7730-4892-7367-b113-2c5c6469fd3f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_PercentageOfAnnualNetSales_019c7730-4892-711f-843c-e8076931eb34" xlink:href="gern-20260331.xsd#gern_PercentageOfAnnualNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7d0f-bb1d-fb75af39aa87" xlink:to="loc_gern_PercentageOfAnnualNetSales_019c7730-4892-711f-843c-e8076931eb34" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_019c7730-4892-7848-9899-8988730d2f95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7d0f-bb1d-fb75af39aa87" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_019c7730-4892-7848-9899-8988730d2f95" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_DebtInstrumentRoyaltyPaymentRatio_019c7730-4892-707c-a932-3214f54ca91c" xlink:href="gern-20260331.xsd#gern_DebtInstrumentRoyaltyPaymentRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7d0f-bb1d-fb75af39aa87" xlink:to="loc_gern_DebtInstrumentRoyaltyPaymentRatio_019c7730-4892-707c-a932-3214f54ca91c" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.geron.com/role/DEBTScheduleofSaleofFutureRoyaltiesDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#DEBTScheduleofSaleofFutureRoyaltiesDetails"/>
  <link:definitionLink xlink:role="http://www.geron.com/role/DEBTScheduleofSaleofFutureRoyaltiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7c1f-b326-223d322c4dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019c7730-4892-7e4f-9b69-f17281314d17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7c1f-b326-223d322c4dd7" xlink:to="loc_us-gaap_DebtInstrumentTable_019c7730-4892-7e4f-9b69-f17281314d17" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_019c7730-4892-7e4a-aeef-f52bba7d94a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019c7730-4892-7e4f-9b69-f17281314d17" xlink:to="loc_us-gaap_TypeOfArrangementAxis_019c7730-4892-7e4a-aeef-f52bba7d94a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019c7730-4892-7e4a-aeef-f52bba7d94a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019c7730-4892-7e4a-aeef-f52bba7d94a1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019c7730-4892-7e4a-aeef-f52bba7d94a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019c7730-4892-7462-a763-3ab862dddc65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019c7730-4892-7e4a-aeef-f52bba7d94a1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019c7730-4892-7462-a763-3ab862dddc65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember_019c7730-4892-7812-b31c-83820a260432" xlink:href="gern-20260331.xsd#gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019c7730-4892-7462-a763-3ab862dddc65" xlink:to="loc_gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember_019c7730-4892-7812-b31c-83820a260432" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_RoyaltiesRollForward_019c7730-4892-7b74-a14a-d39d970b5422" xlink:href="gern-20260331.xsd#gern_RoyaltiesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7c1f-b326-223d322c4dd7" xlink:to="loc_gern_RoyaltiesRollForward_019c7730-4892-7b74-a14a-d39d970b5422" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_019c7730-4892-7cb5-9257-4a42cd595a87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gern_RoyaltiesRollForward_019c7730-4892-7b74-a14a-d39d970b5422" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_019c7730-4892-7cb5-9257-4a42cd595a87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_019c7730-4892-7556-8a55-19adc73b69ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gern_RoyaltiesRollForward_019c7730-4892-7b74-a14a-d39d970b5422" xlink:to="loc_us-gaap_RoyaltyExpense_019c7730-4892-7556-8a55-19adc73b69ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_019c7730-4892-7e88-b383-5bc96a4d671c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gern_RoyaltiesRollForward_019c7730-4892-7b74-a14a-d39d970b5422" xlink:to="loc_us-gaap_PaymentsForRoyalties_019c7730-4892-7e88-b383-5bc96a4d671c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_019c7730-4892-76de-94c2-f59641e0c831" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.geron.com/role/NETLOSSPERCOMMONSHAREDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#NETLOSSPERCOMMONSHAREDetails"/>
  <link:definitionLink xlink:role="http://www.geron.com/role/NETLOSSPERCOMMONSHAREDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_019dc31f-cb9e-7a10-bb06-cb078ccacca7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_019dc31f-cb9e-70f3-89c9-7a5ac70a7bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_019dc31f-cb9e-7a10-bb06-cb078ccacca7" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_019dc31f-cb9e-70f3-89c9-7a5ac70a7bf2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019dc31f-cb9e-79f2-9b55-12d7b71acc82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_019dc31f-cb9e-70f3-89c9-7a5ac70a7bf2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019dc31f-cb9e-79f2-9b55-12d7b71acc82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019dc31f-cb9e-79f2-9b55-12d7b71acc82_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019dc31f-cb9e-79f2-9b55-12d7b71acc82" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019dc31f-cb9e-79f2-9b55-12d7b71acc82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019dc31f-cb9e-790a-8f80-c114fc93c960" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019dc31f-cb9e-79f2-9b55-12d7b71acc82" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019dc31f-cb9e-790a-8f80-c114fc93c960" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_019dc31f-cb9e-7f60-b8f4-e7ba8a896d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019dc31f-cb9e-790a-8f80-c114fc93c960" xlink:to="loc_us-gaap_StockCompensationPlanMember_019dc31f-cb9e-7f60-b8f4-e7ba8a896d3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019dc31f-cb9e-77cf-b634-f2c519603695" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_019dc31f-cb9e-7a10-bb06-cb078ccacca7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019dc31f-cb9e-77cf-b634-f2c519603695" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.geron.com/role/SEGMENTREPORTINGDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#SEGMENTREPORTINGDetails"/>
  <link:definitionLink xlink:role="http://www.geron.com/role/SEGMENTREPORTINGDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019c7730-4892-73fc-b94c-5507e6a859b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAssetReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_019c7730-4892-7c31-bf6a-2906d0b16c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019c7730-4892-73fc-b94c-5507e6a859b9" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_019c7730-4892-7c31-bf6a-2906d0b16c2a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019c7730-4892-7644-b9ff-4c8c2e932896" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_019c7730-4892-7c31-bf6a-2906d0b16c2a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019c7730-4892-7644-b9ff-4c8c2e932896" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c7730-4892-7644-b9ff-4c8c2e932896_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c7730-4892-7644-b9ff-4c8c2e932896" xlink:to="loc_us-gaap_SegmentDomain_019c7730-4892-7644-b9ff-4c8c2e932896_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c7730-4892-7c71-b758-b753b8becce0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c7730-4892-7644-b9ff-4c8c2e932896" xlink:to="loc_us-gaap_SegmentDomain_019c7730-4892-7c71-b758-b753b8becce0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_ReportableSegmentMember_019c7730-4892-7713-a736-0b260d1acf1b" xlink:href="gern-20260331.xsd#gern_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_019c7730-4892-7c71-b758-b753b8becce0" xlink:to="loc_gern_ReportableSegmentMember_019c7730-4892-7713-a736-0b260d1acf1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019c7730-4892-70e9-85fe-cf531cfb5675" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_019c7730-4892-7c31-bf6a-2906d0b16c2a" xlink:to="loc_srt_ProductOrServiceAxis_019c7730-4892-70e9-85fe-cf531cfb5675" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c7730-4892-70e9-85fe-cf531cfb5675_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019c7730-4892-70e9-85fe-cf531cfb5675" xlink:to="loc_srt_ProductsAndServicesDomain_019c7730-4892-70e9-85fe-cf531cfb5675_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c7730-4892-717c-bac4-4eca9bbf1dec" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019c7730-4892-70e9-85fe-cf531cfb5675" xlink:to="loc_srt_ProductsAndServicesDomain_019c7730-4892-717c-bac4-4eca9bbf1dec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_019c7730-4892-7fc4-b421-e388158a6229" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019c7730-4892-717c-bac4-4eca9bbf1dec" xlink:to="loc_us-gaap_ProductMember_019c7730-4892-7fc4-b421-e388158a6229" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_019c7730-4892-7016-8fe7-5a88373fb5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019c7730-4892-717c-bac4-4eca9bbf1dec" xlink:to="loc_us-gaap_RoyaltyMember_019c7730-4892-7016-8fe7-5a88373fb5b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_ResearchAndClinicalExpensesMember_019c7730-4892-7686-ac1a-61da28d58089" xlink:href="gern-20260331.xsd#gern_ResearchAndClinicalExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019c7730-4892-717c-bac4-4eca9bbf1dec" xlink:to="loc_gern_ResearchAndClinicalExpensesMember_019c7730-4892-7686-ac1a-61da28d58089" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_ChemistryManufacturingAndControlExpensesMember_019c7730-4892-7a52-b834-a3a1df11b0ae" xlink:href="gern-20260331.xsd#gern_ChemistryManufacturingAndControlExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019c7730-4892-717c-bac4-4eca9bbf1dec" xlink:to="loc_gern_ChemistryManufacturingAndControlExpensesMember_019c7730-4892-7a52-b834-a3a1df11b0ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CommercialExpensesMember_019c7730-4892-7e96-b887-b29a485a5b56" xlink:href="gern-20260331.xsd#gern_CommercialExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019c7730-4892-717c-bac4-4eca9bbf1dec" xlink:to="loc_gern_CommercialExpensesMember_019c7730-4892-7e96-b887-b29a485a5b56" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_019dc322-c5ec-719f-bf0c-a7921deb88b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_019c7730-4892-7c31-bf6a-2906d0b16c2a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_019dc322-c5ec-719f-bf0c-a7921deb88b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019dc322-c5ec-719f-bf0c-a7921deb88b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019dc322-c5ec-719f-bf0c-a7921deb88b9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019dc322-c5ec-719f-bf0c-a7921deb88b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019dc322-c5ec-711d-92af-2a6ded63e17b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019dc322-c5ec-719f-bf0c-a7921deb88b9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019dc322-c5ec-711d-92af-2a6ded63e17b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019dc322-c5ec-76c7-b6aa-ccf6dfc13448" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019dc322-c5ec-711d-92af-2a6ded63e17b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019dc322-c5ec-76c7-b6aa-ccf6dfc13448" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_019dc324-48d3-782c-86a5-3651c49b5636" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019dc322-c5ec-711d-92af-2a6ded63e17b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_019dc324-48d3-782c-86a5-3651c49b5636" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_019c7730-4892-7f9d-98fb-ac1f772ef985" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019c7730-4892-73fc-b94c-5507e6a859b9" xlink:to="loc_us-gaap_RevenuesAbstract_019c7730-4892-7f9d-98fb-ac1f772ef985" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c7730-4892-71b5-8150-961cf9f28521" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_019c7730-4892-7f9d-98fb-ac1f772ef985" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c7730-4892-71b5-8150-961cf9f28521" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_019c7730-4892-7277-ac16-7282733d715f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019c7730-4892-73fc-b94c-5507e6a859b9" xlink:to="loc_us-gaap_OperatingExpensesAbstract_019c7730-4892-7277-ac16-7282733d715f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_019c7730-4892-78ca-8f0b-fc7502091ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019c7730-4892-7277-ac16-7282733d715f" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_019c7730-4892-78ca-8f0b-fc7502091ba5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_019c7730-4892-7b10-a12a-35ca734f8b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019c7730-4892-7277-ac16-7282733d715f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_019c7730-4892-7b10-a12a-35ca734f8b7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019c7730-4892-7026-a4a7-15e093873fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_019c7730-4892-7b10-a12a-35ca734f8b7b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019c7730-4892-7026-a4a7-15e093873fd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_019dc322-c5ec-7fc3-94a4-0962501e6603" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_019c7730-4892-7b10-a12a-35ca734f8b7b" xlink:to="loc_us-gaap_RestructuringCharges_019dc322-c5ec-7fc3-94a4-0962501e6603" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_019c7730-4892-7bf2-908e-0f7b7cce1b86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019c7730-4892-7277-ac16-7282733d715f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_019c7730-4892-7bf2-908e-0f7b7cce1b86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_019c7730-4892-7fcd-9688-4af05dcaad65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_019c7730-4892-7bf2-908e-0f7b7cce1b86" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_019c7730-4892-7fcd-9688-4af05dcaad65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_019dc326-7d8e-7c78-8d9e-3ba44e8d44de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_019c7730-4892-76da-8cb8-e84221e0a355" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019c7730-4892-7277-ac16-7282733d715f" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_019c7730-4892-76da-8cb8-e84221e0a355" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_019c7730-4892-7ada-a4e8-a59a6751de55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019c7730-4892-7277-ac16-7282733d715f" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_019c7730-4892-7ada-a4e8-a59a6751de55" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019c7730-4892-76b3-9e72-22960ada2312" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019c7730-4892-7277-ac16-7282733d715f" xlink:to="loc_us-gaap_NetIncomeLoss_019c7730-4892-76b3-9e72-22960ada2312" xlink:type="arc" order="6"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>gern-20260331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019c7730-46e9-7212-bc71-75c229f2667a,g:9ff11a8a-3051-4cda-8828-c63f363e56da-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_NontradeReceivablesCurrent_019c7730-4953-7463-bdbc-f1d3eef77bdf_terseLabel_en-US" xlink:label="lab_us-gaap_NontradeReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest and other receivables</link:label>
    <link:label id="lab_us-gaap_NontradeReceivablesCurrent_label_en-US" xlink:label="lab_us-gaap_NontradeReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nontrade Receivables, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NontradeReceivablesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NontradeReceivablesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NontradeReceivablesCurrent" xlink:to="lab_us-gaap_NontradeReceivablesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_019c7730-4953-7f2b-9d05-f9206dcaff5c_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_ScenarioTwoMember_019c7730-4953-78cd-bc13-5e10a3dd6559_terseLabel_en-US" xlink:label="lab_gern_ScenarioTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario Two</link:label>
    <link:label id="lab_gern_ScenarioTwoMember_label_en-US" xlink:label="lab_gern_ScenarioTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario Two [Member]</link:label>
    <link:label id="lab_gern_ScenarioTwoMember_documentation_en-US" xlink:label="lab_gern_ScenarioTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Scenario two .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_ScenarioTwoMember" xlink:href="gern-20260331.xsd#gern_ScenarioTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_ScenarioTwoMember" xlink:to="lab_gern_ScenarioTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_019c7730-4893-7ef6-8fe1-3ba67263b1c6_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_019c7730-4953-7ab2-9fb1-0a701a40eaf0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_CommercialPaperDueInLessThanOneYearMember_019c7730-4893-7578-bfb2-2f40563be36e_terseLabel_en-US" xlink:label="lab_gern_CommercialPaperDueInLessThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper (due in less than one year)</link:label>
    <link:label id="lab_gern_CommercialPaperDueInLessThanOneYearMember_label_en-US" xlink:label="lab_gern_CommercialPaperDueInLessThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper Due In Less Than One Year [Member]</link:label>
    <link:label id="lab_gern_CommercialPaperDueInLessThanOneYearMember_documentation_en-US" xlink:label="lab_gern_CommercialPaperDueInLessThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to unsecured promissory note (generally negotiable) that provides institutions with short-term funds ), due in less than one year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CommercialPaperDueInLessThanOneYearMember" xlink:href="gern-20260331.xsd#gern_CommercialPaperDueInLessThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_CommercialPaperDueInLessThanOneYearMember" xlink:to="lab_gern_CommercialPaperDueInLessThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses_019c7730-4953-734c-9546-02e7a907eb3a_negatedTerseLabel_en-US" xlink:label="lab_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses_label_en-US" xlink:label="lab_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash And Cash Equivalents, Gross Unrealized Losses</link:label>
    <link:label id="lab_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses_documentation_en-US" xlink:label="lab_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted cash and cash equivalents gross unrealized losses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" xlink:href="gern-20260331.xsd#gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" xlink:to="lab_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_IncreaseDecreaseInOperatingLeaseLiabilities_019dd60b-805a-7ff2-9e42-5d0fae31d972_terseLabel_en-US" xlink:label="lab_gern_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_gern_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_gern_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:label id="lab_gern_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_gern_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="gern-20260331.xsd#gern_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_gern_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019c7730-4953-7e1a-a908-9ffa52ec9fa1_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_019dc27c-2979-7ac0-a854-18c7366c78d9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_PrepaymentPremiumOnPercentageOfTermLoan_019c7730-4953-7191-8bde-5cae815cf589_terseLabel_en-US" xlink:label="lab_gern_PrepaymentPremiumOnPercentageOfTermLoan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment premium on percentage of term loan</link:label>
    <link:label id="lab_gern_PrepaymentPremiumOnPercentageOfTermLoan_label_en-US" xlink:label="lab_gern_PrepaymentPremiumOnPercentageOfTermLoan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepayment Premium on Percentage of Term Loan</link:label>
    <link:label id="lab_gern_PrepaymentPremiumOnPercentageOfTermLoan_documentation_en-US" xlink:label="lab_gern_PrepaymentPremiumOnPercentageOfTermLoan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The prepayment premium on percentage of term loan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_PrepaymentPremiumOnPercentageOfTermLoan" xlink:href="gern-20260331.xsd#gern_PrepaymentPremiumOnPercentageOfTermLoan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_PrepaymentPremiumOnPercentageOfTermLoan" xlink:to="lab_gern_PrepaymentPremiumOnPercentageOfTermLoan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_019c7730-4953-7ef2-96b6-0729a534bb1c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash Equivalents, Restricted Cash and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_019c7730-4893-7c49-aab8-e5af8130c24c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total interest and other income (expense)</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_019c7730-4953-7f14-a73f-2ddf89c4f771_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments on royalty agreement</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_019c7730-4953-7847-9f04-e35a3bc552f8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Royalty payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_019c7730-4953-7fa7-b44c-d381a5b394f5_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options and warrants excluded from diluted net loss per share calculation due to net loss position</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019c7730-4954-75b6-956d-eb27531835c1_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_019c7730-4893-7ed2-95a1-d2e0ead3ed04_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_019c7730-4893-723b-a9d5-30865af87ae1_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_019dc2d1-5559-79f8-8758-8698798ba500_netLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Commercial paper (cash equivalent)</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_019c7730-4893-7468-87e7-50f229212e9d_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_019dc2da-497c-7175-be8b-bcf3d804b743_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_019c7730-4893-7c21-9471-71091f48fa29_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">REVENUE RECOGNITION</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_019c7730-4953-7c62-9edb-e651414f91a7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember_019c7730-4893-7efe-9c2d-e3e6c059e6c6_terseLabel_en-US" xlink:label="lab_gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid Prior To Third Anniversary Of Funding Date</link:label>
    <link:label id="lab_gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember_label_en-US" xlink:label="lab_gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Prior To Third Anniversary Of Funding Date [Member]</link:label>
    <link:label id="lab_gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember_documentation_en-US" xlink:label="lab_gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid prior to third anniversary of funding date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember" xlink:href="gern-20260331.xsd#gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember" xlink:to="lab_gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_CashAndCashEquivalentsUnrealizedLosses_019c7730-4953-7b25-9758-b789c5702a00_negatedLabel_en-US" xlink:label="lab_gern_CashAndCashEquivalentsUnrealizedLosses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_gern_CashAndCashEquivalentsUnrealizedLosses_label_en-US" xlink:label="lab_gern_CashAndCashEquivalentsUnrealizedLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents, Unrealized Losses</link:label>
    <link:label id="lab_gern_CashAndCashEquivalentsUnrealizedLosses_documentation_en-US" xlink:label="lab_gern_CashAndCashEquivalentsUnrealizedLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the gross unrealized losses for cash and cash equivalents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CashAndCashEquivalentsUnrealizedLosses" xlink:href="gern-20260331.xsd#gern_CashAndCashEquivalentsUnrealizedLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_CashAndCashEquivalentsUnrealizedLosses" xlink:to="lab_gern_CashAndCashEquivalentsUnrealizedLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_019c7730-4953-77b4-9133-5935aa6d4a73_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: unamortized debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_019c7730-4953-7b24-8df2-daf3169407f2_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_019c7730-4893-7450-8ae8-50cb4a6db218_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019c7730-4953-7ef5-beb3-9adee90d5b4e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_019c7730-4953-7297-b738-6e7f395e7079_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_019c7730-4953-7465-928c-f41e71c391c4_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_019c7730-4953-7dbe-90b0-2cebff045676_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_019c7730-4953-7319-82d3-bf5175bfeb89_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities Available For Sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019c7730-4953-702b-b62c-702372b41731_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting, Asset Reconciling Item [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Asset Reconciling Item [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAssetReconcilingItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:to="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_019c7730-4893-7de0-97e2-10c4445fa4ea_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_019c7730-4893-78b3-94d2-42bee17daba5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_IncreaseDecreaseInAllowanceForDoubtfulAccounts_019c7730-4953-7e14-af3d-f3965e9391fa_terseLabel_en-US" xlink:label="lab_gern_IncreaseDecreaseInAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in allowance for doubtful accounts</link:label>
    <link:label id="lab_gern_IncreaseDecreaseInAllowanceForDoubtfulAccounts_label_en-US" xlink:label="lab_gern_IncreaseDecreaseInAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Allowance For Doubtful Accounts</link:label>
    <link:label id="lab_gern_IncreaseDecreaseInAllowanceForDoubtfulAccounts_documentation_en-US" xlink:label="lab_gern_IncreaseDecreaseInAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Allowance For Doubtful Accounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_IncreaseDecreaseInAllowanceForDoubtfulAccounts" xlink:href="gern-20260331.xsd#gern_IncreaseDecreaseInAllowanceForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_IncreaseDecreaseInAllowanceForDoubtfulAccounts" xlink:to="lab_gern_IncreaseDecreaseInAllowanceForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019c7730-4953-7e91-9072-0cd4a033f741_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019c7730-4953-7149-9e7c-7060bb75569c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at the end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019c7730-4893-79e0-b424-54df818c6cae_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_019c7730-4953-7746-915b-e911d199910a_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_019dc32c-0282-739f-a436-63b4fa066e96_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and related cost, incurred cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019c7730-4953-72ad-b935-64eb7555813c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_019c7730-4953-7a05-b11d-60f7035785e5_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_019c7730-4953-7f59-974b-201f5658397d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019c7730-4893-724a-901e-b93f5072820b_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_019c7730-4953-7615-9688-20298012b230_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit, maturity period</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember_019c7730-4893-726e-9db3-69be4b3b581b_terseLabel_en-US" xlink:label="lab_gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government-sponsored enterprise securities (due in less than one year)</link:label>
    <link:label id="lab_gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember_label_en-US" xlink:label="lab_gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">U S Government Sponsored Enterprises Debt Securities Due In Less Than One Year [Member]</link:label>
    <link:label id="lab_gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember_documentation_en-US" xlink:label="lab_gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae, due in less than one year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember" xlink:href="gern-20260331.xsd#gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember" xlink:to="lab_gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_019c7730-4953-7739-8d07-f6db10c7da4b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_AccruedManufacturingActivitiesCurrent_019c7730-4953-7e89-a0e9-fc57500a3ba4_terseLabel_en-US" xlink:label="lab_gern_AccruedManufacturingActivitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing activities</link:label>
    <link:label id="lab_gern_AccruedManufacturingActivitiesCurrent_label_en-US" xlink:label="lab_gern_AccruedManufacturingActivitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Manufacturing Activities, Current</link:label>
    <link:label id="lab_gern_AccruedManufacturingActivitiesCurrent_documentation_en-US" xlink:label="lab_gern_AccruedManufacturingActivitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet of obligations incurred through the date and payable for manufacturing related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_AccruedManufacturingActivitiesCurrent" xlink:href="gern-20260331.xsd#gern_AccruedManufacturingActivitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_AccruedManufacturingActivitiesCurrent" xlink:to="lab_gern_AccruedManufacturingActivitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties_019c7730-4953-7211-84c2-cd6683e15788_terseLabel_en-US" xlink:label="lab_gern_NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense on liabilities for sales of future royalties</link:label>
    <link:label id="lab_gern_NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties_label_en-US" xlink:label="lab_gern_NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Interest Expense On Liabilities For Sales Of Future Royalties</link:label>
    <link:label id="lab_gern_NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties_documentation_en-US" xlink:label="lab_gern_NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash Interest Expense On Liabilities For Sales Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties" xlink:href="gern-20260331.xsd#gern_NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties" xlink:to="lab_gern_NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsTable_019c7730-4953-76da-b618-a421cd69eb09_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Holdings [Table]</link:label>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsTable_label_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Holdings [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfInvestmentHoldingsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:to="lab_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_019c7730-4893-704b-919a-a1ea9d02f1b1_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_019c7730-4893-7ca1-8bc0-daf40f117457_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_019c7730-4953-7b07-8d9d-54f922bb2950_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_019c7730-4953-74cc-8cc9-4769008f2ca5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_019c7730-4953-72e8-8a86-c1475f3686e5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_019dc2ea-ee00-7877-a03c-965d0833d206_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued bonuses</link:label>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Bonuses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrent" xlink:to="lab_us-gaap_AccruedBonusesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_019c7730-4953-71f1-8232-9565dfe7ad38_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_019c7730-4893-7257-a22b-78d92019b155_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_019dc32d-d392-790c-bafd-22e8455604ee_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Accrued, beginning balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_019dc32e-53d9-7b5e-98da-d0645674a18d_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Accrued, ending balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_019c7730-4953-78f8-8234-e3a17fdaff2c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_019c7730-4893-74bc-8db0-55a8b43b2ff9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedCapitalizedInterestCosts_019c7730-4953-73ce-8952-4ba68f1fe84e_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedCapitalizedInterestCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: amount representing interest</link:label>
    <link:label id="lab_us-gaap_AccumulatedCapitalizedInterestCosts_label_en-US" xlink:label="lab_us-gaap_AccumulatedCapitalizedInterestCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Capitalized Interest Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedCapitalizedInterestCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedCapitalizedInterestCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedCapitalizedInterestCosts" xlink:to="lab_us-gaap_AccumulatedCapitalizedInterestCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_PaymentsUnpaidToAcquirePropertyPlantAndEquipment_019c7730-4953-767b-8a5e-fe97abfb876d_negatedLabel_en-US" xlink:label="lab_gern_PaymentsUnpaidToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_gern_PaymentsUnpaidToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_gern_PaymentsUnpaidToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments (Unpaid) To Acquire Property, Plant, And Equipment</link:label>
    <link:label id="lab_gern_PaymentsUnpaidToAcquirePropertyPlantAndEquipment_documentation_en-US" xlink:label="lab_gern_PaymentsUnpaidToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments (Unpaid) To Acquire Property, Plant, And Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_PaymentsUnpaidToAcquirePropertyPlantAndEquipment" xlink:href="gern-20260331.xsd#gern_PaymentsUnpaidToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_PaymentsUnpaidToAcquirePropertyPlantAndEquipment" xlink:to="lab_gern_PaymentsUnpaidToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_019c7730-4953-7dac-869a-f93279fb7862_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_019c7730-4953-7570-83ad-eabe7c97d8c1_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_019c7730-4893-789d-8483-bfcefefe1847_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_019c7730-4893-747b-b790-8f263b29aac5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under equity plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_019c7730-4953-7312-9cb7-49646459d89e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019c7730-4953-741c-93c9-0eac111a49c3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_019c7730-4953-7447-9b5d-5e64f5748c21_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BASIS OF PRESENTATION, PRINCIPLES OF CONSOLIDATION USE OF ESTIMATES AND RECENT ACCOUNTING PRONOUNCEMENTS</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_019c7730-4893-7d08-a01c-2a4449a91c1c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other segment expenses</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:to="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019c7730-4893-7da0-b886-6749b2549744_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net effect of exchange rates on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_019c7730-4953-728f-b9dc-b73c81c9d532_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INVENTORY</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_019c7730-4893-72ab-aa84-2db05e3cfc30_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_019dc2da-0087-7b72-9a3c-cb433c4ee7ca_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_019c7730-4953-763a-8e01-b6ca90122ee3_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_019c7730-4953-7af8-9a85-64bc5460afbe_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveCurrent_019dc2ea-ee00-7043-8e36-d64d0bc3542d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveCurrent_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveCurrent" xlink:to="lab_us-gaap_RestructuringReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019c7730-4893-725d-956f-ea7dc7e1d23f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_019c7730-4953-7106-b9f8-ae678710c709_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_NumberOfSeverancePlan_019dc31c-6082-7764-825b-ef794b00d19b_terseLabel_en-US" xlink:label="lab_gern_NumberOfSeverancePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of severance plan</link:label>
    <link:label id="lab_gern_NumberOfSeverancePlan_label_en-US" xlink:label="lab_gern_NumberOfSeverancePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Severance Plan</link:label>
    <link:label id="lab_gern_NumberOfSeverancePlan_documentation_en-US" xlink:label="lab_gern_NumberOfSeverancePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of severance plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_NumberOfSeverancePlan" xlink:href="gern-20260331.xsd#gern_NumberOfSeverancePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_NumberOfSeverancePlan" xlink:to="lab_gern_NumberOfSeverancePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019c7730-4893-7a39-809d-c0a341b7bd5e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available For Sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_019c7730-4893-7f96-9b65-5361c5fea7e9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue interest payments</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_019c7730-4953-7e8d-9f77-d6e01bce6447_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_019dc32d-a0cd-712f-8a84-fd8f4e74a7a4_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_RoyaltiesRollForward_019c7730-4953-732d-8efd-8b6c0c33df63_terseLabel_en-US" xlink:label="lab_gern_RoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties [Roll Forward]</link:label>
    <link:label id="lab_gern_RoyaltiesRollForward_label_en-US" xlink:label="lab_gern_RoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalties [Roll Forward]</link:label>
    <link:label id="lab_gern_RoyaltiesRollForward_documentation_en-US" xlink:label="lab_gern_RoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_RoyaltiesRollForward" xlink:href="gern-20260331.xsd#gern_RoyaltiesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_RoyaltiesRollForward" xlink:to="lab_gern_RoyaltiesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_019c7730-4953-73c8-bf8f-6cafad1e4f3b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_019c7730-4953-7cb1-85ef-cc90dfe40e4c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_CashAndCashEquivalentsUnrealizedGains_019c7730-4893-7b36-853c-b571328d60c8_terseLabel_en-US" xlink:label="lab_gern_CashAndCashEquivalentsUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_gern_CashAndCashEquivalentsUnrealizedGains_label_en-US" xlink:label="lab_gern_CashAndCashEquivalentsUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents, Unrealized Gains</link:label>
    <link:label id="lab_gern_CashAndCashEquivalentsUnrealizedGains_documentation_en-US" xlink:label="lab_gern_CashAndCashEquivalentsUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the gross unrealized gains for cash and cash equivalents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CashAndCashEquivalentsUnrealizedGains" xlink:href="gern-20260331.xsd#gern_CashAndCashEquivalentsUnrealizedGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_CashAndCashEquivalentsUnrealizedGains" xlink:to="lab_gern_CashAndCashEquivalentsUnrealizedGains" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_ChemistryManufacturingAndControlExpensesMember_019c7730-4953-75ed-b0d9-afbfe9fee883_terseLabel_en-US" xlink:label="lab_gern_ChemistryManufacturingAndControlExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chemistry, manufacturing, and control expenses</link:label>
    <link:label id="lab_gern_ChemistryManufacturingAndControlExpensesMember_label_en-US" xlink:label="lab_gern_ChemistryManufacturingAndControlExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chemistry Manufacturing And Control Expenses [Member]</link:label>
    <link:label id="lab_gern_ChemistryManufacturingAndControlExpensesMember_documentation_en-US" xlink:label="lab_gern_ChemistryManufacturingAndControlExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Chemistry, manufacturing, and control expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_ChemistryManufacturingAndControlExpensesMember" xlink:href="gern-20260331.xsd#gern_ChemistryManufacturingAndControlExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_ChemistryManufacturingAndControlExpensesMember" xlink:to="lab_gern_ChemistryManufacturingAndControlExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedVacationCurrent_019dc2ea-ee00-78f5-b22e-c4a76a19dba2_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedVacationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued vacation</link:label>
    <link:label id="lab_us-gaap_AccruedVacationCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedVacationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Vacation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedVacationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedVacationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedVacationCurrent" xlink:to="lab_us-gaap_AccruedVacationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_019c7730-4953-7459-a83a-01a15202284c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019c7730-4893-715b-a6e9-5371e5846383_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_019c7730-4953-750b-9fd2-278bd1928daa_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019c7730-4953-72df-95ce-8c4f16fe9132_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_019c7730-4953-7ecd-83b8-65493bad1510_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_019c7730-4893-7d2c-9515-48b741c058fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_019c7730-4893-7380-a1de-279e32cd375b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_019c7730-4893-76b7-baf0-b17b220b3494_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019c7730-4893-72c6-a894-b998fddd4d25_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">12 Months or Longer</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019c7730-4893-7df1-966f-bbc960aa5075_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage added to prime rate for debt instrument interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_019c7730-4893-7f77-b307-bae595e47a09_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_BiopharmaCreditPlcMember_019c7730-4953-7433-9be6-d2b6f09167af_terseLabel_en-US" xlink:label="lab_gern_BiopharmaCreditPlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioPharma Credit PLC</link:label>
    <link:label id="lab_gern_BiopharmaCreditPlcMember_label_en-US" xlink:label="lab_gern_BiopharmaCreditPlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioPharma Credit PLC [Member]</link:label>
    <link:label id="lab_gern_BiopharmaCreditPlcMember_documentation_en-US" xlink:label="lab_gern_BiopharmaCreditPlcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioPharma credit PLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_BiopharmaCreditPlcMember" xlink:href="gern-20260331.xsd#gern_BiopharmaCreditPlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_BiopharmaCreditPlcMember" xlink:to="lab_gern_BiopharmaCreditPlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_DepositsAndOtherAssetsNoncurrent_019c7730-4953-7227-9dad-5838df0c5d50_terseLabel_en-US" xlink:label="lab_gern_DepositsAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deposits and other assets</link:label>
    <link:label id="lab_gern_DepositsAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_gern_DepositsAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deposits And Other Assets, Noncurrent</link:label>
    <link:label id="lab_gern_DepositsAndOtherAssetsNoncurrent_documentation_en-US" xlink:label="lab_gern_DepositsAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer; and amount of noncurrent assets classified as other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_DepositsAndOtherAssetsNoncurrent" xlink:href="gern-20260331.xsd#gern_DepositsAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_DepositsAndOtherAssetsNoncurrent" xlink:to="lab_gern_DepositsAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_019c7730-4893-719d-a3b8-cad7f3370234_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c7730-4893-7805-afc2-9a76fae2a4f3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_019c7730-4953-7323-93cd-260da72b0ce8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_SalesReturnsAndAllowanceMember_019c7730-4893-7119-806b-6f0122018e70_terseLabel_en-US" xlink:label="lab_gern_SalesReturnsAndAllowanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales returns and allowances</link:label>
    <link:label id="lab_gern_SalesReturnsAndAllowanceMember_label_en-US" xlink:label="lab_gern_SalesReturnsAndAllowanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Returns And Allowance [Member]</link:label>
    <link:label id="lab_gern_SalesReturnsAndAllowanceMember_documentation_en-US" xlink:label="lab_gern_SalesReturnsAndAllowanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales returns and allowance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_SalesReturnsAndAllowanceMember" xlink:href="gern-20260331.xsd#gern_SalesReturnsAndAllowanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_SalesReturnsAndAllowanceMember" xlink:to="lab_gern_SalesReturnsAndAllowanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RecordedUnconditionalPurchaseObligation_019c7730-4893-795a-b265-2b1b03a7d362_terseLabel_en-US" xlink:label="lab_us-gaap_RecordedUnconditionalPurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncancelable commercial purchase commitments</link:label>
    <link:label id="lab_us-gaap_RecordedUnconditionalPurchaseObligation_label_en-US" xlink:label="lab_us-gaap_RecordedUnconditionalPurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recorded Unconditional Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RecordedUnconditionalPurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligation" xlink:to="lab_us-gaap_RecordedUnconditionalPurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_019dc2da-f54c-7b9e-875e-5edf5d726a9b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_019dc328-963c-78ba-b06c-901eb9e8fdd2_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RESTRUCTURING</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_019c7730-4953-7d89-8ee3-38f66dc9a6a9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_019c7730-4893-75f4-8ff4-82340167c08d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_019c7730-4953-7a2c-a312-8a23ac0e5b64_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_019c7730-4953-7250-82d1-b0309664aec3_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019c7730-4953-789d-9b24-556fdf4e99b1_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_DebtInstrumentScenarioDomain_019c7730-4953-7908-9592-9b378af20a7e_terseLabel_en-US" xlink:label="lab_gern_DebtInstrumentScenarioDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Scenario [Domain]</link:label>
    <link:label id="lab_gern_DebtInstrumentScenarioDomain_label_en-US" xlink:label="lab_gern_DebtInstrumentScenarioDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Scenario [Domain]</link:label>
    <link:label id="lab_gern_DebtInstrumentScenarioDomain_documentation_en-US" xlink:label="lab_gern_DebtInstrumentScenarioDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_DebtInstrumentScenarioDomain" xlink:href="gern-20260331.xsd#gern_DebtInstrumentScenarioDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_DebtInstrumentScenarioDomain" xlink:to="lab_gern_DebtInstrumentScenarioDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant_019c7730-4893-73f0-a79b-b72ed2aac5fc_terseLabel_en-US" xlink:label="lab_gern_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of pre-funded warrant</link:label>
    <link:label id="lab_gern_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant_label_en-US" xlink:label="lab_gern_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Exercise Of Prefunded Warrant</link:label>
    <link:label id="lab_gern_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant_documentation_en-US" xlink:label="lab_gern_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Exercise Of Prefunded Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant" xlink:href="gern-20260331.xsd#gern_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant" xlink:to="lab_gern_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019c7730-4953-7931-9ab9-d407171c2e0a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c7730-4953-7cc3-a880-7b5f2a007b30_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember_019c7730-4893-7632-9986-4bd0f5fb3d19_terseLabel_en-US" xlink:label="lab_gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Pharma Revenue Participation Right Purchase Agreement</link:label>
    <link:label id="lab_gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember_label_en-US" xlink:label="lab_gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Pharma Revenue Participation Right Purchase Agreement [Member]</link:label>
    <link:label id="lab_gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember_documentation_en-US" xlink:label="lab_gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Pharma Revenue Participation Right Purchase Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember" xlink:href="gern-20260331.xsd#gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember" xlink:to="lab_gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_TrancheAMember_019c7730-4893-72d0-928f-be0db52e1756_terseLabel_en-US" xlink:label="lab_gern_TrancheAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche A</link:label>
    <link:label id="lab_gern_TrancheAMember_label_en-US" xlink:label="lab_gern_TrancheAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche A [Member]</link:label>
    <link:label id="lab_gern_TrancheAMember_documentation_en-US" xlink:label="lab_gern_TrancheAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_TrancheAMember" xlink:href="gern-20260331.xsd#gern_TrancheAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_TrancheAMember" xlink:to="lab_gern_TrancheAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019c7730-4893-7fd4-a621-92258452b335_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019c7730-4893-720b-878a-bb96c821ed8e_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_PercentageOfCommitmentAmountToFundLoan_019c7730-4953-729f-b887-220251bcce81_terseLabel_en-US" xlink:label="lab_gern_PercentageOfCommitmentAmountToFundLoan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of commitment amount to fund loan</link:label>
    <link:label id="lab_gern_PercentageOfCommitmentAmountToFundLoan_label_en-US" xlink:label="lab_gern_PercentageOfCommitmentAmountToFundLoan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Commitment Amount To Fund Loan</link:label>
    <link:label id="lab_gern_PercentageOfCommitmentAmountToFundLoan_documentation_en-US" xlink:label="lab_gern_PercentageOfCommitmentAmountToFundLoan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of commitment amount to fund loan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_PercentageOfCommitmentAmountToFundLoan" xlink:href="gern-20260331.xsd#gern_PercentageOfCommitmentAmountToFundLoan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_PercentageOfCommitmentAmountToFundLoan" xlink:to="lab_gern_PercentageOfCommitmentAmountToFundLoan" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_GovernmentRebatesMember_019c7730-4953-7fe8-aaff-81ebd1308523_terseLabel_en-US" xlink:label="lab_gern_GovernmentRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government rebates</link:label>
    <link:label id="lab_gern_GovernmentRebatesMember_label_en-US" xlink:label="lab_gern_GovernmentRebatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Rebates [Member]</link:label>
    <link:label id="lab_gern_GovernmentRebatesMember_documentation_en-US" xlink:label="lab_gern_GovernmentRebatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government rebates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_GovernmentRebatesMember" xlink:href="gern-20260331.xsd#gern_GovernmentRebatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_GovernmentRebatesMember" xlink:to="lab_gern_GovernmentRebatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_019dbfe9-7b20-7a54-8e7f-e9521ef3058b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_019c7730-4953-7e82-9b5c-931491e926d1_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_019c7730-4893-751c-ba00-607af3883ba5_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_019c7730-4893-7762-9039-249fe7b8bbd7_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_019c7730-4953-7063-8674-758c63e0de7c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_019c7730-4953-7479-ac3d-c81839c21a50_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenue, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_019c7730-4953-731c-ac37-7c43f5de3daa_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_019c7730-4953-7c8b-ad4d-30335ae11dd6_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_MunicipalSecuritiesDueInLessThanOneYearMember_019dc2a8-10b3-7184-90da-99cddfca5e69_terseLabel_en-US" xlink:label="lab_gern_MunicipalSecuritiesDueInLessThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Municipal securities (due in less than one year)</link:label>
    <link:label id="lab_gern_MunicipalSecuritiesDueInLessThanOneYearMember_019dc2d0-b2eb-763d-96f7-d722ef99ff2a_verboseLabel_en-US" xlink:label="lab_gern_MunicipalSecuritiesDueInLessThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Municipal securities (due in less than one year)</link:label>
    <link:label id="lab_gern_MunicipalSecuritiesDueInLessThanOneYearMember_label_en-US" xlink:label="lab_gern_MunicipalSecuritiesDueInLessThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Municipal Securities Due In Less Than One Year [Member]</link:label>
    <link:label id="lab_gern_MunicipalSecuritiesDueInLessThanOneYearMember_documentation_en-US" xlink:label="lab_gern_MunicipalSecuritiesDueInLessThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Municipal securities due in less than one year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_MunicipalSecuritiesDueInLessThanOneYearMember" xlink:href="gern-20260331.xsd#gern_MunicipalSecuritiesDueInLessThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_MunicipalSecuritiesDueInLessThanOneYearMember" xlink:to="lab_gern_MunicipalSecuritiesDueInLessThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_019c7730-4953-759f-a293-32781f939b42_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_TermLoansMember_019c7730-4954-7b98-b0c9-bbe923f4998d_terseLabel_en-US" xlink:label="lab_gern_TermLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loans</link:label>
    <link:label id="lab_gern_TermLoansMember_label_en-US" xlink:label="lab_gern_TermLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loans [Member]</link:label>
    <link:label id="lab_gern_TermLoansMember_documentation_en-US" xlink:label="lab_gern_TermLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term loans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_TermLoansMember" xlink:href="gern-20260331.xsd#gern_TermLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_TermLoansMember" xlink:to="lab_gern_TermLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_019c7730-4893-7a64-8b54-7159cf8586b8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_019dd637-3133-71cc-bf66-fe4cc0d5c7ce_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and related cost, number of positions eliminated, period percent</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_TrancheBMember_019c7730-4953-70c7-9004-f215dfbce38a_terseLabel_en-US" xlink:label="lab_gern_TrancheBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche B</link:label>
    <link:label id="lab_gern_TrancheBMember_label_en-US" xlink:label="lab_gern_TrancheBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche B [Member]</link:label>
    <link:label id="lab_gern_TrancheBMember_documentation_en-US" xlink:label="lab_gern_TrancheBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_TrancheBMember" xlink:href="gern-20260331.xsd#gern_TrancheBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_TrancheBMember" xlink:to="lab_gern_TrancheBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_019c7730-4893-7c0f-9557-c5ec332141d4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_019c7730-4953-7a99-92b8-bec9e27dff29_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_019c7730-4893-79a6-b86d-cd5a69f9831a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_LiabilityRelatedToSaleOfFutureRoyaltiesCurrent_019c7730-4893-7270-9e96-b1b41064cf73_terseLabel_en-US" xlink:label="lab_gern_LiabilityRelatedToSaleOfFutureRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability related to sale of future royalties</link:label>
    <link:label id="lab_gern_LiabilityRelatedToSaleOfFutureRoyaltiesCurrent_label_en-US" xlink:label="lab_gern_LiabilityRelatedToSaleOfFutureRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Related To Sale Of Future Royalties, Current</link:label>
    <link:label id="lab_gern_LiabilityRelatedToSaleOfFutureRoyaltiesCurrent_documentation_en-US" xlink:label="lab_gern_LiabilityRelatedToSaleOfFutureRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability Related To Sale Of Future Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_LiabilityRelatedToSaleOfFutureRoyaltiesCurrent" xlink:href="gern-20260331.xsd#gern_LiabilityRelatedToSaleOfFutureRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_LiabilityRelatedToSaleOfFutureRoyaltiesCurrent" xlink:to="lab_gern_LiabilityRelatedToSaleOfFutureRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_TotalGrossToNetAdjustmentsMember_019c7730-4893-7696-bab4-de00d4171400_terseLabel_en-US" xlink:label="lab_gern_TotalGrossToNetAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total gross-to-net adjustments</link:label>
    <link:label id="lab_gern_TotalGrossToNetAdjustmentsMember_label_en-US" xlink:label="lab_gern_TotalGrossToNetAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Gross To Net Adjustments [Member]</link:label>
    <link:label id="lab_gern_TotalGrossToNetAdjustmentsMember_documentation_en-US" xlink:label="lab_gern_TotalGrossToNetAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total gross to net adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_TotalGrossToNetAdjustmentsMember" xlink:href="gern-20260331.xsd#gern_TotalGrossToNetAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_TotalGrossToNetAdjustmentsMember" xlink:to="lab_gern_TotalGrossToNetAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_019c7730-4893-7791-aabc-c790a6b6f0ca_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_019c7730-4893-7010-bb61-6628cab0fb59_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_019c7730-4893-7ab2-9321-0e691d14e835_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases, right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_019c7730-4893-799b-9bc4-24af4f7405c7_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares_019dc256-615f-7e9c-8fb3-e70b1722ded7_terseLabel_en-US" xlink:label="lab_gern_APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation related to issuances of common stock and options for services (in shares)</link:label>
    <link:label id="lab_gern_APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares_label_en-US" xlink:label="lab_gern_APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition, Shares</link:label>
    <link:label id="lab_gern_APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares_documentation_en-US" xlink:label="lab_gern_APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares" xlink:href="gern-20260331.xsd#gern_APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares" xlink:to="lab_gern_APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_019dc2ea-ee00-72cb-8740-e44edf18b77f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_TrancheCMember_019c7730-4893-7e20-aa28-fc35b8674c13_terseLabel_en-US" xlink:label="lab_gern_TrancheCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche C</link:label>
    <link:label id="lab_gern_TrancheCMember_label_en-US" xlink:label="lab_gern_TrancheCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche C [Member]</link:label>
    <link:label id="lab_gern_TrancheCMember_documentation_en-US" xlink:label="lab_gern_TrancheCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche C [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_TrancheCMember" xlink:href="gern-20260331.xsd#gern_TrancheCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_TrancheCMember" xlink:to="lab_gern_TrancheCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember_019c7730-4893-718e-b40c-c3003cbe04f2_terseLabel_en-US" xlink:label="lab_gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate notes (due in one to two years)</link:label>
    <link:label id="lab_gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember_label_en-US" xlink:label="lab_gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Note Securities Due In One To Two Years [Member]</link:label>
    <link:label id="lab_gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember_documentation_en-US" xlink:label="lab_gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest), due in one to two years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" xlink:href="gern-20260331.xsd#gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" xlink:to="lab_gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_LongTermDebtMaturityAfterYearThree_019c7730-4953-782f-b241-1f5977be32f4_terseLabel_en-US" xlink:label="lab_gern_LongTermDebtMaturityAfterYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_gern_LongTermDebtMaturityAfterYearThree_label_en-US" xlink:label="lab_gern_LongTermDebtMaturityAfterYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, After Year Three</link:label>
    <link:label id="lab_gern_LongTermDebtMaturityAfterYearThree_documentation_en-US" xlink:label="lab_gern_LongTermDebtMaturityAfterYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, After Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_LongTermDebtMaturityAfterYearThree" xlink:href="gern-20260331.xsd#gern_LongTermDebtMaturityAfterYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_LongTermDebtMaturityAfterYearThree" xlink:to="lab_gern_LongTermDebtMaturityAfterYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_019c7730-4893-75c5-937e-d23b00571328_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEGMENT REPORTING</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryNotesSecuritiesMember_019c7730-4953-7c59-821f-593023eb807e_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryNotesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Notes Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryNotesSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c7730-4953-7440-bf55-49c84a3e94a3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_019c7730-4953-7286-bde9-1deb9db61988_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_MunicipalSecuritiesDueInOneToTwoYearsMember_019c7730-4953-7047-a01a-d1aaace79f77_terseLabel_en-US" xlink:label="lab_gern_MunicipalSecuritiesDueInOneToTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Municipal securities (due in one to two years)</link:label>
    <link:label id="lab_gern_MunicipalSecuritiesDueInOneToTwoYearsMember_label_en-US" xlink:label="lab_gern_MunicipalSecuritiesDueInOneToTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Municipal Securities Due In One To Two Years [Member]</link:label>
    <link:label id="lab_gern_MunicipalSecuritiesDueInOneToTwoYearsMember_documentation_en-US" xlink:label="lab_gern_MunicipalSecuritiesDueInOneToTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Municipal Securities Due In One To Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_MunicipalSecuritiesDueInOneToTwoYearsMember" xlink:href="gern-20260331.xsd#gern_MunicipalSecuritiesDueInOneToTwoYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_MunicipalSecuritiesDueInOneToTwoYearsMember" xlink:to="lab_gern_MunicipalSecuritiesDueInOneToTwoYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-4893-7a0e-a5f7-8659fb1c4bb9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019c7730-4953-7a40-a104-02824cc987c2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_DistributorServiceFeesMember_019dc2a1-7101-7e5f-b838-cbcf4bee2315_terseLabel_en-US" xlink:label="lab_gern_DistributorServiceFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor service fees</link:label>
    <link:label id="lab_gern_DistributorServiceFeesMember_label_en-US" xlink:label="lab_gern_DistributorServiceFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor Service Fees [Member]</link:label>
    <link:label id="lab_gern_DistributorServiceFeesMember_documentation_en-US" xlink:label="lab_gern_DistributorServiceFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor Service Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_DistributorServiceFeesMember" xlink:href="gern-20260331.xsd#gern_DistributorServiceFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_DistributorServiceFeesMember" xlink:to="lab_gern_DistributorServiceFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_ChargebacksMember_019c7730-4953-7c02-bafc-708a65ad0abf_terseLabel_en-US" xlink:label="lab_gern_ChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chargebacks</link:label>
    <link:label id="lab_gern_ChargebacksMember_label_en-US" xlink:label="lab_gern_ChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chargebacks [Member]</link:label>
    <link:label id="lab_gern_ChargebacksMember_documentation_en-US" xlink:label="lab_gern_ChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Chargeback and distributor service fees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_ChargebacksMember" xlink:href="gern-20260331.xsd#gern_ChargebacksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_ChargebacksMember" xlink:to="lab_gern_ChargebacksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c7730-4893-718d-b65d-492d8ac10dd7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_019c7730-4953-74ce-ac8f-af1f6177d6c8_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_019c7730-4953-7090-8be4-ff287519a326_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commercial expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_019c7730-4953-7f9d-a4ce-6621114d4a3a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_019c7730-4953-737a-a83e-1985ec1e172b_totalLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalent, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_019c7730-4953-7b48-9346-9e4360cdddf5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest payable</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_019c7730-4893-7a00-82c2-9ee3ed40402d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_019c7730-4893-7482-9e4a-158b5e94c723_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Payments Under Loan Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseAbstract_019c7730-4953-70b3-9f0e-af3dcc1b9fd1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue_019c7730-4954-79e8-8665-b3fdafd8ce7c_terseLabel_en-US" xlink:label="lab_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with exercise of warrants</link:label>
    <link:label id="lab_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue_label_en-US" xlink:label="lab_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance Of Common Stock In Connection With Warrant Exercise Value</link:label>
    <link:label id="lab_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue_documentation_en-US" xlink:label="lab_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity impact of the value of stock issued in connection with exercise of warrants during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" xlink:href="gern-20260331.xsd#gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" xlink:to="lab_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_019dc2a7-5abb-7ab1-839e-8f79cec79921_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_PurchaseObligationWrittenNoticeTerm_019c7730-4954-7f11-9e9a-887992f579c6_terseLabel_en-US" xlink:label="lab_gern_PurchaseObligationWrittenNoticeTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase obligation, written notice term</link:label>
    <link:label id="lab_gern_PurchaseObligationWrittenNoticeTerm_label_en-US" xlink:label="lab_gern_PurchaseObligationWrittenNoticeTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Written Notice Term</link:label>
    <link:label id="lab_gern_PurchaseObligationWrittenNoticeTerm_documentation_en-US" xlink:label="lab_gern_PurchaseObligationWrittenNoticeTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Written Notice Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_PurchaseObligationWrittenNoticeTerm" xlink:href="gern-20260331.xsd#gern_PurchaseObligationWrittenNoticeTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_PurchaseObligationWrittenNoticeTerm" xlink:to="lab_gern_PurchaseObligationWrittenNoticeTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_019c7730-4953-7e91-9e1e-f2c069b98c12_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019c7730-4953-70a3-a764-e2a96c329b5d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_019c7730-4893-7b09-8e12-5d4e2911d9d7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_019c7730-4893-7fc5-a757-0c8da02ad88b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_019c7730-4893-765a-8b39-9d240242bc7e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019c7730-4893-706d-9b62-de53dc03f477_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_019c7730-4953-7564-8a9d-34ec2b4f7521_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_019c7730-4954-72e3-9b74-1efacc409f70_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_019c7730-4954-74b2-9056-8a7662f7fb57_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Noncurrent portion of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_019c7730-4953-7d12-b5c1-9288c600c0eb_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_019c7730-4953-74be-9a50-ab99f55d919d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_019c7730-4953-7f63-bd38-416e0f405f7f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_019c7730-4953-7283-86fc-e90aaa96e4f1_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_019c7730-4893-716d-a547-e52571cff974_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_019c7730-4953-7be3-b0e3-f53fd8e19264_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_019c7730-4953-78b6-81fb-7ae86fe41ab1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019c7730-4953-74f5-a062-f7b5cabc95b2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_019c7730-4893-7f96-af12-03526e1bffc5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_019c7730-4953-7724-b854-855e1f22512b_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense recognized</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_PharmakonLoanAgreementMember_019c7730-4953-7743-941b-4d6398e58b06_terseLabel_en-US" xlink:label="lab_gern_PharmakonLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pharmakon Loan Agreement</link:label>
    <link:label id="lab_gern_PharmakonLoanAgreementMember_label_en-US" xlink:label="lab_gern_PharmakonLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pharmakon Loan Agreement [Member]</link:label>
    <link:label id="lab_gern_PharmakonLoanAgreementMember_documentation_en-US" xlink:label="lab_gern_PharmakonLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pharmakon loan agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_PharmakonLoanAgreementMember" xlink:href="gern-20260331.xsd#gern_PharmakonLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_PharmakonLoanAgreementMember" xlink:to="lab_gern_PharmakonLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_019c7730-4953-7d88-bb2a-d1ab2658bad4_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_019c7730-4953-708d-ac53-0bc8365a1690_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_019c7730-4893-7378-beed-1b5df68d468b_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Municipal securities</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_019c7730-4954-7f4b-b24f-edaa27d6c989_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of future royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_019c7730-4954-758a-8545-9b13c5d49d14_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Carrying value of liability related to sale of future royalties at beginning of period</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_019c7730-4953-7f72-b287-4810ef13194c_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Carrying value of liability related to sale of future royalties at end of period</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_019c7730-4953-7c32-9c7b-bc2680f21750_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019c7730-4893-7dd7-a7c9-6ef593ad979f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less Than 12 Months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_019c7730-4953-7e96-9bfe-120fdc810522_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant_019c7730-4953-798f-bffd-c7ac3d24c96b_terseLabel_en-US" xlink:label="lab_gern_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of pre-funded warrant (in shares)</link:label>
    <link:label id="lab_gern_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant_label_en-US" xlink:label="lab_gern_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Exercise Of Prefunded Warrant</link:label>
    <link:label id="lab_gern_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant_documentation_en-US" xlink:label="lab_gern_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Exercise Of Prefunded Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant" xlink:href="gern-20260331.xsd#gern_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant" xlink:to="lab_gern_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_019c7730-4953-732b-8bdb-95593ef733ba_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_019c7730-4893-705a-af7a-bf7cd937ee16_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_019c7730-4893-70a2-8c4a-235d2d891d85_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government-sponsored enterprise securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_019c7730-4893-772c-8e59-101d8578df7d_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019c7730-4893-7f0f-8c66-06177aa5a251_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accretion and amortization on investments, net</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_019c7730-4953-7723-9872-bbff9326a794_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_019c7730-4893-7b9e-9624-1c7240b460f6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuances of common stock under equity plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember_019c7730-4893-7e46-876b-cfd5db80f239_terseLabel_en-US" xlink:label="lab_gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3rd Anniversary But, Prior To 4th Anniversary Of Funding Date</link:label>
    <link:label id="lab_gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember_label_en-US" xlink:label="lab_gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid On Or After Third Anniversary But Prior To Fourth Anniversary Of Funding Date [Member]</link:label>
    <link:label id="lab_gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember_documentation_en-US" xlink:label="lab_gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid on or after third anniversary but prior to fourth anniversary of funding date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember" xlink:href="gern-20260331.xsd#gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember" xlink:to="lab_gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019c7730-4953-7852-9c9f-bdc8975a44b6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Award Types</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_ScheduleOfAccruedCompensationAndBenefitsTableTextBlock_019dc2e7-7309-7f67-bdbc-f55e50e3db45_terseLabel_en-US" xlink:label="lab_gern_ScheduleOfAccruedCompensationAndBenefitsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Compensation and Benefits</link:label>
    <link:label id="lab_gern_ScheduleOfAccruedCompensationAndBenefitsTableTextBlock_label_en-US" xlink:label="lab_gern_ScheduleOfAccruedCompensationAndBenefitsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Accrued Compensation And Benefits [Table Text Block]</link:label>
    <link:label id="lab_gern_ScheduleOfAccruedCompensationAndBenefitsTableTextBlock_documentation_en-US" xlink:label="lab_gern_ScheduleOfAccruedCompensationAndBenefitsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Accrued Compensation And Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_ScheduleOfAccruedCompensationAndBenefitsTableTextBlock" xlink:href="gern-20260331.xsd#gern_ScheduleOfAccruedCompensationAndBenefitsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_ScheduleOfAccruedCompensationAndBenefitsTableTextBlock" xlink:to="lab_gern_ScheduleOfAccruedCompensationAndBenefitsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_019dc31c-8923-7b1e-989a-012281f99335_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term manufacturing commitments, amount</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Purchase Commitment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_019c7730-4893-7567-b9d9-1662b7b9bdd1_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_ScenarioOneMember_019c7730-4953-7040-a156-cea22840644d_terseLabel_en-US" xlink:label="lab_gern_ScenarioOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario One</link:label>
    <link:label id="lab_gern_ScenarioOneMember_label_en-US" xlink:label="lab_gern_ScenarioOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario One [Member]</link:label>
    <link:label id="lab_gern_ScenarioOneMember_documentation_en-US" xlink:label="lab_gern_ScenarioOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Scenario one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_ScenarioOneMember" xlink:href="gern-20260331.xsd#gern_ScenarioOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_ScenarioOneMember" xlink:to="lab_gern_ScenarioOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_019c7730-4893-72ac-ad01-3c1de47f3623_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019c7730-4953-7b42-9b3e-55aeea4bceb5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_019c7730-4893-783f-92d8-88dda8eed540_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="lab_us-gaap_OperatingCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_019c7730-4893-7a98-98a1-ac76b7845d8f_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificate of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_019c7730-4893-7bcc-93c4-c8ba815f241e_verboseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Certificate of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_019dc27c-2979-7a42-8134-c32e398689f1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_019dc32d-5dc6-7227-b308-1838804c842f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_DebtInstrumentScenarioAxis_019c7730-4954-7ef8-aee3-9cbc84611a20_terseLabel_en-US" xlink:label="lab_gern_DebtInstrumentScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Scenario [Axis]</link:label>
    <link:label id="lab_gern_DebtInstrumentScenarioAxis_label_en-US" xlink:label="lab_gern_DebtInstrumentScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Scenario [Axis]</link:label>
    <link:label id="lab_gern_DebtInstrumentScenarioAxis_documentation_en-US" xlink:label="lab_gern_DebtInstrumentScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Scenario</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_DebtInstrumentScenarioAxis" xlink:href="gern-20260331.xsd#gern_DebtInstrumentScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_DebtInstrumentScenarioAxis" xlink:to="lab_gern_DebtInstrumentScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_019c7730-4893-7c91-91f1-ccbd089f5902_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_ReportableSegmentMember_019c7730-4953-7bd5-81f4-052d25518a19_terseLabel_en-US" xlink:label="lab_gern_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:label id="lab_gern_ReportableSegmentMember_label_en-US" xlink:label="lab_gern_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_gern_ReportableSegmentMember_documentation_en-US" xlink:label="lab_gern_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_ReportableSegmentMember" xlink:href="gern-20260331.xsd#gern_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_ReportableSegmentMember" xlink:to="lab_gern_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_019c7730-4893-79d7-ba13-998532849635_totalLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019c7730-4893-7aac-913b-b2b2402ad3a8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_019c7730-4893-798f-94cd-6fd79a40dbad_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c7730-4953-7dd9-9508-3cbd70d827b4_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_019c7730-4953-70c9-a98f-49e8132b774f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_019c7730-4953-7b9f-9466-095d1226374f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_019c7730-4953-731a-8a45-95d6c6a537d0_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c7730-4953-7c93-8f93-88d606339b0c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_019c7730-4893-70de-ba60-894074c4a843_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_019c7730-4953-7c71-ade7-9faaeafe2a89_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_019c7730-4953-710d-9b61-475fc689b903_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_019c7730-4953-7180-9827-944e61cea0f0_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs/debt discounts</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_019c7730-4953-7f0e-a05b-5bf29705cb4a_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_USTreasurySecuritiesDueInLessThanOneYearMember_019c7730-4953-78ab-8c31-9b941be3355a_terseLabel_en-US" xlink:label="lab_gern_USTreasurySecuritiesDueInLessThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury securities (due in less than one year)</link:label>
    <link:label id="lab_gern_USTreasurySecuritiesDueInLessThanOneYearMember_label_en-US" xlink:label="lab_gern_USTreasurySecuritiesDueInLessThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">U S Treasury Securities Due In Less Than One Year [Member]</link:label>
    <link:label id="lab_gern_USTreasurySecuritiesDueInLessThanOneYearMember_documentation_en-US" xlink:label="lab_gern_USTreasurySecuritiesDueInLessThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">US Treasury Securities Due In less than one Year Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_USTreasurySecuritiesDueInLessThanOneYearMember" xlink:href="gern-20260331.xsd#gern_USTreasurySecuritiesDueInLessThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_USTreasurySecuritiesDueInLessThanOneYearMember" xlink:to="lab_gern_USTreasurySecuritiesDueInLessThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_019c7730-4893-7172-85cc-52d42d1473ff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DEBT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_019dbfe2-bffb-777c-ad21-4b455a9fb894_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_019c7730-4953-79c8-b727-73191569107a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_019c7730-4953-77b8-b179-d8f92f069f62_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_019c7730-4953-7210-8304-498d04b73239_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_019c7730-4953-773d-8649-f4ed71495389_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019c7730-4953-72c0-bc92-ef7748fa9d15_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in calculating diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_019c7730-4953-73a5-b561-baa38578fdf7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_019c7730-4953-7a22-9acb-898060bdd05a_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsAbstract_019c7730-4893-7839-9ae3-dac22fed7c10_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash:</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_019c7730-4953-704d-9cfa-ac780319f3b4_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_ResearchAndClinicalExpensesMember_019c7730-4893-7001-9170-7aa29474828c_terseLabel_en-US" xlink:label="lab_gern_ResearchAndClinicalExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and clinical expenses</link:label>
    <link:label id="lab_gern_ResearchAndClinicalExpensesMember_label_en-US" xlink:label="lab_gern_ResearchAndClinicalExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Clinical Expenses [Member]</link:label>
    <link:label id="lab_gern_ResearchAndClinicalExpensesMember_documentation_en-US" xlink:label="lab_gern_ResearchAndClinicalExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and clinical expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_ResearchAndClinicalExpensesMember" xlink:href="gern-20260331.xsd#gern_ResearchAndClinicalExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_ResearchAndClinicalExpensesMember" xlink:to="lab_gern_ResearchAndClinicalExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_019c7730-4893-76de-aea1-4e507b3abf57_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems_019c7730-4954-7761-82c3-afa7ffe79c4e_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Investment Holdings [Line Items]</link:label>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems_label_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Investment Holdings [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNoteSecuritiesMember_019c7730-4893-7fff-b02b-44fb8f6b9f66_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNoteSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate notes</link:label>
    <link:label id="lab_us-gaap_CorporateNoteSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateNoteSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Note Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNoteSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateNoteSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNoteSecuritiesMember" xlink:to="lab_us-gaap_CorporateNoteSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedInvestmentsAtFairValue_019c7730-4954-7f64-baaf-7cfae596cc3e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedInvestmentsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_RestrictedInvestmentsAtFairValue_label_en-US" xlink:label="lab_us-gaap_RestrictedInvestmentsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Investments, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedInvestmentsAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedInvestmentsAtFairValue" xlink:to="lab_us-gaap_RestrictedInvestmentsAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_019c7730-4893-7895-a433-552143374e9a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_019c7730-4893-73f6-95ed-0d286c9ab451_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019c7730-4893-7138-85f2-cc390e8d6f08_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_019c7730-4953-70e0-9695-64f073dece2d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_CommercialExpensesMember_019c7730-4953-7359-ac45-a6d503278eb5_terseLabel_en-US" xlink:label="lab_gern_CommercialExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial expenses</link:label>
    <link:label id="lab_gern_CommercialExpensesMember_label_en-US" xlink:label="lab_gern_CommercialExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Expenses [Member]</link:label>
    <link:label id="lab_gern_CommercialExpensesMember_documentation_en-US" xlink:label="lab_gern_CommercialExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CommercialExpensesMember" xlink:href="gern-20260331.xsd#gern_CommercialExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_CommercialExpensesMember" xlink:to="lab_gern_CommercialExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_019c7730-4893-7a90-a52b-7e269d585c03_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_019c7730-4893-7789-bb9b-14a6c0206986_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_019c7730-4953-79ab-ace1-9b5894386f79_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_019dc31e-abb0-7d56-a371-7ef1988ff6f2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NET LOSS PER COMMON SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_019c7730-4953-77ed-89b9-1349c6fd52e2_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c7730-4953-7742-b449-f8525ddd8dfc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c7730-4953-738b-85a0-aa4c7ef06ee9_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_019c7730-4953-7062-93c8-346bbd2cb0dc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_019c7730-4893-7dbb-ac9f-291cb27218bd_terseLabel_en-US" xlink:label="lab_gern_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent liability related to sale of future royalties</link:label>
    <link:label id="lab_gern_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_label_en-US" xlink:label="lab_gern_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Related To Sale Of Future Royalties, Noncurrent</link:label>
    <link:label id="lab_gern_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_documentation_en-US" xlink:label="lab_gern_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncurrent liability related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:href="gern-20260331.xsd#gern_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:to="lab_gern_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_019c7730-4893-779d-b2e6-d0d43315072b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_019c7730-4953-78a4-bdb8-44caf3f52f9e_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_019c7730-4953-781e-b073-f7fe56de8d24_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuances of common stock from equity plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock_019c7730-4893-7137-b546-a0a8badb1479_terseLabel_en-US" xlink:label="lab_gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Activity Within Liability Related To Sale Of Future Royalties</link:label>
    <link:label id="lab_gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock_label_en-US" xlink:label="lab_gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Activity Within Liability Related To Sale Of Future Royalties [Table Text Block]</link:label>
    <link:label id="lab_gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock_documentation_en-US" xlink:label="lab_gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of activity within liability related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock" xlink:href="gern-20260331.xsd#gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock" xlink:to="lab_gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_019c7730-4953-71f6-9d09-9ff8a02ec8cc_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of putative securities lawsuits</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_019c7730-4953-793a-8ae1-cbb05a58d17c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_019c7730-4893-7580-b554-d20d6040509d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_019c7730-4953-7751-9df8-ed9ce9188781_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total costs and operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_019c7730-4893-72cf-9e1e-eb41612aa380_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_019c7730-4893-74be-89ee-7b8ab292b144_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_019dc27c-a8c8-7b4f-8ed0-a808fdbc7d30_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_019c7730-4893-730a-addf-14093d4d907c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_019c7730-4893-7343-810a-89434832c5d4_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_019dc31f-cb9e-76af-b069-43d917bf2006_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_019c7730-4953-77d5-8d1a-d593ef3cb50e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_019df88d-ce1e-7276-be7e-3e6d3d1d8f1b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation related to issuances of common stock and options for services</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_GrossToNetAdjustmentsCurrent_019c7730-4953-7cd6-a275-c8353589b7c0_terseLabel_en-US" xlink:label="lab_gern_GrossToNetAdjustmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued revenue adjustments</link:label>
    <link:label id="lab_gern_GrossToNetAdjustmentsCurrent_label_en-US" xlink:label="lab_gern_GrossToNetAdjustmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross To Net Adjustments, Current</link:label>
    <link:label id="lab_gern_GrossToNetAdjustmentsCurrent_documentation_en-US" xlink:label="lab_gern_GrossToNetAdjustmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gross To Net Adjustments, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_GrossToNetAdjustmentsCurrent" xlink:href="gern-20260331.xsd#gern_GrossToNetAdjustmentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_GrossToNetAdjustmentsCurrent" xlink:to="lab_gern_GrossToNetAdjustmentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock_019c7730-4893-7e16-94a9-ce833a73fdca_terseLabel_en-US" xlink:label="lab_gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Gross Product Sales to Net Product Sales</link:label>
    <link:label id="lab_gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock_label_en-US" xlink:label="lab_gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Gross To Net Sales Adjustments [Table Text Block]</link:label>
    <link:label id="lab_gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock_documentation_en-US" xlink:label="lab_gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of gross to net sales adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock" xlink:href="gern-20260331.xsd#gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock" xlink:to="lab_gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedGains_019c7730-4893-7dc2-adfa-6383b7158479_terseLabel_en-US" xlink:label="lab_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedGains_label_en-US" xlink:label="lab_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash And Cash Equivalents, Gross Unrealized Gains</link:label>
    <link:label id="lab_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedGains_documentation_en-US" xlink:label="lab_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Cash And Cash Equivalents, Gross Unrealized Gains</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedGains" xlink:href="gern-20260331.xsd#gern_RestrictedCashAndCashEquivalentsGrossUnrealizedGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedGains" xlink:to="lab_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedGains" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_019c7730-4953-7fde-8668-256759930b96_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_019c7730-4893-7a60-a49b-f6c23be9c749_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_019c7730-4953-727b-86c0-af3fccab505c_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_RevenuesBeforeAdjustmentsMember_019c7730-4954-737a-b5ac-4f207e7f6a43_terseLabel_en-US" xlink:label="lab_gern_RevenuesBeforeAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross product revenue</link:label>
    <link:label id="lab_gern_RevenuesBeforeAdjustmentsMember_label_en-US" xlink:label="lab_gern_RevenuesBeforeAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues Before Adjustments [Member]</link:label>
    <link:label id="lab_gern_RevenuesBeforeAdjustmentsMember_documentation_en-US" xlink:label="lab_gern_RevenuesBeforeAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues before adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_RevenuesBeforeAdjustmentsMember" xlink:href="gern-20260331.xsd#gern_RevenuesBeforeAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_RevenuesBeforeAdjustmentsMember" xlink:to="lab_gern_RevenuesBeforeAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_019c7730-4893-7d25-9e10-69129df4c545_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_019c7730-4893-790f-b91e-e6ec111a0be3_totalLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_019c7730-4953-7a5e-a563-ef3b0098cadc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_019c7730-4953-7c66-bf49-ef38c43ba89d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_019c7730-4953-70ae-bc3d-3713908b6e2c_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_019c7730-4953-7731-863c-26dd07c08292_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_019c7730-4953-7b87-bf5e-fe31a32d7d8f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash Equivalents and Marketable Securities with Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_019c7730-4893-749b-aca2-83a87d1a3053_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_019c7730-4893-7820-80d6-4c507e851f51_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_019dbffb-33c0-7bda-9d5a-23b5d1625cfe_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_019dc326-7d8e-75bc-927f-f0e505e53c82_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expenses and adjustments</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember_019c7730-4893-7767-a6c0-9371e79f1a27_terseLabel_en-US" xlink:label="lab_gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4th Anniversary Of Funding Date</link:label>
    <link:label id="lab_gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember_label_en-US" xlink:label="lab_gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid On Or After Fourth Anniversary Of Funding Date [Member]</link:label>
    <link:label id="lab_gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember_documentation_en-US" xlink:label="lab_gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid on or after fourth anniversary of funding date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember" xlink:href="gern-20260331.xsd#gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember" xlink:to="lab_gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_019c7730-4893-7c88-84a1-052cabd57ae0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_019c7730-4893-7d62-abf6-fa19b166bbe4_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_SignificantAccountingPoliciesPolicyPolicyTextBlock_019c7730-4893-7dd8-a753-bf7c1e653f7e_terseLabel_en-US" xlink:label="lab_gern_SignificantAccountingPoliciesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_gern_SignificantAccountingPoliciesPolicyPolicyTextBlock_label_en-US" xlink:label="lab_gern_SignificantAccountingPoliciesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies, Policy [Policy Text Block]</link:label>
    <link:label id="lab_gern_SignificantAccountingPoliciesPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_gern_SignificantAccountingPoliciesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_SignificantAccountingPoliciesPolicyPolicyTextBlock" xlink:href="gern-20260331.xsd#gern_SignificantAccountingPoliciesPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_SignificantAccountingPoliciesPolicyPolicyTextBlock" xlink:to="lab_gern_SignificantAccountingPoliciesPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_019c7730-4953-77ae-8724-0eb1635b74cf_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_019c7730-4953-7360-b041-dba16315de0e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_019c7730-4953-7982-b079-651e88a0aa11_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019c7730-4953-7e1f-b350-35da706e8993_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Noncash Item [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_019c7730-4893-7e4f-804a-cccb04b9c2a2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019c7730-4893-7544-a0b1-8be10013a9b5_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">12 Months or Longer</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_019c7730-4893-72d2-9d7c-54db538b76b2_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_PercentageOfAnnualNetSales_019c7730-4893-76da-8f54-846b5148fe32_terseLabel_en-US" xlink:label="lab_gern_PercentageOfAnnualNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of annual net sales</link:label>
    <link:label id="lab_gern_PercentageOfAnnualNetSales_label_en-US" xlink:label="lab_gern_PercentageOfAnnualNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Annual Net Sales</link:label>
    <link:label id="lab_gern_PercentageOfAnnualNetSales_documentation_en-US" xlink:label="lab_gern_PercentageOfAnnualNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of annual net sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_PercentageOfAnnualNetSales" xlink:href="gern-20260331.xsd#gern_PercentageOfAnnualNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_PercentageOfAnnualNetSales" xlink:to="lab_gern_PercentageOfAnnualNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019c7730-4893-7afd-9e24-d22d7de9d843_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less Than 12 Months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_019c7730-4893-799a-891c-70f7e78aafd6_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_019c7730-4893-7945-963a-17caecf68146_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_019c7730-4953-7151-858c-bc58c3f61258_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_019df88e-008a-7671-ae7a-dd432743920c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation for equity-based awards to employees and directors</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, ESPP, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_019dc31f-cb9e-76bd-84d1-503476703c57_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019c7730-4893-7062-9fc2-0a59ae481f49_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent_019c7730-4953-70d2-8312-f0a55311008d_terseLabel_en-US" xlink:label="lab_gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract research organization and clinical trial costs</link:label>
    <link:label id="lab_gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent_label_en-US" xlink:label="lab_gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Research Organizations And Clinical Trial Costs, Current</link:label>
    <link:label id="lab_gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent_documentation_en-US" xlink:label="lab_gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" xlink:href="gern-20260331.xsd#gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" xlink:to="lab_gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_UpfrontPaymentReceived_019c7730-4893-7c26-a385-9d5939d023f0_terseLabel_en-US" xlink:label="lab_gern_UpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_gern_UpfrontPaymentReceived_label_en-US" xlink:label="lab_gern_UpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payment Received</link:label>
    <link:label id="lab_gern_UpfrontPaymentReceived_documentation_en-US" xlink:label="lab_gern_UpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront payment received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_UpfrontPaymentReceived" xlink:href="gern-20260331.xsd#gern_UpfrontPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_UpfrontPaymentReceived" xlink:to="lab_gern_UpfrontPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019c7730-4953-7edf-b92e-bfc81f94bd0f_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_019c7730-4893-7138-9120-73ac54f647ff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Financial Instruments Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_019dd60d-3da9-76fc-a572-eecd391c3c74_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities and sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_019c7730-4953-7071-ae98-dbe7a0488a93_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Included in cash and cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019c7730-4893-7fc2-b4e1-2a2f9d47c2a8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential dilutive securities excluded from diluted earnings (loss) per share calculation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_019c7730-4893-72a3-8242-911d7e30b670_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_DebtInstrumentFloorRate_019c7730-4953-75ad-b26d-aaf43efffd52_terseLabel_en-US" xlink:label="lab_gern_DebtInstrumentFloorRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Floor rate</link:label>
    <link:label id="lab_gern_DebtInstrumentFloorRate_label_en-US" xlink:label="lab_gern_DebtInstrumentFloorRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Floor Rate</link:label>
    <link:label id="lab_gern_DebtInstrumentFloorRate_documentation_en-US" xlink:label="lab_gern_DebtInstrumentFloorRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt instrument floor rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_DebtInstrumentFloorRate" xlink:href="gern-20260331.xsd#gern_DebtInstrumentFloorRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_DebtInstrumentFloorRate" xlink:to="lab_gern_DebtInstrumentFloorRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_019c7730-4953-79a2-8d72-9f1c4505ef4a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_019c7730-4953-7cf8-9de8-047233c80a12_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_019c7730-4953-7c6c-93d7-5b2d511ab675_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, variable interest rate, type flag</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:to="lab_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_019c7730-4893-7ae4-97ca-fecf2314892a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019c7730-4893-7642-9ec9-45d534e56432_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in calculating basic net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_CorporateNoteSecuritiesDueInLessThanOneYearMember_019c7730-4954-7225-b5ca-50f491dd05bb_terseLabel_en-US" xlink:label="lab_gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate notes (due in less than one year)</link:label>
    <link:label id="lab_gern_CorporateNoteSecuritiesDueInLessThanOneYearMember_label_en-US" xlink:label="lab_gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Note Securities Due In Less Than One Year [Member]</link:label>
    <link:label id="lab_gern_CorporateNoteSecuritiesDueInLessThanOneYearMember_documentation_en-US" xlink:label="lab_gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest), due in less than one year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" xlink:href="gern-20260331.xsd#gern_CorporateNoteSecuritiesDueInLessThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" xlink:to="lab_gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_019c7730-4953-78c2-870c-19fb9b2f11f1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_019c7730-4953-76b7-bb5c-424aca4a5cc3_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_019c7730-4953-7636-9a6a-2a329356a2de_terseLabel_en-US" xlink:label="lab_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_label_en-US" xlink:label="lab_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure</link:label>
    <link:label id="lab_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_documentation_en-US" xlink:label="lab_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" xlink:href="gern-20260331.xsd#gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" xlink:to="lab_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_019dbfe9-f096-7e34-8154-f3fd6344ef46_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_019c7730-4953-7643-a565-60626f46376a_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_019c7730-4893-7d89-8a98-97920bb5d235_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019c7730-4893-7fc2-a6fa-ba8e6261a1e2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019c7730-4893-73b8-a0b8-c12534a7511e_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_019c7730-4893-7746-bea6-80a552d22c89_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_019c7730-4893-7f56-bb88-dcf2b200edb1_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Reported Revenues to Net (Loss) Income Under Significant Expense Principle</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_019c7730-4953-76e4-937d-3369aacd0d09_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_019dbfe2-08a0-7062-92d2-b472cbf3829a_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_019c7730-4953-74ea-8969-de5ba979f9d9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_019c7730-4954-71b5-9792-0d553a569fee_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019c7730-4953-7090-884a-a2e568786c3a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum borrowing capacity under term loan</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_019c7730-4953-7d72-9e9a-11c0eaaa40ab_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_019c7730-4953-734a-83b5-f5cf0805efb0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs and operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_019c7730-4953-7445-89f4-232e92165ea4_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gern_DebtInstrumentRoyaltyPaymentRatio_019c7730-4893-7b87-9992-e1edaf158c22_terseLabel_en-US" xlink:label="lab_gern_DebtInstrumentRoyaltyPaymentRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payment, ratio</link:label>
    <link:label id="lab_gern_DebtInstrumentRoyaltyPaymentRatio_label_en-US" xlink:label="lab_gern_DebtInstrumentRoyaltyPaymentRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Royalty Payment, Ratio</link:label>
    <link:label id="lab_gern_DebtInstrumentRoyaltyPaymentRatio_documentation_en-US" xlink:label="lab_gern_DebtInstrumentRoyaltyPaymentRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Royalty Payment, Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gern_DebtInstrumentRoyaltyPaymentRatio" xlink:href="gern-20260331.xsd#gern_DebtInstrumentRoyaltyPaymentRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gern_DebtInstrumentRoyaltyPaymentRatio" xlink:to="lab_gern_DebtInstrumentRoyaltyPaymentRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_019c7730-4893-7f71-b499-54264c30ca28_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_019dc329-a754-7c45-84fa-d20c5392560c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Charges and Spending Related to Restructuring</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_019c7730-4893-78f4-aad6-1886c2f15bda_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_019c7730-4953-722b-a047-c5af80bca8cf_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_019c7730-4893-78d6-844a-fb5118d214ec_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_019c7730-4953-764a-9010-b5fbc8ec47d3_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019c7730-4953-7a9d-8d7c-69765106328d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_019c7730-4893-7e89-be1e-d847b2ce8de5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional, legal and accounting fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>gern-20260331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019c7730-46e9-7212-bc71-75c229f2667a,g:9ff11a8a-3051-4cda-8828-c63f363e56da-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.geron.com/role/Cover" xlink:type="simple" xlink:href="gern-20260331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019c7730-47b6-7187-a708-a0d0ac90945c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_DocumentType_019c7730-47b6-7187-a708-a0d0ac90945c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_019c7730-47b6-7c91-9903-26ebf21c3e67" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_DocumentQuarterlyReport_019c7730-47b6-7c91-9903-26ebf21c3e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019c7730-47b6-751a-a40e-c27efc826325" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_DocumentPeriodEndDate_019c7730-47b6-751a-a40e-c27efc826325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_019c7730-47b6-7feb-8c26-5c482eb30628" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_DocumentTransitionReport_019c7730-47b6-7feb-8c26-5c482eb30628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019c7730-47b6-761f-938f-120037d1bcb1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_EntityFileNumber_019c7730-47b6-761f-938f-120037d1bcb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019c7730-47b6-73a2-9ffa-f9fa4f5dfbf9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_EntityRegistrantName_019c7730-47b6-73a2-9ffa-f9fa4f5dfbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019c7730-47b6-7a95-ad46-11725a69facc" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019c7730-47b6-7a95-ad46-11725a69facc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019c7730-47b6-7193-99c7-e38141c52b3b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_EntityTaxIdentificationNumber_019c7730-47b6-7193-99c7-e38141c52b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019c7730-47b6-70de-bd17-1182cee60f5c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_EntityAddressAddressLine1_019c7730-47b6-70de-bd17-1182cee60f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_019c7730-47b6-7ad4-84c5-320fe316e17e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_EntityAddressAddressLine2_019c7730-47b6-7ad4-84c5-320fe316e17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019c7730-47b6-7f20-9e0e-2570f6265bdd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_EntityAddressCityOrTown_019c7730-47b6-7f20-9e0e-2570f6265bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019c7730-47b6-7c43-b8b9-22e3b1172167" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_EntityAddressStateOrProvince_019c7730-47b6-7c43-b8b9-22e3b1172167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019c7730-47b6-7948-877b-7fe54d3081d9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_EntityAddressPostalZipCode_019c7730-47b6-7948-877b-7fe54d3081d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019c7730-47b6-7b51-800d-d99e3cdcef47" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_CityAreaCode_019c7730-47b6-7b51-800d-d99e3cdcef47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019c7730-47b6-74c5-9fd8-1b44c1e9c84c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_LocalPhoneNumber_019c7730-47b6-74c5-9fd8-1b44c1e9c84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019c7730-47b6-7345-9402-d48aa7172bef" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_Security12bTitle_019c7730-47b6-7345-9402-d48aa7172bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019c7730-47b6-7eeb-88cc-c79b3553d960" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_TradingSymbol_019c7730-47b6-7eeb-88cc-c79b3553d960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_019c7730-47b6-71bc-889f-4248a297d7f9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_SecurityExchangeName_019c7730-47b6-71bc-889f-4248a297d7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_019c7730-47b6-7fb7-a2aa-62f622782cc0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_EntityCurrentReportingStatus_019c7730-47b6-7fb7-a2aa-62f622782cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_019c7730-47b6-7b88-b843-1efcd167a200" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_EntityInteractiveDataCurrent_019c7730-47b6-7b88-b843-1efcd167a200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_019c7730-47b6-742e-bfaf-512523473616" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_EntityFilerCategory_019c7730-47b6-742e-bfaf-512523473616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_019c7730-47b6-73f9-801d-5c239a5beb39" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_EntitySmallBusiness_019c7730-47b6-73f9-801d-5c239a5beb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019c7730-47b6-7acb-be30-061405690c06" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_EntityEmergingGrowthCompany_019c7730-47b6-7acb-be30-061405690c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_019c7730-47b6-7661-b4e1-651950dfe6a0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_EntityShellCompany_019c7730-47b6-7661-b4e1-651950dfe6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_019c7730-47b6-7672-85a2-8359e03fb6e6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_019c7730-47b6-7672-85a2-8359e03fb6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019c7730-47b6-76c1-972a-4d6ad50a0b25" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_EntityCentralIndexKey_019c7730-47b6-76c1-972a-4d6ad50a0b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_019c7730-47b6-75c9-9b8b-053247d01032" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_CurrentFiscalYearEndDate_019c7730-47b6-75c9-9b8b-053247d01032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_019c7730-47b6-7b24-a7c1-416bedcc468c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_019c7730-47b6-7b24-a7c1-416bedcc468c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019c7730-47b6-7672-b165-8b6e6236c571" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_AmendmentFlag_019c7730-47b6-7672-b165-8b6e6236c571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_019c7730-47b6-7928-8b98-a52b0a637704" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019c7730-47b6-7188-afcb-3564637a4a4f" xlink:to="loc_dei_DocumentFiscalYearFocus_019c7730-47b6-7928-8b98-a52b0a637704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="gern-20260331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_019c7730-47b6-70e6-b052-d2508c1cc336" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_019c7730-47b6-7077-9e9d-3b8db1e34362" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019c7730-47b6-70e6-b052-d2508c1cc336" xlink:to="loc_us-gaap_AssetsAbstract_019c7730-47b6-7077-9e9d-3b8db1e34362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_019c7730-47b6-7ad8-9ddf-60f5bd8bae79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019c7730-47b6-7077-9e9d-3b8db1e34362" xlink:to="loc_us-gaap_AssetsCurrentAbstract_019c7730-47b6-7ad8-9ddf-60f5bd8bae79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019c7730-47b6-7afc-ae8c-ecc19784d36c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019c7730-47b6-7ad8-9ddf-60f5bd8bae79" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019c7730-47b6-7afc-ae8c-ecc19784d36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_019c7730-47b6-7711-976c-e37649d5a9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019c7730-47b6-7ad8-9ddf-60f5bd8bae79" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_019c7730-47b6-7711-976c-e37649d5a9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_019c7730-47b6-7079-b7f0-d91ca50c17d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019c7730-47b6-7ad8-9ddf-60f5bd8bae79" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_019c7730-47b6-7079-b7f0-d91ca50c17d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_019c7730-47b6-7e3c-97ff-6e5cae393f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019c7730-47b6-7ad8-9ddf-60f5bd8bae79" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_019c7730-47b6-7e3c-97ff-6e5cae393f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NontradeReceivablesCurrent_019c7730-47b6-7ff1-b860-99d96f2e5c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NontradeReceivablesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019c7730-47b6-7ad8-9ddf-60f5bd8bae79" xlink:to="loc_us-gaap_NontradeReceivablesCurrent_019c7730-47b6-7ff1-b860-99d96f2e5c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_019c7730-47b6-7e52-a466-157bb45ea50b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019c7730-47b6-7ad8-9ddf-60f5bd8bae79" xlink:to="loc_us-gaap_InventoryNet_019c7730-47b6-7e52-a466-157bb45ea50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019c7730-47b6-75ae-b939-736984487b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019c7730-47b6-7ad8-9ddf-60f5bd8bae79" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019c7730-47b6-75ae-b939-736984487b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019c7730-47b6-7e38-996e-53831b4c747f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019c7730-47b6-7ad8-9ddf-60f5bd8bae79" xlink:to="loc_us-gaap_AssetsCurrent_019c7730-47b6-7e38-996e-53831b4c747f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_019c7730-47b6-7320-934d-6a875fd1f999" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019c7730-47b6-7077-9e9d-3b8db1e34362" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_019c7730-47b6-7320-934d-6a875fd1f999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019c7730-47b6-7d95-b185-a98177c2d353" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019c7730-47b6-7077-9e9d-3b8db1e34362" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019c7730-47b6-7d95-b185-a98177c2d353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_019c7730-47b6-722a-bfbb-2716b77d35ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019c7730-47b6-7077-9e9d-3b8db1e34362" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_019c7730-47b6-722a-bfbb-2716b77d35ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_DepositsAndOtherAssetsNoncurrent_019c7730-47b6-7490-ad80-b67005c401b9" xlink:href="gern-20260331.xsd#gern_DepositsAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019c7730-47b6-7077-9e9d-3b8db1e34362" xlink:to="loc_gern_DepositsAndOtherAssetsNoncurrent_019c7730-47b6-7490-ad80-b67005c401b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019c7730-47b6-7200-ad98-bca11c34afa3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019c7730-47b6-7077-9e9d-3b8db1e34362" xlink:to="loc_us-gaap_Assets_019c7730-47b6-7200-ad98-bca11c34afa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019c7730-47b6-7518-9c21-16baa2830ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019c7730-47b6-70e6-b052-d2508c1cc336" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019c7730-47b6-7518-9c21-16baa2830ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_019c7730-47b6-79a4-a417-6befc6ae4030" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019c7730-47b6-7518-9c21-16baa2830ce7" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_019c7730-47b6-79a4-a417-6befc6ae4030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019c7730-47b6-71c9-a972-a30cee99857a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019c7730-47b6-79a4-a417-6befc6ae4030" xlink:to="loc_us-gaap_AccountsPayableCurrent_019c7730-47b6-71c9-a972-a30cee99857a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019c7730-47b6-7258-bff9-eba8bf344e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019c7730-47b6-79a4-a417-6befc6ae4030" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019c7730-47b6-7258-bff9-eba8bf344e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_019c7730-47b6-7545-897b-d563409cbb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019c7730-47b6-79a4-a417-6befc6ae4030" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_019c7730-47b6-7545-897b-d563409cbb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_LiabilityRelatedToSaleOfFutureRoyaltiesCurrent_019c7730-47b6-7778-a364-e92a944a9b6e" xlink:href="gern-20260331.xsd#gern_LiabilityRelatedToSaleOfFutureRoyaltiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019c7730-47b6-79a4-a417-6befc6ae4030" xlink:to="loc_gern_LiabilityRelatedToSaleOfFutureRoyaltiesCurrent_019c7730-47b6-7778-a364-e92a944a9b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019c7730-47b6-7adf-af9d-6d2f9f2b5f41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019c7730-47b6-79a4-a417-6befc6ae4030" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_019c7730-47b6-7adf-af9d-6d2f9f2b5f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019c7730-47b6-7b46-a059-8e5d37b94c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019c7730-47b6-79a4-a417-6befc6ae4030" xlink:to="loc_us-gaap_LiabilitiesCurrent_019c7730-47b6-7b46-a059-8e5d37b94c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019c7730-47b6-714b-b0e9-a08bb0268dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019c7730-47b6-7518-9c21-16baa2830ce7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019c7730-47b6-714b-b0e9-a08bb0268dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_019c7730-47b6-736f-aec3-43435af4a8d3" xlink:href="gern-20260331.xsd#gern_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019c7730-47b6-7518-9c21-16baa2830ce7" xlink:to="loc_gern_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_019c7730-47b6-736f-aec3-43435af4a8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_019c7730-47b6-7acb-9a5d-2c99c3bd34eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019c7730-47b6-7518-9c21-16baa2830ce7" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_019c7730-47b6-7acb-9a5d-2c99c3bd34eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019dbfe1-9899-729f-ab1c-973d367662c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019c7730-47b6-7518-9c21-16baa2830ce7" xlink:to="loc_us-gaap_Liabilities_019dbfe1-9899-729f-ab1c-973d367662c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019c7730-47b6-7932-b8c2-43b30c7da033" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019c7730-47b6-7518-9c21-16baa2830ce7" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019c7730-47b6-7932-b8c2-43b30c7da033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_019c7730-47b6-7bc9-a879-fb01594cd40c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019c7730-47b6-7518-9c21-16baa2830ce7" xlink:to="loc_us-gaap_StockholdersEquityAbstract_019c7730-47b6-7bc9-a879-fb01594cd40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_019dbfe2-bffb-788f-9b2b-c12abc1beaa5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019c7730-47b6-7bc9-a879-fb01594cd40c" xlink:to="loc_us-gaap_PreferredStockValue_019dbfe2-bffb-788f-9b2b-c12abc1beaa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_019c7730-47b6-7445-8448-89b033789069" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019c7730-47b6-7bc9-a879-fb01594cd40c" xlink:to="loc_us-gaap_CommonStockValue_019c7730-47b6-7445-8448-89b033789069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_019c7730-47b6-7e07-9450-ca8535889a82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019c7730-47b6-7bc9-a879-fb01594cd40c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_019c7730-47b6-7e07-9450-ca8535889a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019c7730-47b6-7561-8463-c33e9a0b311e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019c7730-47b6-7bc9-a879-fb01594cd40c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019c7730-47b6-7561-8463-c33e9a0b311e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019c7730-47b6-7d8b-9a8f-452a94b77169" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019c7730-47b6-7bc9-a879-fb01594cd40c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019c7730-47b6-7d8b-9a8f-452a94b77169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019c7730-47b6-79f5-a572-fd25f372ee2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019c7730-47b6-7bc9-a879-fb01594cd40c" xlink:to="loc_us-gaap_StockholdersEquity_019c7730-47b6-79f5-a572-fd25f372ee2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019c7730-47b6-78d8-a4bb-fbd714ab7fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019c7730-47b6-7518-9c21-16baa2830ce7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_019c7730-47b6-78d8-a4bb-fbd714ab7fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="gern-20260331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_019dbfea-6645-729a-b951-e2fbb089b707" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019dbff2-a1cb-7a67-95f7-99d3cb97d4cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019dbfea-6645-729a-b951-e2fbb089b707" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019dbff2-a1cb-7a67-95f7-99d3cb97d4cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019dbff2-a1cb-7cc2-bffb-032583c1df6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019dbfea-6645-729a-b951-e2fbb089b707" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019dbff2-a1cb-7cc2-bffb-032583c1df6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="gern-20260331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_019c7730-47b6-75c6-8d5a-358cca5a56dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019c7730-47b6-78eb-907d-f40c0cfcb66e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019c7730-47b6-75c6-8d5a-358cca5a56dc" xlink:to="loc_us-gaap_StatementTable_019c7730-47b6-78eb-907d-f40c0cfcb66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019c7730-47b6-7b1f-b629-1321b325e9b9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019c7730-47b6-78eb-907d-f40c0cfcb66e" xlink:to="loc_srt_ProductOrServiceAxis_019c7730-47b6-7b1f-b629-1321b325e9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c7730-47b6-7ee5-a30b-0fa9c0c04c90" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019c7730-47b6-7b1f-b629-1321b325e9b9" xlink:to="loc_srt_ProductsAndServicesDomain_019c7730-47b6-7ee5-a30b-0fa9c0c04c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_019c7730-47b6-76a9-9f24-513bc1e9a7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019c7730-47b6-7ee5-a30b-0fa9c0c04c90" xlink:to="loc_us-gaap_ProductMember_019c7730-47b6-76a9-9f24-513bc1e9a7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_019c7730-47b6-7af1-b64d-4524584c1c39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019c7730-47b6-7ee5-a30b-0fa9c0c04c90" xlink:to="loc_us-gaap_RoyaltyMember_019c7730-47b6-7af1-b64d-4524584c1c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019c7730-47b6-7be0-94fa-10cb86d6df58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019c7730-47b6-78eb-907d-f40c0cfcb66e" xlink:to="loc_us-gaap_StatementLineItems_019c7730-47b6-7be0-94fa-10cb86d6df58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_019c7730-47b6-768e-92ba-b4563a85b3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019c7730-47b6-7be0-94fa-10cb86d6df58" xlink:to="loc_us-gaap_RevenuesAbstract_019c7730-47b6-768e-92ba-b4563a85b3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c7730-47b6-708d-9e40-d256ee0dcb88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_019c7730-47b6-768e-92ba-b4563a85b3c6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c7730-47b6-708d-9e40-d256ee0dcb88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_019c7730-47b6-7d68-8102-2eda0301f8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019c7730-47b6-7be0-94fa-10cb86d6df58" xlink:to="loc_us-gaap_OperatingExpensesAbstract_019c7730-47b6-7d68-8102-2eda0301f8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_019c7730-47b6-7022-8fed-912b7aafa882" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019c7730-47b6-7d68-8102-2eda0301f8ae" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_019c7730-47b6-7022-8fed-912b7aafa882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019c7730-47b6-758d-a18a-d1611da7e997" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019c7730-47b6-7d68-8102-2eda0301f8ae" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019c7730-47b6-758d-a18a-d1611da7e997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_019c7730-47b6-73e0-ab67-1133fc31c277" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019c7730-47b6-7d68-8102-2eda0301f8ae" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_019c7730-47b6-73e0-ab67-1133fc31c277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_019dbffb-33c0-782d-9e28-567d3eab5590" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019c7730-47b6-7d68-8102-2eda0301f8ae" xlink:to="loc_us-gaap_RestructuringCharges_019dbffb-33c0-782d-9e28-567d3eab5590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019c7730-47b6-7239-bdf3-018172606dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019c7730-47b6-7d68-8102-2eda0301f8ae" xlink:to="loc_us-gaap_OperatingExpenses_019c7730-47b6-7239-bdf3-018172606dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019c7730-47b6-78ba-b96a-d421d0b55ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019c7730-47b6-7be0-94fa-10cb86d6df58" xlink:to="loc_us-gaap_OperatingIncomeLoss_019c7730-47b6-78ba-b96a-d421d0b55ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_019c7730-47b6-7fe0-8ddf-ac84aba4d39e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019c7730-47b6-7be0-94fa-10cb86d6df58" xlink:to="loc_us-gaap_InvestmentIncomeInterest_019c7730-47b6-7fe0-8ddf-ac84aba4d39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_019c7730-47b6-7eff-96f0-3e467eb190d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019c7730-47b6-7be0-94fa-10cb86d6df58" xlink:to="loc_us-gaap_InterestExpenseNonoperating_019c7730-47b6-7eff-96f0-3e467eb190d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_019c7730-47b6-7730-bdff-7e04b5869c81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019c7730-47b6-7be0-94fa-10cb86d6df58" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_019c7730-47b6-7730-bdff-7e04b5869c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019c7730-47b6-7bc9-b911-cc6e0ecbb27b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019c7730-47b6-7be0-94fa-10cb86d6df58" xlink:to="loc_us-gaap_NetIncomeLoss_019c7730-47b6-7bc9-b911-cc6e0ecbb27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019c7730-47b6-7df5-a53b-dfef7ebd58ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019c7730-47b6-7be0-94fa-10cb86d6df58" xlink:to="loc_us-gaap_EarningsPerShareBasic_019c7730-47b6-7df5-a53b-dfef7ebd58ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019c7730-47b6-7668-b575-ca07b20d9ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019c7730-47b6-7be0-94fa-10cb86d6df58" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019c7730-47b6-7668-b575-ca07b20d9ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019c7730-47b6-752a-91bb-32bf8353a7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019c7730-47b6-7be0-94fa-10cb86d6df58" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019c7730-47b6-752a-91bb-32bf8353a7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019c7730-47b6-7650-8523-dea51cbc539f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019c7730-47b6-7be0-94fa-10cb86d6df58" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019c7730-47b6-7650-8523-dea51cbc539f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="gern-20260331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019c7730-47b6-72ca-a37a-b3c1019aac60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019c7730-47b6-7a0e-b8f2-0ca5bee98a06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019c7730-47b6-72ca-a37a-b3c1019aac60" xlink:to="loc_us-gaap_NetIncomeLoss_019c7730-47b6-7a0e-b8f2-0ca5bee98a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_019c7730-47b6-7626-81cd-65c96106d0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019c7730-47b6-72ca-a37a-b3c1019aac60" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_019c7730-47b6-7626-81cd-65c96106d0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019c7730-47b6-71b7-9c5c-a9442e73e2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019c7730-47b6-72ca-a37a-b3c1019aac60" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019c7730-47b6-71b7-9c5c-a9442e73e2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_019c7730-47b6-75b8-bade-d7978aeb6deb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019c7730-47b6-72ca-a37a-b3c1019aac60" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_019c7730-47b6-75b8-bade-d7978aeb6deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="gern-20260331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_019c7730-47b6-77c1-b948-08a0678305ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019c7730-47b6-728a-9de0-26d60ce4d29b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_019c7730-47b6-77c1-b948-08a0678305ea" xlink:to="loc_us-gaap_StatementTable_019c7730-47b6-728a-9de0-26d60ce4d29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019c7730-47b6-7557-98aa-6d3d93eb5dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019c7730-47b6-728a-9de0-26d60ce4d29b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019c7730-47b6-7557-98aa-6d3d93eb5dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019c7730-47b6-7b91-accf-5eed2b21550d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019c7730-47b6-7557-98aa-6d3d93eb5dc4" xlink:to="loc_us-gaap_EquityComponentDomain_019c7730-47b6-7b91-accf-5eed2b21550d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019c7730-47b6-77ab-bda8-2adb04e8a93d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019c7730-47b6-7b91-accf-5eed2b21550d" xlink:to="loc_us-gaap_CommonStockMember_019c7730-47b6-77ab-bda8-2adb04e8a93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_019c7730-47b6-77cf-ae1c-624ddb276295" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019c7730-47b6-7b91-accf-5eed2b21550d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_019c7730-47b6-77cf-ae1c-624ddb276295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_019c7730-47b6-7f31-84b5-580efd89414f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019c7730-47b6-7b91-accf-5eed2b21550d" xlink:to="loc_us-gaap_RetainedEarningsMember_019c7730-47b6-7f31-84b5-580efd89414f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019c7730-47b6-7844-b9fb-59c685dae605" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019c7730-47b6-7b91-accf-5eed2b21550d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019c7730-47b6-7844-b9fb-59c685dae605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019c7730-47b6-70ae-ab10-07119e1ed646" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019c7730-47b6-728a-9de0-26d60ce4d29b" xlink:to="loc_us-gaap_StatementLineItems_019c7730-47b6-70ae-ab10-07119e1ed646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019c7730-47b6-70ae-ab10-07119e1ed646" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019c7730-47b6-771c-9c24-1a21e53f227a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019c7730-47b6-771c-9c24-1a21e53f227a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019c7730-47b6-74dc-919a-5ffd74b8366b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_us-gaap_StockholdersEquity_019c7730-47b6-74dc-919a-5ffd74b8366b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019c7730-47b6-712f-b69b-1877efafac39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_us-gaap_NetIncomeLoss_019c7730-47b6-712f-b69b-1877efafac39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_019c7730-47b6-7160-9b6b-57e1b9f231a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_019c7730-47b6-7160-9b6b-57e1b9f231a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019c7730-47b6-73aa-b71f-c26c1a48e0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019c7730-47b6-73aa-b71f-c26c1a48e0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant_019dd608-eb9e-7e3e-82d3-03a3bc127101" xlink:href="gern-20260331.xsd#gern_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_gern_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant_019dd608-eb9e-7e3e-82d3-03a3bc127101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant_019dd608-eb9e-7e08-a3a6-61aa1eb34a10" xlink:href="gern-20260331.xsd#gern_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_gern_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant_019dd608-eb9e-7e08-a3a6-61aa1eb34a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue_019c7730-47b6-7835-8b8d-a07a5a452679" xlink:href="gern-20260331.xsd#gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue_019c7730-47b6-7835-8b8d-a07a5a452679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_019dc238-fc4e-753c-90df-f9693539671f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_019dc238-fc4e-753c-90df-f9693539671f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_019c7730-47b6-7b41-b853-519f95e2b6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_019c7730-47b6-7b41-b853-519f95e2b6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares_019dc256-615f-76db-a552-b2ad24e57a7a" xlink:href="gern-20260331.xsd#gern_APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_gern_APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares_019dc256-615f-76db-a552-b2ad24e57a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_019df88d-ce1e-7632-92f5-1ced2fa7bbb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_019df88d-ce1e-7632-92f5-1ced2fa7bbb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_019df88e-008a-73c5-bade-73a208144c94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_019df88e-008a-73c5-bade-73a208144c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019c7730-47b6-7858-9c19-b1dacd4dddd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019c7730-47b6-7858-9c19-b1dacd4dddd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019c7730-47b6-7269-9db8-6d2263d2c8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019c7730-47b6-7c46-949a-c3a9d0c529a2" xlink:to="loc_us-gaap_StockholdersEquity_019c7730-47b6-7269-9db8-6d2263d2c8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="gern-20260331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_019c7730-47b6-7dc6-a61a-672792a72811" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019c7730-47b6-79f5-92d6-fc1fab86af6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019c7730-47b6-7dc6-a61a-672792a72811" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019c7730-47b6-79f5-92d6-fc1fab86af6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019c7730-47b6-71f4-9914-7ee64153586b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019c7730-47b6-79f5-92d6-fc1fab86af6e" xlink:to="loc_us-gaap_NetIncomeLoss_019c7730-47b6-71f4-9914-7ee64153586b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019c7730-47b6-7b76-9380-d1901dad1fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019c7730-47b6-79f5-92d6-fc1fab86af6e" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019c7730-47b6-7b76-9380-d1901dad1fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_019c7730-47b6-743f-8769-9a47e16c5f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019c7730-47b6-7b76-9380-d1901dad1fdb" xlink:to="loc_us-gaap_DepreciationAndAmortization_019c7730-47b6-743f-8769-9a47e16c5f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019c7730-47b6-77b7-b601-df970699c56a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019c7730-47b6-7b76-9380-d1901dad1fdb" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019c7730-47b6-77b7-b601-df970699c56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_019c7730-47b6-7101-a95a-a869780f3ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019c7730-47b6-7b76-9380-d1901dad1fdb" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_019c7730-47b6-7101-a95a-a869780f3ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties_019c7730-47b6-7496-8b3c-dc31b26729f9" xlink:href="gern-20260331.xsd#gern_NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019c7730-47b6-7b76-9380-d1901dad1fdb" xlink:to="loc_gern_NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties_019c7730-47b6-7496-8b3c-dc31b26729f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019df974-d96e-7dfc-9157-843aed2dc231" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019c7730-47b6-7b76-9380-d1901dad1fdb" xlink:to="loc_us-gaap_ShareBasedCompensation_019df974-d96e-7dfc-9157-843aed2dc231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_019c7730-47b6-7fd1-8249-bb9ccdfd407e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019c7730-47b6-7b76-9380-d1901dad1fdb" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_019c7730-47b6-7fd1-8249-bb9ccdfd407e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_IncreaseDecreaseInAllowanceForDoubtfulAccounts_019c7730-47b6-7615-a2ce-151699241daa" xlink:href="gern-20260331.xsd#gern_IncreaseDecreaseInAllowanceForDoubtfulAccounts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019c7730-47b6-7b76-9380-d1901dad1fdb" xlink:to="loc_gern_IncreaseDecreaseInAllowanceForDoubtfulAccounts_019c7730-47b6-7615-a2ce-151699241daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019c7730-47b6-7228-8ce4-a4ec299908fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019c7730-47b6-79f5-92d6-fc1fab86af6e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019c7730-47b6-7228-8ce4-a4ec299908fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_019c7730-47b6-7b16-8703-7bce8e2ab422" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019c7730-47b6-7228-8ce4-a4ec299908fe" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_019c7730-47b6-7b16-8703-7bce8e2ab422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_019c7730-47b6-7838-a1c6-f033d33389d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019c7730-47b6-7228-8ce4-a4ec299908fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_019c7730-47b6-7838-a1c6-f033d33389d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019c7730-47b6-7c69-b895-52484068d17c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019c7730-47b6-7228-8ce4-a4ec299908fe" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019c7730-47b6-7c69-b895-52484068d17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019dc27c-2979-73b9-94e5-5c53563d7697" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019c7730-47b6-7228-8ce4-a4ec299908fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019dc27c-2979-73b9-94e5-5c53563d7697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_019dc27c-2979-7f49-87b6-0da2e835b07f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019c7730-47b6-7228-8ce4-a4ec299908fe" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_019dc27c-2979-7f49-87b6-0da2e835b07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_019dc27c-a8c8-7e31-8d36-2e05fcdeb084" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019c7730-47b6-7228-8ce4-a4ec299908fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_019dc27c-a8c8-7e31-8d36-2e05fcdeb084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_019c7730-47b6-77cf-92dc-1bc6a92d2f55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019c7730-47b6-7228-8ce4-a4ec299908fe" xlink:to="loc_us-gaap_PaymentsForRoyalties_019c7730-47b6-77cf-92dc-1bc6a92d2f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_IncreaseDecreaseInOperatingLeaseLiabilities_019dd60b-805a-7f2f-a1e8-8432b9051e0a" xlink:href="gern-20260331.xsd#gern_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019c7730-47b6-7228-8ce4-a4ec299908fe" xlink:to="loc_gern_IncreaseDecreaseInOperatingLeaseLiabilities_019dd60b-805a-7f2f-a1e8-8432b9051e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c7730-47b6-785c-8926-51e35ed7867e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019c7730-47b6-79f5-92d6-fc1fab86af6e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019c7730-47b6-785c-8926-51e35ed7867e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019c7730-47b6-7b87-a5b6-a767a47f8527" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019c7730-47b6-7dc6-a61a-672792a72811" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019c7730-47b6-7b87-a5b6-a767a47f8527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_PaymentsUnpaidToAcquirePropertyPlantAndEquipment_019c7730-47b6-7c04-afb7-b92312c97268" xlink:href="gern-20260331.xsd#gern_PaymentsUnpaidToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019c7730-47b6-7b87-a5b6-a767a47f8527" xlink:to="loc_gern_PaymentsUnpaidToAcquirePropertyPlantAndEquipment_019c7730-47b6-7c04-afb7-b92312c97268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_019c7730-47b6-7405-aaab-51db8a171a76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019c7730-47b6-7b87-a5b6-a767a47f8527" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_019c7730-47b6-7405-aaab-51db8a171a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_019dd60d-3da9-765d-ae7a-75e3da44907f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019c7730-47b6-7b87-a5b6-a767a47f8527" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_019dd60d-3da9-765d-ae7a-75e3da44907f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019c7730-47b6-7fd8-af89-887b0add4ade" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019c7730-47b6-7b87-a5b6-a767a47f8527" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019c7730-47b6-7fd8-af89-887b0add4ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019c7730-47b6-7203-aca9-11f841a54c67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019c7730-47b6-7dc6-a61a-672792a72811" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019c7730-47b6-7203-aca9-11f841a54c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_019c7730-47b6-7956-a386-b0136d79ca2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019c7730-47b6-7203-aca9-11f841a54c67" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_019c7730-47b6-7956-a386-b0136d79ca2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_019c7730-47b6-7d73-b462-9e883f063258" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019c7730-47b6-7203-aca9-11f841a54c67" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_019c7730-47b6-7d73-b462-9e883f063258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019c7730-47b6-7f96-8eab-b06bb6fbdf5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019c7730-47b6-7203-aca9-11f841a54c67" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019c7730-47b6-7f96-8eab-b06bb6fbdf5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019c7730-47b6-7d11-9202-47234ce402e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019c7730-47b6-7dc6-a61a-672792a72811" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019c7730-47b6-7d11-9202-47234ce402e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019c7730-47b6-7e52-b676-34a8d12c639e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019c7730-47b6-7dc6-a61a-672792a72811" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019c7730-47b6-7e52-b676-34a8d12c639e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019c7730-47b6-76c4-a9d3-be405a0f517a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019c7730-47b6-7dc6-a61a-672792a72811" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019c7730-47b6-76c4-a9d3-be405a0f517a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019c7730-47b6-7732-89b0-d1065b907663" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019c7730-47b6-7dc6-a61a-672792a72811" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019c7730-47b6-7732-89b0-d1065b907663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="simple" xlink:href="gern-20260331.xsd#BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTS"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019c7730-47b6-775f-a61e-d1e8c4c084c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_019c7730-47b6-711d-9a32-c4c82cb66871" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019c7730-47b6-775f-a61e-d1e8c4c084c7" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_019c7730-47b6-711d-9a32-c4c82cb66871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/REVENUERECOGNITION" xlink:type="simple" xlink:href="gern-20260331.xsd#REVENUERECOGNITION"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/REVENUERECOGNITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019c7730-4892-7338-8030-98399d001a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_019c7730-4892-772c-ba92-7ec66741c2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019c7730-4892-7338-8030-98399d001a0a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_019c7730-4892-772c-ba92-7ec66741c2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/INVENTORY" xlink:type="simple" xlink:href="gern-20260331.xsd#INVENTORY"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/INVENTORY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_019c7730-4892-785a-86f4-0f4bd22c96d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_019c7730-4892-7bf4-9b65-60eafd9a25b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_019c7730-4892-785a-86f4-0f4bd22c96d2" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_019c7730-4892-7bf4-9b65-60eafd9a25b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/FINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="gern-20260331.xsd#FINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/FINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_019dc2a8-10b3-7a90-8ce1-a2aa18cc9532" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_019dc2a8-10b3-7701-9854-aaf7389bb8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_019dc2a8-10b3-7a90-8ce1-a2aa18cc9532" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_019dc2a8-10b3-7701-9854-aaf7389bb8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="gern-20260331.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019c7730-4892-726f-883c-aba6631d83f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_019c7730-4892-796c-aa7a-fb013802e811" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019c7730-4892-726f-883c-aba6631d83f5" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_019c7730-4892-796c-aa7a-fb013802e811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILS" xlink:type="simple" xlink:href="gern-20260331.xsd#OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILS"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_019c7730-4892-754f-a424-e88d63303b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_019c7730-4892-791b-b118-cdf992a18b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019c7730-4892-754f-a424-e88d63303b0f" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_019c7730-4892-791b-b118-cdf992a18b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/DEBT" xlink:type="simple" xlink:href="gern-20260331.xsd#DEBT"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/DEBT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019c7730-4892-7fd9-b960-f64612292f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_019c7730-4892-7a52-8bf4-328120051b08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019c7730-4892-7fd9-b960-f64612292f6e" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_019c7730-4892-7a52-8bf4-328120051b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="gern-20260331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019c7730-4892-7458-b80a-6faf00013a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_019c7730-4892-772e-adf5-2d9d3493a66a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019c7730-4892-7458-b80a-6faf00013a6e" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_019c7730-4892-772e-adf5-2d9d3493a66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/NETLOSSPERCOMMONSHARE" xlink:type="simple" xlink:href="gern-20260331.xsd#NETLOSSPERCOMMONSHARE"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/NETLOSSPERCOMMONSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019dc31e-0a9d-7d28-8879-306c6febe054" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_019dc31e-abb0-79c0-8fde-f41f51548979" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019dc31e-0a9d-7d28-8879-306c6febe054" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_019dc31e-abb0-79c0-8fde-f41f51548979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/SEGMENTREPORTING" xlink:type="simple" xlink:href="gern-20260331.xsd#SEGMENTREPORTING"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/SEGMENTREPORTING" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019c7730-4892-7bb7-8f56-70136e4244b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_019c7730-4892-75f2-961b-8efdbb3757d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019c7730-4892-7bb7-8f56-70136e4244b5" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_019c7730-4892-75f2-961b-8efdbb3757d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/RESTRUCTURING" xlink:type="simple" xlink:href="gern-20260331.xsd#RESTRUCTURING"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/RESTRUCTURING" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019dc327-c0a9-79ea-9d10-eb068fcdb07f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_019dc328-963c-79a5-93bd-12adaf6c623c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019dc327-c0a9-79ea-9d10-eb068fcdb07f" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_019dc328-963c-79a5-93bd-12adaf6c623c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTSPolicies" xlink:type="simple" xlink:href="gern-20260331.xsd#BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTSPolicies"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTSPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019c7730-47b6-7cc6-ba9d-7a4aa7bab04c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_019c7730-47b6-73d2-99fc-69af2bf4ffe1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019c7730-47b6-7cc6-ba9d-7a4aa7bab04c" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_019c7730-47b6-73d2-99fc-69af2bf4ffe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_019c7730-47b6-7a5d-9334-f5589b5573ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019c7730-47b6-7cc6-ba9d-7a4aa7bab04c" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_019c7730-47b6-7a5d-9334-f5589b5573ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_019c7730-47b6-7cd6-b8c4-fb68e78cde30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019c7730-47b6-7cc6-ba9d-7a4aa7bab04c" xlink:to="loc_us-gaap_UseOfEstimates_019c7730-47b6-7cd6-b8c4-fb68e78cde30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_SignificantAccountingPoliciesPolicyPolicyTextBlock_019c7730-47b6-7669-844f-15e280ffb4f7" xlink:href="gern-20260331.xsd#gern_SignificantAccountingPoliciesPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019c7730-47b6-7cc6-ba9d-7a4aa7bab04c" xlink:to="loc_gern_SignificantAccountingPoliciesPolicyPolicyTextBlock_019c7730-47b6-7669-844f-15e280ffb4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019c7730-47b6-7e68-8f0c-9ca27661f418" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019c7730-47b6-7cc6-ba9d-7a4aa7bab04c" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019c7730-47b6-7e68-8f0c-9ca27661f418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/REVENUERECOGNITIONTables" xlink:type="simple" xlink:href="gern-20260331.xsd#REVENUERECOGNITIONTables"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/REVENUERECOGNITIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019c7730-4892-79cf-bb01-1699115884db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock_019c7730-4892-7722-9793-9b38f2a8ab83" xlink:href="gern-20260331.xsd#gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019c7730-4892-79cf-bb01-1699115884db" xlink:to="loc_gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock_019c7730-4892-7722-9793-9b38f2a8ab83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/INVENTORYTables" xlink:type="simple" xlink:href="gern-20260331.xsd#INVENTORYTables"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/INVENTORYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_019c7730-4892-7a7d-b3d6-82cc9c366384" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_019c7730-4892-70b6-a111-16c17045d390" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_019c7730-4892-7a7d-b3d6-82cc9c366384" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_019c7730-4892-70b6-a111-16c17045d390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/FINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="gern-20260331.xsd#FINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/FINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_019dc2a8-10b3-7861-bd4b-83c9f66d2355" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_019dc2a8-10b3-7dc1-8496-7070892e3b24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_019dc2a8-10b3-7861-bd4b-83c9f66d2355" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_019dc2a8-10b3-7dc1-8496-7070892e3b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_019dc2a8-10b3-7662-a41d-fecd72690386" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_019dc2a8-10b3-7861-bd4b-83c9f66d2355" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_019dc2a8-10b3-7662-a41d-fecd72690386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="gern-20260331.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019c7730-4892-7c77-835b-52dc86f6906e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_019c7730-4892-7cf4-9957-56976f6323d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019c7730-4892-7c77-835b-52dc86f6906e" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_019c7730-4892-7cf4-9957-56976f6323d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSTables" xlink:type="simple" xlink:href="gern-20260331.xsd#OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSTables"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_019c7730-4892-7192-bca9-ae6b6854c0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_019c7730-4892-7fdb-bc08-050ac226464c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019c7730-4892-7192-bca9-ae6b6854c0d5" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_019c7730-4892-7fdb-bc08-050ac226464c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_ScheduleOfAccruedCompensationAndBenefitsTableTextBlock_019dc2e7-7309-70fc-9682-ba4a80936718" xlink:href="gern-20260331.xsd#gern_ScheduleOfAccruedCompensationAndBenefitsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019c7730-4892-7192-bca9-ae6b6854c0d5" xlink:to="loc_gern_ScheduleOfAccruedCompensationAndBenefitsTableTextBlock_019dc2e7-7309-70fc-9682-ba4a80936718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/DEBTTables" xlink:type="simple" xlink:href="gern-20260331.xsd#DEBTTables"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/DEBTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019c7730-4892-71f5-9159-512edaee1973" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_019c7730-4892-7e8a-b579-cb7adddbcb05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019c7730-4892-71f5-9159-512edaee1973" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_019c7730-4892-7e8a-b579-cb7adddbcb05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock_019c7730-4892-74f4-824b-19a8c75a6106" xlink:href="gern-20260331.xsd#gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019c7730-4892-71f5-9159-512edaee1973" xlink:to="loc_gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock_019c7730-4892-74f4-824b-19a8c75a6106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/SEGMENTREPORTINGTables" xlink:type="simple" xlink:href="gern-20260331.xsd#SEGMENTREPORTINGTables"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/SEGMENTREPORTINGTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019c7730-4892-785a-9400-2f5b2abe1466" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_019c7730-4892-7d3f-abce-9d3613f7d1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019c7730-4892-785a-9400-2f5b2abe1466" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_019c7730-4892-7d3f-abce-9d3613f7d1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/RESTRUCTURINGTables" xlink:type="simple" xlink:href="gern-20260331.xsd#RESTRUCTURINGTables"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/RESTRUCTURINGTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019dc327-c0a9-736f-84cc-f279bb4f392c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_019dc329-a754-7b2c-a06e-56a761a81f07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019dc327-c0a9-736f-84cc-f279bb4f392c" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_019dc329-a754-7b2c-a06e-56a761a81f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTSDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019ddabf-f546-7bfc-9cfa-af4ff13e763a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_019ddabf-f546-702a-a196-fb71db247254" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019ddabf-f546-7bfc-9cfa-af4ff13e763a" xlink:to="loc_us-gaap_NumberOfOperatingSegments_019ddabf-f546-702a-a196-fb71db247254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/REVENUERECOGNITIONDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#REVENUERECOGNITIONDetails"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/REVENUERECOGNITIONDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019c7730-4892-7fab-a766-0a7f81d296e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_019c7730-4892-7364-9a9b-d4cfa1b988cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019c7730-4892-7fab-a766-0a7f81d296e2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_019c7730-4892-7364-9a9b-d4cfa1b988cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019c7730-4892-7428-8801-300020f3e936" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019c7730-4892-7364-9a9b-d4cfa1b988cb" xlink:to="loc_srt_ProductOrServiceAxis_019c7730-4892-7428-8801-300020f3e936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c7730-4892-781c-9910-405a5a2bdece" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019c7730-4892-7428-8801-300020f3e936" xlink:to="loc_srt_ProductsAndServicesDomain_019c7730-4892-781c-9910-405a5a2bdece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_019c7730-4892-7b5e-83ec-8f931fba3b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019c7730-4892-781c-9910-405a5a2bdece" xlink:to="loc_us-gaap_ProductMember_019c7730-4892-7b5e-83ec-8f931fba3b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_RevenuesBeforeAdjustmentsMember_019c7730-4892-712a-91e6-1b750a031ebf" xlink:href="gern-20260331.xsd#gern_RevenuesBeforeAdjustmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_019c7730-4892-7b5e-83ec-8f931fba3b2e" xlink:to="loc_gern_RevenuesBeforeAdjustmentsMember_019c7730-4892-712a-91e6-1b750a031ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_TotalGrossToNetAdjustmentsMember_019c7730-4892-755a-a93a-d26afebe95f1" xlink:href="gern-20260331.xsd#gern_TotalGrossToNetAdjustmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_019c7730-4892-7b5e-83ec-8f931fba3b2e" xlink:to="loc_gern_TotalGrossToNetAdjustmentsMember_019c7730-4892-755a-a93a-d26afebe95f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_ChargebacksMember_019c7730-4892-7a20-94bb-c0fa96e8059f" xlink:href="gern-20260331.xsd#gern_ChargebacksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gern_TotalGrossToNetAdjustmentsMember_019c7730-4892-755a-a93a-d26afebe95f1" xlink:to="loc_gern_ChargebacksMember_019c7730-4892-7a20-94bb-c0fa96e8059f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_DistributorServiceFeesMember_019dc2a1-7101-75d9-8795-167c1d2c227f" xlink:href="gern-20260331.xsd#gern_DistributorServiceFeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gern_TotalGrossToNetAdjustmentsMember_019c7730-4892-755a-a93a-d26afebe95f1" xlink:to="loc_gern_DistributorServiceFeesMember_019dc2a1-7101-75d9-8795-167c1d2c227f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_GovernmentRebatesMember_019c7730-4892-7ba0-8e57-9075329cb2c9" xlink:href="gern-20260331.xsd#gern_GovernmentRebatesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gern_TotalGrossToNetAdjustmentsMember_019c7730-4892-755a-a93a-d26afebe95f1" xlink:to="loc_gern_GovernmentRebatesMember_019c7730-4892-7ba0-8e57-9075329cb2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_SalesReturnsAndAllowanceMember_019c7730-4892-72d5-9c96-e01c61bafb7d" xlink:href="gern-20260331.xsd#gern_SalesReturnsAndAllowanceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gern_TotalGrossToNetAdjustmentsMember_019c7730-4892-755a-a93a-d26afebe95f1" xlink:to="loc_gern_SalesReturnsAndAllowanceMember_019c7730-4892-72d5-9c96-e01c61bafb7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_019c7730-4892-7c72-9393-95a735cac451" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019c7730-4892-7364-9a9b-d4cfa1b988cb" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_019c7730-4892-7c72-9393-95a735cac451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c7730-4892-766b-a00d-f33186e6c395" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c7730-4892-7c72-9393-95a735cac451" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c7730-4892-766b-a00d-f33186e6c395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/INVENTORYDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#INVENTORYDetails"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/INVENTORYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_019c7730-4892-7b12-9b5a-1d8d3e995f97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_019c7730-4892-785c-ad3f-0b2c67c7d041" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_019c7730-4892-7b12-9b5a-1d8d3e995f97" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_019c7730-4892-785c-ad3f-0b2c67c7d041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_019c7730-4892-7f44-a3ce-0a8bd016ca80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_019c7730-4892-7b12-9b5a-1d8d3e995f97" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_019c7730-4892-7f44-a3ce-0a8bd016ca80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_019c7730-4892-7f8f-a61f-bd1b2f285b03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_019c7730-4892-7b12-9b5a-1d8d3e995f97" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_019c7730-4892-7f8f-a61f-bd1b2f285b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_019c7730-4892-7fbe-b6e1-10ffc9d601e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_019c7730-4892-7b12-9b5a-1d8d3e995f97" xlink:to="loc_us-gaap_InventoryNet_019c7730-4892-7fbe-b6e1-10ffc9d601e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019dc2a8-10b3-7c91-825a-a3540c1511cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsTable_019dc2a8-10b3-7b57-8d23-809a88972d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfInvestmentHoldingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019dc2a8-10b3-7c91-825a-a3540c1511cb" xlink:to="loc_us-gaap_SummaryOfInvestmentHoldingsTable_019dc2a8-10b3-7b57-8d23-809a88972d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019dc2a8-10b3-7f71-9512-4c01394e66f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable_019dc2a8-10b3-7b57-8d23-809a88972d9d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019dc2a8-10b3-7f71-9512-4c01394e66f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-71ec-b209-6355fc959c28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019dc2a8-10b3-7f71-9512-4c01394e66f9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-71ec-b209-6355fc959c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_019dc2a8-10b3-740b-9a4d-5b57674ad090" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-71ec-b209-6355fc959c28" xlink:to="loc_us-gaap_MoneyMarketFundsMember_019dc2a8-10b3-740b-9a4d-5b57674ad090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_019dc2a8-10b3-7460-9568-0e082d88005a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-71ec-b209-6355fc959c28" xlink:to="loc_us-gaap_CommercialPaperMember_019dc2a8-10b3-7460-9568-0e082d88005a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_019dc2a8-10b3-7bfa-bf5d-0aff040c3e84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-71ec-b209-6355fc959c28" xlink:to="loc_us-gaap_CertificatesOfDepositMember_019dc2a8-10b3-7bfa-bf5d-0aff040c3e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_USTreasurySecuritiesDueInLessThanOneYearMember_019dc2a8-10b3-7150-9847-682a34abe218" xlink:href="gern-20260331.xsd#gern_USTreasurySecuritiesDueInLessThanOneYearMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-71ec-b209-6355fc959c28" xlink:to="loc_gern_USTreasurySecuritiesDueInLessThanOneYearMember_019dc2a8-10b3-7150-9847-682a34abe218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_MunicipalSecuritiesDueInLessThanOneYearMember_019dc2a8-10b3-70b1-80c4-8c36ed935ae2" xlink:href="gern-20260331.xsd#gern_MunicipalSecuritiesDueInLessThanOneYearMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-71ec-b209-6355fc959c28" xlink:to="loc_gern_MunicipalSecuritiesDueInLessThanOneYearMember_019dc2a8-10b3-70b1-80c4-8c36ed935ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_MunicipalSecuritiesDueInOneToTwoYearsMember_019df09a-db2b-7cf6-8ae3-649ee36d8a3b" xlink:href="gern-20260331.xsd#gern_MunicipalSecuritiesDueInOneToTwoYearsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-71ec-b209-6355fc959c28" xlink:to="loc_gern_MunicipalSecuritiesDueInOneToTwoYearsMember_019df09a-db2b-7cf6-8ae3-649ee36d8a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember_019dc2a8-10b3-78dd-a4c7-896ee483496a" xlink:href="gern-20260331.xsd#gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-71ec-b209-6355fc959c28" xlink:to="loc_gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember_019dc2a8-10b3-78dd-a4c7-896ee483496a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CommercialPaperDueInLessThanOneYearMember_019dc2a8-10b3-7339-9b35-3fb9d8c5e6fb" xlink:href="gern-20260331.xsd#gern_CommercialPaperDueInLessThanOneYearMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-71ec-b209-6355fc959c28" xlink:to="loc_gern_CommercialPaperDueInLessThanOneYearMember_019dc2a8-10b3-7339-9b35-3fb9d8c5e6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CorporateNoteSecuritiesDueInLessThanOneYearMember_019dc2a8-10b3-7fa2-a7ff-f216b3f0c3dc" xlink:href="gern-20260331.xsd#gern_CorporateNoteSecuritiesDueInLessThanOneYearMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-71ec-b209-6355fc959c28" xlink:to="loc_gern_CorporateNoteSecuritiesDueInLessThanOneYearMember_019dc2a8-10b3-7fa2-a7ff-f216b3f0c3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember_019dc2a8-10b3-7ffb-8089-c0c87b50fc2d" xlink:href="gern-20260331.xsd#gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-71ec-b209-6355fc959c28" xlink:to="loc_gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember_019dc2a8-10b3-7ffb-8089-c0c87b50fc2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_019dc2a8-10b3-7f9d-b261-10bd44147d08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable_019dc2a8-10b3-7b57-8d23-809a88972d9d" xlink:to="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_019dc2a8-10b3-7f9d-b261-10bd44147d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_019dc2a8-10b3-7e41-b531-6caa9aa752a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_019dc2a8-10b3-7f9d-b261-10bd44147d08" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_019dc2a8-10b3-7e41-b531-6caa9aa752a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_019dc2a8-10b3-7a0c-a835-cbd0d801f262" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_019dc2a8-10b3-7e41-b531-6caa9aa752a2" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_019dc2a8-10b3-7a0c-a835-cbd0d801f262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CashAndCashEquivalentsUnrealizedGains_019dc2a8-10b3-7002-82e0-7d7d4991efb0" xlink:href="gern-20260331.xsd#gern_CashAndCashEquivalentsUnrealizedGains"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_019dc2a8-10b3-7e41-b531-6caa9aa752a2" xlink:to="loc_gern_CashAndCashEquivalentsUnrealizedGains_019dc2a8-10b3-7002-82e0-7d7d4991efb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CashAndCashEquivalentsUnrealizedLosses_019dc2a8-10b3-7758-bfed-39194d70d16d" xlink:href="gern-20260331.xsd#gern_CashAndCashEquivalentsUnrealizedLosses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_019dc2a8-10b3-7e41-b531-6caa9aa752a2" xlink:to="loc_gern_CashAndCashEquivalentsUnrealizedLosses_019dc2a8-10b3-7758-bfed-39194d70d16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019dc2a8-10b3-745c-a1a9-465d24643cca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_019dc2a8-10b3-7e41-b531-6caa9aa752a2" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019dc2a8-10b3-745c-a1a9-465d24643cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_019dc2a8-10b3-7a42-9fd8-4460921d0a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndInvestmentsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_019dc2a8-10b3-7f9d-b261-10bd44147d08" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_019dc2a8-10b3-7a42-9fd8-4460921d0a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_019dc2a8-10b3-72e2-8e58-e33c85a4ecf2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_019dc2a8-10b3-7a42-9fd8-4460921d0a2f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_019dc2a8-10b3-72e2-8e58-e33c85a4ecf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedGains_019dc2a8-10b3-7b7e-baae-c01b6304be64" xlink:href="gern-20260331.xsd#gern_RestrictedCashAndCashEquivalentsGrossUnrealizedGains"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_019dc2a8-10b3-7a42-9fd8-4460921d0a2f" xlink:to="loc_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedGains_019dc2a8-10b3-7b7e-baae-c01b6304be64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses_019dc2a8-10b3-72d9-9673-f0a886ecd514" xlink:href="gern-20260331.xsd#gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_019dc2a8-10b3-7a42-9fd8-4460921d0a2f" xlink:to="loc_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses_019dc2a8-10b3-72d9-9673-f0a886ecd514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsAtFairValue_019dc2a8-10b3-7245-91b4-548aec89269a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedInvestmentsAtFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_019dc2a8-10b3-7a42-9fd8-4460921d0a2f" xlink:to="loc_us-gaap_RestrictedInvestmentsAtFairValue_019dc2a8-10b3-7245-91b4-548aec89269a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_019dc2a8-10b3-7abc-a123-569214012997" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_019dc2a8-10b3-7f9d-b261-10bd44147d08" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_019dc2a8-10b3-7abc-a123-569214012997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_019dc2a8-10b3-7160-8575-fd21763f6c41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_019dc2a8-10b3-7abc-a123-569214012997" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_019dc2a8-10b3-7160-8575-fd21763f6c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019dc2a8-10b3-736f-8298-4a5a8b05e24a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_019dc2a8-10b3-7abc-a123-569214012997" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019dc2a8-10b3-736f-8298-4a5a8b05e24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019dc2a8-10b3-7498-a5d3-728100cb1f39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_019dc2a8-10b3-7abc-a123-569214012997" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019dc2a8-10b3-7498-a5d3-728100cb1f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019dc2a8-10b3-7ee4-8008-eb1a6ea73e95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_019dc2a8-10b3-7abc-a123-569214012997" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019dc2a8-10b3-7ee4-8008-eb1a6ea73e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019dc2a8-10b3-7748-a9b2-77a49484cea3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019dc2a8-10b3-7743-b3ad-d1a2ab7825d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019dc2a8-10b3-7748-a9b2-77a49484cea3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019dc2a8-10b3-7743-b3ad-d1a2ab7825d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019dc2a8-10b3-7556-afd1-40efa550402d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019dc2a8-10b3-7743-b3ad-d1a2ab7825d4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019dc2a8-10b3-7556-afd1-40efa550402d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-7822-b8b7-6654eed56531" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019dc2a8-10b3-7556-afd1-40efa550402d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-7822-b8b7-6654eed56531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember_019dc2cd-a688-79a8-9c1d-38520f6571d6" xlink:href="gern-20260331.xsd#gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-7822-b8b7-6654eed56531" xlink:to="loc_gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember_019dc2cd-a688-79a8-9c1d-38520f6571d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_MunicipalSecuritiesDueInLessThanOneYearMember_019dc2cf-0393-738e-96d0-731e5f56f96c" xlink:href="gern-20260331.xsd#gern_MunicipalSecuritiesDueInLessThanOneYearMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-7822-b8b7-6654eed56531" xlink:to="loc_gern_MunicipalSecuritiesDueInLessThanOneYearMember_019dc2cf-0393-738e-96d0-731e5f56f96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_MunicipalSecuritiesDueInOneToTwoYearsMember_019dc2b8-7e93-72f3-862f-33a9eb1c5dfd" xlink:href="gern-20260331.xsd#gern_MunicipalSecuritiesDueInOneToTwoYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-7822-b8b7-6654eed56531" xlink:to="loc_gern_MunicipalSecuritiesDueInOneToTwoYearsMember_019dc2b8-7e93-72f3-862f-33a9eb1c5dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_019dc2d0-fd45-71c9-bf44-603e37a6b07e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-7822-b8b7-6654eed56531" xlink:to="loc_us-gaap_CommercialPaperMember_019dc2d0-fd45-71c9-bf44-603e37a6b07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CommercialPaperDueInLessThanOneYearMember_019dc2a8-10b3-737b-8955-b6283577d3cb" xlink:href="gern-20260331.xsd#gern_CommercialPaperDueInLessThanOneYearMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-7822-b8b7-6654eed56531" xlink:to="loc_gern_CommercialPaperDueInLessThanOneYearMember_019dc2a8-10b3-737b-8955-b6283577d3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CorporateNoteSecuritiesDueInLessThanOneYearMember_019dc2a8-10b3-7d05-b067-babae2a26448" xlink:href="gern-20260331.xsd#gern_CorporateNoteSecuritiesDueInLessThanOneYearMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-7822-b8b7-6654eed56531" xlink:to="loc_gern_CorporateNoteSecuritiesDueInLessThanOneYearMember_019dc2a8-10b3-7d05-b067-babae2a26448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember_019dc2a8-10b3-7032-a109-948835483eaf" xlink:href="gern-20260331.xsd#gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019dc2a8-10b3-7822-b8b7-6654eed56531" xlink:to="loc_gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember_019dc2a8-10b3-7032-a109-948835483eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019dc2a8-10b3-7bd5-96df-2d060631677f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019dc2a8-10b3-7743-b3ad-d1a2ab7825d4" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019dc2a8-10b3-7bd5-96df-2d060631677f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_019dc2a8-10b3-748e-87fe-c62b522b214e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019dc2a8-10b3-7bd5-96df-2d060631677f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_019dc2a8-10b3-748e-87fe-c62b522b214e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019dc2a8-10b3-7946-abdb-8d1dbd6d33d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_019dc2a8-10b3-748e-87fe-c62b522b214e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019dc2a8-10b3-7946-abdb-8d1dbd6d33d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019dc2a8-10b3-7e0b-867d-ab79ce6f620a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_019dc2a8-10b3-748e-87fe-c62b522b214e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019dc2a8-10b3-7e0b-867d-ab79ce6f620a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019dc2a8-10b3-71cb-9495-0ad1176ddecc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_019dc2a8-10b3-748e-87fe-c62b522b214e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019dc2a8-10b3-71cb-9495-0ad1176ddecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019dc2a8-10b3-7f16-a58e-d7424a9b960b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019dc2a8-10b3-7bd5-96df-2d060631677f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019dc2a8-10b3-7f16-a58e-d7424a9b960b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019dc2a8-10b3-7a6f-a242-d0b4b0adb1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019dc2a8-10b3-7f16-a58e-d7424a9b960b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019dc2a8-10b3-7a6f-a242-d0b4b0adb1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019dc2a8-10b3-7781-bde5-e23c7e1ec0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019dc2a8-10b3-7f16-a58e-d7424a9b960b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019dc2a8-10b3-7781-bde5-e23c7e1ec0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019dc2a8-10b3-735b-974a-4d0444e0edbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019dc2a8-10b3-7f16-a58e-d7424a9b960b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019dc2a8-10b3-735b-974a-4d0444e0edbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#FAIRVALUEMEASUREMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019c7730-4892-7533-8187-184c192f1ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c7730-4892-7fa4-8ded-c0c7958c26ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019c7730-4892-7533-8187-184c192f1ee2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c7730-4892-7fa4-8ded-c0c7958c26ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c7730-4892-7fe8-a261-3af30a8ae13c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c7730-4892-7fa4-8ded-c0c7958c26ac" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c7730-4892-7fe8-a261-3af30a8ae13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c7730-4892-7dd8-8288-19be500b6a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c7730-4892-7fe8-a261-3af30a8ae13c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c7730-4892-7dd8-8288-19be500b6a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_019c7730-4892-7464-b59d-c3fe01ba560b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c7730-4892-7dd8-8288-19be500b6a0b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_019c7730-4892-7464-b59d-c3fe01ba560b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_019c7730-4892-7105-a20c-5f0bada97a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c7730-4892-7dd8-8288-19be500b6a0b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_019c7730-4892-7105-a20c-5f0bada97a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019c7730-4892-7f37-b74d-5a9153a07a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c7730-4892-7dd8-8288-19be500b6a0b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019c7730-4892-7f37-b74d-5a9153a07a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_019c7730-4892-78f0-90c5-cde0df64b4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c7730-4892-7fa4-8ded-c0c7958c26ac" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_019c7730-4892-78f0-90c5-cde0df64b4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019c7730-4892-78a2-bea4-a073ae92faeb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_019c7730-4892-78f0-90c5-cde0df64b4a2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019c7730-4892-78a2-bea4-a073ae92faeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_019c7730-4892-7182-9b51-606006e4352e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019c7730-4892-78a2-bea4-a073ae92faeb" xlink:to="loc_us-gaap_MoneyMarketFundsMember_019c7730-4892-7182-9b51-606006e4352e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_019c7730-4892-7b28-92d7-4c787650cc49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019c7730-4892-78a2-bea4-a073ae92faeb" xlink:to="loc_us-gaap_CertificatesOfDepositMember_019c7730-4892-7b28-92d7-4c787650cc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_019c7730-4892-75ec-9254-fbde420623ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019c7730-4892-78a2-bea4-a073ae92faeb" xlink:to="loc_us-gaap_MunicipalBondsMember_019c7730-4892-75ec-9254-fbde420623ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019c7730-4892-771a-92be-fd1591320b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c7730-4892-7fa4-8ded-c0c7958c26ac" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019c7730-4892-771a-92be-fd1591320b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c7730-4892-792c-91cc-9155ebfdf1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019c7730-4892-771a-92be-fd1591320b1c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c7730-4892-792c-91cc-9155ebfdf1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_019c7730-4892-7662-9d0d-daee55c5ba75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c7730-4892-792c-91cc-9155ebfdf1b2" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_019c7730-4892-7662-9d0d-daee55c5ba75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_019c7730-4892-7215-8a9b-e5901c0a6b71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c7730-4892-792c-91cc-9155ebfdf1b2" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_019c7730-4892-7215-8a9b-e5901c0a6b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_019c7730-4892-7805-bce0-0e73200997ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c7730-4892-792c-91cc-9155ebfdf1b2" xlink:to="loc_us-gaap_CommercialPaperMember_019c7730-4892-7805-bce0-0e73200997ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNoteSecuritiesMember_019c7730-4892-7024-a07e-5e2ab268f6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateNoteSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c7730-4892-792c-91cc-9155ebfdf1b2" xlink:to="loc_us-gaap_CorporateNoteSecuritiesMember_019c7730-4892-7024-a07e-5e2ab268f6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c7730-4892-7f41-a7fe-6fe20f7bc636" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c7730-4892-7fa4-8ded-c0c7958c26ac" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c7730-4892-7f41-a7fe-6fe20f7bc636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_019dc2da-0087-7f83-99df-7479f04df53c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c7730-4892-7f41-a7fe-6fe20f7bc636" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_019dc2da-0087-7f83-99df-7479f04df53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_019c7730-4892-701d-bdef-123b45e4e6a1" xlink:href="gern-20260331.xsd#gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019dc2da-0087-7f83-99df-7479f04df53c" xlink:to="loc_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_019c7730-4892-701d-bdef-123b45e4e6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019c7730-4892-75b7-b99b-287358fda284" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019dc2da-0087-7f83-99df-7479f04df53c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019c7730-4892-75b7-b99b-287358fda284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_019c7730-4892-778b-9afb-8b3f75fbd8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019dc2da-0087-7f83-99df-7479f04df53c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_019c7730-4892-778b-9afb-8b3f75fbd8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019dc2da-497c-7495-9e97-d83b180f8000" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c7730-4892-7f41-a7fe-6fe20f7bc636" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019dc2da-497c-7495-9e97-d83b180f8000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_019dc2d8-5ae1-7531-802d-ffd65bcd54da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019dc2da-497c-7495-9e97-d83b180f8000" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_019dc2d8-5ae1-7531-802d-ffd65bcd54da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_019dc2d8-5ae1-70b3-8557-406f3b9ceee9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019dc2da-497c-7495-9e97-d83b180f8000" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_019dc2d8-5ae1-70b3-8557-406f3b9ceee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_019c7730-4892-7934-a88a-3a2931d1cfdf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent_019c7730-4892-7b36-8d94-389498f201b3" xlink:href="gern-20260331.xsd#gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019c7730-4892-7934-a88a-3a2931d1cfdf" xlink:to="loc_gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent_019c7730-4892-7b36-8d94-389498f201b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_AccruedManufacturingActivitiesCurrent_019c7730-4892-7ff7-be29-1d7a032cb6da" xlink:href="gern-20260331.xsd#gern_AccruedManufacturingActivitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019c7730-4892-7934-a88a-3a2931d1cfdf" xlink:to="loc_gern_AccruedManufacturingActivitiesCurrent_019c7730-4892-7ff7-be29-1d7a032cb6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_019c7730-4892-70b0-b852-70eff7a1e036" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019c7730-4892-7934-a88a-3a2931d1cfdf" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_019c7730-4892-70b0-b852-70eff7a1e036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_019c7730-4892-7f9f-be34-7eb23430b1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019c7730-4892-7934-a88a-3a2931d1cfdf" xlink:to="loc_us-gaap_InterestPayableCurrent_019c7730-4892-7f9f-be34-7eb23430b1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_GrossToNetAdjustmentsCurrent_019c7730-4892-7cdc-bc70-64256e1cf45a" xlink:href="gern-20260331.xsd#gern_GrossToNetAdjustmentsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019c7730-4892-7934-a88a-3a2931d1cfdf" xlink:to="loc_gern_GrossToNetAdjustmentsCurrent_019c7730-4892-7cdc-bc70-64256e1cf45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019c7730-4892-7371-ab43-4ecf2a103596" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019c7730-4892-7934-a88a-3a2931d1cfdf" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019c7730-4892-7371-ab43-4ecf2a103596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019c7730-4892-7c14-9484-53f9f5326876" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019c7730-4892-7934-a88a-3a2931d1cfdf" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_019c7730-4892-7c14-9484-53f9f5326876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedCompensationandBenefitsDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedCompensationandBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedCompensationandBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_019dc2e9-ced9-7af4-b4ce-ec151d964a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_019dc2ea-ee00-758b-9eb9-38b5d0020a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019dc2e9-ced9-7af4-b4ce-ec151d964a1a" xlink:to="loc_us-gaap_AccruedBonusesCurrent_019dc2ea-ee00-758b-9eb9-38b5d0020a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedVacationCurrent_019dc2ea-ee00-7665-8fb6-6a92d3cd83f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedVacationCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019dc2e9-ced9-7af4-b4ce-ec151d964a1a" xlink:to="loc_us-gaap_AccruedVacationCurrent_019dc2ea-ee00-7665-8fb6-6a92d3cd83f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveCurrent_019dc2ea-ee00-73d9-ac5d-8307f07d95b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019dc2e9-ced9-7af4-b4ce-ec151d964a1a" xlink:to="loc_us-gaap_RestructuringReserveCurrent_019dc2ea-ee00-73d9-ac5d-8307f07d95b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_019dc2ea-ee00-775c-abe0-eb2107dc44f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019dc2e9-ced9-7af4-b4ce-ec151d964a1a" xlink:to="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_019dc2ea-ee00-775c-abe0-eb2107dc44f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019dc2ea-ee00-7edc-940f-258862164c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_019dc2e9-ced9-7af4-b4ce-ec151d964a1a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019dc2ea-ee00-7edc-940f-258862164c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/DEBTAdditionalInformationDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#DEBTAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/DEBTAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019c7730-4892-7111-9eb6-2c3385858387" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019c7730-4892-7291-9c20-882f15620e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019c7730-4892-7111-9eb6-2c3385858387" xlink:to="loc_us-gaap_DebtInstrumentTable_019c7730-4892-7291-9c20-882f15620e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019c7730-4892-71cc-bb64-f741753c0019" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019c7730-4892-7291-9c20-882f15620e5e" xlink:to="loc_srt_CounterpartyNameAxis_019c7730-4892-71cc-bb64-f741753c0019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c7730-4892-7a63-aaa6-74da4c9425d2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_019c7730-4892-71cc-bb64-f741753c0019" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c7730-4892-7a63-aaa6-74da4c9425d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_BiopharmaCreditPlcMember_019c7730-4892-7589-aff3-ce2248a2b0d1" xlink:href="gern-20260331.xsd#gern_BiopharmaCreditPlcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c7730-4892-7a63-aaa6-74da4c9425d2" xlink:to="loc_gern_BiopharmaCreditPlcMember_019c7730-4892-7589-aff3-ce2248a2b0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_019c7730-4892-7523-b5b2-8658eac16863" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019c7730-4892-7291-9c20-882f15620e5e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_019c7730-4892-7523-b5b2-8658eac16863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019c7730-4892-7a6b-b94e-61f1a8968148" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019c7730-4892-7523-b5b2-8658eac16863" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019c7730-4892-7a6b-b94e-61f1a8968148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_PharmakonLoanAgreementMember_019c7730-4892-71a5-9d28-96fbb2ff2f03" xlink:href="gern-20260331.xsd#gern_PharmakonLoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019c7730-4892-7a6b-b94e-61f1a8968148" xlink:to="loc_gern_PharmakonLoanAgreementMember_019c7730-4892-71a5-9d28-96fbb2ff2f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember_019c7730-4892-79f7-bb02-f9849eaf775b" xlink:href="gern-20260331.xsd#gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019c7730-4892-7a6b-b94e-61f1a8968148" xlink:to="loc_gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember_019c7730-4892-79f7-bb02-f9849eaf775b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_019c7730-4892-7b7c-be24-18b78f3e59de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019c7730-4892-7291-9c20-882f15620e5e" xlink:to="loc_us-gaap_CreditFacilityAxis_019c7730-4892-7b7c-be24-18b78f3e59de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_019c7730-4892-7e9c-8ad6-a6ec3b9ca72c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_019c7730-4892-7b7c-be24-18b78f3e59de" xlink:to="loc_us-gaap_CreditFacilityDomain_019c7730-4892-7e9c-8ad6-a6ec3b9ca72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_TrancheAMember_019c7730-4892-7583-98e9-137e1c308302" xlink:href="gern-20260331.xsd#gern_TrancheAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_019c7730-4892-7e9c-8ad6-a6ec3b9ca72c" xlink:to="loc_gern_TrancheAMember_019c7730-4892-7583-98e9-137e1c308302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_TrancheBMember_019c7730-4892-7517-8e85-ab4da3d9e7ec" xlink:href="gern-20260331.xsd#gern_TrancheBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_019c7730-4892-7e9c-8ad6-a6ec3b9ca72c" xlink:to="loc_gern_TrancheBMember_019c7730-4892-7517-8e85-ab4da3d9e7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_TrancheCMember_019c7730-4892-7137-b911-c955f7c892f1" xlink:href="gern-20260331.xsd#gern_TrancheCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_019c7730-4892-7e9c-8ad6-a6ec3b9ca72c" xlink:to="loc_gern_TrancheCMember_019c7730-4892-7137-b911-c955f7c892f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_TermLoansMember_019c7730-4892-7d67-aa07-32ade672d5c5" xlink:href="gern-20260331.xsd#gern_TermLoansMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_019c7730-4892-7e9c-8ad6-a6ec3b9ca72c" xlink:to="loc_gern_TermLoansMember_019c7730-4892-7d67-aa07-32ade672d5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019c7730-4892-7168-a472-b8b06ece3fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019c7730-4892-7291-9c20-882f15620e5e" xlink:to="loc_us-gaap_DebtInstrumentAxis_019c7730-4892-7168-a472-b8b06ece3fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019c7730-4892-77e0-97a2-8d380bbb2d48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_019c7730-4892-7168-a472-b8b06ece3fd3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019c7730-4892-77e0-97a2-8d380bbb2d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember_019c7730-4892-752e-83b1-3144fa3bb27e" xlink:href="gern-20260331.xsd#gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019c7730-4892-77e0-97a2-8d380bbb2d48" xlink:to="loc_gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember_019c7730-4892-752e-83b1-3144fa3bb27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember_019c7730-4892-793f-81f5-30fdc5fa8560" xlink:href="gern-20260331.xsd#gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019c7730-4892-77e0-97a2-8d380bbb2d48" xlink:to="loc_gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember_019c7730-4892-793f-81f5-30fdc5fa8560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember_019c7730-4892-7b1a-80ce-4767ac291436" xlink:href="gern-20260331.xsd#gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019c7730-4892-77e0-97a2-8d380bbb2d48" xlink:to="loc_gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember_019c7730-4892-7b1a-80ce-4767ac291436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019c7730-4892-770d-a74f-c03cf12fa8b6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019c7730-4892-7291-9c20-882f15620e5e" xlink:to="loc_srt_RangeAxis_019c7730-4892-770d-a74f-c03cf12fa8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019c7730-4892-7595-8716-63047cefbd12" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019c7730-4892-770d-a74f-c03cf12fa8b6" xlink:to="loc_srt_RangeMember_019c7730-4892-7595-8716-63047cefbd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019c7730-4892-7f45-a8a0-25717d66cc4a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019c7730-4892-7595-8716-63047cefbd12" xlink:to="loc_srt_MinimumMember_019c7730-4892-7f45-a8a0-25717d66cc4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019c7730-4892-70aa-b1c1-526ba43e0426" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019c7730-4892-7595-8716-63047cefbd12" xlink:to="loc_srt_MaximumMember_019c7730-4892-70aa-b1c1-526ba43e0426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_DebtInstrumentScenarioAxis_019c7730-4892-7687-83fa-d5d51b5f1069" xlink:href="gern-20260331.xsd#gern_DebtInstrumentScenarioAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019c7730-4892-7291-9c20-882f15620e5e" xlink:to="loc_gern_DebtInstrumentScenarioAxis_019c7730-4892-7687-83fa-d5d51b5f1069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_DebtInstrumentScenarioDomain_019c7730-4892-7df1-a4a4-7c0e981d84e9" xlink:href="gern-20260331.xsd#gern_DebtInstrumentScenarioDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gern_DebtInstrumentScenarioAxis_019c7730-4892-7687-83fa-d5d51b5f1069" xlink:to="loc_gern_DebtInstrumentScenarioDomain_019c7730-4892-7df1-a4a4-7c0e981d84e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_ScenarioOneMember_019c7730-4892-7420-b097-d2835eb21ac2" xlink:href="gern-20260331.xsd#gern_ScenarioOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gern_DebtInstrumentScenarioDomain_019c7730-4892-7df1-a4a4-7c0e981d84e9" xlink:to="loc_gern_ScenarioOneMember_019c7730-4892-7420-b097-d2835eb21ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_ScenarioTwoMember_019c7730-4892-70b8-bb17-5e754f3bccb8" xlink:href="gern-20260331.xsd#gern_ScenarioTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gern_DebtInstrumentScenarioDomain_019c7730-4892-7df1-a4a4-7c0e981d84e9" xlink:to="loc_gern_ScenarioTwoMember_019c7730-4892-70b8-bb17-5e754f3bccb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7d0f-bb1d-fb75af39aa87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019c7730-4892-7291-9c20-882f15620e5e" xlink:to="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7d0f-bb1d-fb75af39aa87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_019c7730-4892-7af4-8b79-52f23f1d2047" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7d0f-bb1d-fb75af39aa87" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_019c7730-4892-7af4-8b79-52f23f1d2047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019c7730-4892-7496-9410-0110f3e59ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7d0f-bb1d-fb75af39aa87" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019c7730-4892-7496-9410-0110f3e59ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019c7730-4892-7fb9-8381-2172a0156cef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7d0f-bb1d-fb75af39aa87" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019c7730-4892-7fb9-8381-2172a0156cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_019c7730-4892-7090-b38f-e733546d2f37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019c7730-4892-7fb9-8381-2172a0156cef" xlink:to="loc_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_019c7730-4892-7090-b38f-e733546d2f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_DebtInstrumentFloorRate_019c7730-4892-7f9a-bc43-fdbaf72bb606" xlink:href="gern-20260331.xsd#gern_DebtInstrumentFloorRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7d0f-bb1d-fb75af39aa87" xlink:to="loc_gern_DebtInstrumentFloorRate_019c7730-4892-7f9a-bc43-fdbaf72bb606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_019c7730-4892-7606-aa41-03ebc3a9ca55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7d0f-bb1d-fb75af39aa87" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_019c7730-4892-7606-aa41-03ebc3a9ca55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_PercentageOfCommitmentAmountToFundLoan_019c7730-4892-7d91-a21c-2386abffd228" xlink:href="gern-20260331.xsd#gern_PercentageOfCommitmentAmountToFundLoan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7d0f-bb1d-fb75af39aa87" xlink:to="loc_gern_PercentageOfCommitmentAmountToFundLoan_019c7730-4892-7d91-a21c-2386abffd228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_PrepaymentPremiumOnPercentageOfTermLoan_019c7730-4892-7d49-a32c-08906d1eac3d" xlink:href="gern-20260331.xsd#gern_PrepaymentPremiumOnPercentageOfTermLoan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7d0f-bb1d-fb75af39aa87" xlink:to="loc_gern_PrepaymentPremiumOnPercentageOfTermLoan_019c7730-4892-7d49-a32c-08906d1eac3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_UpfrontPaymentReceived_019c7730-4892-7367-b113-2c5c6469fd3f" xlink:href="gern-20260331.xsd#gern_UpfrontPaymentReceived"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7d0f-bb1d-fb75af39aa87" xlink:to="loc_gern_UpfrontPaymentReceived_019c7730-4892-7367-b113-2c5c6469fd3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_PercentageOfAnnualNetSales_019c7730-4892-711f-843c-e8076931eb34" xlink:href="gern-20260331.xsd#gern_PercentageOfAnnualNetSales"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7d0f-bb1d-fb75af39aa87" xlink:to="loc_gern_PercentageOfAnnualNetSales_019c7730-4892-711f-843c-e8076931eb34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_019c7730-4892-7848-9899-8988730d2f95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7d0f-bb1d-fb75af39aa87" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_019c7730-4892-7848-9899-8988730d2f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_DebtInstrumentRoyaltyPaymentRatio_019c7730-4892-707c-a932-3214f54ca91c" xlink:href="gern-20260331.xsd#gern_DebtInstrumentRoyaltyPaymentRatio"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7d0f-bb1d-fb75af39aa87" xlink:to="loc_gern_DebtInstrumentRoyaltyPaymentRatio_019c7730-4892-707c-a932-3214f54ca91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019c7730-4892-7019-b28f-fcbf5aa325c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_019c7730-4892-7db8-a352-4a8bd4f7a45f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019c7730-4892-7019-b28f-fcbf5aa325c6" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_019c7730-4892-7db8-a352-4a8bd4f7a45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_019c7730-4892-757d-a6d7-0cb092a2776f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_019c7730-4892-7db8-a352-4a8bd4f7a45f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_019c7730-4892-757d-a6d7-0cb092a2776f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_019c7730-4892-786c-876a-963d793bf301" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_019c7730-4892-7db8-a352-4a8bd4f7a45f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_019c7730-4892-786c-876a-963d793bf301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_019c7730-4892-7fce-b774-ddfc4df6e3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_019c7730-4892-7db8-a352-4a8bd4f7a45f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_019c7730-4892-7fce-b774-ddfc4df6e3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_019c7730-4892-7504-9794-0aed98dab50b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_019c7730-4892-7db8-a352-4a8bd4f7a45f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_019c7730-4892-7504-9794-0aed98dab50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_LongTermDebtMaturityAfterYearThree_019c7730-4892-7db0-9ffd-9d655d71e962" xlink:href="gern-20260331.xsd#gern_LongTermDebtMaturityAfterYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_019c7730-4892-7db8-a352-4a8bd4f7a45f" xlink:to="loc_gern_LongTermDebtMaturityAfterYearThree_019c7730-4892-7db0-9ffd-9d655d71e962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_019c7730-4892-7c74-88b6-c3d05080342f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_019c7730-4892-7db8-a352-4a8bd4f7a45f" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_019c7730-4892-7c74-88b6-c3d05080342f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedCapitalizedInterestCosts_019c7730-4892-72ea-9682-cfc9d1ed6481" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedCapitalizedInterestCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_019c7730-4892-7db8-a352-4a8bd4f7a45f" xlink:to="loc_us-gaap_AccumulatedCapitalizedInterestCosts_019c7730-4892-72ea-9682-cfc9d1ed6481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_019c7730-4892-744f-bfb1-5da1659a69cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_019c7730-4892-7db8-a352-4a8bd4f7a45f" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_019c7730-4892-744f-bfb1-5da1659a69cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_019c7730-4892-7d98-b84b-9f06c4e5e0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_019c7730-4892-7db8-a352-4a8bd4f7a45f" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_019c7730-4892-7d98-b84b-9f06c4e5e0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/DEBTScheduleofSaleofFutureRoyaltiesDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#DEBTScheduleofSaleofFutureRoyaltiesDetails"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/DEBTScheduleofSaleofFutureRoyaltiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019c7730-4892-7ae9-8e91-0b178416018f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019c7730-4892-7e4f-9b69-f17281314d17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019c7730-4892-7ae9-8e91-0b178416018f" xlink:to="loc_us-gaap_DebtInstrumentTable_019c7730-4892-7e4f-9b69-f17281314d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_019c7730-4892-7e4a-aeef-f52bba7d94a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019c7730-4892-7e4f-9b69-f17281314d17" xlink:to="loc_us-gaap_TypeOfArrangementAxis_019c7730-4892-7e4a-aeef-f52bba7d94a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019c7730-4892-7462-a763-3ab862dddc65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019c7730-4892-7e4a-aeef-f52bba7d94a1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019c7730-4892-7462-a763-3ab862dddc65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember_019c7730-4892-7812-b31c-83820a260432" xlink:href="gern-20260331.xsd#gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019c7730-4892-7462-a763-3ab862dddc65" xlink:to="loc_gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember_019c7730-4892-7812-b31c-83820a260432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7c1f-b326-223d322c4dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019c7730-4892-7e4f-9b69-f17281314d17" xlink:to="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7c1f-b326-223d322c4dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_RoyaltiesRollForward_019c7730-4892-7b74-a14a-d39d970b5422" xlink:href="gern-20260331.xsd#gern_RoyaltiesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019c7730-4892-7c1f-b326-223d322c4dd7" xlink:to="loc_gern_RoyaltiesRollForward_019c7730-4892-7b74-a14a-d39d970b5422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_019c7730-4892-7cb5-9257-4a42cd595a87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gern_RoyaltiesRollForward_019c7730-4892-7b74-a14a-d39d970b5422" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_019c7730-4892-7cb5-9257-4a42cd595a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_019c7730-4892-7556-8a55-19adc73b69ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gern_RoyaltiesRollForward_019c7730-4892-7b74-a14a-d39d970b5422" xlink:to="loc_us-gaap_RoyaltyExpense_019c7730-4892-7556-8a55-19adc73b69ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_019c7730-4892-7e88-b383-5bc96a4d671c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gern_RoyaltiesRollForward_019c7730-4892-7b74-a14a-d39d970b5422" xlink:to="loc_us-gaap_PaymentsForRoyalties_019c7730-4892-7e88-b383-5bc96a4d671c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_019c7730-4892-76de-94c2-f59641e0c831" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gern_RoyaltiesRollForward_019c7730-4892-7b74-a14a-d39d970b5422" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_019c7730-4892-76de-94c2-f59641e0c831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019c7730-4892-7fb7-b35f-c109fdcc48ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_019dc31c-29e8-7659-b25c-054fe91bf40b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019c7730-4892-7fb7-b35f-c109fdcc48ca" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_019dc31c-29e8-7659-b25c-054fe91bf40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_NumberOfSeverancePlan_019dc31c-6082-7c52-a739-2c80fd4c49c1" xlink:href="gern-20260331.xsd#gern_NumberOfSeverancePlan"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019c7730-4892-7fb7-b35f-c109fdcc48ca" xlink:to="loc_gern_NumberOfSeverancePlan_019dc31c-6082-7c52-a739-2c80fd4c49c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_019dd637-3133-7c5a-9e77-7a257619203d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019c7730-4892-7fb7-b35f-c109fdcc48ca" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_019dd637-3133-7c5a-9e77-7a257619203d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligation_019dc31c-8923-7ed7-9d7a-7237119e7f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RecordedUnconditionalPurchaseObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019c7730-4892-7fb7-b35f-c109fdcc48ca" xlink:to="loc_us-gaap_RecordedUnconditionalPurchaseObligation_019dc31c-8923-7ed7-9d7a-7237119e7f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_019dc31c-8923-76ca-a15e-3846444a0323" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019c7730-4892-7fb7-b35f-c109fdcc48ca" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_019dc31c-8923-76ca-a15e-3846444a0323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_PurchaseObligationWrittenNoticeTerm_019dc31c-8923-7dd8-af25-535bd8cae01e" xlink:href="gern-20260331.xsd#gern_PurchaseObligationWrittenNoticeTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019c7730-4892-7fb7-b35f-c109fdcc48ca" xlink:to="loc_gern_PurchaseObligationWrittenNoticeTerm_019dc31c-8923-7dd8-af25-535bd8cae01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/NETLOSSPERCOMMONSHAREDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#NETLOSSPERCOMMONSHAREDetails"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/NETLOSSPERCOMMONSHAREDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019dc31e-0a9d-7fe7-9263-ffcd63c43f46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_019dc31f-cb9e-70f3-89c9-7a5ac70a7bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019dc31e-0a9d-7fe7-9263-ffcd63c43f46" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_019dc31f-cb9e-70f3-89c9-7a5ac70a7bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019dc31f-cb9e-79f2-9b55-12d7b71acc82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_019dc31f-cb9e-70f3-89c9-7a5ac70a7bf2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019dc31f-cb9e-79f2-9b55-12d7b71acc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019dc31f-cb9e-790a-8f80-c114fc93c960" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019dc31f-cb9e-79f2-9b55-12d7b71acc82" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019dc31f-cb9e-790a-8f80-c114fc93c960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_019dc31f-cb9e-7f60-b8f4-e7ba8a896d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019dc31f-cb9e-790a-8f80-c114fc93c960" xlink:to="loc_us-gaap_StockCompensationPlanMember_019dc31f-cb9e-7f60-b8f4-e7ba8a896d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_019dc31f-cb9e-7a10-bb06-cb078ccacca7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_019dc31f-cb9e-70f3-89c9-7a5ac70a7bf2" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_019dc31f-cb9e-7a10-bb06-cb078ccacca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019dc31f-cb9e-77cf-b634-f2c519603695" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_019dc31f-cb9e-7a10-bb06-cb078ccacca7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019dc31f-cb9e-77cf-b634-f2c519603695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/SEGMENTREPORTINGDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#SEGMENTREPORTINGDetails"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/SEGMENTREPORTINGDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019c7730-4892-7d5a-bb0b-bf0355484aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_019c7730-4892-77c6-8bec-a55c85307237" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019c7730-4892-7d5a-bb0b-bf0355484aa7" xlink:to="loc_us-gaap_NumberOfOperatingSegments_019c7730-4892-77c6-8bec-a55c85307237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_019c7730-4892-71c9-b0f1-8e0268f832be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019c7730-4892-7d5a-bb0b-bf0355484aa7" xlink:to="loc_us-gaap_NumberOfReportableSegments_019c7730-4892-71c9-b0f1-8e0268f832be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_019c7730-4892-7c31-bf6a-2906d0b16c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019c7730-4892-7d5a-bb0b-bf0355484aa7" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_019c7730-4892-7c31-bf6a-2906d0b16c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019c7730-4892-7644-b9ff-4c8c2e932896" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_019c7730-4892-7c31-bf6a-2906d0b16c2a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019c7730-4892-7644-b9ff-4c8c2e932896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c7730-4892-7c71-b758-b753b8becce0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c7730-4892-7644-b9ff-4c8c2e932896" xlink:to="loc_us-gaap_SegmentDomain_019c7730-4892-7c71-b758-b753b8becce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_ReportableSegmentMember_019c7730-4892-7713-a736-0b260d1acf1b" xlink:href="gern-20260331.xsd#gern_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_019c7730-4892-7c71-b758-b753b8becce0" xlink:to="loc_gern_ReportableSegmentMember_019c7730-4892-7713-a736-0b260d1acf1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019c7730-4892-70e9-85fe-cf531cfb5675" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_019c7730-4892-7c31-bf6a-2906d0b16c2a" xlink:to="loc_srt_ProductOrServiceAxis_019c7730-4892-70e9-85fe-cf531cfb5675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c7730-4892-717c-bac4-4eca9bbf1dec" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019c7730-4892-70e9-85fe-cf531cfb5675" xlink:to="loc_srt_ProductsAndServicesDomain_019c7730-4892-717c-bac4-4eca9bbf1dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_019c7730-4892-7fc4-b421-e388158a6229" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019c7730-4892-717c-bac4-4eca9bbf1dec" xlink:to="loc_us-gaap_ProductMember_019c7730-4892-7fc4-b421-e388158a6229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_019c7730-4892-7016-8fe7-5a88373fb5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019c7730-4892-717c-bac4-4eca9bbf1dec" xlink:to="loc_us-gaap_RoyaltyMember_019c7730-4892-7016-8fe7-5a88373fb5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_ResearchAndClinicalExpensesMember_019c7730-4892-7686-ac1a-61da28d58089" xlink:href="gern-20260331.xsd#gern_ResearchAndClinicalExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019c7730-4892-717c-bac4-4eca9bbf1dec" xlink:to="loc_gern_ResearchAndClinicalExpensesMember_019c7730-4892-7686-ac1a-61da28d58089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_ChemistryManufacturingAndControlExpensesMember_019c7730-4892-7a52-b834-a3a1df11b0ae" xlink:href="gern-20260331.xsd#gern_ChemistryManufacturingAndControlExpensesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019c7730-4892-717c-bac4-4eca9bbf1dec" xlink:to="loc_gern_ChemistryManufacturingAndControlExpensesMember_019c7730-4892-7a52-b834-a3a1df11b0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gern_CommercialExpensesMember_019c7730-4892-7e96-b887-b29a485a5b56" xlink:href="gern-20260331.xsd#gern_CommercialExpensesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019c7730-4892-717c-bac4-4eca9bbf1dec" xlink:to="loc_gern_CommercialExpensesMember_019c7730-4892-7e96-b887-b29a485a5b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_019dc322-c5ec-719f-bf0c-a7921deb88b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_019c7730-4892-7c31-bf6a-2906d0b16c2a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_019dc322-c5ec-719f-bf0c-a7921deb88b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019dc322-c5ec-711d-92af-2a6ded63e17b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019dc322-c5ec-719f-bf0c-a7921deb88b9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019dc322-c5ec-711d-92af-2a6ded63e17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019dc322-c5ec-76c7-b6aa-ccf6dfc13448" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019dc322-c5ec-711d-92af-2a6ded63e17b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019dc322-c5ec-76c7-b6aa-ccf6dfc13448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_019dc324-48d3-782c-86a5-3651c49b5636" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019dc322-c5ec-711d-92af-2a6ded63e17b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_019dc324-48d3-782c-86a5-3651c49b5636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019c7730-4892-73fc-b94c-5507e6a859b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAssetReconcilingItemLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_019c7730-4892-7c31-bf6a-2906d0b16c2a" xlink:to="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019c7730-4892-73fc-b94c-5507e6a859b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_019c7730-4892-7f9d-98fb-ac1f772ef985" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019c7730-4892-73fc-b94c-5507e6a859b9" xlink:to="loc_us-gaap_RevenuesAbstract_019c7730-4892-7f9d-98fb-ac1f772ef985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c7730-4892-71b5-8150-961cf9f28521" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_019c7730-4892-7f9d-98fb-ac1f772ef985" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c7730-4892-71b5-8150-961cf9f28521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_019c7730-4892-7277-ac16-7282733d715f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019c7730-4892-73fc-b94c-5507e6a859b9" xlink:to="loc_us-gaap_OperatingExpensesAbstract_019c7730-4892-7277-ac16-7282733d715f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_019c7730-4892-78ca-8f0b-fc7502091ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019c7730-4892-7277-ac16-7282733d715f" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_019c7730-4892-78ca-8f0b-fc7502091ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_019c7730-4892-7b10-a12a-35ca734f8b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019c7730-4892-7277-ac16-7282733d715f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_019c7730-4892-7b10-a12a-35ca734f8b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019c7730-4892-7026-a4a7-15e093873fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_019c7730-4892-7b10-a12a-35ca734f8b7b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019c7730-4892-7026-a4a7-15e093873fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_019dc322-c5ec-7fc3-94a4-0962501e6603" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_019c7730-4892-7b10-a12a-35ca734f8b7b" xlink:to="loc_us-gaap_RestructuringCharges_019dc322-c5ec-7fc3-94a4-0962501e6603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_019c7730-4892-7bf2-908e-0f7b7cce1b86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019c7730-4892-7277-ac16-7282733d715f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_019c7730-4892-7bf2-908e-0f7b7cce1b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_019c7730-4892-7fcd-9688-4af05dcaad65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_019c7730-4892-7bf2-908e-0f7b7cce1b86" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_019c7730-4892-7fcd-9688-4af05dcaad65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_019dc326-7d8e-7c78-8d9e-3ba44e8d44de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_019c7730-4892-7bf2-908e-0f7b7cce1b86" xlink:to="loc_us-gaap_RestructuringCharges_019dc326-7d8e-7c78-8d9e-3ba44e8d44de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_019c7730-4892-76da-8cb8-e84221e0a355" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019c7730-4892-7277-ac16-7282733d715f" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_019c7730-4892-76da-8cb8-e84221e0a355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_019c7730-4892-7ada-a4e8-a59a6751de55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019c7730-4892-7277-ac16-7282733d715f" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_019c7730-4892-7ada-a4e8-a59a6751de55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019c7730-4892-76b3-9e72-22960ada2312" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019c7730-4892-7277-ac16-7282733d715f" xlink:to="loc_us-gaap_NetIncomeLoss_019c7730-4892-76b3-9e72-22960ada2312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/RESTRUCTURINGAdditionalInformationDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#RESTRUCTURINGAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/RESTRUCTURINGAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019dc327-c0a9-7e4e-b647-f679a629c96a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_019dd642-a640-705e-849f-b48100b7bcde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019dc327-c0a9-7e4e-b647-f679a629c96a" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_019dd642-a640-705e-849f-b48100b7bcde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_019dc32c-0282-7562-b41b-dbef31c8cc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019dc327-c0a9-7e4e-b647-f679a629c96a" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_019dc32c-0282-7562-b41b-dbef31c8cc4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_019dc32c-0282-7441-b5e0-96a77e44d1af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019dc327-c0a9-7e4e-b647-f679a629c96a" xlink:to="loc_us-gaap_RestructuringCharges_019dc32c-0282-7441-b5e0-96a77e44d1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.geron.com/role/RESTRUCTURINGSummaryofChargesandSpendingRelatedtoRestructuringDetails" xlink:type="simple" xlink:href="gern-20260331.xsd#RESTRUCTURINGSummaryofChargesandSpendingRelatedtoRestructuringDetails"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/RESTRUCTURINGSummaryofChargesandSpendingRelatedtoRestructuringDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019dc32c-1e10-78fb-bf9f-d73f70dbf341" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_019dc32d-a0cd-7361-94a9-dc8dc402a99d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019dc32c-1e10-78fb-bf9f-d73f70dbf341" xlink:to="loc_us-gaap_RestructuringReserveRollForward_019dc32d-a0cd-7361-94a9-dc8dc402a99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_019dc32d-5dc6-7555-9509-3f83389202ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_019dc32d-a0cd-7361-94a9-dc8dc402a99d" xlink:to="loc_us-gaap_RestructuringReserve_019dc32d-5dc6-7555-9509-3f83389202ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_019dc32d-5dc6-7cf2-b168-0ba7804eebb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_019dc32d-a0cd-7361-94a9-dc8dc402a99d" xlink:to="loc_us-gaap_RestructuringCharges_019dc32d-5dc6-7cf2-b168-0ba7804eebb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_019dc32d-5dc6-7964-8aa5-738024490f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_019dc32d-a0cd-7361-94a9-dc8dc402a99d" xlink:to="loc_us-gaap_PaymentsForRestructuring_019dc32d-5dc6-7964-8aa5-738024490f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_019dc32e-53d9-7a7d-b992-074963b111c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_019dc32d-a0cd-7361-94a9-dc8dc402a99d" xlink:to="loc_us-gaap_RestructuringReserve_019dc32e-53d9-7a7d-b992-074963b111c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>May 01, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-20859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GERON CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">75-2287752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">919 EAST HILLSDALE BOULEVARD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">SUITE 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">FOSTER CITY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">473-7700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GERN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">641,520,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000886744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 68,895<span></span>
</td>
<td class="nump">$ 77,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">1,884<span></span>
</td>
<td class="nump">1,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="nump">243,506<span></span>
</td>
<td class="nump">280,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">41,882<span></span>
</td>
<td class="nump">36,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NontradeReceivablesCurrent', window );">Interest and other receivables</a></td>
<td class="nump">2,213<span></span>
</td>
<td class="nump">2,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">133,287<span></span>
</td>
<td class="nump">116,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">6,864<span></span>
</td>
<td class="nump">4,610<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">498,531<span></span>
</td>
<td class="nump">520,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent', window );">Noncurrent marketable securities</a></td>
<td class="nump">26,686<span></span>
</td>
<td class="nump">41,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating leases, right-of-use assets</a></td>
<td class="nump">1,959<span></span>
</td>
<td class="nump">2,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_DepositsAndOtherAssetsNoncurrent', window );">Deposits and other assets</a></td>
<td class="nump">5,944<span></span>
</td>
<td class="nump">5,945<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">534,120<span></span>
</td>
<td class="nump">570,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">12,720<span></span>
</td>
<td class="nump">11,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">9,488<span></span>
</td>
<td class="nump">30,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LiabilityRelatedToSaleOfFutureRoyaltiesCurrent', window );">Liability related to sale of future royalties</a></td>
<td class="nump">19,390<span></span>
</td>
<td class="nump">17,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">30,965<span></span>
</td>
<td class="nump">51,340<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">73,570<span></span>
</td>
<td class="nump">111,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liabilities</a></td>
<td class="nump">1,226<span></span>
</td>
<td class="nump">1,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent', window );">Noncurrent liability related to sale of future royalties</a></td>
<td class="nump">110,383<span></span>
</td>
<td class="nump">112,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Noncurrent debt</a></td>
<td class="nump">119,833<span></span>
</td>
<td class="nump">119,547<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">305,012<span></span>
</td>
<td class="nump">344,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, Value, Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Value, Issued</a></td>
<td class="nump">641<span></span>
</td>
<td class="nump">640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">2,088,141<span></span>
</td>
<td class="nump">2,080,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,859,483)<span></span>
</td>
<td class="num">(1,855,841)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(191)<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">229,108<span></span>
</td>
<td class="nump">225,872<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 534,120<span></span>
</td>
<td class="nump">$ 570,540<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_DepositsAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer; and amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_DepositsAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_LiabilityRelatedToSaleOfFutureRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Related To Sale Of Future Royalties, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_LiabilityRelatedToSaleOfFutureRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncurrent liability related to sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NontradeReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NontradeReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 51,837,000<span></span>
</td>
<td class="nump">$ 39,603,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Cost of goods sold</a></td>
<td class="nump">1,692,000<span></span>
</td>
<td class="nump">1,206,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">14,956,000<span></span>
</td>
<td class="nump">15,078,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">35,425,000<span></span>
</td>
<td class="nump">40,023,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="num">(394,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total costs and operating expenses</a></td>
<td class="nump">51,679,000<span></span>
</td>
<td class="nump">56,307,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">158,000<span></span>
</td>
<td class="num">(16,704,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">3,421,000<span></span>
</td>
<td class="nump">5,152,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(7,147,000)<span></span>
</td>
<td class="num">(8,200,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(74,000)<span></span>
</td>
<td class="num">(83,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,642,000)<span></span>
</td>
<td class="num">$ (19,835,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in calculating basic net loss per share (in shares)</a></td>
<td class="nump">669,375<span></span>
</td>
<td class="nump">665,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in calculating diluted net loss per share (in shares)</a></td>
<td class="nump">669,375<span></span>
</td>
<td class="nump">665,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 51,771,000<span></span>
</td>
<td class="nump">$ 39,436,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 66,000<span></span>
</td>
<td class="nump">$ 167,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,642)<span></span>
</td>
<td class="num">$ (19,835)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on marketable securities</a></td>
<td class="num">(412)<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (4,102)<span></span>
</td>
<td class="num">$ (19,792)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">606,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2024</a></td>
<td class="nump">$ 280,320<span></span>
</td>
<td class="nump">$ 606<span></span>
</td>
<td class="nump">$ 2,051,794<span></span>
</td>
<td class="num">$ (1,772,341)<span></span>
</td>
<td class="nump">$ 261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(19,835)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,835)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Other comprehensive loss</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant', window );">Exercise of pre-funded warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant', window );">Exercise of pre-funded warrant</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances of common stock under equity plans</a></td>
<td class="nump">256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares', window );">Stock-based compensation related to issuances of common stock and options for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation related to issuances of common stock and options for services</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Stock-based compensation for equity-based awards to employees and directors</a></td>
<td class="nump">7,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">636,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Mar. 31, 2025</a></td>
<td class="nump">268,238<span></span>
</td>
<td class="nump">$ 637<span></span>
</td>
<td class="nump">2,059,473<span></span>
</td>
<td class="num">(1,792,176)<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">639,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2025</a></td>
<td class="nump">225,872<span></span>
</td>
<td class="nump">$ 640<span></span>
</td>
<td class="nump">2,080,804<span></span>
</td>
<td class="num">(1,855,841)<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(412)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(412)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(48)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue', window );">Issuance of common stock in connection with exercise of warrants</a></td>
<td class="nump">1,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances of common stock under equity plans</a></td>
<td class="nump">914<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares', window );">Stock-based compensation related to issuances of common stock and options for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation related to issuances of common stock and options for services</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Stock-based compensation for equity-based awards to employees and directors</a></td>
<td class="nump">4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Mar. 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">641,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Mar. 31, 2026</a></td>
<td class="nump">$ 229,108<span></span>
</td>
<td class="nump">$ 641<span></span>
</td>
<td class="nump">$ 2,088,141<span></span>
</td>
<td class="num">$ (1,859,483)<span></span>
</td>
<td class="num">$ (191)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock issued in connection with exercise of warrants during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Exercise Of Prefunded Warrant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Exercise Of Prefunded Warrant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481117/718-50-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,642)<span></span>
</td>
<td class="num">$ (19,835)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion and amortization on investments, net</a></td>
<td class="num">(1,069)<span></span>
</td>
<td class="num">(2,210)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs/debt discounts</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties', window );">Non-cash interest expense on liabilities for sales of future royalties</a></td>
<td class="nump">3,912<span></span>
</td>
<td class="nump">4,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">4,913<span></span>
</td>
<td class="nump">7,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_IncreaseDecreaseInAllowanceForDoubtfulAccounts', window );">Increase in allowance for doubtful accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(16,651)<span></span>
</td>
<td class="num">(17,508)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(4,894)<span></span>
</td>
<td class="nump">4,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(2,234)<span></span>
</td>
<td class="num">(1,688)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,463<span></span>
</td>
<td class="num">(563)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="num">(21,009)<span></span>
</td>
<td class="num">(13,204)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(20,374)<span></span>
</td>
<td class="num">(6,663)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payments on royalty agreement</a></td>
<td class="num">(3,721)<span></span>
</td>
<td class="num">(3,682)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(212)<span></span>
</td>
<td class="num">(191)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(62,906)<span></span>
</td>
<td class="num">(47,979)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PaymentsUnpaidToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(252)<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(34,525)<span></span>
</td>
<td class="num">(46,477)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities and sales of marketable securities</a></td>
<td class="nump">86,633<span></span>
</td>
<td class="nump">98,884<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">51,856<span></span>
</td>
<td class="nump">52,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuances of common stock from equity plans</a></td>
<td class="nump">914<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of warrants</a></td>
<td class="nump">1,511<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,425<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Net effect of exchange rates on cash, cash equivalents and restricted cash</a></td>
<td class="num">(36)<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="num">(8,661)<span></span>
</td>
<td class="nump">4,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at the beginning of the period</a></td>
<td class="nump">79,440<span></span>
</td>
<td class="nump">80,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at the end of the period</a></td>
<td class="nump">$ 70,779<span></span>
</td>
<td class="nump">$ 85,610<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_IncreaseDecreaseInAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Allowance For Doubtful Accounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_IncreaseDecreaseInAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Interest Expense On Liabilities For Sales Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_PaymentsUnpaidToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments (Unpaid) To Acquire Property, Plant, And Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_PaymentsUnpaidToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION, PRINCIPLES OF CONSOLIDATION USE OF ESTIMATES AND RECENT ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION, PRINCIPLES OF CONSOLIDATION USE OF ESTIMATES AND RECENT ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text">BASIS OF PRESENTATION, PRINCIPLES OF CONSOLIDATION, USE OF ESTIMATES AND RECENT ACCOUNTING PRONOUNCEMENTS<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The terms &#8220;Geron&#8221;, the &#8220;Company&#8221;, &#8220;we&#8221; and &#8220;us&#8221; as used in this Report refer to Geron Corporation and its wholly-owned subsidiaries, Geron UK Limited, or Geron UK, a United Kingdom company, and Geron Netherlands B.V., or Geron Netherlands, a Netherlands company. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:18pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by United States, or U.S., generally accepted accounting principles, or GAAP, for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2025, or the 2025 Form 10-K. The accompanying unaudited condensed consolidated balance sheet as of December&#160;31, 2025 has been derived from audited financial statements at that date. Operating results for the three months ended March 31, 2026 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2026 or any other period. We operate as one operating segment.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements include the accounts of Geron Corporation and its wholly-owned subsidiaries, Geron UK and Geron Netherlands. For Geron UK and Geron Netherlands, we have eliminated intercompany accounts and transactions. </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to accrued liabilities, revenue recognition, fair value of marketable securities, inventory valuation, operating leases (right-of-use assets), lease liabilities, income taxes, and stock-based compensation and interest expense related to sale of future royalties. We base our estimates on historical experience and on various other market specific and relevant assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies used in preparation of these unaudited condensed consolidated financial statements as of and for the three months ended March 31, 2026 are consistent with those discussed in Note 1 to the consolidated financial statements in the 2025 Form 10-K.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements &#8211; Issued But Not Yet Adopted</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The amendments in ASU 2024-03 address investor requests for more detailed expense information and require additional disaggregated disclosures in the notes to financial statements for certain categories of expenses that are included on the face of the income statement. This guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">years beginning after December 15, 2027, with early adoption permitted. We are evaluating the impact of this ASU on our consolidated financial statements.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other recent accounting pronouncements issued by the FASB are not believed by management to have a material impact on our financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE RECOGNITION</a></td>
<td class="text">REVENUE RECOGNITION<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net Product Revenue</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To date, our only source of product revenue has been from the U.S. sales of RYTELO, which we began shipping to our customers in June 2024. To date, product revenue pursuant to Named Patient Programs outside of the U.S. have been not material.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of gross product sales to net product sales by each significant category of gross-to-net adjustments was as follows for the three months ended March&#160;31, 2026 and 2025: </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.484%"><tr><td style="width:1.0%"></td><td style="width:54.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.594%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross product revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">65,353&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45,312&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross-to-net adjustments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(8,164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4,171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Distributor service fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,169)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,526)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Government rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,658)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns and allowances</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,591)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total gross-to-net adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(13,582)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5,876)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">51,771&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">39,436&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text">INVENTORY<span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All of our inventories are related to the manufacturing of RYTELO. The following table presents our inventory as of March&#160;31, 2026 and December 31, 2025:</span></div><div style="margin-bottom:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"></td><td style="width:68.685%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,603&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,927&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">99,118&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">91,969&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total inventory</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">133,287&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">116,636&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">FINANCIAL INSTRUMENTS</a></td>
<td class="text">Financial Instruments<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents, restricted cash and marketable securities by security type at March&#160;31, 2026 were as follows: </span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Included in cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">43,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">43,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48,722&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48,722&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market fund</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities (due in less than one year)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 8.2pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Municipal securities (due in less than one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 15.4pt;text-indent:-7.21pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Municipal securities (due in one to two years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 15.4pt;text-indent:-7.21pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Government-sponsored enterprise securities (due in less than one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 15.4pt;text-indent:-7.21pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper (due in less than one year)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 8.2pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">66,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">66,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes (due in less than one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 8.2pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">149,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(130)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">148,979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes (due in one to two years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 8.2pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">270,373&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">34&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(215)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">270,192&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents, restricted cash and marketable securities by security type at December&#160;31, 2025 were as follows: </span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Included in cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">53,929&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">53,930&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market fund</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities (due in less than one year)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Municipal securities (due in less than one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper (due in less than one year)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">79,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">79,403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes (due in less than one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">167,805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">167,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes (due in one to two years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">41,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">41,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">321,417&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">285&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(54)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">321,648&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and marketable securities with unrealized losses that have been in a continuous unrealized loss position for less than 12 months and 12 months or longer at March&#160;31, 2026 and December&#160;31, 2025 were as follows: </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Less Than 12 Months </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">12 Months or Longer </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31, 2026:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Government-sponsored enterprise securities (due in less than one year)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Municipal securities (due in less than one year)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,998&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,998&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Municipal securities (due in one to two years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper (cash equivalent)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,995&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,995&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper (due in less than one year)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes (due in less than one year)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">93,543&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(130)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">93,543&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(130)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes (due in one to two years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">170,934&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(215)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">170,934&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(215)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2025:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes (due in less than one year)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes (due in one to two years)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31,265&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31,265&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">49,252&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(54)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">49,252&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(54)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The gross unrealized losses related to municipal securities, government-sponsored enterprise securities, commercial paper and corporate notes as of March&#160;31, 2026 and December&#160;31, 2025 were due to changes in interest rates and not credit risk. If an available-for-sale security&#8217;s fair value is less than its amortized cost basis, we evaluate whether the decline is the result of a credit loss, in which case an impairment is recorded through an allowance for credit losses. We have not recorded any allowances for credit losses on our available-for-sale securities for the three months ended March&#160;31, 2026 as we have not identified any unrealized losses for these securities attributable to credit factors. Our exposure to unrealized losses may increase in the future due to the economic pressures or uncertainties associated with local or global economic recessions as a result of ongoing geopolitical events, such as the current military conflicts between Ukraine and Russia or the United States and Iran, as well as recent and potential future disruptions in access to bank deposits or lending commitments due to bank failure. We do not intend to sell the investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost basis, which may be maturity.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/825/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We categorize financial instruments recorded at fair value on our condensed consolidated balance sheets based upon the level of judgment associated with inputs used to measure their fair value. The categories are as follows: </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Level 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></td></tr></table></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A financial instrument&#8217;s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Below is a description of the valuation methodologies used for financial instruments measured at fair value on our consolidated balance sheets, including the category for such financial instruments.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds and certificates of deposit are categorized as Level 1 within the fair value hierarchy as their fair values are based on quoted prices available in active markets. Commercial paper, U.S. Treasury securities, municipal securities, government-sponsored enterprise securities and corporate notes are categorized as Level 2 within the fair value hierarchy as their fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The embedded derivatives are classified within Level 3 of the fair value hierarchy. See Note 7 on Debt.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We determined the fair value of the liability related to the sale of future royalties based on our current estimates of future royalties expected to be paid to Royalty Pharma over the life of the arrangement, which are considered Level 3. See Note 7 on Debt.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level 1, Level 2, and Level 3 during the periods presented. In addition, there have been no changes to our valuation techniques as of March 31, 2026 and December 31, 2025.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of March&#160;31, 2026 and December&#160;31, 2025 and indicates the fair value category assigned.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.151%"><tr><td style="width:1.0%"></td><td style="width:37.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices in<br/>Active Markets for<br/>Identical Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other<br/>Observable Inputs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31, 2026:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45,337&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45,337&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Municipal securities</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)(4)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12,038&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12,038&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Government-sponsored enterprises</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,959&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,959&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">71,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">71,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">173,648&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">173,648&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45,611&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">275,187&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">320,798&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sale of future royalties</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129,773&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129,773&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2025:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">50,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">50,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">274&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">274&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Municipal securities</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)(4)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22,951&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22,951&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">84,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">84,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)(4)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">209,253&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">209,253&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">50,831&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">326,627&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">377,458&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sale of future royalties</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129,582&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129,582&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt">Included in cash and cash equivalents on our condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt">Included in restricted cash on our condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt">Included in current portion of marketable securities on our condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt">Included in noncurrent portion of marketable securities on our condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt">Included in current portion of liabilities related to sale of future royalties on our consolidated balance sheets.</span></div><div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Included in noncurrent portion of liabilities related to sale of future royalties on our consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS</a></td>
<td class="text">OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS<div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following as of March&#160;31, 2026 and December&#160;31, 2025: </span></div><div style="margin-bottom:12pt;text-align:center;text-indent:64.8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.818%"><tr><td style="width:1.0%"></td><td style="width:65.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">MARCH 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">DECEMBER 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contract research organization and clinical trial costs</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">38,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Professional, legal and accounting fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued revenue adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30,965&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">51,340&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation and benefits consisted of the following as of March&#160;31, 2026 and December&#160;31, 2025:</span></div><div style="margin-bottom:12pt;text-align:center;text-indent:64.8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.818%"><tr><td style="width:1.0%"></td><td style="width:65.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">MARCH 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">DECEMBER 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued bonuses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued vacation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued restructuring charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,488&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text">DEBT<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Pharmakon Loan Agreement </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2024, we entered into a loan agreement, or the Pharmakon Loan Agreement, with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership, each, a Lender, which are investment funds managed by Pharmakon Advisors, LP, and BioPharma Credit PLC, as collateral agent, that provides for a 5-year senior secured term loan facility of up to $250.0&#160;million, divided into three committed tranches: (i) a Tranche A Loan in an aggregate principal amount of $125.0&#160;million, or the Tranche A Loan, which was funded on November 1, 2024, or the Tranche A Closing Date; (ii) a Tranche B Loan in an aggregate principal amount of $75.0&#160;million, or the Tranche B Loan, which is available, subject to certain limited conditions, at our option; and (iii) a Tranche C Loan in an aggregate principal amount of $50.0&#160;million, or the Tranche C Loan, and together with the Tranche A Loan and the Tranche B Loan, collectively, the Term Loans, which is available to us upon reaching a specified trailing twelve-month RYTELO revenue milestone. The Tranche B Loan and the Tranche C Loan, once available, could have been requested on or prior to December 31, 2025. A portion of the proceeds from the Tranche A Loan were used to repay, in full, all amounts owed under the Hercules Loan Agreement, which was terminated effective November 1, 2024. The remaining proceeds will be used to fund our general corporate and working capital requirements.</span></div><div style="text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On January 5, 2026, the Pharmakon Loan Agreement was amended to extend the date for requesting the Tranche B Loan and Tranche C Loan, once available, from December 31, 2025 to July 30, 2026. The amendment also extended the date before which any Term Loan prepayment is subject to a make&#8209;whole premium, or the Makewhole Date, from November 1, 2026 to May 1, 2027. The amendment was evaluated under ASC 470-50 and determined to be a modification. The unamortized debt issuance costs will continue to be amortized over the remaining term using a revised effective interest rate. Fees incurred in connection with the amendment were not material and were expensed as incurred.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loans mature on November 1, 2029. The Term Loans bear interest at a variable rate per annum equal to 5.75% plus the three-month Secured Overnight Financing Rate, or SOFR, with a <span style="-sec-ix-hidden:f-571">SOFR</span> floor of 3.00%. As of inception of the Tranche A Loan, the interest rate applicable to the Tranche A Loan was 10.32%. As of March&#160;31, 2026, the applicable interest rate was 10.80%. Interest is due and payable quarterly on the last day of each quarter. The Pharmakon Loan Agreement requires we pay an amount equal to 2.50% of the Lenders&#8217; total committed amount to fund the Term Loans, payable with respect to each Term Loan on the funding date of such Term Loan. </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may elect to prepay the Term Loans in part or in whole prior to the Maturity Date with such prepayments being subject to a prepayment premium equal to the principal amount so prepaid multiplied by 3% if made prior to the 3rd anniversary of the funding date of the applicable Term Loan, 2% if made on or after the 3rd anniversary of the funding date of the applicable Term Loan but prior to the 4th anniversary of the funding date of the applicable Term Loan, and 1% if made on or after the 4th anniversary of the funding date of the applicable Term Loan but prior to the Maturity Date. In addition to the prepayment premium, prepayments of any Term Loan prior to the 2nd anniversary of the funding date of such Term Loan are subject to a make-whole amount equal to the sum of all interest that would have accrued through such 2nd anniversary. </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations under the Pharmakon Loan Agreement are secured by substantially all of our assets, including our intellectual property. Certain of our subsidiaries may, from time to time after the Tranche A Closing Date, be required to guarantee our obligations under the Pharmakon Loan Agreement and, in connection with such guarantee, pledge substantially all of their assets, including intellectual property, to secure such guarantee.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Loan Agreement contains customary affirmative and restrictive covenants and representations and warranties. We are bound by certain affirmative covenants setting forth actions that are required during the term of the Pharmakon Loan Agreement, including, without limitation, certain information delivery requirements, obligations to maintain certain insurance, and certain notice requirements. There are no financial covenants. Additionally, we are bound by certain restrictive covenants setting forth actions that are not permitted to be taken during the term of the Pharmakon Loan Agreement, including, without limitation, (i) selling or disposing of assets, (ii) amending, modifying or waiving our rights under material agreements, (iii) consummating change in control transactions unless all amounts becoming due under the Loan Agreement are paid in full immediately upon (and concurrent with) the consummation of any such change in control transaction, (iv) incurring additional indebtedness, (v) incurring non-permitted liens or encumbrance on our or our subsidiaries&#8217; assets, (vi) paying dividends or making any distribution or payment on or redeeming, retiring or purchasing any equity interests, and (vii) making payments on subordinated indebtedness, in each case, subject to specified exceptions. The Pharmakon Loan Agreement also contains the following events of default: (i) failure to pay principal, interest and other amounts when due, (ii) the breach of the covenants under the Loan Agreement, (iii) the occurrence of a material adverse change or the occurrence of a withdrawal event in respect of RYTELO, (iv) certain attachments of the credit parties assets and restraints on their business, (v) certain insolvency, liquidation, bankruptcy or similar events, (vi) certain cross-default of third-party indebtedness and royalty revenue contracts, (vii) the failure to pay certain judgments, (viii) material misrepresentations, (ix) the loan documents ceasing to create a valid security interest in a material portion of the collateral, (x) the occurrence of certain ERISA events, and (xi) the occurrence of a default under any subordination or intercreditor agreement, in each case subject to the grace periods, cure period and thresholds as specified in the Pharmakon Loan Agreement. Upon the occurrence and during the continuance of an event of default, the Lenders may, among other things, accelerate our obligations under the Pharmakon Loan Agreement (including all obligations for principal, interest and any applicable make-whole and prepayment premiums); provided that upon an event of default relating to certain insolvency, liquidation, bankruptcy or similar events, all outstanding obligations will be immediately accelerated. We concluded that the likelihood of such acceleration is remote, and therefore all debt is classified as long&#8209;term. As of March&#160;31, 2026, we were in compliance with our Pharmakon Loan Agreement covenants.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:90%">Future Minimum Payments</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents future minimum payments, including interest and the end of term charge, under the Loan Agreement as of March&#160;31, 2026 (in thousands): </span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.000%"><tr><td style="width:1.0%"></td><td style="width:72.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11,927&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11,960&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">134,966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">170,780&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Less: amount representing interest</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(45,780)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Less: unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5,167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Noncurrent portion of debt</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">119,833&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Embedded Derivatives</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The conditional exercisable call option related to the event of default is considered to be an embedded derivative which is required to be bifurcated and accounted for as a separate financial instrument. In the periods presented, the value of the embedded derivative is not material and therefore, no amount has been recognized. If an event of default becomes more probable than is currently estimated, then the embedded derivative could become material in future periods and would be recognized as a separate financial instrument at that time.  The embedded derivatives are classified within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Liabilities Related to Sale of Future Royalties</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2024, we entered into a revenue participation right purchase and sale agreement, or the Royalty Pharma Agreement, with Royalty Pharma Development Funding, LLC, or Royalty Pharma. Pursuant to the Royalty Pharma Agreement, we received an upfront payment of $125.0&#160;million, or the Purchase Price, in exchange for which Royalty Pharma obtained the right, or the Revenue Participation Right, to receive certain amounts calculated as a percentage of future U.S. net sales of RYTELO for each calendar quarter, or Royalty Payments, during the term contemplated by the Royalty Pharma Agreement. Specifically, the revenue participation rate commences at 7.75% for annual U.S. net sales of up to and equal to $500.0&#160;million declining to 1.0% for annual U.S. net sales exceeding $1.0&#160;billion until the date when the aggregate Royalty Payments equal or exceed 1.65 times the Purchase Price, if this occurs by June 30, 2031, or the date when the aggregate Royalty Payments equal or exceed 2.0 times the Purchase Price.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have the option to repurchase all of the Revenue Participation Right from Royalty Pharma for a purchase price of equal to the Buy-Out-Payment, as defined below, if we entered into a definitive agreement to consummate a change of control, or Buy-Back Option. </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Buy-Out Payment&#8221; means an amount equal to (a) 1.65 times the Purchase Price minus the aggregate Royalty Payments as of the change of control, if the change of control occurs on or prior to December 31, 2027, or (b) 2.0 times the Purchase Price minus the aggregate Royalty Payments as of the change of control, if the change of control occurs after December 31, 2027. </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for the Royalty Pharma Agreement as a financing liability, primarily because it has significant continuing involvement in generating the future revenue on which the Royalty Payments are based. The liability related to Revenue Participation Right and the related interest expense are measured based on our current estimate of the timing and amount of expected future Royalty Payments expected to be paid over the estimated term of the Royalty Pharma Agreement using a discounted cashflow model. The liability is amortized using the effective interest rate method, resulting in recognition of interest expense over the estimated term of the agreement. </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have determined the fair value of the liability related to the sale of future royalties is based on our current estimates of future royalties expected to be paid to Royalty Pharma over the life of the arrangement, which are considered Level 3.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity within the liability related to sale of future royalties during the three months ended March&#160;31, 2026: </span></div><div style="text-align:center;text-indent:24.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.121%"><tr><td style="width:1.0%"></td><td style="width:81.003%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Liability Related to Sale of Future Royalties</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of liability related to sale of future royalties at December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">129,582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,912&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Royalty payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,721)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of liability related to sale of future royalties at March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129,773&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 13 and March 14, 2025, we and certain of our current and former officers were named as defendants in two putative securities class action lawsuits filed in the United States District Court for the Northern District of California captioned </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dabestani v. Geron Corporation, et al.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, No. 3:25-cv-02507 and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Potvin v. Geron Corporation, et al.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, No. 3:25-cv-02563, respectively. Both lawsuits allege violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder in connection with allegedly false and misleading statements concerning the commercial potential of RYTELO. The plaintiffs allege, among other things, that we overstated RYTELO's commercial potential by making materially false and misleading statements and/or concealing material adverse facts concerning RYTELO's commercial potential, including the lack of awareness among healthcare providers for RYTELO, the burden of monitoring requirements in administering the drug, and the impacts of seasonality and existing competition on RYTELO's sales, and that our stock price dropped when we disclosed in our earnings call on February 26, 2025 that we had observed flat revenue trends over the prior few months. The plaintiffs seek damages and interest, and an award of reasonable costs, including attorneys' and experts' fees. On May 29, 2025, the Court consolidated the Dabestani and Potvin cases into one consolidated action captioned </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Geron Corporation Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, or the Securities Class Action, and appointed lead plaintiffs and counsel for lead plaintiffs. On August 8, 2025, lead plaintiffs filed a consolidated amended complaint. On October 7, 2025, we filed our motion to dismiss the consolidated amended complaint.  A hearing on the motion to dismiss was held on March 19, 2026, and on March 30, 2026, the Court entered an order granting our motion to dismiss without prejudice. On April 13, 2026, lead plaintiffs filed a second amended complaint. We intend to move to dismiss the second amended complaint.   </span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on April 15, 2025 and April 16, 2025, three purported stockholders filed derivative complaints, each filed in the United States District Court for the Northern District of California, captioned </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bishop v. Scarlett, et al.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, No. 3:25-cv-03356,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Lerner v. Scarlett, et al.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, No. 3:25-cv-03401, and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Willis v. Scarlett, et al.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, No: 3:25-cv-03396, respectively. The three lawsuits name certain of our current and former directors and officers and allege that they breached their fiduciary duties and violated federal securities laws by issuing allegedly false and misleading statements concerning the commercial potential of RYTELO. The allegations in each of the three derivative complaints are substantially similar to the Securities Class Action. The plaintiff seeks damages and interest, and an award of reasonable costs, including attorneys' and experts' fees. The plaintiffs in </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bishop v. Scarlett, et al. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Willis v. Scarlett, et al.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> also seek punitive damages. On May 16, 2025, the Court consolidated the three derivative complaints into one consolidated action captioned </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Geron Corporation Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, or the Consolidated Derivative Action.  On June 17, 2025, the Court stayed the Consolidated Derivative Action pending a final ruling on the anticipated motion to dismiss in the Securities Class Action.</span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 29, 2025, a purported stockholder made a demand on our board of directors to commence a civil action against certain of our current and former directors for breaching their fiduciary duties and violating the </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">securities laws by issuing allegedly false and misleading statements concerning the commercial potential of RYTELO.  On September 19, 2025, the board of directors responded that it would defer a final decision on the demand given the other pending derivative lawsuits and the Securities Class Action.  On October 7, 2025, the purported stockholder filed a suit in the United States District Court for the Northern District of California, captioned </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jae Hyung v. Bir, et al.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, No. 3:25-cv-08575.  The derivative lawsuit names certain of our current and former directors and officers. The allegations in the derivative lawsuit are substantially similar to the Securities Class Action and the Consolidated Derivative Action.  The plaintiff seeks damages and an award of reasonable costs, including attorneys&#8217; and experts&#8217; fees. On January 23 and February 19, 2026, respectively, two additional purported stockholders each made a similar demand on our board of directors. On March 25, 2026, the board of directors similarly responded that it would defer a final decision on the demands given the other pending derivative lawsuits and the Securities Class Action.</span></div><div style="text-indent:64.79pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that additional lawsuits will be filed or allegations made by stockholders with respect to these same or other matters and also naming us and/or our officers and directors as defendants. We intend to vigorously defend against the claims brought by the plaintiffs in these matters.    </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Such lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. The outcome of the pending lawsuits and any other related lawsuits is necessarily uncertain.  We could be forced to expend significant resources and may incur substantial legal fees and costs in defending against the pending lawsuits and any other related lawsuits, and we may not prevail. Monitoring, initiating and defending against legal actions is time-consuming for our management, is likely to be expensive, and may detract from our ability to fully focus our internal resources on our business activities.  Additionally, we may not be successful in having any such lawsuits dismissed or settled within the limits of our insurance coverage. Given the early stage of these lawsuits and the inherent uncertainly of litigation, we cannot predict how long it may take to resolve the pending lawsuits or the potential outcome or possible amount of any damages. As such, we currently are unable to reasonably estimate the possible losses or a range of possible losses that may result from these matters, if any. Expenses associated with the pending lawsuits and any potential related lawsuits could be material to our consolidated financial statements if we do not prevail in the defense of such lawsuits, or even if we do prevail. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Indemnifications to Officers and Directors</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate bylaws require that we indemnify our directors, as well as those who act as directors and officers of other entities at our request, against expenses, judgments, fines, settlements and other amounts actually and reasonably incurred in connection with any proceedings arising out of their services to Geron. In addition, we have entered into separate indemnification agreements with each of our directors and officers which provide for indemnification of these directors and officers under similar circumstances and under additional circumstances. The indemnification obligations are more fully described in our bylaws and the indemnification agreements. We purchase standard insurance to cover claims or a portion of the claims made against our directors and officers. Since a maximum obligation is not explicitly stated in our bylaws or in our indemnification agreements and will depend on the facts and circumstances that arise out of any future claims, the overall maximum amount of the obligations cannot be reasonably estimated.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Severance Plan</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We maintain two severance plans: one applied to (i) employees hired on or before December 31, 2021, and (ii) employees at the Senior Vice President level and above (i.e., executives), and the other applies to non&#8209;executive employees hired on or after January 1, 2022. The plans provide severance benefits upon qualifying terminations, including enhanced benefits in connection with a change of control. As of March&#160;31, 2026, all executive officers have employment agreements with severance provisions and will receive the greater of the severance benefits provided under their agreements or the applicable plan (without duplication).</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2025, we implemented a workforce reduction, representing approximately one-third of our workforce prior to the reduction in headcount. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See Note 11 on Restructuring for additional information.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have engaged third&#8209;party contract manufacturers to manufacture and supply additional quantities of RYTELO that meet applicable regulatory standards for current and potential future clinical trials and commercial uses. Related to those contract manufacturing agreements, we have binding commercial purchase commitments of approximately $15.9 million that can be cancelled, but would incur cancellation penalties, and approximately $37.7 million in agreed upon manufacturing commitments that can be adjusted based on commercial demand of RYTELO as of March 31, 2026. Based on current plans and information available, the related commercial purchase commitments are intended to be utilized.</span></div><div style="margin-bottom:18pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we enter into agreements with CROs for clinical trials for clinical and commercial supply manufacturing and with other vendors for non-clinical research studies, investigator-led trials and other services and products for operating purposes. We have not considered these payments to be contractual obligations since the contracts are generally cancellable at any time by us upon less than 180 days&#8217; prior written notice. We also have certain in-license agreements that require us to pay milestones to such third parties upon achievement of certain development, regulatory or commercial milestones. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval and commercial milestones, which may not be achieved.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER COMMON SHARE</a></td>
<td class="text">NET LOSS PER COMMON SHARE<div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of shares of common stock outstanding for the periods presented without consideration of potential common shares.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net income per share would be calculated by adjusting the weighted-average number of shares of common stock outstanding for the dilutive effect of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued, as determined using the treasury-stock method. Potential dilutive securities consist of outstanding stock options and warrants to purchase our common stock. Diluted net loss per share excludes potential dilutive securities for all periods presented as their effect would be anti-dilutive. Accordingly, basic and diluted net loss per share is the same for all periods presented in the accompanying condensed consolidated statements of operations. Since we incurred a net loss for the three months ended March 31, 2026 and 2025, the diluted net loss per share calculation excludes potential dilutive securities of 91,845,095 and 80,776,089, respectively, related to outstanding stock options and warrants as their effect would have been anti-dilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT REPORTING</a></td>
<td class="text">SEGMENT REPORTING<div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are currently developing therapies for the treatment of hematologic malignancies. To date, our main source of product revenue has been from U.S. sales of RYTELO, which began shipping to customers in June 2024. Additionally, we have generated insignificant royalty and license fee revenue under agreements that out-license technology to various companies.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have one operating and reportable segment. We define our operating segment based on internally reported financial information that is regularly reviewed by the Chief Operating Decision Maker, or CODM, to analyze financial performance, make decisions, and allocate resources. Our President and Chief Executive Officer is the CODM. </span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The CODM reviews the segment's profit or loss based on net (loss) income reported on the consolidated statement of operations and comprehensive (loss) income and considers forecast-to-actuals variances on a quarterly basis for expenses that are deemed significant. Further, the CODM reviews the segment's assets based on total assets reported on the condensed consolidated balance sheet. All long-lived assets are held in the U.S.</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our CODM views specific categories within research and development expenses and selling, general and administrative expenses as significant given the correlation between cash burn and profitability.  The following table reconciles reported revenues to net (loss) income under the significant expense principle for the three months ended March 31, 2026 and 2025:</span></div><div style="margin-bottom:12pt;text-align:center;text-indent:64.8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.727%"><tr><td style="width:1.0%"></td><td style="width:61.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.030%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">51.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">39.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">51.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">39.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and clinical expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chemistry, manufacturing, and control expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other segment expenses*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total interest and other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(19.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*Other segment expenses includes stock-based compensation expense and other general and administrative expenses largely resulting from personnel costs for individuals in administrative functions and legal and professional fees.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">RESTRUCTURING</a></td>
<td class="text">RESTRUCTURING<div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2025, the board of directors approved a workforce reduction representing approximately one-third of our workforce prior to the reduction in headcount. In 2025, we incurred approximately $17.0&#160;million in restructuring and restructuring-related charges, primarily consisting of one-time employee severance payments, healthcare and related benefits, and other employee-related costs. The charges were recorded within restructuring charges in the consolidated statements of operations. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The workforce reduction was substantially completed in the first quarter of 2026. There were no restructuring charges during the three months ended March 31, 2025.</span></div><div style="margin-bottom:12pt;text-align:center;text-indent:64.8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.606%"><tr><td style="width:1.0%"></td><td style="width:68.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Restructuring</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of December 31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expenses and adjustments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(13,532)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of March 31, 2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,106&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION, PRINCIPLES OF CONSOLIDATION USE OF ESTIMATES AND RECENT ACCOUNTING PRONOUNCEMENTS (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:18pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by United States, or U.S., generally accepted accounting principles, or GAAP, for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2025, or the 2025 Form 10-K. The accompanying unaudited condensed consolidated balance sheet as of December&#160;31, 2025 has been derived from audited financial statements at that date. Operating results for the three months ended March 31, 2026 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2026 or any other period. We operate as one operating segment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div>The unaudited condensed consolidated financial statements include the accounts of Geron Corporation and its wholly-owned subsidiaries, Geron UK and Geron Netherlands. For Geron UK and Geron Netherlands, we have eliminated intercompany accounts and transactions.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to accrued liabilities, revenue recognition, fair value of marketable securities, inventory valuation, operating leases (right-of-use assets), lease liabilities, income taxes, and stock-based compensation and interest expense related to sale of future royalties. We base our estimates on historical experience and on various other market specific and relevant assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_SignificantAccountingPoliciesPolicyPolicyTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies used in preparation of these unaudited condensed consolidated financial statements as of and for the three months ended March 31, 2026 are consistent with those discussed in Note 1 to the consolidated financial statements in the 2025 Form 10-K.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements &#8211; Issued But Not Yet Adopted</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The amendments in ASU 2024-03 address investor requests for more detailed expense information and require additional disaggregated disclosures in the notes to financial statements for certain categories of expenses that are included on the face of the income statement. This guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">years beginning after December 15, 2027, with early adoption permitted. We are evaluating the impact of this ASU on our consolidated financial statements.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:64.79pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other recent accounting pronouncements issued by the FASB are not believed by management to have a material impact on our financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_SignificantAccountingPoliciesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Accounting Policies, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_SignificantAccountingPoliciesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock', window );">Schedule of Reconciliation of Gross Product Sales to Net Product Sales</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of gross product sales to net product sales by each significant category of gross-to-net adjustments was as follows for the three months ended March&#160;31, 2026 and 2025: </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.484%"><tr><td style="width:1.0%"></td><td style="width:54.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.594%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross product revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">65,353&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45,312&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross-to-net adjustments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(8,164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4,171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Distributor service fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,169)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,526)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Government rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,658)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns and allowances</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1,591)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total gross-to-net adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(13,582)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5,876)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">51,771&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">39,436&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of gross to net sales adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text">The following table presents our inventory as of March&#160;31, 2026 and December 31, 2025:<div style="margin-bottom:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"></td><td style="width:68.685%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,603&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8,927&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">99,118&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">91,969&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total inventory</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">133,287&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">116,636&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Schedule of Cash Equivalents, Restricted Cash and Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents, restricted cash and marketable securities by security type at March&#160;31, 2026 were as follows: </span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Included in cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">43,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">43,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48,722&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48,722&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market fund</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities (due in less than one year)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 8.2pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Municipal securities (due in less than one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 15.4pt;text-indent:-7.21pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Municipal securities (due in one to two years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 15.4pt;text-indent:-7.21pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Government-sponsored enterprise securities (due in less than one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 15.4pt;text-indent:-7.21pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper (due in less than one year)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 8.2pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">66,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">66,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes (due in less than one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 8.2pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">149,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(130)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">148,979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes (due in one to two years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 8.2pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">270,373&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">34&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(215)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">270,192&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents, restricted cash and marketable securities by security type at December&#160;31, 2025 were as follows: </span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Included in cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">53,929&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">53,930&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market fund</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities (due in less than one year)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Municipal securities (due in less than one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper (due in less than one year)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">79,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">79,403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes (due in less than one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">167,805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">167,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes (due in one to two years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">41,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">41,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">321,417&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">285&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(54)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">321,648&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Cash Equivalents and Marketable Securities with Unrealized Losses</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and marketable securities with unrealized losses that have been in a continuous unrealized loss position for less than 12 months and 12 months or longer at March&#160;31, 2026 and December&#160;31, 2025 were as follows: </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Less Than 12 Months </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">12 Months or Longer </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31, 2026:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Government-sponsored enterprise securities (due in less than one year)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Municipal securities (due in less than one year)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,998&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,998&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Municipal securities (due in one to two years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper (cash equivalent)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,995&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,995&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper (due in less than one year)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes (due in less than one year)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">93,543&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(130)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">93,543&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(130)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes (due in one to two years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">170,934&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(215)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">170,934&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(215)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2025:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes (due in less than one year)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes (due in one to two years)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31,265&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31,265&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">49,252&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(54)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">49,252&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(54)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Instruments Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of March&#160;31, 2026 and December&#160;31, 2025 and indicates the fair value category assigned.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.151%"><tr><td style="width:1.0%"></td><td style="width:37.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices in<br/>Active Markets for<br/>Identical Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other<br/>Observable Inputs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31, 2026:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45,337&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45,337&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Municipal securities</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)(4)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12,038&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12,038&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Government-sponsored enterprises</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,959&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,959&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">71,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">71,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">173,648&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">173,648&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45,611&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">275,187&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">320,798&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sale of future royalties</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129,773&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129,773&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2025:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">50,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">50,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">274&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">274&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Municipal securities</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)(4)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22,951&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22,951&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">84,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">84,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)(4)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">209,253&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">209,253&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">50,831&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">326,627&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">377,458&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.4pt;text-indent:-7.21pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sale of future royalties</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129,582&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129,582&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt">Included in cash and cash equivalents on our condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt">Included in restricted cash on our condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt">Included in current portion of marketable securities on our condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt">Included in noncurrent portion of marketable securities on our condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt">Included in current portion of liabilities related to sale of future royalties on our consolidated balance sheets.</span></div><div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Included in noncurrent portion of liabilities related to sale of future royalties on our consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following as of March&#160;31, 2026 and December&#160;31, 2025: </span></div><div style="margin-bottom:12pt;text-align:center;text-indent:64.8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.818%"><tr><td style="width:1.0%"></td><td style="width:65.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">MARCH 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">DECEMBER 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contract research organization and clinical trial costs</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">38,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Professional, legal and accounting fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued revenue adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30,965&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">51,340&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ScheduleOfAccruedCompensationAndBenefitsTableTextBlock', window );">Schedule of Accrued Compensation and Benefits</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation and benefits consisted of the following as of March&#160;31, 2026 and December&#160;31, 2025:</span></div><div style="margin-bottom:12pt;text-align:center;text-indent:64.8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.818%"><tr><td style="width:1.0%"></td><td style="width:65.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">MARCH 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">DECEMBER 31,<br/>2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued bonuses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued vacation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued restructuring charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,488&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ScheduleOfAccruedCompensationAndBenefitsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Accrued Compensation And Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ScheduleOfAccruedCompensationAndBenefitsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Minimum Payments Under Loan Agreement</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents future minimum payments, including interest and the end of term charge, under the Loan Agreement as of March&#160;31, 2026 (in thousands): </span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.000%"><tr><td style="width:1.0%"></td><td style="width:72.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11,927&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11,960&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">134,966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">170,780&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Less: amount representing interest</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(45,780)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Less: unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5,167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Noncurrent portion of debt</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">119,833&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock', window );">Schedule Of Activity Within Liability Related To Sale Of Future Royalties</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:64.8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity within the liability related to sale of future royalties during the three months ended March&#160;31, 2026: </span></div><div style="text-align:center;text-indent:24.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.121%"><tr><td style="width:1.0%"></td><td style="width:81.003%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Liability Related to Sale of Future Royalties</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of liability related to sale of future royalties at December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">129,582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,912&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Royalty payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,721)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of liability related to sale of future royalties at March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129,773&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of activity within liability related to sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock', window );">Schedule of Reconciliation of Reported Revenues to Net (Loss) Income Under Significant Expense Principle</a></td>
<td class="text">The following table reconciles reported revenues to net (loss) income under the significant expense principle for the three months ended March 31, 2026 and 2025:<div style="margin-bottom:12pt;text-align:center;text-indent:64.8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.727%"><tr><td style="width:1.0%"></td><td style="width:61.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.030%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">51.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">39.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">51.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">39.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and clinical expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chemistry, manufacturing, and control expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other segment expenses*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total interest and other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(19.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*Other segment expenses includes stock-based compensation expense and other general and administrative expenses largely resulting from personnel costs for individuals in administrative functions and legal and professional fees.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Summary of Charges and Spending Related to Restructuring</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:center;text-indent:64.8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.606%"><tr><td style="width:1.0%"></td><td style="width:68.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Restructuring</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of December 31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expenses and adjustments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(13,532)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance as of March 31, 2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,106&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION, PRINCIPLES OF CONSOLIDATION USE OF ESTIMATES AND RECENT ACCOUNTING PRONOUNCEMENTS (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenue</a></td>
<td class="nump">$ 51,837<span></span>
</td>
<td class="nump">$ 39,603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenue</a></td>
<td class="nump">51,771<span></span>
</td>
<td class="nump">39,436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gern_RevenuesBeforeAdjustmentsMember', window );">Gross product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenue</a></td>
<td class="nump">65,353<span></span>
</td>
<td class="nump">45,312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gern_TotalGrossToNetAdjustmentsMember', window );">Total gross-to-net adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenue</a></td>
<td class="num">(13,582)<span></span>
</td>
<td class="num">(5,876)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gern_ChargebacksMember', window );">Chargebacks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenue</a></td>
<td class="num">(8,164)<span></span>
</td>
<td class="num">(4,171)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gern_DistributorServiceFeesMember', window );">Distributor service fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenue</a></td>
<td class="num">(2,169)<span></span>
</td>
<td class="num">(1,526)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gern_GovernmentRebatesMember', window );">Government rebates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenue</a></td>
<td class="num">(1,658)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gern_SalesReturnsAndAllowanceMember', window );">Sales returns and allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenue</a></td>
<td class="num">$ (1,591)<span></span>
</td>
<td class="num">$ (113)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gern_RevenuesBeforeAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gern_RevenuesBeforeAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gern_TotalGrossToNetAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gern_TotalGrossToNetAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gern_ChargebacksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gern_ChargebacksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gern_DistributorServiceFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gern_DistributorServiceFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gern_GovernmentRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gern_GovernmentRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gern_SalesReturnsAndAllowanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gern_SalesReturnsAndAllowanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORY (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 15,603<span></span>
</td>
<td class="nump">$ 8,927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">99,118<span></span>
</td>
<td class="nump">91,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">18,566<span></span>
</td>
<td class="nump">15,740<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 133,287<span></span>
</td>
<td class="nump">$ 116,636<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Cash Equivalents and Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Included in cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="nump">$ 48,722<span></span>
</td>
<td class="nump">$ 53,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_CashAndCashEquivalentsUnrealizedGains', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_CashAndCashEquivalentsUnrealizedLosses', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">48,722<span></span>
</td>
<td class="nump">53,930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsAbstract', window );"><strong>Restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="nump">1,884<span></span>
</td>
<td class="nump">1,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedGains', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsAtFairValue', window );">Fair Value</a></td>
<td class="nump">1,884<span></span>
</td>
<td class="nump">1,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">270,373<span></span>
</td>
<td class="nump">321,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(215)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">270,192<span></span>
</td>
<td class="nump">321,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Included in cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="nump">43,727<span></span>
</td>
<td class="nump">48,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_CashAndCashEquivalentsUnrealizedGains', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_CashAndCashEquivalentsUnrealizedLosses', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">43,727<span></span>
</td>
<td class="nump">48,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsAbstract', window );"><strong>Restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="nump">1,610<span></span>
</td>
<td class="nump">1,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedGains', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsAtFairValue', window );">Fair Value</a></td>
<td class="nump">1,610<span></span>
</td>
<td class="nump">1,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Included in cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="nump">4,995<span></span>
</td>
<td class="nump">4,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_CashAndCashEquivalentsUnrealizedGains', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_CashAndCashEquivalentsUnrealizedLosses', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">4,995<span></span>
</td>
<td class="nump">4,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">71,557<span></span>
</td>
<td class="nump">84,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsAbstract', window );"><strong>Restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedGains', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsAtFairValue', window );">Fair Value</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_USTreasurySecuritiesDueInLessThanOneYearMember', window );">U.S. Treasury securities (due in less than one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">14,980<span></span>
</td>
<td class="nump">22,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">14,985<span></span>
</td>
<td class="nump">22,951<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_MunicipalSecuritiesDueInLessThanOneYearMember', window );">Municipal securities (due in less than one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">10,023<span></span>
</td>
<td class="nump">10,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">10,022<span></span>
</td>
<td class="nump">10,041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_MunicipalSecuritiesDueInOneToTwoYearsMember', window );">Municipal securities (due in one to two years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">2,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">2,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember', window );">Government-sponsored enterprise securities (due in less than one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">2,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">2,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_CommercialPaperDueInLessThanOneYearMember', window );">Commercial paper (due in less than one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">66,584<span></span>
</td>
<td class="nump">79,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(28)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">66,561<span></span>
</td>
<td class="nump">79,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInLessThanOneYearMember', window );">Corporate notes (due in less than one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">149,086<span></span>
</td>
<td class="nump">167,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(130)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">148,979<span></span>
</td>
<td class="nump">167,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember', window );">Corporate notes (due in one to two years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">24,716<span></span>
</td>
<td class="nump">41,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">$ 24,669<span></span>
</td>
<td class="nump">$ 41,289<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_CashAndCashEquivalentsUnrealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the gross unrealized gains for cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_CashAndCashEquivalentsUnrealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_CashAndCashEquivalentsUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the gross unrealized losses for cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_CashAndCashEquivalentsUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash And Cash Equivalents, Gross Unrealized Gains</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_RestrictedCashAndCashEquivalentsGrossUnrealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted cash and cash equivalents gross unrealized losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of all restricted investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_USTreasurySecuritiesDueInLessThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_USTreasurySecuritiesDueInLessThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_MunicipalSecuritiesDueInLessThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_MunicipalSecuritiesDueInLessThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_MunicipalSecuritiesDueInOneToTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_MunicipalSecuritiesDueInOneToTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_CommercialPaperDueInLessThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_CommercialPaperDueInLessThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInLessThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInLessThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Cash Equivalents and Marketable Securities with Unrealized Losses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">$ 170,934<span></span>
</td>
<td class="nump">$ 49,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">170,934<span></span>
</td>
<td class="nump">49,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="num">(215)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(215)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember', window );">Government-sponsored enterprise securities (due in less than one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">2,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">2,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_MunicipalSecuritiesDueInLessThanOneYearMember', window );">Municipal securities (due in less than one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">4,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">4,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_MunicipalSecuritiesDueInOneToTwoYearsMember', window );">Municipal securities (due in one to two years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">2,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">2,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper (cash equivalent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">4,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">4,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_CommercialPaperDueInLessThanOneYearMember', window );">Commercial paper (due in less than one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">37,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">37,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInLessThanOneYearMember', window );">Corporate notes (due in less than one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">93,543<span></span>
</td>
<td class="nump">17,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">93,543<span></span>
</td>
<td class="nump">17,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="num">(130)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(130)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember', window );">Corporate notes (due in one to two years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">24,669<span></span>
</td>
<td class="nump">31,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">24,669<span></span>
</td>
<td class="nump">31,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">$ (47)<span></span>
</td>
<td class="num">$ (38)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_MunicipalSecuritiesDueInLessThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_MunicipalSecuritiesDueInLessThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_MunicipalSecuritiesDueInOneToTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_MunicipalSecuritiesDueInOneToTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_CommercialPaperDueInLessThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_CommercialPaperDueInLessThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInLessThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInLessThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable securities</a></td>
<td class="nump">$ 270,192<span></span>
</td>
<td class="nump">$ 321,648<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">320,798<span></span>
</td>
<td class="nump">377,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Sale of future royalties</a></td>
<td class="nump">129,773<span></span>
</td>
<td class="nump">129,582<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">129,773<span></span>
</td>
<td class="nump">129,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable securities</a></td>
<td class="nump">14,985<span></span>
</td>
<td class="nump">22,951<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable securities</a></td>
<td class="nump">2,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable securities</a></td>
<td class="nump">71,557<span></span>
</td>
<td class="nump">84,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateNoteSecuritiesMember', window );">Corporate notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable securities</a></td>
<td class="nump">173,648<span></span>
</td>
<td class="nump">209,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">45,337<span></span>
</td>
<td class="nump">50,557<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MunicipalBondsMember', window );">Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">12,038<span></span>
</td>
<td class="nump">10,041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">45,611<span></span>
</td>
<td class="nump">50,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Sale of future royalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">45,337<span></span>
</td>
<td class="nump">50,557<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">275,187<span></span>
</td>
<td class="nump">326,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Sale of future royalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable securities</a></td>
<td class="nump">14,985<span></span>
</td>
<td class="nump">22,951<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable securities</a></td>
<td class="nump">2,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable securities</a></td>
<td class="nump">71,557<span></span>
</td>
<td class="nump">84,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable securities</a></td>
<td class="nump">173,648<span></span>
</td>
<td class="nump">209,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">12,038<span></span>
</td>
<td class="nump">10,041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Sale of future royalties</a></td>
<td class="nump">129,773<span></span>
</td>
<td class="nump">129,582<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">129,773<span></span>
</td>
<td class="nump">129,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateNoteSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateNoteSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS - Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent', window );">Contract research organization and clinical trial costs</a></td>
<td class="nump">$ 4,696<span></span>
</td>
<td class="nump">$ 3,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_AccruedManufacturingActivitiesCurrent', window );">Manufacturing activities</a></td>
<td class="nump">16,107<span></span>
</td>
<td class="nump">38,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional, legal and accounting fees</a></td>
<td class="nump">2,632<span></span>
</td>
<td class="nump">881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_GrossToNetAdjustmentsCurrent', window );">Accrued revenue adjustments</a></td>
<td class="nump">5,562<span></span>
</td>
<td class="nump">3,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,968<span></span>
</td>
<td class="nump">1,529<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 30,965<span></span>
</td>
<td class="nump">$ 51,340<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_AccruedManufacturingActivitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet of obligations incurred through the date and payable for manufacturing related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_AccruedManufacturingActivitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_GrossToNetAdjustmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross To Net Adjustments, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_GrossToNetAdjustmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS - Schedule of Accrued Compensation and Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonuses</a></td>
<td class="nump">$ 3,530<span></span>
</td>
<td class="nump">$ 10,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Accrued vacation</a></td>
<td class="nump">2,405<span></span>
</td>
<td class="nump">2,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Accrued restructuring charges</a></td>
<td class="nump">3,106<span></span>
</td>
<td class="nump">17,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">447<span></span>
</td>
<td class="nump">549<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">$ 9,488<span></span>
</td>
<td class="nump">$ 30,497<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483070/710-10-25-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred for employer-related costs classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 01, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 31, 2026</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_DebtInstrumentRoyaltyPaymentRatio', window );">Royalty payment, ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_DebtInstrumentRoyaltyPaymentRatio', window );">Royalty payment, ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gern_PharmakonLoanAgreementMember', window );">Pharmakon Loan Agreement | Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity under term loan</a></td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">10.32%<span></span>
</td>
<td class="nump">10.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gern_PharmakonLoanAgreementMember', window );">Pharmakon Loan Agreement | Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity under term loan</a></td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gern_PharmakonLoanAgreementMember', window );">Pharmakon Loan Agreement | Tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity under term loan</a></td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gern_PharmakonLoanAgreementMember', window );">Pharmakon Loan Agreement | Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Percentage added to prime rate for debt instrument interest rate</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration', window );">Debt instrument, variable interest rate, type flag</a></td>
<td class="text">Secured Overnight Financing Rate (SOFR) [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_DebtInstrumentFloorRate', window );">Floor rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PercentageOfCommitmentAmountToFundLoan', window );">Percentage of commitment amount to fund loan</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gern_PharmakonLoanAgreementMember', window );">Pharmakon Loan Agreement | Term Loans | Prepaid Prior To Third Anniversary Of Funding Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PrepaymentPremiumOnPercentageOfTermLoan', window );">Prepayment premium on percentage of term loan</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gern_PharmakonLoanAgreementMember', window );">Pharmakon Loan Agreement | Term Loans | 3rd Anniversary But, Prior To 4th Anniversary Of Funding Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PrepaymentPremiumOnPercentageOfTermLoan', window );">Prepayment premium on percentage of term loan</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gern_PharmakonLoanAgreementMember', window );">Pharmakon Loan Agreement | Term Loans | 4th Anniversary Of Funding Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PrepaymentPremiumOnPercentageOfTermLoan', window );">Prepayment premium on percentage of term loan</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember', window );">Royalty Pharma Revenue Participation Right Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember', window );">Royalty Pharma Revenue Participation Right Purchase Agreement | Scenario One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PercentageOfAnnualNetSales', window );">Percentage of annual net sales</a></td>
<td class="nump">7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember', window );">Royalty Pharma Revenue Participation Right Purchase Agreement | Scenario Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PercentageOfAnnualNetSales', window );">Percentage of annual net sales</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember', window );">Royalty Pharma Revenue Participation Right Purchase Agreement | Minimum | Scenario Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue interest payments</a></td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember', window );">Royalty Pharma Revenue Participation Right Purchase Agreement | Maximum | Scenario One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue interest payments</a></td>
<td class="nump">$ 500,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=gern_BiopharmaCreditPlcMember', window );">BioPharma Credit PLC | Pharmakon Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Line of credit, maturity period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity under term loan</a></td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_DebtInstrumentFloorRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument floor rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_DebtInstrumentFloorRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_DebtInstrumentRoyaltyPaymentRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Royalty Payment, Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_DebtInstrumentRoyaltyPaymentRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_PercentageOfAnnualNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_PercentageOfAnnualNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_PercentageOfCommitmentAmountToFundLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commitment amount to fund loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_PercentageOfCommitmentAmountToFundLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_PrepaymentPremiumOnPercentageOfTermLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The prepayment premium on percentage of term loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_PrepaymentPremiumOnPercentageOfTermLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of variable interest rate on debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gern_PharmakonLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gern_PharmakonLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=gern_TrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=gern_TrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=gern_TrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=gern_TrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=gern_TrancheCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=gern_TrancheCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=gern_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=gern_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_DebtInstrumentScenarioAxis=gern_ScenarioOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_DebtInstrumentScenarioAxis=gern_ScenarioOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_DebtInstrumentScenarioAxis=gern_ScenarioTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_DebtInstrumentScenarioAxis=gern_ScenarioTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=gern_BiopharmaCreditPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=gern_BiopharmaCreditPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Schedule of Future Minimum Payments Under Loan Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-Term Debt, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2026</a></td>
<td class="nump">$ 11,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2027</a></td>
<td class="nump">11,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2028</a></td>
<td class="nump">11,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2029</a></td>
<td class="nump">134,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LongTermDebtMaturityAfterYearThree', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">170,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedCapitalizedInterestCosts', window );">Less: amount representing interest</a></td>
<td class="num">(45,780)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: unamortized debt discount and issuance costs</a></td>
<td class="num">(5,167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Noncurrent portion of debt</a></td>
<td class="nump">$ 119,833<span></span>
</td>
<td class="nump">$ 119,547<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_LongTermDebtMaturityAfterYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Maturity, After Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_LongTermDebtMaturityAfterYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedCapitalizedInterestCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated interest costs capitalized as part of property, plant and equipment cost basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedCapitalizedInterestCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Schedule of Sale of Future Royalties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_RoyaltiesRollForward', window );"><strong>Royalties [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Carrying value of liability related to sale of future royalties at beginning of period</a></td>
<td class="nump">$ 129,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalty payments</a></td>
<td class="num">(3,721)<span></span>
</td>
<td class="num">$ (3,682)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Carrying value of liability related to sale of future royalties at end of period</a></td>
<td class="nump">129,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember', window );">Royalty Pharma Revenue Participation Right Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_RoyaltiesRollForward', window );"><strong>Royalties [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Carrying value of liability related to sale of future royalties at beginning of period</a></td>
<td class="nump">129,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Interest expense recognized</a></td>
<td class="nump">3,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalty payments</a></td>
<td class="num">(3,721)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Carrying value of liability related to sale of future royalties at end of period</a></td>
<td class="nump">$ 129,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_RoyaltiesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_RoyaltiesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 29, 2025 </div>
<div>action</div>
</th>
<th class="th">
<div>May 16, 2025 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Apr. 16, 2025 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Mar. 14, 2025 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Feb. 19, 2026 </div>
<div>action</div>
</th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>plan</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of putative securities lawsuits</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_NumberOfSeverancePlan', window );">Number of severance plan | plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Restructuring and related cost, number of positions eliminated, period percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligation', window );">Noncancelable commercial purchase commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Long-term manufacturing commitments, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PurchaseObligationWrittenNoticeTerm', window );">Purchase obligation, written notice term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_NumberOfSeverancePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of severance plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_NumberOfSeverancePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_PurchaseObligationWrittenNoticeTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation, Written Notice Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_PurchaseObligationWrittenNoticeTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the recorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Stock options and warrants excluded from diluted net loss per share calculation due to net loss position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential dilutive securities excluded from diluted earnings (loss) per share calculation (in shares)</a></td>
<td class="nump">91,845,095<span></span>
</td>
<td class="nump">80,776,089<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 51,837,000<span></span>
</td>
<td class="nump">$ 39,603,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Cost of goods sold</a></td>
<td class="nump">1,692,000<span></span>
</td>
<td class="nump">1,206,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">14,956,000<span></span>
</td>
<td class="nump">15,078,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="num">(394,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>Selling, general and administrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Commercial expenses</a></td>
<td class="nump">35,425,000<span></span>
</td>
<td class="nump">40,023,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="num">(394,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,642,000)<span></span>
</td>
<td class="num">(19,835,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">51,771,000<span></span>
</td>
<td class="nump">39,436,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">66,000<span></span>
</td>
<td class="nump">167,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=gern_ReportableSegmentMember', window );">Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">51,800,000<span></span>
</td>
<td class="nump">39,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Cost of goods sold</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>Selling, general and administrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment expenses</a></td>
<td class="nump">19,800,000<span></span>
</td>
<td class="nump">19,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Total interest and other income (expense)</a></td>
<td class="num">(3,700,000)<span></span>
</td>
<td class="num">(3,100,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,600,000)<span></span>
</td>
<td class="num">(19,800,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=gern_ReportableSegmentMember', window );">Reportable Segment | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="num">(200,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>Selling, general and administrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="num">(200,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=gern_ReportableSegmentMember', window );">Reportable Segment | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="num">(200,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>Selling, general and administrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="num">(200,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=gern_ReportableSegmentMember', window );">Reportable Segment | Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">51,800,000<span></span>
</td>
<td class="nump">39,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=gern_ReportableSegmentMember', window );">Reportable Segment | Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=gern_ReportableSegmentMember', window );">Reportable Segment | Research and clinical expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">13,000,000.0<span></span>
</td>
<td class="nump">13,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=gern_ReportableSegmentMember', window );">Reportable Segment | Chemistry, manufacturing, and control expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=gern_ReportableSegmentMember', window );">Reportable Segment | Commercial expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>Selling, general and administrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Commercial expenses</a></td>
<td class="nump">$ 17,000,000.0<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=gern_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=gern_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gern_ResearchAndClinicalExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gern_ResearchAndClinicalExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gern_ChemistryManufacturingAndControlExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gern_ChemistryManufacturingAndControlExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gern_CommercialExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gern_CommercialExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Restructuring and related cost, number of positions eliminated, period percent</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring and related cost, incurred cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (394,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING - Summary of Charges and Spending Related to Restructuring (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued, beginning balance</a></td>
<td class="nump">$ 17,032,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expenses and adjustments</a></td>
<td class="num">(394,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="num">(13,532,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued, ending balance</a></td>
<td class="nump">$ 3,106,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>167</ContextCount>
  <ElementCount>217</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>52</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - BASIS OF PRESENTATION, PRINCIPLES OF CONSOLIDATION USE OF ESTIMATES AND RECENT ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTS</Role>
      <ShortName>BASIS OF PRESENTATION, PRINCIPLES OF CONSOLIDATION USE OF ESTIMATES AND RECENT ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - REVENUE RECOGNITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/REVENUERECOGNITION</Role>
      <ShortName>REVENUE RECOGNITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/INVENTORY</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/FINANCIALINSTRUMENTS</Role>
      <ShortName>FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILS</Role>
      <ShortName>OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/DEBT</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - NET LOSS PER COMMON SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/NETLOSSPERCOMMONSHARE</Role>
      <ShortName>NET LOSS PER COMMON SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - SEGMENT REPORTING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/SEGMENTREPORTING</Role>
      <ShortName>SEGMENT REPORTING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - RESTRUCTURING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/RESTRUCTURING</Role>
      <ShortName>RESTRUCTURING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - BASIS OF PRESENTATION, PRINCIPLES OF CONSOLIDATION USE OF ESTIMATES AND RECENT ACCOUNTING PRONOUNCEMENTS (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTSPolicies</Role>
      <ShortName>BASIS OF PRESENTATION, PRINCIPLES OF CONSOLIDATION USE OF ESTIMATES AND RECENT ACCOUNTING PRONOUNCEMENTS (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - REVENUE RECOGNITION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/REVENUERECOGNITIONTables</Role>
      <ShortName>REVENUE RECOGNITION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.geron.com/role/REVENUERECOGNITION</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/INVENTORYTables</Role>
      <ShortName>INVENTORY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.geron.com/role/INVENTORY</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/FINANCIALINSTRUMENTSTables</Role>
      <ShortName>FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.geron.com/role/FINANCIALINSTRUMENTS</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.geron.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSTables</Role>
      <ShortName>OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILS</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/DEBTTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.geron.com/role/DEBT</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - SEGMENT REPORTING (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/SEGMENTREPORTINGTables</Role>
      <ShortName>SEGMENT REPORTING (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.geron.com/role/SEGMENTREPORTING</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - RESTRUCTURING (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/RESTRUCTURINGTables</Role>
      <ShortName>RESTRUCTURING (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.geron.com/role/RESTRUCTURING</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - BASIS OF PRESENTATION, PRINCIPLES OF CONSOLIDATION USE OF ESTIMATES AND RECENT ACCOUNTING PRONOUNCEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTSDetails</Role>
      <ShortName>BASIS OF PRESENTATION, PRINCIPLES OF CONSOLIDATION USE OF ESTIMATES AND RECENT ACCOUNTING PRONOUNCEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.geron.com/role/BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTSPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - REVENUE RECOGNITION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/REVENUERECOGNITIONDetails</Role>
      <ShortName>REVENUE RECOGNITION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.geron.com/role/REVENUERECOGNITIONTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - INVENTORY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/INVENTORYDetails</Role>
      <ShortName>INVENTORY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.geron.com/role/INVENTORYTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - FINANCIAL INSTRUMENTS - Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - FINANCIAL INSTRUMENTS - Cash Equivalents and Marketable Securities with Unrealized Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Cash Equivalents and Marketable Securities with Unrealized Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.geron.com/role/FAIRVALUEMEASUREMENTSTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedLiabilitiesDetails</Role>
      <ShortName>OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS - Schedule of Accrued Compensation and Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedCompensationandBenefitsDetails</Role>
      <ShortName>OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS - Schedule of Accrued Compensation and Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - DEBT - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/DEBTAdditionalInformationDetails</Role>
      <ShortName>DEBT - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - DEBT - Schedule of Future Minimum Payments Under Loan Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails</Role>
      <ShortName>DEBT - Schedule of Future Minimum Payments Under Loan Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - DEBT - Schedule of Sale of Future Royalties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/DEBTScheduleofSaleofFutureRoyaltiesDetails</Role>
      <ShortName>DEBT - Schedule of Sale of Future Royalties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.geron.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - NET LOSS PER COMMON SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/NETLOSSPERCOMMONSHAREDetails</Role>
      <ShortName>NET LOSS PER COMMON SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.geron.com/role/NETLOSSPERCOMMONSHARE</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - SEGMENT REPORTING (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/SEGMENTREPORTINGDetails</Role>
      <ShortName>SEGMENT REPORTING (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.geron.com/role/SEGMENTREPORTINGTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - RESTRUCTURING - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/RESTRUCTURINGAdditionalInformationDetails</Role>
      <ShortName>RESTRUCTURING - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="gern-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - RESTRUCTURING - Summary of Charges and Spending Related to Restructuring (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/RESTRUCTURINGSummaryofChargesandSpendingRelatedtoRestructuringDetails</Role>
      <ShortName>RESTRUCTURING - Summary of Charges and Spending Related to Restructuring (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="gern-20260331.htm">gern-20260331.htm</File>
    <File>gern-20260331.xsd</File>
    <File>gern-20260331_cal.xml</File>
    <File>gern-20260331_def.xml</File>
    <File>gern-20260331_lab.xml</File>
    <File>gern-20260331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="534">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>65
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "gern-20260331.htm": {
   "nsprefix": "gern",
   "nsuri": "http://www.geron.com/20260331",
   "dts": {
    "inline": {
     "local": [
      "gern-20260331.htm"
     ]
    },
    "schema": {
     "local": [
      "gern-20260331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "gern-20260331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "gern-20260331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "gern-20260331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gern-20260331_pre.xml"
     ]
    }
   },
   "keyStandard": 185,
   "keyCustom": 32,
   "axisStandard": 13,
   "axisCustom": 1,
   "memberStandard": 21,
   "memberCustom": 29,
   "hidden": {
    "total": 10,
    "http://fasb.org/us-gaap/2025": 4,
    "http://xbrl.sec.gov/dei/2025": 6
   },
   "contextCount": 167,
   "entityCount": 1,
   "segmentCount": 52,
   "elementCount": 457,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 534,
    "http://xbrl.sec.gov/dei/2025": 30,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://www.geron.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "longName": "9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "longName": "9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "longName": "9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "longName": "9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.geron.com/role/BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTS",
     "longName": "9952157 - Disclosure - BASIS OF PRESENTATION, PRINCIPLES OF CONSOLIDATION USE OF ESTIMATES AND RECENT ACCOUNTING PRONOUNCEMENTS",
     "shortName": "BASIS OF PRESENTATION, PRINCIPLES OF CONSOLIDATION USE OF ESTIMATES AND RECENT ACCOUNTING PRONOUNCEMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.geron.com/role/REVENUERECOGNITION",
     "longName": "9952158 - Disclosure - REVENUE RECOGNITION",
     "shortName": "REVENUE RECOGNITION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.geron.com/role/INVENTORY",
     "longName": "9952159 - Disclosure - INVENTORY",
     "shortName": "INVENTORY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.geron.com/role/FINANCIALINSTRUMENTS",
     "longName": "9952160 - Disclosure - FINANCIAL INSTRUMENTS",
     "shortName": "FINANCIAL INSTRUMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.geron.com/role/FAIRVALUEMEASUREMENTS",
     "longName": "9952161 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILS",
     "longName": "9952162 - Disclosure - OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS",
     "shortName": "OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.geron.com/role/DEBT",
     "longName": "9952163 - Disclosure - DEBT",
     "shortName": "DEBT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.geron.com/role/COMMITMENTSANDCONTINGENCIES",
     "longName": "9952164 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.geron.com/role/NETLOSSPERCOMMONSHARE",
     "longName": "9952165 - Disclosure - NET LOSS PER COMMON SHARE",
     "shortName": "NET LOSS PER COMMON SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.geron.com/role/SEGMENTREPORTING",
     "longName": "9952166 - Disclosure - SEGMENT REPORTING",
     "shortName": "SEGMENT REPORTING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.geron.com/role/RESTRUCTURING",
     "longName": "9952167 - Disclosure - RESTRUCTURING",
     "shortName": "RESTRUCTURING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.geron.com/role/BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTSPolicies",
     "longName": "9955511 - Disclosure - BASIS OF PRESENTATION, PRINCIPLES OF CONSOLIDATION USE OF ESTIMATES AND RECENT ACCOUNTING PRONOUNCEMENTS (Policies)",
     "shortName": "BASIS OF PRESENTATION, PRINCIPLES OF CONSOLIDATION USE OF ESTIMATES AND RECENT ACCOUNTING PRONOUNCEMENTS (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.geron.com/role/REVENUERECOGNITIONTables",
     "longName": "9955512 - Disclosure - REVENUE RECOGNITION (Tables)",
     "shortName": "REVENUE RECOGNITION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "gern:ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "gern:ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.geron.com/role/INVENTORYTables",
     "longName": "9955513 - Disclosure - INVENTORY (Tables)",
     "shortName": "INVENTORY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.geron.com/role/FINANCIALINSTRUMENTSTables",
     "longName": "9955514 - Disclosure - FINANCIAL INSTRUMENTS (Tables)",
     "shortName": "FINANCIAL INSTRUMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.geron.com/role/FAIRVALUEMEASUREMENTSTables",
     "longName": "9955515 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSTables",
     "longName": "9955516 - Disclosure - OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS (Tables)",
     "shortName": "OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.geron.com/role/DEBTTables",
     "longName": "9955517 - Disclosure - DEBT (Tables)",
     "shortName": "DEBT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.geron.com/role/SEGMENTREPORTINGTables",
     "longName": "9955518 - Disclosure - SEGMENT REPORTING (Tables)",
     "shortName": "SEGMENT REPORTING (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.geron.com/role/RESTRUCTURINGTables",
     "longName": "9955519 - Disclosure - RESTRUCTURING (Tables)",
     "shortName": "RESTRUCTURING (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.geron.com/role/BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTSDetails",
     "longName": "9955520 - Disclosure - BASIS OF PRESENTATION, PRINCIPLES OF CONSOLIDATION USE OF ESTIMATES AND RECENT ACCOUNTING PRONOUNCEMENTS (Details)",
     "shortName": "BASIS OF PRESENTATION, PRINCIPLES OF CONSOLIDATION USE OF ESTIMATES AND RECENT ACCOUNTING PRONOUNCEMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R30": {
     "role": "http://www.geron.com/role/REVENUERECOGNITIONDetails",
     "longName": "9955521 - Disclosure - REVENUE RECOGNITION (Details)",
     "shortName": "REVENUE RECOGNITION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-36",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "gern:ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.geron.com/role/INVENTORYDetails",
     "longName": "9955522 - Disclosure - INVENTORY (Details)",
     "shortName": "INVENTORY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails",
     "longName": "9955523 - Disclosure - FINANCIAL INSTRUMENTS - Cash Equivalents and Marketable Securities (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Cash Equivalents and Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails",
     "longName": "9955524 - Disclosure - FINANCIAL INSTRUMENTS - Cash Equivalents and Marketable Securities with Unrealized Losses (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Cash Equivalents and Marketable Securities with Unrealized Losses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails",
     "longName": "9955525 - Disclosure - FAIR VALUE MEASUREMENTS (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedLiabilitiesDetails",
     "longName": "9955526 - Disclosure - OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS - Schedule of Accrued Liabilities (Details)",
     "shortName": "OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS - Schedule of Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "gern:AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "gern:AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedCompensationandBenefitsDetails",
     "longName": "9955527 - Disclosure - OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS - Schedule of Accrued Compensation and Benefits (Details)",
     "shortName": "OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS - Schedule of Accrued Compensation and Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccruedBonusesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "gern:ScheduleOfAccruedCompensationAndBenefitsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccruedBonusesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "gern:ScheduleOfAccruedCompensationAndBenefitsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.geron.com/role/DEBTAdditionalInformationDetails",
     "longName": "9955528 - Disclosure - DEBT - Additional Information (Details)",
     "shortName": "DEBT - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-138",
      "name": "gern:DebtInstrumentRoyaltyPaymentRatio",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-138",
      "name": "gern:DebtInstrumentRoyaltyPaymentRatio",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.geron.com/role/DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails",
     "longName": "9955529 - Disclosure - DEBT - Schedule of Future Minimum Payments Under Loan Agreement (Details)",
     "shortName": "DEBT - Schedule of Future Minimum Payments Under Loan Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.geron.com/role/DEBTScheduleofSaleofFutureRoyaltiesDetails",
     "longName": "9955530 - Disclosure - DEBT - Schedule of Sale of Future Royalties (Details)",
     "shortName": "DEBT - Schedule of Sale of Future Royalties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccruedRoyaltiesCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-140",
      "name": "us-gaap:AccruedRoyaltiesCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "gern:ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.geron.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "longName": "9955531 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-145",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "unitRef": "lawsuit",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-145",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "unitRef": "lawsuit",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.geron.com/role/NETLOSSPERCOMMONSHAREDetails",
     "longName": "9955532 - Disclosure - NET LOSS PER COMMON SHARE (Details)",
     "shortName": "NET LOSS PER COMMON SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-149",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-149",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.geron.com/role/SEGMENTREPORTINGDetails",
     "longName": "9955533 - Disclosure - SEGMENT REPORTING (Details)",
     "shortName": "SEGMENT REPORTING (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:NumberOfOperatingSegments",
       "us-gaap:NumberOfReportableSegments",
       "us-gaap:NumberOfOperatingSegments",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.geron.com/role/RESTRUCTURINGAdditionalInformationDetails",
     "longName": "9955534 - Disclosure - RESTRUCTURING - Additional Information (Details)",
     "shortName": "RESTRUCTURING - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-167",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-167",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.geron.com/role/RESTRUCTURINGSummaryofChargesandSpendingRelatedtoRestructuringDetails",
     "longName": "9955535 - Disclosure - RESTRUCTURING - Summary of Charges and Spending Related to Restructuring (Details)",
     "shortName": "RESTRUCTURING - Summary of Charges and Spending Related to Restructuring (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20260331.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "gern_APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation related to issuances of common stock and options for services (in shares)",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition, Shares",
        "documentation": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r33",
      "r38",
      "r975"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r720"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion and amortization on investments, net",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedCompensationandBenefitsDetails": {
       "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedCompensationandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued bonuses",
        "label": "Accrued Bonuses, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract research organization and clinical trial costs",
        "label": "Accrued Clinical Research Organizations And Clinical Trial Costs, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Accrued liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "gern_AccruedManufacturingActivitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "AccruedManufacturingActivitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing activities",
        "label": "Accrued Manufacturing Activities, Current",
        "documentation": "Carrying value as of the balance sheet of obligations incurred through the date and payable for manufacturing related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional, legal and accounting fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/DEBTScheduleofSaleofFutureRoyaltiesDetails",
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of future royalties",
        "periodStartLabel": "Carrying value of liability related to sale of future royalties at beginning of period",
        "periodEndLabel": "Carrying value of liability related to sale of future royalties at end of period",
        "label": "Accrued Royalties",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_AccruedVacationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedVacationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedCompensationandBenefitsDetails": {
       "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedCompensationandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued vacation",
        "label": "Accrued Vacation, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r33"
     ]
    },
    "us-gaap_AccumulatedCapitalizedInterestCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedCapitalizedInterestCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: amount representing interest",
        "label": "Accumulated Capitalized Interest Costs",
        "documentation": "Amount of accumulated interest costs capitalized as part of property, plant and equipment cost basis."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r51",
      "r97",
      "r520",
      "r556",
      "r557",
      "r983"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r11",
      "r16",
      "r410",
      "r413",
      "r469",
      "r552",
      "r553",
      "r848",
      "r849",
      "r850",
      "r906",
      "r907",
      "r908",
      "r909"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r906",
      "r907",
      "r908",
      "r909",
      "r984",
      "r1043"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Noncash Item [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation for equity-based awards to employees and directors",
        "label": "APIC, Share-Based Payment Arrangement, ESPP, Increase for Cost Recognition",
        "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r386"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation related to issuances of common stock and options for services",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r943",
      "r948"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r748",
      "r758",
      "r768",
      "r800"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r761",
      "r771",
      "r803"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r762",
      "r772",
      "r796",
      "r804",
      "r808",
      "r816"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance costs/debt discounts",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r683",
      "r684",
      "r897",
      "r998"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.geron.com/role/NETLOSSPERCOMMONSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential dilutive securities excluded from diluted earnings (loss) per share calculation (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.geron.com/role/NETLOSSPERCOMMONSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.geron.com/role/NETLOSSPERCOMMONSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails",
      "http://www.geron.com/role/DEBTScheduleofSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r79",
      "r95",
      "r116",
      "r119",
      "r120",
      "r154",
      "r164",
      "r182",
      "r186",
      "r225",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r400",
      "r402",
      "r450",
      "r508",
      "r509",
      "r516",
      "r601",
      "r672",
      "r673",
      "r685",
      "r720",
      "r727",
      "r728",
      "r739",
      "r940",
      "r941",
      "r1000"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r99",
      "r116",
      "r119",
      "r120",
      "r225",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r400",
      "r402",
      "r450",
      "r720",
      "r940",
      "r941",
      "r1000"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425",
      "r708"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesAbstract",
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities:",
        "label": "Debt Securities, Available-for-Sale [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.geron.com/role/BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTSPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "gern_BiopharmaCreditPlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "BiopharmaCreditPlcMember",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioPharma Credit PLC",
        "label": "BioPharma Credit PLC [Member]",
        "documentation": "BioPharma credit PLC."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAbstract",
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Included in cash and cash equivalents:",
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and restricted cash",
        "label": "Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure",
        "documentation": "Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r94",
      "r650"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_CashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r446",
      "r447",
      "r986",
      "r987"
     ]
    },
    "gern_CashAndCashEquivalentsUnrealizedGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "CashAndCashEquivalentsUnrealizedGains",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_CashEquivalentsAtCarryingValue",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Cash And Cash Equivalents, Unrealized Gains",
        "documentation": "Represents the gross unrealized gains for cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "gern_CashAndCashEquivalentsUnrealizedLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "CashAndCashEquivalentsUnrealizedLosses",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_CashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Unrealized Losses",
        "label": "Cash And Cash Equivalents, Unrealized Losses",
        "documentation": "Represents the gross unrealized losses for cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r56",
      "r115"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r56"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r835",
      "r1010"
     ]
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails",
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certificate of deposit",
        "verboseLabel": "Certificate of deposit",
        "label": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r734",
      "r735",
      "r736",
      "r737"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "gern_ChargebacksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "ChargebacksMember",
     "presentation": [
      "http://www.geron.com/role/REVENUERECOGNITIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chargebacks",
        "label": "Chargebacks [Member]",
        "documentation": "Chargeback and distributor service fees."
       }
      }
     },
     "auth_ref": []
    },
    "gern_ChemistryManufacturingAndControlExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "ChemistryManufacturingAndControlExpensesMember",
     "presentation": [
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chemistry, manufacturing, and control expenses",
        "label": "Chemistry Manufacturing And Control Expenses [Member]",
        "documentation": "Chemistry, manufacturing, and control expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "gern_CommercialExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "CommercialExpensesMember",
     "presentation": [
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial expenses",
        "label": "Commercial Expenses [Member]",
        "documentation": "Commercial expenses."
       }
      }
     },
     "auth_ref": []
    },
    "gern_CommercialPaperDueInLessThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "CommercialPaperDueInLessThanOneYearMember",
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper (due in less than one year)",
        "label": "Commercial Paper Due In Less Than One Year [Member]",
        "documentation": "Represents information pertaining to unsecured promissory note (generally negotiable) that provides institutions with short-term funds ), due in less than one year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails",
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper",
        "netLabel": "Commercial paper (cash equivalent)",
        "verboseLabel": "Commercial paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r279",
      "r734",
      "r735",
      "r736",
      "r737"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r73",
      "r517",
      "r588"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.geron.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r271",
      "r272",
      "r644",
      "r926",
      "r934"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r731",
      "r732",
      "r734",
      "r735",
      "r736",
      "r737",
      "r906",
      "r907",
      "r909",
      "r984",
      "r1041",
      "r1043"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "periodEndLabel": "Balance at end of period (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r42",
      "r589",
      "r607",
      "r1043",
      "r1044"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, Value, Issued",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r322",
      "r328",
      "r519",
      "r720"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r104",
      "r106",
      "r110",
      "r506",
      "r527",
      "r528"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.geron.com/role/BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTSPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r663"
     ]
    },
    "gern_CorporateNoteSecuritiesDueInLessThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "CorporateNoteSecuritiesDueInLessThanOneYearMember",
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate notes (due in less than one year)",
        "label": "Corporate Note Securities Due In Less Than One Year [Member]",
        "documentation": "This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest), due in less than one year."
       }
      }
     },
     "auth_ref": []
    },
    "gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "CorporateNoteSecuritiesDueInOneToTwoYearsMember",
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate notes (due in one to two years)",
        "label": "Corporate Note Securities Due In One To Two Years [Member]",
        "documentation": "This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest), due in one to two years."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateNoteSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateNoteSecuritiesMember",
     "presentation": [
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate notes",
        "label": "Corporate Note Securities [Member]",
        "documentation": "This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r116",
      "r122",
      "r123",
      "r293",
      "r331",
      "r470",
      "r487",
      "r515",
      "r655",
      "r656",
      "r657",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r979",
      "r980",
      "r981",
      "r982"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r939"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r939"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.geron.com/role/DEBT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DEBT",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r116",
      "r118",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r278",
      "r279",
      "r289",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r305",
      "r312",
      "r313",
      "r315",
      "r408",
      "r462"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r32",
      "r33",
      "r70",
      "r72",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r719",
      "r900",
      "r901",
      "r902",
      "r905",
      "r927",
      "r928",
      "r929",
      "r997",
      "r999",
      "r1008"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage added to prime rate for debt instrument interest rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r72",
      "r316"
     ]
    },
    "gern_DebtInstrumentFloorRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "DebtInstrumentFloorRate",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Floor rate",
        "label": "Debt Instrument, Floor Rate",
        "documentation": "Debt instrument floor rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective interest rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r318",
      "r462",
      "r463",
      "r719"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails",
      "http://www.geron.com/role/DEBTScheduleofSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r314",
      "r408",
      "r511",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r719",
      "r900",
      "r901",
      "r902",
      "r905",
      "r997",
      "r999"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r719",
      "r900",
      "r901",
      "r902",
      "r905",
      "r927",
      "r928",
      "r929",
      "r997",
      "r999",
      "r1008"
     ]
    },
    "gern_DebtInstrumentRoyaltyPaymentRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "DebtInstrumentRoyaltyPaymentRatio",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty payment, ratio",
        "label": "Debt Instrument, Royalty Payment, Ratio",
        "documentation": "Debt Instrument, Royalty Payment, Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "gern_DebtInstrumentScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "DebtInstrumentScenarioAxis",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Scenario [Axis]",
        "label": "Debt Instrument, Scenario [Axis]",
        "documentation": "Debt Instrument, Scenario"
       }
      }
     },
     "auth_ref": []
    },
    "gern_DebtInstrumentScenarioDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "DebtInstrumentScenarioDomain",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Scenario [Domain]",
        "label": "Debt Instrument, Scenario [Domain]",
        "documentation": "Debt Instrument, Scenario [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails",
      "http://www.geron.com/role/DEBTScheduleofSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r24",
      "r25",
      "r29",
      "r65",
      "r66",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r314",
      "r408",
      "r511",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r719",
      "r900",
      "r901",
      "r902",
      "r905",
      "r997",
      "r999"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: unamortized debt discount and issuance costs",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r317",
      "r461",
      "r462",
      "r463",
      "r681",
      "r682",
      "r719"
     ]
    },
    "us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentVariableInterestRateTypeExtensibleEnumeration",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, variable interest rate, type flag",
        "label": "Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]",
        "documentation": "Indicates type of variable interest rate on debt instrument."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss",
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "12 Months or Longer",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r236",
      "r678"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "12 Months or Longer",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r236"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less Than 12 Months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r236",
      "r678"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less Than 12 Months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r236"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails",
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "verboseLabel": "Marketable securities",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current",
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncurrent marketable securities",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Noncurrent",
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities Available For Sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r234",
      "r678"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r235"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash Equivalents and Marketable Securities with Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r678",
      "r925"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract",
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_DepositsAndOtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "DepositsAndOtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits and other assets",
        "label": "Deposits And Other Assets, Noncurrent",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer; and amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r22"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.geron.com/role/REVENUERECOGNITIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r345",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.geron.com/role/REVENUERECOGNITIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r345",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694"
     ]
    },
    "gern_DistributorServiceFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "DistributorServiceFeesMember",
     "presentation": [
      "http://www.geron.com/role/REVENUERECOGNITIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distributor service fees",
        "label": "Distributor Service Fees [Member]",
        "documentation": "Distributor Service Fees"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net loss per share (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r111",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r142",
      "r144",
      "r147",
      "r148",
      "r149",
      "r153",
      "r320",
      "r385",
      "r393",
      "r398",
      "r421",
      "r422",
      "r507",
      "r529",
      "r664"
     ]
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://www.geron.com/role/NETLOSSPERCOMMONSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r147",
      "r149"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net loss per share (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r111",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r144",
      "r147",
      "r148",
      "r149",
      "r153",
      "r320",
      "r385",
      "r393",
      "r398",
      "r421",
      "r422",
      "r507",
      "r529",
      "r664"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.geron.com/role/NETLOSSPERCOMMONSHARE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NET LOSS PER COMMON SHARE",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r150",
      "r151",
      "r152"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net effect of exchange rates on cash, cash equivalents and restricted cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedCompensationandBenefitsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedCompensationandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and benefits",
        "totalLabel": "Accrued compensation and benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r87",
      "r88",
      "r89",
      "r107",
      "r108",
      "r109",
      "r125",
      "r126",
      "r127",
      "r129",
      "r136",
      "r138",
      "r140",
      "r155",
      "r226",
      "r227",
      "r250",
      "r319",
      "r334",
      "r385",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r394",
      "r397",
      "r398",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r420",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r464",
      "r465",
      "r469",
      "r525",
      "r552",
      "r553",
      "r554",
      "r562",
      "r627"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r748",
      "r758",
      "r768",
      "r800"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r745",
      "r755",
      "r765",
      "r797"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value on a Recurring Basis",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425",
      "r435",
      "r708"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425",
      "r435",
      "r708"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash Equivalents, Restricted Cash and Marketable Securities",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r448",
      "r648",
      "r718",
      "r995"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r434",
      "r435",
      "r437",
      "r444",
      "r474",
      "r475",
      "r476",
      "r648",
      "r681",
      "r682",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r708",
      "r711",
      "r718"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r430",
      "r432",
      "r433",
      "r434",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r505",
      "r708",
      "r712"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r348",
      "r353",
      "r354",
      "r425",
      "r435",
      "r444",
      "r474",
      "r648",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r708",
      "r718"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r348",
      "r353",
      "r354",
      "r356",
      "r425",
      "r426",
      "r435",
      "r444",
      "r475",
      "r648",
      "r681",
      "r682",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r708",
      "r718"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r425",
      "r426",
      "r427",
      "r428",
      "r435",
      "r444",
      "r476",
      "r648",
      "r681",
      "r682",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r708",
      "r711",
      "r718"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r434",
      "r435",
      "r437",
      "r444",
      "r474",
      "r475",
      "r476",
      "r648",
      "r681",
      "r682",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r708",
      "r711",
      "r718"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails",
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r237",
      "r238",
      "r314",
      "r332",
      "r408",
      "r419",
      "r442",
      "r449",
      "r452",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r514",
      "r526",
      "r678",
      "r708",
      "r709",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r721",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r919",
      "r920",
      "r921",
      "r922",
      "r985",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994"
     ]
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCIAL INSTRUMENTS",
        "label": "Financial Instruments Disclosure [Text Block]",
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r762",
      "r772",
      "r804"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r762",
      "r772",
      "r804"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r762",
      "r772",
      "r804"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r762",
      "r772",
      "r804"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r762",
      "r772",
      "r804"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "gern_GovernmentRebatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "GovernmentRebatesMember",
     "presentation": [
      "http://www.geron.com/role/REVENUERECOGNITIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government rebates",
        "label": "Government Rebates [Member]",
        "documentation": "Government rebates."
       }
      }
     },
     "auth_ref": []
    },
    "gern_GrossToNetAdjustmentsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "GrossToNetAdjustmentsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued revenue adjustments",
        "label": "Gross To Net Adjustments, Current",
        "documentation": "Gross To Net Adjustments, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r258",
      "r263",
      "r404",
      "r405",
      "r406",
      "r407",
      "r429",
      "r431",
      "r436",
      "r451",
      "r452",
      "r453",
      "r549",
      "r551",
      "r612",
      "r647",
      "r648",
      "r701",
      "r702",
      "r706",
      "r707",
      "r710",
      "r718",
      "r977",
      "r978",
      "r1012"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r263",
      "r404",
      "r405",
      "r406",
      "r407",
      "r429",
      "r431",
      "r436",
      "r451",
      "r452",
      "r453",
      "r549",
      "r551",
      "r612",
      "r647",
      "r648",
      "r701",
      "r702",
      "r706",
      "r707",
      "r710",
      "r718",
      "r977",
      "r978",
      "r1012"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, net",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "gern_IncreaseDecreaseInAllowanceForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "IncreaseDecreaseInAllowanceForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in allowance for doubtful accounts",
        "label": "Increase (Decrease) In Allowance For Doubtful Accounts",
        "documentation": "Increase (Decrease) In Allowance For Doubtful Accounts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and benefits",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) In Operating Lease Liabilities",
        "documentation": "Increase (Decrease) In Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r762",
      "r772",
      "r796",
      "r804",
      "r808",
      "r816"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r820"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r820"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r820"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r659",
      "r662",
      "r852"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total interest and other income (expense)",
        "label": "Interest Income (Expense), Nonoperating",
        "documentation": "Amount of interest income (expense) classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r705",
      "r852",
      "r913"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest payable",
        "label": "Interest Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory Disclosure [Abstract]",
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.geron.com/role/INVENTORY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVENTORY",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/INVENTORYDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/INVENTORYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r652"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.geron.com/role/INVENTORYDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.geron.com/role/INVENTORYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r651",
      "r720"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/INVENTORYDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/INVENTORYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r654"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/INVENTORYDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/INVENTORYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work-in-process",
        "label": "Inventory, Work in Process, Net of Reserves",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r653"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r167",
      "r186",
      "r672",
      "r851"
     ]
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "IssuanceOfCommonStockInConnectionWithWarrantExerciseValue",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with exercise of warrants",
        "label": "Issuance Of Common Stock In Connection With Warrant Exercise Value",
        "documentation": "Equity impact of the value of stock issued in connection with exercise of warrants during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r32",
      "r33",
      "r34",
      "r37",
      "r38",
      "r39",
      "r40",
      "r116",
      "r119",
      "r120",
      "r225",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r401",
      "r402",
      "r403",
      "r450",
      "r587",
      "r666",
      "r685",
      "r739",
      "r940",
      "r1000",
      "r1001"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r74",
      "r522",
      "r720",
      "r727",
      "r728",
      "r900",
      "r904",
      "r923",
      "r996"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r93",
      "r116",
      "r119",
      "r120",
      "r225",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r401",
      "r402",
      "r403",
      "r450",
      "r720",
      "r940",
      "r1000",
      "r1001"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r986"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities:",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_LiabilityRelatedToSaleOfFutureRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability related to sale of future royalties",
        "label": "Liability Related To Sale Of Future Royalties, Current",
        "documentation": "Liability Related To Sale Of Future Royalties, Current"
       }
      }
     },
     "auth_ref": []
    },
    "gern_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncurrent liability related to sale of future royalties",
        "label": "Liability Related To Sale Of Future Royalties, Noncurrent",
        "documentation": "Noncurrent liability related to sale of future royalties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityExpirationPeriod",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit, maturity period",
        "label": "Line of Credit Facility, Expiration Period",
        "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum borrowing capacity under term loan",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r36"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtByMaturityAbstract",
     "presentation": [
      "http://www.geron.com/role/DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Fiscal Year Maturity [Abstract]",
        "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r117",
      "r124",
      "r307",
      "r511"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r117",
      "r124",
      "r307",
      "r511"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r117",
      "r124",
      "r307",
      "r511"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r901",
      "r905"
     ]
    },
    "gern_LongTermDebtMaturityAfterYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "LongTermDebtMaturityAfterYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Long-Term Debt, Maturity, After Year Three",
        "documentation": "Long-Term Debt, Maturity, After Year Three"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.geron.com/role/DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.geron.com/role/DEBTScheduleofFutureMinimumPaymentsUnderLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncurrent debt",
        "totalLabel": "Noncurrent portion of debt",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermPurchaseCommitmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term manufacturing commitments, amount",
        "label": "Long-Term Purchase Commitment, Amount",
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyNewClaimsFiledNumber",
     "presentation": [
      "http://www.geron.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of putative securities lawsuits",
        "label": "Loss Contingency, New Claims Filed, Number",
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period."
       }
      }
     },
     "auth_ref": [
      "r935",
      "r936"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r159",
      "r274",
      "r275",
      "r276",
      "r277",
      "r357",
      "r380",
      "r381",
      "r382",
      "r387",
      "r428",
      "r503",
      "r548",
      "r550",
      "r558",
      "r577",
      "r578",
      "r630",
      "r632",
      "r633",
      "r634",
      "r636",
      "r638",
      "r639",
      "r640",
      "r641",
      "r645",
      "r646",
      "r677",
      "r686",
      "r700",
      "r701",
      "r703",
      "r704",
      "r711",
      "r712",
      "r716",
      "r717",
      "r723",
      "r942",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r159",
      "r274",
      "r275",
      "r276",
      "r277",
      "r357",
      "r380",
      "r381",
      "r382",
      "r387",
      "r428",
      "r503",
      "r548",
      "r550",
      "r558",
      "r577",
      "r578",
      "r630",
      "r632",
      "r633",
      "r634",
      "r636",
      "r638",
      "r639",
      "r640",
      "r641",
      "r645",
      "r646",
      "r677",
      "r686",
      "r700",
      "r701",
      "r703",
      "r704",
      "r711",
      "r712",
      "r716",
      "r723",
      "r942",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails",
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "verboseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r946",
      "r947"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_MunicipalBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MunicipalBondsMember",
     "presentation": [
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Municipal securities",
        "label": "Municipal Bonds [Member]",
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments."
       }
      }
     },
     "auth_ref": []
    },
    "gern_MunicipalSecuritiesDueInLessThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "MunicipalSecuritiesDueInLessThanOneYearMember",
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Municipal securities (due in less than one year)",
        "verboseLabel": "Municipal securities (due in less than one year)",
        "label": "Municipal Securities Due In Less Than One Year [Member]",
        "documentation": "Municipal securities due in less than one year."
       }
      }
     },
     "auth_ref": []
    },
    "gern_MunicipalSecuritiesDueInOneToTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "MunicipalSecuritiesDueInOneToTwoYearsMember",
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Municipal securities (due in one to two years)",
        "label": "Municipal Securities Due In One To Two Years [Member]",
        "documentation": "Municipal Securities Due In One To Two Years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r58"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r58",
      "r75",
      "r89",
      "r91",
      "r103",
      "r105",
      "r109",
      "r116",
      "r119",
      "r120",
      "r121",
      "r128",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r139",
      "r140",
      "r146",
      "r225",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r320",
      "r323",
      "r325",
      "r329",
      "r385",
      "r393",
      "r398",
      "r422",
      "r450",
      "r524",
      "r608",
      "r625",
      "r626",
      "r659",
      "r661",
      "r662",
      "r738",
      "r940"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.geron.com/role/BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTSPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r762",
      "r772",
      "r796",
      "r804"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "gern_NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense on liabilities for sales of future royalties",
        "label": "Noncash Interest Expense On Liabilities For Sales Of Future Royalties",
        "documentation": "Noncash Interest Expense On Liabilities For Sales Of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NontradeReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NontradeReceivablesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest and other receivables",
        "label": "Nontrade Receivables, Current",
        "documentation": "The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.geron.com/role/BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTSDetails",
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r673",
      "r912"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r676",
      "r912"
     ]
    },
    "gern_NumberOfSeverancePlan": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "NumberOfSeverancePlan",
     "presentation": [
      "http://www.geron.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of severance plan",
        "label": "Number Of Severance Plan",
        "documentation": "Number of severance plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of goods sold",
        "label": "Operating Costs and Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total costs and operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs and operating expenses:",
        "verboseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r659",
      "r662",
      "r667",
      "r911",
      "r913",
      "r914",
      "r915",
      "r916"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncurrent operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases, right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.geron.com/role/BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BASIS OF PRESENTATION, PRINCIPLES OF CONSOLIDATION USE OF ESTIMATES AND RECENT ACCOUNTING PRONOUNCEMENTS",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r834",
      "r898"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustment",
        "verboseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r525"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net unrealized gain (loss) on marketable securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r102",
      "r224"
     ]
    },
    "us-gaap_OtherEmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherEmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedCompensationandBenefitsDetails": {
       "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedCompensationandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued other",
        "label": "Other Employee-related Liabilities, Current",
        "documentation": "Amount of obligations incurred for employer-related costs classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r705"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r750",
      "r760",
      "r770",
      "r802"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r763",
      "r773",
      "r805"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r763",
      "r773",
      "r805"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payables and Accruals [Abstract]",
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/role/RESTRUCTURINGSummaryofChargesandSpendingRelatedtoRestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments",
        "label": "Payments for Restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r896"
     ]
    },
    "us-gaap_PaymentsForRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRoyalties",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.geron.com/role/DEBTScheduleofSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on royalty agreement",
        "negatedTerseLabel": "Royalty payments",
        "label": "Payments for Royalties",
        "documentation": "The amount of cash paid for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "gern_PaymentsUnpaidToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "PaymentsUnpaidToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments (Unpaid) To Acquire Property, Plant, And Equipment",
        "documentation": "Payments (Unpaid) To Acquire Property, Plant, And Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "gern_PercentageOfAnnualNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "PercentageOfAnnualNetSales",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of annual net sales",
        "label": "Percentage Of Annual Net Sales",
        "documentation": "Percentage of annual net sales."
       }
      }
     },
     "auth_ref": []
    },
    "gern_PercentageOfCommitmentAmountToFundLoan": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "PercentageOfCommitmentAmountToFundLoan",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of commitment amount to fund loan",
        "label": "Percentage Of Commitment Amount To Fund Loan",
        "documentation": "Percentage of commitment amount to fund loan."
       }
      }
     },
     "auth_ref": []
    },
    "gern_PharmakonLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "PharmakonLoanAgreementMember",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharmakon Loan Agreement",
        "label": "Pharmakon Loan Agreement [Member]",
        "documentation": "Pharmakon loan agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r330"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, Value, Issued",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r322",
      "r327",
      "r518",
      "r720"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4th Anniversary Of Funding Date",
        "label": "Prepaid On Or After Fourth Anniversary Of Funding Date [Member]",
        "documentation": "Prepaid on or after fourth anniversary of funding date."
       }
      }
     },
     "auth_ref": []
    },
    "gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3rd Anniversary But, Prior To 4th Anniversary Of Funding Date",
        "label": "Prepaid On Or After Third Anniversary But Prior To Fourth Anniversary Of Funding Date [Member]",
        "documentation": "Prepaid on or after third anniversary but prior to fourth anniversary of funding date."
       }
      }
     },
     "auth_ref": []
    },
    "gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "PrepaidPriorToThirdAnniversaryOfFundingDateMember",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Prior To Third Anniversary Of Funding Date",
        "label": "Prepaid Prior To Third Anniversary Of Funding Date [Member]",
        "documentation": "Prepaid prior to third anniversary of funding date."
       }
      }
     },
     "auth_ref": []
    },
    "gern_PrepaymentPremiumOnPercentageOfTermLoan": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "PrepaymentPremiumOnPercentageOfTermLoan",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment premium on percentage of term loan",
        "label": "Prepayment Premium on Percentage of Term Loan",
        "documentation": "The prepayment premium on percentage of term loan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuances of common stock from equity plans",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities and sales of marketable securities",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the exercise of warrants",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductMember",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.geron.com/role/REVENUERECOGNITIONDetails",
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product revenue, net",
        "verboseLabel": "Net product revenue",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r658",
      "r662",
      "r687",
      "r688"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.geron.com/role/REVENUERECOGNITIONDetails",
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r504",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r649",
      "r658",
      "r661",
      "r662",
      "r687",
      "r688",
      "r722",
      "r723",
      "r724",
      "r726",
      "r729",
      "r826",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r891",
      "r892",
      "r893",
      "r894",
      "r937",
      "r938",
      "r1011",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.geron.com/role/REVENUERECOGNITIONDetails",
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r504",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r649",
      "r658",
      "r661",
      "r662",
      "r687",
      "r688",
      "r722",
      "r723",
      "r724",
      "r726",
      "r729",
      "r826",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r891",
      "r892",
      "r893",
      "r894",
      "r937",
      "r938",
      "r1011",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r468",
      "r512",
      "r523",
      "r720"
     ]
    },
    "gern_PurchaseObligationWrittenNoticeTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "PurchaseObligationWrittenNoticeTerm",
     "presentation": [
      "http://www.geron.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase obligation, written notice term",
        "label": "Purchase Obligation, Written Notice Term",
        "documentation": "Purchase Obligation, Written Notice Term"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r159",
      "r274",
      "r275",
      "r276",
      "r277",
      "r347",
      "r357",
      "r380",
      "r381",
      "r382",
      "r384",
      "r387",
      "r428",
      "r477",
      "r486",
      "r503",
      "r548",
      "r550",
      "r558",
      "r577",
      "r578",
      "r630",
      "r632",
      "r633",
      "r634",
      "r636",
      "r638",
      "r639",
      "r640",
      "r641",
      "r645",
      "r646",
      "r677",
      "r686",
      "r700",
      "r701",
      "r703",
      "r704",
      "r711",
      "r712",
      "r716",
      "r717",
      "r723",
      "r732",
      "r930",
      "r942",
      "r989",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r159",
      "r274",
      "r275",
      "r276",
      "r277",
      "r347",
      "r357",
      "r380",
      "r381",
      "r382",
      "r384",
      "r387",
      "r428",
      "r477",
      "r486",
      "r503",
      "r548",
      "r550",
      "r558",
      "r577",
      "r578",
      "r630",
      "r632",
      "r633",
      "r634",
      "r636",
      "r638",
      "r639",
      "r640",
      "r641",
      "r645",
      "r646",
      "r677",
      "r686",
      "r700",
      "r701",
      "r703",
      "r704",
      "r711",
      "r712",
      "r716",
      "r717",
      "r723",
      "r732",
      "r930",
      "r942",
      "r989",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007"
     ]
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTable",
     "presentation": [
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Assets from Segment to Consolidated [Table]",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table]",
        "documentation": "Disclosure of information about identification, description, and amounts of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21"
     ]
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.geron.com/role/SEGMENTREPORTINGTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Reported Revenues to Net (Loss) Income Under Significant Expense Principle",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r21"
     ]
    },
    "us-gaap_RecordedUnconditionalPurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RecordedUnconditionalPurchaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncancelable commercial purchase commitments",
        "label": "Recorded Unconditional Purchase Obligation",
        "documentation": "Amount of the recorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts)."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r745",
      "r755",
      "r765",
      "r797"
     ]
    },
    "gern_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r116",
      "r122",
      "r123",
      "r293",
      "r331",
      "r470",
      "r487",
      "r515",
      "r655",
      "r656",
      "r657",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r979",
      "r980",
      "r981",
      "r982"
     ]
    },
    "gern_ResearchAndClinicalExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "ResearchAndClinicalExpensesMember",
     "presentation": [
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and clinical expenses",
        "label": "Research And Clinical Expenses [Member]",
        "documentation": "Research and clinical expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseAbstract",
     "presentation": [
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r746",
      "r756",
      "r766",
      "r798"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r747",
      "r757",
      "r767",
      "r799"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r754",
      "r764",
      "r774",
      "r806"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "totalLabel": "Amortized Cost",
        "label": "Restricted Cash and Cash Equivalent, Current",
        "documentation": "Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r94",
      "r115"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "gern_RestrictedCashAndCashEquivalentsGrossUnrealizedGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "RestrictedCashAndCashEquivalentsGrossUnrealizedGains",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Restricted Cash And Cash Equivalents, Gross Unrealized Gains",
        "documentation": "Restricted Cash And Cash Equivalents, Gross Unrealized Gains"
       }
      }
     },
     "auth_ref": []
    },
    "gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "RestrictedCashAndCashEquivalentsGrossUnrealizedLosses",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross Unrealized Losses",
        "label": "Restricted Cash And Cash Equivalents, Gross Unrealized Losses",
        "documentation": "Restricted cash and cash equivalents gross unrealized losses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndInvestmentsAbstract",
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash:",
        "label": "Restricted Cash and Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedInvestmentsAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedInvestmentsAtFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Restricted Investments, at Fair Value",
        "documentation": "The aggregate value of all restricted investments."
       }
      }
     },
     "auth_ref": [
      "r631",
      "r635",
      "r637",
      "r642",
      "r643"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.geron.com/role/RESTRUCTURING"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RESTRUCTURING",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r262",
      "r265",
      "r270"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/role/RESTRUCTURINGAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and related cost, incurred cost",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r264",
      "r267",
      "r269"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.geron.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.geron.com/role/RESTRUCTURINGAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and related cost, number of positions eliminated, period percent",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.geron.com/role/RESTRUCTURINGAdditionalInformationDetails",
      "http://www.geron.com/role/RESTRUCTURINGSummaryofChargesandSpendingRelatedtoRestructuringDetails",
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges",
        "verboseLabel": "Expenses and adjustments",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r112",
      "r113",
      "r266",
      "r267",
      "r660",
      "r931"
     ]
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/role/RESTRUCTURINGSummaryofChargesandSpendingRelatedtoRestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Accrued, beginning balance",
        "periodEndLabel": "Accrued, ending balance",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r268"
     ]
    },
    "us-gaap_RestructuringReserveCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringReserveCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedCompensationandBenefitsDetails": {
       "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSScheduleofAccruedCompensationandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued restructuring charges",
        "label": "Restructuring Reserve, Current",
        "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r932",
      "r933"
     ]
    },
    "us-gaap_RestructuringReserveRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringReserveRollForward",
     "presentation": [
      "http://www.geron.com/role/RESTRUCTURINGSummaryofChargesandSpendingRelatedtoRestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Reserve [Roll Forward]",
        "label": "Restructuring Reserve [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r67",
      "r521",
      "r555",
      "r557",
      "r560",
      "r590",
      "r720"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r125",
      "r126",
      "r127",
      "r129",
      "r136",
      "r138",
      "r140",
      "r226",
      "r227",
      "r250",
      "r319",
      "r385",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r394",
      "r397",
      "r398",
      "r409",
      "r411",
      "r412",
      "r414",
      "r420",
      "r464",
      "r465",
      "r552",
      "r554",
      "r562",
      "r1043"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.geron.com/role/REVENUERECOGNITIONDetails",
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenues",
        "verboseLabel": "Net product revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r154",
      "r165",
      "r166",
      "r180",
      "r186",
      "r189",
      "r191",
      "r192",
      "r343",
      "r344",
      "r345",
      "r504",
      "r659",
      "r662"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue interest payments",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r154",
      "r165",
      "r166",
      "r180",
      "r186",
      "r189",
      "r191",
      "r192",
      "r343",
      "r344",
      "r345",
      "r504"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.geron.com/role/REVENUERECOGNITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUE RECOGNITION",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r345",
      "r346"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_RevenuesBeforeAdjustmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "RevenuesBeforeAdjustmentsMember",
     "presentation": [
      "http://www.geron.com/role/REVENUERECOGNITIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross product revenue",
        "label": "Revenues Before Adjustments [Member]",
        "documentation": "Revenues before adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "gern_RoyaltiesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "RoyaltiesRollForward",
     "presentation": [
      "http://www.geron.com/role/DEBTScheduleofSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties [Roll Forward]",
        "label": "Royalties [Roll Forward]",
        "documentation": "Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/role/DEBTScheduleofSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense recognized",
        "label": "Royalty Expense",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties",
        "label": "Royalty [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r944",
      "r945"
     ]
    },
    "gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails",
      "http://www.geron.com/role/DEBTScheduleofSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Pharma Revenue Participation Right Purchase Agreement",
        "label": "Royalty Pharma Revenue Participation Right Purchase Agreement [Member]",
        "documentation": "Royalty Pharma Revenue Participation Right Purchase Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "gern_SalesReturnsAndAllowanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "SalesReturnsAndAllowanceMember",
     "presentation": [
      "http://www.geron.com/role/REVENUERECOGNITIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales returns and allowances",
        "label": "Sales Returns And Allowance [Member]",
        "documentation": "Sales returns and allowance."
       }
      }
     },
     "auth_ref": []
    },
    "gern_ScenarioOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "ScenarioOneMember",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario One",
        "label": "Scenario One [Member]",
        "documentation": "Scenario one."
       }
      }
     },
     "auth_ref": []
    },
    "gern_ScenarioTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "ScenarioTwoMember",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario Two",
        "label": "Scenario Two [Member]",
        "documentation": "Scenario two ."
       }
      }
     },
     "auth_ref": []
    },
    "gern_ScheduleOfAccruedCompensationAndBenefitsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "ScheduleOfAccruedCompensationAndBenefitsTableTextBlock",
     "presentation": [
      "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Compensation and Benefits",
        "label": "Schedule Of Accrued Compensation And Benefits [Table Text Block]",
        "documentation": "Schedule Of Accrued Compensation And Benefits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.geron.com/role/OTHERCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTDETAILSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock",
     "presentation": [
      "http://www.geron.com/role/DEBTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Activity Within Liability Related To Sale Of Future Royalties",
        "label": "Schedule Of Activity Within Liability Related To Sale Of Future Royalties [Table Text Block]",
        "documentation": "Schedule of activity within liability related to sale of future royalties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available For Sale Securities [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "presentation": [
      "http://www.geron.com/role/NETLOSSPERCOMMONSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]",
        "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r147",
      "r149"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Instruments Measured at Fair Value on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r986",
      "r987"
     ]
    },
    "gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock",
     "presentation": [
      "http://www.geron.com/role/REVENUERECOGNITIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Gross Product Sales to Net Product Sales",
        "label": "Schedule Of Gross To Net Sales Adjustments [Table Text Block]",
        "documentation": "Schedule of gross to net sales adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.geron.com/role/INVENTORYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r48",
      "r49",
      "r50"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.geron.com/role/DEBTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Payments Under Loan Agreement",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "presentation": [
      "http://www.geron.com/role/RESTRUCTURINGTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Charges and Spending Related to Restructuring",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r61"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r78",
      "r79",
      "r154",
      "r161",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r188",
      "r192",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r264",
      "r269",
      "r395",
      "r396",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r669",
      "r672",
      "r673",
      "r679",
      "r725",
      "r1011",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingAssetReconcilingItemLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAssetReconcilingItemLineItems",
     "presentation": [
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting, Asset Reconciling Item [Line Items]",
        "label": "Segment Reporting, Asset Reconciling Item [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.geron.com/role/SEGMENTREPORTING"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEGMENT REPORTING",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r154",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r176",
      "r178",
      "r179",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r192",
      "r668",
      "r670",
      "r671",
      "r672",
      "r674",
      "r675",
      "r676"
     ]
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other segment expenses",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r178",
      "r179",
      "r186",
      "r672"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "verboseLabel": "Commercial expenses",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r658",
      "r659",
      "r660",
      "r662",
      "r890"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r701",
      "r702"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Award Types",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383"
     ]
    },
    "gern_SignificantAccountingPoliciesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "SignificantAccountingPoliciesPolicyPolicyTextBlock",
     "presentation": [
      "http://www.geron.com/role/BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTSPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies, Policy [Policy Text Block]",
        "documentation": "Significant Accounting Policies, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.geron.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r78",
      "r79",
      "r90",
      "r154",
      "r161",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r188",
      "r192",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r252",
      "r264",
      "r269",
      "r395",
      "r396",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r669",
      "r672",
      "r673",
      "r679",
      "r725",
      "r1011",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r42",
      "r45",
      "r46",
      "r87",
      "r88",
      "r89",
      "r107",
      "r108",
      "r109",
      "r125",
      "r126",
      "r127",
      "r129",
      "r136",
      "r138",
      "r140",
      "r155",
      "r226",
      "r227",
      "r250",
      "r319",
      "r334",
      "r385",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r394",
      "r397",
      "r398",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r420",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r464",
      "r465",
      "r469",
      "r525",
      "r552",
      "r553",
      "r554",
      "r562",
      "r627"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r155",
      "r321",
      "r322",
      "r324",
      "r326",
      "r465",
      "r504",
      "r559",
      "r563",
      "r564",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r589",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r610",
      "r611",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r627",
      "r661",
      "r662",
      "r733",
      "r1042"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r155",
      "r193",
      "r321",
      "r322",
      "r324",
      "r326",
      "r465",
      "r504",
      "r559",
      "r563",
      "r564",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r589",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r610",
      "r611",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r627",
      "r661",
      "r662",
      "r733",
      "r1042"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r749",
      "r759",
      "r769",
      "r801"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974"
     ]
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://www.geron.com/role/NETLOSSPERCOMMONSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options and warrants excluded from diluted net loss per share calculation due to net loss position",
        "label": "Share-Based Payment Arrangement [Member]",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "gern_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of pre-funded warrant (in shares)",
        "label": "Stock Issued During Period, Shares, Exercise Of Prefunded Warrant",
        "documentation": "Stock Issued During Period, Shares, Exercise Of Prefunded Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under equity plans (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r41",
      "r42",
      "r67"
     ]
    },
    "gern_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of pre-funded warrant",
        "label": "Stock Issued During Period, Value, Exercise Of Prefunded Warrant",
        "documentation": "Stock Issued During Period, Value, Exercise Of Prefunded Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuances of common stock under equity plans",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r41",
      "r42",
      "r67"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at end of period",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r45",
      "r46",
      "r59",
      "r591",
      "r607",
      "r628",
      "r629",
      "r720",
      "r739",
      "r900",
      "r903",
      "r904",
      "r923",
      "r996",
      "r1043"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfInvestmentHoldingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SummaryOfInvestmentHoldingsLineItems",
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Investment Holdings [Line Items]",
        "label": "Summary of Investment Holdings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r579",
      "r580",
      "r609",
      "r732"
     ]
    },
    "us-gaap_SummaryOfInvestmentHoldingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SummaryOfInvestmentHoldingsTable",
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Holdings [Table]",
        "label": "Investment Holdings [Table]",
        "documentation": "Disclosure of information about summary of investment holding, including, but not limited to, investment with value exceeding one percent of net asset value of registrant."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r579",
      "r580",
      "r609",
      "r732"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "gern_TermLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "TermLoansMember",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loans",
        "label": "Term Loans [Member]",
        "documentation": "Term loans."
       }
      }
     },
     "auth_ref": []
    },
    "gern_TotalGrossToNetAdjustmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "TotalGrossToNetAdjustmentsMember",
     "presentation": [
      "http://www.geron.com/role/REVENUERECOGNITIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total gross-to-net adjustments",
        "label": "Total Gross To Net Adjustments [Member]",
        "documentation": "Total gross to net adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "gern_TrancheAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "TrancheAMember",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche A",
        "label": "Tranche A [Member]",
        "documentation": "Tranche A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TrancheBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "TrancheBMember",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche B",
        "label": "Tranche B [Member]",
        "documentation": "Tranche B [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TrancheCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "TrancheCMember",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche C",
        "label": "Tranche C [Member]",
        "documentation": "Tranche C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails",
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r314",
      "r332",
      "r408",
      "r419",
      "r442",
      "r449",
      "r452",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r514",
      "r526",
      "r708",
      "r709",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r721",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r919",
      "r920",
      "r921",
      "r922",
      "r985",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails",
      "http://www.geron.com/role/DEBTScheduleofSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember",
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritieswithUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government-sponsored enterprise securities (due in less than one year)",
        "label": "U S Government Sponsored Enterprises Debt Securities Due In Less Than One Year [Member]",
        "documentation": "Represents information pertaining to debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae, due in less than one year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "presentation": [
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government-sponsored enterprise securities",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae)."
       }
      }
     },
     "auth_ref": [
      "r946",
      "r947",
      "r1009"
     ]
    },
    "us-gaap_USTreasuryNotesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasuryNotesSecuritiesMember",
     "presentation": [
      "http://www.geron.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasury securities",
        "label": "US Treasury Notes Securities [Member]",
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one to ten years, are interest bearing, and are backed by the full faith and credit of the United States government."
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "gern_USTreasurySecuritiesDueInLessThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "USTreasurySecuritiesDueInLessThanOneYearMember",
     "presentation": [
      "http://www.geron.com/role/FINANCIALINSTRUMENTSCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasury securities (due in less than one year)",
        "label": "U S Treasury Securities Due In Less Than One Year [Member]",
        "documentation": "US Treasury Securities Due In less than one Year Member."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "gern_UpfrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20260331",
     "localname": "UpfrontPaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/role/DEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment received",
        "label": "Upfront Payment Received",
        "documentation": "Upfront payment received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.geron.com/role/BASISOFPRESENTATIONPRINCIPLESOFCONSOLIDATIONUSEOFESTIMATESANDRECENTACCOUNTINGPRONOUNCEMENTSPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r156",
      "r157",
      "r158",
      "r159",
      "r508",
      "r510",
      "r665"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares used in calculating diluted net loss per share (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r149"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.geron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares used in calculating basic net loss per share (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r149"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483070/710-10-25-3"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-6"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481117/718-50-35-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/825/tableOfContent"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-9"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-4"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478600/954-210-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-13"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>66
<FILENAME>0000886744-26-000032-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000886744-26-000032-xbrl.zip
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MICD*# <"X<T.?!==:MZ6KOJ%#>-V4U]0C5(.!IQG@$#SF@T@+:,9;J9S%_H
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M)L\5N*N8 W^N0A2@)=_3D/RZU?U F:GQJG"5R6(\:Q '@[<\6)3W54 _C2K
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M<[CC,D==)DICPI7G#Z)E,LV, 4FK) *RR"+F&T^P$'([$RF4""E,BRW:I$W
M#>>=7.]RMH82;J2D:2'&:RD%%Y!_GI:ES#A!75-20HJBL /V[^0&$T@V&$,<
M*<K*"H._%\-5+*W\\6"3@#_+G1#>.[&=S,HT\P\;B]1 -FZ:CI1UG"OG+&44
M<:.$D$_X-]B8*8[A2>LTY5E#,>.(JY 2NQG>UI+2C*J-87Y/2H,@*YO@QWO
MJLKJ%D1PE2EXC+>FY6.]RA0DU=5!.<L[EN0B-6OZ17<K2I[[RN@#OVG&T%(:
MG%Z*6,D@1/'3T-)0>%__0WF&$+>=) 2*E:/FT/D#Q>@A$,>KSTQ !"(O TRE
M\SRU7?0V&31A-:U2*7,-H$>@M%6-HXF!6NB,LH7.($%EQP+I"B.71(S=RRS%
M=A0==":5!?-'>K*0)B8+IYM+F \R!+^[)K=BL%3.+/=R+%UQ5KF!L<%G)(6I
M?A +BO, O(W3Z(ISUPT6PTGC<(/EL73$N2R=TW91&$OQ "AF*4>F_>%.=[J^
M@3=%R-W&L;19OE 2.,I\JZ"OL2"+2A:.EN,7RC*G@!R#.?"6,1PVP9G58_4[
M;+O*7GU[V^G;>J"T6"X-9U>T%LM+6QGP.UW5V,$:VJ&F9+TIB[1P<25&D#LC
M>D%&@5^66>:$=\5@*9G) -KO+!OKH#4EEY1DRLE &H,/1'*:S-\'[G EI/S$
M4N1.1?0H;"6S5/J7>B<Q^2N5<-(Q^',)"7J(JU1Y&E-%2E;2H&VC/5R05_J/
M9DME!B),!0K.UXI2*4M)>*WQ1AE*%JGPO[E,'6I&..1KL >.6RL$2=<+":R3
M @YPO#<.P(&4I0%I'5(H)DASBJI'B?XRUWJ1_%.>C3Q'"3+8@ -(ACN=("[I
M$KYYN&NW0[+I&OCZ0]> M==)O4$1I7J9W'3MR@KCD A^(&5[)((?A;E*9N<L
M^ &>VPK3_LFJ&E%VHI",U)]ZNRS';"X=U9_,V>ETLYIMNUX?2I#AL8&#\K&]
M^;AIYY_UL--VZI-F/=]VG96%.I3!H]2]0_<=3!2%Q$US4<9"("8K@TG<QU]P
MD1(>G4S TQS"/M^^Y7^;?-17=Q-Y0Q=5[)ZU:0)H8$X!K,U89:@93X7RI8ZR
M&>>IMW>;DO "R[DM([\7 ^8*4H"0]$A@3=M.'.4_"5-<GDD;M1YK4)K:>AS5
MKOW1TODHHS'<U81C?YP+)W]XC'<@1Z9&_] P&UM6_99RRAWI@US-X#B.&L2.
MS+]B6]E.B"9/W#BD7.4[NNAXQ=(\?P$,\HXX32I4=Y0HC$RES[SC"6?,J&TJ
MX/KS9YQ#3(WIHNS%RVGU>7(7ZUR,%E0B .'_-'J68J<V$>L5B( H?QC]-!)U
M47*K:!:ML?RGOI0:R:[&:EF]GE/23*#XJ&L./D+7*+'*[PV3F@2@3;VOFHJ$
M@^,OC3(-/RG!Y[MXE&(T7<%,+20:7([*RG=5D#:Z2]X906Z@TA?7.-&R72]T
M1UB1-LI$_B0HI!U$Q:)AEIA$TI^[*26/42EEQ(>ZR%+N3\!5&'%WE/&K^W9=
MSY:D?4*\(@[-]'ZLB2P' ;@*=TV+#\021;G5RGHOQA-5*OP)YG<=7_VE7FV6
MFK+A6\""^(L&Z'LQ9LDM:-M[K-[$%NN6L'N(8CC,D62&4' L<VIC554 M\G+
M,;1=;K]L*2O=G!<V)GPG9XV+S @B!RKG4!)8?(7),$K+29X&2!RFP:W,\\Q)
M_1J%F^2Y\*>?YRK-3.UM#BEM3RD:5I9.HI\XS%5E 62GID$3*K+<MJ/?B6,4
M667Z7!$HJK#25AC>B^4X"X ;1#2]*7/7<_CV!6U[4!29K=R_%Q,6PLI)>K.3
M&!/B^!DE><=(L?]>C%>I-/>OHDB3\5Y<;]IE,V](Q[]Y]:X,* 4/8<#I0.6Q
M\?F>DCI9R !)G61F-ALGQ.W<(K%L C\PTONQI8+HK? G%)I$#J' J;L H%':
M3F K\_FV]9V'*$Q2>U??4ZJV*"2/"[DNT@9^+F-A:MCOCYFF5!V Z\=5_0XB
MFJ6(SW516/5TO^LU@RO-N&1#@T$9'[&O5 B",VZ;F5KR'KW_E8K##'8V;:/G
MS4TSKY=+PI83@QC7)4@0HPT+$0"N/X7R'/:II:-I$86W9*4,4 47;(P1D#V(
ME-J"L]S,5!V%7(P;ED/:K@4+,0PZA:-EVO Q'RWLN_O7245NB-8A$EG<T]:Y
M>9[;R"I:@^&4F?]P+CEQ'R\JNXY8?2!.T/FGM<4(XR0NGV$OL_@&W8@HCIA@
M/ "(TQXQ2I%%P85=1Z1'3'#+%QLFS!A:PI4(&;>ED%O<VU)R5X$F7(AD5L I
M6M\GI=6Z\VZ]EH>5#4H@0)G&',"+,H@HIFVX7UPOVN6RIF2VS_)4O9\BE,QL
MC]OSN*F=[-&JW:X'0GTQB7)GCM&[*(Z;1-YT?T+?8J3#_LOZOB56)BBE;8:]
MDP-7%BGSUX2;!*..K*JT<MQMO A TD+=_,Y"3!9,AU-.2>X<+HC"7NC\16#2
M8OII<L,PX%UQHP4H0!#,X@ H,"D,6PX.JO^Z;9#.WFI"#.T3(?Y*'T1!IWS1
M(I-T9/ AA2#*$?@\/V<A"&$5."^N_P0[97@\<5Q\L)0\>Y/]-8,LV3LHEFE%
M3=6++-G^2LGPDH2T07$R;]=K/<>?H.S]*:<@7HA0N*+N4/ RP'R2X-58.L 9
MB0-=D=_]4')67/4)O+M5LS8?E-1]4J\3O=HLVT>MD_;&XH(O#_5(ZMN.5 C1
M:)*P@&$,Z=4O6!$+N9#(1E9R)&)/2(5-2^F<Y_"GQQ1FII74-T"67+W47O$[
M \*P=%U<]T,[_TP)5&0I<Q3P_7,P8=1@:>]B)DUMR=>KCY,;[0:_E5)!2^9&
MCC1>@\DJ+;*@$B,06YB2QVT']RDI++BT5+_Q&J]4]G8]^Q8TJZ03.!6'J:HB
M!)=ZD5KJRV9%B:^4;L;@\GG-/D0T0FTZR"-LUST,M]-BV]'"?^%*<VG61G'4
M^"@D& /#,\_YZ81@A!FB(<:7Y@$:9'#6LIV2=]-2:IS!M<;980_S';G-(#?>
M%"CRD3K()6X0?.P7#B&UY1!N6QXZ%_^VR4[1[:XA3.8$YV;D+=JZ21A(JK+C
MQ!?7ME"*W2Q:@%GA.'MQV*P4!ECJMY!B;,-02D2*BAG*@O<2JR!/D+]KG,J,
MA42Q8)?F4@QI@424:8 $W$:6#PUE T!*N,G>45H@I3)D Y[&*XUFD^D"$ [&
MR'RLD4=[TO(B@#B68",7R+WN:0>F$>F8O:/3ALA'X7W:=IE;3=E,9\S).QFE
MY9@T5<;SS[D5%TZZWBCB?A5 A&X26;4255KRYX"56&\VQ%!7!_4\[Z/&E 'W
M7EPC@(:8$*UXOJ[3:-+ESSGN3HI-$EDLO&E[>L1%34BJD%>VDG&* C<WPHFT
M+&K</Y^$2-EJ&;0WR13*;:@@Y<2[A%!>+JC[\.#!(V$C98;%\FU;!9EV)+=5
M/M9^_8RUTZ)#W"8EX5L!^<&A"W18[@A3C]2>$F7< ACRZ=11\A0B.[R+:S**
M4U>5J3\%PXX\?;O&\@TE"I#CN+-KIC\&@Z'DES\GUU0@TB@1E1V3XX3<7'D0
M>8G)0*0Y^ O7919%R B7MFVV1! S"HB&5,RG2R#Y9[A\FC34$$(Y3U8<QH*K
M6?GSSTPGUA!%[IPX",&D1FXP".29=R O,X-IQ1GZ?NB:.:G)) J>'Y.BB]IF
M".S(@TS0F>CPCI0- X$ +HQ1# =,RM+@/ST7LE,^VJZ;@9+=*:^."+B<0&@H
M"QX Z3 54%%9&<*;HQ$$49>A9,4# /98MI,5HV0%RKC35E'<6BH+(;H@F:5\
MFR,M_'))&6<HF3NGYN*PF(0XW+L,-0G4$%)N'=$1RN=4:2?M>4L9"Q77%%!*
M*&?OBF\"X%UR:K[*/+?1MI\3KM@86!OFE$4]Z-_]H*JK9">L>IG<M0_Z7G>7
MB?F.X4XGI@J=V.)F,C()(,G: 5,/_,6?]:S;UMUCPO++A$-,>9G<M%U2J.PR
MRS)B#^(?QI,R]Z@B%7%X"I&5XRROR5Y[)'Z:MZL5;""[S9#/9YWH+[J;-[U&
M1K^Y88?Z)P8W6K+176)^,/F .Q.9I7AV1<7F)G)N%N,YXU6F5B$"#TWR5W/,
M:&LP 4!0HC",:1?7QD3LZD<TVW*)=&Y#L]YJ]!]8(4RH1_ CX_@J,CK6R;">
M0LEQ0@0/^B^Z6R64T07+[,#*B=#K)34DFC%NPZDPO9N!%!;-D(1 _F.\CW_9
M4DR @E,P0_KD>?J8Z09=7/\!.1@1"'E)R:TDK%>+UF9E80L2OE-:S/!O]MO9
M?^DY(<".L]()S(K16W+. ]#<3('\B\,F<HT<1''4N)!6*B$"! E7F5-CY0@T
M-@7UR ^'F##8*2,5D\5BE6/L.$K#Y;DY^;[%*\,M#H=N#M^^H)671?26<*"W
M8KSB!,_\H<BL&L4$D"&<$NM4I2XMYQB/GY#"\HE$P,(G5&Y5[F(-4$2>!2 A
MXG(4S$'.?4J>KU*E[R@1$&5EQMG/OYTF</3D=$0;Y):3&0\A!S<)'RDA/7&1
M)$9I.X@KA+_+Y+8)PTI*S"%S$@+'&)D@AM2_S,PK0UB^4W>BQ"!*TUX_&@B!
MW%XH'Q<"=%Y9>:>Y7@_-/25X#UQ'%G,XJ3A/_84DX$.X,=G?EO6:L!.@P%_P
M=Y1U(Y O&(<4.8[/T<*)C,JF%+'(;$F^*[BM]!K!873[I\JMKN"1W+1@Q >]
M"L'*("RGMNE*)*09"(-'D2[FJB,0[%,+'C.A["ROKU8">YHCIR1[@5"S.#31
ML>:&Q A](V6VR:VXIY^K5&,R5>_P$I3==^Z$2P2A_J,^;9RIK][9WVBR8I0K
MW<+=UBT?:96 X,BYXJ,HCAFV (6_A\Q&7]]OYX0-)%[FJ3JFZB>YM<HJ #'*
MKJ+&.66?EMF5'&762QBP##'+AC3#*9X+$6.";_'G)Q9(?]ZL+"Q )UJ#J<QV
M,'WGRBL3</P';2N]X!;9$:LG1!H1_T%EA&:*D69C0PK-E%EQ7-ECZN!0LLR0
MOY\_%E.RTF8F)V+,ISYJ$GV:OV069.+&,3Z-)^(,$BNN*-DWBL+)]15C/42B
M5)C_9!P;"W/M=NC!D O:23'!C\A.-(' 1"''F7]@,A'RRJ]V',)3H"M"(H$J
MCX4\?SI4FN5QE9DEM8>&!+_T'X.8")]WEEN1I-/<KHK:=BRK D!$D=_,7J\X
M3V_I&I/:3.3?-7V"WB99U(_),SF$!%M+B-Y.QDP&![EQ0O=@>/UR]S5X%OP1
MVLUA]%3.>ZH;4YI(F&*02XH; I)ZL3 ?4R^3D0IB!I^PVN]$V$"=-J7Y9+/M
M^BW2C(S[JEFM]**I![U\3."CYQH#0UC;&K;;7%\>$I.8=@PU[L&_[$VZ^R"B
MBX1]!'>?V+/?X%:RJO2&J09^9'YWN'=6X/SV1"2ZAK_$KL-N?QZRXO0CNX5N
M<-?"1DX^-#\>?#XQO<5Y;S^11T-I@=O/O,D=W5+2K,TV^5EO:OOSR7[@WERU
M?]=+7>/V ]_6F>\''SA[-'\WT\.#UNMG[LX"/^!+JTV]?J1$ZN'&\T\F27>>
MK&)!<K&*C05-I/Q:(%\7>+QZUFZM&\2O)GCAMC>7>RXPPO:C= \P9%5PM&!%
M#:OF$(HK?Y7>R@B.CK<;=8<<XAX78"]&"\(!X]Z0E+Q(GX.($DC$* ?5A:J<
ML@='@.V2H^5%SD+T9LNQ#:9O;B!%-@R+E)-\V5$I/3)RHU4B0(MV/W39T0XA
MNKBI(G2:,E-6-=%[YM)$9A^:YD?:;JV+HRI&VW%F^JQ^"T'=UG)'\J?K;ME
M^MS>)!^^4%JRDL[.492FK H;J_G%+LQHQ8VF_+)I[(]0,WN>=P::\V@Z>YG)
MI6T"2DKE64J;U9_B=(]*/91]O@)VT.&2O,]Y;KAS[#EOQX8/L?@R6/1X\2VG
M9GYGJ@B0E#!NN.(@3'HDO%M9@7[@@&[Y=/@V1F['0J05/^Q%>[=P>2K,6?Q0
MU]AOZ#3AS!]G^>E&?"=@3LXJ.^,8!O&R@E]S1ZD=JUA:. A_HG"C7*D 98+"
M3$G4-_"*DBDA3(603G1B%.83.^UPOX7(D:!I!V^AG"R  W=$)G)ZBQ4R !/Y
M%-@K!.0,S#'E$H>I($WP9]#:R_'5E"V+JG#G=S'82F8C1;=OZ&C3.(OMHPP<
MI126_"):BTEO+YCSL7S2WB3_JKMVG=!2Z*JL<IZR8PRT4(]&8/;LS5,G52H/
MA@"3FE)B=C\?<<;ET2*/!1>++6.365AT(6&]D)L'B98/K\S3[+ &$RZ!)Q]9
M8:Q,CY@!DIN.\1 *WU(H,V4*!C-@W>&N7K^>8$ @Y8?9;"RJ);8XD]BT'[\9
M:;6;M45LPI6,^E8'R$WBNSDJ23N40H\$?@Z^Q_(9O#4[0WBN9&:>ZS0=L>R)
M9>2M)<_;9=M]^L'^MJO?^ (*2U+[':^@.,HKP/W[$4GY,/Z_U]W0S.OE> 3Z
M[49W+J"X83" 75X_?RW-&CQ6,[SZ9;NO_Y^/S7JAOWQB%PFXK9M_N?BA650U
MK$ NZH+74FE5S\J2P9=NJGFVJ'3QG^SBFJ6__^?Z^OGA/OSGP4'?'\[]$?[X
M\?7+F-7SS[==NUTO/H[V_+/Y<S5KNX7N/K'-EP2^M5DD/_P$?ZY0%13\YL?[
MIF]FS;(9'C_5VZ&]NEFV]6!?Y9-QLZN=HZG0SZSJ[K99?V(9?";^4++_MZL6
M7CE\Q,.GNV:QT.NK#<X<@56S)_MU>EDC _$+[W*PXC=,#58M(&"S[&&'WSM:
MS_(>N5[AJP_\CL\XE=,M"CK<P9.^;I7Y%P\+@TE9G+CE^;0&YI]C(>>V<0=_
M;.=;C"_,3Z24K91,!I"Y$$JFV0NJ#@B=ELNDW\Y6C;D>;:VC6=^WS1S6@7-:
MK[LNR8V&O\.037_9Z'6O:4'3)K,^;^!1Q6))K%61EFH'5X'M@S+")SXY!\Z
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MQ3.[CEA](#;P@LZ$3K&7QUVA?0 #TG7RP.5'P@Q]9IT\_X,OQJ"<5HF-'_:
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MUBQS83.@XR#["FKP 42A98C9<\ME-MQU[?:64(*)9<RT)HZ#%=G!%TG!(C*
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M4:2.EEI\QXOS+"W]>9CALC-8GKM3CW ?K$3 UG$4P%CYW&[\3(?=#E8KLP
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M>,A96-*-6*I8NB9P$9B>26WR@GX_ TKHNWF5GHZ@MR2_JH2P94V_[DAF.(+
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MOZOO]4XH!^):1.(NVOG6PG#76B\PV&W!SZTV<$<@&G=]KQ_MP&V'JCJ#GH\
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MK]W?ZT_RE PF;E9?8*<G@-N"5R,MIRAV'5,LQ&QR$LA.T+P><[Z)(E@\B#?
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MIY-:W]D5.[S(@HCFR<(\=66Q9^8-=R_^7P!:H!7)12Q(2&(>Q7G;K=OFL5J
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M:G[/-DY,(6$^>EEW-IM_2CAS:/YEV3S+LIOS?"\P#/-W$'04EJO;:]2QG@S
M1R999BU  4MD V:JQI4)[I\;W?4:N5%%O0$"N,>K>009Q_%*[!  L]X?@[<S
M[VQ-!T5@Q+V<#R@ZOYE:-EP!#W7+S_\T2CJ,XT='*_/'4^3XE$R2!='K<_*O
M5[<_/6I,%@*5XSY6(:Q-L;$4A()4\]Y$VSMR^:"W4B%J0A#+X]['E9UL_BNP
MDR-P?S)O.:JI #NA,!=CA(0H-EQ>./E67SR, U8L&HU)@03Z2,R5!Y"TI/]
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M[!)%K$2(?CHX(EBIC/NRQ=Q8,A]%XD<1K")+O5L1D\)T4RJM7LQ9;D5\ HQ
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M[J^EJDNT]7%PNDNPILSE";Q3RK9_OGZ][!95-Z^;#BQ'[W6R*OM-JQ/41I0
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M6-*MB_GF9(\&JW@P^B>HLI VS S  C@D)2%#:U5X;VV7QIIIV8^N28Q"&[+
M"VM13!WTG>#88.GJ&8?$A*@:.^T"!_:'+X"N65#*^F]UC&@:7AD.?Q?C.W4U
M).@EMN(+_'"]M,G['S^E#55Z0S['(XKP.''0%F(J&S6H9J>,1)I<@*_64BK4
M_4DVY"$MU6OALE<'$HLDSS$VJ@T/-S,6QP[:V1HDQA4D\7:26#$[?KB:W,/Z
M8XIIK),J*F,]N:OJ$K*1$B=6YEDO+!81)+^$P[H-34*BDUE5S1<37@+R.V^B
M-=V)'8GN'0:J56%$F[CQ^&M5J3PWZN/&,F\=5&U*%)+"$(66@X>+UG?H2C16
MI[SN*;D_;4%B\/55,:V_<5#;R0TIZBX!-@Z*WNEM8OI@0&D;J0NZ]_98PB&Y
M^55G;FI9L%T0\Q!P3)G2O.X=*F&BA9]>G.J2? $( "'RE&5C>/%AF50<HOT!
M._!G$%7A2RP1K1>KH.I\[X]4C)!6$%*IS_&,+ZY!&W5(DH7I3R2R_;!?2ER(
M;2&3"/UR_@Z2WU4^4/Q\.[@7.QI%K+]H)&.&-'H9^(.V@V?6/!M)'/@:N,DB
M[*#FL-0\J&9\#MB"2A-B[2'VPUS]=8^7MIKQ>\A">A9M[!CQ)5JD6>J =O,P
M!)T8ME-%^V KY@3S0(@&SLE%D-] &HL:1GE?C473AEZY9X^=Z9N8BVM8T@2D
M-;(W!O/N:5'!6=E5X3+J#^0C)D:<%B6D():65[3EJ'SPM331?<H^Y!,C1$.+
MH_E@J@A%8=P?9=G(A;XX%=.I& ,"'!0=;VS9Q;R(Y"-*'6A(MF O#LD=P.Q8
M%"\\BS'=N.!#)*\+XCL,#A_W=^RU"(YC+:?J01$\0LPTF)C4L^9[*<K\.E_P
M^:H@7KT*Y(X:*(AUD"_DZX?@MBS&0JB6Q8"7>:7^WBTFHE2=WDWCHB*?+M8X
MIU\%@H]G@28: )Z;J2\-Q)@V^6</YF/,3% P$Z6X>@B^\?P>,BF+<;I#2!:!
M1SMB!<GJS576";L!O1K3V)KG<T#%B: ["C'=0+/M)D%;J@\#'%G<B,=X:[F8
MAA%S"7LZ!+4XG!!K2L*%4$L&OC@FD0NA%F2"@Y+G%20\+9.KM-=[69:&L2=[
M&<&L(;GP=$4DN.%:[$])K&TU$5.Q@'0N$N'=,:0>@KTBYD#U>=DP"(D=5)H7
MNZ/=A[=4'#]M1.[+99#I4>G3&*3ILKB1[_#5=%FF^UGZ)]9U9\,5KP1@%802
M%A*?PT.ET>T /*BS-8I<%1A[9HLVO#!51!P0@QP418$2Q-FA]#.\R;*DX6 X
M>HH"AI+0<N[R8==BV(E&]X$0%,C=TZI-X8.Q2.]:QT&1$R1&*,57<Z7(!442
M>",0RW S#E]S3TQNQTGOK.Y2T_E&\ 4DSH(0:ZJP?_N(]"MH<RE&[/YEKT,(
M+B(:66$67GA61&4<B!T*HBR[M:J[\>RP2,SW0;%#C$H0#%2!40V&]@"J0!56
MB]@8)"H%@[E1:AM"J2V)5E*I.3F*2<#;X"E8O9W/.])*OV@6]9#C+$R/_"'+
MZ/+/B]'H',X_L[0I4+AM?84MD"'%F)2YP#U)^WP"- XF+'3?*PF,Q$FL.3BT
MM@GTF7]OS\Y&7RY'YUJ!P<%BHW+R1[_8 .NPIUBCQ#>:_M<W?-#IG+(06T(:
ME[/YK"AOS176N;QYXA*4;)JXG?>MQH[T0.R3K 73XO86IV]JK9EF[M0HBRBY
MD3F_K<2@?3&<Y-7MG#\,\H5V./VF]M".T!_R9G79WL1X(U+_G"S'ME0-,=%=
M@_Q^\[J>_-]E\<]<1"*RNNQU76[X,A@; K;.;3J/K1LEJN<WO!=EK>(<\S]I
MAZ=? ^;]EO&QI^,SQKPJZKJX&4B3MVHQ<BH/M_[P9^>I><1K]OWE]9HTK3N/
M[]9='HPF3N.:P_TL%J1//Y'A(ZKT[^#]VXO/_UP&7T=_CRX^?GC[R2X<Y'C:
M[6Q:M!(,]BWX\0R)B,L9$CW=SX]\ALC ]6+T;_ Q#.0)X_+]7Z,/STV2K=<&
M;95=+PPD"K=;%^(PLSS#_:T+:)]6AUX+'$^#9Q>"QS/B)]:!+6;$SM:!O<Z(
M7?J^>P]7>/^MMWYP%U];V/-:CGF\*X-^*465:P5;U9]V-LO%-!@UZ(Q[$7R>
M3O/Q"K&V<[_?=>CI>VCMWH7B]'?T_(P+G?-:Z&10@.G)YW%]0A")#M=EMMD0
MUZS_.S)V8WWMT*]ULF+C-4]_7Q63!_EG5M_,3W\ 4$L#!!0    ( "J&IEQ<
MI1_>*7,  ':%"0 >    96UP;&]Y;65N=&%G<F5E;65N=&)Y86YD8F4N:'1M
M[+UM<QLWTC;Z_?P*'.=Y\DA5$DU*LF5)V50YCK*KJJR3LKV;<W\Z!<Z ).+A
M8 )@1//\^H,&9H9#<:@H3JQNQWW7':](S@NFI]%H=%]]]3<+ORR^_6:A9/[M
M__7-_WU\++XW6;U4I1>95=*K7-1.EW/Q2Z[<>W%\W!SURE1KJ^<++T[&)\_%
M+\:^U[<R_>ZU+]2W[76^>9H^?_,TWN2;J<G7WWZ3ZUNA\W\\T9/\=#:3\F1R
M?O+B+#M[)M6SYQ?Y\XN3LTS)[/G)_SMY$DX-AZ=SG%\7ZA]/EKH\7BBX_^7Y
M2>6O5CKWB\O)>/R_GVP=Y]4'?RP+/2\OXVC#KS,3GJWY.3.%L9=?C>/_7<$O
MQS.YU,7Z\O^\TTOEQ&NU$F_,4I;_Y\@IJV?I&*?_/W4YF83[QH^K9B#A$H4N
M53NP%S"8ZP\+/=5>3,:CLV^>PN'MT^P\4R7S/$CZN% S'Q[E8G0&3]9^&X>_
M^;KW8%D0LK*/^623T<FX"K*\_O?//_[T/_^^?OVN?;1/.P3EPX,>NTIF02*7
MQ^/1^)E:#HY,8 UH_&+/B%[^\\WU]>.)ZCZ9=)J7!A&FI/UVY[=NIDD[#Y/-
MF^IRTM?'I*7GHXMG.TIZ^GQ;07^MG=>S=?I*EWG0UWC,IU39L[M".('9^&ZA
MW2>7_]FP9IQ.[FI&'-*GU]1A45POJ\*LDX'&$<@9*7F\G%NE6!SM?0^^_NK%
MR<GXZO&M%<;;V+E_?/K)U2$;BWA?MIK-?9<R5UBB.#DG)0HUFZG,ZUN61[JO
MY#F2[FMF6((87XRW_H^67%Y65A=HD^6$E"PFIT=8DIB\V%826H*!: I[H-$#
M]0M>6GK>*)HO?MTN].)[Z1_IE>QUR(_$="UDF:,M,;0FR53YE5(E2R.%=_32
M^,5:_**+0LNE$\B[V.L/*JL?ST7>.VEXPG3W_:>RAJ=+NN\K8RMCI=>F/!*2
MA1+O^[TJY$I:);*-= 3X(@+7EKPRRTJ6:V1+,GI8GF T[F<%4JK@!<D\P;"P
M?UDHJQYK0[]S=[RMT>GVUHC6_AEQ/T#+1#VJ*?C<-M"Y<MHJM%@<L3B+-QR4
M3-'JF.[D*4-@F_*YB0=O#NV@6U#E4%ESJQ'37[2THE+6F5*B!?1I^VKAM%N=
M\3*,;D*(+<.8,7U:*M$X\1":$]Z(QKB*;BT6*^T7(E/62UV*+!RM2I>B$7#*
M5)5JIKT3X4>K?&U+,3-V<SILV"?G5TZT,_'KKYY=7#UL]_Y7;=V?17 @[]Z_
MS*05>Y7WBF>EW0)O?:0M&[SEDM@<FO+DN6<WK]"26L1\B2E>8(/T+@31VZ0]
M?[ CR*2U!C%93LRN($=\:,\A[  0;; K=@"(MNZP@[M9H44;"=F.9/QNY",&
M-/K(IC\.22!;O3@<UWAM5D?B'00W@H"P,&5'(KZ4TH6%H4''F)F ][BL?2T+
MB&0MM0OW@I>5F5M5RM([. 7>I\H%/( NPW6\T"Y^ D@G%'SE#;A3-+#&>-E*
M6J]5.M ;(5U0CZ(P*U" %P^+:$U&+W;>_8O19*"\NOD6M[KZ;/0LE0R_>7?S
MZL=KK%+FDXN[IJ(=&%IU]=G.(M<.Z6:O(MQ][>/=*=]^^_BO_2.6]=/1:7SB
M[Z]_N'E]\^[FI]=O/RZL^^QTG_E[_,+L'XSE#$ER*VM;&<>9,RXFHQK:(*8A
M7:DXPR994^Z51/(;P^!X4SJH*,HN>=EI8H"/M;\B+XD\;+9+Q$P+K7@%7I$_
M*=OQL=[2']ZY[VQ:7ES<'[-I C3'CQ*A^5@Q3$:3K[^:/!]?[?[[1588?V>D
M?20+LZ^RB7>?\;Y+)4OV =AQ1IN?Y#T O( $,4%\KZW*O+%.L$AZV2S:#EB3
M:WM@&>_?U/DZ8>>KKQ*R=L@$%>Q\L?.U \)B=!K['T3=\[]1+":<\R>B,1]9
M&70^>9S*H(\5S8$\).8B #YJI8MB5A="9EX8*P!EXP!^,UWWJL8 F>.U#Q_*
MN<BU6YA2A6$>B9F5=1[/"Q/'BJ4L9DHZ669*R+G4X2S1 V/]F6JQCT9502<'
MNCHQI:83N[5^X>7?ZJS%9$DQ4X4)BE,'\=KX=@NY<BU<ZS^EANX>;[WT83A!
M,4#'''R"GZT*AS5?)HWYM;;:Y<WE=2E6"YTM^CH#M\_KS#LQA98AROVIFL._
MJ19EY+4(S1E_OBU 6IP[N9I*B]H>@!89!%[)$;%-&Z(;2DP2_QF]'?'>I($S
M&K1X.2V[B5A,16J7MAL^MS4:#HG8;'F9+W6IG4_E!#QOHJ/XP_<O\;K/D';%
M9M8L><E-)!+0=C%L],-V+.S54KDF?&ZK[X!9!G9FU2(XKS)3P='/9 ''3K7Q
M*EN488SS=2RRDEL[Q7^J,@PI$V"FQ'4Y,S:+(%OQ$J(/,S&YN#@YVH03PLC"
MADQ/=:%]>QFX8-APPD%6S>LB%0L!UXVRX7K+ ;*:O(ZE/N&8N[$(L2D0^(,;
MR?'YZ,5#DE:PXZ2\<\QYY_AY3,JI53);\-J.G:Z@Y>\Q82\Y#2'FUW!":U]>
M7(;Q:J;:W%,P: J=:69:H&9=B"W$;%T8.?>GD7.GQ+8@R,BYA2SGGWY6[7EG
M:+N>86'H3Q^XVR,(*LOSOKX]I;?FD7P7:@!+8FN@6\B"^;H&1;.03-3+CM,?
MABMC%M,3,?O[^._0D"+$C.[,6(\7#:4U91[!2?H\!,%&=5]2Y;=:>RY]&)3-
M30FL;)@=!2B)YV,]S)\+67[948PSCF)L;5 ?B^&9VNZ45OJ'J_](N ?$)'$#
M-*3<9FZ/=-ZH6U76[$HB&W;RLXA1**WS<_'B.?-D#@-T.(/^9]QJN53!^\\_
M<F=!G(K_X_<:SWBOL9M$_S*W&[0*^%"W&\2*&?^I+%[="2U1O#*V,JD0!\U/
M((;G1D3NTHI0K!:F*-;'9H7(!TQKMKAZZG2NI=7*\71!K_BDI1S:\_K:3I,L
M4\X!5Z0&[I P7.7\XV\5'JDA^<?O%I[S;N'N;L'*::'$=6SX^WC\&_OV#B*Z
MS4)UPQ%0T@B-$X1?2-^48"IQ( ]C":,+VV(H@)Q;!44,P@*]CIF)J730V6P-
MOSE92+L6''_8AYD0:C93&1J>AI@7II=+%5P.KXIU4#<=% BOFR0QT>P6%,/4
MU&7:SHB#Z692'@GU6ZUO98%(Z4-[WN%U9"..E U_*Y;-H&Q^-5-.+@PFM+4O
MT))QM'4&^KT6ZE85B#SRM)4G;)8J:+B;V#485HR<KJ,]G3H?B'W"IK %CX",
MM%6)>P>>0X.KM=GE)F))#4IJ:W^5H3"6T5N;<+>6]%(".':&/)$=WDZ27&IQ
M:LH:Q<22DX2I*F-]72)Y^N3D@>/GDQ,#$B*>G!S84+"AV%MGS')@2]'==ZTD
M*T3:Z*M,Y4A,#?3 *(CS@Y8@OM0)\N B'5WB(2TU'H,P,37%;+!".GS0B[VQ
MJB27.,MJBP?$)1:%1 3B$M.+@QRME08MDR%9#$WJJ\QTA5=53RP^#VU$6#/@
MOH7)>$'M^UX2#1U)2Q(:KY:#E!RF!H_,C]CD.-#L5<3[EFCX\]_3B)W*HN:P
M\UA59)P&6W]I%?2FNE57*YW[Q>5D#-?HGQ64WIOEY7ASBIPZ4]1^_RF]4B0@
MK5,V_.QC*4MW39N'IPE2*F3EU&7[QU6N757(]:4NXX/%DZZ:BJAF(%#^=*ML
M;.;5W"3>+_W<C.EL=/Y\ J/R-OR7M_=M!CR* W[J\]W?+EZ,+L;[?QZ/)MUO
M3^.UT_7# X174_[CR>F3]H2F1.ORI/H@)MOU65#*=?<9TO"WY;A=^O77%F^-
M/SHZ-#J)=623;3WKB^2.PDW.XM#O%]-8I ?<7.=I?/O=]7O_+NSF[+DZAIY3
M[X_E+(S]4A8KN7;;8EP&Y>GK_@/4-M;5->+^]ILIC&;K83]=T=ZG+-#;0X9@
M+ >9]GF [ QW"4:_/IXA0FMIJ\K!V;-#$2X9+@8M.@?:.W;[;@$[3M%NML10
M2=O Z;V IX"J@0.M#T5I!,Q>*+\LPS\ZO"-Q<#KN1B)M;%#Y^R-2ZGTNU\(J
MIW-59LT55]+]V0>!DK/>T)DAJ:\TD]$YUSSW[O[*!*?H$>@U_M1+P^JE\NZQ
M,Q[[RL"))2J_2 XIVM458>FX*6_#'K'TTJ+5;%&9SL,R>O3I_+F58/^B_<+4
M7KR2M6/2^[T1:I'ROBR@04/D8R-VKX'SX-.-(5[L4OO@AF8/RL!%GI0<56U<
MG2VV-A69*8/[[&L?[B%%XP@Z!20T\?>XB0AWO-69:@EA5F&.ZC(Z^4U#).!W
M>:NR>,;9^.(E?$[M[',5]RWPP:IY7<2KPF["+.MB'K8-\3>KZN"XVR,1]AA%
M#<Z^>&>5=+5=BS?=:=TM)B.XR?'D8'$H#KI1(WEH;^\(ZVT2%JZW=LA;KNTM
MUPO><O7NWO/31,\E$0BK[^_03NT&(G+MEMHY60"15/B0+8)"*V%BS",&, [T
MH9B%'^-3',%A,6P20\7!&@4CLWGZ\./FPTP7C3&3HE(^YCU$M$PBW*6"T\_A
MC,D$CIE,T'Q<6E&P_[Q]M3'-8Y9*4Q'K1V'A_&UT!"HGG0N&\_'(W,A+!^8G
M. 535:J99JDT:,Z9R*S*M3?6!;T1A?ZMUGFRS8U+E24^\<X<!LU2/I),!I$N
M@U4,KE6F8O$#F*IH%E?:14H^\(J3G80F(AXNJ4MGBO A6XOINO'9X@W %XLG
M9!*,Z*I9&20,9!:N$,X=)"N\<YEX6]&Q88:'RL(C6?#UX)<9F-R&(+!WU@A+
M'XBAU'[ HZN@-3&JVE;&*48D-6:"Y9"VM(Q12_=].;=*@?GE2@ NH>$2&K:F
M'R$',OQ/M,2B'IF'FSHL/,=K/DC<LI+%!&,;$I$KZ1=-O$XF3L^PHRP*41K?
M2T&$G6(_-]'%\+[LWLT7:*'KX>!Q$[J^*?,Z4X]B%_<($,WE')8+=!G_0C$Z
MM'Q_W+;2M&3!;:4W,,.MP"E+)=[W9#QYP<'6)BGZ: O:YV$[7JZD1>-3P)7%
MQWIKX -\:F^5?$NOR9C!%OWMT&_U8Q 6?AY.\DT)M:&/45#T><B#-PU$%CM<
M8#]I3#;O(8CM(6BK"^:6@IA1>:2E_[-4D\?S!#Y+\>!NOE!E\0B;K]'XV=W]
MU^3%Z.1D9__5?CM$;O)XKN+9Z-D8MGPOW[R[>?7C-9KO?'%7[NW 'LE]'AC2
MOA'=W.S5A+NO_73PM9_BO_;3T6E\ENM___SC3__S[^O7[]#$O"/G=FP(&Z?V
MUM_]#YU-) %QO/L7FF'8C>0^LCP^8LEH1_CJIW___/+U_SQLW?A"ZJ5.1A-B
M2>>?&QHR+'5Z=D=N6-"38>D\!N_Q/L'0DL3WM=?*??KZ@0%ID*^+?EM/?U49
M'HR-R!2BAMY"FT'DHGW$\7W*+M%"?K0GCU-X5H66)( Q#XTMF+:2 ,V#+M$*
M5(B!9!'-+&TU:7(L;$^29P^%7;SJL,MVGR!2B<J&*T,T[#PM=S=45V]^_*_.
ME/BY(?WT1^+50JN9^%'-92%^FLW"KQ:E_GH\FKR@M6'ZOK901@^BW*UIV-0%
M)7%KU\G[J"?M6.9@%30N;9E1H\#1LEZDMZ@;N;$F#LO%+62!UL2'V (03D-,
M'Y.>2)&\H[%12HE,PLC].I*Q1142E;+ &)(HX?(8-A,R_+]5#5L-4+/U.*D[
M8H^X7.Q,5+CRD5 ?,E5YN,Z&>$27SMLZ ZJW^R]QE,:2&$JV1Y35S@=YV" C
M&)W)=*2. U827NG^NI7NWE6N$W;'$'-GE<O5K?%#2^54.2_4#/;&+FE@/75>
MEEX'143S](F5'R":=6*H*;R"?-H!2#(%^K3%-*U=^,ZQ=(8WS>$Z;'$?+6OZ
M65!<R#"^$I41AI0X#I(7RX'J-J/!EG1(,+<2N7$J*6F$[:0V.2^ZPP:6Y4(M
M;TS/RB)VF24EBI0GCG$"Z %@RL@PV]B7R%E;%.#?=_2VT#4@Q;<T7JJ,=C5)
M!;1*OA^"NT,C/%>ELK+HQWLJ4^@,8G! U-L/Z(59*Z*^=HF/CG[RL,UQM)NP
M?<2^]\)L)Z,7N^49?U>D[0DQI&V/REEZ\4N8;$AH2FHQTN_,=OPS6JA-"%1F
M[TNS*E0^3RU/8N9>Q*XK?RBL2KO&"J\9?=OF188C@U(B5Z_3-O>@?T"M-VM(
MWUVE,CW3P?RG931:Y7 O-# 6,9<#Y+64:S'%*W2G%8)O:1@?H2WG9[EQD7C[
M%EIR0%RO:$D",ZY.S'A,T72"F" ZOX_ED1*[>)%D6MXL)J,.+95HL23LQP])
M!_:&[("Q*?D=%3$UNZ/)FL2.CVQ+B*$=:)L2-K)L9-G(_H%<DM7&0G@QM@1_
M=G$EVM;F1V)A5NH6D-PQ[JUG?RST+;03F\A3VWE7VZQ> EPX"\./U]WJ&/+*
MA!N&HWM]C'>0R5,E5*'G&A*)W@BK,@6_9<IZJ4OA8,QP?5').+*$4FYZDT80
M^E;.ZZ4-SQXN=?/?<$QA5J-^Z54XO'!F<S^(P6YNT%TS/1P\_,MP1^@+#[=\
MH\*#PK._[<[XDZQF?]>TV2G=M-G/3>*4\V;QON^"CO<FO55%G*1NH:LP'?Q*
MJ:9:4=I8\I'*4^(D"O-V#M.[Q(M#TW;J\$)MM-.%B $6VG5A#<Z#@_:]PFG4
MEA^T[$F+^>')0VP+37L9JJS,8#O >C.\CXX8.)8-Q00 L15)EUE1PTZ-_;KA
MVCY>J=-] =Y5Z*5&A.C07I,B$-DX%+,;A'-!J[X T[$#:9 21@I!X-C8\8B6
M1<4AT0I2(*83E35>95CU?/3D@4/"$.0P.24EA\R4LT@?HW&B)J 99X0],ET"
MBQ!:(2RYM04I1D#/@"02*:S86M"+%]NY=5K3!LN\_JY?NI-A; X[C[TO&IJM
MR^1!W:JKE<[]XG(RAFOTSYH:[\WR<KPY14Z=*6J__Y2A7CL^UGYVU[1Y>)@@
MI$)63EVV?USEVE6%7%_J,CY8/.FJR8PV X$<Z*V"O*TLFIO$^Z6?FS&=C<Z?
M3V!4WH;_\O:^S8!'<<!/?;[[V\6+T<5X_\]A<G:_/8W73M</#Q#>3/F/)Z=/
MVA.:/.WE2?5!3+:3M)#/O?L,:?A/[FEO]-<F<<<?O5<>G<2FQ2?;>M87R1V%
MFYS%H=\OIK%(#[BYSM/X]KOK]_Y=V,W9<W4\M4J^/Y:S,/9+6:SDVFV+<1F4
MIZ_[#U#;F%QOQ/WM-U,8S=;#?M+D_:?,U>];^F\3;<PC9+H'C=GI<UJ^X@WO
M'=KLJU"WB%DU8N0.3&BWQT5DL>S;<A8:KU$/L=G38(08?,G EOL$@]F=A[8]
MP5M^B*O,0K/&#$JFX_/A)8B!/T27(V(E(G<(M=BN$$2?$JM]QD>?$C.S?<:Y
M#E)X=(=BKJD/")LD;TWQT,J8R6YP[<4]D;7/HP;FC%@-S$V0VK+4,YV(<;G^
MI:M_:0O<FM8KJ5XNEH;I;9FU?(D]7CEWEW!1B3N"[DT.Z;W,%BH7P*+I#9R-
M\MAI&N4J,S8.\3+6N\%10(NRT%/MQ4ND%_(GJNE>Q#3&';/1?CN4P'J\&7@V
M>A;[V;]\\^[FU8_7&',OKK$[H>AV8(_4$GQ@2/M&='-SLU<5[K[WT_.A]QZ_
M??SW_A%+QNGH-#[SJY_^_?/UZ[<OW]W\]/IA\^ +*2D]'4V(+:??2:?$6UE(
M^TA5?OLMY6,ZIO16\#O=][KZ\53:;6]UK$R/Y:H6:KEML_ZF&N_8U$R692T+
M,857ZN(KA:49BL4K\ 8VQ,S?&6ES<(#;NGA5NK3(AP^1PUFU/D(\] AJUB-*
MPB3?P*IY':X/7P?_N!"Y].HN#3-T6IO^JK+8DE*7&?!L=UU#G0D7R[4+W_8]
MDFY@#QB4.( _&\+6+W;V-!2UASR+4E"QT\+KV0R@MF$&?1^4,WW;W^(=#=!&
M]%XG3)O_]>QD?!2&^F!"\2]F%:/&)_Z=*>M'"H?Q^K5OYG$"B%ABC*/ZGZ/"
M= L7BV=(/+":LV3V5H#C99MI"V?([V-)#4F*F[]O[HO7JX&VCK3$<RP=.N6N
M!/D#E+0EDVZD^T(<3\D,C066]FY@IEW&C&'-?==AWK!EY<TT;Z;_*L0<FF$A
M372D2B:!VAMF4)E:3A7;X4'IG$Y$7EM6GM_+Y6(C=6EK$3XVE=A^";-+!#LX
MG^4<ZL 6LFSQ'QM8!>2Q,^D68@KY47$0CL'%2[Q,(\1,U[: ">&EG2MH@R"]
MF.F97T/?6L#6B8-GX_]]"(B!880 [U+C?1-.@K/?M%9\8DJR;8L>?_J3%U#3
M.H:ED8ISI$8K@J2]I4C;K82=]++, 0#I]1*^F^&UT"*F/A X/59E[$ ?&0-C
M-R2P-E#BU76"2MDK7>BPY@>K;6:S"&"-4-O8(";354*>3A4(^*?,FZFR8N)\
MBU_MWP#N&L]=+71$X:X;?RMU>Q>@U",!%3I]^Q?[4.G@?D0.825DMM#J-A78
M!->C;1O5O]'<R,()Z-XT+;2# IQ9#\,+]X7V3I!D@(H??:MSN!M\5UDHD>F=
ML/F]<VUTJ8%_<NN.X6]M\N X.E='7<O,,HPPZX;9Z[G32&:I\[R(>$L9?,]"
M@:I&$1W^3A^O4D3JM0;CO-7:*OBM6Z+;/,7>(0] 0)=U>'_3B&$.YT]5.$6)
MMZKR,= C3L=^D5Z3-QY@U/%6E3&%2"6EB"S8Q/:IB!:']C8UN#O>ZFD=&\3Q
M0C8D(HV6PB$VB3 ;4A K4D<$K=$V)RIUJN2%IYTS>)%B6C,&DQ.%-/O')N#
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M^J!L%OQ4GBZ UK$:)ZY(3A+J-Z2T1'"R2 D"IU"6NM5 2G\'Y2 V3V92H^!
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M>ZB;< *;BW;%U<MI;1U3G6+'F8@I!GJ.G)@\\%QV6A.$O=#[PY$1=I? KQ:
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M72:Z'EGFX?-MD&3XY'IL/0=P%O!!G:"]Y#\Z9B391R%-K@Z%]%YFBX:,#5Z
MPU&'9%ARE9G$7'\9(4UP%"C*0D^U%]\C">MC7="_JV$](698WX29E&OEV*YN
MV]6.&2\/'\.EVXJTC["L"3_N:GL;R=0VFS78QPTT<^AR-6*E_:+9Z2TK*!"%
M>\#G[8MPD 4=K4@[8/V(WM,P7^CY"6'IX,>>:,E#9N]+LRI4/L=C0"(F$K_
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MKBML0K-".A>_/KI#R2"D%]K#]E4O@4/8)&Q58;)4V1ZKW4V?M\$/U,O+/+=
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M01T+U;D142HIYE6[I! K)8R*7-!"< IG@QYC5RCI<:R,#F,/+@D/D07X)A[
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MI@%)E+Q8*=T0+$6\@LQ:>#D>9;[BM>%*B(2,V*.2Z$XA[PN\FV'_L()69HU
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M(OKPWK1 CH&>)=_OVT/G)YX\8V?+6NX=I)/QA)EE^BOQ?Q<^KDZ%U1E8-R>
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MR2W'8@UX5"Y)]70 <7(G]0"*J)7D>DR*6'WT.$"<W#]*#@BPL>+I\@_FV'&
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M9V"_+0)MDD@V=_J#5D^X;0_^E=I(5#IWG4?'?@4.7VX"2>")-7<;SFE',?)
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M=^XC.K3XHU!:>D1.U^E[)%CS#S2>X>57 \4F+CBNOIO)M\U'/=%\:F*A 9Z
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M2AV$[#&>(0LV"2>29$&%I$0BBR!0L]X5+<^&:P=[ HGOGB:>DY?=H62+SH%
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M*T&9(25XO='[=M#M?:/9.T%?V'51F([!V[N""'Y*+L+:@8]M7D)TVZ(H3E'
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M_[C%GT&:2FSQGX2F2)V!HE;CGL!Y/8$IFA-%GBL=D&_[[6 'X-%'=6+.)-D
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M6DHSO!SLS1PK.&Y.DK7H>=SL>0798,^-1B*7D_]5D1IM]:,Z81UCM"67_YS
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M6./0GWQ4X8,K+UQS-&!RP>C9BMW60,W(4E&5JNE6QCF6%M@N3<5% !<!AXN
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ME*]72Q0L4?#53/EZK53;C@>[]JBV;1J*K]>+H9R]Z5B\/_9\N"/-]<*RM/T
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M8HJ&07-:$.U1:6N7/8A.%KOF-"':(W:5':Y.%[OF9!"\@O3K%DGZ[2EL$^-
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M^*C^\<FR@[%C3#[:+IV<'OJ4?6E.SC&]D+^6$J7;KG1K710J,F=&OEC*FPI
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MP#&,<TUN<!Z-\-WD>X#T)7!J^(%K&QI0-;X"DR1?#8MIL8]4]F^N@#E?C+[
M+O6V]ES1?A<^ .#2\\>>+]O<"QP+4CD0T>D T8K6^%AOG9G/9X#)U0Y/R"L*
M].Z\\!D0Y!A UV[H:JP)8+\SJ6B?O7"88+OA..)):,^VY\23>QZ$G"-4JV+R
M'(*^7L4D1!E%?4A(Z$J5:EPPUH/"T*144)I\A*5E^/1]!(I0K=H_:V$]VBAR
MGMB:P$HW[M:<,P:-=V8Y$VT _(,YV<@.'&%0"GJ )"E'B8"ZAY.9XT$7HQ%6
M%-*HD%#0Q+2D5(.3AL8.3F:Q!P,%@?Q1%SRQC[-^Z(667.6_@_S7]"=JD(\J
ME%MA__#-;\!*Z!B&DWXXGF4SP.$LZ8,NW$:Z93;%53%I%F=^O!C ^6D(#!UV
M"*\+AZ;!=8(X*\/G*1QJ^@W-Z(E =R6\@&=PU@FNFA[[1>-9+&S;'>"NY3LM
M/WJ*1U)H]FA,)\"Z.V$$6/>)=B65=?R"YVBHE3<:BU"F7KG)":GX0"T%]T'3
MG$)0J61FLN5[XS%6 V+6.ER6Q<H7,W'\L3 (9H&L+G6UKZ+O1S@6#B=<H*B,
M+WIH6!J7 F*2&Y!$G, 7^CP42J45<-;I0+S(L/,,7@5"_-0L8V0\":Z-5+ED
MNAQH0M=![<M]!@D5P'I!MN6Y 4J8[XI)\-\26CC*#_X8")Q&1QH G*.G1#YN
MC:43)C6@G:%(34MX/BXD>1@.J0DX-QLD5/8A*1D+*+ZN,5%OEOFF.=,W^!\>
MO7(P5BS5@]2F+DGCN)"3SP@-QF//IMQ&9 P9OD2#UB(W$ [1Y-3W=/<7T5,4
MA%I7W?[T&JS+&%/7RJR9Y[G@3VFI6S/T,+3822F/_#B2T,A3)09 7<#%@GCD
MVZ)EM0MD,3P,C?6IV75P./I0.)0#)/77GAH^0S/$U,=<JJ*&K3..J]H"G(^-
M%C;.5^).4OF;5L/\QK[X$\C+% Q%H&4'=&BU_CPH@NKHN;D'_8-S2UWRD(V\
M9S$-J?F/:BN;&)W>6DF*N0\>JES%BZ'<DAP7[U9^U%8HM[Z%T=R_A=$""P/3
MC?)L#.1$2 LDGG".%PE40I],0;V\?6#T5#2Z<Y-#+R+3_FP'0V^,6O,#J!R.
M",-B*<N-1JNM%P9:VC>X7N!HQ057LUK3BV67_8$UGD'!0/8QC6&]]K0YAEKC
M4?"]]ER^%QN3N(<5O$T66 Z@;?BLX\2^)U*'V!Q5T^\F<D(H:[ VZ-NV%8&M
MXV-##XXZP4-LO*+"+BR< YGV\>#>T"K#%GIRYN#K696TN!SWIZ9 2IOY**ZX
M,_>*<Z47SVW/C"57 Q%EYO<<U7?*5B)3*7AU6VG*/D./9E$8UWS1^(I[7+BC
MDJ\O%,XT,YDL_'$DJYDE^L8V>:+6+K#)CX(M=-=D"^1-6/]DR_ITO,+)>N_.
M04>>/=>1NT&2YG %<H-<IF&:VJ$2"4@WU).BUIDE'! Q$TDRB]?1QH)'[W*1
MKZ/YD9/R/Z"@HMI9>';6/2 ML'E2J]CV=N(.2KR!1KY-JHT,2U OAI%TL:"F
MUO>DB$WT,^K+P.V#T(MD/X.Y+LG!>,)Q\>%:ZAY:KZS02:UJL4:G5*^RDG;E
M2MK>%*S*2MJRDO;$*VDY@24OK:7QZA.$\ZGP$.8G2L\',0YEZ\-,/"B'L:,/
MPG/C0?-V*#MW8L:''\M.5,<"&8ZCF![+BR?@I?P!1TN5R$UI@TE\608 YUJ"
MN;$'"K#E2J[8%P^KG[S'].^&T/XVB3 GMZ)]MOT">+-2#L!NJ].2S5IG;YYT
M]V!C9U"N/R7,?].F7H@8-Y=JILN\%6O[)VCJ5.=3VDNA/HKCNG\W7(Y1<VY7
M'+-.PF-I1^*"X G_/6MOM?=N;]6J<[*S5* (N5M^$(5\:5)M5=>[3'V5IC@&
M#^NM=/ PAR'*-9W)5JPQV"EOW'U@L*"= JZIF3<HWX$M6U6':92( ?9B.PZV
M?)!Q:3_#( @Y0-1FT(8RB22=2'808$.*D<#'^8H ?\/$_QQX2 9X95&<F8/H
ME7%3IYA6.DMR*A#\;#]YOA<%@%3\F]AH(HE.Q 3VD!=A"R?9]#7KH.3MR@UB
MK/CHFG,]1&8ZVXQ9]9_R-FP7,\"H_[84%$@$2=80L(>(:&W 3:P(\H$RTIB_
M,E)8 @E-BX!R 5SN!%;\Z7HO+B5.>4J>>%%(3<RE3U[19H8@\6'&"U7T$G^-
MW=J%*8* NX3%FX:+^2-IDXXLT>1:&2JMM#+]PP 7 9M,*3A&Q@3% R8T)0),
M<RCY&06!3 ().,F*D8@$20J/UCP%0_=%T+NQ^?S8%\^&[52T[W%Z%\HL #%;
MX 3UF3?S'@V9* B0P4YV9]S$$7\WD&0#EV&HABOP*\?^"<)*=F[ARE-@B7H,
M#$M0]U=N2XG/JPHD>&(043*=9P)AXE<4(R 73PQ3)0JP^9>0N;W/Q%DQ&27F
M*"@N4Q#H(U*:>+'P"@3TT'CFDT_PBQ3^2D<1,Y] A*&3=*'G!B8CF[/<>(-!
MY,NY3<_"!SA4M-]C^2!(V@2JPS23^HQLF"41>(AJLY1?CXX"N"7OTD+5=NB]
M: YF^-DAG3(T?@KN#QI@R[I\O)&*<LJ\4.3B)[PYZ06'T(E]WA<!08KW$D\8
M0'*/6!>BETO-*!D](%\HUW8\[.]+?%WS5=?"Z6]).."9N&T;8TJ&3U+K0]A=
M19/%M\BE P]LIU#>UF*Z20 PPP%B&H\3-#%O+O*S#N-DQ$'*GN-FJ):7IKE$
MJ64&A]F1:7PCWRGF'R9/Q]2ZHB X2/7&-<B<$;,\Y@\ I=NT_/RBY.>QB;-;
MNFOVM*.V0?:]3(:-DTAM>?P)H4:L*U!>](L :64@&GL!-EKVD$>1%I$?%$=6
M0GP<45+56>*R^%(.D$J.+.OXX35_1M:3[#./_7CA?YA5Q=G&<DG5^I[%K,/I
MN"DJM;F*SLK-SD9"2<IS@-3M@//N0LG-;.20_K.-?!GNGZ(4-#!EMHEQID5P
M/"G$SF)1TEM1JG4JO)X!<A9ZW.)+YC:33)I>-.:\<U;@]'1E<9BV;T8C%-1*
M@O/W*64U\Q-6.V;>V7=LI;528TX<U,+2S1*!Z=O])'=9HE@B#N;!A'3/N&<S
MOM]"(R>10>3+Q^QEJ7ARD^=D#%E*)V4[2^+5?/!6M >;(P,CXY<]BD:IDZG1
M-H"5CFW:(8NZ<.9@="526LZ];M)84FJ>M+DX*9Y4I,R]L/T ""D4.B*VRH)E
M/B+;@22585FU_42XT;>I:Y+RE0;;S$@Q:]56X@=AQ@\"3XGW=.<8[K$QW#]0
MU@)?,!85H('1-.O?F./=H"Y][+VX'<2PN:,5UG-FU.8X,X(8X+BOX",EUAMC
MH .V"M[;'S2<]>%-4,,?TC@J[F3=I[E/,VV>9)K=>SOS(&=(:0_"Q4*$?V E
MQ!WH1#9>%ZCGV,:0-)H^IB._MRNBHN.H+3.B44H?$BM+"@/:(+%J. UZHZJ]
M3_'OYVR8>T@K3Q7OMAYGVKA!S'H3F/2%*P:H2Y&MABW.05"2EYNZ2S*]I9UF
MPAWB@U;R9)XXFNUS34HI_)G3"%"G[OC)X6)NS]*(CLK-HJ=$3NIJ\6 !LW#%
MG=1H&00J/(@JHN(E.>>7H%$BA"5FZH52':=[,4F'1I!J[U4.NQ71%PB##Y4R
M1+HJ0ZE7RQ!I&2)]>R'2QE'TC+UV$^D7ER'9P)")*5+D#R3R3W*Q ;^U(EE*
ME9DB#RS3]WZ1:H;.$FS!"D++4K9"LD \.8)[Y\O5R ,D#(N:SN<G8,X=U[P/
MCZK 8";81[4:E4D*'$4!%IROW&XI8\1V6:59&$TH0O.->/I%JJG&$:JJTII]
M NF!NA4@G52D<"[;A#43M/?A-1%:+V"0<)95Z@.>.QB!V)^DK_+?.!20/0#)
MV#EVA@F,"B=J@B^><)"=YT]B,Y!3K]+1U\3)%=M%MHL=9K00_5K*\QPG'40!
M6K/WZ<;>Z,#(.1%[B94:DQCY?9O];>E,!G7K9G+K9*YE"'BM86-S9A@FD\9,
M+!2T?KBI";0*^6YC@V]VOEN[AIV!6I7>K+ZO)KO198"AB%:BB;J>XV !?#]2
M$43V],NO#)6MR,V+XFK030]>6WQP-?=9G36ALPLR>O-.#"*CT:G,#K&/3VQ+
M*ST)O*1P('VG:= 8%@Y-38\A26&$"NG&&&XD.GS<6*RB?8X?5>/4'<-5E0,Q
MR],,=)4B3:@AB8R]RS 0?3(<Q8N;S(.=X-#0W5694K<@3$D.*'81)@[ZKWWV
M,ZL023(=50[HFK)X+N]O)?.8X@^9SZ:8A>1>4SS!E<YWMC>? ;PJ)Q20ZRQ>
M"^4X77<0@@$HR!9\1E?+$_*T,XRXI%@4+Q8[&HFU^1Y*<E[:&ZNA/)180%Q,
M,6KTZ*0G2),?4/6&E!>O&!P-NTLYA +R?,DB:/H%XPU/ 4)7GJ)SBIJ$Y(+"
M&!D&>B-I_3J"RH,-=\7.4SSG<89;_>';(6 K* 4  R3R64^&%?F6,4E(&R<(
M=JO37:0T^$V<B,+*T0NOC;"B<FD<MH0Q<@*@RNX!O ?APS':!'^(Z)5O/"*
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M N!#09")]0(?C+"#7;KU*U#%/[U(8U327"_4 "M-&A\<84#3L<DN\0BT@5A
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M"Y!@^$'S,=BM9".]@NB$([+T(6&C/0+A)D,9 [I*?"9&]9$!EK=I4I17Q5+
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MY&KA@ O:G@!6>6**N9#@G)/[@.V@5%!;2H^LJU&XSS;(2R(.?D7\?OEG"@Q
MQ)E2.[1CJ'Q"?99NA:44@I4;:P5:X*%G(6#/2%^88-QJ/UWOQ4T5GAA)7:81
METPJ%2/-6>!ML0]VJMW*GY'UE)!7IB>H)'U%0?+R$FZ#S?/4TGJ:LZC.D,Q
MO#49*AH$ \-&PY,^S>6G^7PSA\&FE#A=IAA3O %#QHD5)S\TTCI:GK=9A@94
MX[!4MF@989L389N>+51&V#8L44L1^Q1IDP/6<Z53"OX->\<*)Y1XJ=0B_-,W
M)H:S$8;+;V;TB-BS0J[;N.^*KA+_T%3S?&D#_4KX#2;\A,+EA@O\1B7]J4M,
MCGK2Y^ZG0LHT;F,5 KHH5862?X?4,09X0,S,CBX01#KHO-LFSDP%M:F.HM1D
ML:.K%HF7ZN&+Y.&[M!2(M8E4LT]$B>DFA)RID$@UU\MX291<E$\OWC-J9O%E
MKC'2L:VKV@_2KB4VK_,NUDF3;HY3I]S4.NO6"VJ=K=C1O?A$D,^)"!T'#H:,
M4Z4XI-93DP?^5UY@+GXH&Y2HI+N!IEY$F;087>459:Y7Y*IP._D3%SW(&K&T
M.("8(HSO)ZJT>CC5+1G6QSI+,K)BE^ES.A0\$QN?#<)B @'5+;[$M/L4N3*!
MTP/R_8_(.JZENR3KO\ZH3M)3*R@@ -\4K7X\/^RCXE3*+:4N;DD +.WY^R-5
MEBVU6?YM7%,PA6//F/<_!R5G99W MOQD?4@[3<KF)2$L:;S,/S%AWHL=B+C)
MW-%)0>6&52Y09Q(C:!Q=XF;<R@D^[;&-/7?T.U6I,M/ ,.7<1$[ U]I75M94
ME2X'NW>5@J L,MBB=-2SC9H?,>"P0^Z*S&FR400) OXJ%7[AD(6?*>/AKN6X
M.L>MN7VLG<CVN-D[H9\D!.H]BT/=$Y=XRG.J4\HT<C55'(1A7'Z3TM,4-#(K
M)+6C0L^#A.2O"_LJ?4H9LU1SA='[;*I+U@$=<W)_3K@&,,@!_D>.B4_ID/94
M0"#56B#I_XX1,)SUT$_U;HS-U;2W&<6&\N6@+FV >H_U9,9 A)-XDUPTJ0[@
M99(C\#7$JX@S&?QGW+. 49V"D9PMG=HN>6FH\CQRV8*F.=+29Z#HAQT%<LP#
M>6\L;"TZ-[(#[T**^#1-*1+364[;U'";,VAE#_]TH$J/2X)-U6P)R_X"/5MM
MRWULJ4*8+BR_='9IU"LN!UL2'EH:M/M$+5E@%=F6W8_&,6G^IL+,@6H8-\)
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MPOA,P;+#0JA6E&',>&DCI6-;$"%1[!*04A8=>BPXU;*4:/V4B WK18MV03N
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MDN(;YCGSMDKMBX(3@T/N '5NS=2KNDG1)YC"]L[)<2OSC!AUP'[@H\18A8,
MDU%Y<W";3.LXZQ:>E!2NM_!H"=WTUV\5PF+ZOW38.OU1_QNP+<K\3/%BN!GC
MZ+BNDI33EL<58L3@%)BEL$)JOT2XJ3F:PA:55V<I.UP!F<H2<T:*2Y8H7<CS
M%5NKIWF?(*A(JIN/ZNB< 2N<81R$^%^<.(@AIBA%2P8];#1;H E!9[&L[/;X
MZ^89'^5<VD,J+@@KGW62*7O/#O:W2N0>H8\*[PZV8N^282TVO#]^]NIVVJ."
M\3A\OO\<7Y[P"IAC3*8K+0/;>(P\\'RE 9F>L!R9VG0G^I/UJVTR6]<]/]>5
M>[B;DX06$G/'%*$;B6CGGVFFM)@:F??Q";F#HT\VXM9&'^X^/OKU%!R(F*-.
M2EVPHX 1'\1N#:4/"J7HPLJ$U4 -(MV+(N)> &:R2=Y+Z'_-^GN4$RM6X]\:
M= -C\1/7.+.:TU'?4.,^]5DM_#U/$TK^UYY"Z P56\5-HL (SS4I.83^B'6Y
M.>9 ;WU\-?_>T1D']PV=L3L/KG >4 !"&]*ZPMQ$59"B<D8.=ST%?[Y0TY(6
MJ.%,V2[8%NKE-[ >7'J0Y7CM5V+-\[G\.^,3>@FSCD[S)D?0;@U<T2>@XT;/
M(HF3*>M"PV]L*!(II>?&A%O[.M7,NVOQEO-F-W$_=.*$XFI)R"V(GIDB@QDS
M2JQ -;(1*66%ZNJ:1V*GCS7%Z;<IUF.F+LF?SE/MQFO2'/'?+>?4EFG5K#R1
M69YDBYW/?@/3'/AYL?J ]-_61],)] G7ON='54AM6*%6H:R:[6'+["HZ@VF'
M>%G@R]49X7BY<U(^I7+;!-,4A#_D]D*&WR[2!!<3UO(#/K_01Z57>K45U]EN
MS6RS9BP&VR>9=YOTQV4_N$#&>X*PXT*!PD Q*:K9;5:EV6("$0\W\^TFZ08F
MB5I?PVX-JM B! !CQSTN@"OJ ,%(DM WU5H)<,^8%BXHW&IYESSBX">8AR7T
M(5:<V >FXB1A9J7_W*7,30*=@T],_)8<45-N#?$1JR7[9V$MFKNMW=N!(^?>
M:;>Z;F%U55QKNT.E6AI JOUADD%;"PE:BFN7RY@,QC- GP /(BP,R.A+)!MI
M4'I2L%$_;10Z)1XUY--)U'!J<T<087#6J&T0^*JY92Z!9$(YC1W,VE[42U11
M62:XV WX';<YMVLVQ^T]UO"N\2"L 8J/I40?R[9A5+9I;X"80Z ZLJRHQ^RT
MS&=46"6<%?XD3\[K-A-"&I]L,-@7C6+TFS&WD>8YZ1RX=8CU/^[^^/$&=+=X
MMC6YM (PMZXMEMLP]UO;-;H@=3&&ZTB25F9Q[$S+'5D=U-2@1:Z03HBAOCJ]
M!+V\)7RR1M>FMVSGG]U$'L4EO3B=X1"6\V2*$5S&X)C7X$B 7U$(@@.?[!\(
M-EH%AX1H5X1"(!5X]ODNP?%C)G-30!0C]QG$#;YMVL];$3I0X=@5VP*%(KCK
MFD8CI/=*Y[!:3".11SSWL&AKX3/"ZHC0%7!)X9^[Q?+#=WZ*"$_7%J R.12R
ME=4WF*!%V1 #F\%T4^:3RF&(G:)@!^?1MR>Y2!\!C;BB$+LE4=""(,QIA=PU
M^.^LHJPKMO%-Q-)<BSS!G6G./.98COHY/$!\ '3N>@E-(XOOZ3#CWR&T&N);
M<)P=PLNQ,6/?1IT4O,$QE+? !"'2T^Y2"\/45\L),QJT0 X8%>D(U;Z'_@B9
M9HH+>AHQ=Q0B; ,H/<^!F#NY>JSPX0DEBJ<\6[,2'HN9]9C]0IA(*NJC8IPH
M<>Z8CE)AY*20V\E^1+,L;Q6 @MQ157V:+1WLBR[.89NP@"&<<RG";A+L2P,-
ME[2X@X8,-56C^66D8YLV6U4N2VP:,>TTITG-_(2A((GK/9@88'CCD-0:.^A)
M$SN(% 4!"@F=YHP6%P+L2X-W%3]Z290N_=&^14+>^$;X6T&"7@[D^Q# N]>$
MGM4.P"X8'W>N66MB 1B6:LQ+6RR1@&#*>YI>%O'Q8<\TI8N+IBISVC"U7VWT
M9]\T)8OUK,2YR;4[/=BK.R#4"!#J\3T'0MW*T8][(FC(]J0"?KOBOA?CYS>M
MF.]NTQK[[&"Z\HPIR[H._& G6^V8'OP)$)NU7R#S";>\",\)[E0^SHB$,6#R
MXEMP.P5=?3_ZPEA#=!.Y%A/:>!-_T([$_<@:C WZ_MT-:89&C(;AD@@)23P?
MX]*1\=$MU,;+P-I'J9%KMB#&B:#_LM^EL/>#.Q1^R&C0-:F-7PROI=/8>&Q"
M3"Q?8!:<,4IXQA?IG0/H*9RLAM>Q?2)2U_7G)0XARB;6[G1S K=R)W= 1HBO
MI0[-]8,R2QN4Z:BXX]IW$8>BO=M[)>:,-X[)58_W2W<DW3>_(.,\A&.I\X$B
MDTM5.J4^+E@@3VS0Z2*-A&1GD>\FQPM" %N)8SY/SLH@-4&7P. W9XH6OB(Z
MY&<IK24I4?H0X:*&0 H7QF(YJLAAP(==D"6U>6"XC:P0N7B0: %&J79,85$P
M$N%W\3.,( Q8@LENW$V;TW0#]A!?>=3 )VS)B_EYN3<O@:4V*PMN[*1,SP:]
M@?>.4REH9I2CKT[3;T/QZ$S)BLB_-,==69D>>:4JDE@ $P+" *&\&NK1&E8+
M/K]=4Y '"XLCW:'MV(_>\+-<.7IS+TWV<X''((6VL&_AP/6[%1<$EIPA$"4\
MSZ@/ M])="/A8*4I^T-([88>D64 Z;W55PDC!5! Q&SIFA2*^#L*_*+@S24U
MX?W/D+L/=S@9&TM+LEV>)>X%[;J#R*K0SA%7@?TI#H68&(.)I60'NE9A2J?2
M(6QS"3@E5>8XJ'N)U4:IQ1VIJ@M6PY1"=UVS5$%95>6Y/FT8JM'[T-_CH:&F
M/MJL@%LUK?PIM#%T,IFTCLMO=<V2::\\@;LUIV.3@5\<51LH3;=UO@I^A[1F
M?>N*!TI*NRI'%8"J]JDB>FM9OLBPS1XQ)<ALM.\DDM<\EU"-Z=2[LYO,/UB"
M1/(&WNF2#R-T]1OI:G<_DX2M\?P;/$C1U<!8(W+P)T,=(JSK9@YQ\:,5^,84
M/CRA5+:!KY ?026 :<XDF&"TP7Z1Q_\>#L[2<.1<$'<HHTK<.;^(/'&0864(
M42,&B58L$>B#U48VD5/B:V2Q"]X"#FNOA"==<I&3BL(Q!H*9R65"-:'X,-X#
M4GS<65HTHD1]C=Q+[_+RO(Y^%>F?C\Z*'CEBAOMV#']00:(!/:/M-/PBU25C
M><9GC_=?AOHS3U^,Z<]P(M9%(EGA=9*N_%A;2^**LZ&:Z[:_9$AUF@TZ%A^P
M*64I2@F7H/*\65S#,/>?6>1T[AP3Z/0'KO#;Q)9\,%I<:'@I4SK(AW<##^,&
MVG"\7&G_'1YT]]_A8Z]N/;3_K.Q:,3@V5W_(RPM4Z]/-//N[\SXY%=,8,;H1
M3KPAA3;6#W4;=_37#V-'>S;>!W!FV<7ITQC7M8/,=N$-]&C_R=;GUX6/.+#4
M!=\32@1FHK\RIC1 (0F'8)X6*+P$1W@8-;!PVSEYA)>AG;Y!.MK76'I*N!/P
MHT>MW3OED#ZOGL8 ?@50!J-N-,(T(#V99,M3KYI,MI7#^"K,U-ZE:9"\H>GW
M,(1@(3*-L 2;.^5W9J3E91QA+^9 \&5F*FA5FG%)A?T9<5$2 'U+ S@!#<H<
M EY37!H@!PT2LOA913 /;'H@XG]/0$T!&[$.2_..R];T>]/':(@E,#:8P XC
M);':K)F[WWNY]<D]+[?>E<WVKPZO.F44$)+WZ.4K3:BS_;:;KNKNPL V^22'
MD>+R&72&6.)^D=YRRDMX7@"2=$TJR>IJ1G<01M_E?N@DUEJR?Y^MA'S)F@[=
M-R+S:C)6+N^7*59KO=TNYW<+X?Z'_WU'6,H/#DT4P^E:INF?HB^4YYA2G;1.
M1023</HG-IAPSK(88>SI?+Y3 IY(T)_O/[<"<"*^1D7Y;O^XGRW['*R$COZ=
MDGZ;N9ZE"SX^9.U2YI-KZ93R8E5BDE88I+:[S06@7 OK5^Z]4W#;@)[?'/1>
M6IGJ&),D5YJR/QX<O-Q_X=9.98W$[U$S=CPO+Q6/*0*?.66FN>?:(E5CEN0V
M+J^5Y_:HV1$=;GBH*B5M[XQN-V_Q:D-/;Q W:Z\7*!?N9)F'9)F-.6,N7<%F
M2&>*90WG.6&B8$KVU!:^.JN2\P@1&ET]\2,_%+W3V_W(@66XPF=TNR\&6^^T
MI6_63HRK0P]*6SJ]:$3.+V%5HNX:9^;9"C_NRMQOI0W=TU@NW2HE0D*CJNS\
M3YQ5%$T&#P +FDF%;FJ%G>TS=A6T&.UH27M:DGT=R=Z#T!WTPLZW&'THD<&H
MY#($CF)A6EB(IUIQ3KHM!KW;:FE.00F,"V[$6I/B50N;,/=VC- P?'&5>.N_
M# EZ$A@0TU'K-;&IY$GW(PTI(E[LBU=?Z?[KU*UW M/7V953X LBO@]I9W X
M?,.-6@<AA/ 9*7(/7G_^* '<0(Q&WV!CK]11<U([2=VW4>6%F/WKIIT)\(2J
M%R<8)>[EN/?\!44IC9MC7>J4F54(&^3Q,FV%S1ZU%VP6W4>"'K&=Z01W\'83
M'S722C1>#@P'2ZJ[;_ N%#01YI0DGI&MB& ^TJ##'A(!$.<D6'@*,WSPXA'L
MBU6-,?C!\U?HP2(A?Y4UF,*"9Z4ECG8(70 &R$ICD6&C,;-!P4XHYX%*OK!:
M8#3+@O<$H2 "- $_E_!TJ;G6.P5<LB9T#Q@US"WVHR-1VC)^-J-<46/8?]-7
M;=60F9D9FP%F4%_13\Q%94<:=I(MW\9I+G32"OZ]!L1KY!ZS@0V?S?[7'[+9
M[%DR30Y>/ID_?_YT]NQQ,GM^D#Q_\B0Y>/3B\/&3%__WQ8L_W,U$_O'7M^^C
M)_O1?_UZ].'K\=>CK\?_YVUT].$-?O"+_OO-\9?7OWS\\NOGMU^BH[]]_/5K
M]/[H\S_??HT^'W_YYWVK4[TQ_L!( 2KRX6=#*H04QA2EPZ,YH+*D]"4E)E!6
M6%AXM.F_9UD]S4O!=D\@?E($(E$E)QV/X!/LU.CX.(Z.X;B*GA]%?_BO[L7_
MRUS\C;GX$5W\/5_\,US\#UJSH/#C'?:>'CS:^^>E5_'+@[N\BI_N1Z\_?OCZ
M^>,O7V@%?_K\\?7;-[AH[W(E[2VAN!2/[*<S>LW=77SN?<*2X0QG^;YMMX]<
M\4I.U,5UO#YX)!'T5=M"X9NOP<[.H[??B:\4EO='A 2+\K/_N_?JY.]QE/(P
MIOPUO^6T2<Y47F>\$Q&\,*<@!';=9THV'#Q)]@X.?TK_3%\^.)S)OWS ^O8[
M[WRLT\=RC$L,)8RKH7-I9 ?IR$[=;,=7>5]Q$4K&5<[HVE1XDN FY?PFTR<1
MB(-X"%56QCU>O.EHD0%T30$NL%&QI-2HLQ+;RMTN7OLNDV-N:<UUMT4?L=/2
MCS</$\SK?=MV7X-SJZ.RE^E;RW1S?ZEODJGTK6WPK&&O2P38&(H]0/%+:7%:
MZ+;TO')C>F76S2K*LV\*C>_^(-[N6<>7W.^]K/KT?I=5;\5&_(+X<TUY%]%;
M-7U$'06F]8JG\QU*",Q2ZM556G\YH CX?M&Q$"N>14YWDG"#:_U'+0&)=%/'
M'>.C^"IQ=,I:LXR3X <0Z4>.Z=%68"E/<%HP X3$ZI\V7,@@94K9G/9O] S<
M"U9G+MA$&T+\'3"=[L24IT3KM$B;3L.(7N*D< *$<B'Y&1A"S@:"@46_AN-L
M#46M A(' 'A!LGS9:5G242WY3=:_!:\A%>%/Y7GU^9"L.)7&#;M$YYU'JC5T
M62N@+B]%:EFB6T@%5PIWB?(!!<T:\JM.2LS+X%]S7ZK/JFF[J$DF"/,!TVE)
M<KO8$[VI'U:E?@4P;P=-N9_M.)C?N/L>5&((YG/XSITIQN>(P^@+YN8LO4Z_
M+/8Y8N;\\>[?I9PUIT"]O<<V.+)7'4JZ!VZ7W=$[<O0>CA^]6X3=3_]PG\YK
M[P/?U. /'^&?CCY_C8Z/]Z./7__^]G-T_.'=Q\_OC[X>?_QPZ?S'\[N<_SC8
MCWYY^_/1+YSX>/OF^,//FV8^[DS8XJH\+]!HOC;Y>C1OKS4//!5FQNLJ_W1J
M/GEZHJK!*1YG0X":S58,[+0[O62.]AEOL^W_Q\1O].[H]=>/G_MK[,;?!7.=
MT3OB48J^M L8W=6UD.G=%2_];VE>GJ.3F8"71J_'_3"2C%8&*:&Y)&J)CH0R
MM=';]@1LDVASUX^*J>@5>+T+W!*B'$^;1.\W*^%-R ^;S2JBS\US]5KPQUW>
ML4Q#@/,4GR_=C_Z[;*/ZE!"!E$\C%%'075\BV+JN,U5\9Q(LDEG X<_F*[HK
ME;7DG?=IOQ-_"SWSRM_$UIG"=^'27T)-3WG:<(:^97H5]._A'A[6PB\'SS#P
M;BSW;:GDA$G(DAB"6VQZCX,[K1L\?EA8)-*9#L]/]0)^<7V7 &TN[/8;S$:L
M8<&<N.$XOTF<G;"U_6:B>N7C@U>^+B%EB8.C7I[S*U7E>( GNEZI##+/^!TP
MEL!!K=)FQ:XM#B%3DPQ.!$WTR.O89NQS)81(F1,%+Y<B0EGJ)56RS&;<!E"<
M4*-'<9959<'H#]R>NH/@A*A.!&=%U5S,[>+_$EQN[2K%N=39GYO=4:?NZF71
M8;<<TB?G?O<V%TH#0R9B-I!;UU.(9A!4MUJ[EB"^FE;9)+V.F<:%1B$N?+RB
M]J:@@'&AY=F2YO1'V%JZV%^Q[3^;;GBZU"'@/"779(1-!D[(YT]?13\=0V24
MYA@]__ERIU' 8_NDQ^U[.^QN=X?9]^#I_B&. %:8BC2I%!RLU%,8Z"-X$KO'
M20E<\ ,&]4WA.N51B(H,PV_D(/%%JK4"NF04!LB3/#AAA#TID-<=D<XE<.J2
M[4YM17+A =I:TA2&"8.1*4T:*J^=I<@XAFEWT6:#X9G#RI??4>)GDE[$LS((
M?-@MTFT6Z9$1?N+>'"7%"N'\AE&!NF\04:B414Z1$<4KLDDK]'CS*H%_M]RR
M$U!BC2]P8N>M+?D]TL)*J2<@L7(IK_Y62.>8-W/</VUA4#FXJ-%--!\1$LKP
M':UIA-LMJHT6U1!SFZ493"E_F:KC<?%BXA[EIASA?#L?(),>LCO:0BGV9V<\
MKCC/_V*OW3NV"(A&']6Q72DNTFG/H8,_HRS(D'*=8-_H8J6P=PE@COBB',RR
M^U-EGJS3];?L"-])EA_<ZYDJMC-[XC21AMJVD'-L@F$$Y<'I#%2Z0F0OW#/I
M;+0E3LY4.\T,Z6S(ZCK.!1B=94:MT9,)$M*=+XJ5JG2,@8SHNTPQFCSWV/GX
M]"/W#^>;>'XT);0+O8H-N 5W>^K*>TJ]'T/GC_SV:AE#84Z!D"JA.8&!6M1
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M?SU2I)@'-!.F2&&/6CS/EW4Z^TN5SBM:+:OH_;O=WKSBM'/X.V-*!LYVS:*
M"@Z3C=/=X79]@UTK>4^>3-* 69"JM[[]GT<>I2.9\<\[E4BRX+B ?3(Q)/@H
M)]BKQ  [93LPK=C*Y-"A.=" % _B3Z>8_'SB" \Z3=2[]7 -SNPT67+T('-!
M%'414]3YAOQTW=FH)!D&(352I'^U.R:OZ9C$9G?3N.N!;LZS@?T+LS%U,%YJ
M9M7C]2S)<CUCN=?OPHK[*]R\N^G[$5Z.Y\ 01@OK;A*U119 8_ G*=CB6;J@
MQ"S37Z&*[#1=-G15;#-8QXMU?U!07G5J/?J'1]5A9$QKX#A&)J"SY4F9(NV
MPF7R-*BZ8&DZ-J-*FL7@.-*!%]\\W*Z^#-YN*Z30QA@\Y9O&MVFKXB[TYO\
M^,_O'8G^8H=$WQCY>_/Z0R&%X@5P +1XL-\HPY1?2DWH&LZ4)[=QH!S5HE@(
MIKLOV<2<<QWA)H-^\1-3AN/+7_ YW%G5.I68<&;DS*';%J6]E]PHWO(N6DJ3
M7B<Z2KYNXIBKGE3 !P\/N"CQSN1&0CQ0G-""E,YKQBY0^2COK=:XOUR# &,
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M=IH2[AR\$@R=Q'N&$<9O,*IKK@P:S 3 X1UE-S-8 N )PPM^P5O@X@_>4:>
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MF6_N>0[6-\XX:J!N@W166>V_BO28F5#30B85#)D59V5^YDNT_:%W.0/J+/)
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M\':S3;BXHYUOXM^R.\L\K>I=7#"[,J&$[B6DIJ3HAF:X0SG8$<GN+%0GF4U
M/(8A$\L/+6$W^@$K>>PR@S%C;YNLUD0O?']12J[-@$%Z%.A#YYHML9H-4\ZU
M7X1 II.5 T9WP?=C:C%?Q5X&J3\NTWOPJRC)T\ ;DMIP)UMXLU_:-1,[2@56
M."S*F1+RE&?9"1S8W&8OK00Q[2FB26*,=G"42V'L9[S(^V#"/LD%V,/Y^?VG
M.'POSFTQ%%*54Z1W.O92*K61)(U(3@Y1R,*A3CS\B6C 52G\>2:ZZ^6T-8=:
MY[XG2363)>56 (D))5/#[6$(*K#%-J6A!]?\X99K/5BV?X1OX4AH)5XMK3<Q
MCEHI5D687F=%N+Q".P3[R#4G^$8BX3EV,\FI"(;5$FWW=L@'XY:7;0^Q$: *
M0K/49S5U@$]95HSDK?L%W5W1]OJB;A7]Z:-2J&DD(]NQRU1= YPY*&JY^HC9
M''%8ZD*P!^J&[(;^6H<^EJ#L-)M(2UB"C7&HNN'L=2R8)\EU8!ZX,K)WNSFY
MNM5Q==MU)V483>V&_:K#/L= +H:37)15N#4-J2FY=*\?:)5_D\:+W=%PQ4DY
M*_.6-1O86YKQ*>S;7Q'(PZDDUM4HRL:U"#)[_\RR(;E0)T\K+G6,N>:[#77E
MKA4J#6F'I?+=JHKE>*W"IW1\$M?4&G83<YT3,]<$ Q7PYFW-:3&M"V)M3\C,
M<HM7VJ1>N)NHJTZ42+<JM0F+,&'R6M!>GC5C;]X6V',>6C.4M7&I5^91968O
MI0E$L;,9+@*C6<3XM&D <7X5A9LY//O6)RYW9^#U=?]%T^PLPR1\A3U0FM86
MA*HJWVJ!Q:8\Q+E!=]]I,I64SC@IJQ-'+\?\;\)[QZ6]W2Z^ZOPYUX.[0KB=
MFRJQ.R-Y#<.;%;^UA6\.(SJ.A4(8J5B.>X;")=TU;HNP-NAN!JXG3<8N^#7+
M5M^IM/;7WN(*]3ML;5M)D!S\PD#'K6G&F!Y.3$)7V]\/_U* X%1B0V4N.!M&
M"D .7/)#Q)[";/I:Y:D->?.B+P, #RFY<!DMZ'!*J/6MBR'90:)'(-&']PT2
M?;\-!0+'C$^->C7@>9VXO8%$XB>PI,^R4BGLX-,\.7>=>]R=PGNE[I+O"_L_
M[0V5G>4>5J95XBH:7DBP6YZFUUKIH&+>>#8X-E'+$K_'QNBDS69:'/7\7*]'
M2V]JAU:6^PV?JN!0T^0X,=!O&[F-'S++[J>0XR*AWDXA][8P/*7(&8Q%I)>S
M)X+ S>2.>%U8[$OW(FD'#N K^RQ=2]JL??:Z//L&L=9I6<YBQV2G'&4BM\'G
MY>#;>NJ"I,(68([\) POG=9?CG7TW*6Y.C$ 5PF=^G&G034A=KF'BMD\)M 7
M1L">77;>YG-$7C#;]>;5YV'D3LQ^IA?S+%FKA)(?#/<0\C'/N[:.[6"R$MZ$
M_O9Q8JG^79)9LFP\^I<VOA/%&$/'T1(IEWICW(5KOJH[7Q1 G0R'-R(*&"[[
MU+F"9QDAC34\=[^2!B85LJ=9-6T7S#C'8E!2,D>+)MJ;(ANF_'I5/0 NI&&7
M6$ H!Y-)B;*HIH./P5T#4BFVZGX[W,$/U6^6[OT%2<DBD VEF[F*SG05;15M
M+6-T*31<K,9A0V"KQ\?-L\)[R)=%R"D>S6 %,4*5ZPA2:4\=W@ZO$&E=[$=T
M]E1R_IC7J%HE]1_4V]+<K)B1'BHN*/$Z$$SLNA"'M56(.?*<3[ADQ(0I:&9S
MP(R@6]Q)*=![>((0P4L[DZ0*X&"L.#98:1$[H"!1KE'D4:Q2 T<WH)Q9//(*
MHQVX&D 8A)^D((:93JT=LJPDU([>RZN.D[F%&?S@7OO1>]AE.-Q.HV,3X*+=
M9@,@Q?6H:S+XO>,'RPH/UZ(- ]QPFQ4]C1_JBQ/V5 I;9?\IFP":@"[S1[B
M](R*1\WDL/*1E_F2CG;:6?IGB//!<X>IQDP"GV[$;WN"ZH?JZH_<,-;UJMR\
MWKJ,0O!PEW;&+6W6>V1C^+\>+BYP@.-U23]$QF9.9!6-J+^,D.MTBF'RWNF%
MDU:22A /W^BX]9L>U&I3,=M_01+&2"CD]GL<V(B*%*O< E@[74W9\$^HC(1G
M4F!$Y*;TU5#@*ER)EM7.O?92^X-"'B23FHT[MY,N0=:QE6.K/U6QM//2$N.S
M9M-&(D76WU ST6WH&O=$-(1@>LCO7J.'L '3&L8+ <^:='^:UAJ;G?!LM3/R
MB^HRUD2IU5&\14V.AW$(_4M%<\]H::H@ZC6H-'0F''9>XW4H%_B-59JPS*XL
M.G]"(5>%(X6OY>_HS;(2;O11^CX2[-WP]%:H6\AKQG>@PD(K<$5$]0(]))A0
M3*"BT)X[/+H]JUV-C0XK/J\U\O]']"#2V4!B+$^+D^94O9K@8OCGMI $D)'.
MTJ# YVRZ6)?."289K)#C6>)@<VPJU?-E.KUPXCIS+J3BR:"L3JQK8H!J47UT
M](&7=3K["YR8E8B8O7\7#]YN/WK7?1'_\$-<ZRQ"O8DE8!H5EN&V!?,!!E9N
MI87I)36ZML!NCS.65?V]6Y0OZ92/^8'TB)R5W)-GZ?/GVJ%UEJX)@9U2N^C
M=QN+PBC#4A:0\&_"LJ%5LB2!0[,6J8U/$W4!P:++]+I6#]/IE*)P03)USKA3
MX9-W$IV X=(:K/OS%&45Z[ Y:M(5Z!CL\'"\^[Z;H.X%<J8O37U.SD*.C)(H
MA# %5*8,5@DMBC>H"7ODL5FTKUEKH+/O$U1=DID_"@*,[L_?'_F?O_UU/SK*
M41#ZY'3(0QL1[1KHJVS6:V6J-W?18;<]2?GXP;C6$;+Q_) =#"LDP9'Z T+C
MWWN5\]G#J7+><+%RP-[KA@M(G#=P)-=1-'-A"V/N2>HT2RFA95)-MB6EZK;D
MFNI,KQV3GMC19W"G<ZUP-G(/Y-E)W,R9!_ SSC(^_6W:?U/?X\'FN#Z/,PC1
M%.(H*E X8$[DMDE)>%58>\933U#\L[3.N'%9#;5WQ8=M=D*Q@?<XM8 4J)0G
M>OQL)5N8!8J' [(L5H-P30S=5S!<J==OGF&:0]!$-2Z_N<C5%%?8["Z)[76+
M8 TS/4?_%F73JPIO%ZB0D0?OKD>I\-HS2L.5*"F5SKK5,O!HR7V1VGXG%2=E
M"]T7)@WNR^9AZ7"(1GN@<\_B@W1:Z5W92TKK*?Q &KI=G>=T50NGFVGLX+-&
M!I38_A$)79V@0!-IG'%,%Q'G)H54[CX-V G'@N"K2*<E7#QMW'W19]S#9X9G
M(@4NVPCNKI-ZECER2(NJS'/AVN2>]Y6VY%LXEV X_)AY$4/:&KC,@LR>722<
ML:5L2:@4/:B##1MFS8H,.2;#I2?Q-U9P^!5AG2REPN36F$)68+=FR,F'7\-]
M2WRDK8$JF+\/>L=Q9S$KK2D_/(JBS2A^1-K>AQJ'X9'<3P=T$N@NW2<M\5[8
MZ1J4%,JJQW5;#,-K0E.FGD(P:WYQ*;P)PIE4X!C*)V8 CQT+$2JLR3Z8I0NR
MU^%VH/B!RADVJ<\>P4Q![?0CQ]Q5K-:&"I<>P4ME/'M83/ZJI)70/4H0%63Y
MIY,ETD;1$!=I.L/:2*,2]I;'OL0%7$Z_Q7<TM7H':+5<#%M62[1!9+_083F1
MSK53.*=(34:/4U_X56_&GRHP]AA8XD!"(#C*QQ4+>MC<AX\!]*\FJ6.3PXFU
M_FF:4[E$<J"3M$BI=\/0;G)Y;OA5;.@J.TK:C<ZH4&V7K3^/,-U?SCCEX[ZL
MD(J>EO<&D;@PA<EMOJ5;Y/P>JNW_*KZI+K&QM>B7GO=B#PY'UN&[2(WEX!J%
M*[P!PTVY>+Q*[-,TKR]\D.Z/+]P4[W0#_*.%^0;G^M'HD^U''\U=[:*;EL4<
M'3^TJ4Q+! >$E"4ZZ[//<18;9!F2]\_!62O/PTJ[+1=2;G"U!F'GQ'[)1."S
M9=5"$"KFJ<J1EPE4AO51:#<[X)S,\;.8@A46:6V"')L+LGL!"8RBAC+/8XUF
MPLG= 'Z%@)Q"7Z$'-M '2$>6V48:ZT2M \\>X_]CP11L'";1GC1RN3K\,69:
MX3FRNF2P%+A+#*@Z_'<T7:$<4I%BHO@G3$G#'^'S/X.)*C#:83XH-#S@[)\F
MF(R%L,%E@'ER!4N-CA9C,&&G4@^EA*[PJ)AS7989CMO>A#P,3E&O?DAV[V+K
M-$FFWTZJ$B*@/3%4<_J_5S=@MMX8BQ"L%+87)=RDN)6FI3_\;SA'3]J$%KKD
MD<?PMIQ=1K+6G&'S/403$;.A^VBD=WD+QM;H<79_9A/F2E=EK%&,6?# @V31
M=+!(!:9*<-#@Y/7GKZDOCKZ"0Z"L.3B&L/!SW[($TY-IDH(VL51(%FF0='"Y
M&/0] V11X ^ IP[?;F@\ZY9<"'U03>4\T*-<"O0Y9DS&3+\]G"RL%4.63HDA
M<\T7/55N9=!,:\X0C,W]>5);(?%9.A=X=:ETJ=+1D!9U2V5RU?=&="IRHV2I
MC2\;29;@_3'ZH+^ID0\I+N6)S,-HIJ&L&P6AC1U#\&RLQV,A^>[--3,3O+JU
M1Q45DY!J,L7441,4HIV_.O!+ZDZIU4%-$X?NAZ//!V5>V9T9+6L:!N.)FXUJ
MYO[!KGNC;MX;W#6N3V 9F?G3?T\C(A9U8]YR,#<-NF@6*8M $:>B4F(=D>/7
M,"LE#HC_,.%ML*#3'$NN7()T[I5+5B<+Q@!F)J&%[X0P6$G3N._9BPJU-NSF
M;(E9C#)/IRUBT, RME,&B S<TZ;+O.T5 7F&:W:.6N>/>>?0)UF#QI0>TRH9
M(9L3WY@KVK.3XDL@H3FAL1'#$1Y&X3G42Q8J3>30^ U/06S-(GQ*#*?&*@IQ
M(UX\8P! %4?8B>!7DN0POR$.$?[W-^J^+7S.VJ>'(Z368%^_G#)A*2=9@C[@
M@"G^*L&SBY$Q) BT@=Q!2[GF)E74.0M)HFN[>?DJ0#N-5NXTS8</*U2M^<K)
M4P4Y6A54$\P-@9C&H8F[:O9(-?OY?:EFW_C0V+TQZNF@)U](!V0-K@2F![IH
M0>JC+<IJP,^G/PT<3E\,3[)A80XRP[P#8=MSV(/Q!VY:C:.]3K5<="#*J'K0
MQ?WH0XF^STI1,E[;FO5UIJ=8I*&>0")0I^V-YF:8[%:DD;3+%TUG6KGSRYHH
M:KES;-'X5TG*,*YH:B5&L<&&,87GI9RT:#&<W;9'E*M(F2>?!IZ6]CART,9I
M<H%7-0J<<I4!SJ27U8SSLJ;GEP8:MX6O2>.YDTTQ)4'A$*$W'VI&49@5\E5L
ML\Z:R.DE?R_K:F%%7G-7Y&=T&U0VRR-)HVVW_KZE*P(_[WDB3NU(T/]CCU"'
MKL8([-!%3&%_KH@R>ZLQ$D+1KQ/W+/UQ"%TA>5:;Y:O1K)V3>X+=#4.>C2,B
M83EIP6+F*Q>':S@#\W1"=Q\;$VJ^N,X0C%-[L(;@-]R4QU>7=]+K&F_6#R2O
MQWG6,&J'DBCK%C/I)F')<<;-']\1>=F@C8%5>?"(\[/B9A'N86Q2-EL9KKV2
M'J8NRR*M!F/A[IFESI<I[YG+"A9KV59U&QQ-=,IP/MRD#[RGY<X;.@4>O])@
M /=T"?8'(]6,NZ_E&^#X!L>7GI_=LY/5+_"I?<J,7O*]/W$(6YVK@KP[S1ZH
MK3U&I&R5Y6BSGCA31*0;M&$2' !P3;DGAVK5C#=2^0.13Z!%17 E6&CG9?4M
MQ)KR>6Q*"OV5SV$*(E8-6017XI$* *-"W,RJF(X;HTFJ1O@<88N1C5]DLSUX
ME1=\M4L^.^WU8E;SS\XR$;<:VP8L=^6W, NQN!V$$5W=8*U QZ QC[;N8--.
M,#4&#NRE+Z"V !_T)?\GA-I.?X28&DKGWO!7]:)P]]H5!^IR#PTMW(/XNAZ]
M(A==,=JC!P]]^>#5?O1)6J5A<,"MKQEP)_(=VD)>H*08OK[<XB0O)\:"#V?2
MY X=*3AGF#E8M_0L*7JX3;IF5.E]4PS(+:&*?'_81-8&+\Z =;P7;F"JGZ')
M6:4-.[=F[\ =+JJV9XJIPD#:N;NHT$P 4#O9QD2:7=;S6B2HM8EO)<2@8]9S
M@W3VVD!Z[ZX#("BK9(&4V*F!T#:*I:G1?;DGC;B&"$&$>%27!S-(2=$BX!.M
MH':W7@*3N0YS&63-AUS C9Z5_9+&850S\BTH'"#_2;U6=YP)*<-JD)S8)]KH
M"![J"'C82=^[M'8,A"&,)+8 \M[2.G)H#=%CRLZH>UL:!RWW$$.^-/" $6<'
MTC?KJ#>*PX.&6EQ;\K[YO"6PV6CG%2WHW4(/73R?+Z4H3< D.M2L+L<>#8WA
M\7ND2\*N2$Q*Z)+AKXV.GT^IMQ5RQ0D 3WK4(V;B!'^2D+ZJ68=)W^ IO)1>
MPHL;OYDJ*73"\:)PIS1ZE7H*QVV;2[%<8+@+C_2G2[N5C$D:SH(+DA_/PPSG
M*&/,3,+:]DWY'9P 4=73)^C$J_4RQS-?T1?8 .P T.%=V>- .P&>Y;+,J-[X
M-P)AP**G;D/9IY.D^F9'_G%/!Q#?4I4 9YRY*D5J-62C'VGR4DNC!L+!/O&F
M.ODZWS \\I3$3H ]$^F9##4ZMC)B?JYTQ *4G&T<YN\22J:(/GYQ\J[UP+!!
M;+*P@^920N9%O5,%RPG]7V$7XQ9.IATZ.4$?G!Z:;J])'WIB]2J;X#%-^B'0
MD!7>"7H07"*$/S1P-1H"*H;C>+G*-]^ &-%F%VX#V8PZ451"S_@*9:"-R&$$
MXJG\>-3E+&L7;N/X[0'S_'+_:;0X^<NW$ZSZ5.@'5BD,0)I^@^6(BIPTOW,R
MUP8S,D&'DC3H,+7R55'+<;?;>^3=%$;M!W<^4,\> OJ'YR6]S;8GPIBYZCY4
M?_')0QJA8I^<(KB[=&=PJ92I'0<ZT\)M.?Y(AK-OVZ/OP1Y>(TU=5$LP.M1$
MVE6E;E_:LK'M8IXF16_FX 6'&/^\H]-#T7<[#T+Z4V7<,5%IT&8>4-*( <6S
M;0(/B-D$E4*@E;)@W%076],7TKOR=._8PS=B#X>%EIR S:3SQN6\Q5[CVEB(
MTHC7CFD'.(A\<HPH(/#;=2,L!$F^JC.N756FM6)<F>+W7GE^<5\JS[N]MIW&
MF7<2+"B3O+A.>.KH,=2G%=Y56\Y*\0-Q_37+[S:F-*3LY%^N.&=M,4_.2@89
MR)CN-26G*+R:MG/CIPGWSO%^@GEP$ZD2[-X+!XN68FE(:5$$ E![%)#WAMT)
MO9O0J^KY8.&U9?>I+5S]!:L@COF5^.PX*JX-RQIEFIT,%"MZ#QV'>&Y.&( .
M6[3%3]K::W22DT;0#'6)'11[-[O7[L[@_%#( 1&-=V)\@B+P994HN$^SN)N9
M*VO=_B:<TS8LG#L9%9H15V*3ME]%-#J].YB/#T(!7]-_>":LVIG-@9*19AYP
MMI4KU?5R-$A(2O>7I 75-7R3/?V:/O-ZEI@_GNXDD*^N'\6)2H?JF1.4A089
MIK5-J<TET;0&T9' 1O:,-"RY9_IOC$2X4:I0ZOQ\Y<CSJ8N@24\J606R .D/
M[X^.'$N8KL$/DK!1<!P^5'])QPB^B+?-=^RLRU5%L%QB,M$)V2BA1DOD B['
M^I26$%9[F/MEQKCK6<KI<T<@PFED<0FDRNU9(498V :XT,;,&'V7D\N6XK/&
MFE^C) ^[I72=+@0LC:1R0EN&2R7V?$OBV1,L#2EOYN[4L1*>NVFYVK30^$L
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M:V]HZG]S%T1T@;5D?X-KE"36Y[C[/,8?RX$!PZ)R1DY[YI!]D?$(WN'&4^R
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M8>1J2^=@+SC%:RL/1C%X&L2$(<F0%8QIC.OYB$:;0:-]^5#0:'_ZT&0-QE_
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M/JWU_)=6HG*@LT,+FY5V;E)*&_@08OT)XTXU7!>%(.?=ZN F5M4# GAW"J*
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M8C51W01.I)=+^_@-0\B24DDQ4YH.FRK6^<(:<TIT7%'SA:NY>M3-%6R/-H\
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M /1N89K T12<K"T:*LAG.VFZ[AW[8^$3RJ_4<\-%W30[PT)?[OK+#B_1"NC
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MB%^ !K]*GLRC9\_V29.@,JU*J!/;3A4?@9A%P5++AC&5JR@S\(=@;1&X_<%
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MN3ZC9I]\KPU&86Q]O3A#RV/TJW]K6;[$:LE^&@)>S]>D8<>AYRID]\C46VR
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M..[4F:'!VPWNJ+8C?TLY23UR#'H13E,&1B)C3#+.[H19=14;V\N>4\0E]Z.
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M*Y$QG8Q<I<@<[[!#*+V:Q"7BB6=$K]=PI$7;C>XD/K+$R7N4/C8[9GLS#QP
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M>R>0P$4G[&AC%AE1?T4-MV\UO;4;=KA@6L(*7V\Z+!'+Y:$>XYW053B]]F:
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MB><[G[0+D%?HGXFG+5;+IDXP[N?6<9 C.AHN7$YLD/3B>^M3QOYUK8<Z1A"
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M."5Q8&HGQID*-49G77WM7^0OM];5UX&AT?X"2*_@"K,%3#Q5Q^:T&:4%X.7
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M@;!N5 =!V(X (GQJ1)5@!^)GBT3$7BB@+8JP0) 5:SF^NYFVL=/3=1.%7*$
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M\+$I&OIY=_!1\1GOZH<[K53;&@@P  38?9A @!]I)3SB9$QM\E&(Q,UTZ&Q
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MGG#&^/CH;$<RQG(L$RF@"5V(-)!ZK:E;AY0L(1",%@Y/@HN#9X5#/.*6T.*
MQ)+;B1KY<!0.W>,BWV@G,N 9<2(11D IXB@V3A<SVUXD+H$,<CQ?TGDSAW]L
MM_/($(-3AOG?+:%% 0V'9MBR^!**"P(,$)4RX,##AYV8L\I\<YE$Y>-;2"<>
M[14%L\+) -MX&#S(AAH6&Q^Y3$S9!7C#GQB,Z)MV"^#JO4%::;LA:30O+>CB
M9<LJIL%IO]J"A01Y9)7QO/&.U 6V"?BJ<]9;-8O >TR"T326J;/2O7:=WF9=
MI;3KFW5QAW$QBK:-QE14O?JU-CIS%0:I]%EC'[Z73LG@/Q(+,J/V37E@#:<&
MW@I!5%\7 _. 5G\+3G_5J<FCKE*FD%76Z8INF1%RT.2WVT\I'2%]%)%NHK0B
M)ZH=-/0P9RV<%1#8E4F!!(;#P!AI 4I0P-A6G0AR+Y@O!AM(*HJYQGU<K.-*
MX"HB,_V9:S 6 +>#+JBC)6^0.V;9&CKTHMMH38$6"&B:4VI^;R^R4:#F+S)0
MC9:.,;H/4'<M<!R#8\ @4AO5E1BW7D4^V\N*K1+5S-[+X7&H+P',BO2MD4("
MYD$7B<\_[G"I+JFOL*HZ:&V?GQ(>P'_;?B-6)\PF&\KXF&<T)[WQ>Y'S<\Q@
MH!6E\5.7/=.A.)5F5.\KY^V0OI^S[/J%T,<083X]0#PL0:$' "]/G&.488 2
M,YJPT.S0\6=V/C! -ZL?HA:@"L 0[0)KV9,(%.1-\ X>!2=,S;_\L$*RSS;\
MTF5&;[LKBQWV=@Z.EEZNTB;UKT=$_$CJM5W-X;!MX7A\D3 4&JO[>D'A0VZ0
M5IM2D<=<$['N#&;,>D8$QZEJO8%L*^4JY<UH/$N3"\*QVU\R-:KSHZ[1"RM,
MJ:O,C1]>*Z) A7KO0<,*,9H\GID(3@RX1MTKL<#X@.%PGR[-3:C;M8O2>YMK
M0B>'*U$WZ>@=SD6M[O3U(<C*<S,& @B4D M=90PC%IY&QBFSXM]8I(NJR;30
M<9CQKXCCP;@#!=8AX3'AX&M]ER&+5I]!4\M:$0[2C[#RIEC%D+#\>DJE#BX=
M:M72LD^"5(5QK[MMQE5=+!9$$)P/+DA[@9!(EZB3I^V_5&_\0MH F*Z\#I[Q
MS1"7LF2KN8F:%ZWMLDY8K/ -$XFD-3/)8$,_N\W,)E);+4OL 8,&#&KI@O6R
M?&.'WG85O^%F,-(NEAYM)(#BTIU?.?UF@)[O58^YGD;$R:?3X.#DPX>3X^#L
M_.3@=Y2!>'=TO']\<+3_WGSSX\GI^='QKU]'VS]8B?FA_2>_I8"PA;4/M8&V
M1ALPI2#_EIDLL#Q06R11-UJ#2\*P6D4V,(300H3$*\;]@?O!UD!MHV$O8ZA<
MY];5JQ_A/GSUV&P&OR3U)7SVURAOHG+YO__7]M[6F^T0JBI[.'(?(!ZB/^_B
MWW?V]"UFS!5*O9I(F6+^^]_V-G=?@1GBB <C=1-3%Y?XZ=;FJY_=I^XA]LT#
M9^H1=EX,/\*Z=CM0N_WYH=5NOY.]63EJ7,ODW5(">ASJ"K0L(UK7YK3YM^W-
MGU^TUS4N:_IPZ[E>UE!0T^Z9]-KC?289'&,.7"?L)5CMHITE9,%"G<0)$)\(
M"[M#S,6(  :X336M[R1J)Y9?#VZ<!3AS^70C2R;UZ]V]EFW;V/XAI@WS[WMO
MOKDX4]_=WW@CLOU\\P6, +8E4SEHPG."TUH@46*3@^L$Q4:>GRK**/O.;M)Z
M^&\W_$ 6"E5=2>U,H[(MP"1<.A0UY!ONWU99&P+3?-D+B2M(UV\LX1:X[%*3
MSZ)1DNF/<:;IFF&;0PC)BR%)U$$YLV*[B6;6R^$;+0="?'(VM\T!!873>5(G
M&>3-*&1W09^96E9>B29@12GK7Z%.TX18TA334XW$F"8<XF> '%=99-G<=>H1
M8_>$."XHH!+@)T60?%%-W\G9:"C=L8Y.03$30::QVT+(,L72=$0Q^ZBG7'(F
MTXSS4(P:&J#U&KWE&FUE[[EJH(M>$6I\AI 7(TK3)$?\+^>+9(5@G6E,R3@]
M7:S;L)ZH6TZ4]#RF>2_+MLJCFDD1J^]*]GV_4:4":RH\?CIW)G7!45W(NCK9
M.E*U:D5XU9RUXW$W)PT?$=XPJ^F%36GNV8#+;<RQC^88H !T[#2L>RSTY,ZM
M(']$_3(N@$T.A3>P9QB6(X84U7J*[\"UAVN@$9Z6Q27!S^#/ TZ^<R?!H7,-
M3;11!4:1+[NGM?V&\B;7$WC+"01-S:8FMIV"/;6V4>1",,^<YMX@G*S'S(%"
MX97'G,F"@+82WL/K*:A/\CLQX<V2XZIQE4)')D-29CSY8NY>0=^.M\3D=AK^
MLUXO=[#AS62*YE<ZYZH"[%CQJBVQ!($ZN96O<H!B&Q,XAXSKB8-'O;3:(46O
MP(S7LWFGL2# *G67GI*L [8.*(9-34@O#6:S=%&%_FR;?_]9F T*>)\:<?C@
MHI&OCM.;UG2KT=)C(B%L6%&N]^=M9]0UMU$HC4J[L$4MD);8W-8#?<N!%H[
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M@;F@:XP:N7DK8X9R\>15PUA(@(]'](IG\1[:>1KJ$7$JHCK:#,Y8"I20T\C
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MD6E-;LMGO%Q"E<_/CG9]OF:#4GR:Y']M,/FB#6\AH6KF[:3"(R>?4HE -X,
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M"-."@/!@1'T[9.+0G1;"4W CMOEE:X8]<?"7./T/QKA*0M_U/%$ZOFP!#.+
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MZ6,HE,6$2_#FWKMB[HP' $:TV==NKU:%*V'='/5I^3ZYYM>?0_]3>-P+];3
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M5RWA_<F[JR/G)A>I)C-"4=[JZDV'B@DKK]FU:L)ZH!-53J@<U\?)GL:QR,$
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ML92 X(P. AO#8;M%T(8;[%H&W;J79*;+GH;Y5($G(7@[ZGWUT<>*;OE(7R^
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M;[4R)B W?]#H2V!]26W\W9"^U*X9W+,9L(8B\!&'H1@!3Z1$3&J.<>HIE6<
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MAM(,LX^K/XP>^K__Y?\#4$L#!!0    ( "J&IEQXI&'LL;P  (6B!P 5
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M)[;X'28D#SQ U.245S\6,&WNT&<;MVT<*=KQP(Y,+1<:-1PFMB:5ER0ZJPV
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M(?=?1WX0QJYO6$3XKR7B60%481[MN:-5(?!)&&*-D*BY<D]7+)X!($B]>NU
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M/^*/YWR7LT1%DV;.*,=O,>,H2]&RR!G^[W3=38!>X^#%@]Q,\]TJ@"3;NS*
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M%%FA"TK%[*$Q^?IX$)&HVD7V$!K9%?$L@6':]1 _TX1O88L4?2KR)\SWK>@
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MX%:F08+#U/=QXE'#C&+J.7)%Q"5H36QX!"EDP<S,$#1RYD23P#"SL=OS<.O
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M]KM% WM_#U]/17^;Q]73WXIOG_.7[#*O$O9OZ HZ/,O4NW).'#UF*]%MF+&
M/M_<7?/B-U66\!X\\JOC"!KCZZ$^(& *-(K!!&N=G*Q*J]O(U+.M9W(B=E<P
MR1$*BKI</I8DX6?_LN1]$<5M.BRE:&B.J95TN40M;=0E#M#-(0 D-%.3[$"]
M/"&VYM0B&>'4%'%HXOG44$*\/264>1ZN@MO^7HODGQ]S\")Y8OC$BK??QZZ3
MZG:!/A9%G1>0:KJG$!A7/PW"PS1/0NX)UL01,95T\-2<LZG?B%!=S1M[%*YT
MXD;XX9F4]+E8LB'W=?Y;=4=I^6M9K%_ 2B@YW<1*V?2,[+#1QL2BWRK$F4&"
M&WF]E 5I7$\GP >FMW+03*"Z0,F55%F6QFRJ#12ZJ^K0H8J90D?M*TYTT"-6
MC(EM6C@@EDUB@[J1!RJ??9+2U#OCMMO*4K4?C31$EFO@P$I,'!FV$7J>0VAL
M0T*#]$ $CPJ:$*)ABZA5<.#)X;@)SP3- D<%TY4*=9+.O!E08^(>)3Z-#E S
M:Y>[@/A%GC2%=)]H'N]=XY_*A0S"!(>1Y6#7]=(D=6@81B;$U(&H3W_CM>%%
MQ++L<;,7QJ+85P &M9P]F Q H-M<(W9@TZ&$@29S J,]JXE1@N70[*A-HE1*
MKEM/]R&F.2FSXJB@BC [H1'@T TM9GML/R"I91!?JI70**6)3<Q1Y><-=6!I
ME7'$AJV'5AQ@EF(^"$#%X_1 H99R>08DT")KXV*.%%@;F&#.XFKC<AP45I,8
MH)(O7K-SY755L8W9!Q$-V020B0CMJ^\\]["BM^D=@W2=)S3Y.^%.X*-^2W9J
M8.*'$8Y\BR86(;&;QO)YY$H\3.WK;0GSV,27DN*&-OK6$(<D5JLA+&'^IL<-
M9A@%/ZAA"#4<M?&(%TTJQ@7:HGJ;HBUCZ.]S@0K)8I\<7,7L]JE !F; GP7/
M<&:\VM0S9LR?)?M^)OUY4ZD=F&]H?4FJY[NR>,W8I._?OE0TN<ZO\U=:\<WQ
M+@S^U*DYM$T<DBC$B6/XIF_&%C4(Y-0,9V'JHS/C!J7+XEN%^-M&V8831+:L
M  L,*< L=V*>%CS@L9GCMN$$16_H)\X,@^\=VO*SR:5YNV _BY=K<8//SUY-
MSR/V>!OT7.23G*[5\=)TQ%9@8-9SMCI AX?M,V92J C\^B+Z;TM7 6Z?G]B4
MW)$W],HOV,JT*%>B'H]$"NIIZ<8O&E4$@ZGYH$QM0WM=I7T/A%$KY[N99+X2
MO@=L[Y7M/?R=UG5[FS&R4Z[#]3J.;4R"P,!^Y*86,0P_L@W(;94\Z8FOKQ@C
M*.9KSKI99CK5X'<+M99UN@_6L];G,\'2MB[O\LCDU^7)%^,!<*9=A/L(_QD6
MWP% )!?=H1D4/$7WQ1M9UF]-*YM[^DK9%W+'.T#$V8OX1D2NVJ:$S^*II")4
ML+_PH&=;. P##SM18J1N&MF)*97->CXK$Z_^+6^H;?G3<H?VV&LR-W>EJK8<
M CP@Y[T.">_2;"###-M9^*H41CP/:(#':3; U1Q/9P&OJ_"B%HP&O4_G49C/
M":4%B3U?E)X9%5:6QY(=*)[IHG^IL!(#AU:0XH@:2>1:U/1=3WJIV)][8MO?
M$D,+@'DY$%[",*N+!+.T6VE4K.:!6  SJ"Z>FET#B FS5?V"#!J?@R'S69-^
M7O?,PXE'U/N/GVZ&?O6]/8VT(6/7;>OMHR[!B8.)9YG,/EANX+A69-O@;N1P
M-B:V(KO29? NX^=C:AD1#OR X"@*O3BP3)H$].LK+:/BSX-JEQUI7'N;!LP"
ML9S;8'K88/9?HK< OVO<. XV0;8;QO1V?5<'1F,/> 4F9N\(KPY47W_X,V93
MV C>4?8ELO7[B=ZFN["]A>CG^%A\7.?)IX(<Q=)9(=L;!H&/+?[2S"B.:2 5
MP@N@.?65P98)'FZRJ_"]Z659%XA? *,E8P6P"9/$4V+/J1\EX/W##J#;%.TX
M0 T+Z+% G GT:1*  +M7_4"I[6HA7Y2NPSE,]L&-L.14\VV08;+M;9R!0Q7L
MYJ^\1G+.9[VG$:EI=722%H8RI0$F)$UQ8-(H,6TC<"VI_G!#1":VC#NJJ&S(
M M3[%"X2!D^#M# +UQ&TI:AR[#XE,<"":9!<S60=OVI=AFE$I$%+=&KL?*9G
MA/L]6S/VK-IIG<>?B=[?(ESMCI2WY0.OU][$J3'[)E)714WE**4A]B/+P#YQ
M'1Q0/\4T=-DQ,K4--X@@IW,YLE-OS39,H(IS<<&[GK?]T7_*<I04RR4I*_1"
M2U1Q=M[!3I22T,J=(/4#!MRE;;%Z:+"Z:YJW-TRTY=@9&TU*NKX#(DQN30="
M2:*S'@!A0!P>^("CU6S) UVRWS[]2G-:DB7O'I6LLCSCP6!U]DK;JJ8G=C T
MX!E3;HQ#VW1"DX:6EX"R-4'4)[8L+2\7Z*GAIFE5ML</S); H)4S*9,!!K,L
M6ZQ^[6"USPK:\*+1CW\6"IKL#(SVK.9&"99#JZ,VB4K%*5[$B)LRL2U=5-5Z
M]<+_]B%+F=FC3&*E0E2062>V*&V=IBTW:,<.VO&C5JP*!-ZP;9D6-YAA@4(V
M29TK%2@4RU^!2,U8%4L%@OUB64HS* 2=TT)4ZQ'EE5>U=.SY_K"I#RU7MZ@I
M_K1?SEOXG  AZ >RCJOU&6("CQI*$L("T?ME48M'/YAKOK#T?B'VHM-//**V
MO_]<Y/2MN6KEKLWCC7Q3&=R,<40, WN&3U([".R(@&[N^\E,K%:"*%H)JL)]
M#KP^EL/&]]@AQ[!#;#EA2OTHB*+$A]W GX^.V@W[-/C(G53.EQEF@1IA&X+B
M\FF*@\>P4)I.&">(S'J4&!;T\,PP\K2B9V+3@K+92W!SR,CPLC'?LZ.,&L.S
M<>#Y#C-E0>S9U$BH+U7Q0(K:/.>$'4V@GV$0*$F_@B[QE;;[.W+H=TY0IZM
M1C!=KH%!6O.Z F3$/CKZ2PV"[]%OBOQ^O:2F$;GFHBP72?%2T^3CDCS);M=/
MSS"Q:C+"F%-&G#0VNX7.4<N%_/Y] (?QK;P>"&#J*2$]^IVSH.GH/2ZCTFY_
M8-K9-O[CHG7/ !)/JUX=%KP/7;\[W_%#3&([P7%@!G886R9Q#=@-86?VR2\"
M!2U4-ID1%RBGDD=I*2QL=B)B6/C8CQT[=1-J)X3 =OW*:"AM]GDF[LL^)N?
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MJJ+'V3B1A4/;,K%!O=!,3(<&L(;*@]0F-@];VFC)B;/#=LGIXR+%ZXHBPED
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M$9@O;870V25D(7WK[PYMAMW/:@MM5/D3_:#-TE7L-E&S/2;G[B[=+6I=J?[
MNM%T5'53'*Q<@N,X9@?%*(QM H(8DB%J.I#>L<!#Z?O=5,>%C/VKZU/./>O6
M$C!D?KZ"X+TF !+KZC,A0W+9'A, )9STEX",A=^0_ZN\SI.O'+[C+KW^[_KC
M\J\RJ7XO\YJWMG\ODW^5=]NZ2IB;RI,?^7M5)VT*N.3]N>K\AGW%OR@I,<V3
M/A@.,PI>U%E_H/;B^?>2Y'6S0[PJWFG)_LK'H?J%U(B4%''6:]+DA_,B/B8
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M'SP KWF:Q*0X2\D2MP=F] MSNF95J_FN44%C:O<6 #K+W6; A3^XXU 8K@C
M3C[XNZ\N\T1@O)/-4!INT\(Y9&?IT(JQOTI]Z@>$;4#7(/SU<5JFS],M97&W
MWM%6SIV:TIG<ID^3)H G:U4EP/'7Y\73!;\^06E9]/5YD4_ UR6&G-$IY;;(
MB\,JO1:;^\2N70^':X=@RX\)C=-U8+D@NYXF9]BTF\XA65OT21N:ORH ?,TH
M3<ZP]:D"9MN-%OJ$=W6P+6V=I;!20NILH#).;/D&*K."#S90F1]U9E[TTQ&$
MGZB<L3P+!UX0XRAF_W?2M65[@5(&]!+H0/M4WCGL&QE5R!FLNH P Y6733T;
M>0[/YZR\XP51?:8%&\TE/@?%9Z *XJFX3!(1"" ;CLIYDU^1MZPFF\<74M+?
M2$63_AGJ^O5M4WQ0^E@7\;_OV5?PPIZX+XOGDKP^\(X_55;31UJ^9S%M.FWS
MPHKG7% 0W3_2(*!XM0H(]M>^A0GU"4X2U[%]UPGM5:Q8\;:D',8=!.,)1YQE
M%/?/KVE1BJY*]4?[6]+DW=8%HJT\S;8WR4H:,W,"!HH_Z[.0\V'_%[QL8)SC
M_N;J @F6L> 9L;URTQEBWR7B ET_WM]?H!V>*?\(KHJJ1CT>C13%?8:2]=?*
M+2K%9Y70?<:KFJBL^Q1V%#>6;8?LN[3#>F 4.C:S^#<>DGHM\JL-J:K=WC.)
M'2O%<112MH9%"0[<Q,+>RG'9BK9R8D^JW8<R!X97GQT\"6.C<4X72'!RP6MV
M&V:0X$8XI<U65',\_55@\4/TG=8O1:*XMP6_#<GMKTD=PYS^0NJ%;Z]55:1K
M!PZFO^PF754])_MXY8G4'-PMK8=*F-MZQ!E<"A$X6ZUM'*:QC5?$"PEU RMU
M0XB'@[-@.@F4XPJDF^*OJ@&-2SM.U#$D%-0LY[K,*@_FNR80'';\]! <]NZ+
MH\\VU]#L\;L.HL](4%Y=7YH<F0(#BWHR=04=N[(S9CHCF8#M,ZOKG_'F^9]D
M\_!6\H+#X\M#Q9P"Z9E-[\ .BFI[^VIV%OS9F51S%=Z_\M:212"O74 R@1'%
M K==:CJM7^B"*01@/9V722!/;OF$ K J!O,*X+,HI.FW3>.OV.^SF-&A%643
MO-R5SR3/_J<!H[W,=[]_*C.RX0&<KK?\\6W&*K%QX%@V3MF&RW,L:[4*$NED
M_G.Y,;WU8ML OA*@LF6,Z7G/F0A>QBUKJ.:\H9@S!TB(/_MU3#NVQ94,C"DV
MG*&.-.IX0P?,(<;=_AG!GP@J,G?8LKBDQ@&%"DMJ7JV<X8J4Y0=?3=[%:D(J
MGJ_&UY&(L.=BBJH72FO1DY+_IH@VV7/[4K(\YEPF[/&RV#Z_-, 9XDEN&&]-
M)H6( .^,I*1-^K PD_] 8D,NT//2#65FQ@G';0&8Z,S"NV8V_&PR$F4;L3]#
MOR2,U;^R^H4CZN44?? B,4:F_1%_/"_*5T9O?_,>?\2,F2Q%&U%_^*NN2@U=
MKWBRGN-L(LM5?>C2QT%MB+9)%1;,'V],PKQN+SN:SEXT.>G+9Z\Q<0(/AXD7
M.F&RLIUT);T,#M,PO+BU1+FABFN<LB4+\*4CNI%8D\Z7&+;2=,)V=U8/VH0%
M+ ?G"ZWFY,?>M"X?."W7I&<;&;J<OYKF_< +S3QJHCIMN ABO :M@>9-4AR%
M-L51&@=6&KI1LDJ[&K0G^189&EB3^K8/R\V>X)TUQ!"=569R:I<+B2ZE17,5
M8^-E8I]5$0;2VB)U7W(<_8VJNT JA-5PP:8^]R:<E]J(4-AE5=&:;P._[8\*
MWRGAC?N2N_R!LUNRDP"_N&KNJD;[OEE.@$/+7F'?(;'GIFO73U.U6W(-W)G.
MWVIY/81JW6/3\TO<ADW$CG?]PJ8<[=@6E\+ _"V]KQ!ZM;[PBX&YY8-WLM,X
M\[>"5W&\[G&[?T&GKZ2]>I=J2G?&+;Q&;6J_H=?!VR?=WFM4Z_C-ODXBBO5N
M91%3FE1?F2KX L)8^$YJOKI\W*7?2?EO6G-R^Q5'I#4EZU6"G82$V%^G,2:>
M;V-*X\0)K=B)?:GVU\H<&';*'3_-C?]KPTK6YLL*I!'N&EYWC*%JQQFP; ZL
M>CE':U2A,&=ZJ$O.C-!BQPY7Y)ZAWF988^F=JC)T%>2!Z2];IJ>JGI/B/>6)
MU/P6SR?@84?V![^Q?6<DV7YIK&/.2M0/A %.(NJ3E1L$!-8Q9YJ<88_4I,<T
M]\RBTXFX_.)_H7M>@&E(,_J3\S3ZM )S*U>=$L1?>J2-) K)2:G)7\P06]0Y
MR E^[ DD1RG6(^5UEF0;@7>\]R5-8@9-N//A%_;;)DA[FCG9 $ <GSEYRF+D
M4@O;Q$[#Q/5CFX"J K5P97I;4]3L/?#S9<=I;^.":,MKLU"+)]@_Z*X!9=,X
M]XV6J.(<,^^SB7E @=\2_L+<DOCI1'M9@R]3SE4M_HJ M_$]]GK[('1]\%YZ
M+ ILDX$,\891C64^.O6FJVA'"T_+EN#H5.-)08W6R>$9EY>;S67R7T\%IP++
MJ#P=:=@+,H+HJ'U@/VM//@]R0.9I1W2^N$"/,BVIYLS$<<F4,@\'IELLLW!<
ME'[FX,13<!SM2_:*$OZ:OF[(\PEX-G%P8+LV#BTK\:FSBM:^5'K#R<RF;:NC
MA3@Q>8SL0^FGK>@LF8 &)"<."/]ZD'4ET.O#F19#NAX4H ]O/?R 0NX/O^?:
MWX1\W11%^7 (+2].]AY)<&2O$TQ(ZCHT3=/$DP>T'B%BV% $'51* \E/ZF/:
M7G1)"3,=<;6]IWB!&HD?]$@,R/K1(+E:VH_00+9O\9WN7KFNQ)\9T28S?\;&
M+I?Z,\/]0>[/W+-JD03>"^.)EJ]\]N^[(/\#;1.UJKOTOLSR.'OCS<(Y3O_3
M7\6Q\PF)C8/$YU6/5NQZ*X^F+H$$#E28,.R<V-<2P([Q2IJ4.[6;U@_,K7%N
M,&<'<7XN=M<8%TVK#$9;W[G[',DU';.56%CT5'V.DHX/T6?-!3\S/Y7)95ER
M@EDNEA;1%4;RV#PXV+!?Z%$#], 9%W7^M'RVE##K?BJ)J.WK0>H@::%!A^5)
MP93.R\,S+G9DGA2H?VJ>?M T;L'Q\AVG 0X3&N"5Z]N.$P<K8K&S@WR6KCQI
MD''"LW!Y/QAQ(?C6J[D? BLPA56@':/ \.6A/FR"SP DT+S0 PC_30$(QA9U
MA1G@2SD[F[#)2^;;[HM-%K/)>#+$95*\U301,2W)97UV(N-Y!H(^ZE;"C@MQ
MU2X2/)(M&XY:CN1W /,:FM\-:%4.S&, ]8+^X.QH"JQ+BZVT;YB??;$]A+2@
M_?V$_""X6;?IEY#>X;TAADVUI01H$]X79][:%"6!V55+1&L?\ '&E2RC/\]B
M-C# ?/]K'_JU>N7;/J3V3U)F/#GO)F=?(JUJ'EU[8A-?_ZPI,S#VF^N</=CL
M=TXVT>L8AT[B8R^R$\^R2+3V/4@,[ Q>#!O941#W KVWS+$?-MR)B.X%XC.A
M5/K22\=;D-MO+Z3;,V\'.KY0QYBX*;A G#?TQYX[U&-/8WZ?!B5IK'-3Y63Q
M^K8S5394UW;NE&K.\"9_9Q2+\N.!_/6=T>$(!A4[.=RE'.R@?#_MHDNHBT,_
M)CBE<6H[%ONI#8K[SY,T[-H875[:T!"&>2T)=<DY)[U*@&[I6]H7B*MB1_Y"
MM-8M4M2QH,_-R(NKR9M($%S4:<@KX-@W $:JN8#_I-GS"SLR7+XSE_),;[<\
MH><N%>EQU=VVKFIVU&OKK^*3GMH\-X?&(7:]Q'-<ZJU=N9[:2M0-.X:.%TP:
M9MK,7K2MNOJ#-O&7G8,CSH]HP,S3@WO9P<H9P;#W(.=FC&D7YG$Z-E#+!VH8
MX;ZF807U>&F1GO4Y'R4E:/)#,-J+NB0EM1Q[)[5)%%*BKHKRK> GCMNB[B7Z
M?MFR;5+7G/4NI_QRLDU)[9_57.S;MH<CC^U;O%7JAE:2K+PHDDZ6 I,W[*IV
M_*"<,=1"DS'/L]DU4.X RB2]D**2I]V0>=4!KS]V6N.\]&L-&#?L!(;V7<09
M1TUFPVRNL XU M*ZC*I3+>'KZ26KV.)8TV>V3>'X?#SWG@/UI1P-KX&LC(IM
MS=;%HJQQS;-($GX0[A7A"! _OGYF5;5M[J9H)AK9$904K^P8Q);;HN2P?LSE
ML+5X]RJC;97E_+WQ$I_Z0Z#Q\4'\=S$M:\+,XHUYOZP2N 9EE]4@(MB$_;O>
MECE/$>?X?2_%AD>[.7@@_V>=O=(6HI#7/3.;^D"_B 9#/\GK&P>IV85%.&_9
M3[%1:(YMOUZ@4:/4E0BG_#%,ILC!9UTN>4Y9XH.T.O59%&%CZ'.#W270)?-G
M8*WIV'!SGK*EB'8DC527SLFE"Y-CC,RR\!HSPIX@9<P]#[_6N7]_.X*OD;S<
M.1EH>'MS3S[0NZCM$TL(!X3E&0CLJ+7EA7Y W/93L><O@<Z2&&9K \*:0,^9
ME$KIGNATML5NBT8%Z=\9C3^D?G.T_PS'\!:"V,:!OXJQ%:91&-FI9:46]%+H
ME,P2]SU[JLK]T$=T)']E<Y[D"K<Q,*&5;EC&9=)X>3) 9/%[D7%!AZX\)IZ&
MKVU?&=]L>\V;WKW3\H-MY9Z*?V;%IBW\_0<[0USQ6M_RXQOYZ_*UEEWZH/,:
MMM.6'=3Q(\X8[/"R8XD?5#A3J.4*,;9F2^//U^;\BFI2D3"S-Z-#T$*LJ@RE
M=1I,;+%E7%4-_55>>0YXK?*UB# \D9\W"0\VI%DLB#11S^-]P#KR<11Y,79M
ME\3$)5X<2^$NS5(R[&(:VFR3_1,=4F_#]O+5S=/ZFG896K4 \P_*"@#50TL)
MIU0?/3WS8O724@+VZZ?E!JA<'@S#,N7) V7[CBRNJ?C=#I%ROS$Y,6IGC4.R
M)M@FCATZWIK8B53ITIE\F+Y.8%0O3F#51(2TW+$F?@\)@ZMK7>9:81%= N\7
MN (OA[#9^ _WC*%&WSU0XSUWRR@8<N&PB*)5VP@95#@P%'^VFJ9C\NK3+QB<
M/UL'AU'Z\Z=3"_2(^;<Q+X3-GP4]@1^OW)Y6>CYSKNF !>'86R;0G@LC\0^P
M[)I"(O)T%XV2@-5Q'#B!3Z GEG+]D^-G\8[<_%HW%C7"9X911J;\I A*RXT
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M_KAO$AP>>)+7<?9I%/@X#$,;4XLF)+6\(+:E*OWDR!FVXI8B:E,X+I#HM S
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MXO&N?FU+.1[[^(_;<*T+I0/*4Y@Z^G#OH8M2R_\XR=YD]@NS=KC8#++.E%0
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M7+0%^#?/9;S/B=4?]'A@UPX'LV(X8H +/D1+Z9C,_K[51D+ZK1C+C)/VHB[
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M"K"SZ]R]"'&1[+*UL3J60%I/@:;>8J44E"'_P]U-J>OWF'7DT&Q'2BL2CBF
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M1,FJG>U *25TA7A;//,.+YJYN$L0"@)C4AG&!/'Y \;;Z>FW^U-'L,JF@ +
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M)0<^5DU-9FT4L..]</37JO[M?'155S8:R9TL!4J!)C:]%R:-@XA;+7.W+6M
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MR3<]&*;+D$]5G9K4O=Z?;16726<C3 #C45@4(JRRM_-YGZI^35SGIXC,:BD
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M:)#.'1W>3$F_=[U=82B#U/O>R'ZIJ_'XMKKPDQ/WG]/Q9):WL841ZRPP5D#
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M?_F\^O>+7M6P:J=R=L?3390\8YAHV=+3=')0@A_.OX9F%EBT].AILKF)(>$
M&[MT-D6J()S@!1Q::G2((S010<@9+L6V5+"^\ P2+2DZW!4.":'E"8$$&T=%
MRX>.\H/D9#MM&,2V.+XN#N0)^XAX*= AWG"$#Q):W?[>%0)2JAX@7H)SB%)F
M-D@(-=\?#0.0J(/"2U<.$:?/  E9GO-L+PI5Y'*VV<P.:<&C+\I;</$2CD,$
MLW+S=QP'+RI>9'4'%J+*KG@<?-',%8Z#Q[L!?AQ\WM1@C "<"YOQHPY-6GAV
M#@VU]W:C$SDZMNIV>=+BR1?Z89C)SL=*M:;"Q/O]6R$2_H_4V<+?]3UZ^P_]
M8Y7*_-NG_P%02P,$%     @ *H:F7+R1H2WL!P  ?"<  !@   !G97)N+3(P
M,C8P,S,Q>&5X>#,Q,2YH=&WM6N]3(S<2_7Y_A0[J-E!E&X]M?AF6*B]XLUQE
M86.\E=RG*WE&@W7,C":2QL;WU^>U-,8V-AM3;#B'NE2%94:M5DO]]/I)S.G0
MILG9Z5#PZ.QOIW^O5MF%"HM49):%6G K(E88F=VR7R)A[EBU6EJ=JWRBY>W0
MLD:]<<!^4?I.CKAOM](FXFSJYW3//Y_NN4%.!RJ:G)U&<L1D]'Y+QHUF(ZH?
M';?BX[!5/S@\.AC$ WYTR/D1/SALQ/\.MM 5YKZ/L9-$O-]*958="AJ_W=K/
M[<E81G;8#NKU?VPMVG%]"].!LE:E[:/<HCE6F448&F[]K][[\A@+?8,&AK'B
MWE9Y(F^SMIM\Z6W:(U2)TNWMNOOOA%JJ,4]E,FG_T)>I,.Q*C%E/I3S[H6*$
MEK&W,?*_ K'#OWL<^WD=PD4B,S&=9]"@R75__73YX;+/FD$M6(Q_+O*Y,$-D
M0.C7C_.\V^M??KP\[_0OKZ_8EZ^]FZ^=JS[K7V]RT!^O>Y_9]4?6^_I3EP7-
M3C5H[71V-SGBS@WK7%Q_Z7<OUEKC;T/Z?S6)F^ZY0TFSWL!R4P+ZG[KLIM/[
MT+GJWE2O?_VI^R_6.>]32Z->;ZPYO8/\3]V?K95SN:RP3URKPK(;D0K]'\FS
M"@N%MC*>,#OD]MWV_M')^C,XR7D4@7^KB8AM^Z!5.YKF3&81\M6N^G>O/].@
M-IW%JPZ\N"#[A[4F3?Z2#?E(,"U&4HQ1L^Q0&O9;P34 G4SP/E?:,I6QCTJG
M+*A7?V8J9C\*C5?G2J.56ZDR).?X322GL4G)^< -4H*53B?L+E/C1$2WHN)S
M5&8F4A@]4Q =&('+C/%LPHK,ZD(@>,@0ITB0,LY2/&G)$Q;S$*\T4ZFTS"IO
MMV20B5 8P_6$3%)^)S#NG$^#=Q&"P9")DS,8@PQ"J2%?8):A.R*)A&;CH0R'
MS!3T8]9_++0HG= $4FD2Z!R23&-IAYB@R47H B2_.4)3$:8Y0K>(#2;SR_!F
MX-?\2\!/L%AF2#!A99;0"K '<S3KN7:9Q6 .1Q+X/4R*"#X!FKGL50 X26R3
M(^<$5X)QDLSP6$+!/!H:D(\D.:Z019'  "!40(H;SKAX0FZ&+$[4V$P1JL6M
M-%9S#,3II8\;45;F@&:FP2Q%^V:PUMHDK/47$O-N^Z@1')Z8$DVE#"!J4'$L
M\;AC=EW6+AG7PN$#^9:#1% >F0 H!XDT0^I!9BF8D=B1GB-IPD29 OV(,[5*
M/%!RK4(1X;5A.\!%)  TG_SN?3CDV:U@'=!1KTA@$31Y-=C?$3Z*8#_R3_Y1
MDAK,/$#)/R/.FL.MQQ'%LO9 \<) ,0:B>3Y&,RRHFK](*07->FU_4R"ZPW<W
M :/-VF% T[\0!G(?N7*E[(^!5*$J&_+"K-^%RMU  !3E2+Z JD+# 9AI)(WC
M.UB)S/DA:3QCRGFVU2+A#F5E!9TAI5(R,35*L"9B,2J1D;NU,,7 R$AR+6D"
MTM=YQ_\9>2H,U5ZW+XTKU(X=E1$(R(*-J5,.^2C#(N%$ZIB6"V)6P]'#*X)Y
M(8/?!H(,P;OH+Z(7\>QFH7BP(2@.6LLH7INLEL"\/LVMC6GL@Y&,"*K<J(P3
MGW,#F).8)/QR'4VQ!'1+/I")M!,J[*N&I9WE8.<0Y3?%@NF<&'5EX[Z<4%[@
M8&.0 1(B8:ATY )PLO169- 7"8"-%I'3CB$32&X/7NPLF8.YWQ!\PPV!KR?A
M[H@GA6,JRJV(8RA#.4)6S J%]R DUF!>_[A:]#FTHB-8TWAI.:"KBB<C6*<V
M\ =K0;HY_N-C#AM,%;G;@,*OQ/3X30.\#<!%&P*XDB]]+I<Q04?M4K"YEI7
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M P"RL$]W>?:'9>5/__7;GOOJ[G=02P,$%     @ *H:F7,CW4I8M"   #B@
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MZ!:S<+(X#:\&?HV_!/P$2V2& !-6Y@&M 'L01[->:)=9@LSAD@2^1VD10R=
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M9&ER96-T;RYH=&U02P$"% ,4    "  JAJ9<.Q,OT4[<   FVPT '@
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M+3(P,C8P,S,Q7W!R92YX;6Q02P$"% ,4    "  JAJ9<O)&A+>P'  !\)P
M&               @ 'R/04 9V5R;BTR,#(V,#,S,7AE>'@S,3$N:'1M4$L!
M A0#%     @ *H:F7,CW4I8M"   #B@  !@              ( !%$8% &=E
M<FXM,C R-C S,S%X97AX,S$R+FAT;5!+ 0(4 Q0    ( "J&IEQ*[URX$04
M %,3   8              "  7=.!0!G97)N+3(P,C8P,S,Q>&5X>#,R,2YH
M=&U02P$"% ,4    "  JAJ9<YK[!@DX%  #$$P  &               @ &^
M4P4 9V5R;BTR,#(V,#,S,7AE>'@S,C(N:'1M4$L%!@     -  T A@,  $)9
$!0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>gern-20260331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:gern="http://www.geron.com/20260331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="gern-20260331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <instant>2026-05-01</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:RevenuesBeforeAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:RevenuesBeforeAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:DistributorServiceFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:DistributorServiceFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:GovernmentRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:GovernmentRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:SalesReturnsAndAllowanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:SalesReturnsAndAllowanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:TotalGrossToNetAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:TotalGrossToNetAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USTreasurySecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:MunicipalSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:MunicipalSecuritiesDueInOneToTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CommercialPaperDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CorporateNoteSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CorporateNoteSecuritiesDueInOneToTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USTreasurySecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:MunicipalSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CommercialPaperDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CorporateNoteSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CorporateNoteSecuritiesDueInOneToTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gern:BiopharmaCreditPlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-01</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gern:BiopharmaCreditPlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-01</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-01</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-01</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-01</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-01</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-01</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:PrepaidPriorToThirdAnniversaryOfFundingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-01</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-01</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-01</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-01</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gern:DebtInstrumentScenarioAxis">gern:ScenarioOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-01</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gern:DebtInstrumentScenarioAxis">gern:ScenarioOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-01</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gern:DebtInstrumentScenarioAxis">gern:ScenarioTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-01</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gern:DebtInstrumentScenarioAxis">gern:ScenarioTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-01</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <startDate>2025-03-13</startDate>
            <endDate>2025-03-14</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <startDate>2025-04-15</startDate>
            <endDate>2025-04-16</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <startDate>2025-05-16</startDate>
            <endDate>2025-05-16</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <startDate>2026-01-23</startDate>
            <endDate>2026-02-19</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <startDate>2025-08-29</startDate>
            <endDate>2025-08-29</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <startDate>2025-12-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:ResearchAndClinicalExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:ResearchAndClinicalExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:ChemistryManufacturingAndControlExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:ChemistryManufacturingAndControlExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:CommercialExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:CommercialExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">gern:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>gern:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="lawsuit">
        <measure>gern:lawsuit</measure>
    </unit>
    <unit id="action">
        <measure>gern:action</measure>
    </unit>
    <unit id="plan">
        <measure>gern:plan</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0000886744</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-26">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-27">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-28">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-29">2026</dei:DocumentFiscalYearFocus>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-30">DE</dei:EntityIncorporationStateCountryCode>
    <us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration contextRef="c-127" id="f-571">http://fasb.org/us-gaap/2025#SecuredOvernightFinancingRateSofrMember</us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-147"
      decimals="INF"
      id="f-615"
      unitRef="action">1</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent contextRef="c-148" decimals="4" id="f-616" unitRef="number">0.3333</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent contextRef="c-148" decimals="4" id="f-658" unitRef="number">0.3333</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2026-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">000-20859</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">GERON CORPORATION</dei:EntityRegistrantName>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-7">75-2287752</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-8">919 EAST HILLSDALE BOULEVARD</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-9">SUITE 250</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">FOSTER CITY</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">94404</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">473-7700</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">GERN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">641520974</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-31" unitRef="usd">68895000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-32" unitRef="usd">77560000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-33" unitRef="usd">1884000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-34" unitRef="usd">1880000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-3" decimals="-3" id="f-35" unitRef="usd">243506000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-4" decimals="-3" id="f-36" unitRef="usd">280359000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-3" decimals="-3" id="f-37" unitRef="usd">41882000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-38" unitRef="usd">36987000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:NontradeReceivablesCurrent contextRef="c-3" decimals="-3" id="f-39" unitRef="usd">2213000</us-gaap:NontradeReceivablesCurrent>
    <us-gaap:NontradeReceivablesCurrent contextRef="c-4" decimals="-3" id="f-40" unitRef="usd">2239000</us-gaap:NontradeReceivablesCurrent>
    <us-gaap:InventoryNet contextRef="c-3" decimals="-3" id="f-41" unitRef="usd">133287000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-42" unitRef="usd">116636000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-43" unitRef="usd">6864000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-44" unitRef="usd">4610000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-45" unitRef="usd">498531000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">520271000</us-gaap:AssetsCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent contextRef="c-3" decimals="-3" id="f-47" unitRef="usd">26686000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">41289000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-49" unitRef="usd">1000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">884000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-51" unitRef="usd">1959000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">2151000</us-gaap:OperatingLeaseRightOfUseAsset>
    <gern:DepositsAndOtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-53" unitRef="usd">5944000</gern:DepositsAndOtherAssetsNoncurrent>
    <gern:DepositsAndOtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">5945000</gern:DepositsAndOtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-55" unitRef="usd">534120000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">570540000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-57" unitRef="usd">12720000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">11257000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-59" unitRef="usd">9488000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">30497000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-61" unitRef="usd">1007000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-62" unitRef="usd">1000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <gern:LiabilityRelatedToSaleOfFutureRoyaltiesCurrent contextRef="c-3" decimals="-3" id="f-63" unitRef="usd">19390000</gern:LiabilityRelatedToSaleOfFutureRoyaltiesCurrent>
    <gern:LiabilityRelatedToSaleOfFutureRoyaltiesCurrent contextRef="c-4" decimals="-3" id="f-64" unitRef="usd">17448000</gern:LiabilityRelatedToSaleOfFutureRoyaltiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-65" unitRef="usd">30965000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-66" unitRef="usd">51340000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-67" unitRef="usd">73570000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-68" unitRef="usd">111542000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-69" unitRef="usd">1226000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-70" unitRef="usd">1445000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <gern:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent contextRef="c-3" decimals="-3" id="f-71" unitRef="usd">110383000</gern:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent>
    <gern:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent contextRef="c-4" decimals="-3" id="f-72" unitRef="usd">112134000</gern:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-3" decimals="-3" id="f-73" unitRef="usd">119833000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-3" id="f-74" unitRef="usd">119547000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-75" unitRef="usd">305012000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-76" unitRef="usd">344668000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-77" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-78" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-79"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-80"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="-3" id="f-81" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-82" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-83"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-84"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-85" unitRef="usd">641000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-86" unitRef="usd">640000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-3" decimals="-3" id="f-87" unitRef="usd">2088141000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-88" unitRef="usd">2080804000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-89" unitRef="usd">-1859483000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-90" unitRef="usd">-1855841000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-91" unitRef="usd">-191000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-92" unitRef="usd">269000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-93" unitRef="usd">229108000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-94" unitRef="usd">225872000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-95" unitRef="usd">534120000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-96" unitRef="usd">570540000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-97" unitRef="usd">51771000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-98" unitRef="usd">39436000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-99" unitRef="usd">66000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-3" id="f-100" unitRef="usd">167000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-101" unitRef="usd">51837000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-3" id="f-102" unitRef="usd">39603000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-1" decimals="-3" id="f-103" unitRef="usd">1692000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-9" decimals="-3" id="f-104" unitRef="usd">1206000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-1" decimals="-3" id="f-105" unitRef="usd">14956000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-9" decimals="-3" id="f-106" unitRef="usd">15078000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-107" unitRef="usd">35425000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-9" decimals="-3" id="f-108" unitRef="usd">40023000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-3" id="f-109" unitRef="usd">-394000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-9" decimals="-3" id="f-110" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-111" unitRef="usd">51679000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-9" decimals="-3" id="f-112" unitRef="usd">56307000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-113" unitRef="usd">158000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-9" decimals="-3" id="f-114" unitRef="usd">-16704000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-3" id="f-115" unitRef="usd">3421000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-9" decimals="-3" id="f-116" unitRef="usd">5152000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-117" unitRef="usd">7147000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-9" decimals="-3" id="f-118" unitRef="usd">8200000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-119" unitRef="usd">-74000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-9" decimals="-3" id="f-120" unitRef="usd">-83000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-121" unitRef="usd">-3642000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="-3" id="f-122" unitRef="usd">-19835000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-123"
      unitRef="usdPerShare">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-124"
      unitRef="usdPerShare">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-9"
      decimals="2"
      id="f-125"
      unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-9"
      decimals="2"
      id="f-126"
      unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-127" unitRef="shares">669375</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-128" unitRef="shares">669375</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-9" decimals="0" id="f-129" unitRef="shares">665905</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-9" decimals="0" id="f-130" unitRef="shares">665905</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-131" unitRef="usd">-3642000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="-3" id="f-132" unitRef="usd">-19835000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-133" unitRef="usd">-412000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-9" decimals="-3" id="f-134" unitRef="usd">55000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-135" unitRef="usd">-48000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-9" decimals="-3" id="f-136" unitRef="usd">-12000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-137" unitRef="usd">-4102000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-9" decimals="-3" id="f-138" unitRef="usd">-19792000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-10" decimals="-3" id="f-139" unitRef="shares">639856000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-140" unitRef="usd">640000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-141" unitRef="usd">2080804000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-142" unitRef="usd">-1855841000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="-3" id="f-143" unitRef="usd">269000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-144" unitRef="usd">225872000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-145" unitRef="usd">-3642000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-146" unitRef="usd">-3642000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax contextRef="c-15" decimals="-3" id="f-147" unitRef="usd">-412000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax contextRef="c-1" decimals="-3" id="f-148" unitRef="usd">-412000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-15" decimals="-3" id="f-149" unitRef="usd">-48000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-150" unitRef="usd">-48000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue contextRef="c-16" decimals="-3" id="f-151" unitRef="usd">1511000</gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue>
    <gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue contextRef="c-1" decimals="-3" id="f-152" unitRef="usd">1511000</gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-17" decimals="-3" id="f-153" unitRef="shares">1172000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-17" decimals="-3" id="f-154" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-16" decimals="-3" id="f-155" unitRef="usd">913000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="-3" id="f-156" unitRef="usd">914000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <gern:APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares contextRef="c-17" decimals="-3" id="f-157" unitRef="shares">5000</gern:APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-16" decimals="-3" id="f-158" unitRef="usd">13000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-1" decimals="-3" id="f-159" unitRef="usd">13000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition contextRef="c-16" decimals="-3" id="f-160" unitRef="usd">4900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition contextRef="c-1" decimals="-3" id="f-161" unitRef="usd">4900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-18" decimals="-3" id="f-162" unitRef="shares">641033000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-163" unitRef="usd">641000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-164" unitRef="usd">2088141000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-165" unitRef="usd">-1859483000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-166" unitRef="usd">-191000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-167" unitRef="usd">229108000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-22" decimals="-3" id="f-168" unitRef="shares">606388000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-169" unitRef="usd">606000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-170" unitRef="usd">2051794000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-171" unitRef="usd">-1772341000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-172" unitRef="usd">261000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-173" unitRef="usd">280320000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-3" id="f-174" unitRef="usd">-19835000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="-3" id="f-175" unitRef="usd">-19835000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax contextRef="c-28" decimals="-3" id="f-176" unitRef="usd">55000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax contextRef="c-9" decimals="-3" id="f-177" unitRef="usd">55000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-28" decimals="-3" id="f-178" unitRef="usd">-12000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-9" decimals="-3" id="f-179" unitRef="usd">-12000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <gern:StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant contextRef="c-29" decimals="-3" id="f-180" unitRef="shares">30370000</gern:StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrant>
    <gern:StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant contextRef="c-29" decimals="-3" id="f-181" unitRef="usd">31000</gern:StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant>
    <gern:StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant contextRef="c-9" decimals="-3" id="f-182" unitRef="usd">31000</gern:StockIssuedDuringPeriodValueExerciseOfPrefundedWarrant>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-29" decimals="-3" id="f-183" unitRef="shares">155000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-30" decimals="-3" id="f-184" unitRef="usd">256000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-9" decimals="-3" id="f-185" unitRef="usd">256000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <gern:APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares contextRef="c-29" decimals="-3" id="f-186" unitRef="shares">5000</gern:APICShareBasedPaymentArrangementOptionIncreaseForCostRecognitionShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-30" decimals="-3" id="f-187" unitRef="usd">15000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-9" decimals="-3" id="f-188" unitRef="usd">15000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition contextRef="c-30" decimals="-3" id="f-189" unitRef="usd">7408000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition contextRef="c-9" decimals="-3" id="f-190" unitRef="usd">7408000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-31" decimals="-3" id="f-191" unitRef="shares">636918000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-192" unitRef="usd">637000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-193" unitRef="usd">2059473000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-194" unitRef="usd">-1792176000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-195" unitRef="usd">304000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-196" unitRef="usd">268238000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-197" unitRef="usd">-3642000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="-3" id="f-198" unitRef="usd">-19835000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">134000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-9" decimals="-3" id="f-200" unitRef="usd">131000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-201" unitRef="usd">1069000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-9" decimals="-3" id="f-202" unitRef="usd">2210000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">286000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-9" decimals="-3" id="f-204" unitRef="usd">253000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <gern:NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties contextRef="c-1" decimals="-3" id="f-205" unitRef="usd">3912000</gern:NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties>
    <gern:NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties contextRef="c-9" decimals="-3" id="f-206" unitRef="usd">4801000</gern:NoncashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalties>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-207" unitRef="usd">4913000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-9" decimals="-3" id="f-208" unitRef="usd">7423000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">192000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-9" decimals="-3" id="f-210" unitRef="usd">177000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <gern:IncreaseDecreaseInAllowanceForDoubtfulAccounts contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">0</gern:IncreaseDecreaseInAllowanceForDoubtfulAccounts>
    <gern:IncreaseDecreaseInAllowanceForDoubtfulAccounts contextRef="c-9" decimals="-3" id="f-212" unitRef="usd">131000</gern:IncreaseDecreaseInAllowanceForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-213" unitRef="usd">16651000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-9" decimals="-3" id="f-214" unitRef="usd">17508000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">4894000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-9" decimals="-3" id="f-216" unitRef="usd">-4649000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-217" unitRef="usd">2234000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-9" decimals="-3" id="f-218" unitRef="usd">1688000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-219" unitRef="usd">1463000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-9" decimals="-3" id="f-220" unitRef="usd">-563000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-1" decimals="-3" id="f-221" unitRef="usd">-21009000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-9" decimals="-3" id="f-222" unitRef="usd">-13204000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities contextRef="c-1" decimals="-3" id="f-223" unitRef="usd">-20374000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities contextRef="c-9" decimals="-3" id="f-224" unitRef="usd">-6663000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:PaymentsForRoyalties contextRef="c-1" decimals="-3" id="f-225" unitRef="usd">3721000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties contextRef="c-9" decimals="-3" id="f-226" unitRef="usd">3682000</us-gaap:PaymentsForRoyalties>
    <gern:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="c-1" decimals="-3" id="f-227" unitRef="usd">-212000</gern:IncreaseDecreaseInOperatingLeaseLiabilities>
    <gern:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="c-9" decimals="-3" id="f-228" unitRef="usd">-191000</gern:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-229" unitRef="usd">-62906000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-9" decimals="-3" id="f-230" unitRef="usd">-47979000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <gern:PaymentsUnpaidToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-231" unitRef="usd">252000</gern:PaymentsUnpaidToAcquirePropertyPlantAndEquipment>
    <gern:PaymentsUnpaidToAcquirePropertyPlantAndEquipment contextRef="c-9" decimals="-3" id="f-232" unitRef="usd">-32000</gern:PaymentsUnpaidToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-1" decimals="-3" id="f-233" unitRef="usd">34525000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-9" decimals="-3" id="f-234" unitRef="usd">46477000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-1" decimals="-3" id="f-235" unitRef="usd">86633000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-9" decimals="-3" id="f-236" unitRef="usd">98884000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-237" unitRef="usd">51856000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-9" decimals="-3" id="f-238" unitRef="usd">52439000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-1" decimals="-3" id="f-239" unitRef="usd">914000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-9" decimals="-3" id="f-240" unitRef="usd">256000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-1" decimals="-3" id="f-241" unitRef="usd">1511000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-9" decimals="-3" id="f-242" unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-243" unitRef="usd">2425000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-9" decimals="-3" id="f-244" unitRef="usd">256000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-245" unitRef="usd">-36000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-9" decimals="-3" id="f-246" unitRef="usd">18000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-247" unitRef="usd">-8661000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-9" decimals="-3" id="f-248" unitRef="usd">4734000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-4" decimals="-3" id="f-249" unitRef="usd">79440000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-26" decimals="-3" id="f-250" unitRef="usd">80876000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-3" decimals="-3" id="f-251" unitRef="usd">70779000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-35" decimals="-3" id="f-252" unitRef="usd">85610000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-253">BASIS OF PRESENTATION, PRINCIPLES OF CONSOLIDATION, USE OF ESTIMATES AND RECENT ACCOUNTING PRONOUNCEMENTS&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms &#x201c;Geron&#x201d;, the &#x201c;Company&#x201d;, &#x201c;we&#x201d; and &#x201c;us&#x201d; as used in this Report refer to Geron Corporation and its wholly-owned subsidiaries, Geron UK Limited, or Geron UK, a United Kingdom company, and Geron Netherlands B.V., or Geron Netherlands, a Netherlands company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:18pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by United States, or U.S., generally accepted accounting principles, or GAAP, for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2025, or the 2025 Form 10-K. The accompanying unaudited condensed consolidated balance sheet as of December&#160;31, 2025 has been derived from audited financial statements at that date. Operating results for the three months ended March 31, 2026 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2026 or any other period. We operate as one operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited condensed consolidated financial statements include the accounts of Geron Corporation and its wholly-owned subsidiaries, Geron UK and Geron Netherlands. For Geron UK and Geron Netherlands, we have eliminated intercompany accounts and transactions. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to accrued liabilities, revenue recognition, fair value of marketable securities, inventory valuation, operating leases (right-of-use assets), lease liabilities, income taxes, and stock-based compensation and interest expense related to sale of future royalties. We base our estimates on historical experience and on various other market specific and relevant assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant accounting policies used in preparation of these unaudited condensed consolidated financial statements as of and for the three months ended March 31, 2026 are consistent with those discussed in Note 1 to the consolidated financial statements in the 2025 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements &#x2013; Issued But Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The amendments in ASU 2024-03 address investor requests for more detailed expense information and require additional disaggregated disclosures in the notes to financial statements for certain categories of expenses that are included on the face of the income statement. This guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;years beginning after December 15, 2027, with early adoption permitted. We are evaluating the impact of this ASU on our consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:64.79pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recent accounting pronouncements issued by the FASB are not believed by management to have a material impact on our financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-254">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:18pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by United States, or U.S., generally accepted accounting principles, or GAAP, for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2025, or the 2025 Form 10-K. The accompanying unaudited condensed consolidated balance sheet as of December&#160;31, 2025 has been derived from audited financial statements at that date. Operating results for the three months ended March 31, 2026 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2026 or any other period. We operate as one operating segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-255"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-256">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;The unaudited condensed consolidated financial statements include the accounts of Geron Corporation and its wholly-owned subsidiaries, Geron UK and Geron Netherlands. For Geron UK and Geron Netherlands, we have eliminated intercompany accounts and transactions.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-257">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to accrued liabilities, revenue recognition, fair value of marketable securities, inventory valuation, operating leases (right-of-use assets), lease liabilities, income taxes, and stock-based compensation and interest expense related to sale of future royalties. We base our estimates on historical experience and on various other market specific and relevant assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <gern:SignificantAccountingPoliciesPolicyPolicyTextBlock contextRef="c-1" id="f-258">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant accounting policies used in preparation of these unaudited condensed consolidated financial statements as of and for the three months ended March 31, 2026 are consistent with those discussed in Note 1 to the consolidated financial statements in the 2025 Form 10-K.&lt;/span&gt;&lt;/div&gt;</gern:SignificantAccountingPoliciesPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-259">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements &#x2013; Issued But Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The amendments in ASU 2024-03 address investor requests for more detailed expense information and require additional disaggregated disclosures in the notes to financial statements for certain categories of expenses that are included on the face of the income statement. This guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;years beginning after December 15, 2027, with early adoption permitted. We are evaluating the impact of this ASU on our consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:64.79pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recent accounting pronouncements issued by the FASB are not believed by management to have a material impact on our financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-260">REVENUE RECOGNITION&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, our only source of product revenue has been from the U.S. sales of RYTELO, which we began shipping to our customers in June 2024. To date, product revenue pursuant to Named Patient Programs outside of the U.S. have been not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of gross product sales to net product sales by each significant category of gross-to-net adjustments was as follows for the three months ended March&#160;31, 2026 and 2025: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.484%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;65,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross-to-net adjustments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Distributor service fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,658)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales returns and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,591)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total gross-to-net adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <gern:ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock contextRef="c-1" id="f-261">&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of gross product sales to net product sales by each significant category of gross-to-net adjustments was as follows for the three months ended March&#160;31, 2026 and 2025: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.484%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;65,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross-to-net adjustments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Distributor service fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,658)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales returns and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,591)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total gross-to-net adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</gern:ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-36" decimals="-3" id="f-262" unitRef="usd">65353000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-37" decimals="-3" id="f-263" unitRef="usd">45312000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-38" decimals="-3" id="f-264" unitRef="usd">-8164000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-39" decimals="-3" id="f-265" unitRef="usd">-4171000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-40" decimals="-3" id="f-266" unitRef="usd">-2169000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-41" decimals="-3" id="f-267" unitRef="usd">-1526000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-42" decimals="-3" id="f-268" unitRef="usd">-1658000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-43" decimals="-3" id="f-269" unitRef="usd">-66000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-44" decimals="-3" id="f-270" unitRef="usd">-1591000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-45" decimals="-3" id="f-271" unitRef="usd">-113000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-46" decimals="-3" id="f-272" unitRef="usd">-13582000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-47" decimals="-3" id="f-273" unitRef="usd">-5876000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-274" unitRef="usd">51771000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-275" unitRef="usd">39436000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c-1" id="f-276">INVENTORY&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our inventories are related to the manufacturing of RYTELO. The following table presents our inventory as of March&#160;31, 2026 and December 31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.685%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.413%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;99,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;91,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;133,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;116,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-277">The following table presents our inventory as of March&#160;31, 2026 and December 31, 2025:&lt;div style="margin-bottom:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.685%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.413%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;99,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;91,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;133,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;116,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-3" decimals="-3" id="f-278" unitRef="usd">15603000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-4" decimals="-3" id="f-279" unitRef="usd">8927000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-3" decimals="-3" id="f-280" unitRef="usd">99118000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-4" decimals="-3" id="f-281" unitRef="usd">91969000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-3" decimals="-3" id="f-282" unitRef="usd">18566000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-4" decimals="-3" id="f-283" unitRef="usd">15740000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet contextRef="c-3" decimals="-3" id="f-284" unitRef="usd">133287000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-285" unitRef="usd">116636000</us-gaap:InventoryNet>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="c-1" id="f-286">Financial Instruments&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents, restricted cash and marketable securities by security type at March&#160;31, 2026 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market fund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury securities (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 8.2pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal securities (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 15.4pt;text-indent:-7.21pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal securities (due in one to two years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 15.4pt;text-indent:-7.21pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government-sponsored enterprise securities (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 15.4pt;text-indent:-7.21pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 8.2pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;66,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;66,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 8.2pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;149,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;148,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes (due in one to two years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 8.2pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;270,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;270,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents, restricted cash and marketable securities by security type at December&#160;31, 2025 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market fund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury securities (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal securities (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;79,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;79,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;167,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;167,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes (due in one to two years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;321,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;321,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents and marketable securities with unrealized losses that have been in a continuous unrealized loss position for less than 12 months and 12 months or longer at March&#160;31, 2026 and December&#160;31, 2025 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Less Than 12 Months &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;12 Months or Longer &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of March 31, 2026:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government-sponsored enterprise securities (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal securities (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal securities (due in one to two years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper (cash equivalent)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes (due in one to two years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2025:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes (due in one to two years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gross unrealized losses related to municipal securities, government-sponsored enterprise securities, commercial paper and corporate notes as of March&#160;31, 2026 and December&#160;31, 2025 were due to changes in interest rates and not credit risk. If an available-for-sale security&#x2019;s fair value is less than its amortized cost basis, we evaluate whether the decline is the result of a credit loss, in which case an impairment is recorded through an allowance for credit losses. We have not recorded any allowances for credit losses on our available-for-sale securities for the three months ended March&#160;31, 2026 as we have not identified any unrealized losses for these securities attributable to credit factors. Our exposure to unrealized losses may increase in the future due to the economic pressures or uncertainties associated with local or global economic recessions as a result of ongoing geopolitical events, such as the current military conflicts between Ukraine and Russia or the United States and Iran, as well as recent and potential future disruptions in access to bank deposits or lending commitments due to bank failure. We do not intend to sell the investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost basis, which may be maturity.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock contextRef="c-1" id="f-287">&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents, restricted cash and marketable securities by security type at March&#160;31, 2026 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market fund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury securities (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 8.2pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal securities (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 15.4pt;text-indent:-7.21pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal securities (due in one to two years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 15.4pt;text-indent:-7.21pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government-sponsored enterprise securities (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 15.4pt;text-indent:-7.21pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 8.2pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;66,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;66,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 8.2pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;149,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;148,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes (due in one to two years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 8.2pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;270,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;270,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents, restricted cash and marketable securities by security type at December&#160;31, 2025 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market fund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury securities (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal securities (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;79,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;79,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;167,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;167,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes (due in one to two years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;321,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;321,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-48" decimals="-3" id="f-288" unitRef="usd">43727000</us-gaap:CashEquivalentsAtCarryingValue>
    <gern:CashAndCashEquivalentsUnrealizedGains contextRef="c-48" decimals="-3" id="f-289" unitRef="usd">0</gern:CashAndCashEquivalentsUnrealizedGains>
    <gern:CashAndCashEquivalentsUnrealizedLosses contextRef="c-48" decimals="-3" id="f-290" unitRef="usd">0</gern:CashAndCashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-48" decimals="-3" id="f-291" unitRef="usd">43727000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-49" decimals="-3" id="f-292" unitRef="usd">4995000</us-gaap:CashEquivalentsAtCarryingValue>
    <gern:CashAndCashEquivalentsUnrealizedGains contextRef="c-49" decimals="-3" id="f-293" unitRef="usd">0</gern:CashAndCashEquivalentsUnrealizedGains>
    <gern:CashAndCashEquivalentsUnrealizedLosses contextRef="c-49" decimals="-3" id="f-294" unitRef="usd">0</gern:CashAndCashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-49" decimals="-3" id="f-295" unitRef="usd">4995000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-296" unitRef="usd">48722000</us-gaap:CashEquivalentsAtCarryingValue>
    <gern:CashAndCashEquivalentsUnrealizedGains contextRef="c-3" decimals="-3" id="f-297" unitRef="usd">0</gern:CashAndCashEquivalentsUnrealizedGains>
    <gern:CashAndCashEquivalentsUnrealizedLosses contextRef="c-3" decimals="-3" id="f-298" unitRef="usd">0</gern:CashAndCashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-3" decimals="-3" id="f-299" unitRef="usd">48722000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-48" decimals="-3" id="f-300" unitRef="usd">1610000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <gern:RestrictedCashAndCashEquivalentsGrossUnrealizedGains contextRef="c-48" decimals="-3" id="f-301" unitRef="usd">0</gern:RestrictedCashAndCashEquivalentsGrossUnrealizedGains>
    <gern:RestrictedCashAndCashEquivalentsGrossUnrealizedLosses contextRef="c-48" decimals="-3" id="f-302" unitRef="usd">0</gern:RestrictedCashAndCashEquivalentsGrossUnrealizedLosses>
    <us-gaap:RestrictedInvestmentsAtFairValue contextRef="c-48" decimals="-3" id="f-303" unitRef="usd">1610000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-50" decimals="-3" id="f-304" unitRef="usd">274000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <gern:RestrictedCashAndCashEquivalentsGrossUnrealizedGains contextRef="c-50" decimals="-3" id="f-305" unitRef="usd">0</gern:RestrictedCashAndCashEquivalentsGrossUnrealizedGains>
    <gern:RestrictedCashAndCashEquivalentsGrossUnrealizedLosses contextRef="c-50" decimals="-3" id="f-306" unitRef="usd">0</gern:RestrictedCashAndCashEquivalentsGrossUnrealizedLosses>
    <us-gaap:RestrictedInvestmentsAtFairValue contextRef="c-50" decimals="-3" id="f-307" unitRef="usd">274000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-308" unitRef="usd">1884000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <gern:RestrictedCashAndCashEquivalentsGrossUnrealizedGains contextRef="c-3" decimals="-3" id="f-309" unitRef="usd">0</gern:RestrictedCashAndCashEquivalentsGrossUnrealizedGains>
    <gern:RestrictedCashAndCashEquivalentsGrossUnrealizedLosses contextRef="c-3" decimals="-3" id="f-310" unitRef="usd">0</gern:RestrictedCashAndCashEquivalentsGrossUnrealizedLosses>
    <us-gaap:RestrictedInvestmentsAtFairValue contextRef="c-3" decimals="-3" id="f-311" unitRef="usd">1884000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-51" decimals="-3" id="f-312" unitRef="usd">14980000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-51" decimals="-3" id="f-313" unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-51" decimals="-3" id="f-314" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-51" decimals="-3" id="f-315" unitRef="usd">14985000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-52" decimals="-3" id="f-316" unitRef="usd">10023000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-52" decimals="-3" id="f-317" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-52" decimals="-3" id="f-318" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-52" decimals="-3" id="f-319" unitRef="usd">10022000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-53" decimals="-3" id="f-320" unitRef="usd">2024000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-53" decimals="-3" id="f-321" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-53" decimals="-3" id="f-322" unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-53" decimals="-3" id="f-323" unitRef="usd">2017000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-54" decimals="-3" id="f-324" unitRef="usd">2960000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-54" decimals="-3" id="f-325" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-54" decimals="-3" id="f-326" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-54" decimals="-3" id="f-327" unitRef="usd">2959000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-55" decimals="-3" id="f-328" unitRef="usd">66584000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-55" decimals="-3" id="f-329" unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-55" decimals="-3" id="f-330" unitRef="usd">28000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-55" decimals="-3" id="f-331" unitRef="usd">66561000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-56" decimals="-3" id="f-332" unitRef="usd">149086000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-56" decimals="-3" id="f-333" unitRef="usd">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-56" decimals="-3" id="f-334" unitRef="usd">130000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-56" decimals="-3" id="f-335" unitRef="usd">148979000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-57" decimals="-3" id="f-336" unitRef="usd">24716000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-57" decimals="-3" id="f-337" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-57" decimals="-3" id="f-338" unitRef="usd">47000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-57" decimals="-3" id="f-339" unitRef="usd">24669000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-3" decimals="-3" id="f-340" unitRef="usd">270373000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-3" decimals="-3" id="f-341" unitRef="usd">34000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-3" decimals="-3" id="f-342" unitRef="usd">215000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-3" decimals="-3" id="f-343" unitRef="usd">270192000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-58" decimals="-3" id="f-344" unitRef="usd">48950000</us-gaap:CashEquivalentsAtCarryingValue>
    <gern:CashAndCashEquivalentsUnrealizedGains contextRef="c-58" decimals="-3" id="f-345" unitRef="usd">1000</gern:CashAndCashEquivalentsUnrealizedGains>
    <gern:CashAndCashEquivalentsUnrealizedLosses contextRef="c-58" decimals="-3" id="f-346" unitRef="usd">0</gern:CashAndCashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-58" decimals="-3" id="f-347" unitRef="usd">48951000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-59" decimals="-3" id="f-348" unitRef="usd">4979000</us-gaap:CashEquivalentsAtCarryingValue>
    <gern:CashAndCashEquivalentsUnrealizedGains contextRef="c-59" decimals="-3" id="f-349" unitRef="usd">0</gern:CashAndCashEquivalentsUnrealizedGains>
    <gern:CashAndCashEquivalentsUnrealizedLosses contextRef="c-59" decimals="-3" id="f-350" unitRef="usd">0</gern:CashAndCashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-59" decimals="-3" id="f-351" unitRef="usd">4979000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-352" unitRef="usd">53929000</us-gaap:CashEquivalentsAtCarryingValue>
    <gern:CashAndCashEquivalentsUnrealizedGains contextRef="c-4" decimals="-3" id="f-353" unitRef="usd">1000</gern:CashAndCashEquivalentsUnrealizedGains>
    <gern:CashAndCashEquivalentsUnrealizedLosses contextRef="c-4" decimals="-3" id="f-354" unitRef="usd">0</gern:CashAndCashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-355" unitRef="usd">53930000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-58" decimals="-3" id="f-356" unitRef="usd">1606000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <gern:RestrictedCashAndCashEquivalentsGrossUnrealizedGains contextRef="c-58" decimals="-3" id="f-357" unitRef="usd">0</gern:RestrictedCashAndCashEquivalentsGrossUnrealizedGains>
    <gern:RestrictedCashAndCashEquivalentsGrossUnrealizedLosses contextRef="c-58" decimals="-3" id="f-358" unitRef="usd">0</gern:RestrictedCashAndCashEquivalentsGrossUnrealizedLosses>
    <us-gaap:RestrictedInvestmentsAtFairValue contextRef="c-58" decimals="-3" id="f-359" unitRef="usd">1606000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-60" decimals="-3" id="f-360" unitRef="usd">274000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <gern:RestrictedCashAndCashEquivalentsGrossUnrealizedGains contextRef="c-60" decimals="-3" id="f-361" unitRef="usd">0</gern:RestrictedCashAndCashEquivalentsGrossUnrealizedGains>
    <gern:RestrictedCashAndCashEquivalentsGrossUnrealizedLosses contextRef="c-60" decimals="-3" id="f-362" unitRef="usd">0</gern:RestrictedCashAndCashEquivalentsGrossUnrealizedLosses>
    <us-gaap:RestrictedInvestmentsAtFairValue contextRef="c-60" decimals="-3" id="f-363" unitRef="usd">274000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-364" unitRef="usd">1880000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <gern:RestrictedCashAndCashEquivalentsGrossUnrealizedGains contextRef="c-4" decimals="-3" id="f-365" unitRef="usd">0</gern:RestrictedCashAndCashEquivalentsGrossUnrealizedGains>
    <gern:RestrictedCashAndCashEquivalentsGrossUnrealizedLosses contextRef="c-4" decimals="-3" id="f-366" unitRef="usd">0</gern:RestrictedCashAndCashEquivalentsGrossUnrealizedLosses>
    <us-gaap:RestrictedInvestmentsAtFairValue contextRef="c-4" decimals="-3" id="f-367" unitRef="usd">1880000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-61" decimals="-3" id="f-368" unitRef="usd">22910000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-61" decimals="-3" id="f-369" unitRef="usd">41000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-61" decimals="-3" id="f-370" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-61" decimals="-3" id="f-371" unitRef="usd">22951000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-62" decimals="-3" id="f-372" unitRef="usd">10032000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-62" decimals="-3" id="f-373" unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-62" decimals="-3" id="f-374" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-62" decimals="-3" id="f-375" unitRef="usd">10041000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-63" decimals="-3" id="f-376" unitRef="usd">79354000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-63" decimals="-3" id="f-377" unitRef="usd">49000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-63" decimals="-3" id="f-378" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-63" decimals="-3" id="f-379" unitRef="usd">79403000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-64" decimals="-3" id="f-380" unitRef="usd">167805000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-64" decimals="-3" id="f-381" unitRef="usd">175000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-64" decimals="-3" id="f-382" unitRef="usd">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-64" decimals="-3" id="f-383" unitRef="usd">167964000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-65" decimals="-3" id="f-384" unitRef="usd">41316000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-65" decimals="-3" id="f-385" unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-65" decimals="-3" id="f-386" unitRef="usd">38000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-65" decimals="-3" id="f-387" unitRef="usd">41289000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-4" decimals="-3" id="f-388" unitRef="usd">321417000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-389" unitRef="usd">285000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-390" unitRef="usd">54000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-4" decimals="-3" id="f-391" unitRef="usd">321648000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock contextRef="c-1" id="f-392">&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents and marketable securities with unrealized losses that have been in a continuous unrealized loss position for less than 12 months and 12 months or longer at March&#160;31, 2026 and December&#160;31, 2025 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Less Than 12 Months &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;12 Months or Longer &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of March 31, 2026:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government-sponsored enterprise securities (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal securities (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal securities (due in one to two years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper (cash equivalent)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes (due in one to two years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2025:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes (due in less than one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 15.4pt;text-align:left;text-indent:-7.21pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes (due in one to two years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-54" decimals="-3" id="f-393" unitRef="usd">2959000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-54" decimals="-3" id="f-394" unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-54" decimals="-3" id="f-395" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-54" decimals="-3" id="f-396" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-54" decimals="-3" id="f-397" unitRef="usd">2959000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-54" decimals="-3" id="f-398" unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-52" decimals="-3" id="f-399" unitRef="usd">4998000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-52" decimals="-3" id="f-400" unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-52" decimals="-3" id="f-401" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-52" decimals="-3" id="f-402" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-52" decimals="-3" id="f-403" unitRef="usd">4998000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-52" decimals="-3" id="f-404" unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-53" decimals="-3" id="f-405" unitRef="usd">2017000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-53" decimals="-3" id="f-406" unitRef="usd">7000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-53" decimals="-3" id="f-407" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-53" decimals="-3" id="f-408" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-53" decimals="-3" id="f-409" unitRef="usd">2017000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-53" decimals="-3" id="f-410" unitRef="usd">7000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-49" decimals="-3" id="f-411" unitRef="usd">4995000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-49" decimals="-3" id="f-412" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-49" decimals="-3" id="f-413" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-49" decimals="-3" id="f-414" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-49" decimals="-3" id="f-415" unitRef="usd">4995000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-49" decimals="-3" id="f-416" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-55" decimals="-3" id="f-417" unitRef="usd">37753000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-55" decimals="-3" id="f-418" unitRef="usd">28000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-55" decimals="-3" id="f-419" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-55" decimals="-3" id="f-420" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-55" decimals="-3" id="f-421" unitRef="usd">37753000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-55" decimals="-3" id="f-422" unitRef="usd">28000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-56" decimals="-3" id="f-423" unitRef="usd">93543000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-56" decimals="-3" id="f-424" unitRef="usd">130000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-56" decimals="-3" id="f-425" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-56" decimals="-3" id="f-426" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-56" decimals="-3" id="f-427" unitRef="usd">93543000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-56" decimals="-3" id="f-428" unitRef="usd">130000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-57" decimals="-3" id="f-429" unitRef="usd">24669000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-57" decimals="-3" id="f-430" unitRef="usd">47000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-57" decimals="-3" id="f-431" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-57" decimals="-3" id="f-432" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-57" decimals="-3" id="f-433" unitRef="usd">24669000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-57" decimals="-3" id="f-434" unitRef="usd">47000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-3" decimals="-3" id="f-435" unitRef="usd">170934000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-3" decimals="-3" id="f-436" unitRef="usd">215000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-3" decimals="-3" id="f-437" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-3" decimals="-3" id="f-438" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-3" decimals="-3" id="f-439" unitRef="usd">170934000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-3" decimals="-3" id="f-440" unitRef="usd">215000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-64" decimals="-3" id="f-441" unitRef="usd">17987000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-64" decimals="-3" id="f-442" unitRef="usd">16000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-64" decimals="-3" id="f-443" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-64" decimals="-3" id="f-444" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-64" decimals="-3" id="f-445" unitRef="usd">17987000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-64" decimals="-3" id="f-446" unitRef="usd">16000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-65" decimals="-3" id="f-447" unitRef="usd">31265000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-65" decimals="-3" id="f-448" unitRef="usd">38000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-65" decimals="-3" id="f-449" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-65" decimals="-3" id="f-450" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-65" decimals="-3" id="f-451" unitRef="usd">31265000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-65" decimals="-3" id="f-452" unitRef="usd">38000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-4" decimals="-3" id="f-453" unitRef="usd">49252000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-4" decimals="-3" id="f-454" unitRef="usd">54000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-4" decimals="-3" id="f-455" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-4" decimals="-3" id="f-456" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-4" decimals="-3" id="f-457" unitRef="usd">49252000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-4" decimals="-3" id="f-458" unitRef="usd">54000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-459">FAIR VALUE MEASUREMENTS&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We categorize financial instruments recorded at fair value on our condensed consolidated balance sheets based upon the level of judgment associated with inputs used to measure their fair value. The categories are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.172%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.447%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument&#x2019;s anticipated life.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inputs reflect management&#x2019;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A financial instrument&#x2019;s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Below is a description of the valuation methodologies used for financial instruments measured at fair value on our consolidated balance sheets, including the category for such financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds and certificates of deposit are categorized as Level 1 within the fair value hierarchy as their fair values are based on quoted prices available in active markets. Commercial paper, U.S. Treasury securities, municipal securities, government-sponsored enterprise securities and corporate notes are categorized as Level 2 within the fair value hierarchy as their fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The embedded derivatives are classified within Level 3 of the fair value hierarchy. See Note 7 on Debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined the fair value of the liability related to the sale of future royalties based on our current estimates of future royalties expected to be paid to Royalty Pharma over the life of the arrangement, which are considered Level 3. See Note 7 on Debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between Level 1, Level 2, and Level 3 during the periods presented. In addition, there have been no changes to our valuation techniques as of March 31, 2026 and December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of March&#160;31, 2026 and December&#160;31, 2025 and indicates the fair value category assigned.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.151%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.723%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.472%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.521%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.472%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.521%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.472%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.521%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.472%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Quoted Prices in&lt;br/&gt;Active Markets for&lt;br/&gt;Identical Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant Other&lt;br/&gt;Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of March 31, 2026:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.4pt;text-indent:-7.21pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.4pt;text-indent:-7.21pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.4pt;text-indent:-7.21pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.4pt;text-indent:-7.21pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.4pt;text-indent:-7.21pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.4pt;text-indent:-7.21pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;173,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;173,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;275,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;320,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.4pt;text-indent:-7.21pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sale of future royalties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2025:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.4pt;text-indent:-7.21pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.4pt;text-indent:-7.21pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.4pt;text-indent:-7.21pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.4pt;text-indent:-7.21pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.4pt;text-indent:-7.21pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;209,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;209,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;326,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;377,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.4pt;text-indent:-7.21pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sale of future royalties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt"&gt;Included in cash and cash equivalents on our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt"&gt;Included in restricted cash on our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt"&gt;Included in current portion of marketable securities on our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt"&gt;Included in noncurrent portion of marketable securities on our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt"&gt;Included in current portion of liabilities related to sale of future royalties on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt"&gt;Included in noncurrent portion of liabilities related to sale of future royalties on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-460">&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of March&#160;31, 2026 and December&#160;31, 2025 and indicates the fair value category assigned.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.151%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.723%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.472%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.521%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.472%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.521%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.472%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.521%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.472%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Quoted Prices in&lt;br/&gt;Active Markets for&lt;br/&gt;Identical Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant Other&lt;br/&gt;Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of March 31, 2026:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.4pt;text-indent:-7.21pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.4pt;text-indent:-7.21pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.4pt;text-indent:-7.21pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.4pt;text-indent:-7.21pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.4pt;text-indent:-7.21pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.4pt;text-indent:-7.21pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;173,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;173,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;275,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;320,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.4pt;text-indent:-7.21pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sale of future royalties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2025:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.4pt;text-indent:-7.21pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.4pt;text-indent:-7.21pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Municipal securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.4pt;text-indent:-7.21pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.4pt;text-indent:-7.21pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.4pt;text-indent:-7.21pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;209,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;209,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;326,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;377,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.4pt;text-indent:-7.21pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sale of future royalties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt"&gt;Included in cash and cash equivalents on our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt"&gt;Included in restricted cash on our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt"&gt;Included in current portion of marketable securities on our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt"&gt;Included in noncurrent portion of marketable securities on our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:53.14pt"&gt;Included in current portion of liabilities related to sale of future royalties on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:64.8pt;text-indent:-63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt"&gt;Included in noncurrent portion of liabilities related to sale of future royalties on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure contextRef="c-66" decimals="-3" id="f-461" unitRef="usd">45337000</gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure contextRef="c-67" decimals="-3" id="f-462" unitRef="usd">0</gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure contextRef="c-68" decimals="-3" id="f-463" unitRef="usd">0</gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure contextRef="c-69" decimals="-3" id="f-464" unitRef="usd">45337000</gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure contextRef="c-70" decimals="-3" id="f-465" unitRef="usd">274000</gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure contextRef="c-71" decimals="-3" id="f-466" unitRef="usd">0</gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure contextRef="c-72" decimals="-3" id="f-467" unitRef="usd">0</gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure contextRef="c-73" decimals="-3" id="f-468" unitRef="usd">274000</gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure contextRef="c-74" decimals="-3" id="f-469" unitRef="usd">0</gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure contextRef="c-75" decimals="-3" id="f-470" unitRef="usd">12038000</gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure contextRef="c-76" decimals="-3" id="f-471" unitRef="usd">0</gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure contextRef="c-77" decimals="-3" id="f-472" unitRef="usd">12038000</gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-78" decimals="-3" id="f-473" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-79" decimals="-3" id="f-474" unitRef="usd">14985000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-80" decimals="-3" id="f-475" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-81" decimals="-3" id="f-476" unitRef="usd">14985000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-82" decimals="-3" id="f-477" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-83" decimals="-3" id="f-478" unitRef="usd">2959000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-84" decimals="-3" id="f-479" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-85" decimals="-3" id="f-480" unitRef="usd">2959000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-86" decimals="-3" id="f-481" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-87" decimals="-3" id="f-482" unitRef="usd">71557000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-88" decimals="-3" id="f-483" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-49" decimals="-3" id="f-484" unitRef="usd">71557000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-89" decimals="-3" id="f-485" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-90" decimals="-3" id="f-486" unitRef="usd">173648000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-91" decimals="-3" id="f-487" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-92" decimals="-3" id="f-488" unitRef="usd">173648000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-93" decimals="-3" id="f-489" unitRef="usd">45611000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-94" decimals="-3" id="f-490" unitRef="usd">275187000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-95" decimals="-3" id="f-491" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-3" decimals="-3" id="f-492" unitRef="usd">320798000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c-93" decimals="-3" id="f-493" unitRef="usd">0</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c-94" decimals="-3" id="f-494" unitRef="usd">0</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c-95" decimals="-3" id="f-495" unitRef="usd">129773000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c-3" decimals="-3" id="f-496" unitRef="usd">129773000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-93" decimals="-3" id="f-497" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-94" decimals="-3" id="f-498" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-95" decimals="-3" id="f-499" unitRef="usd">129773000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-3" decimals="-3" id="f-500" unitRef="usd">129773000</us-gaap:LiabilitiesFairValueDisclosure>
    <gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure contextRef="c-96" decimals="-3" id="f-501" unitRef="usd">50557000</gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure contextRef="c-97" decimals="-3" id="f-502" unitRef="usd">0</gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure contextRef="c-98" decimals="-3" id="f-503" unitRef="usd">0</gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure contextRef="c-99" decimals="-3" id="f-504" unitRef="usd">50557000</gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure contextRef="c-100" decimals="-3" id="f-505" unitRef="usd">274000</gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure contextRef="c-101" decimals="-3" id="f-506" unitRef="usd">0</gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure contextRef="c-102" decimals="-3" id="f-507" unitRef="usd">0</gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure contextRef="c-103" decimals="-3" id="f-508" unitRef="usd">274000</gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure contextRef="c-104" decimals="-3" id="f-509" unitRef="usd">0</gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure contextRef="c-105" decimals="-3" id="f-510" unitRef="usd">10041000</gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure contextRef="c-106" decimals="-3" id="f-511" unitRef="usd">0</gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure contextRef="c-107" decimals="-3" id="f-512" unitRef="usd">10041000</gern:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-108" decimals="-3" id="f-513" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-109" decimals="-3" id="f-514" unitRef="usd">22951000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-110" decimals="-3" id="f-515" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-111" decimals="-3" id="f-516" unitRef="usd">22951000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-112" decimals="-3" id="f-517" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-113" decimals="-3" id="f-518" unitRef="usd">84382000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-114" decimals="-3" id="f-519" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-59" decimals="-3" id="f-520" unitRef="usd">84382000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-115" decimals="-3" id="f-521" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-116" decimals="-3" id="f-522" unitRef="usd">209253000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-117" decimals="-3" id="f-523" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-118" decimals="-3" id="f-524" unitRef="usd">209253000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-119" decimals="-3" id="f-525" unitRef="usd">50831000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-120" decimals="-3" id="f-526" unitRef="usd">326627000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-121" decimals="-3" id="f-527" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-528" unitRef="usd">377458000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c-119" decimals="-3" id="f-529" unitRef="usd">0</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c-120" decimals="-3" id="f-530" unitRef="usd">0</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c-121" decimals="-3" id="f-531" unitRef="usd">129582000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c-4" decimals="-3" id="f-532" unitRef="usd">129582000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-119" decimals="-3" id="f-533" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-120" decimals="-3" id="f-534" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-121" decimals="-3" id="f-535" unitRef="usd">129582000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-4" decimals="-3" id="f-536" unitRef="usd">129582000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-537">OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following as of March&#160;31, 2026 and December&#160;31, 2025: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center;text-indent:64.8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.818%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.130%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;MARCH 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;DECEMBER 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract research organization and clinical trial costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Manufacturing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Professional, legal and accounting fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued revenue adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation and benefits consisted of the following as of March&#160;31, 2026 and December&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center;text-indent:64.8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.818%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.130%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;MARCH 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;DECEMBER 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued bonuses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued vacation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-538">&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following as of March&#160;31, 2026 and December&#160;31, 2025: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center;text-indent:64.8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.818%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.130%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;MARCH 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;DECEMBER 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract research organization and clinical trial costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Manufacturing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Professional, legal and accounting fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued revenue adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <gern:AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent contextRef="c-3" decimals="-3" id="f-539" unitRef="usd">4696000</gern:AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent>
    <gern:AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent contextRef="c-4" decimals="-3" id="f-540" unitRef="usd">3677000</gern:AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent>
    <gern:AccruedManufacturingActivitiesCurrent contextRef="c-3" decimals="-3" id="f-541" unitRef="usd">16107000</gern:AccruedManufacturingActivitiesCurrent>
    <gern:AccruedManufacturingActivitiesCurrent contextRef="c-4" decimals="-3" id="f-542" unitRef="usd">38657000</gern:AccruedManufacturingActivitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-3" decimals="-3" id="f-543" unitRef="usd">2632000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-4" decimals="-3" id="f-544" unitRef="usd">881000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:InterestPayableCurrent contextRef="c-3" decimals="-3" id="f-545" unitRef="usd">0</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="c-4" decimals="-3" id="f-546" unitRef="usd">3110000</us-gaap:InterestPayableCurrent>
    <gern:GrossToNetAdjustmentsCurrent contextRef="c-3" decimals="-3" id="f-547" unitRef="usd">5562000</gern:GrossToNetAdjustmentsCurrent>
    <gern:GrossToNetAdjustmentsCurrent contextRef="c-4" decimals="-3" id="f-548" unitRef="usd">3486000</gern:GrossToNetAdjustmentsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-549" unitRef="usd">1968000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-550" unitRef="usd">1529000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-551" unitRef="usd">30965000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-552" unitRef="usd">51340000</us-gaap:AccruedLiabilitiesCurrent>
    <gern:ScheduleOfAccruedCompensationAndBenefitsTableTextBlock contextRef="c-1" id="f-553">&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation and benefits consisted of the following as of March&#160;31, 2026 and December&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center;text-indent:64.8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.818%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.130%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;MARCH 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;DECEMBER 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued bonuses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued vacation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</gern:ScheduleOfAccruedCompensationAndBenefitsTableTextBlock>
    <us-gaap:AccruedBonusesCurrent contextRef="c-3" decimals="-3" id="f-554" unitRef="usd">3530000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent contextRef="c-4" decimals="-3" id="f-555" unitRef="usd">10335000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="c-3" decimals="-3" id="f-556" unitRef="usd">2405000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="c-4" decimals="-3" id="f-557" unitRef="usd">2581000</us-gaap:AccruedVacationCurrent>
    <us-gaap:RestructuringReserveCurrent contextRef="c-3" decimals="-3" id="f-558" unitRef="usd">3106000</us-gaap:RestructuringReserveCurrent>
    <us-gaap:RestructuringReserveCurrent contextRef="c-4" decimals="-3" id="f-559" unitRef="usd">17032000</us-gaap:RestructuringReserveCurrent>
    <us-gaap:OtherEmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-560" unitRef="usd">447000</us-gaap:OtherEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherEmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-561" unitRef="usd">549000</us-gaap:OtherEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-562" unitRef="usd">9488000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-563" unitRef="usd">30497000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-564">DEBT&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Pharmakon Loan Agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 1, 2024, we entered into a loan agreement, or the Pharmakon Loan Agreement, with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership, each, a Lender, which are investment funds managed by Pharmakon Advisors, LP, and BioPharma Credit PLC, as collateral agent, that provides for a 5-year senior secured term loan facility of up to $250.0&#160;million, divided into three committed tranches: (i) a Tranche A Loan in an aggregate principal amount of $125.0&#160;million, or the Tranche A Loan, which was funded on November 1, 2024, or the Tranche A Closing Date; (ii) a Tranche B Loan in an aggregate principal amount of $75.0&#160;million, or the Tranche B Loan, which is available, subject to certain limited conditions, at our option; and (iii) a Tranche C Loan in an aggregate principal amount of $50.0&#160;million, or the Tranche C Loan, and together with the Tranche A Loan and the Tranche B Loan, collectively, the Term Loans, which is available to us upon reaching a specified trailing twelve-month RYTELO revenue milestone. The Tranche B Loan and the Tranche C Loan, once available, could have been requested on or prior to December 31, 2025. A portion of the proceeds from the Tranche A Loan were used to repay, in full, all amounts owed under the Hercules Loan Agreement, which was terminated effective November 1, 2024. The remaining proceeds will be used to fund our general corporate and working capital requirements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On January 5, 2026, the Pharmakon Loan Agreement was amended to extend the date for requesting the Tranche B Loan and Tranche C Loan, once available, from December 31, 2025 to July 30, 2026. The amendment also extended the date before which any Term Loan prepayment is subject to a make&#x2011;whole premium, or the Makewhole Date, from November 1, 2026 to May 1, 2027. The amendment was evaluated under ASC 470-50 and determined to be a modification. The unamortized debt issuance costs will continue to be amortized over the remaining term using a revised effective interest rate. Fees incurred in connection with the amendment were not material and were expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Term Loans mature on November 1, 2029. The Term Loans bear interest at a variable rate per annum equal to 5.75% plus the three-month Secured Overnight Financing Rate, or SOFR, with a &lt;span style="-sec-ix-hidden:f-571"&gt;SOFR&lt;/span&gt; floor of 3.00%. As of inception of the Tranche A Loan, the interest rate applicable to the Tranche A Loan was 10.32%. As of March&#160;31, 2026, the applicable interest rate was 10.80%. Interest is due and payable quarterly on the last day of each quarter. The Pharmakon Loan Agreement requires we pay an amount equal to 2.50% of the Lenders&#x2019; total committed amount to fund the Term Loans, payable with respect to each Term Loan on the funding date of such Term Loan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may elect to prepay the Term Loans in part or in whole prior to the Maturity Date with such prepayments being subject to a prepayment premium equal to the principal amount so prepaid multiplied by 3% if made prior to the 3rd anniversary of the funding date of the applicable Term Loan, 2% if made on or after the 3rd anniversary of the funding date of the applicable Term Loan but prior to the 4th anniversary of the funding date of the applicable Term Loan, and 1% if made on or after the 4th anniversary of the funding date of the applicable Term Loan but prior to the Maturity Date. In addition to the prepayment premium, prepayments of any Term Loan prior to the 2nd anniversary of the funding date of such Term Loan are subject to a make-whole amount equal to the sum of all interest that would have accrued through such 2nd anniversary. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our obligations under the Pharmakon Loan Agreement are secured by substantially all of our assets, including our intellectual property. Certain of our subsidiaries may, from time to time after the Tranche A Closing Date, be required to guarantee our obligations under the Pharmakon Loan Agreement and, in connection with such guarantee, pledge substantially all of their assets, including intellectual property, to secure such guarantee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pharmakon Loan Agreement contains customary affirmative and restrictive covenants and representations and warranties. We are bound by certain affirmative covenants setting forth actions that are required during the term of the Pharmakon Loan Agreement, including, without limitation, certain information delivery requirements, obligations to maintain certain insurance, and certain notice requirements. There are no financial covenants. Additionally, we are bound by certain restrictive covenants setting forth actions that are not permitted to be taken during the term of the Pharmakon Loan Agreement, including, without limitation, (i) selling or disposing of assets, (ii) amending, modifying or waiving our rights under material agreements, (iii) consummating change in control transactions unless all amounts becoming due under the Loan Agreement are paid in full immediately upon (and concurrent with) the consummation of any such change in control transaction, (iv) incurring additional indebtedness, (v) incurring non-permitted liens or encumbrance on our or our subsidiaries&#x2019; assets, (vi) paying dividends or making any distribution or payment on or redeeming, retiring or purchasing any equity interests, and (vii) making payments on subordinated indebtedness, in each case, subject to specified exceptions. The Pharmakon Loan Agreement also contains the following events of default: (i) failure to pay principal, interest and other amounts when due, (ii) the breach of the covenants under the Loan Agreement, (iii) the occurrence of a material adverse change or the occurrence of a withdrawal event in respect of RYTELO, (iv) certain attachments of the credit parties assets and restraints on their business, (v) certain insolvency, liquidation, bankruptcy or similar events, (vi) certain cross-default of third-party indebtedness and royalty revenue contracts, (vii) the failure to pay certain judgments, (viii) material misrepresentations, (ix) the loan documents ceasing to create a valid security interest in a material portion of the collateral, (x) the occurrence of certain ERISA events, and (xi) the occurrence of a default under any subordination or intercreditor agreement, in each case subject to the grace periods, cure period and thresholds as specified in the Pharmakon Loan Agreement. Upon the occurrence and during the continuance of an event of default, the Lenders may, among other things, accelerate our obligations under the Pharmakon Loan Agreement (including all obligations for principal, interest and any applicable make-whole and prepayment premiums); provided that upon an event of default relating to certain insolvency, liquidation, bankruptcy or similar events, all outstanding obligations will be immediately accelerated. We concluded that the likelihood of such acceleration is remote, and therefore all debt is classified as long&#x2011;term. As of March&#160;31, 2026, we were in compliance with our Pharmakon Loan Agreement covenants.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:90%"&gt;Future Minimum Payments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents future minimum payments, including interest and the end of term charge, under the Loan Agreement as of March&#160;31, 2026 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: amount representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(45,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Noncurrent portion of debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Embedded Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The conditional exercisable call option related to the event of default is considered to be an embedded derivative which is required to be bifurcated and accounted for as a separate financial instrument. In the periods presented, the value of the embedded derivative is not material and therefore, no amount has been recognized. If an event of default becomes more probable than is currently estimated, then the embedded derivative could become material in future periods and would be recognized as a separate financial instrument at that time.  The embedded derivatives are classified within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Liabilities Related to Sale of Future Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 1, 2024, we entered into a revenue participation right purchase and sale agreement, or the Royalty Pharma Agreement, with Royalty Pharma Development Funding, LLC, or Royalty Pharma. Pursuant to the Royalty Pharma Agreement, we received an upfront payment of $125.0&#160;million, or the Purchase Price, in exchange for which Royalty Pharma obtained the right, or the Revenue Participation Right, to receive certain amounts calculated as a percentage of future U.S. net sales of RYTELO for each calendar quarter, or Royalty Payments, during the term contemplated by the Royalty Pharma Agreement. Specifically, the revenue participation rate commences at 7.75% for annual U.S. net sales of up to and equal to $500.0&#160;million declining to 1.0% for annual U.S. net sales exceeding $1.0&#160;billion until the date when the aggregate Royalty Payments equal or exceed 1.65 times the Purchase Price, if this occurs by June 30, 2031, or the date when the aggregate Royalty Payments equal or exceed 2.0 times the Purchase Price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we have the option to repurchase all of the Revenue Participation Right from Royalty Pharma for a purchase price of equal to the Buy-Out-Payment, as defined below, if we entered into a definitive agreement to consummate a change of control, or Buy-Back Option. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;Buy-Out Payment&#x201d; means an amount equal to (a) 1.65 times the Purchase Price minus the aggregate Royalty Payments as of the change of control, if the change of control occurs on or prior to December 31, 2027, or (b) 2.0 times the Purchase Price minus the aggregate Royalty Payments as of the change of control, if the change of control occurs after December 31, 2027. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for the Royalty Pharma Agreement as a financing liability, primarily because it has significant continuing involvement in generating the future revenue on which the Royalty Payments are based. The liability related to Revenue Participation Right and the related interest expense are measured based on our current estimate of the timing and amount of expected future Royalty Payments expected to be paid over the estimated term of the Royalty Pharma Agreement using a discounted cashflow model. The liability is amortized using the effective interest rate method, resulting in recognition of interest expense over the estimated term of the agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have determined the fair value of the liability related to the sale of future royalties is based on our current estimates of future royalties expected to be paid to Royalty Pharma over the life of the arrangement, which are considered Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the activity within the liability related to sale of future royalties during the three months ended March&#160;31, 2026: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:24.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.121%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.003%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.059%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liability Related to Sale of Future Royalties&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of liability related to sale of future royalties at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,721)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of liability related to sale of future royalties at March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityExpirationPeriod contextRef="c-122" id="f-565">P5Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-123" decimals="-5" id="f-566" unitRef="usd">250000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-124" decimals="-5" id="f-567" unitRef="usd">125000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-125" decimals="-5" id="f-568" unitRef="usd">75000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-126" decimals="-5" id="f-569" unitRef="usd">50000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-127" decimals="4" id="f-570" unitRef="number">0.0575</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <gern:DebtInstrumentFloorRate contextRef="c-128" decimals="4" id="f-572" unitRef="number">0.0300</gern:DebtInstrumentFloorRate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-124" decimals="4" id="f-573" unitRef="number">0.1032</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-129" decimals="4" id="f-574" unitRef="number">0.1080</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <gern:PercentageOfCommitmentAmountToFundLoan contextRef="c-128" decimals="4" id="f-575" unitRef="number">0.0250</gern:PercentageOfCommitmentAmountToFundLoan>
    <gern:PrepaymentPremiumOnPercentageOfTermLoan contextRef="c-130" decimals="2" id="f-576" unitRef="number">0.03</gern:PrepaymentPremiumOnPercentageOfTermLoan>
    <gern:PrepaymentPremiumOnPercentageOfTermLoan contextRef="c-131" decimals="2" id="f-577" unitRef="number">0.02</gern:PrepaymentPremiumOnPercentageOfTermLoan>
    <gern:PrepaymentPremiumOnPercentageOfTermLoan contextRef="c-132" decimals="2" id="f-578" unitRef="number">0.01</gern:PrepaymentPremiumOnPercentageOfTermLoan>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-579">&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents future minimum payments, including interest and the end of term charge, under the Loan Agreement as of March&#160;31, 2026 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: amount representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(45,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Noncurrent portion of debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-580" unitRef="usd">11927000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-3" decimals="-3" id="f-581" unitRef="usd">11927000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-3" decimals="-3" id="f-582" unitRef="usd">11960000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-3" decimals="-3" id="f-583" unitRef="usd">134966000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <gern:LongTermDebtMaturityAfterYearThree contextRef="c-3" decimals="-3" id="f-584" unitRef="usd">0</gern:LongTermDebtMaturityAfterYearThree>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-3" decimals="-3" id="f-585" unitRef="usd">170780000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:AccumulatedCapitalizedInterestCosts contextRef="c-3" decimals="-3" id="f-586" unitRef="usd">45780000</us-gaap:AccumulatedCapitalizedInterestCosts>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c-3" decimals="-3" id="f-587" unitRef="usd">5167000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-3" decimals="-3" id="f-588" unitRef="usd">119833000</us-gaap:LongTermDebtNoncurrent>
    <gern:UpfrontPaymentReceived contextRef="c-133" decimals="-5" id="f-589" unitRef="usd">125000000.0</gern:UpfrontPaymentReceived>
    <gern:PercentageOfAnnualNetSales contextRef="c-134" decimals="4" id="f-590" unitRef="number">0.0775</gern:PercentageOfAnnualNetSales>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-135" decimals="INF" id="f-591" unitRef="usd">500000000.0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <gern:PercentageOfAnnualNetSales contextRef="c-136" decimals="3" id="f-592" unitRef="number">0.010</gern:PercentageOfAnnualNetSales>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-137" decimals="INF" id="f-593" unitRef="usd">1000000000.0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <gern:DebtInstrumentRoyaltyPaymentRatio contextRef="c-138" decimals="2" id="f-594" unitRef="number">1.65</gern:DebtInstrumentRoyaltyPaymentRatio>
    <gern:DebtInstrumentRoyaltyPaymentRatio contextRef="c-139" decimals="1" id="f-595" unitRef="number">2.0</gern:DebtInstrumentRoyaltyPaymentRatio>
    <gern:DebtInstrumentRoyaltyPaymentRatio contextRef="c-138" decimals="2" id="f-596" unitRef="number">1.65</gern:DebtInstrumentRoyaltyPaymentRatio>
    <gern:DebtInstrumentRoyaltyPaymentRatio contextRef="c-139" decimals="1" id="f-597" unitRef="number">2.0</gern:DebtInstrumentRoyaltyPaymentRatio>
    <gern:ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock contextRef="c-1" id="f-598">&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the activity within the liability related to sale of future royalties during the three months ended March&#160;31, 2026: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:24.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.121%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.003%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.059%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liability Related to Sale of Future Royalties&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of liability related to sale of future royalties at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,721)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of liability related to sale of future royalties at March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</gern:ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c-140" decimals="-3" id="f-599" unitRef="usd">129582000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:RoyaltyExpense contextRef="c-141" decimals="-3" id="f-600" unitRef="usd">3912000</us-gaap:RoyaltyExpense>
    <us-gaap:PaymentsForRoyalties contextRef="c-141" decimals="-3" id="f-601" unitRef="usd">3721000</us-gaap:PaymentsForRoyalties>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c-142" decimals="-3" id="f-602" unitRef="usd">129773000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-603">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 13 and March 14, 2025, we and certain of our current and former officers were named as defendants in two putative securities class action lawsuits filed in the United States District Court for the Northern District of California captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dabestani v. Geron Corporation, et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, No. 3:25-cv-02507 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Potvin v. Geron Corporation, et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, No. 3:25-cv-02563, respectively. Both lawsuits allege violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder in connection with allegedly false and misleading statements concerning the commercial potential of RYTELO. The plaintiffs allege, among other things, that we overstated RYTELO's commercial potential by making materially false and misleading statements and/or concealing material adverse facts concerning RYTELO's commercial potential, including the lack of awareness among healthcare providers for RYTELO, the burden of monitoring requirements in administering the drug, and the impacts of seasonality and existing competition on RYTELO's sales, and that our stock price dropped when we disclosed in our earnings call on February 26, 2025 that we had observed flat revenue trends over the prior few months. The plaintiffs seek damages and interest, and an award of reasonable costs, including attorneys' and experts' fees. On May 29, 2025, the Court consolidated the Dabestani and Potvin cases into one consolidated action captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Geron Corporation Securities Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, or the Securities Class Action, and appointed lead plaintiffs and counsel for lead plaintiffs. On August 8, 2025, lead plaintiffs filed a consolidated amended complaint. On October 7, 2025, we filed our motion to dismiss the consolidated amended complaint.  A hearing on the motion to dismiss was held on March 19, 2026, and on March 30, 2026, the Court entered an order granting our motion to dismiss without prejudice. On April 13, 2026, lead plaintiffs filed a second amended complaint. We intend to move to dismiss the second amended complaint.   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:64.79pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:64.79pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, on April 15, 2025 and April 16, 2025, three purported stockholders filed derivative complaints, each filed in the United States District Court for the Northern District of California, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bishop v. Scarlett, et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, No. 3:25-cv-03356,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Lerner v. Scarlett, et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, No. 3:25-cv-03401, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Willis v. Scarlett, et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, No: 3:25-cv-03396, respectively. The three lawsuits name certain of our current and former directors and officers and allege that they breached their fiduciary duties and violated federal securities laws by issuing allegedly false and misleading statements concerning the commercial potential of RYTELO. The allegations in each of the three derivative complaints are substantially similar to the Securities Class Action. The plaintiff seeks damages and interest, and an award of reasonable costs, including attorneys' and experts' fees. The plaintiffs in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bishop v. Scarlett, et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Willis v. Scarlett, et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; also seek punitive damages. On May 16, 2025, the Court consolidated the three derivative complaints into one consolidated action captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Geron Corporation Derivative Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, or the Consolidated Derivative Action.  On June 17, 2025, the Court stayed the Consolidated Derivative Action pending a final ruling on the anticipated motion to dismiss in the Securities Class Action.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:64.79pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 29, 2025, a purported stockholder made a demand on our board of directors to commence a civil action against certain of our current and former directors for breaching their fiduciary duties and violating the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;securities laws by issuing allegedly false and misleading statements concerning the commercial potential of RYTELO.  On September 19, 2025, the board of directors responded that it would defer a final decision on the demand given the other pending derivative lawsuits and the Securities Class Action.  On October 7, 2025, the purported stockholder filed a suit in the United States District Court for the Northern District of California, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Jae Hyung v. Bir, et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, No. 3:25-cv-08575.  The derivative lawsuit names certain of our current and former directors and officers. The allegations in the derivative lawsuit are substantially similar to the Securities Class Action and the Consolidated Derivative Action.  The plaintiff seeks damages and an award of reasonable costs, including attorneys&#x2019; and experts&#x2019; fees. On January 23 and February 19, 2026, respectively, two additional purported stockholders each made a similar demand on our board of directors. On March 25, 2026, the board of directors similarly responded that it would defer a final decision on the demands given the other pending derivative lawsuits and the Securities Class Action.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:64.79pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is possible that additional lawsuits will be filed or allegations made by stockholders with respect to these same or other matters and also naming us and/or our officers and directors as defendants. We intend to vigorously defend against the claims brought by the plaintiffs in these matters.    &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Such lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. The outcome of the pending lawsuits and any other related lawsuits is necessarily uncertain.  We could be forced to expend significant resources and may incur substantial legal fees and costs in defending against the pending lawsuits and any other related lawsuits, and we may not prevail. Monitoring, initiating and defending against legal actions is time-consuming for our management, is likely to be expensive, and may detract from our ability to fully focus our internal resources on our business activities.  Additionally, we may not be successful in having any such lawsuits dismissed or settled within the limits of our insurance coverage. Given the early stage of these lawsuits and the inherent uncertainly of litigation, we cannot predict how long it may take to resolve the pending lawsuits or the potential outcome or possible amount of any damages. As such, we currently are unable to reasonably estimate the possible losses or a range of possible losses that may result from these matters, if any. Expenses associated with the pending lawsuits and any potential related lawsuits could be material to our consolidated financial statements if we do not prevail in the defense of such lawsuits, or even if we do prevail. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Indemnifications to Officers and Directors&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our corporate bylaws require that we indemnify our directors, as well as those who act as directors and officers of other entities at our request, against expenses, judgments, fines, settlements and other amounts actually and reasonably incurred in connection with any proceedings arising out of their services to Geron. In addition, we have entered into separate indemnification agreements with each of our directors and officers which provide for indemnification of these directors and officers under similar circumstances and under additional circumstances. The indemnification obligations are more fully described in our bylaws and the indemnification agreements. We purchase standard insurance to cover claims or a portion of the claims made against our directors and officers. Since a maximum obligation is not explicitly stated in our bylaws or in our indemnification agreements and will depend on the facts and circumstances that arise out of any future claims, the overall maximum amount of the obligations cannot be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Severance Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain two severance plans: one applied to (i) employees hired on or before December 31, 2021, and (ii) employees at the Senior Vice President level and above (i.e., executives), and the other applies to non&#x2011;executive employees hired on or after January 1, 2022. The plans provide severance benefits upon qualifying terminations, including enhanced benefits in connection with a change of control. As of March&#160;31, 2026, all executive officers have employment agreements with severance provisions and will receive the greater of the severance benefits provided under their agreements or the applicable plan (without duplication).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2025, we implemented a workforce reduction, representing approximately one-third of our workforce prior to the reduction in headcount. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 11 on Restructuring for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Purchase Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have engaged third&#x2011;party contract manufacturers to manufacture and supply additional quantities of RYTELO that meet applicable regulatory standards for current and potential future clinical trials and commercial uses. Related to those contract manufacturing agreements, we have binding commercial purchase commitments of approximately $15.9 million that can be cancelled, but would incur cancellation penalties, and approximately $37.7 million in agreed upon manufacturing commitments that can be adjusted based on commercial demand of RYTELO as of March 31, 2026. Based on current plans and information available, the related commercial purchase commitments are intended to be utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:18pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, we enter into agreements with CROs for clinical trials for clinical and commercial supply manufacturing and with other vendors for non-clinical research studies, investigator-led trials and other services and products for operating purposes. We have not considered these payments to be contractual obligations since the contracts are generally cancellable at any time by us upon less than 180 days&#x2019; prior written notice. We also have certain in-license agreements that require us to pay milestones to such third parties upon achievement of certain development, regulatory or commercial milestones. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval and commercial milestones, which may not be achieved.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-143"
      decimals="INF"
      id="f-604"
      unitRef="lawsuit">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-144"
      decimals="INF"
      id="f-605"
      unitRef="lawsuit">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-144"
      decimals="INF"
      id="f-606"
      unitRef="lawsuit">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-144"
      decimals="INF"
      id="f-607"
      unitRef="lawsuit">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-144"
      decimals="INF"
      id="f-608"
      unitRef="lawsuit">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-145"
      decimals="INF"
      id="f-609"
      unitRef="lawsuit">1</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-146"
      decimals="INF"
      id="f-610"
      unitRef="action">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <gern:NumberOfSeverancePlan contextRef="c-1" decimals="INF" id="f-611" unitRef="plan">2</gern:NumberOfSeverancePlan>
    <us-gaap:RecordedUnconditionalPurchaseObligation contextRef="c-3" decimals="-5" id="f-612" unitRef="usd">15900000</us-gaap:RecordedUnconditionalPurchaseObligation>
    <us-gaap:LongTermPurchaseCommitmentAmount contextRef="c-1" decimals="-5" id="f-613" unitRef="usd">37700000</us-gaap:LongTermPurchaseCommitmentAmount>
    <gern:PurchaseObligationWrittenNoticeTerm contextRef="c-1" id="f-614">P180D</gern:PurchaseObligationWrittenNoticeTerm>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-617">NET LOSS PER COMMON SHARE&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of shares of common stock outstanding for the periods presented without consideration of potential common shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted net income per share would be calculated by adjusting the weighted-average number of shares of common stock outstanding for the dilutive effect of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued, as determined using the treasury-stock method. Potential dilutive securities consist of outstanding stock options and warrants to purchase our common stock. Diluted net loss per share excludes potential dilutive securities for all periods presented as their effect would be anti-dilutive. Accordingly, basic and diluted net loss per share is the same for all periods presented in the accompanying condensed consolidated statements of operations. Since we incurred a net loss for the three months ended March 31, 2026 and 2025, the diluted net loss per share calculation excludes potential dilutive securities of 91,845,095 and 80,776,089, respectively, related to outstanding stock options and warrants as their effect would have been anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-149" decimals="0" id="f-618" unitRef="shares">91845095</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-150" decimals="0" id="f-619" unitRef="shares">80776089</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-620">SEGMENT REPORTING&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are currently developing therapies for the treatment of hematologic malignancies. To date, our main source of product revenue has been from U.S. sales of RYTELO, which began shipping to customers in June 2024. Additionally, we have generated insignificant royalty and license fee revenue under agreements that out-license technology to various companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have one operating and reportable segment. We define our operating segment based on internally reported financial information that is regularly reviewed by the Chief Operating Decision Maker, or CODM, to analyze financial performance, make decisions, and allocate resources. Our President and Chief Executive Officer is the CODM. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CODM reviews the segment's profit or loss based on net (loss) income reported on the consolidated statement of operations and comprehensive (loss) income and considers forecast-to-actuals variances on a quarterly basis for expenses that are deemed significant. Further, the CODM reviews the segment's assets based on total assets reported on the condensed consolidated balance sheet. All long-lived assets are held in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our CODM views specific categories within research and development expenses and selling, general and administrative expenses as significant given the correlation between cash burn and profitability.  The following table reconciles reported revenues to net (loss) income under the significant expense principle for the three months ended March 31, 2026 and 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center;text-indent:64.8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.030%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chemistry, manufacturing, and control expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segment expenses*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest and other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;___________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*Other segment expenses includes stock-based compensation expense and other general and administrative expenses largely resulting from personnel costs for individuals in administrative functions and legal and professional fees.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-621"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-622"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-623"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-624"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock contextRef="c-1" id="f-625">The following table reconciles reported revenues to net (loss) income under the significant expense principle for the three months ended March 31, 2026 and 2025:&lt;div style="margin-bottom:12pt;text-align:center;text-indent:64.8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.030%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chemistry, manufacturing, and control expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segment expenses*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest and other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;___________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*Other segment expenses includes stock-based compensation expense and other general and administrative expenses largely resulting from personnel costs for individuals in administrative functions and legal and professional fees.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-151" decimals="-5" id="f-626" unitRef="usd">51800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-152" decimals="-5" id="f-627" unitRef="usd">39400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-153" decimals="-5" id="f-628" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-154" decimals="-5" id="f-629" unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-155" decimals="-5" id="f-630" unitRef="usd">51800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-156" decimals="-5" id="f-631" unitRef="usd">39600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-155" decimals="-5" id="f-632" unitRef="usd">1700000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-156" decimals="-5" id="f-633" unitRef="usd">1200000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-157" decimals="-5" id="f-634" unitRef="usd">13000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-158" decimals="-5" id="f-635" unitRef="usd">13700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-159" decimals="-5" id="f-636" unitRef="usd">600000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-160" decimals="-5" id="f-637" unitRef="usd">1500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:RestructuringCharges contextRef="c-161" decimals="-5" id="f-638" unitRef="usd">-200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-162" decimals="-5" id="f-639" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-163" decimals="-5" id="f-640" unitRef="usd">17000000.0</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-164" decimals="-5" id="f-641" unitRef="usd">20000000.0</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCharges contextRef="c-165" decimals="-5" id="f-642" unitRef="usd">-200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-166" decimals="-5" id="f-643" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-155" decimals="-5" id="f-644" unitRef="usd">19800000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-156" decimals="-5" id="f-645" unitRef="usd">19900000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-155" decimals="-5" id="f-646" unitRef="usd">-3700000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-156" decimals="-5" id="f-647" unitRef="usd">-3100000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:NetIncomeLoss contextRef="c-155" decimals="-5" id="f-648" unitRef="usd">-3600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-156" decimals="-5" id="f-649" unitRef="usd">-19800000</us-gaap:NetIncomeLoss>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-650">RESTRUCTURING&lt;div style="margin-bottom:12pt;text-indent:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2025, the board of directors approved a workforce reduction representing approximately one-third of our workforce prior to the reduction in headcount. In 2025, we incurred approximately $17.0&#160;million in restructuring and restructuring-related charges, primarily consisting of one-time employee severance payments, healthcare and related benefits, and other employee-related costs. The charges were recorded within restructuring charges in the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The workforce reduction was substantially completed in the first quarter of 2026. There were no restructuring charges during the three months ended March 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center;text-indent:64.8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.606%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.800%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restructuring&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance as of December 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expenses and adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13,532)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance as of March 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-167" decimals="-5" id="f-651" unitRef="usd">17000000.0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringCharges contextRef="c-9" decimals="INF" id="f-652" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="c-1" id="f-653">&lt;div style="margin-bottom:12pt;text-align:center;text-indent:64.8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.606%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.800%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restructuring&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance as of December 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expenses and adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13,532)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance as of March 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve contextRef="c-4" decimals="-3" id="f-654" unitRef="usd">17032000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-3" id="f-655" unitRef="usd">-394000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-1" decimals="-3" id="f-656" unitRef="usd">13532000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-3" decimals="-3" id="f-657" unitRef="usd">3106000</us-gaap:RestructuringReserve>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-1" id="f-659">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-660">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1" id="f-661">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-662">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
